Filed Pursuant to Rule 424(b)(3)
Registration No. 333-73786
PROSPECTUS
Hewlett-Packard Erste Vermogensverwaltungs- und Beteiligungsgesellschaft mbH
A Newly-Purchased Indirect Subsidiary of
Hewlett-Packard Company
Offer to Exchange Each Outstanding Common Share
of
Indigo N.V.
for either:
$7.50 (not more than 0.4494 and not less than 0.3167 shares) in common stock of
Hewlett-Packard Company
or
$6.00 (not more than 0.3595 and not less than 0.2534 shares) in common stock of
Hewlett-Packard Company and one non-transferable contingent value right
The exchange offer and withdrawal rights will expire at 12:00 noon, New York
City time, on March 22, 2002, unless extended. You may withdraw shares tendered
pursuant to this exchange offer at any time prior to the expiration of the
exchange offer.
On September 6, 2001, we entered into an offer agreement with Indigo N.V. to
acquire all of the outstanding common shares of Indigo. The management board,
the supervisory board and the combined board of Indigo separately and,
excluding a former HP executive whom we designated to serve on the supervisory
and combined boards of Indigo and therefore recused himself from the vote,
unanimously recommend that Indigo shareholders tender their shares pursuant to
the exchange offer as the boards believe that the consideration is fair to, and
in the best interests of, Indigo and its affiliated and unaffiliated
shareholders.
We are offering to exchange for each Indigo common share that is validly
tendered and not properly withdrawn either:
. Fixed Offer Price: $7.50 (not more than 0.4494 and not less than 0.3167
shares) in common stock of HP
or
. Contingent Offer Price: $6.00 (not more than 0.3595 and not less than
0.2534 shares) in common stock of HP, plus a contingent value right to
receive between $0 and $4.50 in cash in 2005 to the extent that HP
generates between $1.0 billion and $1.6 billion in cumulative net revenue
during the three-year post-closing period from the sale or lease of LEP
Digital Press Products and Consumables (as such terms are defined in the
contingent value rights agreement)
The total number of Indigo common shares exchangeable for the fixed offer
price and the contingent offer price is limited. As a result, you may receive,
for some of the Indigo common shares you tender, a form of consideration that
is different from what you elect. If you elect the fixed offer price and that
form of consideration is over-subscribed by the other shareholders, you may
receive the contingent offer price for as much as 18% of your tendered Indigo
common shares. If you elect the contingent offer price and that form of
consideration is over-subscribed by the other shareholders, you may receive the
fixed offer price for as much as 13.4% of your tendered Indigo common shares.
For the Indigo common shares for which you receive the contingent offer price,
you will receive $6.00 in HP common stock and one non-transferable contingent
value right, which may pay as little as $0 in 2005. For the Indigo common
shares for which you receive the fixed offer price, you will receive $7.50 in
HP common stock and no contingent value right, which may pay as much as $4.50
in cash in 2005.
Our obligation to complete the exchange offer is subject to a number of
conditions, including a requirement that the total number of shares tendered
into the exchange offer, when added to the Indigo common shares then owned by
HP (currently 14,814,814 shares representing approximately 13.4% of the
outstanding Indigo common shares), constitutes at least 95% of Indigo's
outstanding common shares (including Indigo common shares issuable upon
exercise of certain warrants). We describe these conditions in the section of
this prospectus titled "The Offer Agreement--Conditions to the Exchange Offer."
HP common stock is listed on the New York Stock Exchange and the Pacific
Exchange under the trading symbol "HWP," and Indigo common shares are listed on
the Nasdaq National Market under the trading symbol "INDG."
The section titled "Risk Factors" beginning on page 30 of this prospectus
contains a description of risks that you should consider.
We are not asking you for a proxy and you are requested not to send us a
proxy. Any request for proxies will be made only pursuant to separate proxy
solicitation materials.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of the shares of HP common stock or the
CVRs to be issued in connection with the exchange offer, passed upon the merits
or fairness of the offer agreement and the exchange offer or determined whether
this prospectus is truthful or complete. Any representation to the contrary is
a criminal offense.
This prospectus is dated February 19, 2002.
This prospectus does not constitute an offer to sell, or a solicitation of
an offer to purchase, the securities offered by this prospectus in any
jurisdiction to or from any person to whom or from whom it is unlawful to make
such offer or solicitation of an offer in such jurisdiction. Neither the
delivery of this prospectus nor any distribution of securities pursuant to this
prospectus shall, under any circumstances, create any implication that there
has been no change in the information set forth or incorporated by reference
into this prospectus or in our affairs since the date of this prospectus.
The exchange offer is not being made in or into Israel and will not be
capable of acceptance in Israel or by persons in Israel, except to certain
persons referred to in Section 15A(B)(1) of the Securities Law, 5728-1968, of
Israel and listed in Appendix One thereto (which includes certain mutual,
provident and venture capital funds, banks, insurers, portfolio managers,
investment advisors, stock exchange members, underwriters and certain
corporations controlled by any of the above). Should you receive this
prospectus in Israel and are not a person referred to above, this prospectus
does not constitute an offer to you to sell, or a solicitation from you of an
offer to purchase, the securities offered by this prospectus or an invitation
or solicitation to tender your Indigo common shares. An election form/letter of
transmittal contained in an envelope postmarked in Israel, requesting the HP
common stock or CVRs to be delivered to an address in Israel, signed or
signature guaranteed in Israel, or otherwise appearing to HP or its agents to
have been sent from Israel, will not constitute a valid acceptance of the
exchange offer, unless from a person referred to above, or otherwise in
accordance with, the Securities Law, 5728-1968, and any regulations promulgated
thereunder, of Israel.
TABLE OF CONTENTS
Page
----
QUESTIONS AND ANSWERS ABOUT THE EXCHANGE OFFER........................... 1
SUMMARY.................................................................. 6
The Exchange Offer and the Offer Agreement............................ 6
Parties to the Exchange Offer......................................... 6
Contingent Value Rights............................................... 8
Irrevocable Proxies................................................... 10
Reasons for the Exchange Offer........................................ 10
Recommendation of the Indigo Boards................................... 11
Opinion of Indigo Financial Advisor Regarding the Exchange Offer...... 11
Indigo Directors and Executive Officers Have Interests in the
Exchange Offer...................................................... 11
Indigo's Management and Supervisory Boards Following the Exchange
Offer............................................................... 12
Extension, Termination, Waiver and Amendment of the Exchange Offer.... 12
What is Needed to Complete the Exchange Offer......................... 13
We Have Not Yet Obtained All Required Regulatory Approvals to
Complete the Exchange Offer......................................... 13
Procedure for Tendering............................................... 14
Withdrawal Rights..................................................... 14
Exchange of Indigo Common Shares; Delivery of Shares of HP Common
Stock and CVRs...................................................... 14
Indigo is Prohibited from Considering Other Offers.................... 14
We and Indigo May Terminate the Offer Agreement....................... 14
We or Indigo May Be Required to Pay a Termination Fee................. 15
The Exchange Offer is Taxable for United States Federal Income Tax
Purposes............................................................ 16
Accounting Treatment of the Exchange Offer............................ 17
We Will List Shares of HP Common Stock on the New York Stock Exchange
and the Pacific Exchange............................................ 17
Indigo Appraisal Rights............................................... 17
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF HP............ 18
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF COMPAQ........ 20
Page
----
SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL
DATA OF HP AND COMPAQ.................................................. 22
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF INDIGO........ 24
COMPARATIVE HISTORICAL AND PRO FORMA PER SHARE DATA...................... 26
COMPARATIVE PER SHARE MARKET PRICE DATA.................................. 28
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION............... 29
RISK FACTORS............................................................. 30
HP'S BUSINESS FOLLOWING THE COMPLETION OF THE COMPAQ MERGER.............. 53
Overview of Business Structure........................................ 53
Integration Office.................................................... 54
SPECIAL FACTORS.......................................................... 55
Background of the Exchange Offer...................................... 55
Indigo's Purposes and Reasons for the Exchange Offer.................. 59
Indigo's Belief Regarding the Fairness of the Exchange Offer.......... 61
Recommendation of the Indigo Boards................................... 63
Opinion of Indigo Financial Advisor Regarding the Exchange Offer...... 63
Interests of Indigo Directors and Executive Officers in the Exchange
Offer............................................................... 71
HP's Purposes and Reasons for the Exchange Offer...................... 73
Mr. Landa's Belief Regarding the Fairness of the Exchange Offer....... 74
HP's Belief Regarding the Fairness of the Exchange Offer.............. 74
Effects of the Exchange Offer; Plans or Proposals After the Exchange
Offer............................................................... 76
United States Federal Income Tax Consequences of the Exchange Offer... 78
Relationships Between HP and Indigo................................... 81
Summary Indigo Financial Projections.................................. 84
THE EXCHANGE OFFER....................................................... 87
Description of the Exchange Offer..................................... 87
Allocation Rules for the Fixed Offer Price and Contingent Offer Price. 90
Post-Closing Restructuring............................................ 106
i
TABLE OF CONTENTS--(continued)
Page
----
Timing of the Exchange Offer........................................... 109
Extension, Termination, Waiver and Amendment of the Exchange Offer..... 109
Exchange of Indigo Common Shares; Delivery of Consideration............ 110
Cash Instead of Fractional Shares of HP Common Stock................... 111
Withdrawal Rights...................................................... 111
Election Procedures.................................................... 112
Procedure for Tendering................................................ 112
Guaranteed Delivery.................................................... 113
Accounting Treatment of the Exchange Offer............................. 114
Regulatory Filings and Approvals Required to Complete the Exchange
Offer................................................................ 115
Indigo Appraisal Rights................................................ 117
U.S. State Takeover Laws............................................... 117
Rule 13e-3 Transactions................................................ 118
Fees and Expenses...................................................... 118
Source and Amount of Funds............................................. 119
Restrictions on Sales of Shares of HP Common Stock Received in the
Exchange Offer....................................................... 119
Listing of Shares of HP Common Stock Issued in the Exchange Offer on
the New York Stock Exchange and Pacific Exchange..................... 119
Delisting and Deregistration of Indigo Common Shares after the
Exchange Offer....................................................... 120
THE OFFER AGREEMENT....................................................... 121
The Exchange Offer..................................................... 121
Indigo's Management and Supervisory Boards following the
Exchange Offer....................................................... 123
Treatment of Indigo Stock Options and Warrants......................... 123
Termination of Indigo Employee Stock Purchase Plans.................... 125
Representations and Warranties......................................... 125
Conduct of Indigo's Business Prior to Completion of the Exchange Offer. 125
Commercially Reasonable Efforts to Complete the Exchange Offer......... 127
Indigo is Prohibited from Considering Other Acquisition Proposals...... 127
Page
----
Employee Benefits..................................................... 128
Conditions to the Exchange Offer...................................... 129
Termination of the Offer Agreement.................................... 133
Payment of Termination Fee; Expenses.................................. 134
Amendments to the Offer Agreement..................................... 135
DESCRIPTION OF THE CVRs.................................................. 136
Summary............................................................... 136
Selected Definitions Related to the CVR Agreement..................... 138
Description of the CVR Certificates................................... 139
AGREEMENTS RELATED TO THE OFFER AGREEMENT................................ 140
Parties to the Related Agreements..................................... 140
Voting Agreements..................................................... 140
Tender Agreements..................................................... 141
Tender and Option Agreements.......................................... 141
Affiliate Agreements.................................................. 141
INDIGO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.................................................. 142
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK OF INDIGO..... 154
INDIGO MARKET PRICE DATA AND DIVIDEND INFORMATION........................ 156
COMPARISON OF RIGHTS OF HOLDERS OF HP COMMON STOCK AND INDIGO COMMON
SHARES................................................................. 157
Comparison of the Certificate of Incorporation and Bylaws of HP and
Articles of Association of Indigo................................... 157
Indemnification of Directors and Officers............................. 162
Shareowner Rights Plan................................................ 163
LEGAL MATTERS............................................................ 165
EXPERTS.................................................................. 165
WHERE YOU CAN FIND MORE INFORMATION...................................... 166
INDIGO N.V. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS................................................... F-1
ii
TABLE OF CONTENTS--(continued)
Page
-----
SCHEDULE I--Information Concerning Directors and Executive Officers of
HP................................................................... I-1
ANNEX A--Offer Agreement by and between HP and Indigo.................. A-1
ANNEX B-1--Form of Contingent Value Rights Agreement by and between
Hewlett- Packard Erste Vermogensverwaltungs- und
Beteiligungsgesellschaft mbH and J.P. Morgan Trust Company........... B-1-1
ANNEX B-2--Form of Corporate Guaranty by HP............................ B-2-1
ANNEX C-1--Tender and Option Agreement by and among HP and Certain
Principal Shareholders of Indigo..................................... C-1-1
ANNEX C-2--Tender and Option Agreement by and between HP and Oscar &
Zlata Foundation..................................................... C-2-1
Page
-----
ANNEX C-3--Tender Agreement by and between HP and S-C Indigo CV........ C-3-1
ANNEX C-4--Form of Tender Agreement by and among HP and Certain
Principal Shareholders of Indigo..................................... C-4-1
ANNEX C-5--Voting Agreement by and between HP and Oscar & Zlata
Foundation........................................................... C-5-1
ANNEX C-6--Voting Agreement by and between HP and S-C Indigo CV........ C-6-1
ANNEX C-7--Form of Voting Agreement and Irrevocable Proxy by and among
HP and Certain Shareholders of Indigo................................ C-7-1
ANNEX C-8--Form of Affiliate Agreement by and among HP and Certain
Principal Shareholders of Indigo..................................... C-8-1
ANNEX D--Opinion of Gleacher & Co. LLC................................. D-1
iii
This prospectus incorporates important business and financial information
about HP, Indigo and Compaq Computer Corporation from documents that each
company has filed with the Securities and Exchange Commission but that have not
been included in or delivered with this prospectus. For a listing of documents
incorporated by reference into this prospectus, please see the section titled
"Where You Can Find More Information" beginning on page 166 of this prospectus.
HP will provide you with copies of this information relating to HP, without
charge, upon written or oral request to:
Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: Investor Relations
Telephone Number: (650) 857-1501
In addition, you may obtain copies of this information by making a request
through HP's investor relations website, http://www.hp.com/hpinfo/investor, or
by sending an e-mail to investor_relations@hp.com.
Indigo will provide you with copies of this information relating to Indigo,
without charge, upon written or oral request to:
Indigo N.V.
c/o Indigo America, Inc.
400 Unicorn Park Drive
Woburn, Massachusetts 01801
Attention: Investor Relations
Telephone Number: (781) 937-8999
In addition, you may obtain copies of this information by making a request
by e-mail to Michael King at indigoir@indigousa.com.
Compaq will provide you with copies of this information relating to Compaq,
without charge, upon written or oral request to:
Compaq Computer Corporation
P.O. Box 692000
Houston, Texas 77269-2000
Attention: Compaq Investor Relations, MS 110605
Telephone Number: (800) 433-2391
In addition, you may obtain copies of this information by making a request
through Compaq's investor relations website,
http://www.shareholder.com/cpq/document-request.cfm, or by sending an e-mail to
investor.relations@compaq.com.
In order for you to receive timely delivery of the documents in advance of
the closing of the exchange offer, HP, Indigo or Compaq should receive your
request no later than March 14, 2002.
iv
QUESTIONS AND ANSWERS ABOUT THE EXCHANGE OFFER
Q: What are HP and Indigo proposing? (see page 87)
A: We have entered into an offer agreement with Indigo, pursuant to which we
will offer through a newly-purchased subsidiary of ours, to acquire all of
the outstanding Indigo common shares not already owned by us or our
affiliates.
Q: What would I receive in exchange for my Indigo common shares? (see page 87)
A: In the exchange offer, at your election and subject to the allocation
mechanism described in this prospectus, we are offering through our
newly-purchased subsidiary to exchange for each Indigo common share either:
. the fixed offer price, which consists of a fraction of a share of HP
common stock that has a value equal to $7.50, subject to adjustment, as
determined in accordance with the offer agreement;
or
. the contingent offer price, which consists of (1) a fraction of a share
of HP common stock that has a value equal to $6.00, subject to
adjustment, as determined in accordance with the offer agreement, plus
(2) one non-transferable contingent value right, which we refer to as a
CVR.
As described in more detail in this prospectus, each CVR will entitle its
holder to a contingent cash payment in 2005 from our newly-purchased
subsidiary of up to $4.50 in cash if our consolidated net revenues from the
sale or lease of LEP Digital Press Products and Consumables (as such terms
are defined in the CVR agreement) reach specified revenue milestones over a
three-year period, which will begin after completion of the exchange offer.
The three-year period for determining whether the specified revenue
milestones have been met will commence on the first day of the first
calendar month occurring after the closing date of the exchange offer and
will end on the last day prior to the third anniversary of such day. As
described in more detail in this prospectus, the present value of such
future potential payout will be lower than any amount paid in 2005. For
example, as of the close of the exchange offer, the present value of
receiving $4.50 39 months later is $3.05, $2.77 and $2.52 based on discount
rates of 12%, 15% and 18%, respectively. If the specified revenue thresholds
are not reached, there will be no payout under the CVRs.
Q: How will you calculate the amount of HP common stock to be issued for each
Indigo common share pursuant to the fixed offer price and the contingent
offer price? (see page 87)
A: We will calculate the amount of HP common stock to be issued, which we refer
to as the exchange ratio, by dividing $7.50, in the case of the fixed offer
price, or $6.00, in the case of the contingent offer price, by the average
closing sales price of HP common stock on the New York Stock Exchange during
the twenty consecutive trading days ending on the trading day on which the
third most recent closing of the U.S. markets prior to the expiration of the
exchange offer occurs. However, the offer agreement provides that the
average HP closing sales price to be used in this calculation will not be
less than $16.69 or more than $23.68. As a result, each Indigo common share
exchanged for the fixed offer price will receive between 0.3167 and 0.4494
of a share of HP common stock, and (2) each Indigo common share exchanged
for the contingent offer price will receive (A) between 0.2534 and 0.3595 of
a share of HP common stock, plus (B) one CVR.
The trading price of HP common stock on the date that you receive HP common
stock in exchange for your Indigo common shares could be more or less than
the average closing sales price of the HP common stock during the relevant
twenty trading day pricing period described above. This means that the
then-current market value of the HP common stock that you receive for each
Indigo common share could be more or less than $7.50, in the case of the
fixed offer price, or $6.00, in the case of the contingent offer price,
regardless of the average HP closing sales price.
1
We will not issue any fractional shares of HP common stock in connection
with the exchange offer. You will instead receive cash for any fractional
share otherwise issuable to you as further described in this prospectus.
Q: How can I find out the final exchange ratios?
A: No later than two business days before the exchange offer expires, we will
notify you by issuing a press release announcing the final exchange ratios
for the fixed offer price and the contingent offer price and filing that
press release with the Securities and Exchange Commission. You can also call
our information agent, Georgeson Shareholder Communications, at (212)
806-6741 and, if you are in North America, toll-free at (866) 233-9045 for
the final exchange ratios and the final average closing sales price of HP
common stock. Persons will be available to answer questions at these phone
numbers throughout the entire period that the exchange offer is open.
Q: Can I elect to exchange some of my Indigo common shares for the fixed offer
price and some of my Indigo common shares for the contingent offer price?
(see page 112)
A: No. You must elect to exchange all of your Indigo common shares for one
consideration alternative. To the extent that you validly tender your Indigo
common shares but do not indicate in the election form/letter of transmittal
whether you elect to receive the fixed offer price or the contingent offer
price, you will be deemed to have elected to receive the fixed offer price
for all of the Indigo common shares that you tender, subject to the
allocation mechanism described in this prospectus.
Q. Is my election to receive the fixed offer price or the contingent offer
price subject to any limitations? (see page 90)
A. Yes. The terms of the offer agreement limit the total number of Indigo
common shares that are permitted to be exchanged for each of the fixed offer
price and contingent offer price. Based on Indigo's capitalization as of
December 31, 2001, approximately 39.6 million Indigo common shares may be
exchanged for the fixed offer price, and approximately 56.2 million Indigo
common shares may be exchanged for the contingent offer price. However, the
number of Indigo common shares that may be exchanged for the fixed offer
price may increase depending upon the exercise of outstanding options and
warrants. As a result, you may receive for some of the Indigo common shares
that you tender a form of consideration alternative that is different than
what you elect. Pursuant to tender and option agreements, the holders of
approximately 47.6 million Indigo outstanding common shares have agreed, to
the extent that either the fixed offer price or the contingent offer price
is oversubscribed, to elect automatically to receive the undersubscribed
consideration alternative for up to all of the Indigo common shares held by
each of those shareholders. If either election remains oversubscribed after
giving effect to the automatic election provided for in the tender and
option agreements, all other Indigo shareholders who have tendered into the
exchange offer for the oversubscribed consideration alternative will be
required to accept some portion of the undersubscribed consideration
alternative. However, as a result of the tender and option agreements
described above, no more than 18% of the Indigo common shares that you
tender will be exchanged for the form of consideration that you do not
elect. One of Indigo's other large shareholders, which holds 24.6 million
shares, has agreed to tender its Indigo common shares into the exchange
offer but has not agreed to elect automatically to receive the
undersubscribed consideration alternative. Because such shareholder must
elect to exchange all of its 24.6 million shares for either the fixed offer
price or the contingent offer price, the likelihood that the offer price
that such shareholder elects to receive will be oversubscribed is increased.
Based upon Indigo's capitalization as of December 31, 2001, the 24.6 million
shares held by such shareholder would represent approximately 62% of the
Indigo common shares that may be exchanged for the fixed offer price and
approximately 44% of the Indigo common shares that may be exchanged for the
contingent offer price. In the event that the offer price that such
shareholder elects to receive is oversubscribed, such shareholder's election
will result in a decrease in the percentage of your Indigo common shares
(but by no more than the 18% amount noted above) that will be exchanged for
the offer
2
price that you elect if you also have elected to receive the oversubscribed
form of consideration. To find and calculate the range of potential
valuations that may result after the close of the exchange offer, please see
the section titled "The Exchange Offer" beginning on page 87 of this
prospectus.
Q: How can I learn the degree to which I may not receive the consideration
alternative that I requested?
A: If either of the fixed offer price or contingent offer price elections are
oversubscribed, then the allocation of these consideration alternatives will
be determined after completion of the exchange offer in accordance with the
terms of the offer agreement. We will notify you by issuing a press release
announcing the degree of the allocation, if any, and filing that press
release with the Securities and Exchange Commission. You can also call our
information agent, Georgeson Shareholder Communications, at (212) 806-6741
and, if you are in North America, toll-free at (866) 233-9045 to learn the
degree to which the fixed offer price or contingent offer price elections
may have been allocated after completion of the exchange offer.
Q: How long will it take to complete the exchange offer? (see page 109)
A: The exchange offer will commence on February 21, 2002 and is currently
scheduled to expire at 12:00 noon, New York City time, on March 22, 2002.
However, we may extend the exchange offer as described in this prospectus.
Q: Do Indigo's management, supervisory and combined boards support the exchange
offer? (see page 63)
A: Yes. Indigo's management, supervisory and combined boards, excluding the
member designated by HP who recused himself from the vote, unanimously
support the exchange offer and recommend that you tender your Indigo common
shares in the exchange offer.
Q: Have any Indigo shareholders agreed to tender their shares? (see page 140)
A: Yes. Some shareholders of Indigo have agreed to tender their Indigo common
shares into the exchange offer. These shareholders comprise all of the
directors and executive officers of Indigo who hold Indigo common shares, as
well as S-C Indigo CV and a foundation, which we refer to as the Landa
Family Trust, of which Benzion Landa, Indigo's Chairman and Chief Executive
Officer, is a beneficiary, and entities directly or indirectly owned by the
Landa Family Trust, which are the major shareholders of Indigo other than
HP. These shareholders, who have entered into tender and option or tender
agreements with HP, hold an aggregate of 72,394,307 Indigo common shares
representing approximately 65.4% of the Indigo common shares outstanding as
of December 31, 2001.
All Indigo board members and executive officers who hold Indigo common
shares have entered into tender agreements with HP.
Q: Is the exchange offer conditioned upon the completion of the proposed
business combination between HP and Compaq?
A: No. The exchange offer is not conditioned upon the completion of the
pending merger of a wholly-owned subsidiary of HP with and into Compaq
Computer Corporation, which we refer to as the Compaq merger. The Compaq
merger is subject to customary conditions to closing as set forth in the
merger agreement among HP, a wholly-owned subsidiary of HP and Compaq, which
we refer to as the Compaq merger agreement. These closing conditions to the
Compaq merger are separate and independent from the closing conditions to
the exchange offer. We cannot assure you that we will complete the Compaq
merger. If the Compaq merger is not completed, HP common stock will not
reflect any actual or anticipated interest in Compaq. See the section titled
"Risk Factors--Risks Regarding the Compaq Merger and HP and Compaq as a
Combined Company" in this prospectus for a discussion of important factors
that you should consider in connection with the Compaq merger.
3
Q: What percentage of HP common stock will Indigo shareholders own after the
exchange offer?
A: If we acquire all of the Indigo common shares pursuant to the exchange
offer, former shareholders of Indigo, other than us and our affiliates,
would own approximately 1.9% of the shares of common stock of HP, assuming
that 0.4494 of a share of HP common stock will be issued for each Indigo
common share that receives the fixed offer price and that 0.3595 of a share
of HP common stock will be issued for each Indigo common share that receives
the contingent offer price, and based upon the 95,865,713 Indigo common
shares (excluding treasury shares and the 14,814,814 Indigo common shares
held by us and our affiliates) outstanding on December 31, 2001 and the
1,941,391,000 shares of HP common stock outstanding on January 28, 2002, not
taking into account stock options, warrants or convertible securities of
Indigo or HP. This ownership percentage would be reduced to approximately
1.2% if the Compaq merger is completed, in which case we would issue an
aggregate of approximately 1,078,182,486 shares of HP common stock to Compaq
shareowners, not taking into account a total of approximately 320,808,010
shares of HP common stock that will be reserved for issuance upon the
exercise of options to purchase Compaq common stock assumed by HP in
connection with the Compaq merger.
Q: How do I participate in the exchange offer? (see page 112)
A: You are urged to read this entire prospectus carefully, and to consider how
the exchange offer affects you. Then, if you wish to tender your Indigo
common shares, you should do the following:
. If you hold your common shares in your own name, complete and sign the
enclosed election form/letter of transmittal and return it with your
share certificates to Computershare Trust Company of New York, at the
address on the back cover of this prospectus, before the expiration time
of the exchange offer which, unless extended, will occur at 12:00 noon,
New York City time, on March 22, 2002.
. If you hold your common shares in "street name" through a broker, bank
or nominee, ask your broker, bank or nominee to tender your shares
before the expiration time of the exchange offer.
Please read this prospectus carefully for more information about the
procedures for tendering your shares, electing to receive the fixed offer
price or the contingent offer price, timing of the exchange offer,
extensions of the offering period and your rights to withdraw your shares
from the exchange offer before the expiration time.
Q: Do I have to pay any brokerage fees or commissions? (see page 90)
A: If you are the record owner of your Indigo common shares and you tender your
shares in the exchange offer, you will not incur any brokerage fees or
commissions. If you own your Indigo common shares through a broker, bank or
nominee who tenders the shares on your behalf, you may be charged a
commission for doing so. You should consult with your broker, bank or
nominee to determine whether any charges will apply.
Q: What happens if the exchange offer is completed and I have not tendered my
Indigo common shares? (see page 76)
A: You will continue to own your Indigo common shares. After the completion of
the exchange offer, we may, among other things, delist the Indigo common
shares from the Nasdaq National Market and terminate Indigo's reporting
obligations under the United States federal securities laws, such that there
would no longer be a public market for Indigo common shares. In that event,
the value of your Indigo common shares may decline and you may be unable to
sell your Indigo common shares readily or at all after the completion of the
exchange offer.
In addition, we may, but are not required to, effectuate a corporate
restructuring of Indigo, which we refer to as the post-closing
restructuring. The post-closing restructuring, if implemented by us in our
sole discretion,
4
may include, without limitation, the commencement of a compulsory
acquisition by us of Indigo common shares from any remaining minority Indigo
shareholders, which is permitted under Dutch law only if we own 95% or more
of Indigo's outstanding common shares, or other actions that may make it
unattractive for the remaining minority Indigo shareholders to own Indigo
common shares. If we in our sole discretion implement a post-closing
restructuring to acquire any remaining Indigo common shares not tendered
into the exchange offer, we will offer consideration equivalent to the fixed
offer price to the remaining minority Indigo shareholders. However, the form
of the consideration paid to remaining minority Indigo shareholders in any
post-closing restructuring will consist solely of cash. In addition, under
Dutch law the amount of consideration to be paid to the remaining minority
Indigo shareholders in a compulsory acquisition is subject to judicial
determination.
Q: Is HP's financial condition relevant to my decision to tender my common
shares in the exchange offer?
A: Yes. Since Indigo common shares accepted in the exchange offer will be
exchanged for shares of HP common stock and, with respect to Indigo common
shares exchanged for the contingent offer price, CVRs, you should consider
our financial condition before you decide to tender your Indigo shares in
the exchange offer. In considering our financial condition, you should
review carefully the information in this prospectus and the documents
incorporated by reference into this prospectus because they contain detailed
business, financial and other information about us.
Q: Who can help answer my questions? (see page 168)
A: If you have any questions about the exchange offer or how to tender your
Indigo common shares, or if you need additional copies of this prospectus,
you should contact:
Georgeson Shareholder
111 Commerce Road
Carlstadt, New Jersey 07072
Indigo@Georgeson.com
Banks and Brokers please call (201) 896-1900
Shareholders in North America call toll-free (866) 233-9045
Shareholders outside of North America call (212) 806-6741
5
SUMMARY
The following is a summary of the information contained in this prospectus.
This summary may not contain all of the information about the exchange offer
that is important to you. For a more complete description of the exchange
offer, we encourage you to read carefully this entire prospectus, including the
attached annexes. In addition, we encourage you to read the information
incorporated by reference into this prospectus, which includes important
business and financial information about HP, Indigo and Compaq. You may obtain
the information incorporated by reference into this prospectus without charge
by following the instructions in the section titled "Where You Can Find More
Information" beginning on page 166 of this prospectus.
The Exchange Offer and the Offer Agreement (see pages 87 and 121)
We and Indigo have agreed to the exchange offer under the terms of an offer
agreement that is described in this prospectus. A copy of the offer agreement
is attached to this prospectus as Annex A. Upon the terms and subject to the
conditions to the exchange offer described in the offer agreement, we will
offer to exchange for each Indigo common share that is validly tendered and not
properly withdrawn, at your election and subject to the allocation mechanism
described in this prospectus, either the fixed offer price or the contingent
offer price.
We will make the exchange offer through a newly-purchased indirect
subsidiary of ours. References in this prospectus to HP, we and us mean HP, HP
and this subsidiary, or HP together with its consolidated subsidiaries, as
appropriate.
Parties to the Exchange Offer
Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
(650) 857-1501
HP is a leading global provider of computing, printing and imaging solutions
and services for business and home, and is focused on making technology and its
benefits accessible to all.
HP currently organizes its operations into three major businesses.
Imaging and Printing Systems provides printer hardware, supplies, imaging
products and related professional and consulting services. Printer hardware
consists of laser and inkjet printing devices, which include color and
monochrome printers for the business and home, multi-function laser devices and
wide- and large-format inkjet printers. Supplies offer laser and inkjet printer
cartridges and other related printing media. Imaging products include
all-in-one inkjet devices, scanners, digital photography products, personal
color copiers and faxes. Professional and consulting services are provided to
customers on the optimal use of printing and imaging assets.
Computing Systems provides commercial personal computers (PCs), home PCs,
workstations, UNIX(R) servers, PC servers, storage and software solutions.
Commercial PCs include the Vectra desktop series, as well as OmniBook and
Pavilion notebook PCs. Home PCs include the Pavilion series of multi-media
consumer desktop PCs. Workstations provide UNIX(R), Windows and Linux-based
systems. The UNIX(R) server offering ranges from low-end servers to high-end
scalable systems such as the Superdome line, all of which run on HP's PA-RISC
architecture and the HP-UX operating system. PC servers offer primarily low-end
and mid-range products that run on the Windows and Linux operating systems.
Storage provides mid-range and high-end array offerings, storage area networks
and storage area management and virtualization software, as well as tape and
optical
6
libraries, tape drive mechanisms and tape media. The software category offers
OpenView and other solutions designed to manage large-scale systems and
networks. In addition, software includes telecommunications infrastructure
solutions and middleware.
IT Services provides customer support, consulting, outsourcing, technology
financing and complementary third-party products delivered with the sales of HP
solutions. Customer support offers a range of high-value solutions from
mission-critical and networking services that span the entire IT environment to
low-cost, high-volume product support. Consulting provides industry-specific
business and IT consulting and system integration services in areas such as
financial services, telecommunications and manufacturing, as well as
cross-industry expertise in Customer Relationship Management (CRM), e-commerce
and IT infrastructure. Outsourcing offers a range of IT management services,
both comprehensive and selective, including transformational infrastructure
services, client computing managed services, managed web services and
application services to medium and large companies. Technology financing
capabilities include leasing, solution financing and computing and printing
utility offerings.
HP was incorporated in 1947 under the laws of the State of California as the
successor to a partnership founded in 1939 by William R. Hewlett and David
Packard. Effective in May 1998, HP changed its state of incorporation from
California to Delaware.
On September 4, 2001, we entered into the Compaq merger agreement. Reference
in this prospectus to the Compaq merger refers to the proposed merger of a
wholly-owned subsidiary of HP with and into Compaq pursuant to the Compaq
merger agreement. Compaq is a leading global provider of information technology
products, services and solutions for enterprise customers. Compaq designs,
develops, manufactures and markets information technology equipment, software,
services and solutions, including industry-leading enterprise storage and
computing solutions, fault-tolerant business-critical solutions, communication
products, personal desktop and notebook computers and personal entertainment
and Internet access devices.
Upon completion of the Compaq merger, holders of Compaq common stock will be
entitled to receive 0.6325 of a share of HP common stock for each share of
Compaq common stock they hold at that time. HP shareowners will continue to own
their existing shares of HP common stock after the Compaq merger. The shares of
HP common stock issued in exchange for shares of Compaq common stock in
connection with the Compaq merger will represent approximately 35.7% of the
outstanding shares of HP common stock immediately following the completion of
the Compaq merger, based on the number of shares of HP and Compaq common stock
outstanding on January 28, 2002, which excludes the shares of HP common stock
issuable in the exchange offer to acquire Indigo.
There are uncertainties and risks associated with the Compaq merger. See the
section titled "Risk Factors--Risks Regarding the Compaq Merger and HP and
Compaq as a Combined Company" in this prospectus for a discussion of important
factors that you should consider in connection with the Compaq merger.
Indigo N.V.
5 Limburglaan
6221 SH Maastricht
The Netherlands
(011) 31-43-356-5656
Indigo N.V. is a leading provider of high performance digital printing
systems used in the production of on-demand, short-run color digitally-printed
products. Indigo's Digital Offset Color technology combines the quality of
ink-based offset printing with the performance advantages of digital imaging.
As in conventional offset printing, Indigo's Digital Offset Color printing
transfers the ink image from the imaging surface to a blanket and
7
from the blanket to paper. However, unlike conventional offset printing,
Indigo's Digital Offset Color printing creates a new ink image with each
impression without leaving residual ink on the printing blanket. This complete
transfer is enabled by ElectroInk, Indigo's proprietary liquid ink, which has a
high degree of cohesiveness during transfer. The unique features of the Digital
Offset Color printing system include (1) ElectroInk, a dispersion of
tentacle-shaped particles, and (2) a heated blanket to which the ElectroInk
image is transferred. The heated printing blanket transfers the ElectroInk
image to the paper, where the ink forms a dry film and sets immediately. Since
the entire ink image is transferred to the paper, the blanket can receive a
different image with each turn of the machine. In addition, Indigo's automatic
"on-the-fly" ink color switching technology enables each turn of the machine to
print not only a new image, but each one in a different color.
Indigo's products, including its proprietary ElectroInk, provide solutions
for the commercial, industrial and photographic printing markets. Indigo's
commercial printing products include the Indigo e-Print Pro+, a four-color
low-cost, entry-level press, suitable for simple digital printing applications;
the Indigo Platinum, which adds value applications such as electronic
collation, versioning and personalization, and six-color printing capability;
the Indigo UltraStream 2000, which is designed for high-volume printing and
applications requiring seven-color capability; and the Publisher presses,
expected to be commercially available in the second half of 2002, which are
appropriate for mid-volume and mainstream commercial printing, publishing and
direct mail markets. Indigo's industrial printing products include the Omnius
WebStream family of One-Shot Color presses, which bring on-demand color
printing to the main packaging and labeling markets, and the Omnius MultiStream
which permits printing on plastic sheets for the production of specialty
products. Indigo's photographic printing products, which are not expected to be
commercially available before 2002, include the Photo-e-Print line, which will
provide high quality, high speed and low cost solutions for retail and
professional photographic labs as well as centralized wholesale photo-finishing
operations. In addition, Indigo manufactures a number of presses that are
marketed through OEM channels under agreements with DataCard, A.B. Dick
Company, Werner Kammann Maschinenfabrik and HP. Indigo also manufactures and
sells proprietary imaging products essential to the operation of its presses,
including ElectroInk(R) products, photo imaging plates and image transfer
blankets. Indigo products combine the print quality and production capability
of offset presses with the workflow efficiencies and personalization of digital
printing. The Indigo products complement our existing line of digital printing
and imaging products for the home and office markets by expanding our digital
product and technology capabilities to the commercial printing market. Indigo
is headquartered in The Netherlands, with research and development and
manufacturing operations in Israel.
Indigo was incorporated in The Netherlands in 1977 under the name Spectrum
Sciences B.V.
Hewlett-Packard Erste Vermogensverwaltungs- und Beteiligungsgesellschaft mbH
Herrenbergerstr. 140
71034 Boeblingen
Germany
Hewlett-Packard Erste Vermogensverwaltungs- und Beteiligungsgesellschaft mbH
is a newly-purchased indirect subsidiary of HP. We purchased this subsidiary
solely to effect the exchange offer. This subsidiary has no prior operating
history and will not conduct any business prior to the completion of the
exchange offer. We refer to this subsidiary as Newco throughout this prospectus.
Contingent Value Rights (see page 136)
Upon completion of the exchange offer, Newco and J.P. Morgan Trust Company,
National Association, as trustee, will enter into a CVR agreement that will
govern the CVRs. A copy of the form of CVR agreement is attached to this
prospectus as Annex B-1. Under the terms of the CVR agreement, each CVR will
entitle the holder thereof to a contingent cash payment in 2005 from Newco of
up to $4.50 if our cumulative consolidated
8
net revenues from the sale or lease of LEP Digital Press Products and
Consumables (as such terms are defined in the CVR agreement) reach specified
revenue milestones over a three-year period, which will begin after completion
of the exchange offer, as described in more detail in this prospectus. The
amount payable under each CVR increases linearly from $0 to $4.50 as the
cumulative net revenue increases from $1.0 billion to $1.6 billion during the
three-year period. No payment will be made under the CVR if the three-year
cumulative net revenue is less than or equal to $1.0 billion, which we refer to
in the CVR agreement as the lower limit. No payment in excess of $4.50 will be
made under the CVR if the three-year cumulative net revenue is greater than
$1.6 billion, which we refer to in the CVR agreement as the upper limit.
Hewlett-Packard Company will guarantee the contingent payment obligations of
Newco under the CVRs. A copy of the form of corporate guaranty by
Hewlett-Packard Company is attached to this prospectus as Annex B-2.
The $1.0 billion lower limit and the $1.6 billion upper limit for the
three-year cumulative net revenue thresholds as specified in the CVR agreement
were proposed by us based on projections made by Indigo in 2001 of what Indigo
could achieve as a stand-alone entity. Based on Indigo's then stated long-term
revenue growth projections of greater than 30% per year, we set the lower limit
threshold at $1.0 billion, which corresponds to an approximate compound annual
revenue growth rate beginning 2002 of 33%, and the upper limit threshold at
$1.6 billion, which corresponds to an approximate compound annual revenue
growth rate beginning 2002 of 64%. The $1.6 billion upper limit which we would
need to achieve in order to trigger the full $4.50 payout under the CVRs was
determined by us as a highly optimistic scenario that most likely would not be
achieved unless Indigo was correct that its stand-alone business is positioned
to achieve annual revenue growth of at least 30% beginning 2002 and we are able
to integrate successfully Indigo into our organization as well as generate
significant near term synergies to drive a much higher annual revenue growth
rate, approximately 64% beginning 2002. It is very possible that these growth
rates may not be achieved since even a 33% annual revenue growth rate is
significantly higher than that historically achieved by Indigo and that, based
on the current economic climate, Indigo now believes that the revenue growth
rate it would likely achieve as a stand-alone entity for 2002 is no more than
approximately 15-20%. See the section titled "Special Factors--Summary Indigo
Financial Projections" in this prospectus. Furthermore, pursuant to the CVR
agreement, we have retained complete freedom on how to operate the Indigo
business after the completion of the exchange offer. As a result, we are free
to decide at any time to abandon efforts to research, develop, commercialize,
market or sell any or all LEP Digital Press Products and Consumables (as such
terms are defined in the CVR agreement).
For us to achieve the revenue threshold required for there to be any payout
under the CVRs, we will have to expand the revenue base considerably with
respect to LEP Digital Press Products and Consumables (as such terms are
defined in the CVR Agreement). The following table sets forth the potential CVR
payout based on different scenarios of rates of compound annual growth in our
consolidated net revenue from the sale or lease of LEP Digital Press Products
and Consumables (as such terms are defined in the CVR Agreement). These
compound annual revenue growth rate scenarios are calculated off of a base of
$184 million, Indigo's revenues for the twelve-month period ended September 30,
2001. The CVR payment amounts shown below set forth the nominal dollar amounts
that would be payable in 2005 and have not been adjusted to reflect the net
present value of any such payments. Please see the section of this prospectus
titled "The Exchange Offer--Description of the Exchange Offer--Illustrative
Table of Fixed Offer Prices and Contingent Offer Prices and Value of Offer
Consideration" for illustrative values of the total consideration that would be
issued in connection with the exchange offer in exchange for one Indigo common
share.
9
Cumulative Revenue over the CVR Measuring Period at Various Compound Annual
Revenue Growth Rates ($ in millions, except for CVR payout amounts)
Year 1-Year 3 Payout
Cumulative Revenue Per CVR
------------------ -------
Less than $1,000 $0
$1,000-$1,600 Up to $4.50 (linear)
Greater than $1,600 $4.50
Indigo Revenue
Compounded for the CVR Measuring Period
Annual 12 months ended Revenue per year Three Year
Revenue September 30, -------------------- Cumulative CVR
Growth Rate 2001 Year 1 Year 2 Year 3 Revenue Payout
----------- --------------- ------ ------ ------ ---------- ------
0% $184 $184 $184 $184 $ 552 $0.00
5% 184 193 203 213 609 0.00
10% 184 202 223 245 670 0.00
15% 184 212 243 280 735 0.00
20% 184 221 265 318 804 0.00
25% 184 230 288 359 877 0.00
30% 184 239 311 404 954 0.00
33% 184 245 325 433 1,003 0.02
35% 184 248 335 453 1,036 0.27
40% 184 258 361 505 1,124 0.92
45% 184 267 387 561 1,215 1.61
50% 184 276 414 621 1,311 2.33
55% 184 285 442 685 1,412 3.09
60% 184 294 471 754 1,519 3.89
64% 184 302 495 812 1,609 4.50
65% 184 304 501 827 1,632 4.50
70% 184 313 532 904 1,749 4.50
There are many uncertainties associated with the CVRs, and there is no
assurance that any payment on the CVRs will be made. See the section titled
"Risk Factors--Risks Related to the Contingent Value Rights" in this prospectus
for a discussion of important factors that you should consider in connection
with the CVRs.
Irrevocable Proxies (see page 140)
Pursuant to the voting agreements further described in this prospectus,
certain major shareholders, directors and executive officers of Indigo granted
us irrevocable proxies to vote their shares of Indigo common shares at all
shareholder meetings in favor of (a) appointment of the new members of Indigo's
management board as set forth in the offer agreement, (b) amendment of Indigo's
articles of association as contemplated in the offer agreement, (c) the
post-closing restructuring, and (d) waiving any notice that may have been or
may be required relating to the exchange offer or any of the other transactions
contemplated by the offer agreement, and against certain alternative
transactions intended to undermine the transactions contemplated by the offer
agreement and subsequent restructuring. Each proxy terminates upon the earlier
of valid termination of the offer agreement or the closing of the exchange
offer.
Reasons for the Exchange Offer
Indigo (see page 59). Indigo's management board, supervisory board and
combined board believe that the transaction could result in a number of
benefits to Indigo and its affiliated and unaffiliated shareholders. Indigo's
10
reasons for entering into the offer agreement and a number of factors
considered by Indigo's management board, supervisory board and combined board
in determining whether to enter into the offer agreement are described in the
section titled "Special Factors--Indigo's Purposes and Reasons for the Exchange
Offer" in this prospectus.
HP (see page 73). We believe that the exchange offer is fair to the
affiliated and unaffiliated Indigo shareholders. Our reasons for entering into
the offer agreement and a number of factors considered by our board of
directors in determining whether to enter into the offer agreement are
described in the section titled "Special Factors--HP's Purposes and Reasons for
the Exchange Offer" in this prospectus.
Recommendation of the Indigo Boards (see page 63)
Indigo's management board, including Mr. Landa, supervisory board, and
combined board, including Mr. Landa, separately and, excluding the member
designated by us, unanimously have approved the offer agreement, determined
that the offer agreement and the exchange offer are at a price and terms that
are fair to, and in the best interests of, Indigo and its affiliated and
unaffiliated shareholders and recommend that Indigo shareholders accept the
exchange offer and tender their shares pursuant to the exchange offer.
Information about the recommendation of Indigo's management board, supervisory
board and combined board is more fully described in Indigo's
Solicitation/Recommendation Statement on Schedule 14D-9, which is being mailed
to you together with this prospectus. None of Indigo's management board,
supervisory board and combined board makes any recommendation as to whether
Indigo shareholders should elect to receive the fixed offer price or the
contingent offer price.
Opinion of Indigo Financial Advisor Regarding the Exchange Offer (see page 63)
The combined board of Indigo has received a written opinion, dated September
6, 2001, from Gleacher & Co. LLC, to the effect that, as of the date of the
opinion and based on and subject to the matters described in its opinion, the
aggregate consideration provided for in the offer agreement to be received by
all holders of Indigo common shares was fair, from a financial point of view,
to the holders of Indigo common shares, other than HP and our affiliates.
Gleacher expressed no opinion as to the fairness of either the fixed offer
price or the contingent offer price separately. The Gleacher fairness
determination addresses only the fairness, from a financial point of view, of
the aggregate consideration to be offered to the holders of Indigo common
shares as opposed to the actual consideration that could be received by an
individual Indigo shareholder.
The full text of Gleacher's opinion is attached to this prospectus as Annex
D, and we urge you to read this opinion in its entirety. Gleacher's opinion is
addressed only to Indigo's combined board and does not constitute a
recommendation to any holder of Indigo common shares regarding whether that
holder should tender common shares pursuant to the exchange offer.
The full text of Gleacher's presentations to the Indigo boards on September
5, 2001 has been included as exhibits (c)(iii), (c)(iv) and (c)(v) to the
Transaction Statement on Schedule 13E-3 filed by HP, Indigo and Benzion Landa
in connection with the exchange offer.
Indigo Directors and Executive Officers Have Interests in the Exchange Offer
(see page 71)
When you consider Indigo's boards' recommendation that Indigo shareholders
tender their shares in the exchange offer, you should be aware that some Indigo
officers and directors may have interests in the exchange offer that may be
different from, or in addition to, those of Indigo's affiliated and
unaffiliated shareholders generally. These interests include a cash payment of
$2,500,000 to Mr. Landa in settlement of payments due to him under his
employment relationship with Indigo, which will terminate upon the completion
of the exchange offer, severance and retention payments to Indigo's three other
executive officers of up to $2,135,000 in the
11
aggregate, and the continued employment by us of these executive officers.
These interests are described in more detail in the section titled "Special
Factors--Interests of Indigo Directors and Executive Officers in the Exchange
Offer" in this prospectus, as well as Indigo's Solicitation/Recommendation
Statement on Schedule 14D-9, which is being mailed to you together with this
prospectus.
Indigo's Management and Supervisory Boards Following the Exchange Offer (see
page 123)
Pursuant to a resolution to be passed at an extraordinary general meeting of
its shareholders prior to the expiration date of the exchange offer, Indigo
will accept the resignation from its management board and supervisory board of
the existing members thereof and the shareholders will appoint new members to
the management board as designated by us. The new members designated by us for
appointment to the management board will be Charles N. Charnas, J.C.A. van
Diemen and R.E.J. De-Boer. Mr. Charnas is employed by HP as its Assistant
Secretary and Senior Managing Counsel, while Messrs. De-Boer and van Diemen are
employed by our Netherlands subsidiary as Legal Counsel and Tax Manager,
respectively. These resignations and appointments will be effective as of, and
conditional upon the occurrence of, the closing of the exchange offer. We do
not intend to maintain Indigo's supervisory board after the completion of the
exchange offer.
Extension, Termination, Waiver and Amendment of the Exchange Offer (see page
109)
We expressly reserve the right, subject to the provisions of the offer
agreement, to extend the period of time during which our exchange offer remains
open, and we can do so by giving oral or written notice to the exchange agent.
We are not making any assurances that we will exercise our right to extend the
exchange offer, although, subject to the terms of the offer agreement, we have
agreed to extend the exchange offer for successive extension periods not in
excess of ten business days per extension under specified circumstances. During
an extension, all Indigo common shares previously tendered and not properly
withdrawn will remain subject to the exchange offer, subject to your right to
withdraw your Indigo common shares.
We reserve the right to make any changes in the terms and conditions of the
exchange offer by giving oral or written notice of the changes to the exchange
agent. However, without the prior written consent of Indigo, we cannot:
. decrease the offer price;
. change the form or combination of consideration to be paid in the
exchange offer;
. reduce the number of Indigo common shares to be purchased in the
exchange offer;
. amend the conditions to the exchange offer to broaden the scope of those
conditions, add any additional conditions, or otherwise amend any other
material terms of the exchange offer in a manner materially adverse to
Indigo shareholders;
. extend the exchange offer, except as described below and except that we
may extend the exchange offer without Indigo's consent (1) if at the
scheduled expiration date of the exchange offer any of the conditions to
the exchange offer have not been satisfied or waived, or (2) for any
period required by any rule, regulation, interpretation or position of
the Securities and Exchange Commission or its staff; or
. amend the minimum condition that Indigo common shares that, together
with Indigo common shares already held by HP and its affiliates,
represent at least 95% of Indigo's common shares be tendered into the
exchange offer (including Indigo common shares issuable upon exercise of
certain warrants), except as described below.
We expressly reserve the right to and may unilaterally amend or waive the
minimum condition to reduce the percentage of outstanding Indigo shares
required to be validly tendered in accordance with the terms of the
12
exchange offer, provided that we will extend the exchange offer for a period of
not fewer than ten business days after any such amendment or waiver.
We will follow any extension, termination, amendment or delay, as promptly
as practicable, with a public announcement. Any announcement about an extension
will be issued no later than 9:00 a.m., New York City time, on the next
business day after the previously scheduled expiration date. Subject to
applicable law, including Rules 14d-4(d) and 14d-6(c) under the Securities
Exchange Act of 1934, as amended, which require that any material change in the
information published, sent or given to shareholders in connection with the
exchange offer be promptly sent to shareholders in a manner reasonably designed
to inform shareholders of the change, and without limiting the manner in which
we may choose to make any public announcement, we assume no obligation to
publish, advertise or otherwise communicate the public announcement other than
by making a release to the Dow Jones News Service.
What is Needed to Complete the Exchange Offer (see page 129)
Our obligation to accept Indigo common shares for exchange in the exchange
offer is subject to the satisfaction of a number of conditions, which may, in
some instances, be waived. These conditions include:
. the tender into the exchange offer of Indigo common shares that,
together with Indigo common shares already held by us and our
affiliates, represent at least 95% of Indigo's common shares (including
Indigo common shares issuable upon exercise of certain warrants);
. the expiration of all waiting periods under United States antitrust law
and receipt of all other foreign antitrust approvals;
. the receipt of the other regulatory approvals specified in Annex I of
the offer agreement, including the approval of (1) the Office of the
Chief Scientist of the Israeli Ministry of Industry and Trade and
(2) the Investment Center of the Israeli Ministry of Industry and Trade;
. the absence of specified events including (1) a general suspension of
trading on the New York Stock Exchange, (2) a commencement of a war,
armed hostilities or other international or national calamity directly
involving the United States or (3) a commencement of a war, escalation
of armed hostilities or a general mobilization or other international or
national calamity directly involving Israel that is or is reasonably
likely to be materially adverse to Indigo's ability to conduct business
in Israel;
. the accuracy in all material respects of Indigo's representations and
warranties in the offer agreement, except in some cases as does not, and
could not reasonably be expected to, constitute a material adverse
effect on Indigo; and
. Indigo's compliance in all material respects with its covenants in the
offer agreement.
HP has not waived any of the conditions to the exchange offer. See the
discussion below for a description of progress to date with respect to the
regulatory conditions to the exchange offer.
We Have Not Yet Obtained All Required Regulatory Approvals to Complete the
Exchange Offer (see page 115)
The exchange offer is subject to antitrust laws. We and Indigo have made the
required filings under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, with the United States Department of Justice and the Federal
Trade Commission, and the waiting period under the Hart-Scott-Rodino Act was
terminated on October 1, 2001. We and Indigo are also required to make
antitrust filings in Austria, Brazil, Germany, Israel, Italy and Portugal. We
and Indigo have made all these required foreign antitrust filings. The
applicable antitrust clearances in Austria, Germany and Italy have been
granted. However, we have not yet
13
received antitrust clearance in Brazil, Israel or Portugal. We and Indigo are
not permitted (except with respect to Brazil) to complete the exchange offer
until the applicable waiting periods associated with these filings have expired
or been terminated and required approvals are obtained. In addition, the
reviewing agencies or governments, states or private persons may challenge the
exchange offer at any time before or after its completion.
Completion of the exchange offer also may be subject to the Israeli
Securities Law, 1968 and subject to compliance with the rules and regulations
of the Office of the Chief Scientist of Israel's Ministry of Industry and
Trade, the Investment Center of Israel's Ministry of Industry and Trade and the
Israeli Income Tax Commissioner, all of which may require approvals, consents
or pre-rulings. Such clearances are more fully described in the section titled
"The Exchange Offer--Regulatory Filings and Approvals Required to Complete the
Exchange Offer" in this prospectus.
Procedure for Tendering (see page 112)
For you to tender Indigo common shares validly pursuant to the exchange
offer, before the expiration of the exchange offer, a properly completed and
duly executed election form/letter of transmittal or manually executed
facsimile of those documents, along with any required signature guarantees, or
an agent's message in connection with a book-entry transfer, and any other
required documents, must be transmitted to and received by our exchange agent
at the address on the back cover of this prospectus. In addition, certificates
for Indigo common shares must be tendered pursuant to the procedures for
book-entry tender before the expiration date of the exchange offer.
Withdrawal Rights (see page 111)
Your tender of Indigo common shares pursuant to the exchange offer is
irrevocable, except that you may withdraw Indigo common shares tendered
pursuant to the exchange offer at any time prior to the expiration date of the
exchange offer, as it may be extended.
Exchange of Indigo Common Shares; Delivery of Shares of HP Common Stock and
CVRs (see page 110)
If the terms and conditions of the exchange offer, including the terms and
conditions of any extension or amendment, are satisfied, we are required to
accept for exchange and to deliver shares of HP common stock and, as
applicable, CVRs in exchange for Indigo common shares validly tendered and not
properly withdrawn promptly after the expiration date of the exchange offer.
Indigo is Prohibited from Considering Other Offers (see page 127)
Indigo has agreed not to solicit, initiate, encourage or discuss any
proposal for a business combination or other similar transaction with any party
other than us prior to the completion of the exchange offer or the termination
of the offer agreement.
We and Indigo May Terminate the Offer Agreement (see page 133)
We and Indigo may agree jointly to terminate the offer agreement at any
time. In addition, either we or Indigo may terminate the offer agreement if:
. the exchange offer expires, or is terminated in accordance with the
terms of the offer agreement, without our having accepted for exchange
any Indigo common shares;
. the exchange offer has not been completed by August 30, 2002;
14
. any applicable law or regulation makes completion of the exchange offer
illegal or otherwise prohibited; or
. a final, non-appealable order of a court or other governmental body
prohibits the completion of the exchange offer.
We also may terminate the offer agreement if:
. any of Indigo's boards approves or recommends to Indigo shareholders any
other acquisition proposal;
. any of Indigo's boards withholds, withdraws, amends or modifies its
recommendation in favor of the exchange offer;
. Indigo fails to include its boards' recommendation in favor of the
exchange offer in this prospectus or in Indigo's
Solicitation/Recommendation Statement on Schedule 14D-9, which is being
mailed to you together with this prospectus;
. Indigo breaches in any material respect the provision in the offer
agreement that prohibits Indigo from considering other acquisition
proposals;
. any of the Indigo shareholders who are party to the tender and option
agreements, or its affiliates, breaches the provisions of the tender and
option agreements or the voting agreements with us to which it is also a
party; or
. a person unaffiliated with us commences a tender or exchange offer for
Indigo common shares and Indigo does not send to its shareholders within
ten business days a statement disclosing that Indigo recommends
rejection of such tender or exchange offer and reaffirming its boards'
recommendation in favor of our exchange offer.
We also may terminate the offer agreement if Indigo breaches its
representations, warranties or covenants in the offer agreement such that the
conditions to our obligation to complete the exchange offer regarding
representations, warranties or covenants would not be satisfied. However, if
Indigo's breach is curable through its commercially reasonable efforts, we may
not terminate the offer agreement based on Indigo's breach until the earlier of
(1) thirty days after we deliver written notice of such breach to Indigo, or
(2) Indigo's ceasing to use its commercially reasonable efforts to cure such
breach.
Indigo also may terminate the offer agreement if (1) we materially breach
our covenants in the offer agreement, or (2) we breach our representations and
warranties in the offer agreement and such breach would reasonably be expected
to have a material adverse effect on us. However, if our breach is curable
through our commercially reasonable efforts, Indigo may not terminate the offer
agreement based on our breach until the earlier of (1) thirty days after Indigo
delivers a written notice of such breach to us, or (2) our ceasing to use our
commercially reasonable efforts to cure such breach.
We or Indigo May Be Required to Pay a Termination Fee (see page 134)
The offer agreement requires Indigo to pay us a termination fee of $27
million in cash and to reimburse us for up to $2 million in our expenses if we
terminate the offer agreement because of the occurrence of a triggering event,
which includes the Indigo boards' approval or recommendation of any other
acquisition proposal, the withholding, withdrawal, amendment or modification of
the Indigo boards' recommendation in favor of the exchange offer or failure to
recommend rejection of any other third party tender or exchange offer. See the
section titled "The Offer Agreement--Termination of the Offer
Agreement--Termination by HP" for a fuller definition of a triggering event.
15
The offer agreement requires Indigo to reimburse us for up to $2 million of
our expenses related to the exchange offer if we terminate the offer agreement
because Indigo breached any of its covenants or agreements in the offer
agreement or any of Indigo's representations or warranties were untrue or have
become untrue such that we would not be required to complete the exchange offer
pursuant to the terms of the exchange offer.
The offer agreement requires us to reimburse Indigo for up to $2 million of
its expenses if the offer agreement is terminated by Indigo because we breached
any of our covenants or agreements in the offer agreement or any of our
representations or warranties were untrue or have become untrue in a material
manner.
The Exchange Offer is Taxable for United States Federal Income Tax Purposes
(see page 78)
The receipt of shares of HP common stock and CVRs in exchange for Indigo
common shares pursuant to the exchange offer will be a taxable transaction for
United States federal income tax purposes. Each Indigo shareholder receiving
only HP common stock and cash instead of fractional shares will recognize gain
or loss equal to the difference between (1) the sum of the fair market value of
the HP common stock and the cash received instead of fractional shares, and (2)
the shareholder's adjusted tax basis in such shares. In the case of Indigo
shareholders receiving HP common stock and CVRs, unless the "open transaction"
method of reporting applies, the shareholder's gain or loss will be computed as
described above taking into account the fair market value of the CVRs on the
date of the exchange, and the shareholder's tax basis in the CVRs will equal
such fair market value. Gain or loss must be calculated separately for each
block of Indigo common shares acquired at the same cost in a single
transaction. Assuming that such shares constitute capital assets in the hands
of the Indigo shareholder, such gain or loss will be capital gain or loss and
will be long-term capital gain or loss if the shareholder's holding period is
more than one year.
The treatment of a payment in the future to a holder of a CVR is not
entirely clear, but should be treated as a payment under a contract for the
sale or exchange of Indigo common shares to which Section 483 of the Internal
Revenue Code of 1986, as amended, which is referred to in this prospectus as
the Internal Revenue Code, applies. Under Section 483, a portion of the payment
pursuant to the CVRs will be treated as interest, which will be ordinary income
to the holder of the CVRs when the payment is received, and the remainder will
be treated as sales proceeds from the exchange of the CVRs. Assuming open
transaction treatment does not apply, a shareholder will recognize gain in the
amount by which the payment, other than the portion characterized as interest,
exceeds the shareholder's tax basis in the CVRs. In such event, if no payment
is made or the payment is less than the shareholder's tax basis in the CVRs,
the shareholder will recognize a loss. The gain or loss will be long-term
capital gain or loss.
In the event that the CVRs are treated as debt instruments for United States
federal income tax purposes, a holder would be required to include over the
term of the CVR an amount in income as interest, based on the yield of
"comparable" debt instruments, in advance of the receipt of any payment,
regardless of the holder's method of accounting.
Indigo shareholders may be subject to backup withholding at the rate of 30%
with respect to cash received instead of fractional shares pursuant to the
exchange offer or upon a payment under the CVRs unless the shareholder provides
a correct taxpayer identification number in the manner required or certifies
that it is not subject to backup withholding or is an "exempt recipient." The
rate of withholding is scheduled to be reduced over time to 29% in 2005. Backup
withholding is not an additional tax, but rather may be credited against the
taxpayer's tax liability for the year.
Indigo shareholders are urged to consult their own tax advisors regarding
the United States federal, state, local, foreign, and other tax consequences of
the exchange offer in light of their particular circumstances.
16
Accounting Treatment of the Exchange Offer (see page 114)
We will account for the exchange offer under the purchase method of
accounting for business combinations in accordance with United States generally
accepted accounting principles.
We Will List Shares of HP Common Stock on the New York Stock Exchange and the
Pacific Exchange (see page 119)
We will use our commercially reasonable efforts to cause the shares of HP
common stock issuable or required to be reserved for issuance in connection
with the exchange offer to be listed on the New York Stock Exchange and the
Pacific Exchange, effective as of the closing time of the exchange offer,
subject to official notice of issuance.
Indigo Appraisal Rights (see page 117)
Dutch law does not recognize the concept of appraisal or dissenters' rights,
and, accordingly, Indigo shareholders have no appraisal rights for their common
shares under Dutch law in connection with the exchange offer.
17
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF HP
The table below presents a summary of selected historical consolidated
financial data with respect to HP as of the dates and for the periods
indicated. The historical consolidated statements of earnings data presented
below for the fiscal years ended October 31, 2001, 2000 and 1999 and the
historical consolidated balance sheets data as of October 31, 2001 and 2000
have been derived from HP's historical consolidated financial statements, which
are incorporated by reference into this prospectus. The historical consolidated
statements of earnings data presented below for the fiscal years ended October
31, 1998 and 1997 and the historical consolidated balance sheets data as of
October 31, 1999, 1998 and 1997 have been derived from HP's historical
consolidated financial statements, which are not incorporated by reference into
this prospectus.
It is important for you to read the following summary selected historical
consolidated financial data together with the consolidated financial statements
and accompanying notes contained in HP's Annual Report on Form 10-K, as amended
on January 30, 2002, for its fiscal year ended October 31, 2001 as filed with
the Securities and Exchange Commission, as well as the sections of HP's Annual
Report on Form 10-K, as amended on January 30, 2002, titled "Management's
Discussion and Analysis of Financial Condition and Results of Operations," all
of which are incorporated by reference into this prospectus.
18
HEWLETT-PACKARD COMPANY AND SUBSIDIARIES
Summary Selected Historical Consolidated Financial Data/(1)(2)/
(In millions, except per share amounts)
As of or For the Year Ended October 31,
---------------------------------------
2001 2000 1999 1998 1997
------- ------- ------- ------- -------
Historical Consolidated Statements of Earnings Data:
Net revenue.......................................... $45,226 $48,870 $42,371 $39,330 $35,358
Earnings from operations/(3)/........................ 1,439 4,025 3,818 3,456 3,476
Net earnings from continuing operations before
extraordinary item and cumulative effect of change
in accounting principle/(4)(5)/.................... 624 3,561 3,104 2,678 2,515
Net earnings per share from continuing operations
before extraordinary item and cumulative effect of
change in accounting principle:/(4)(5)(6)/
Basic............................................ $ 0.32 $ 1.80 $ 1.54 $ 1.29 $ 1.23
Diluted.......................................... 0.32 1.73 1.49 1.26 1.19
Cash dividends declared per share/(6)/............... 0.32 0.32 0.32 0.30 0.26
Historical Consolidated Balance Sheets Data:
Total assets/(1)/.................................... $32,584 $34,009 $35,297 $31,708 $29,852
Long-term debt....................................... 3,729 3,402 1,764 2,063 3,158
--------
(1) HP's consolidated financial statements and notes for all periods present
the businesses of Agilent Technologies, Inc. as a discontinued operation
through the spin-off date of June 2, 2000. Accordingly, total assets
includes net assets of discontinued operations of $3,533 million at October
31, 1999, $3,084 million at October 31, 1998 and $3,171 million at October
31, 1997.
(2) Certain reclassifications have been made to prior year balances in order to
conform to the current year presentation.
(3) Earnings from operations includes restructuring charges of $384 million in
fiscal 2001, $102 million in fiscal 2000 and $122 million in fiscal 1998.
(4) Net earnings and net earnings per share from continuing operations before
extraordinary item and cumulative effect of change in accounting principle
include the following items before related tax effects: $384 million of
restructuring charges, $471 million of impairment losses on investments, a
$400 million charge for litigation settlement and a $131 million loss on
divestiture in fiscal 2001; $102 million of restructuring charges and $203
million of gains from divestitures in fiscal 2000; and $122 million of
restructuring charges in fiscal 1998.
(5) HP adopted Staff Accounting Bulletin No. 101, "Revenue Recognition in
Financial Statements" in the fourth quarter of fiscal year 2001,
retroactive to November 1, 2000.
(6) All per-share amounts reflect the retroactive effects of the two-for-one
stock split in the form of a stock dividend effective October 27, 2000.
19
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF COMPAQ
We have included in this prospectus the summary selected historical
consolidated financial data of Compaq set forth below for informational
purposes because we are required to include unaudited pro forma condensed
combined consolidated financial data after giving effect to the Compaq merger
as a purchase of Compaq by HP using the purchase method of accounting. However,
you should be aware that the exchange offer is not conditioned upon the
completion of the Compaq merger. If we do not complete the Compaq merger, the
HP stock that you receive in the exchange offer will not reflect any actual or
anticipated interest in Compaq, its operating results or its assets and
liabilities.
The table below presents a summary of selected historical consolidated
financial data with respect to Compaq as of the dates and for the periods
indicated. The historical consolidated statements of income data presented
below for the fiscal years ended December 31, 2001, 2000 and 1999 and the
historical consolidated balance sheets data as of December 31, 2001 and 2000
have been derived from Compaq's historical consolidated financial statements,
which are incorporated by reference into this prospectus. The historical
consolidated statements of income data presented below for the fiscal years
ended December 31, 1998 and 1997 and the historical consolidated balance sheets
data as of December 31, 1999, 1998 and 1997 have been derived from Compaq's
historical consolidated financial statements, which are not incorporated by
reference into this prospectus.
It is important for you to read the following summary selected historical
consolidated financial data together with the consolidated financial statements
and accompanying notes contained in Compaq's Annual Report on Form 10-K for its
fiscal year ended December 31, 2001 as filed with the Securities and Exchange
Commission on January 30, 2002, as well as the sections of Compaq's Annual
Report on Form 10-K titled "Management's Discussion and Analysis of Financial
Condition and Results of Operations," all of which are incorporated by
reference into this prospectus.
20
COMPAQ COMPUTER CORPORATION
Summary Selected Historical Consolidated Financial Data
(In millions, except per share amounts)
As of or For the Year Ended December 31,
------------------------------------------
2001 2000 1999 1998/(1)/ 1997
------- ------- ------- -------- -------
Historical Consolidated Statements of Income Data:
Total revenue/(2)/........................................... $33,554 $42,222 $38,447 $31,169 $24,584
Income (loss) before income taxes/(3)(4)(5)/................. (773) 875 934 (2,662) 2,758
Income (loss) before cumulative effect of accounting
change..................................................... (563) 595 569 (2,743) 1,855
Net income (loss)/(6)/....................................... $ (785) $ 569 $ 569 $(2,743) $ 1,855
Earnings (loss) per common share:
Basic:
Before cumulative effect of accounting change............ $ (0.34) $ 0.35 $ 0.35 $ (1.71) $ 1.23
Cumulative effect of accounting change, net of tax....... (0.13) (0.02) -- -- --
------- ------- ------- ------- -------
$ (0.47) $ 0.33 $ 0.35 $ (1.71) $ 1.23
======= ======= ======= ======= =======
Diluted:
Before cumulative effect of accounting change............ $ (0.34) $ 0.34 $ 0.34 $ (1.71) $ 1.19
Cumulative effect of accounting change, net of tax....... (0.13) (0.01) -- -- --
------- ------- ------- ------- -------
$ (0.47) $ 0.33 $ 0.34 $ (1.71) $ 1.19
======= ======= ======= ======= =======
Shares used in computing earnings (loss) per common share:
Basic.................................................... 1,688 1,702 1,693 1,608 1,505
Diluted.................................................. 1,688 1,742 1,735 1,608 1,564
Cash dividends declared per common share..................... $ 0.10 $ 0.10 $ 0.085 $ 0.065 $ 0.015
Historical Consolidated Balance Sheets Data:
Current assets............................................... $13,278 $15,111 $13,849 $15,167 $12,017
Total assets................................................. 23,689 24,856 27,277 23,051 14,631
Current liabilities.......................................... 11,133 11,549 11,838 10,733 5,202
Long-term obligations........................................ 600 575 -- 422 --
Stockholders' equity......................................... 11,117 12,080 14,834 11,351 9,429
--------
(1) 1998 results reflect the acquisition of Digital Equipment Corporation
(Digital) in June 1998.
(2) 2000 and 1999 reflect reclassifications between product revenue and other
income and expense to reflect the adoption of Emerging Issues Task Force
Issue 01-9, "Accounting for Consideration Given by a Vendor to a Customer
or a Reseller of the Vendor's Products" (EITF 01-9).
(3) Includes a $742 million charge for restructuring and related charges in
2001; an $86 million release of restructuring reserves in fourth quarter
2000; an $868 million charge for restructuring and related charges in 1999;
a $393 million charge for restructuring and asset impairments in 1998 in
connection with the Digital acquisition and the closing of certain Compaq
facilities.
(4) Includes non-recurring, non-tax-deductible charges associated with
purchased in-process technology of $3.2 billion in connection with the
Digital acquisition in 1998, and $208 million in connection with
acquisitions in 1997.
(5) Includes a $613 million charge for impairment of investments and related
assets in 2001; a $1.8 billion charge for impairment of investments in
2000; and a $1.2 billion gain on the sale of an 81.5 percent interest in
AltaVista Company in 1999.
(6) Includes a $222 million cumulative effect in 2001 for the adoption of EITF
01-9 and a $26 million cumulative effect in 2000 for the adoption of
Securities and Exchange Commission Staff Accounting Bulletin No. 101,
"Revenue Recognition in Financial Statements," as amended.
21
SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED
CONSOLIDATED FINANCIAL DATA OF HP AND COMPAQ
We have included in this prospectus the selected unaudited pro forma
condensed combined consolidated financial data set forth below after giving
effect to the Compaq merger as a purchase of Compaq by HP using the purchase
method of accounting, as required under the rules of the Securities and
Exchange Commission. Under these rules, the selected unaudited pro forma
condensed combined consolidated financial data set forth below is not required
to, and does not, give effect to the exchange offer. You should be aware that
the exchange offer is not conditioned upon the completion of the Compaq merger.
If we do not complete the Compaq merger, the HP stock you receive in the
exchange offer will not reflect any actual or anticipated interest in Compaq,
its operating results or its assets and liabilities.
The following selected unaudited pro forma condensed combined consolidated
financial data was prepared using the purchase method of accounting. Due to
different fiscal period ends for HP and Compaq, the unaudited pro forma
condensed combined consolidated statement of earnings data combines the
historical consolidated statements of earnings data of HP for the year ended
October 31, 2001 with Compaq's historical consolidated statements of income
data for the twelve months ended September 30, 2001, giving effect to the
merger as if it had occurred on November 1, 2000. The unaudited pro forma
condensed combined consolidated balance sheet data combines HP's historical
consolidated balance sheet data as of October 31, 2001 with Compaq's historical
consolidated balance sheet data as of September 30, 2001, giving effect to the
merger as if it had occurred as of October 31, 2001.
The selected unaudited pro forma condensed combined consolidated financial
data is based on estimates and assumptions which are preliminary. This data is
presented for informational purposes only and is not intended to represent or
be indicative of the consolidated results of operations or financial condition
of HP that would have been reported had the merger been completed as of the
dates presented, and should not be taken as representative of future
consolidated results of operations or financial condition of HP.
This selected unaudited pro forma condensed combined consolidated financial
data should be read in conjunction with the summary selected historical
consolidated financial data of each of HP and Compaq, respectively, contained
elsewhere in this prospectus, the unaudited pro forma condensed combined
consolidated financial statements and accompanying notes included in HP's
current report on Form 8-K filed with the Securities and Exchange Commission on
February 14, 2002 incorporated by reference into this prospectus, and the
separate historical consolidated financial statements and accompanying notes of
HP and Compaq incorporated by reference into this prospectus. See the section
titled "Where You Can Find More Information" beginning on page 166 of this
prospectus.
22
HP AND COMPAQ
Selected Unaudited Pro Forma Condensed Combined Consolidated Financial Data/(1)/
(In millions, except per share amounts)
Year Ended
October 31, 2001
----------------
Unaudited Pro Forma Condensed Combined Consolidated Statements of Earnings Data:
Net revenue................................................................... $81,733
Earnings from operations...................................................... 1,167
Net earnings (loss) from continuing operations................................ (1,026)
Net earnings (loss) per share from continuing operations:
Basic..................................................................... $ (0.34)
Diluted................................................................... $ (0.34)
Average number of shares and share equivalents:
Basic..................................................................... 3,004
Diluted................................................................... 3,004
As of
October 31, 2001
----------------
Unaudited Pro Forma Condensed Combined Consolidated Balance Sheet Data:
Cash, cash equivalents and short-term investments............................. $ 8,276
Working capital............................................................... 11,347
Total assets.................................................................. 69,188
Long-term debt................................................................ 4,329
Total stockholders' equity.................................................... 36,803
--------
(1) See the unaudited pro forma condensed combined consolidated financial
statements and accompanying notes included in HP's current report on Form
8-K filed with the Securities and Exchange Commission on February 14, 2002
and incorporated herein by reference.
23
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA OF INDIGO
The table below presents a summary of selected historical consolidated
financial data with respect to Indigo as of the dates and for the periods
indicated. The historical consolidated statements of operations data presented
below for the fiscal years ended December 31, 2000, 1999 and 1998 and the
historical consolidated balance sheets data as of December 31, 2000 and 1999
have been derived from Indigo's historical consolidated financial statements,
which are incorporated by reference into this prospectus. The historical
consolidated statements of operations data presented below for the fiscal years
ended December 31, 1997 and 1996 and the historical consolidated balance sheets
data as of December 31, 1998, 1997 and 1996 have been derived from Indigo's
historical consolidated financial statements, which are not incorporated by
reference into this prospectus. The selected historical consolidated financial
data as of and for the nine months ended September 30, 2001 and 2000 has been
derived from Indigo's unaudited historical condensed consolidated interim
financial statements which are included elsewhere in this prospectus and
reflect, in the opinion of Indigo's management, all adjustments, consisting of
only normal recurring adjustments, which Indigo considers necessary for a fair
presentation of the results of operations for those periods and financial
position at those dates.
It is important for you to read the following summary selected historical
consolidated financial data together with the consolidated financial statements
and accompanying notes contained in Indigo's Annual Report on Form 20-F for its
fiscal year ended December 31, 2000 as filed with the Securities and Exchange
Commission, which are incorporated by reference into this prospectus and the
condensed consolidated interim financial statements and accompanying notes
which are included elsewhere in this prospectus as well as the section titled
"Indigo Management's Discussion and Analysis of Financial Condition and Results
of Operations" also included elsewhere in this prospectus.
24
INDIGO N.V.
SUMMARY SELECTED HISTORICAL CONSOLIDATED FINANCIAL DATA
(In thousands, except per share amounts)
As of or For the
Nine Months Ended As of or For the
September 30, Year Ended December 31,
------------------ ------------------------------------------------
2001 2000 2000 1999 1998 1997 1996
-------- -------- -------- -------- -------- -------- --------
(unaudited)
Historical Consolidated Statements of Operations Data:
Revenues:
Equipment and post-sales revenue.................... $134,736 $115,386 $164,719 $140,704 $137,037 $105,493 $100,424
License fees, royalties and other................... -- 62 89 4,328 10,335 1,357 3,449
-------- -------- -------- -------- -------- -------- --------
Total revenues.................................... 134,736 115,448 164,808 145,032 147,372 106,850 103,873
Costs and expenses:
Equipment and post-sales cost of goods sold......... 80,562 61,754 83,658 74,644 71,037 69,590 77,209
Research and development, net....................... 13,044 14,487 19,534 14,160 16,682 15,314 13,396
Selling, general and administrative/(3)/............ 55,910 51,111 71,927 57,596 61,549 62,734 72, 940
Restructuring charges............................... -- -- -- -- 2,764 3,565 3,514
Litigation settlement............................... -- -- -- -- (1,200) -- 6,770
-------- -------- -------- -------- -------- -------- --------
Total costs and expenses.......................... 149,516 127,352 175,119 146,400 150,832 151,203 173,829
-------- -------- -------- -------- -------- -------- --------
Operating loss......................................... (14,780) (11,904) (10,311) (1,368) (3,460) (44,353) (69,956)
Other income (expenses)
Interest expenses................................... (920) (1,551) (1,240) (1,671) (2,641) (2,508) (4,068)
Interest income and other income, net............... 3,370 1,757 3,013 2,406 3,458 3,732 3,817
-------- -------- -------- -------- -------- -------- --------
Loss before provision for income taxes................. (12,330) (11,698) (8,538) (633) (2,643) (43,129) (70,207)
Provision for income taxes............................. 135 828 1,097 739 2,428 1,961 3,602
-------- -------- -------- -------- -------- -------- --------
Net loss before cumulative effect of an accounting
change, net/(2)/...................................... (12,465) (12,526) (9,635) (1,372) (5,071) (45,090) (73,809)
Cumulative effect of an accounting change, net as of
beginning of the year/(2)/............................ -- (1,935) (1,935) -- -- -- --
-------- -------- -------- -------- -------- -------- --------
Net loss before dividend requirements.................. (12,465) (14,461) (11,570) (1,372) (5,071) (45,090) (73,809)
Dividend on Convertible Preferred Shares
Current/(1)/........................................ -- (8,793) (8,793) (11,098) (10,961) (11,383) (5,472)
Inducement regarding conversion of Series A Preferred
Shares/(1)/........................................... -- (58,685) (58,685) -- -- -- --
-------- -------- -------- -------- -------- -------- --------
Net loss applicable to common shares outstanding....... $(12,465) $(81,939) $(79,048) $(12,470) $(16,032) $(56,473) $(79,281)
======== ======== ======== ======== ======== ======== ========
Basic and diluted weighted average number of common
shares outstanding.................................... 110,418 78,816 85,298 77,282 71,822 63,924 53,712
======== ======== ======== ======== ======== ======== ========
Basic and diluted loss per common share before
cumulative effect of an accounting change, net........ $ (0.11) $ (1.01) $ (0.90) $ (0.16) $ (0.22) $ (0.88) $ (1.48)
Basic and diluted loss per common share of cumulative
effect of an accounting change, net................... -- (0.03) (0.03) -- -- -- --
-------- -------- -------- -------- -------- -------- --------
Basic and diluted loss per common share after
cumulative effect of an accounting change, net........ $ (0.11) $ (1.04) $ (0.93) $ (0.16) $ (0.22) $ (0.88) $ (1.48)
======== ======== ======== ======== ======== ======== ========
Pro forma amounts assuming the accounting change is
applied retroactively:
Net loss applicable to common shares
outstanding/(4)/................................... $(80,005) $(77,113) $(11,896) $(16,769)
======== ======== ======== ========
Basic and diluted loss per common share/(4)/........ $ (1.02) $ (0.90) $ (0.15) $ (0.23)
======== ======== ======== ========
Historical Consolidated Balance Sheets Data:
Working capital........................................ $ 78,711 $ 14,368 $108,551 $ 46,108 $ 47,142 $ 25,462 $ 33,213
Total assets........................................... 201,725 127,443 216,870 140,638 125,859 122,207 163,666
Short-term debt........................................ 18,374 15,489 5,428 17,191 -- 5,607 35,950
Long-term debt......................................... -- -- -- -- -- -- --
Total shareholders' equity/(1)/........................ 107,534 26,869 124,397 57,835 57,086 44,292 56,993
--------
(1) In 2000, Indigo granted stock dividends to the holders of the Series A
preferred shares in a total amount of $104,867, of which $46,182 was in
respect of accumulated dividends and $58,685 in respect of the inducement.
(2) Pursuant to Securities and Exchange Commission Staff Accounting Bulletin
No. 101, "Revenue Recognition in Financial Statements," Indigo has
implemented a change in its revenue recognition policy in the year ended
December 31, 2000.
(3) Royalty expenses in the annual periods presented are included within
selling, general and administrative expenses. Royalty expenses in the
nine month period ended September 30, 2000 and 2001 are included in cost of
goods sold.
The amounts for the nine month period ended September 30, 2001 and 2000
were $3,050,000 and $2,308,000, respectively, and for the five years ended
December 31, 2000, 1999, 1998, 1997 and 1996 were $3,029,000, $2,711,000,
$2,243,000, $980,000 and $1,287,000, respectively.
Indigo will classify royalty expenses in its 2001 financial statements
within cost of goods sold and will reclassify comparative prior period
amounts at that time.
(4) The pro forma amounts for the years ending December 31, 1997 and 1996 were
not calculated.
25
COMPARATIVE HISTORICAL AND PRO FORMA PER SHARE DATA
The following table presents comparative historical per share data regarding
the net earnings (loss), book value and dividends of each of HP, Indigo and
Compaq and unaudited combined pro forma per share data of HP and Indigo after
giving effect to the exchange offer as a purchase of Indigo by HP assuming the
exchange offer had been completed on November 1, 2000. The following data
assumes (1) that 0.3345 of a share of HP common stock will be issued in
exchange for each Indigo common share that receives the fixed offer price, (2)
that 0.2676 of a share of HP common stock will be issued in exchange for each
Indigo common share that receives the contingent offer price and (3) the
assumption of Indigo outstanding options based upon the fixed offer price
exchange ratio. The fixed offer price and contingent offer price exchange
ratios were based on HP's closing market price of $22.42 per share of its
common stock on January 16, 2002. The actual exchange ratios will be based on
the average sales price of HP common stock during the twenty consecutive
trading days ending on the trading day on which the third most recent closing
of the U.S. markets prior to the expiration of the exchange offer occurs.
The following table also presents unaudited combined pro forma per share
data of HP, Compaq and Indigo after giving effect to the Compaq merger as a
purchase of Compaq by HP and after giving effect to the exchange offer as a
purchase of Indigo by HP assuming both of these transactions had been completed
on November 1, 2000. The following data for HP, Compaq and Indigo further
assumes that 0.6325 of a share of HP common stock will be issued in exchange
for each share of Compaq common stock in connection with the Compaq merger and
the assumption of Compaq options based upon the same exchange ratio in addition
to the issuance of HP common stock and assumption of options in connection with
the Indigo exchange offer based on the exchange ratios discussed above. This
data has been derived from and should be read in conjunction with the summary
selected historical consolidated financial data contained elsewhere in this
prospectus, and the separate historical consolidated financial statements and
accompanying notes of each of HP, Indigo and Compaq, included in, or
incorporated by reference into, this prospectus. The unaudited combined pro
forma per share data is presented for informational purposes only and is not
necessarily an indication of the consolidated results of operations or
financial condition that would have been achieved had the exchange offer or the
Compaq merger been completed as of the date presented, and should not be taken
as representative of future consolidated results of operations or financial
condition of HP.
As of and For the Twelve Months
Ended October 31, 2001
--------------------------------------------------
Pro Forma
---------------------------------
Indigo Indigo
Equivalent Equivalent
Fixed Contingent
HP and Offer Offer
HP Indigo/(1)/ Indigo/(2)/ Price/(3)/ Price/(3)/
----- ---------- ---------- ----------- ----------
(Unaudited)
Net earnings (loss) per share from continuing operations/(4)/:
Basic...................................................... $0.32 $(0.09) $0.28 $0.09 $0.07
Diluted.................................................... $0.32 $(0.09) $0.28 $0.09 $0.07
Book value per common share at period end/(5)/................ $7.20 $ 0.98 $7.41 $2.48 $1.98
Cash dividends declared per share............................. $0.32 $ -- $0.32 $0.11 $0.09
26
As of and For the Twelve Months
Ended October 31, 2001
------------------------------------------
Pro Forma
-------------------------------
Indigo Indigo
HP, Equivalent Equivalent
Indigo Fixed Contingent
and Offer Offer
Compaq/(1)/ Compaq/(2)/ Price/(3)/ Price/(3)/
---------- ---------- ---------- ----------
(Unaudited)
Net earnings (loss) per share from continuing operations/(4)/:
Basic...................................................... $(0.81) $(0.36) $(0.12) $(0.10)
Diluted.................................................... $(0.81) $(0.36) $(0.12) $(0.10)
Book value per common share at period end/(5)/................ $ 6.64 $12.32 $ 4.12 $ 3.30
Cash dividends declared per share............................. $ 0.10 $ 0.38 $ 0.13 $ 0.10
--------
(1) Indigo historical per share data is as of or for the twelve months ended
September 30, 2001. Compaq historical per share data is as of or for the
twelve months ended September 30, 2001.
(2) Because of different fiscal period ends, financial information for HP as of
or for the year ended October 31, 2001 has been combined with financial
information for Indigo as of or for the twelve months ended September 30,
2001 and with financial information of Compaq as of or for the twelve
months ended September 30, 2001.
(3) The Indigo equivalent pro forma combined per share amounts are calculated
by multiplying HP and Indigo pro forma combined share amounts and HP,
Indigo and Compaq pro forma combined share amounts by the exchange ratios
of shares of HP common stock for Indigo common shares in the exchange offer
(i.e., 0.3345, with respect to the fixed offer price, and 0.2676, with
respect to the contingent offer price).
(4) Net earnings (loss) per share from continuing operations are presented
before extraordinary item and cumulative effect of accounting change.
(5) Historical book value per share is computed by dividing stockholders'
equity by the number of shares of HP, Indigo or Compaq common stock
outstanding. Pro forma book value per share is computed by dividing pro
forma stockholders' equity by the pro forma number of shares of HP common
stock outstanding.
27
COMPARATIVE PER SHARE MARKET PRICE DATA
HP common stock trades on the New York Stock Exchange and the Pacific
Exchange under the symbol "HWP." Indigo common shares trade on the Nasdaq
National Market under the symbol "INDG."
The following table shows the high and low sales prices per share of HP
common stock as reported on the New York Stock Exchange composite transactions
tape and Indigo common shares as reported on the Nasdaq National Market on (1)
September 5, 2001, the last full trading day preceding public announcement that
HP and Indigo had entered into the offer agreement, and (2) February 15, 2002,
the last full trading day for which high and low sales prices were available as
of the date of this prospectus.
The table also includes the equivalent high and low sales prices per Indigo
common share on those dates for (1) the fixed offer price and (2) the
contingent offer price. These equivalent high and low sales prices per share
reflect the fluctuating value of HP common stock that an Indigo shareholder
would receive in exchange for each Indigo common share if the exchange offer
were completed on either of those dates. We have calculated the equivalent per
share price by applying the exchange ratio in the offer agreement for the fixed
offer price and the contingent offer price, which would have applied if we had
initially accepted for payment Indigo common shares on those dates, to the
market price of HP common stock on those dates. For purposes of the following
table, we determined these hypothetical exchange ratios by dividing $7.50 or
$6.00, as the case may be, by the average HP trading price during the twenty
trading days ending on the third trading day prior to those dates; provided
that the average trading price used in this calculation was not less than
$16.69 or more than $23.68. The following table excludes any value that may be
attributable to the CVRs to be received by Indigo shareholders whose Indigo
common shares are exchanged for the contingent offer price.
Equivalent Equivalent
Price per Share Price per Share
HP Indigo Fixed Offer Contingent
Common Stock Common Shares Price Offer Price
------------- ------------- --------------- ---------------
High Low High Low High Low High Low
------ ------ ----- ----- ----- ----- ----- -----
September 5, 2001............ $19.00 $17.00 $5.89 $5.31 $6.02 $5.38 $4.81 $4.31
February 15, 2002............ $21.13 $20.15 $7.25 $7.16 $7.25 $6.92 $5.80 $5.53
The above table shows only historical comparisons. These comparisons may not
provide meaningful information to you in determining whether to tender your
Indigo common shares in the exchange offer or whether to elect to receive the
fixed offer price or the contingent offer price. The actual value of HP common
stock you will receive in the exchange offer may be higher or lower than the
prices set forth above. We urge you to obtain current market quotations for HP
common stock and Indigo common shares and to review carefully the other
information contained in this prospectus or incorporated by reference into this
prospectus in considering whether to tender your Indigo common shares in the
exchange offer. See the section titled "Where You Can Find More Information"
beginning on page 166 of this prospectus.
28
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This prospectus and the documents incorporated by reference into this
prospectus contain forward-looking statements that involve risks and
uncertainties, as well as assumptions, that, if they never materialize or prove
incorrect, could cause the results of HP and its consolidated subsidiaries, on
the one hand, or Indigo and its consolidated subsidiaries, on the other, to
differ materially from those expressed or implied by such forward-looking
statements. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements including any
projections of earnings, revenues, synergies, accretion, margins or other
financial items; any statements of the plans, strategies and objectives of
management for future operations, including the execution of integration and
restructuring plans and the anticipated timing of filings, approvals and
closings relating to the exchange offer, the Compaq merger or other planned
acquisitions; any statements concerning proposed new products, services,
developments or industry rankings; any statements regarding future economic
conditions or performance; any statements of belief; and any statements of
assumptions underlying any of the foregoing.
The risks, uncertainties and assumptions referred to above include the
challenge of managing asset levels, including inventory; the difficulty of
keeping expense growth at modest levels while increasing revenues; the
challenges of integration and restructuring associated with the exchange offer,
the Compaq merger or other planned acquisitions and the challenges of achieving
anticipated synergies; the possibility that the exchange offer, the Compaq
merger or other planned acquisitions may not close or that HP, Compaq or other
parties to planned acquisitions may be required to modify some aspects of the
acquisition transactions in order to obtain regulatory approvals; the
assumption of maintaining revenues on a combined company basis following the
close of the Compaq merger or other planned acquisitions; and other risks that
are described in the section titled "Risk Factors," which follows on the next
page, and in the documents that are incorporated by reference into this
prospectus. Any references to the statutory safe harbor for forward-looking
statements in the Exchange Act reports that are incorporated by reference into
this prospectus are inapplicable to this prospectus.
If any of these risks or uncertainties materializes or any of these
assumptions proves incorrect, results of HP and Indigo could differ materially
from the expectations in these statements. HP and Indigo are not under any
obligation and do not intend to update their respective forward-looking
statements.
29
RISK FACTORS
We and Indigo operate in a market environment that cannot be predicted and
that involves significant risks, many of which are beyond our control. In
addition to the other information contained in, or incorporated by reference
into, this prospectus, you should carefully consider the risks described below
before deciding whether to tender your Indigo common shares in the exchange
offer. Additional risks and uncertainties not presently known to us or Indigo
or that are not currently believed to be important to you, if they materialize,
also may adversely affect the exchange offer, HP, HP and Compaq as a combined
company, Indigo or the CVRs.
Risks Related to the Exchange Offer
The value of the HP common stock that you receive may be less than $7.50 or
$6.00, as applicable, under some circumstances due to stock market fluctuation.
The amount of HP common stock that will be issued in the exchange offer for
each Indigo common share that is tendered and not properly withdrawn, which we
refer to as the HP stock exchange ratio, will be calculated by dividing $7.50,
in the case of the fixed offer price, and $6.00, in the case of the contingent
offer price, by the average closing sales price of HP common stock on the New
York Stock Exchange for the twenty consecutive trading days ending on the
trading day on which the third most recent closing of the U.S. markets prior to
expiration of the exchange offer occurs. However, the offer agreement provides
that the average trading price of HP common stock to be used in determining the
exchange ratios will not be less than $16.69 or more than $23.68. As a result,
the amount of HP stock that you may receive in the exchange offer may not
exceed 0.4494 of a share of HP common stock for the fixed offer price or 0.3595
of a share of HP common stock for the contingent offer price. Moreover, the
trading price of HP common stock on the date that you receive HP common stock
in exchange for your Indigo common shares could be less than the average
closing price of the HP common stock during the relevant twenty day pricing
period. This means that the then-current market value of the HP common stock
that you receive for each Indigo common share could be less than $7.50 or
$6.00, as the case may be, depending on fluctuations in HP's stock price.
HP's stock price is subject to market volatility, has historically fluctuated
and may continue to fluctuate.
The share price of HP common stock is subject to price fluctuations in the
market for publicly-traded equity securities and, like other technology
companies, has experienced historical volatility. Some of the factors that can
affect our stock price are:
. the announcement of new products, services or technological innovations
by HP or our competitors;
. quarterly increases or decreases in HP's revenue or earnings;
. changes in the business, operations or prospects of HP;
. market and economic considerations;
. changes in quarterly revenue or earnings estimates by the investment
community; and
. speculation in the press or investment community about HP's strategic
position, financial condition, results of operations, business or
significant transactions.
In addition, the market value of HP common stock will continue to vary prior
to completion of the Compaq merger due to market assessments of the Compaq
merger, regulatory considerations and other factors. Because the market price
of HP common stock fluctuates, the overall value of the HP common stock that
you will receive after the exchange offer is completed may be adversely
affected by changes in the market price of HP common stock. You should obtain
recent market quotations of HP common stock before you tender your shares.
30
If either the fixed offer price or the contingent offer price is over
subscribed, you may receive for some of the Indigo common shares that you
tender a different form of consideration than you request.
The total number of Indigo common shares that will be exchanged for each of
the fixed offer price and the contingent offer price is limited as described in
the offer agreement. As a result, you may receive a form of consideration which
is different from the form of consideration you elected for some of the Indigo
shares you tender. Pursuant to tender and option agreements, the Landa Family
Trust and entities directly or indirectly owned by the Landa Family Trust have
agreed, to the extent that either the fixed offer price or the contingent offer
price is oversubscribed, to elect automatically to receive the undersubscribed
consideration alternative for up to all of the Indigo common shares held by
each of those shareholders. However, despite such an election by the Landa
Family Trust entities, there is no guarantee that you will receive the offer
price of your election for all of the Indigo common shares tendered by you. If
either election is oversubscribed after giving effect to the tender and option
agreements, Indigo's shareholders who have tendered into the exchange offer
will be subject to allocation and required to accept some prorated amount of
the undersubscribed election as further described in this prospectus.
S-C Indigo CV, Indigo's largest shareholder after the Landa Family Trust,
has agreed to tender its Indigo common shares into the exchange offer but has
not agreed to elect to automatically receive the undersubscribed consideration
alternative. However, because S-C Indigo owns 24.6 million shares and must
elect to exchange all of its shares for either the fixed offer price or the
contingent offer price as discussed in this prospectus, the likelihood that the
offer price that S-C Indigo elects to receive will be oversubscribed is
increased. Based upon Indigo's capitalization as of December 31, 2001, the 24.6
million shares held by such shareholder would represent approximately 62% of
the Indigo common shares that may be exchanged for the fixed offer price and
approximately 44% of the Indigo common shares that may be exchanged for the
contingent offer price. In the event that the offer price that S-C Indigo
elects to receive is oversubscribed, its election will result in a decrease in
the percentage of your Indigo common shares that will be exchanged for the
offer price that you elect if you also have elected to receive the
oversubscribed form of consideration.
We are not required to acquire Indigo common shares from any remaining minority
Indigo shareholders after the completion of the exchange offer.
The offer agreement does not require us to acquire Indigo common shares from
any remaining minority shareholders following the completion of the exchange
offer. After the exchange offer is completed, we may, among other things,
delist the Indigo common shares from the Nasdaq National Market and terminate
Indigo's reporting obligations under the United States federal securities laws,
such that there would no longer be a public market for Indigo common shares. In
addition, if the Indigo common shares are delisted, such shares can be validly
transferred only by means of a notarial deed of transfer to be executed in the
presence of a civil law notary in The Netherlands, the costs of which will have
to be borne by the transferor or the transferee of those shares. As a result,
if you do not tender your Indigo common shares into the exchange offer, the
value of your Indigo common shares may decline and you may be unable to sell
your Indigo common shares readily or at all after the completion of the
exchange offer.
The directors and executive officers of Indigo have interests and arrangements
that could have affected their decision to support or approve the exchange
offer.
The interests of the directors and executive officers of Indigo in the
exchange offer and their participation in arrangements that are different from,
or are in addition to, those of Indigo shareholders generally could have
affected their decision to support or approve the exchange offer. These
interests include the following:
. the continuation of indemnification arrangements for directors and
executive officers of Indigo after the completion of the exchange offer;
. the termination and payout of Mr. Landa's employment agreement and the
signing of the consulting agreement between us and Mr. Landa;
31
. severance arrangements and/or ongoing employment arrangements for
Indigo's executive officers; and
. the tender and option agreements pursuant to which a foundation, which
we refer to as the Landa Family Trust, of which Mr. Landa is a
beneficiary, and entities directly or indirectly owned by the Landa
Family Trust have agreed, to the extent that either the fixed offer
price or the contingent offer price is oversubscribed, to elect
automatically to receive the undersubscribed consideration alternative
for up to all the Indigo common shares held by each of those
shareholders.
As a result, these directors and executive officers may be more likely to
recommend that you tender your Indigo common shares than if they did not have
these interests.
If we or Indigo terminate the exchange offer, or if the exchange offer is
otherwise not completed, Indigo's stock price and business could be adversely
affected.
If the exchange offer is not completed, Indigo may be subject to the
following material risks, among others:
. the price of Indigo common shares may decline to the extent that the
current market prices of Indigo common shares reflect a market
assumption that the exchange offer will be completed; and
. Indigo may not be able to find an equivalent or more attractive partner.
In addition to the above risks, if we terminate the exchange offer because
Indigo has breached any of its covenants or agreements in the offer agreement
or any of Indigo's representations or warranties were untrue or have become
untrue such that we would not be required to complete the exchange offer
pursuant to the terms of the exchange offer, Indigo will be required to
reimburse us for up to $2 million of our fees and expenses related to the
exchange offer, including attorney, accounting and consulting fees and expenses.
In addition to the above risks, if Indigo terminates the exchange offer
because we have breached any of our covenants or agreements in the offer
agreement or any of our representations or warranties were untrue or have
become untrue in a material manner, while we will be required to reimburse
Indigo for up to $2 million of its fees and expenses related to the exchange
offer, including attorney, accounting and consulting fees and expenses,
Indigo's fees and expenses are expected to exceed $2 million.
In addition to the above risks, if we terminate the exchange offer due to
the occurrence of a triggering event, which would include the Indigo boards'
approval or recommendation of any other acquisition proposal, the withholding,
withdrawal, amendment or modification of the Indigo boards' recommendation in
favor of the exchange offer or failure to recommend rejection of any other
third party tender or exchange offer, Indigo will be required to pay us a
termination fee of $27 million which represents approximately 16.4% of Indigo's
total revenues for the year ended December 31, 2000 and Indigo will be required
to reimburse us for up to $2 million of our fees and expenses related to the
exchange offer, including attorney, accounting and consulting fees and
expenses. Indigo does not foresee a situation where a triggering event will
occur in the absence of a higher offer for Indigo common shares. See the
section titled "The Offer Agreement--Termination of the Offer
Agreement--Termination by HP" for the full definition of a triggering event.
Regulatory agencies must approve the exchange offer and could impose conditions
on, delay or refuse to approve the exchange offer.
We and Indigo intend to comply with the securities and antitrust laws of the
United States and any other jurisdiction in which the exchange offer is subject
to review, as well as with Israeli regulatory requirements. The reviewing
authorities may seek to impose conditions on us and Indigo before giving their
approval or consent to the exchange offer, and those conditions could harm the
combined company's business. In addition, a delay in obtaining the necessary
regulatory approvals will delay the completion of the exchange offer. Although
the waiting period under United States antitrust laws was terminated, we and
Indigo may be unable to obtain the other required regulatory approvals, or
obtain them within the time frame contemplated by the offer agreement.
32
Risks Related to the Contingent Value Rights
Each of the risks listed in this section, if it materializes, could have a
material adverse effect on the results of the operation of the Indigo business
and, therefore, affect the likelihood of any payments being made under the CVRs
and the magnitude of any payments that are so made.
You may not receive any payment under the CVRs.
To the extent that your Indigo common shares are exchanged for the
contingent offer price, your right to receive any future payment from Newco,
our newly-purchased indirect subsidiary, under the CVRs will be contingent upon
our achievement of revenue targets specified in the CVR agreement. If these
revenue targets are not achieved for any reason, no payment will be made under
the CVRs.
We have not achieved any material revenue related to digital press products
that utilize Indigo's technology.
Our experience in penetrating and selling in the commercial printing market
for digital press products is limited. Prior to entering into a commercial
relationship with Indigo in September 2000, we had not derived any revenue from
digital press products. Our commercial relationship with Indigo has been our
sole attempt at entry into the commercial digital press market. To date, we
have not achieved any material revenue from digital press products that utilize
Indigo's technology. We cannot assure you that we will be able to successfully
enter the market for digital press products.
If we do not achieve and maintain substantial revenue growth with respect to
digital press products that utilize Indigo technology, we will not achieve the
revenue milestones required for there to be any payout under the CVRs.
For us to achieve the revenue milestones required for there to be any payout
under the CVRs, we will have to expand the revenue base considerably with
respect to digital press products that utilize Indigo technology. During the
three-year period ended December 31, 2000, Indigo's revenue grew at a compound
annual growth rate of 15.5% including the decrease in actual revenues from 1998
to 1999. Indigo's revenues for the trailing twelve month period ended September
30, 2001 were $184 million. Assuming a similar level of revenue at the
completion of the exchange offer, our consolidated net revenue from the sale or
lease of LEP Digital Press Products and Consumables (as such terms are defined
in the CVR agreement) would need to grow over a three-year period at a compound
annual growth rate of approximately 33% to achieve the revenue milestones
required for there to be any payout under the CVRs and approximately 64% to
achieve the revenue milestones required for there to be a full payment of $4.50
under each CVR. These growth rates are significantly higher than any growth
rate historically achieved by Indigo and significantly higher than the
approximately 15-20% annual growth rate that Indigo now believes it would be
unlikely to exceed as a stand-alone entity for 2002. We cannot assure you that
we will be able to achieve or sustain any such revenue growth. If we do not
achieve and sustain this revenue growth, the revenue milestones required for
there to be any payout under the CVRs will not be achieved. Furthermore, we
will operate the Indigo business in a manner which will balance a variety of
our operational and financial objectives, including profitability and other
objectives which may, to some extent, conflict with the CVR holders' interest
that we generate higher rates of revenue growth for LEP Digital Press Products
and Consumables (as such terms are defined in the CVR agreement).
The market for digital presses may not develop quickly.
Printing presses for the commercial print market are dominated by offset
printing products that utilize mechanical systems that have been widely
accepted in the market for many years. Although Indigo is a leading vendor of
digital press products, the overall adoption rate for digital press products is
still low when compared to traditional offset printing solutions. If the
adoption rates for digital presses to serve the commercial print market do not
increase quickly enough during the three-year period after the close of the
exchange offer, we may be unable to achieve the revenue milestones required for
there to be any payout under the CVRs.
33
The overall demand for printing presses and printed pages may be adversely
impacted by the economic downturn.
The demand for commercial printing presses will depend significantly on the
overall demand for commercial-quality print pages. Softening demand for
commercial-quality print pages caused by the ongoing economic downturn may
result in lower demand for new press purchases by commercial print providers
and lower demand for related consumable products and support services.
Reductions or delays in capital spending by commercial print providers or
orders by their customers for printed pages may adversely affect our ability to
achieve the revenue milestones required for there to be any payout under the
CVRs.
The benefits of Indigo's technology may not be sufficiently realized or
perceived by the market.
We believe that Indigo's digital technology will provide commercial print
providers with capabilities not currently available from traditional offset
printing solutions, including the capability to generate short and highly
customized print runs and the capability to integrate existing information
systems with the process of generating commercial-quality print pages. If we
are unable to realize these capabilities on a cost-effective basis or if the
market does not perceive these capabilities as important, we may have
difficulty marketing and selling LEP Digital Press Products and Consumables (as
such terms are defined in the CVR agreement) and achieving the revenue
milestones required for there to be any payout under the CVRs.
If we do not successfully integrate Indigo with HP, our ability to achieve our
future revenue results for the Indigo products may be adversely impacted.
Achieving the payout of the CVRs will depend in part on the integration of
the Indigo business into HP. Integration issues are complex, time-consuming and
expensive and, without proper planning and implementation, could significantly
disrupt the Indigo business. The challenges involved in integrating Indigo with
HP include:
. demonstrating to the customers of Indigo that the acquisition will not
result in adverse changes in client service standards or business focus
and helping customers conduct business easily with us;
. consolidating and rationalizing corporate IT and administrative
infrastructures;
. coordinating sales and marketing efforts to effectively communicate our
capabilities;
. coordinating and rationalizing research and development activities to
enhance introduction of new products and technologies with reduced cost;
. combining product offerings;
. coordinating Indigo's Israeli operations, which are geographically
distant from most of HP's existing operations;
. preserving distribution, marketing or other important relationships of
both HP and Indigo and resolving potential conflicts that may arise;
. minimizing the diversion of management attention, on behalf of the
Indigo business, from ongoing business concerns;
. persuading employees of the Indigo business that the business cultures
of HP and Indigo are compatible, maintaining employee morale and
retaining key employees;
. coordinating and combining overseas operations, relationships and
facilities, which may be subject to additional constraints imposed by
local laws and regulations; and
. managing integration issues shortly after or pending the completion of
other independent reorganizations.
The integration of the Indigo business into our business may not be
successfully completed in a timely manner, or at all, and we may not realize
any of the anticipated benefits of the acquisition to the extent, or in the
time frame, anticipated. The failure to integrate the Indigo business
successfully or to realize any of the anticipated benefits of the exchange
offer could seriously harm our business related to digital press products that
34
utilize Indigo's technology and adversely affect our ability to achieve the
revenue milestones required for there to be any payout under the CVRs.
We do not have any obligations to you regarding the operation of the Indigo
business after the completion of the exchange offer.
The CVR agreement provides, among other things, that:
. we will be entitled in our sole discretion to establish and modify from
time to time all aspects of our program for the development,
manufacturing, marketing and sale of any Indigo products; and
. we have no obligation to initiate or continue research, development,
commercialization, marketing or sales activities with respect to any
Indigo products, and, in our sole and subjective discretion, we may
abandon efforts to research, develop, commercialize, market or sell any
or all products.
As a consequence, we will have complete discretion relating to whether to
grow, continue, shut-down or exit the Indigo business, without regard to the
economic interests of the CVR holders. Furthermore, we are free to make
operational and investment decisions which may conflict with the CVR holders'
interest that we generate higher rates of revenue growth for LEP Digital Press
Products and Consumables (as such terms are defined in the CVR agreement). For
example, any determination by us to focus the Indigo business on achieving
profitability may cause us, among other things, to take actions to reduce
operating expenses in areas such as sales, marketing and research and
development, to forego sales opportunities in order to maintain higher prices
and margins, or to take other actions, any of which may have the effect of
impeding revenue growth for LEP Digital Press Products and Consumables (as such
terms are defined in the CVR agreement). In addition, we may decide that our
financial, technical, marketing, sales, operating or other resources should be
deployed in ways which benefit our overall company or specific business
operations but which may be detrimental to the CVR holders' interest that we
generate higher rates of revenue growth for LEP Digital Press Products and
Consumables (as such terms are defined in the CVR agreement).
The CVRs are non-transferable and you will not be permitted to sell any CVRs
that you receive as a result of the exchange offer.
The CVRs are, by their terms, non-transferable, except for specified
permitted transfers under very limited circumstances, and therefore represent
an illiquid investment unless and until such time in 2005 that any payments due
thereunder may be made.
If third parties terminate their strategic or business alliances with Indigo,
our ability to develop, market, sell or support digital press products that use
Indigo technology may be harmed.
Indigo depends on strategic relationships and business alliances for
continued growth of its business. Indigo's development, marketing and
distribution strategies rely increasingly on its ability to form strategic
relationships with third parties. These relationships range from OEM and
distribution relationships with other companies to cooperative marketing
programs and joint customer seminars with software companies. In some of these
relationships, the third party is not contractually committed to make any
particular level of purchases from Indigo and effectively can terminate the
relationship at will. A decision by any of these third party companies to
change their strategy or focus may interfere with our ability to develop,
market, sell or support LEP Digital Press Products and Consumables (as such
terms are defined in the CVR agreement) and could damage our ability to achieve
the revenue milestones required for there to be any payout under the CVRs.
Further, some of these companies may choose to terminate their strategic or
business alliances with Indigo as a result of the exchange offer. However,
since the announcement of the exchange offer, Indigo's strategic relationships
and business alliances have not been negatively affected in any material way as
a result of the announcement of exchange offer.
In addition, Indigo has contracts with some of its suppliers, distributors,
customers, licensors and other business partners. Some of these contracts
require Indigo to obtain the consent of these other parties in
35
connection with the exchange offer. If the respective parties' consent cannot
be obtained, these contracts may be terminated and we may need to locate
alternate suppliers or may suffer a loss of potential future revenue from the
sale or lease of LEP Digital Press Products and Consumables (as such terms are
defined in the CVR agreement). Any such revenue loss would damage our ability
to achieve the revenue milestones required for there to be any payout under the
CVRs. However, since the announcement of the exchange offer, Indigo has not
become aware of any difficulty with its major suppliers, distributors,
customers, licensors or other business partners, individually or in the
aggregate, that would have a material impact on its operations.
Strategic partner, customer and supplier uncertainty related to the exchange
offer could harm the Indigo business.
Indigo has numerous strategic relationships and business alliances with
other companies to supply raw materials to Indigo and to deliver and market
Indigo products to customers. As a result of the exchange offer, some of these
relationships may change in a manner adverse to the Indigo business. In
addition, customers of Indigo, in response to the announcement of the exchange
offer or due to ongoing uncertainty about the exchange offer, may delay or
defer purchasing decisions or elect to switch to other suppliers. Any delay,
deferral or change in purchasing decisions by the customers of Indigo could
seriously harm the Indigo business. Since the announcement of the offer
agreement, Indigo has not experienced any material change in its customers'
purchasing decisions to date and its strategic relationships and business
alliances have not been negatively affected in any material way as a result of
the announcement of the exchange offer.
Indigo's failure to retain key executives and employees could diminish the
benefits of the exchange offer.
The successful integration of the Indigo business into our business will
depend in part on the retention and continued service of key executive officers
and other key employees of Indigo. Upon the completion of the exchange offer,
Mr. Landa, Indigo's Chief Executive Officer and Chairman as well as its founder
and chief technology inventor, will terminate his employment with Indigo. After
that time, Mr. Landa may provide services to us under a consulting agreement,
although he is not obligated to apply any minimum level of effort and time in
providing consulting services, and he may, in any event, terminate the
consulting agreement anytime after the second anniversary of the completion of
the exchange offer. Moreover, Indigo does not have long-term employment
agreements with most of its key personnel. These executives or employees of
Indigo may experience uncertainty about their future role with Indigo until or
after strategies with regard to the integration of the Indigo business into our
business are announced or executed. This uncertainty may adversely affect
Indigo's ability to attract and retain key management, technical,
administrative, marketing, sales and customer support personnel.
Indigo's research and development facilities and manufacturing operations are
located in Israel, and terrorist attacks and threats or actual war involving
Israel may negatively impact all aspects of Indigo's operations and revenue.
Indigo's research and development and manufacturing operations are located
in Israel. Future terrorist attacks against Israeli targets, rumors or threats
of war, actual conflicts involving Israel or its allies, or trade disruptions
impacting Indigo's suppliers or customers may materially harm the revenues,
results of operations and financial condition of the Indigo business. Any of
these events could cause Indigo's customers to defer or cancel purchases of
Indigo products. The Indigo business operations depend on the availability of
highly-skilled and relatively low-cost scientific and technical personnel in
Israel. The Indigo business also depends on trading relationships between
Israel and other countries. In addition to the risks associated with
international sales and operations generally, the operation of the Indigo
business could be adversely affected if major hostilities involving Israel
should occur or if trade between Israel and its current trading partners,
including, without limitation, the United States, were interrupted or
curtailed. These risks are compounded due to the restrictions on our ability to
manufacture outside of Israel the Indigo products or transfer certain
technologies developed under research and development grants from the Office of
the Chief Scientist without the prior written consent of the Office of the
Chief Scientist of the Ministry of Industry and Trade, an agency of the
Government of Israel. If we
36
are unable to obtain the consent of the Office of the Chief Scientist, we may
not be able to take advantage of strategic manufacturing and other
opportunities outside of Israel. In the past, Indigo has obtained
royalty-bearing grants from various Israeli governmental agencies. Any of these
occurrences could adversely impact the Indigo business, financial condition or
results of operations, as well as our ability to achieve the revenue thresholds
required to trigger any payments under the CVRs.
Due to regulations in Israel, access to our worldwide research and development
resources to develop certain Indigo technologies may be constrained.
We have significant research and development resources in the area of
imaging and printing throughout the world. In order to enhance our commercial
printing business and further the Indigo technologies, we intend to utilize our
worldwide research and development resources. To the extent that these efforts
involve technologies developed in Israel under research and development grants
from the Office of the Chief Scientist, we may be unable to take advantage of
our research and development resources outside of Israel without obtaining the
consent of the Office of the Chief Scientist. If we are unable to obtain such
consent, our ability to take full advantage of our research and development
resources may be constrained. Any such constraints could adversely impede our
ability to achieve the revenue thresholds required to trigger any payments
under the CVRs.
Foreign currency fluctuations may negatively impact the financial results of
the Indigo business.
The results of operations or financial condition of the Indigo business may
be negatively impacted by foreign currency fluctuations. The Indigo business
operations throughout the world are generally transacted through international
sales subsidiaries and branches. As a result, these sales and related expenses
are denominated in currencies other than the U.S. dollar. Because its financial
results are reported in U.S. dollars, including the financial results to be
used to measure the CVR revenue thresholds, the results of operations for the
Indigo business and therefore the likelihood of payments made under the CVRs,
may be harmed by fluctuations in the rates of exchange between the U.S. dollar
and other currencies, including a decrease in the value of European currencies
relative to the U.S. dollar, which would decrease reported U.S. dollar revenue
for the Indigo business, as the Indigo business generates revenues in these
local currencies and reports the related revenues in U.S. dollars; and an
increase in the value of European or Israeli currencies relative to the U.S.
dollar, which would increase the sales and marketing costs for the Indigo
business in these countries as well as the research and development costs in
Israel. We may attempt to limit foreign exchange exposure through operational
strategies and by using forward contracts to offset the effects of exchange
rate changes on intercompany trade balances. This would require us to estimate
the volume of transactions in various currencies. We may not be successful in
making these estimates. If these estimates are overstated or understated during
periods of currency volatility, the Indigo business may experience material
currency gains or losses.
Product protection and infringement may harm the Indigo business and its
financial condition.
If we fail to protect the proprietary rights and intellectual property used
in the Indigo business adequately, we may lose valuable assets, experience
reduced revenues and incur costly litigation to protect these rights and
property. Indigo relies on a combination of patents, copyrights, trademark,
service mark and trade secret laws and contractual restrictions to establish
and protect its proprietary rights in its products and services. We will not be
able to protect these proprietary rights and intellectual property if we are
unable to enforce our rights or are unable to detect unauthorized use of these
proprietary rights and intellectual property. Despite precautions, it may be
possible for unauthorized third parties to copy products and use information
that we regard as proprietary to create products that compete with the Indigo
business. Further, the laws of some countries do not protect proprietary rights
to the same extent as the laws of the United States. Indigo also relies, to
some extent, on unpatented trade secrets. It is Indigo's policy to have
employees sign confidentiality agreements, to have selected parties sign
non-competition agreements and to have third parties sign non-disclosure
agreements. These agreements may not be effective in controlling access to and
distribution of products and proprietary information or trade secrets of the
Indigo business. Further, these agreements do not and may not prevent
competitors of the
37
Indigo business from independently developing technologies that are
substantially equivalent or superior to Indigo's products. Litigation may be
necessary in the future to enforce intellectual property rights relating to the
Indigo business and to protect trade secrets. Litigation like this, whether
successful or unsuccessful, could result in substantial costs and diversions of
the Indigo business management resources, either of which could seriously harm
the results of the Indigo business. Third parties could assert that the
products and services of the Indigo business infringe their intellectual
property rights, which could expose Indigo to litigation that, with or without
merit, could be costly to defend. From time to time we may be subject to claims
of infringement of other parties' proprietary rights. We could incur
substantial costs in defending the Indigo business and its customers against
these claims. Parties making these claims may be able to obtain injunctive or
other equitable relief that could effectively block our ability to sell Indigo
products in the United States and abroad and could result in an award of
substantial damages against us. In the event of a claim of infringement, we may
be required to obtain licenses from third parties to develop alternative
technology, to alter the products or processes of the Indigo business or to
cease activities that infringe the intellectual property rights of third
parties. If we are required to obtain licenses, we cannot be sure that we will
be able to do so at a commercially reasonable cost, or at all. Defense of any
lawsuit or failure to obtain required licenses could delay shipment of Indigo's
products and increase its costs. In addition, any such lawsuit could result in
incurring significant costs or the diversion of the attention of the management
of the Indigo business.
Noncompliance with regulatory laws could have a material adverse effect on the
Indigo business and its financial condition.
Indigo's presses and consumable products are subject to a variety of
regulations throughout the world, including those relating to product safety,
environmental protection and hazardous materials. The areas of product safety
and environmental regulation are quickly evolving ones, and some jurisdictions
may adopt regulations in the future with which we will not be able to comply or
with which we will be able to comply only at significant cost. Such
developments could have a material adverse affect on the Indigo business, its
results of operations or its financial condition as well as upon the marketing,
sale and use of its products.
Product development and difficulties with new or existing technologies could
have a material adverse effect on the Indigo business or its financial
condition.
The likelihood of success of the Indigo business must be considered in light
of the difficulties and delays frequently encountered, and which Indigo has
encountered in the past, in connection with the development of new technologies
and related products. Market and customer acceptance of Indigo's presses
depends, among other things, on their operational performance. Indigo and some
of its customers have, in the past, encountered certain operational problems
with the presses, including problems relating to the presses' paper-handling
capabilities, contamination of inks and durability and consistency of the photo
imaging plates. The Indigo business may not continue to be successful in
improving the reliability and productivity of Indigo's presses and imaging
products. Further, there can be no assurance that we will not encounter
additional problems in the future, or, as indicated above, that we will
continue research, development, commercialization, marketing or sales
activities with respect to any Indigo products, and, in our sole and subjective
discretion, we may abandon efforts to research, develop, commercialize, market
or sell any or all products.
Continued significant research and development expenditures will be required to
develop new Indigo products and to increase the adoption rate for Indigo
digital press products, and HP may elect not to incur such costs.
The development of Indigo's Digital Offset Color printing technology has
required, and will continue to require, significant research and development
expenditures. The printing equipment industry is highly competitive. Future
sales of certain Indigo digital presses will be dependent upon the ability to
develop, independently and through relationships with strategic partners,
commercial applications for such presses. In addition, we believe that
increasing the adoption rate for Indigo digital press products will require
investment in the areas of low-cost design and ease-of-use. We believe that our
ability to compete after completion of the
38
exchange offer will depend on factors both within and outside of our control,
including the performance and acceptance of Indigo products as well as the
successful manufacturing, marketing, distribution and customer support of these
products. Some of Indigo's competitors have developed color-printing products
that target the short-run color printing market and thereby compete with
Indigo's presses. Any failure to anticipate or respond adequately to changes in
technology or customer preferences, or to any significant delays in product
development or introduction, would have a material adverse effect on the Indigo
business. Further, as indicated above, we have no obligation to initiate or
continue research, development, commercialization, marketing or sales
activities with respect to any Indigo products, and, in our sole and subjective
discretion, we may abandon efforts to research, develop, commercialize, market
or sell any or all Indigo products.
Indigo is highly dependent on a few key products for a large percentage of its
revenue and such key products may not gain in customer acceptance, which may
cause revenue to fall short of the targets necessary to earn payments under the
CVRs.
The Indigo business is dependent on the success of LEP Digital Press
Products and Consumables (as such terms are defined in the CVR agreement) and
the payment of the CVRs is dependent upon our achieving specified consolidated
revenue targets from these products and consumables ("post-sales"). The
percentage of Indigo's revenues generated from digital press products was 54%
in 1999, 58% in 2000 and 57% for the first nine months of 2001. The percentage
of Indigo's revenues generated from related post-sales activities was 43% in
1999, 42% in 2000 and 43% for the first nine months of 2001. In addition to
manufacturing and selling presses, Indigo manufactures and sells certain
consumable products, which we call imaging products, including ElectroInk
products, photo-imaging plates, and image transfer blankets, all of which are
essential to the operation of Indigo's presses. These consumable products may
only be used in conjunction with Indigo's digital printing systems and thus the
market for these consumables is limited to users of Indigo's digital printing
systems. In order for Indigo's business strategy to succeed, a significant
portion of its revenues must be generated from sales of such consumable
products. To date, Indigo's actual revenues from sales of consumable products
has been lower than originally expected due to the slower than expected
development of the short-run color printing market as well as the lower than
expected operational efficiency of the machines sold. These challenges may not
be solved, and revenues from consumable products may not continue to increase
in the future. At present, there are no known alternative suppliers of products
that can readily substitute for Indigo's consumables. However, there can be no
assurance that substitute consumable products will not be developed and offered
for sale by others in the future. If such substitute consumables are developed
and offered for sale by others in the future, the sales of Indigo's consumables
will not increase significantly and we may not achieve the revenue targets
necessary to earn payments under the CVRs.
The exchange of Indigo common shares for HP common stock will be a taxable
transaction for United States federal income tax purposes.
The exchange of Indigo common shares for HP common stock will be a taxable
transaction for United States federal income tax purposes. A shareholder will
be required to include in taxable income the excess of the fair market value of
the HP common stock received in the exchange (plus any cash received instead of
fractional shares) over his or her tax basis in the Indigo common shares
exchanged, even though the shareholder will not receive cash with which to pay
the related tax (other than cash received instead of fractional shares). See
the section titled "Special Factors--United States Federal Income Tax
Consequences of the Exchange Offer" for a further discussion of the United
States federal income tax consequences of the exchange offer to Indigo
shareholders.
The exchange of Indigo common shares for HP common stock and CVRs will be a
taxable transaction for United States federal income tax purposes, and the
value of the CVRs and, accordingly, the amount realized are uncertain.
The exchange of Indigo common shares for HP common stock and CVRs will be a
taxable transaction for United States federal income tax purposes. Although the
tax treatment of the CVRs is not entirely clear for
39
United States federal income tax purposes, a shareholder receiving the
contingent offer price likely will be required to include in the amount of
consideration received in the exchange the estimated fair market value of the
CVRs on the date of the exchange, and to include in income the excess of the
fair market value of the consideration received over his or her basis in the
Indigo common shares exchanged, even though the shareholder will not receive
cash with which to pay the related tax (other than cash received instead of
fractional shares). It is possible that the Internal Revenue Service could
challenge the value of the CVRs as determined by an Indigo shareholder,
possibly requiring the shareholder to recognize more gain (or less loss) on the
transaction. The shareholder's tax basis in the CVRs will equal their fair
market value on the date of the exchange.
Although the treatment of a payment in the future to a holder of a CVR is
not entirely clear for United States federal income tax purposes, it is
anticipated that a portion of the payment will be treated as interest under
Section 483 of the Internal Revenue Code, which will be ordinary income to the
holder of the CVRs when the payment is received, and the remainder will be
treated as sales proceeds from the sale or exchange of the CVRs. Assuming open
transaction treatment does not apply, a shareholder will recognize gain in the
amount by which the payment, other than the portion characterized as interest,
exceeds the shareholder's tax basis in the CVRs. In such event, if no payment
is made or the payment is less than the shareholder's tax basis in the CVRs,
the shareholder will recognize a loss. The gain or loss will be long-term
capital gain or loss.
In the event that the CVRs are treated as debt instruments for United States
federal income tax purposes, the tax treatment would be as described above
except that, instead of including interest income at the time of payment under
Section 483 of the Internal Revenue Code, a holder would be required to include
over the term of the CVR an amount in income as interest (based on the yield of
"comparable" debt instruments) in advance of the receipt of any payment,
regardless of a holder's method of accounting. See the section titled "Special
Factors--United States Federal Income Tax Consequences of the Exchange Offer"
for a further discussion of the United States federal income tax consequences
of the exchange to Indigo shareholders.
Indigo is dependent upon sole and limited suppliers for many of its components
and the Indigo business would be harmed if these components were no longer
available or if costs for these components increase significantly.
Some components and sub-assemblies used in Indigo's presses and consumable
products are currently available only from sole sources and other components
and sub-assemblies are currently available from only a limited number of
sources. Indigo employs many unaffiliated subcontractors to manufacture most of
the components and sub-assemblies for Indigo's products. In the past, Indigo
has experienced delays in obtaining timely deliveries of certain components and
sub-assemblies, although such delays have not had a material adverse effect on
Indigo's results of operations. Our failure to develop alternative sources for
certain such components, sub-assemblies or raw materials on a timely basis, if
and as required, or to obtain sufficient sole-source or limited-source
components, sub-assemblies or raw materials on a timely basis, could result in
delays or reductions in product shipments and/or in decreases in sales of
consumable products, which could have a material adverse effect on the
operating results of the Indigo business. Indigo has established a procedure to
monitor that the components, sub-assemblies and raw materials provided by its
subcontractors and suppliers and used in the manufacture of Indigo's products
meet its specifications and quality standards. However, because of the large
number of subcontractors, suppliers, components, sub-assemblies and raw
materials, there is no assurance that we will be able to ensure that all such
parts, components, sub-assemblies and raw materials will continue to satisfy
quality standards and delivery requirements of the Indigo business.
40
Risks Related to the Fixed Offer Price
If your Indigo common shares are exchanged for the fixed offer price, you will
not be entitled to receive any CVRs and will not receive any portion of any
payment made under the CVRs.
If you tender your Indigo common shares in the exchange offer, you must
tender all of your Indigo common shares for either the fixed offer price or the
contingent offer price. You will not be entitled to receive any CVRs in
exchange for your Indigo common shares unless:
. you indicate in the election form/letter of transmittal that you are
tendering all of your Indigo common shares for the contingent offer
price; or
. you are subject to an allocation of CVRs because the fixed offer price
is oversubscribed.
If you do not receive any CVRs in exchange for your Indigo common shares,
under no circumstances will you receive or be entitled to receive any portion
of any payment made under the CVRs.
The contingent offer price may yield greater value than the fixed offer price.
If the revenue thresholds for the maximum CVR payout are achieved, Indigo
shareholders whose common shares are exchanged for the contingent offer price
would receive between $8.52 and $9.05 in aggregate present value for each such
Indigo common share assuming a payout of the CVR 39 months after the close of
the exchange offer, a discount rate range of between 12% to 18%, and the
receipt of $6.00 in value of HP common stock at the close of the exchange offer.
Risks Regarding the Compaq Merger and HP and Compaq as a Combined Company
The exchange offer is not conditioned upon the completion of the Compaq merger,
and, if the Compaq merger is not completed, HP common stock will not reflect
any actual or anticipated interest in Compaq.
The exchange offer is not conditioned upon the completion of the Compaq
merger. The Compaq merger is subject to customary conditions to closing, as set
forth in the Compaq merger agreement, which are separate and independent
conditions from the closing conditions to the exchange offer. The conditions to
the Compaq merger include, among others, that our shareowners approve the
issuance of HP common stock in connection with the Compaq merger and that
Compaq shareowners approve the Compaq merger agreement and the Compaq merger
and receipt of required antitrust approvals. If any of the conditions to the
Compaq merger is not satisfied or, if waiver is permissible, waived, the Compaq
merger will not be completed. In addition, under circumstances specified in the
Compaq merger agreement, we or Compaq may terminate the Compaq merger
agreement. As a result, we cannot assure you that we will complete the Compaq
merger. If we do not complete the Compaq merger, the HP common stock that you
receive in the exchange offer will not reflect any interest in Compaq.
Although HP expects that the Compaq merger will result in benefits to the
combined company, the combined company may not realize those benefits because
of integration and other challenges.
The failure of the combined company to meet the challenges involved in
integrating the operations of HP and Compaq successfully or otherwise to
realize any of the anticipated benefits of the Compaq merger, including
anticipated cost savings, could seriously harm the results of operations of the
combined company. Realizing the benefits of the Compaq merger will depend in
part on the integration of technology, operations, and personnel. The
integration of the companies is a complex, time-consuming and expensive process
that, without proper planning and implementation, could significantly disrupt
the businesses of HP and Compaq. The challenges involved in this integration
include risks associated with consolidating manufacturing operations and
combining product offerings and those described in the risk factor titled "--If
we do not successfully integrate Indigo with HP, our ability to achieve our
future revenue results for the Indigo products may be adversely impacted."
41
The combined company may not successfully integrate the operations of HP and
Compaq in a timely manner, or at all, and the combined company may not realize
the anticipated benefits or synergies of the Compaq merger to the extent, or in
the timeframe, anticipated. The anticipated benefits and synergies relate to
cost savings associated with anticipated restructurings and other operational
efficiencies, greater economies of scale and revenue enhancement opportunities.
However, these anticipated benefits and synergies are based on projections and
assumptions, not actual experience, and assume a successful integration. In
addition to the integration risks discussed above, the combined company's
ability to realize these benefits and synergies could be adversely impacted by
practical or legal constraints on its ability to combine operations or
implement workforce reductions.
HP and Compaq may be unable to obtain the regulatory approvals required to
complete the Compaq merger or, in order to do so, the combined company may be
required to comply with material restrictions or conditions.
The Compaq merger is subject to review by the United States Federal Trade
Commission under the Hart-Scott-Rodino Improvements Act of 1976, and was
subject to review by the European Commission under Council Regulation No.
4064/89 of the European Community and by the Canadian Competition Bureau under
the Competition Act (Canada). Under each of these statutes, HP and Compaq were
required to make pre-merger notification filings and, in the case of the
Hart-Scott-Rodino review, HP and Compaq are awaiting the expiration or early
termination of statutory waiting periods prior to completing the Compaq merger.
By September 25, 2001, each of HP and Compaq had completed its initial
Hart-Scott-Rodino filing. On October 25, 2001, each of HP and Compaq received a
request for additional information and other documentary material from the
Federal Trade Commission under the Hart-Scott-Rodino Act in connection with the
Compaq merger. This request effectively extends the waiting period for the
Compaq merger under the Hart-Scott-Rodino Act until 30 days after both parties
substantially comply with the request for additional information. In practice,
complying with a request for additional information or material under the
Hart-Scott-Rodino Act can take a significant amount of time. HP and Compaq
responded to the request for additional information and continue to cooperate
with the FTC in its investigation. In addition, HP formally notified the
European Commission of the Compaq merger by Form CO on December 20, 2001. The
Compaq merger also may be subject to review by the governmental authorities of
various other jurisdictions under the antitrust laws of those jurisdictions. On
January 31, 2002, the European Commission issued a formal decision clearing the
Compaq merger on the basis that it does not create or strengthen a dominant
position as a result of which effective competition would be significantly
impeded in the European Economic Area (as defined by European Community
regulations) or in a substantial part of it. On December 20, 2001, the Canadian
Competition Bureau completed its review of the proposed Compaq merger and found
no issues of competitive concern. Other than the European Commission and the
Canadian Competition Bureau, HP and Compaq have not yet obtained any of the
governmental or regulatory approvals required to complete the Compaq merger.
The reviewing authorities may not permit the Compaq merger at all or may
impose restrictions or conditions on the Compaq merger that may seriously harm
the combined company if the Compaq merger is completed. These conditions could
include a complete or partial license, divestiture, spin-off or the holding
separate of assets or businesses. Either HP or Compaq may refuse to complete
the Compaq merger if restrictions or conditions are required by governmental
authorities that would materially adversely impact the combined company's
results of operations or the benefits anticipated to be derived by the combined
company. Any delay in the completion of the Compaq merger could diminish the
anticipated benefits of the Compaq merger or result in additional transaction
costs, loss of revenue or other effects associated with uncertainty about the
transaction.
HP and Compaq also may agree to restrictions or conditions imposed by
antitrust authorities in order to obtain regulatory approval, and these
restrictions or conditions could harm the combined company's operations. No
additional shareowner approval is expected to be required for any decision by
HP or Compaq, after the special meeting of Compaq shareowners and the special
meeting of HP shareowners, to agree to any terms and conditions necessary to
resolve any regulatory objections to the Compaq merger.
42
In addition, during or after the statutory waiting periods, and even after
completion of the Compaq merger, governmental authorities could seek to block
or challenge the Compaq merger as they deem necessary or desirable in the
public interest. In addition, in some jurisdictions, a competitor, customer or
other third party could initiate a private action under the antitrust laws
challenging or seeking to enjoin the Compaq merger, before or after it is
completed. HP, Compaq or the combined company may not prevail, or may incur
significant costs, in defending or settling any action under the antitrust laws.
The stock price and business of HP may be adversely affected if the Compaq
merger is not completed.
If the Compaq merger is not completed, the price of HP common stock may
decline to the extent that the current market price of HP common stock reflects
a market assumption that the Compaq merger will be completed. In addition, HP's
business may be harmed to the extent that customers, suppliers and others
believe that the company cannot effectively compete in the marketplace without
the Compaq merger, or there is customer and employee uncertainty surrounding
the future direction of the product and service offerings and strategy of HP on
a standalone basis. In the event the Compaq merger is not completed, HP intends
to evaluate its strategic options for addressing the lack of profitability in
certain of its businesses. These strategic options may include further
workforce reductions, but HP currently has no specific plans regarding
workforce reductions in the event that the Compaq merger is not completed.
Completion of the Compaq merger is subject to several closing conditions,
including obtaining requisite regulatory and shareowner approvals, and HP and
Compaq may be unable to obtain such approvals on a timely basis or at all.
Walter B. Hewlett, Eleanor Hewlett Gimon, Mary Hewlett Jaffe and The William R.
Hewlett Revocable Trust have announced that they intend to vote against the
proposal to approve the issuance of HP common stock in connection with the
Compaq merger. In addition, each of The William and Flora Hewlett Foundation
and the David and Lucile Packard Foundation has announced its intention to vote
against the proposal to approve the issuance of HP common stock in connection
with the Compaq merger. Mr. Hewlett (co-trustee of The William R. Hewlett
Revocable Trust and Chairman of The William and Flora Hewlett Foundation),
Edwin van Bronkhorst (co-trustee of The William R. Hewlett Revocable Trust and
trustee of certain Hewlett family trusts) and The William R. Hewlett Revocable
Trust have mailed a proxy statement to HP shareowners to solicit proxies
against the proposal to approve the issuance of shares of HP common stock in
connection with the Compaq merger and have disseminated to HP shareowners
soliciting materials encouraging HP shareowners to vote against the issuance of
shares in connection with the Compaq merger. If the Compaq merger is not
completed, HP would not derive the strategic benefits expected to result from
the Compaq merger, such as creating a more complete and balanced product and
services portfolio and providing economies of scale in businesses such as PCs.
HP also will be required to pay significant costs incurred in connection with
the Compaq merger, including legal, accounting and a portion of the financial
advisory fees, whether or not the Compaq merger is completed. Moreover, under
specified circumstances, HP may be required to pay Compaq a termination fee of
$675 million in connection with the termination of the Compaq merger agreement.
Charges to earnings resulting from the application of the purchase method of
accounting may adversely affect the market value of HP's common stock following
the Compaq merger.
In accordance with United States generally accepted accounting principles,
the combined company will account for the Compaq merger using the purchase
method of accounting, which will result in charges to earnings that could have
a material adverse effect on the market value of the common stock of HP
following completion of the Compaq merger. Under the purchase method of
accounting, the combined company will allocate the total estimated purchase
price to Compaq's net tangible assets, amortizable intangible assets,
intangible assets with indefinite lives and in-process research and development
based on their fair values as of the date of completion of the Compaq merger
and record the excess of the purchase price over those fair values as goodwill.
The portion of the estimated purchase price allocated to in-process research
and development will be expensed by the combined company in the quarter in
which the Compaq merger is completed. The combined company will incur
additional depreciation and amortization expense over the useful lives of
certain of the net tangible and intangible assets acquired in connection with
the Compaq merger. In addition, to the extent the value of goodwill or
intangible assets with indefinite lives becomes impaired, the combined company
may be
43
required to incur material charges relating to the impairment of those assets.
These depreciation, amortization, in-process research and development and
potential impairment charges could have a material impact on the combined
company's results of operations.
Customer uncertainties related to the Compaq merger could adversely affect the
businesses, revenues and gross margins of HP and the combined company.
In response to the announcement of the Compaq merger or due to ongoing
uncertainty about the Compaq merger, customers of HP or Compaq may delay or
defer purchasing decisions or elect to switch to other suppliers. In
particular, prospective customers could be reluctant to purchase the combined
company's products due to uncertainty about the direction of the combined
company's product offerings and willingness to support and service existing
products. To the extent that the Compaq merger creates uncertainty among those
persons and organizations contemplating hardware, software or service purchases
such that one large customer, or a significant group of smaller customers,
delays, defers or changes purchases in connection with the planned Compaq
merger, the revenues of HP or the combined company would be adversely affected.
HP continues to believe that, consistent with prior assumptions, there is a
risk of customer loss due to uncertainties relating to the Compaq merger.
However, neither HP nor Compaq is aware of any loss of customers, individually
or in the aggregate, as a result of the Compaq merger process that would have a
material impact on their respective results of operations. Customer assurances
may be made by HP and Compaq to address their customers' uncertainty about the
direction of the combined company's product and related support offerings which
may result in additional obligations of HP or the combined company.
Accordingly, quarterly revenues and net earnings of HP or the combined company
could be substantially below expectations of market analysts and a decline in
HP's stock price could result.
Changes in HP's and Compaq's credit ratings could adversely affect the costs
and expenses of the combined company.
Any downgrade in the credit ratings of HP, Compaq or the combined company
associated with the Compaq merger could adversely affect the ability of the
combined company to borrow and result in more restrictive borrowing terms,
including increased borrowing costs, more restrictive covenants and the
extension of less open credit. This in turn could affect the combined company's
internal cost of capital estimates and therefore operational decisions. Prior
to the announcement of the Compaq merger, HP's senior unsecured debt ratings
were Aa3 (with negative outlook) from Moody's Investors Service and AA- from
Standard & Poor's, and Compaq's senior unsecured debt ratings were Baa2 from
Moody's and BBB from Standard & Poor's. After the Compaq merger announcement,
Moody's downgraded HP to A2 (with negative outlook), and Standard & Poor's
maintained its AA- rating but placed HP on CreditWatch with negative
implications pending further review, while Moody's and Standard & Poor's
maintained Compaq's rating and placed it under review for a possible upgrade.
Subsequently, in December 2001, Standard & Poor's placed Compaq on CreditWatch
with developing implications. The ultimate impact of the Compaq merger on the
combined company's credit ratings, however, cannot be predicted.
In order to be successful, the combined company must retain and motivate key
employees, which will be more difficult in light of uncertainty regarding the
Compaq merger, and failure to do so could seriously harm the combined company.
In order to be successful, the combined company must retain and motivate
executives and other key employees, including those in managerial, technical,
marketing and information technology support positions. In particular, the
combined company's product generation efforts depend on hiring and retaining
qualified engineers. Attracting and retaining skilled solutions providers in
the IT support business and qualified sales representatives is also critical to
the combined company's future. Experienced management and technical, marketing
and support personnel in the information technology industry are in high demand
and competition for their talents is intense. This is particularly the case in
Silicon Valley, where HP's headquarters and certain key research and
development facilities are located. Employee retention may be a particularly
challenging issue in
44
connection with the Compaq merger. Accordingly, the compensation committee of
the HP board of directors (consisting of Philip M. Condit, Sam Ginn and Walter
B. Hewlett) and the human resources committee of the Compaq board of directors
(then consisting of Lawrence T. Babbio, Judith L. Craven and Kenneth L. Lay),
acting on the authority of the HP board of directors and the Compaq board of
directors, respectively, designed and adopted retention programs to assure the
continued dedication of key employees and to provide key employees with
financial incentives to remain with the combined company following the
completion of the Compaq merger. A number of factors, however, may counteract
the benefits of these retention programs. In particular, employees of HP or
Compaq may experience uncertainty about their future role with the combined
company until or after strategies with regard to the combined company are
announced or executed. This circumstance may adversely affect the combined
company's ability to attract and retain key management, marketing and technical
personnel. The combined company also must continue to motivate employees and
keep them focused on the strategies and goals of the combined company, which
may be particularly difficult due to the potential distractions of the Compaq
merger, morale challenges posed by the separate workforce reductions being
implemented by HP and Compaq and the additional workforce reductions of the
combined company anticipated in connection with the Compaq merger.
The economic downturn could adversely affect the revenues, gross margins and
expenses of the combined company.
The revenues and gross margins of the combined company will depend
significantly on the overall demand for computing and imaging products and
services, particularly in the product and service segments in which it will
compete. Softening demand for the products and services of HP and Compaq caused
by the ongoing economic downturn may result in decreased revenues, earnings
levels or growth rates and problems with the saleability of inventory and
realizability of customer receivables for the combined company. The global
economy has weakened and market conditions continue to be challenging. As a
result, individuals and companies are delaying or reducing expenditures,
including those for information technology. HP and Compaq have observed effects
of the global economic downturn in many areas of their businesses. The downturn
has contributed to reported net revenue declines during the 2001 fiscal year
for both companies. Each of HP and Compaq has also experienced gross margin
declines, reflecting the effect of competitive pressures as well as, in the
case of HP, inventory writedowns and charges associated with the cancellation
of planned production line expansion. HP's selling, general and administrative
expense also was impacted due in part to an increase in bad debt write-offs and
additions to reserves in its receivables portfolio. The economic downturn has
also led to restructuring actions and contributed to writedowns to reflect the
impairment of certain investments in HP's and Compaq's respective investment
portfolios. Further delays or reductions in information technology spending
could have a material adverse effect on demand for the combined company's
products and services, and consequently, its results of operations, prospects
and stock price.
The competitive pressures the combined company will face could harm its
revenues, gross margins and prospects.
The combined company will encounter aggressive competition from numerous and
varied competitors in all areas of its business, and will compete primarily on
the basis of technology, performance, price, quality, reliability, brand,
distribution, customer service and support. If the combined company fails to
develop new products, services and support, periodically enhance its existing
products, services and support, or otherwise compete successfully, it could
harm its operations and prospects. Further, the combined company may have to
continue to lower the prices of many of its products, services and support to
stay competitive, while at the same time trying to maintain or improve gross
margins. We believe that the Compaq merger will result in improvements to gross
margin on a combined company basis, principally through lower procurement costs
and the elimination of redundant headcount. In businesses such as PCs and
low-end servers, the ability to respond to competitive pricing pressures by
effectively managing inventory costs will be particularly important. The Compaq
merger will also bring to HP Compaq's low-cost sales model and distribution
capabilities in PCs and low-end servers. However, if the combined company
cannot proportionately decrease its cost structure in response to competitive
price pressures, its gross margins and therefore the profitability of the
combined company could be adversely affected.
45
If the combined company cannot continue to develop, manufacture and market
innovative products and services rapidly that meet customer requirements for
performance and reliability, it may lose market share and its revenues may
suffer.
The process of developing new high technology products and services is
complex and uncertain, and failure to anticipate customers' changing needs and
emerging technological trends accurately and to develop or obtain appropriate
intellectual property could significantly harm the combined company's results
of operation. The combined company must make long-term investments and commit
significant resources before knowing whether its predictions will eventually
result in products that the market will accept. After a product is developed,
the combined company must be able to manufacture sufficient volumes quickly and
at low costs. To accomplish this, it must accurately forecast volumes, mix of
products and configurations that meet customer requirements, and it may not
succeed.
If the combined company does not effectively manage the transition from
existing products to new products, its revenues may suffer.
If the combined company does not make an effective transition from existing
products to new products, its revenues may be seriously harmed. Among the
factors that make a smooth transition from current products to new products
difficult are delays in product development or manufacturing, variations in
product costs, delays in customer purchases of existing products in
anticipation of new product introductions and customer demand for the new
product. The combined company's revenues and gross margins also may suffer due
to the timing of product or service introductions by its suppliers and
competitors. This is especially challenging when a product has a short life
cycle or a competitor introduces a new product just before the combined
company's own product introduction. Furthermore, sales of the combined
company's new products may replace sales of some of the current products of HP
and Compaq, offsetting the benefit of even a successful product introduction.
There also may be overlaps in the current products of HP and Compaq product
portfolios that must be managed in connection with the Compaq merger. If the
combined company incurs delays in new product introductions, or does not
accurately estimate the market effects of new product introductions, given the
competitive nature of its industry, future demand for its products and its
revenues may be seriously harmed.
The combined company's revenues and selling, general and administrative
expenses will suffer if it cannot continue to license or enforce the
intellectual property rights on which its business will depend or if third
parties assert that the combined company violates their intellectual property
rights.
The combined company generally will rely upon patent, copyright, trademark
and trade secret laws in the United States and similar laws in other countries,
and agreements with its employees, customers, partners and other parties, to
establish and maintain its intellectual property rights in technology and
products used in the combined company's operations. However, any of its
intellectual property rights could be challenged, invalidated or circumvented,
or its intellectual property rights may not provide competitive advantages,
which could significantly harm its business. Also, because of the rapid pace of
technological change in the information technology industry, much of the
combined company's business and many of its products will rely on key
technologies developed by third parties, and the combined company may not be
able to obtain or renew licenses and technologies from these third parties at
all or on reasonable terms. Third parties also may claim that the combined
company is infringing upon their intellectual property rights. Even if the
combined company does not believe that its products or business are infringing
upon third parties' intellectual property rights, the claims can be
time-consuming and costly to defend and divert management's attention and
resources away from the combined company's business. Claims of intellectual
property infringement also might require the combined company to enter into
costly settlement or license agreements. If the combined company cannot or does
not license the infringed technology at all or on reasonable terms or
substitute similar technology from another source, its operations could suffer.
In addition, it is possible that as a consequence of the Compaq merger, some
intellectual property rights of the combined company may be licensed to a third
party that had not been licensed prior to the creation of the combined company
or that certain restrictions could be imposed on the business of the
46
combined company that had not been imposed on the business of HP or Compaq
prior to the Compaq merger. Consequently, the combined company may lose a
competitive advantage with respect to these intellectual property rights or the
combined company may be required to enter into costly arrangements in order to
terminate or limit these agreements.
If the combined company fails to manage distribution of its products and
services properly, or if its distributors' financial condition or operations
weaken, the combined company's revenues and gross margins could be adversely
affected.
The combined company will use a variety of different distribution methods to
sell its products and services, including third-party resellers and
distributors and both retail and direct sales to both enterprise accounts and
consumers. Since each distribution method has distinct risks and gross margins,
the failure of the combined company to implement the most advantageous balance
in the delivery model for its products and services could adversely affect the
gross margins and therefore profitability of the combined company. For example:
. As the combined company continues to increase its commitment to direct
sales, it could risk alienating channel partners and adversely affecting
its distribution model.
Since direct sales made by the combined company may compete with the
sales made by third-party resellers and distributors, these third-party
resellers and distributors may elect to use other suppliers that do not
directly sell their own products. Because not all of the combined
company's customers will prefer to or seek to purchase directly, any
increase by the combined company of its commitment to direct sales in
order to increase its gross margins could alienate some of its channel
partners. As a result, the combined company may lose some of its
customers who purchase from third-party resellers or distributors.
Moreover, uncertainty regarding the Compaq merger may cause some of the
combined company's distributors to strengthen relationships with other
vendors.
. Some of the combined company's wholesale and retail distributors may be
unable to withstand changes in business conditions.
Some of the combined company's wholesale and retail distributors may
have insufficient financial resources and may not be able to withstand
changes in business conditions, including the recent economic downturn
and changes that may result from the Compaq merger. Revenues from
indirect sales by the combined company could suffer if its distributors'
financial condition or operations weaken.
. Inventory management of the combined company will be complex as the
combined company will continue to sell a significant mix of products
through distributors.
The combined company must manage inventory effectively, particularly
with respect to sales to distributors. Distributors may increase orders
during periods of product shortages, cancel orders if their inventory is
too high, or delay orders in anticipation of new products. Distributors
also may adjust their orders in response to the supply of the combined
company's products and the products of its competitors that are
available to the distributor and seasonal fluctuations in end-user
demand. If the combined company has excess inventory, it may have to
reduce its prices and write down inventory, which in turn could result
in lower gross margins.
The combined company will depend on third-party suppliers and its revenues and
gross margins could be adversely affected if it fails to receive timely
delivery of quality components or if it fails to manage inventory levels
properly.
The manufacturing operations of the combined company will depend on the
combined company's ability to anticipate its needs for components and products
and its suppliers' ability to deliver quality components and products in time
to meet critical manufacturing and distribution schedules. Given the wide
variety of systems, products and services that the combined company will offer
and the large number of its suppliers and contract
47
manufacturers that are dispersed across the globe, problems could arise in
planning production and managing inventory levels that could seriously harm the
combined company. Among the problems that could arise are component shortages,
excess supply and risks related to fixed-price contracts that would require the
combined company to pay more than the open market price.
. Supply shortages. The combined company occasionally may experience a
short supply of certain component parts as a result of strong demand in
the industry for those parts or problems experienced by suppliers. If
shortages or delays persist, the price of these components may increase,
or the components may not be available at all. The combined company may
not be able to secure enough components at reasonable prices and of
acceptable quality to build new products in a timely manner in the
quantities and configurations needed. Accordingly, the revenues and
gross margins of the combined company could suffer until other sources
can be developed.
. Oversupply. In order to secure components for the production of new
products, at times the combined company may make advance payments to
suppliers, or it may enter into non-cancelable purchase commitments with
vendors. If the combined company fails to anticipate customer demand
properly, a temporary oversupply of parts could result in excess or
obsolete components which could adversely affect the combined company's
gross margins.
. Long-term pricing commitments. As a result of binding price or purchase
commitments with vendors, the combined company may be obligated to
purchase components at prices that are higher than those available in
the current market. In the event that the combined company becomes
committed to purchase components for prices in excess of the current
market price, it may be at a disadvantage to competitors who have access
to components at lower prices, and the combined company's gross margins
could suffer.
Due to the international nature of the combined company's business, political
or economic changes could harm its future revenues, costs and expenses and
financial condition.
At the time of the completion of the Compaq merger, sales outside the United
States will make up more than half of the combined company's revenues. The
future revenues, costs and expenses of the combined company could be adversely
affected by a variety of international factors, including:
. changes in a country's or region's political or economic conditions;
. longer accounts receivable cycles;
. trade protection measures;
. overlap of different corporate structures;
. unexpected changes in regulatory requirements;
. differing technology standards and/or customer requirements;
. import or export licensing requirements, which could affect the combined
company's ability to obtain favorable terms for components or lead to
penalties or restrictions;
. problems caused by the conversion of various European currencies to the
Euro and macroeconomic dislocations that may result; and
. natural disasters.
A portion of the combined company's product and component manufacturing,
along with key suppliers, also will be located outside of the United States,
and also could be disrupted by some of the international factors described
above. In particular, each of HP and Compaq, along with most other PC vendors,
has engaged manufacturers in Taiwan for the production of notebook computers.
In 1999, Taiwan suffered a major earthquake, and in 2000 it suffered a typhoon,
both of which resulted in temporary communications and supply disruptions. In
addition, the combined company will procure components from Japan, which also
suffers from earthquakes periodically.
48
The combined company will be exposed to foreign currency exchange rate and
interest rate risks that could adversely affect the revenues and gross margins
of the combined company.
The combined company will be exposed to foreign currency exchange rate risk
that will be inherent in its sales commitments, anticipated sales, and assets
and liabilities that are denominated in currencies other than the United States
dollar. The combined company also will be exposed to interest rate risk
inherent in its debt and investment portfolios. Failure to sufficiently hedge
or otherwise manage foreign currency risks properly could adversely affect the
combined company's revenues and gross margins.
Impairment of investment and financing portfolios could harm the combined
company's net earnings.
The combined company will have an investment portfolio that will include
minority equity and debt investments and financing for the purchase of the
combined company's products and services. In most cases, the combined company
will not attempt to reduce or eliminate its market exposure on these
investments and may incur losses related to the impairment of these investments
and therefore charges to net earnings. Some of the combined company's
investments will be in publicly and privately held companies that are still in
the start-up or development stage, which have inherent risks because the
markets for the technologies or products they have under development are
typically in the early stages and may never develop. Furthermore, the values of
the combined company's investments in publicly-traded companies will be subject
to significant market price volatility. The combined company's investments in
technology companies often will be coupled with a strategic commercial
relationship. The combined company's commercial agreements with these companies
may not be sufficient to allow it to obtain and integrate such products or
technology into its technology or product lines or otherwise benefit from the
relationship, and these companies may be subsequently acquired by third
parties, including competitors of the combined company. Moreover, due to the
economic downturn and difficulties that may be faced by some of the companies
to which HP, Compaq or the combined company has supplied financing, the
combined company's investment portfolio could be further impaired.
In order to manage their portfolios of products and technology and further
their competitive objectives, HP and Compaq must successfully complete
acquisitions and alliances that enhance their strategic businesses and product
lines and divest non-strategic businesses and product lines.
As part of their business strategies, HP and Compaq frequently engage in
discussions with third parties regarding, and enter into agreements relating
to, possible acquisitions, strategic alliances, joint ventures and divestitures
in order to manage their respective product and technology portfolios and
further strategic objectives. It is expected that the combined company will
engage in similar transactions. In order to pursue this strategy successfully,
the combined company must identify suitable acquisition, alliance or
divestiture candidates, complete these transactions, some of which may be large
and complex, and integrate acquired companies. Integration and other risks of
acquisitions and strategic alliances can be more pronounced for larger and more
complicated transactions, or if multiple acquisitions are pursued
simultaneously. The integration of HP and Compaq may make the completion and
integration of subsequent acquisitions more difficult. However, if the combined
company fails to identify and complete these transactions, it may be required
to expend resources to internally develop products and technology or may be at
a competitive disadvantage or may be adversely affected by negative market
perceptions, which may have a material effect on the revenues and selling,
general and administrative expenses of the combined company taken as a whole.
In 2001, HP completed acquisitions of StorageApps, Inc., a provider of
storage virtualization solutions, and Bluestone Software, Inc., which became
part of HP's middleware division. Compaq acquired assets from InaCom Corp. to
add custom configuration capabilities and direct fulfillment logistics in 2000.
These and other acquisitions and strategic alliances may require the combined
company to integrate with a different company culture, management team and
business infrastructure and otherwise manage integration risks. Even if an
acquisition or alliance is successfully integrated, the combined company may
not receive the expected benefits of the transaction. Managing acquisitions,
alliances and divestitures requires varying levels of management
49
resources, which may divert the combined company's attention from other
business operations. These transactions also may result in significant costs
and expenses and charges to earnings. As a result, any completed, pending or
future transactions may contribute to the combined company's financial results
differing from the investment community's expectations in a given quarter.
Terrorist acts and acts of war may seriously harm the combined company's
business and revenues, costs and expenses and financial condition.
Terrorist acts or acts of war (wherever located around the world) may cause
damage or disruption to the combined company, its employees, facilities,
partners, suppliers, distributors and resellers, and customers, which could
significantly impact the combined company's revenues, costs and expenses and
financial condition. The terrorist attacks that took place in the United States
on September 11, 2001 were unprecedented events that have created many economic
and political uncertainties, some of which may materially harm the combined
company's business and results of operations. The long-term effects on the
combined company of the September 11, 2001 attacks are unknown. The potential
for future terrorist attacks, the national and international responses to
terrorist attacks, and other acts of war or hostility have created many
economic and political uncertainties, which could adversely affect the business
and results of operations of HP or the combined company in ways that cannot
presently be predicted. In addition, as major multi-national companies with
headquarters and significant operations located in the United States, any of
HP, Compaq or the combined company may be impacted by actions against the
United States. The combined company will be predominantly uninsured for losses
and interruptions caused by terrorist acts and acts of war.
Business disruptions could seriously harm the future revenues and financial
condition and increase the costs and expenses of the combined company.
The combined company's worldwide operations could be subject to natural
disasters and other business disruptions which could seriously harm its
revenues and financial condition and increase its costs and expenses. The
corporate headquarters of the combined company, a portion of its research and
development activities, other critical business operations and some of its
suppliers will be located in California, near major earthquake faults. The
ultimate impact on the combined company, its significant suppliers and its
general infrastructure of being located near major earthquake faults is
unknown, but the combined company's revenues, financial condition and costs and
expenses could be significantly impacted in the event of a major earthquake. In
addition, some areas, including California, have experienced, and may continue
to experience, ongoing power shortages, which have resulted in "rolling
blackouts." These blackouts could cause disruptions to the operations of the
combined company or the operations of its suppliers, distributors and
resellers, or customers. The combined company will be predominantly uninsured
for losses and interruptions caused by earthquakes, power outages and other
natural disasters.
Unforeseen environmental costs could impact the future net earnings of the
combined company.
Some of the combined company's operations will use substances regulated
under various federal, state and international laws governing the environment.
The combined company could be subject to liability for remediation if it does
not handle these substances in compliance with applicable laws. It will be the
combined company's policy to apply strict standards for environmental
protection to sites inside and outside the United States, even when not subject
to local government regulations. The combined company will record a liability
for environmental remediation and related costs when it considers the costs to
be probable and the amount of the costs can be reasonably estimated. Neither HP
nor Compaq has incurred environmental costs that are presently material to it,
and neither HP nor Compaq is presently subject to known environmental
liabilities that it expects to be material.
The revenues and profitability of the operations of HP and Compaq have
historically varied.
The revenues and profit margins of HP and Compaq vary among their respective
products, customer groups and geographic markets. The revenue mix of the
combined company will be different than the revenue
50
mix of either HP or Compaq alone, particularly with respect to the proportion
contributed by personal computers and printing and imaging devices and
supplies. Overall profitability in any given period is dependent partially on
the product, customer and geographic mix reflected in that period's net
revenue, and therefore revenue and gross margin trends cannot be reliably
predicted. Actual trends may cause the combined company to adjust its
operations, which could cause period-to-period fluctuations in the combined
company's results of operations.
Failure to successfully execute planned cost reductions could result in total
costs and expenses for the combined company that are greater than expected.
Historically, each of HP and Compaq has separately undertaken restructuring
plans to bring operational expenses to appropriate levels for each of its
businesses, while simultaneously implementing extensive new company-wide
expense-control programs. In addition to the previously announced workforce
reductions of the separate companies, the combined company may have additional
workforce reductions. The planned workforce reductions are expected to involve
approximately 15,000 employees of the combined company worldwide, representing
approximately 10% of the combined company's workforce, and workforce reductions
would also be expected if the proposed Compaq merger were not completed.
Significant risks associated with these actions that may impair the ability of
the combined company to achieve anticipated cost reductions or that may
otherwise harm its integration efforts or business include delays in
implementation of anticipated reductions in force in highly regulated locations
outside of the United States, particularly in Europe and Asia, redundancies
among restructuring programs, and the failure to meet operational targets due
to the loss of employees or decreases in employee morale.
The effective tax rate of the combined company is uncertain.
The impact of the Compaq merger on the overall effective tax rate of the
combined company is uncertain. Although the combined company will attempt to
optimize its overall effective tax rate, it is impossible to predict the
effective tax rate of the combined company accurately. The combination of the
operations of HP and Compaq may result in an overall effective tax rate for the
combined company that is higher than HP's currently reported tax rate, and it
is possible that the combined effective tax rate of HP and Compaq as a combined
company may exceed the weighted average of the pre-Compaq merger tax rates of
HP and Compaq.
Some anti-takeover provisions contained in HP's certificate of incorporation,
bylaws and shareowner rights plan, as well as provisions of Delaware law, could
impair a takeover attempt.
HP has provisions in its certificate of incorporation and bylaws, each of
which could have the effect of rendering more difficult or discouraging an
acquisition deemed undesirable by the HP board of directors. These include
provisions:
. authorizing blank check preferred stock, which could be issued with
voting, liquidation, dividend and other rights superior to its common
stock;
. limiting the liability of, and providing indemnification to, directors
and officers;
. limiting the ability of HP shareowners to call special meetings;
. requiring advance notice of shareowner proposals for business to be
conducted at annual meetings of HP shareowners and for nominations of
candidates for election to the HP board of directors;
. controlling the procedures for conduct of board and shareowner meetings
and election and removal of directors; and
. specifying that shareowners may take action only at a duly called annual
or special meeting of shareowners.
These provisions, alone or together, could deter or delay hostile takeovers,
proxy contests and changes in control or management of HP.
51
In addition, HP has adopted a shareowner rights plan. The rights are not
intended to prevent a takeover of HP. However, the rights may have the effect
of rendering more difficult or discouraging an acquisition of HP deemed
undesirable by the HP board of directors. The rights will cause substantial
dilution to a person or group that attempts to acquire HP on terms or in a
manner not approved by the HP board of directors, except pursuant to an offer
conditioned upon redemption of the rights.
As a Delaware corporation, HP is also subject to provisions of Delaware law,
including Section 203 of the Delaware General Corporation law, which prevents
some shareowners from engaging in certain business combinations without
approval of the holders of substantially all of HP's outstanding common stock.
Any provision of HP's certificate of incorporation or bylaws, HP's
shareowner rights plan or Delaware law that has the effect of delaying or
deterring a change in control could limit the opportunity for HP shareowners
(including former Indigo shareholders who become HP shareowners upon completion
of the exchange offer) to receive a premium for their shares of HP common
stock, and could also affect the price that some investors are willing to pay
for HP common stock.
52
HP'S BUSINESS FOLLOWING THE COMPLETION OF THE COMPAQ MERGER
The following section of this prospectus provides information regarding HP's
business following the completion of the Compaq merger. You should be aware
that the exchange offer is not conditioned upon the completion of the Compaq
merger. There are uncertainties and risks associated with the Compaq merger.
See the section titled "Risk Factors--Risks Regarding the Compaq Merger and HP
and Compaq as a Combined Company." We cannot assure you that we will complete
the Compaq merger. If the Compaq merger is not ultimately completed, we
currently expect that we would continue our business as a separate business.
Overview of Business Structure
Following completion of the Compaq merger, the combined company will operate
in over 160 countries and expects to have approximately 145,000 employees after
expected headcount reductions through attrition and targeted job reductions. As
of October 31, 2001, unaudited pro forma combined consolidated total assets of
HP and Compaq were approximately $69.2 billion. In addition, for the year ended
October 31, 2001, unaudited pro forma combined consolidated total net revenue
for HP and Compaq was $81.7 billion and earnings from operations were
$1.2 billion. These amounts are not intended to represent or be indicative of
the amounts that would have been reported had the Compaq merger been completed
as of the dates presented, and should not be taken as representative of the
future consolidated results of operations or financial condition of HP. See the
unaudited pro forma condensed combined consolidated financial statements and
accompanying notes included in HP's current report on Form 8-K filed with the
Securities and Exchange Commission on February 14, 2002 incorporated by
reference into this prospectus.
As soon as practicable following the Compaq merger, HP intends to merge
Compaq into HP. The combined company will retain its headquarters in Palo Alto,
California and will retain a significant presence in Houston, Texas, which will
be a key strategic center of engineering excellence and product development for
the combined company.
HP and Compaq plan to integrate their businesses and product lines and
organize the combined company's business into four major groups:
. Enterprise Systems;
. Services;
. Imaging and Printing Systems; and
. Personal Systems.
In addition to these primary business groups, the combined company will
include several corporate level organizations. Among these will be HP Labs,
which will include part of Compaq's research and development function, an
organization focused on corporate philanthropy and community responsibility and
a corporate operations organization focused on areas of cross-company
opportunity, including procurement. We currently intend that the combined
company will use the HP brand for existing HP branded products and new products
that will be introduced after the completion of the merger, while retaining the
Compaq brand and Compaq sub-brands for selected enterprise, commercial and
consumer product lines.
Enterprise Systems
The Enterprise Systems group will be led by Mr. Blackmore, currently
Compaq's Executive Vice President, Worldwide Sales and Services, and will
include servers, storage and software. It will provide a full line of computing
systems from high-volume industry standard servers to high-end, fault-tolerant
systems; a wide range of storage solutions from mid-range and high-end array
systems, to storage area networks and storage area management software; and
industry leading offerings in management software, integrated services
management and next generation operating environments.
Services
The Services group will be led by Ms. Livermore, currently President of HP
Services, and will provide support, consulting and outsourcing to help design,
build, and manage and support the Enterprise Systems group.
53
The combined services organization is expected to include 65,000 professionals
around the world. The business offerings of the Services group will include
ongoing support and maintenance, in addition to proactive services like
mission-critical support, and networking services, IT consulting and system
integration services, and comprehensive and selective outsourcing.
Imaging and Printing Systems
The Imaging and Printing group will be led by Mr. Joshi, currently HP's
President of Imaging and Printing Systems. The offerings of the Imaging and
Printing group will continue to include HP LaserJet and Inkjet printer hardware
(both monochrome and color), multi-function laser devices, wide- and
large-format Inkjet printers, printing supplies, scanners, digital photography
products, personal color copiers, faxes and all-in-one products that combine
multiple functions like scanning, copying and printing in one device. HP's
investment in, and pending acquisition of, Indigo, N.V., a leading provider of
high performance digital printing systems used in the production of on-demand,
short-run color digitally-printed products, is designed to enhance HP's
strategy in the evolving commercial printing market. Indigo is expected to add
a third high-speed color print technology to HP's highly successful Inkjet and
LaserJet technologies.
Personal Systems
The Personal Systems group will be led by Mr. Zitzner, currently HP's
President of Computing Systems, and will include business and consumer desktop
and mobile personal computers, workstations, handheld computing devices, new
types of Internet-access devices, personal storage devices, and digital music
and entertainment devices. The Personal Systems group will focus on serving
customers through multiple channels including strong distributor, reseller, and
retail channel efforts, in addition to directly serving customers through the
Internet and by telephone.
Integration Office
HP recognizes the challenge inherent in integrating enterprises of the size
and complexity of HP and Compaq. HP also recognizes that a swift and successful
integration of the two companies is crucial to capturing the potential value of
the Compaq merger. Accordingly, HP has established an integration office that
will report directly to Ms. Fiorina. This office will be run jointly by Mr.
McKinney and Mr. Clarke, each a key executive officer at HP and Compaq,
respectively. Mr. McKinney currently serves as the President of HP's Business
Customer Organization and provides a proven record as a line manager and deep
expertise in the HP organization. Mr. Clarke currently serves as Compaq's
Senior Vice President, Finance and Administration, and Chief Financial Officer
and provides his depth of knowledge of the IT industry and of Compaq. Mr.
Clarke also brings significant expertise in finance and general corporate
matters. The integration office now consists of more than 450 dedicated
employees, supported by advisors and divided into teams with specifically
defined functions.
By the time of completion of the Compaq merger, the integration office plans
to have established:
. an operating model and organization to design and implement a transition
plan and provide internal clarity regarding asset and resource
allocation and priorities, go-to-market strategy and customer account
responsibilities;
. management structure, roles and responsibilities multiple layers into
the organization, as well as compensation and human resource policies,
which we believe will encourage our employees to focus on business
performance and avoid the distraction of personal and organizational
uncertainty;
. clear product roadmaps and investment protection programs, which we
believe will give our customers a high degree of confidence in our
ability to meet or exceed their business requirements without disrupting
their existing relationship with us or their installed technology
platform; and
. standard policies, practices and procedures to govern our relationships
with our partners and facilitate a smooth transition of our respective
commercial arrangements to the combined company.
54
SPECIAL FACTORS
Background of the Exchange Offer
The offer agreement and the terms and conditions of the exchange offer are
the result of negotiations between representatives of HP and representatives of
Indigo. The following summary describes the background of these negotiations.
HP and Indigo have been familiar with each other's businesses for many
years, and, in November 1998, HP and Indigo entered into a strategic
affiliation agreement providing for, among other things, the exploration of the
development and sale of digital color printing products combining HP's and
Indigo's respective technologies as more fully described in the section titled
"--Relationships Between HP and Indigo" in this prospectus.
At various times over the past three years, senior executives of HP and
Indigo discussed the possibility of entering into a more extensive strategic
relationship involving the two companies. In the fall of 1998, HP explored
strategic alternatives with Indigo but no action was taken. In January 2000, HP
and Indigo held meetings and Indigo suggested that HP consider a more formal
strategic relationship, including a potential business combination, as a means
for HP to penetrate the high-end digital printing market. In the spring of
2000, Indigo and HP again held discussions regarding a possible business
combination and engaged in various levels of analysis regarding such a
combination. However, the parties could not agree as to pricing. During this
period, Indigo also held discussions with other competitors of Indigo to
consider possible business combinations or other strategic alternatives.
Indigo's combined board considered each of these options as well as the
prospect of continuing to operate Indigo as an independent publicly-traded
company and determined that the value to Indigo's shareholders from each of
these other strategic alternative options would be less than the likely value
that would be realized by continuing to operate Indigo independently.
Therefore, Indigo determined to continue operations as a stand-alone entity.
During the various occasions on which business combination discussions were
held between HP and Indigo, the parties could not reach preliminary agreement
on the valuation of Indigo. Since the parties were unable to reach an agreement
on valuation, they did not believe that it would be productive to take further
action with respect to these business combination discussions. The primary
reason behind the parties' disagreement on the valuation of Indigo was based on
the fact that Indigo had maintained the belief that its products would gain
more acceptance in the near term and HP had not been willing to increase its
valuation of Indigo based on the projected increase in future sales. Although
other strategic alternatives had been considered, Indigo had been unable to
find other suitors which would pay a price Indigo believed was justified by its
own projections of future growth.
In September 2000, HP and Indigo entered into a commercial relationship
providing for (1) HP's sale of specified digital color printing products on an
OEM basis pursuant to an OEM agreement; and (2) the co-development by HP and
Indigo of future digital color printing systems and products pursuant to a
co-development agreement. In connection with the September 2000 commercial
relationship, Hewlett-Packard Europe B.V., a subsidiary of HP, purchased
14,814,814 Indigo common shares for an aggregate purchase price of
approximately $100 million and received a performance warrant to purchase up to
12,000,000 Indigo common shares at an exercise price of $6.75 per share
exercisable in tranches of 2,000,000 shares for each $100 million of cash
revenues generated and paid by us to Indigo under our commercial agreements and
an acquisition warrant to purchase 14,814,815 Indigo common shares at an
exercise price of $6.75 per share upon the acquisition of Indigo by us or one
of our subsidiaries. In connection with the September 2000 commercial
relationship, HP, Hewlett-Packard Europe B.V., Gemini Systems Corporation N.V.,
Toscal N.V., OZF Ltd., Visionvest Corporation N.V., Walthroup Corporation N.V.,
Deering Corporation N.V., S-C Indigo CV, and Indigo also entered into a
shareholders' agreement dated as of September 13, 2000. Pursuant to the
shareholders' agreement, Hewlett-Packard Europe B.V. agreed that prior to
October 17, 2002 neither it nor any of its affiliates, including HP, would
directly or indirectly acquire, announce an intention to acquire, offer, seek,
or propose to acquire any common shares or other voting securities of Indigo,
except at the invitation of the chief executive officer or the
55
supervisory board of Indigo. The September 2000 transactions between HP and
Indigo are more fully described in the section titled "--Relationships Between
HP and Indigo" in this prospectus.
Between September 2000 and May 2001, both parties directed their efforts
towards performing their obligations under the terms of the co-development and
OEM agreements. However, as time progressed, it became evident that some
aspects of the agreements should be revisited with a view to adapting them to
more readily meet strategic needs of the companies.
In March 2001, representatives of HP, including Mr. William P. McGlynn, Vice
President and General Manager, Digital Publishing Solutions, and Mr. Landa held
discussions regarding the existing agreements and the relationships between HP
and Indigo. A discussion ensued among the parties regarding a potential
acquisition of Indigo by HP as well as a re-negotiation of the existing
agreements.
In April 2001, following a meeting of the Indigo combined board, Mr. Landa
informed HP that the board had rejected the concept of a potential acquisition
of Indigo by HP.
On May 30, 2001 and May 31, 2001, representatives of HP and Indigo,
including Mr. Landa, met in San Diego, California, to discuss the existing
agreements and the relationship between HP and Indigo. A discussion ensued
among the parties regarding a potential acquisition of Indigo by HP.
From June 19, 2001 through June 21, 2001, representatives of HP and Indigo,
including Mr. Landa, met in New York, New York, to discuss further the
possibility of an acquisition of Indigo by HP. At these meetings, the parties
discussed the business, strategy and integration issues that would be involved
in any acquisition of Indigo by HP.
On July 11, 2001, a teleconference was held between representatives of HP
and representatives of Gleacher, Indigo's financial advisor. Gleacher had been
formally engaged by Indigo on August 3, 2000 to act as Indigo's financial
advisor in connection with the September 2000 transactions between HP and
Indigo and in connection with any future business combination transaction
involving Indigo. In late May 2001, Indigo had requested that Gleacher again
become involved in connection with seeking a proposed business combination
transaction involving Indigo.
On July 20, 2001, the full HP board of directors met and discussed a
potential business combination with Indigo. The HP board of directors
authorized HP's management to continue its discussions with Indigo.
On July 23, 2001, John D. Brennan, HP's Vice President of Strategy and
Corporate Development, had a telephone conversation with Mr. Landa. As required
under the shareholders' agreement, Mr. Brennan confirmed that Mr. Landa, in his
capacity as the Chief Executive Officer of Indigo, was inviting HP to make a
proposal regarding a potential business combination between HP and Indigo.
Mr. Brennan then outlined to Mr. Landa the terms of a non-binding proposal by
HP to acquire Indigo. Messrs. Brennan and Landa did not engage in any further
discussions regarding the non-binding proposal presented by Mr. Brennan at that
time. Following the telephone conversation, Mr. Brennan sent Mr. Landa a letter
summarizing HP's non-binding proposal. Terms of that proposal included
consideration for each Indigo common share comprised of $6.75 in HP common
stock and CVRs providing for up to $2.25 of additional consideration upon the
achievement of certain revenue goals by Indigo after the closing of the
transaction. Terms of this proposal included an exchange offer structure, which
HP proposed as the most practicable structure for the transaction under Dutch
law.
On July 25, 2001, Indigo's combined board conducted its quarterly meeting
and discussed, among other matters, the terms of HP's proposal. The combined
board concluded that a higher proportion of the aggregate consideration should
be in the form of HP common stock payable at the closing and a smaller portion
attributable to the CVR component. Dr. Joel S. Birnbaum, a member of Indigo's
supervisory board designated by HP, did not attend or participate in this
meeting or any other Indigo board meeting since his election on January 24,
2001 other than one meeting on April 30, 2001.
56
On July 26, 2001, a teleconference to discuss HP's non-binding proposal was
held between representatives of HP, HP's outside counsel, Wilson Sonsini
Goodrich & Rosati, Indigo's outside counsel, Gibson, Dunn & Crutcher, and
Gleacher. The Indigo representatives reviewed with HP the results of Indigo's
board meeting of the previous day, including the board's conclusion that a
higher proportion of the aggregate consideration should be in the form of HP
common stock payable at the closing and a smaller portion attributable to the
CVR component. Specifically, the Indigo boards authorized a counterproposal
consisting of $7.50 of HP common stock payable at closing with a CVR providing
for up to $1.50 of additional consideration, a ratio of up-front consideration
to CVR of 5 to 1. A discussion ensued among the parties on the call, with no
resolution reached as to the pricing of the possible transaction.
On July 27, 2001, Mr. Landa telephoned Mr. McGlynn to clarify the terms of
HP's non-binding proposal. Mr. Landa reiterated with Mr. McGlynn the conclusion
of Indigo's board that a higher proportion of the aggregate consideration
should be in the form of HP common stock payable at the closing and a smaller
portion attributable to the CVR component.
On July 27, 2001, a teleconference to discuss HP's non-binding proposal
further was held between Mr. Landa and representatives of HP. Mr. Landa
reiterated to HP that a higher proportion of the aggregate consideration should
be in the form of HP common stock payable at the closing and a smaller portion
attributable to the CVR component. No resolution was reached as to the pricing
of the possible transaction.
On July 30, 2001, a teleconference to discuss the pricing of the possible
transaction was held between representatives of HP, Wilson Sonsini Goodrich &
Rosati, Gibson, Dunn & Crutcher, and Gleacher. A discussion ensued among the
parties on the call, with no resolution reached as to the pricing of the
possible transaction.
On July 31, 2001, a teleconference to further discuss the pricing of the
possible transaction was held between representatives of HP, including Mr.
Brennan, HP's and Indigo's respective legal counsel and Gleacher. Mr. Brennan
reviewed the terms of HP's written proposal with Indigo's representatives. A
discussion ensued among the parties on the call, with no resolution reached as
to the pricing of the possible transaction.
On August 8, 2001, a teleconference to further discuss the pricing of the
possible transaction was held between representatives of HP, Gibson Dunn &
Crutcher and Gleacher. During the call, representatives of HP indicated that HP
would consider a modification to the structure of its proposal, provided that
the aggregate amount of up-front and contingent consideration was not changed.
A discussion ensued among the parties on the call, with no resolution reached
as to the pricing of the possible transaction.
On August 9, 2001, Mr. Landa and Mr. McGlynn had a telephone conversation in
which Mr. Landa indicated that Indigo was willing to discuss a structure in
which Indigo shareholders could elect between receiving solely HP common stock
or a combination of HP common stock and CVRs. No resolution as to the structure
of the possible transaction was reached.
On August 10, 2001, Mr. Brennan and Mr. Landa had a telephone conversation
in which Mr. Landa proposed a structure in which fifty percent of Indigo common
shares would receive a combination of HP stock and CVRs, and fifty percent of
Indigo common shares would receive solely HP common stock. Subject to obtaining
the necessary corporate approvals and resolution of remaining issues, Mr. Landa
and Mr. Brennan agreed to continue discussions based on this pricing structure.
The consideration election structure was devised in order to meet the goals
of both parties. Because HP wished to limit the aggregate amount of up-front
consideration in HP common stock issuable to Indigo shareholders at the closing
of this transaction, Indigo proposed a structure in which the Indigo
shareholders would be offered a choice between electing (1) to receive the
entire consideration for each Indigo common share in $7.50 worth of HP common
stock at the closing, with no contingent right to share in the potential future
success of the combined Indigo business, or (2) to take $6.00 in HP common
stock at the closing but have the
57
opportunity to share the benefits from potential future success of the combined
Indigo business. This structure would give Indigo shareholders the ability to
make a choice between the two consideration alternatives based upon their
individual preferences and meet HP's requirement that the aggregate amounts of
up-front and contingent consideration as proposed by HP remain unchanged. Also,
given the willingness of the Landa Family Trust and the entities directly or
indirectly owned by the Landa Family Trust to receive the undersubscribed
consideration, each shareholder other than the Landa Family Trust was assured
that he or she would receive at least 82% of the preferred choice of
consideration.
From August 14, 2001 through August 16, 2001, several meetings between
representatives of HP and Indigo were held at HP's corporate offices in Palo
Alto, California to discuss, among other things, the proposed business strategy
and operational structure of Indigo in light of the proposed transaction.
On August 15, 2001, a teleconference to initiate due diligence in connection
with the proposed transaction was held between representatives of HP, Indigo,
Gibson Dunn & Crutcher and Gleacher. A discussion among the parties ensued
regarding the due diligence process.
On August 22, 2001, a teleconference to discuss open issues regarding the
proposed transaction was held between representatives of HP, Indigo, their
respective legal counsel and Gleacher. A discussion among the parties ensued
regarding the structure of the proposed transaction.
On August 24, 2001, Mr. Brennan and Mr. Chris Robell, HP's Strategy and
Corporate Development Director, met at the San Francisco International Airport
with Mr. Landa and Mr. Alon Bar-Shany, Indigo's Chief Financial Officer, to
discuss further the structure of the proposed transaction.
On August 27, 2001, HP and Wilson Sonsini Goodrich & Rosati circulated an
initial draft of the offer agreement, together with initial drafts of the
voting agreements, tender agreements, tender and option agreement, and
affiliate agreements, to Indigo and Gibson, Dunn & Crutcher.
On August 28, 2001, HP and Wilson Sonsini Goodrich & Rosati circulated an
initial draft of the form of CVR agreement to Indigo and Gibson, Dunn &
Crutcher.
On August 29, 2001, Gibson, Dunn & Crutcher prepared and sent to Wilson
Sonsini Goodrich & Rosati Indigo's comments to the initial draft of the offer
agreement, the form of CVR agreement and the other related agreements. HP and
Indigo continued to negotiate the terms of the offer agreement, the form of CVR
agreement and the related agreements from this date through September 6, 2001,
the date the definitive offer agreement was executed.
On August 30, 2001, HP and Indigo entered into a Confidential Disclosure
Agreement, which superceded an earlier non-disclosure agreement under which the
parties had been operating and which had expired.
From August 30, 2001 to August 31, 2001, representatives of HP and Indigo,
their respective legal counsel and Gleacher met at the offices of Wilson
Sonsini Goodrich & Rosati in Palo Alto, California to continue negotiations on
all agreements.
On August 31, 2001, Mr. Landa met with Carleton S. Fiorina, Chairman of the
Board, President and Chief Executive Officer of HP, and Vyomesh Joshi,
President of HP's Imaging and Printing Systems, to discuss the structure of the
CVRs.
On August 31, 2001, the HP board of directors authorized HP to acquire all
the outstanding Indigo common shares by way of an exchange offer.
From September 3, 2001 through September 6, 2001, representatives of HP and
Indigo, their respective legal counsel and Gleacher met at the offices of
Wilson Sonsini Goodrich & Rosati in Palo Alto, California to
58
continue negotiations on all agreements. On September 4, 2001, the parties
discussed the announcement of the merger agreement entered into by HP and
Compaq. The parties continued to negotiate the terms of the agreements.
On September 4, 2001, Indigo's management board, supervisory board and
combined board met to consider the terms of the exchange offer. At the meeting,
representatives of Gleacher summarized the terms of the exchange offer.
Representatives from Gibson, Dunn & Crutcher reviewed and explained the terms
of the drafts of the exchange offer documents that had been previously
distributed to the members of the boards. Dr. Birnbaum did not attend or
participate in this meeting.
On September 5, 2001, Indigo's management board, supervisory board and
combined board met again to consider the terms of the exchange offer. A copy of
a memorandum had been previously sent to each member of the boards summarizing
the terms of the latest drafts of the exchange offer agreement. Representatives
of Gibson, Dunn & Crutcher reviewed with the boards and discussed in detail the
provisions of the exchange offer documents. Representatives of Gleacher
provided a detailed review of a document that had been distributed to each of
the combined board members prior to the meeting and that outlined the terms of
the exchange offer. Based on that document, Gleacher rendered its oral opinion
that, as of that date and based upon and subject to the matters set forth in
Gleacher's written opinion, the aggregate consideration to be offered to the
holders of Indigo common shares was fair, from a financial point of view, to
the holders of Indigo common shares, other than HP and its affiliates. Gleacher
expressed no opinion as to the fairness of either the fixed price consideration
or the contingent price consideration separately. Each of the supervisory,
management and combined board, acting without Dr. Birnbaum, separately and
unanimously approved the offer agreement and the transactions contemplated
thereby.
On September 5, 2001, the executive committee of HP's board of directors,
pursuant to authority delegated to it by HP's board of directors, approved the
exchange offer.
On September 6, 2001, upon completion of all negotiations and finalization
of all agreements, HP and Indigo executed and delivered the offer agreement,
the applicable parties signed the related agreements, and HP and Indigo issued
a joint press release announcing the transaction.
Indigo's Purposes and Reasons for the Exchange Offer
In approving the offer agreement and the transactions contemplated thereby,
and recommending that all affiliated and unaffiliated shareholders of Indigo
tender their common shares pursuant to the offer, the management board, the
supervisory board and the combined board of Indigo, excluding Dr. Birnbaum,
considered a number of factors in favor of recommending acceptance of the
offer, including the following:
. The current financial condition and results of operations, as well as
the prospects and future strategy, of Indigo, including the risks
involved in achieving those prospects and objectives without a
well-financed, strategically placed parent company, such as HP. The
boards of Indigo, in their deliberations, focused on the current and
expected trends in the digital printing market and in the printing
industry generally. In particular, the Indigo boards were concerned that
two of Indigo's larger competitors, both of which are better financed
and possess greater marketing prowess than Indigo, were introducing new
digital high-speed printers which, if successful, could greatly impair
the growth of Indigo's business. The current financial condition and
results of operations, as well as Indigo's position as one of the
industry leaders in commercial printing, led the boards to believe that
Indigo could continue to operate successfully as an independent
publicly-traded company. However, the boards also believed that the
risks involved in attempting to continue to operate Indigo independently
without a well-financed, strategically placed parent company outweighed
the benefits of operating the Indigo business with an established
business partner such as HP and that the consideration offered in the
offer is a superior alternative to the Indigo shareholders to continuing
to operate Indigo independently in light of the uncertainty inherent in
59
forecasting future market conditions and trends. As indicated above, the
Indigo boards were most concerned about new products that were
introduced by its competitors in 2001 and were concerned as to how those
introductions could impact Indigo's ability to grow its revenue.
. The fact that, pursuant to the offer agreement (1) the holders of Indigo
common shares can elect either to participate in the potential success
of the Indigo business by electing the contingent offer price of $6.00,
subject to adjustment, in HP common stock and a CVR or to choose the
fixed offer price of $7.50, subject to adjustment, in HP common stock
and (2) if a holder wished to elect one or the other offer price option,
such election would be honored as much as possible because, pursuant to
the tender and option agreement, entities directly or indirectly owned
by a foundation, the Landa Family Trust, of which Benzion Landa,
Indigo's Chairman and Chief Executive Officer, is a beneficiary, have
agreed, to the extent that either the fixed offer price or the
contingent offer price is oversubscribed, to elect automatically to
receive the undersubscribed consideration alternative for up to all of
the Indigo common shares held by each of those shareholders.
. The opinion rendered by Gleacher on September 6, 2001 to the effect
that, as of the date of the opinion and based on and subject to the
matters described in its opinion, the aggregate consideration provided
for in the offer agreement to be received by the holders of Indigo
common shares was fair, from a financial point of view, to the holders
of Indigo common shares, other than HP and its affiliates. Gleacher
expressed no opinion as to the fairness of either the fixed price
consideration or the contingent price consideration separately. The full
text of Gleacher's opinion is attached to this prospectus as Annex D.
The full text of Gleacher's presentations to the Indigo boards on
September 5, 2001 has been included as exhibits (c)(iii), (c)(iv) and
(c)(v) to the Transaction Statement on Schedule 13E-3 filed by HP,
Indigo and Benzion Landa in connection with the exchange offer.
. The consideration to be offered to the holders of Indigo common shares
receiving the contingent offer price, assuming no value is ascribed to
the CVR, implies premiums relative to Indigo's closing share price one
day, one week and four weeks prior to May 31, 2001, the date of the
commencement of Indigo's share repurchase program of 32.3%, 34.4%, and
51.4% respectively, and the consideration to be offered to the holders
of Indigo common shares receiving the fixed offer price implies premiums
relative to Indigo's closing share price one day, one week and four
weeks prior to May 31, 2001 of 50.0%, 52.4% and 71.6%, respectively.
. The ability of the combined company to access markets beyond Indigo's
reach, particularly the enterprise market.
. The ability of the combined company to link together database mining
capabilities, digital workflow tools, design tools and web-based
publishing capabilities in a seamless network, for corporate customers
to be able to more easily generate digital printing jobs--creating more
demand for Indigo digital presses.
. The ability of the combined company more rapidly to develop new products
as well as enhancements to Indigo's existing products.
. The ability of the combined company to enable its customers to be better
able to grow their businesses by delivering complete workflow
solutions--from document creation to print production.
. The size, stability and reputation of HP, as well as the HP brand, which
are expected to induce more customers to adopt Indigo digital printing
products.
Indigo's management board, supervisory board and combined board, excluding
Dr. Birnbaum, each considered each of the following factors to be against
recommending acceptance of the exchange offer:
. The likelihood that while some Indigo shareholders will prefer to
receive HP common stock and, if applicable, a CVR, some may have
preferred to continue as shareholders of Indigo, and that if the
exchange offer is completed, the shareholders of Indigo will no longer
be able to or it will be very unattractive for them to maintain an
equity ownership interest in Indigo.
60
. That the current Indigo shareholders, particularly the unaffiliated
shareholders who are not directly involved in the transaction and the
future operation of the combined Indigo business, invested in Indigo
with a view towards reaping the benefit of successful operation of the
Indigo business, and, unless an Indigo shareholder chooses the
contingent consideration alternative and receives a CVR, under which
there is no guarantee of a payout, any benefit to be received by an
Indigo shareholder from the future success of the Indigo business after
the exchange offer will be limited to the indirect gain through
ownership of HP common stock.
. The possibility that HP may not be able to or may choose not to
implement the underlying business plans of Indigo and thus diminish the
likelihood of any payments being made under the CVRs and the magnitude
of any payments that are made.
. The fact that the offer will be a taxable transaction to United States
Indigo shareholders.
. The Landa Family Trust and the entities directly or indirectly owned by
the Landa Family Trust, which have agreed to receive the undersubscribed
consideration, do not have the choice to elect to receive the
consideration alternative of their preference.
The foregoing includes the material factors considered by Indigo's
management board, supervisory board and combined board.
In view of its many considerations, the management board, the supervisory
board and the combined board did not quantify or otherwise assign relative
weights to the specific factors considered. In addition, individual members of
the management board, supervisory board and combined board may have given
different weights to different factors. After weighing all these
considerations, the management board, the supervisory board and the combined
board, excluding Dr. Birnbaum, were unanimous in determining to approve the
offer agreement and to recommend that the affiliated and unaffiliated
shareholders of Indigo tender their common shares in the exchange offer.
Indigo's Belief Regarding the Fairness of the Exchange Offer
Indigo's management board, supervisory board and combined board, excluding
Dr. Birnbaum, believe that the offer is fair to and in the best interests of
Indigo's affiliated and unaffiliated shareholders based upon numerous factors,
including the following:
. The fact that the consideration to be offered to the holders of Indigo
common shares receiving the contingent offer price, assuming no value is
ascribed to the CVR, implies premiums relative to Indigo's closing share
price one day, one week and four weeks prior to May 31, 2001, the date
of the commencement of Indigo's share repurchase program of 32.3%, 34.4%
and 51.4%, respectively, and the consideration to be offered to the
holders of Indigo's common shares receiving the fixed offer price
implies premiums relative to Indigo's closing share price one day, one
week and four weeks prior to May 31, 2001 of 50.0%, 52.4% and 71.6%,
respectively.
. The unanimous approval and recommendation of Indigo's supervisory,
management and combined boards, acting without Dr. Birnbaum, that Indigo
shareholders tender their Indigo common shares in the exchange offer.
. The fact that Indigo engaged Gleacher, an internationally recognized
investment bank, and that Gleacher rendered an opinion that subject to
the assumptions and limitations in the opinion, the aggregate
consideration provided for pursuant to the offer agreement to be
received by the holders of Indigo common shares was fair to the holders
of Indigo common shares, other than HP or its affiliates, from a
financial point of view.
. The fact that the various valuation, financial and comparative analyses
considered by Gleacher and described below implied enterprise values for
Indigo ranging from $42 million to $513 million based on a comparable
company analysis, from $47 million to $825 million based on a precedent
transaction
61
analysis, from $280 million to $664 million based on a discounted cash
flow analysis, from $319 million to $713 million based on a discounted
equity value analysis and from $715 million to $775 million based on a
premiums paid analysis. The aggregate consideration to be offered to
holders of Indigo common shares by HP compared favorably with these
analyses. As calculated by Gleacher, the aggregate consideration to be
offered to holders of Indigo common shares is $738 million and
$932 million, assuming values ascribed to the CVR of $0 and $3.00 (the
present value of the maximum CVR payout of $4.50, discounted at 12.0%).
. The fact that the offer agreement was extensively negotiated between the
representatives of Indigo and representatives of HP.
. The factors considered by the Indigo boards referred to above under
"Special Factors--Indigo's Purposes and Reasons for the Exchange Offer."
. In addition, the Indigo boards expressly adopt Gleacher's analyses
described below regarding Indigo's net book value and going concern
value. As to liquidation value, Gleacher informed the Indigo boards
that, in Gleacher's professional opinion, given the specific
characteristics of Indigo and the proposed transaction, Gleacher did not
deem a liquidation value to be a relevant metric because liquidation
analyses assess the value of assets of a company were they to be sold,
as opposed to a company's going concern value. The going concern metric
was deemed to be the more appropriate metric for Indigo as its value as
a going concern was more favorable.
The Indigo boards did not consider whether this transaction was fair or
advisable from the perspective of one who will receive the minimum
consideration. While the Indigo boards have recommended that the Indigo
shareholders accept the exchange offer and tender their shares pursuant to the
exchange offer, they have not recommended that a shareholder select the fixed
or the contingent price consideration. In evaluating the offer agreement, the
Indigo boards considered the overall value of the consideration being offered
and the fact that each shareholder had the ability to elect the consideration
alternative of preference, subject to proration. In light of the contractual
commitment by the LFT Entities to receive the underscribed consideration, each
shareholder is guaranteed to receive at least 82% of her preferred
consideration election. This means that if all Indigo shareholders elected the
fixed price consideration and assuming the CVR had no value, each unaffiliated
Indigo shareholder would receive a minimum blended per share price of $7.23
($7.50 per share for 82% of his or her Indigo common shares and $6.00 per share
for 18% of his or her Indigo common shares).
The Indigo boards, excluding Dr. Birnbaum, further believe that the
following procedural safeguards were sufficient to ensure that the exchange
offer was considered in a manner that was procedurally fair to Indigo's
affiliated and unaffiliated shareholders notwithstanding any actual or
potential conflicts of interest with HP:
. Dr. Birnbaum did not participate in any deliberations of the Indigo
boards regarding the exchange offer; and
. the approval by the Indigo boards of the exchange offer included an
approval by a majority of the non-management, non-affiliated independent
directors who have no relationship with HP.
The independent Indigo directors did not retain an "unaffiliated
representative," within the meaning of Regulation M-A under the Securities Act
and the Exchange Act, to act solely on behalf of unaffiliated shareholders of
Indigo for purposes of negotiating the terms of the exchange offer, because the
independent directors of Indigo, who have no affiliation with HP, believe that
they acted solely on behalf of the unaffiliated shareholders of Indigo. In
addition, the sale of Indigo was not structured to require the approval of a
majority of Indigo's shareholders other than HP, because of Mr. Landa's role in
negotiating the transaction with HP. As indicated above, the Landa Family
Trust, of which Mr. Landa is a beneficiary, holds 47.6 million Indigo common
shares or approximately 49.62% of the outstanding Indigo common shares not
including Indigo common shares owned by HP, as of December 31, 2001.
Notwithstanding the absence of an "unaffiliated representative" and a vote of
the majority of the shareholders unaffiliated with HP, the Indigo boards,
excluding Dr. Birnbaum (who has recused himself), believe that the exchange
offer is fair to and in the best interests of Indigo's affiliated and
unaffiliated shareholders.
62
As noted above, Dr. Birnbaum did not participate in the board meetings
relating to the offer agreement or the exchange offer. Due to HP's interest in
the proposed transaction, Dr. Birnbaum received the opinion of Gleacher to
Indigo's combined board referred to in "--Opinion of Indigo Financial Advisor
Regarding the Exchange Offer" solely in his capacity as a member of Indigo's
supervisory board, and not for use in his capacity as a representative of HP or
in any other capacity and not for the use of HP.
Recommendation of the Indigo Boards
After careful consideration, and in light of the factors described above
under the headings "--Indigo's Purposes and Reasons for the Exchange Offer" and
"--Indigo's Belief Regarding the Fairness of the Exchange Offer," Indigo's
management board, supervisory board and combined board separately and,
excluding Dr. Birnbaum, unanimously have determined that the offer agreement
and the exchange offer are at a price and terms that are favorable and fair to,
and in the best interests of, Indigo and its affiliated and unaffiliated
shareholders and recommends that Indigo shareholders accept the exchange offer
and tender their shares pursuant to the exchange offer. The Indigo boards do
not make any recommendations as to whether the Indigo shareholders should elect
to receive the fixed offer price or the contingent offer price.
Opinion of Indigo Financial Advisor Regarding the Exchange Offer
Indigo engaged Gleacher to act as its financial advisor in connection with a
proposed business combination transaction with HP based upon Gleacher's
qualifications, expertise and reputation. In connection with this engagement,
the combined board of Indigo requested Gleacher to evaluate the fairness, from
a financial point of view, of the consideration to be offered to the holders of
Indigo common shares (other than HP and its affiliates) pursuant to the offer
agreement. On September 5, 2001, the combined board convened (via telephone
conference) to review the proposed transaction with HP and the terms of the
offer agreement and other relevant agreements. During this meeting, Gleacher
rendered its oral opinion, which, on September 6, 2001, was subsequently
confirmed in writing, that, as of that date, based upon and subject to the
various matters set forth in Gleacher's opinion, the aggregate consideration to
be offered was fair, from a financial point of view, to the holders of Indigo
common shares (other than HP and its affiliates). The Gleacher fairness
determination addresses only the fairness, from a financial point of view, of
the aggregate consideration to be offered to the holders of Indigo common
shares as opposed to the actual consideration that could be received by an
individual Indigo shareholder. Gleacher expressed no opinion as to the fairness
of either the fixed price consideration or the contingent price consideration
separately. Gleacher expressed no opinion as to the prices at which the Indigo
common shares and HP common stock would trade following announcement of the
execution of the offer agreement or upon consummation of the transactions
contemplated thereby.
The full text of Gleacher's opinion, which sets forth, among other things,
the assumptions made, procedures followed, matters considered, and limitations
on the review undertaken in connection with the delivery of this opinion, is
attached to this prospectus as Annex D. Holders of Indigo common shares are
urged to read Gleacher's opinion carefully and in its entirety. The summary of
Gleacher's opinion set forth in this prospectus is qualified in its entirety by
reference to the full text of this opinion which is incorporated herein by
reference.
Gleacher's opinion is addressed to the combined board of Indigo and is
directed only to the fairness, from a financial point of view, of the aggregate
consideration to be offered to the holders of Indigo common shares (other than
HP and its affiliates) and is not intended to and does not constitute a
recommendation as to whether Indigo, or any holder of Indigo common shares,
should elect to engage in any transaction contemplated by the offer agreement
or to exchange Indigo's common shares in the exchange offer or as to what
election any holder of Indigo common shares should make with respect to the
exchange offer if such holder chooses to exchange Indigo common shares in the
exchange offer. Although Gleacher evaluated the financial terms of the exchange
offer, Gleacher was not asked to and did not express any opinion as to whether
Indigo should engage in the transactions contemplated by the offer agreement on
terms set forth therein, which were the result of negotiations between Indigo
and HP.
63
In connection with rendering its opinion, Gleacher, among other things:
. reviewed certain publicly-available financial statements and other
information of Indigo and HP;
. reviewed certain internal financial statements and other financial and
operating data concerning Indigo prepared by the management of Indigo;
. analyzed certain financial forecasts prepared by the management of
Indigo, which forecasts Indigo's management represented to Gleacher were
consistent with their best judgments as to the future financial
performance of Indigo and were the best then available forecasts with
respect to such future financial performance of Indigo and which
forecasts did not materially differ from those financial projections
described in the section titled "Summary Indigo Financial Projections"
on page 84 except that the financial projections relied on by Gleacher
included a long-term revenue growth rate of approximately 25%, in
contrast to the long-term growth rate set forth on page 86 of 30% or
higher;
. discussed with Indigo's management and other senior executives the past
and current operations and financial condition and the prospects of
Indigo;
. discussed with senior executives of HP the past and current operations
and financial condition and the prospects of HP;
. reviewed the reported prices and historical trading activity of Indigo
common shares and the HP common stock;
. compared the financial performance of Indigo and HP and the reported
prices and historical trading activity of Indigo common shares and the
HP common stock with that of certain other comparable publicly-traded
companies and their securities;
. reviewed the financial terms, to the extent publicly available, of
certain comparable acquisition transactions;
. reviewed a draft of the offer agreement and certain related documents;
and
. performed such other analyses and considered such other factors as
Gleacher deemed appropriate.
In rendering its opinion, Gleacher assumed and relied upon, without
independent verification, the accuracy and completeness of the financial and
other information reviewed by it for the purposes of its opinion. With respect
to the financial projections provided to Gleacher, with the consent of the
combined board of Indigo, Gleacher assumed that they had been reasonably
prepared and were consistent with the best then-available estimates and
judgments of Indigo's management as to the future financial performance of
Indigo. Gleacher did not, with the permission of the combined board of Indigo,
discuss with HP financial forecasts, with respect to HP, which were prepared by
unaffiliated financial analysts, but Gleacher assumed that such forecasts
represent the best then available estimates of the future financial performance
of HP. Further, HP did not provide to Gleacher any internally prepared
financial forecasts with respect to HP. Gleacher assumed no responsibility for
and expressed no view as to such forecasts or the assumptions on which they
were based, and, with respect to Indigo, relied upon the assurances of Indigo's
management that they were unaware of any facts that would make the information
provided to or reviewed by it incomplete or misleading. Gleacher also assumed,
based upon the information which was provided to it and without assuming
responsibility for independent verification therefore, that no material
undisclosed liability existed with respect to Indigo or HP. Gleacher did not
make any independent valuation or appraisal of the assets or liabilities
(contingent or otherwise) of Indigo or HP or any of their subsidiaries, nor was
Gleacher furnished with any such valuations or appraisals. Gleacher assumed
that the acquisition transaction described in the offer agreement will be
accounted for as a purchase transaction in accordance with U.S. generally
accepted accounting principles, commonly referred to as "U.S. GAAP," and will
constitute a taxable transaction under the Internal Revenue Code. Gleacher also
assumed that the acquisition transaction will be consummated in accordance with
the terms set forth in the offer agreement (which Gleacher assumed would be
substantially in the form of the draft provided to it) and that all of the
representations and warranties of the parties to the offer agreement were true,
that the covenants of each party to the offer agreement
64
will be fully complied with, and that all conditions to the acquisition
transaction set forth in the offer agreement will be satisfied and not waived,
in each case, in all respects material to Gleacher's analysis. In addition,
with the consent of the combined board of Indigo, Gleacher did not consider the
effects of, either on the financial projections of HP or otherwise, nor did
Gleacher analyze, any recently announced transactions involving HP, including
the announced merger transaction between HP and Compaq Computer Corporation.
Gleacher's opinion is necessarily based on economic, market and other
conditions as in effect on, and the information made available to it as of, the
date of its opinion. It should be understood that, although subsequent
developments may affect its opinion, Gleacher does not have any obligation to
update, revise or reaffirm its opinion.
Gleacher's opinion addresses only the fairness, from a financial point of
view, of the consideration to be offered to the holders of Indigo common shares
(other than HP and its affiliates), and Gleacher does not express any view as
to any other term of the proposed acquisition transaction or any other matters
contemplated by the offer agreement. Gleacher's opinion does not address
Indigo's underlying business decision to effect the transactions contemplated
by the offer agreement, nor does it value the HP common stock.
The following is a brief summary of the material valuation, financial and
comparative analyses considered by Gleacher in connection with the rendering of
its opinion. This summary does not purport to be a complete description of the
analyses underlying Gleacher's opinion. This summary of the analyses also
contains information in tabular format. In order fully to understand the
financial analyses used by Gleacher, the tables must be read in conjunction
with the related text. The tables alone do not constitute a complete
description of the financial analyses summarized therein.
Transaction Summary. Gleacher reviewed the principal terms of the offer
agreement, noting, among other things, the following:
. The transaction is to be structured as an exchange offer pursuant to
which each outstanding Indigo common share tendered into the offer would
be exchanged, at the election of the holder thereof and subject to the
proration and other provisions contained in the offer agreement, for (i)
the fixed offer price or (ii) the contingent offer price. The fixed
offer price is equal to a number of shares of HP common stock computed
as follows:
. if the average of the closing sales prices of the HP common stock on
the New York Stock Exchange for the twenty consecutive trading days
ending on the third trading day prior to the date on which we
initially accept for payment Indigo common shares tendered into the
exchange offer is less than or equal to $23.68 and greater than or
equal to $16.69, the fixed offer price shall be equal to the quotient
obtained by dividing $7.50 by such average HP closing sales price;
. if such average HP closing sales price is less than $16.69, the fixed
offer price shall be equal to 0.4494; and
. if such average HP closing sales price is greater than $23.68, the
fixed offer price shall be equal to 0.3167.
The contingent offer price is equal to the contingent price exchange
ratio plus one contingent value right, or CVR. The contingent price
exchange ratio equals a number of shares of HP common stock computed as
follows:
. if the average of the closing sales prices of the HP common stock on
the New York Stock Exchange for the twenty consecutive trading days
ending on the third trading day prior to the date on which we
initially accept for payment Indigo common shares tendered into the
exchange offer is less than or equal to $23.68 and greater than or
equal to $16.69, the contingent price exchange ratio shall be equal
to the quotient obtained by dividing $6.00 by such average HP closing
sales price;
. if such average HP closing sales price is less than $16.69, the
contingent price exchange ratio shall be equal to 0.3595; and
65
. if such average HP closing sales price is greater than $23.68, the
contingent price exchange ratio shall be equal to 0.2534.
Each CVR entitles the holder to receive a cash payment equal to:
. if the LEP revenue during the three-year measuring period commencing
on the later of the first day of the first month subsequent to the
closing of the offer or February 1, 2002 is equal to or greater than
$1.6 billion, $4.50;
. if the LEP revenue during the measuring period is equal to or less
than $1.0 billion, $0; and
. if the LEP revenue during the measuring period is less than $1.6
billion but greater than $1.0 billion, the dollar amount equal to the
product of $4.50 and the quotient obtained by dividing (x) the number
by which LEP revenue exceeds $1.0 billion by (y) $600 million.
LEP revenue means the actual net revenue (to be based on U.S. GAAP, as
applied by HP consistent with its financial Securities and Exchange
Commission reporting practices as of the beginning of the measuring
period) from the sale or lease of LEP Digital Press Products and
Consumables (as such terms are defined in the CVR agreement) by HP and
its affiliates during the measuring period plus the present value, as of
the end of the measuring period, of remaining minimum contractually
committed payments associated with such digital press products placed
during the measuring period under operating leases (as more fully
described in the CVR agreement).
. Entities directly or indirectly controlled by the Landa Family Trust
agreed to formally support the transaction, through a commitment to
tender and to receive the undersubscribed consideration and the granting
of voting proxies, and to grant to HP options for their shares,
exercisable at the contingent offer price, which become exercisable upon
the breach by the Landa Family Trust entities of such tender agreements.
. The offer agreement provided for a termination fee of $27 million (plus
a maximum of $2 million of expenses), subject to the provisions of the
offer agreement.
. The acquisition transaction will be accounted for as a purchase
transaction in accordance with U.S. GAAP.
. The acquisition transaction is expected to constitute a taxable
transaction under the Internal Revenue Code.
Historical Trading Analysis. Gleacher reviewed the historical closing
prices of the HP common stock and Indigo common shares and the implied
historical exchange ratios, determined by dividing the closing price per Indigo
common share by the closing price per share of HP common stock, on certain
dates and over certain periods of time. The table below summarizes (i) the
implied historical exchange ratio as of September 4, 2001 and the average
implied historical exchange ratios for various periods leading up to and
including September 4, 2001 and (ii) the premium of an assumed fixed offer
price of 0.3975, based on the closing price of the HP common stock on September
4, 2001, to these implied historical exchange ratios.
Implied
Historical Fixed Offer
Day / Period Exchange Ratio Price Premium
------------ -------------- -------------
09/04/01.................................... 0.2814 41.2%
5 Trading Days.............................. 0.2694 47.5
10 Trading Days............................. 0.2628 51.2
15 Trading Days............................. 0.2623 51.5
30 Trading Days............................. 0.2537 56.7
60 Trading Days............................. 0.2294 73.2
90 Trading Days............................. 0.2088 90.3
180 Trading Days............................ 0.1727 130.2
252 Trading Days............................ 0.1585 150.7
66
Comparable Company Analysis. Gleacher reviewed selected financial
information, ratios, and public market multiples for certain selected
publicly-traded companies that Gleacher deemed relevant, with respect to Indigo
and HP, respectively.
For Indigo, the selected comparison group included a total of thirteen
companies: Agfa-Gevaert N.V.; Canon Inc.; Creo Products Inc.; Heidelberger
Druckmaschinen AG; Koenig & Bauer AG; Komori Corporation; NUR Macroprinters
Ltd.; Oce N.V.; Presstek, Inc.; Ricoh Company, Ltd.; Scitex Corporation Ltd.;
Xeikon N.V.; and Xerox Corporation, collectively referred to as the Indigo
comparable companies. Gleacher reviewed, among other information, the Indigo
comparable companies' ratios, or multiples, of enterprise value (equal to the
value of fully-diluted common equity plus total debt, preferred stock, and
minority interests, if any; less cash, cash equivalents, and the estimated
value of any unconsolidated assets, if any) to latest twelve months (or LTM),
calendar year 2001, and calendar year 2002 revenues and to calendar year 2002
earnings before interest, taxes, depreciation and amortization (or EBITDA), and
the ratio of equity value (equal to the value of fully-diluted common equity)
to book value. All data are based on publicly-available information and on
market information as of September 4, 2001. Estimated 2001 and 2002 revenues
and 2002 EBITDA figures were based upon estimates from various Wall Street
research analysts. The range, mean, and median of these ratios are summarized
in the table below.
Enterprise Value /
Revenues
----------------- Enterprise Value / Equity Value /
LTM 2001E 2002E 2002E EBITDA Book Value
---- ----- ----- ------------------ --------------
High.................... 2.87x 2.11x 1.50x 12.7x 3.2x
Low..................... 0.29 0.24 0.24 2.6 0.7
Mean.................... 1.05 0.98 0.87 7.5 1.6
Median.................. 1.02 0.99 0.80 7.6 1.3
Indigo (CVR @ $0)....... 4.13 3.74 2.99 40.8 6.6
Indigo (CVR @ $3.00).... 5.22 4.73 3.77 51.5 8.2
Gleacher calculated the multiples implied by enterprise values of $738
million and $932 million, based on the aggregate consideration to be offered to
holders of Indigo common shares assuming values ascribed to the CVR of $0 and
$3.00 (the present value of the maximum CVR payout of $4.50, discounted at
12.0%), respectively. Gleacher noted that the aggregate consideration to be
offered to holders of Indigo common shares, assuming no value ascribed to the
CVR, implies enterprise value multiples of 4.13x LTM revenues, 3.74x calendar
year 2001 revenues, 2.99x calendar year 2002 revenues, and 40.8x calendar year
2002 EBITDA, respectively, and an equity value multiple of 6.6x book value.
Gleacher further noted, for illustrative purposes only, that the aggregate
consideration to be offered to holders of Indigo common shares, assuming $3.00
of value ascribed to the CVR (the present value of the maximum CVR payout of
$4.50, discounted at 12.0%), implies enterprise value multiples of 5.22x LTM
revenues, 4.73x calendar year 2001 revenues, 3.77x calendar year 2002 revenues,
and 51.5x calendar year 2002 EBITDA, respectively, and an equity value multiple
of 8.2x book value.
67
For HP, the selected comparison group included a total of six companies:
Canon Inc.; Dell Computer Corporation; International Business Machines
Corporation; Lexmark International, Inc.; Sun Microsystems, Inc.; and Xerox
Corporation, collectively referred to as the HP comparable companies. Gleacher
reviewed, among other information, the HP comparable companies' ratios, or
multiples, of enterprise value to LTM revenues, EBITDA, and earnings before
interest and taxes (or EBIT); of equity value to LTM net income and book value;
and of price to estimated earnings per share (or EPS) for calendar years 2001
and 2002. All data are based on publicly available information and on market
information as of September 4, 2001. Estimated earnings per share figures are
based on Institutional Brokers Estimate System mean estimates. The range, mean,
and median of these ratios are summarized in the table below.
Enterprise Value / LTM Equity Value / LTM Price / EPS
--------------------- -------------------- ----------
Revenues EBITDA EBIT Net Income Book Value 2001E 2002E
-------- ------ ---- ---------- ---------- ----- -----
High............... 2.27x 20.0x 22.0x 28.7x 12.0x 34.1x 32.2x
Low................ 1.17 7.5 11.4 20.0 2.0 18.0 16.0
Mean............... 1.67 13.6 16.7 22.9 5.7 25.3 22.8
Median............. 1.67 12.5 16.1 21.4 4.9 22.2 21.0
HP................. 0.83 11.0 18.4 17.5 2.7 22.3 16.4
Gleacher noted that HP's current share price implies enterprise value
multiples of 0.83x LTM revenues, 11.0x LTM EBITDA, and 18.4x LTM EBIT,
respectively; equity value multiples of 17.5x LTM net income and 2.7x book
value, respectively; and price / EPS multiples of 22.3x and 16.4x estimated
earnings per share for calendar years 2001 and 2002, respectively.
No company used in the comparable company analysis is identical to Indigo or
HP. Accordingly, any comparable company analysis necessarily involves complex
considerations and judgments concerning differences in financial and operating
characteristics of Indigo and HP and other factors that could affect the public
trading value of the companies to which they are being compared. Mathematical
analysis (such as determining the mean or median) is not in itself a meaningful
method of using comparable company data.
Precedent Transaction Analysis. Gleacher reviewed the multiples and
premiums paid in certain selected public change of control transactions that
Gleacher deemed relevant. The selected comparison group included a total of
eight transactions (with respective announced enterprise values and closing
dates included in parentheses):
. Salsa Digital, Ltd. acquisition by NUR Macroprinters Ltd. ($30 million,
07/05/00);
. Scitex Corporation Ltd. (digital pre-print business) acquisition by Creo
Products Inc. ($537 million, 04/04/00);
. Tektronix Inc. (color printing division) acquisition by Xerox
Corporation ($950 million, 01/03/00);
. Idanit Technologies Ltd. acquisition by Scitex Corporation Ltd. ($60
million, first quarter of 1998);
. Linotype-Hell AG acquisition by Heidelberger Druckmaschinen AG ($152
million, fourth quarter of 1996);
. Rockwell International Corporation (graphic systems business)
acquisition by Stonington Partners, Inc. ($600 million, 10/15/96);
. Scitex Corporation Ltd. acquisition by an investor group led by Mr.
Davidi Gilo ($933 million, Canceled); and
. Imaje, S.A. acquisition by Dover Corporation ($212 million, 10/16/95)
(collectively referred to as the precedent transactions).
The consideration in each of the precedent transactions consisted of 100% cash,
with the exception of the Salsa Digital, Ltd. acquisition by NUR Macroprinters
Ltd., which consisted of a combination of cash and stock. None of the above
transactions had an election feature or a contingent value right component.
68
Gleacher reviewed, among other information, the ratios of enterprise value
to LTM revenues and of equity value to book value implied by the precedent
transactions. All data are based on publicly-available information. The range,
mean, and median of these ratios are summarized in the table below.
Enterprise Value / Equity Value /
LTM Revenues Book Value
------------------ --------------
High................................... 4.62x 5.0x
Low.................................... 0.26 1.5
Mean................................... 1.44 3.0
Median................................. 1.17 2.7
Indigo (CVR @ $0)...................... 4.13 6.6
Indigo (CVR @ $3.00)................... 5.22 8.2
Gleacher noted that the aggregate consideration to be offered to the holders
of Indigo common shares, assuming no value ascribed to the CVR, implies an
enterprise value multiple of 4.13x LTM revenues and an equity value multiple of
6.6x book value. Gleacher further noted, for illustrative purposes only, that
the aggregate consideration to be offered to holders of Indigo common shares,
assuming $3.00 of value ascribed to the CVR (the present value of the maximum
CVR payout of $4.50, discounted at 12.0%), implies an enterprise value multiple
of 5.22x LTM revenues and an equity value multiple of 8.2x book value.
No transaction used in the precedent transaction analysis is identical to
the exchange offer. Accordingly, any precedent transaction analysis necessarily
involves complex considerations and judgments concerning differences in
financial and operating characteristics of Indigo and other factors that could
affect the value of the companies to which it is being compared and of the
transactions to which the exchange offer is being compared. Mathematical
analysis (such as determining the mean or median) is not in itself a meaningful
method of using precedent transaction data.
Premiums Paid Analysis. Gleacher reviewed the premiums paid in a broad
group of selected public change-of-control transactions in the technology
sector with transaction values greater than $100 million, announced during 2000
and 2001. The analysis reflects approximately 225 transactions announced since
January 1, 2000, for which public data are available. Gleacher reviewed the
purchase premiums based on the targets' closing share prices one day, one week,
and four weeks prior to the announcement date of the respective transactions.
All data are based on publicly-available information and on market information
as of September 4, 2001. The mean and median of these premiums are summarized
in the table below.
Purchase Premiums
--------------------------
One Day One Week Four Weeks
------- -------- ----------
Mean........................................ 35.1% 42.8% 54.5%
Median...................................... 31.5 36.4 49.5
Indigo (CVR @ $0)........................... 32.3 34.4 51.4
Indigo (CVR @ $3.00)........................ 67.7 70.5 91.9
Gleacher noted that the aggregate consideration to be offered to the holders
of Indigo common shares, assuming no value ascribed to the CVR, implies
premiums relative to Indigo's closing share price one day, one week, and
four weeks prior to May 31, 2001, the date of the commencement of Indigo's
share repurchase program, of 32.3%, 34.4%, and 51.4%, respectively. Gleacher
further noted, for illustrative purposes only, that the aggregate consideration
to be offered to the holders of Indigo common shares, assuming $3.00 of value
ascribed to the CVR (the present value of the maximum CVR payout of $4.50,
discounted at 12.0%), implies premiums relative to Indigo's closing share price
one day, one week, and four weeks prior to May 31, 2001, of 67.7%, 70.5%, and
91.9%, respectively.
Discounted Cash Flow Analysis. Gleacher performed a discounted cash flow
analysis to calculate an estimate of the theoretical present value per
fully-diluted common share of Indigo using financial forecasts
69
through the fiscal year ending December 2005 that were prepared by the
management of Indigo. Gleacher utilized discount rates ranging from 12.0% to
13.0% and EBITDA terminal value multiples ranging from 8.0x to 10.0x. This
analysis showed a range of present values per fully-diluted Indigo share of
$5.00 to $6.12. Gleacher also performed a discounted cash flow analysis using a
separate set of financial forecasts through the fiscal year ending December
2005 that were prepared by the management of Indigo to reflect the potential
projected financial performance of Indigo under a more conservative scenario.
For the same respective ranges of discount rates and EBITDA terminal value
multiples, this analysis showed a range of present values per fully-diluted
Indigo share of $2.87 to $3.49. The Discounted Cash Flow Analysis did not
purport to be indicative of actual values or expected values of the Indigo
common shares before or after the acquisition transaction.
Discounted Equity Value Analysis. Gleacher performed a discounted equity
value analysis to calculate an estimate of the theoretical present value per
fully-diluted common share of the projected equity value for Indigo at the end
of 2003 and 2004, derived from net income valuation multiples applied to
projected 2003 and 2004 net income, respectively. Gleacher utilized discount
rates ranging from 12.0% to 13.0% and net income multiples ranging from 18.0x
to 22.0x. This analysis showed a range of present values per fully-diluted
Indigo share of $3.21 to $3.97 based on 2003 net income and $5.23 to $6.52
based on 2004 net income. This analysis did not purport to be indicative of
actual values or expected values of the Indigo common shares before or after
the acquisition transaction.
* * *
The preparation of a fairness opinion is a complex process and is not
necessarily susceptible to a partial analysis or summary description. Gleacher
believes that its analyses must be considered as a whole and that selecting
portions of its analyses, without considering all analyses, would create an
incomplete view of the process underlying its opinion and the presentation to
Indigo's management board, supervisory board and combined board. Gleacher has
not indicated that any of the analyses which it performed had a greater
significance than any other. In addition, Gleacher may have deemed various
assumptions more or less probable than other assumptions, so that the ranges of
valuations resulting from any particular analysis described above should not be
taken to be Gleacher's view of the actual value of Indigo.
In performing its analyses, Gleacher made numerous assumptions with respect
to industry performance, general business and economic conditions, and other
matters, many of which are beyond the control of either Indigo or HP. The
analyses performed by Gleacher are not necessarily indicative of actual values,
which may be significantly more or less favorable than suggested by such
analyses. Such analyses were prepared solely as a part of Gleacher's analysis
of the fairness, from a financial point of view, of the consideration to be
offered to the holders of Indigo common shares (other than HP and its
affiliates) and were provided to Indigo's combined board in connection with the
delivery of Gleacher's opinion. The analyses do not purport to be appraisals or
necessarily reflect the prices at which businesses or securities might actually
be sold, which are inherently subject to uncertainty. In addition, Gleacher's
opinion and presentation to Indigo's management board, supervisory board and
combined board was one of many factors taken into consideration by the
management board, supervisory board and combined board in connection with their
consideration of the exchange offer and the transactions contemplated by the
offer agreement. Consequently, analyses performed by Gleacher described above
should not be viewed as determinative of the opinion of the management board,
supervisory board and combined board or Indigo's management with respect to the
acquisition transaction.
Gleacher is an internationally-recognized investment banking and advisory
firm that regularly engages in the valuation of businesses and their securities
in connection with mergers and acquisitions.
Indigo has agreed to pay Gleacher a financial advisory fee of $5,500,000
pursuant to the terms of Gleacher's engagement letter dated August 3, 2000, as
amended on September 5, 2001. In addition, Indigo has agreed, among other
things, to reimburse Gleacher for all reasonable travel and other reasonable
out-of-pocket expenses incurred by Gleacher in connection with its engagement,
and to indemnify and hold harmless Gleacher and
70
certain related parties from and against certain liabilities and expenses,
including certain liabilities under the federal securities laws, in connection
with its engagement.
The consideration to be offered to the holders of Indigo common shares in
connection with the exchange offer was determined through negotiations between
the boards of directors of HP and Indigo. Gleacher provided advice to the
boards of Indigo during such negotiations; however, Gleacher did not recommend
any specific consideration to the Indigo boards or that any specific
consideration constituted the only appropriate consideration for the exchange
offer.
Gleacher delivered to the combined board of Indigo a document titled
"Cumulative 2002-2004 Revenue at Various Growth Rates." This document
summarizes:
. the revenue thresholds and CVR payouts of the contingent payment
mechanism initially proposed by HP (on July 23, 2001);
. the projected three-year (2002-2004) cumulative revenue generated by
Indigo assuming a range of hypothetical annual revenue growth rates and
an estimated 2001 revenue figure provided by Indigo management;
. the CVR payout that would be delivered based on such hypothetical
cumulative revenue figures; and
. the implied total consideration.
A copy of this document has been included as exhibit (c)(v) to the Transaction
Statement on Schedule 13E-3 filed by HP, Indigo and Benzion Landa in connection
with this exchange offer.
The full text of Gleacher's presentations to the Indigo boards on September
5, 2001 has been included as exhibits (c)(iii), (c)(iv) and (c)(v) to the
Transaction Statement on Schedule 13E-3 filed by HP, Indigo and Benzion Landa
in connection with this exchange offer.
Interests of Indigo Directors and Executive Officers in the Exchange Offer
In considering the recommendation of Indigo's management board, supervisory
board and combined board with respect to the exchange offer, you should be
aware that some of Indigo's directors and executive officers have interests in
the exchange offer that may be different from, or in addition to, your
interests. Those material interests of Indigo's directors and executive
officers are summarized below:
. The indemnification arrangements for directors and executive officers of
Indigo will continue until the sixth anniversary of the closing of the
exchange offer.
. As of the closing of the exchange offer, all unvested Indigo stock
options held by non-employee members of Indigo's boards who resign on
the closing of the exchange offer will fully vest, which will result in
the accelerated vesting of options to purchase approximately 169,500
Indigo common shares held by those members.
. Upon the closing of the exchange offer, the positions of Chairman and
Chief Executive Officer of Indigo, presently held by Mr. Landa, will no
longer be available with their current responsibilities. Therefore, at
the closing of the exchange offer, the employment of Mr. Landa will
terminate and Mr. Landa will receive a $2.5 million cash payment in
settlement of payments due to him under his employment relationship with
Indigo.
. Pursuant to a consulting agreement entered into between Mr. Landa and
HP, which becomes effective upon the closing of the exchange offer, Mr.
Landa will be appointed to the position of a strategic advisor to the HP
chief executive officer and may, among other things, advise HP regarding
(1) identification of technical synergies and business opportunities
both within HP and outside HP, (2) integration of Indigo's business into
the operations of HP and (3) strategic planning and tactics
71
regarding printing and imaging products and markets. Under the
consulting agreement, Mr. Landa will not be compensated by HP, except
that HP will provide Mr. Landa with a private laboratory at Indigo's
business facilities, technical support of up to two full-time laboratory
engineers, as well as office space and secretarial support, all of which
will be available for Mr. Landa's personal use or his consulting
services, and that Mr. Landa will be reimbursed for all reasonable
travel, entertainment or other expenses incurred in connection with his
consulting services. Under the terms of the consulting agreement, Mr.
Landa is free to determine the level of effort and time that he wants to
devote as a consultant to HP and therefore is not obligated to provide
any minimum amount of consulting services. The consulting agreement may
be terminated with or without cause by either party upon sixty days
notice after the second anniversary of the closing of the exchange offer.
. Upon closing of the exchange offer, three other Indigo executive
officers, Mr. Rafi Maor, Indigo's President and Chief Operating Officer;
Mr. Alon Bar-Shany, Indigo's Chief Financial Officer; and Ms. Mimi Sela,
Indigo's Corporate Vice President of Strategic Alliances, will have
employment arrangements with us which will entitle them to receive
severance and retention payments under certain circumstances, as well as
equity incentive compensation as summarized below. In addition, the
closing of the exchange offer will trigger the full acceleration of all
unvested Indigo stock options held by Mr. Maor to purchase approximately
284,500 Indigo common shares.
. Mr. Maor. At the closing of the exchange offer, Mr. Maor will be
employed by us pursuant to the terms of our recently executed
employment agreement with him. Under the employment agreement, Mr.
Maor or his heirs shall be entitled to receive a cash payment of
$860,000 (24 times his monthly salary under the employment agreement)
if he continues to be employed by us for three years or if he is
terminated beforehand without cause or as a result of his death. If
Mr. Maor's employment under the agreement continues for more than
three years, he will be entitled to receive an additional cash
payment of $215,000 (6 times his monthly salary under the employment
agreement) upon his subsequent resignation or termination. Mr. Maor
also will be granted an option to purchase 75,000 shares of HP common
stock at an exercise price equal to 75% of the fair market value on
the date of the grant. Subject to Mr. Maor's continued employment
with us, the shares covered under such option grant shall be fully
exercisable upon the third anniversary of the closing of the exchange
offer or his death.
. Mr. Bar-Shany. At the closing of the exchange offer, Mr. Bar-Shany
will be employed by us. The terms of his employment agreement, which
are presently being negotiated by us, are expected to include a
three-year term and to provide that upon the earlier of the
completion of his employment term or termination by us without cause,
he will be entitled to receive a payment equal to 24 times his
expected monthly base salary for an approximate total of $560,000 and
accelerated vesting of all unvested stock options. If Mr. Bar-Shany's
employment with us continues for more than three years and he is
subsequently terminated by us without cause, it is expected he will
be entitled to receive an additional cash payment of $140,000 (6
times his expected monthly base salary). In addition, it is expected
that Mr. Bar-Shany also will be granted an option to purchase 50,000
shares of HP common stock at an exercise price equal to 75% of the
fair market value on the date of the grant and that, subject to Mr.
Bar-Shany's continued employment with us, the shares covered under
such option grant shall be fully exercisable upon the third
anniversary of the closing of the exchange offer or his death.
. Ms. Sela. At the closing of the exchange offer, Ms. Sela will
continue to be employed by us. The terms of her employment agreement,
which are presently being negotiated by us, are expected to include a
one-year to three-year term and to provide that upon the earlier of
the completion of the first year of such term or termination by us
without cause, she will be entitled to receive a payment equal to
approximately 24 times her expected monthly base salary for an
approximate total of $360,000 and accelerated vesting of all unvested
stock options.
The aggregate amount of the cash severance and retention payments for
these three executive officers, if paid in full, will total
approximately $2,135,000.
72
. The tender and option agreement pursuant to which entities directly or
indirectly controlled by a foundation, which we refer to as the Landa
Family Trust, of which Mr. Landa is a beneficiary, agreed, to the extent
that either the fixed offer price or the contingent offer price is
oversubscribed, to elect automatically to receive the undersubscribed
consideration alternative for up to all the Indigo common shares held by
each of those shareholders, and in a separate tender and option
agreement, the Landa Family Trust agreed to support such agreements by
the entities controlled by the trust.
The members of Indigo's management board, supervisory board and combined
board were aware of these differing interests and considered them, among other
matters, in recommending that you tender your Indigo common shares in the
exchange offer.
HP's Purposes and Reasons for the Exchange Offer
We are making the exchange offer to acquire all the outstanding common
shares of Indigo. The offer agreement provides that following completion of the
exchange offer, we may, but are not required to, effectuate a corporate
restructuring of Indigo and its subsidiaries, which we refer to as the
post-closing restructuring, as further discussed below under "--Effects of the
Exchange Offer; Plans or Proposals After the Exchange Offer-- Post-Closing
Restructuring."
Our primary reasons for seeking to complete the exchange offer are the
beliefs of our board of directors and management that the completion of the
exchange offer could result in a number of benefits to us, including:
. the ability of the combined company to create a more compelling
combination of products and support services for its customers;
. the addition of a third high-speed color print technology to our highly
successful Inkjet and LaserJet technologies to serve as a platform for
addressing the high-end digital commercial printing market;
. the further ability of the combined company to develop products
utilizing Indigo's high-speed color print technology to address the
commercial printing market and potentially certain industrial printing
applications in areas such as CDs, labels and packaging;
. faster time to market for new products and solutions in the commercial
printing market;
. the potential to utilize Indigo's high-speed color print technology for
the high-end of digital photo-finishing; and
. the acquisition of an experienced, specialized sales force.
In reaching its determination to approve the exchange offer, our board of
directors also considered the following factors:
. the judgment, advice and analysis of our management with respect to the
potential strategic, financial and operational benefits of the
transaction, including management's favorable recommendation of the
transaction, based in part on the business, technical, financial,
accounting and legal due diligence investigations performed with respect
to Indigo;
. the judgment, advice and analysis of our management that the commercial
printing industry is ready for significant transition to digital work
flows, which could represent a growth opportunity for us;
. the terms of the offer agreement and related agreements, including the
exchange offer being structured to offer both the fixed offer price and
the contingent offer price alternatives;
. the fact that a significant portion of the total purchase price is
contingent and payable pursuant to the CVRs only in the event that we
are successful in generating significant revenue growth in the business
over a three-year period; and that if such revenue targets are not met
for any reason, no payment will be made under the CVRs; and
73
. the benefits that the acquisition would provide as compared to the
alternative of leaving the existing commercial relationship between us
and Indigo in place.
Our board of directors also considered a number of potentially negative
factors in its deliberations considering the transaction. The potentially
negative factors considered by our board of directors included:
. the risk that the transaction might not be completed in a timely manner
or at all; and
. the general difficulties of integrating products, technologies and
companies.
The above discussion of information and factors considered by our board of
directors is not intended to be exhaustive but is believed to include all
material factors considered by the board. In view of the wide variety of
factors considered by our board of directors, the board did not find it
practicable to quantify or otherwise assign relative weight to the specific
factors considered. In addition, our board did not reach any specific
conclusion on each factor considered, or any aspect of any particular factor,
but conducted an overall analysis of these factors.
Individual members of our board may have given different weight to different
factors. However, after taking into account all of the factors described above,
our board of directors unanimously approved the exchange offer and authorized
us to proceed with the transaction.
Mr. Landa's Belief Regarding the Fairness of the Exchange Offer
Mr. Landa has concluded that the offer is fair to Indigo's affiliated and
unaffiliated shareholders for the express reasons set forth above with respect
to Indigo's management board, supervisory board and combined board and Mr.
Landa expressly adopts the conclusions and analyses of Indigo's management
board, supervisory board and combined board described above.
HP's Belief Regarding the Fairness of the Exchange Offer
Because we currently own approximately 13.4% of the outstanding Indigo
common shares through Hewlett-Packard B.V., a wholly-owned subsidiary, and
because we have designated one member of Indigo's combined board and
supervisory board, we may be deemed to be an affiliate of Indigo for purposes
of Rule 13e-3 under the Exchange Act. As a result, we may be required, under
Rule 13e-3, to state whether we reasonably believe that the exchange offer is
fair to unaffiliated shareholders of Indigo.
WE ARE MAKING THE STATEMENTS INCLUDED IN THIS SUB-SECTION SOLELY FOR THE
PURPOSES OF COMPLYING WITH THE REQUIREMENTS OF RULE 13E-3 AND RELATED RULES
UNDER THE EXCHANGE ACT. DUTCH LAW DOES NOT RECOGNIZE THE CONCEPT OF A FIDUCIARY
RELATIONSHIP BETWEEN SHAREHOLDERS, AND WE HEREBY EXPRESSLY DISCLAIM ANY
FIDUCIARY RELATIONSHIP OR OBLIGATION TO INDIGO SHAREHOLDERS OTHER THAN
OBLIGATIONS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGATED
THEREUNDER IN CONNECTION WITH THE EXCHANGE OFFER AND SALE OF HP COMMON STOCK
AND CVRS IN CONNECTION WITH THE EXCHANGE OFFER.
We have concluded that the exchange offer is fair to unaffiliated Indigo
shareholders. Our conclusion is based on the following material factors:
. The fact that, pursuant to the offer agreement (1) the holders of Indigo
common shares can elect either to participate in the potential success
of the Indigo business by electing the contingent offer price of $6.00,
subject to adjustment, in HP common stock and a CVR or to choose the
fixed offer price of $7.50, subject to adjustment, in HP common stock,
and (2) if a holder wished to elect one or the other offer price option,
such election would be honored as much as possible because, pursuant to
the tender
74
and option agreement, entities directly or indirectly owned by a
foundation, the Landa Family Trust, of which Benzion Landa, Indigo's
Chairman and Chief Executive Officer, is a beneficiary, have agreed, to
the extent that either the fixed offer price or the contingent offer
price is oversubscribed, to elect automatically to receive the
undersubscribed consideration alternative for up to all of the Indigo
common shares held by each of those shareholders.
. The fact that the value of the consideration offered in the exchange
offer represents a premium over the market price at which Indigo common
shares have recently traded.
. The fact that the members of Indigo's supervisory, management and
combined boards, excluding and acting without Dr. Birnbaum, who are not
employed by or otherwise affiliated with us and are elected by holders
of Indigo common shares, represented Indigo and the interests of the
shareholders of Indigo unaffiliated with HP in the sale process and
selected and were advised by Gleacher as a financial advisor and Gibson,
Dunn & Crutcher LLP as legal counsel in connection with the exchange
offer process.
. The fact that executive officers of Indigo, who are not HP employees or
affiliates negotiated with us with respect to the exchange offer and the
offer agreement.
. The fact that acting without Dr. Birnbaum, the members of Indigo's
supervisory, management and combined boards have confirmed that they
engaged in numerous and lengthy deliberations to evaluate the offer
agreement and alternatives to the offer agreement, and engaged in
lengthy negotiations that resulted in the terms of the offer agreement,
as described above in "--Background of the Exchange Offer."
. The terms and conditions of the offer agreement, including the amount
and form of the consideration, as well as the parties' mutual
representations, warranties and covenants, and the conditions to their
respective obligations.
. The unanimous approval of Indigo's supervisory, management and combined
boards, acting without Dr. Birnbaum, and their recommendation that
Indigo shareholders tender their Indigo common shares in the exchange
offer.
. Our belief that the value of the consideration offered to Indigo
shareholders in the exchange offer, without attributing any value to the
CVRs, is higher than the going concern value for the equity of Indigo.
. The fact that we are not aware of any firm offers made by any
unaffiliated person during the past two years for a merger or
consolidation of Indigo, a purchase or other transfer of all or
substantially all of Indigo's assets, or a purchase of Indigo common
shares that would enable the holder to exercise control of Indigo.
. The fact that Indigo's combined board engaged Gleacher to act as
Indigo's financial advisor in connection with the proposed business
combination with HP and that Gleacher has issued an opinion to Indigo's
combined board, dated September 6, 2001, that as of that date and
subject to the assumptions and limitations set forth in the opinion, the
consideration provided for pursuant to the offer agreement was fair to
the holders of Indigo common shares, other than HP and its subsidiaries,
from a financial point of view.
The HP board considered the overall value of the consideration offered in
the exchange offer. In light of the contractual commitment by the LFT Entities
to receive the undersubscribed consideration, HP was aware that unaffiliated
Indigo shareholders would receive the consideration form of their choice for
most of their tendered Indigo stock, and did not consider whether the
transaction was fair or advisable from the perspective of one who will receive
the minimum consideration. As discussed elsewhere in this prospectus, in light
of the contractual commitment by the LFT Entities to receive the
undersubscribed consideration, each unaffiliated Indigo shareholder is
guaranteed to receive at least 82% of her preferred consideration election.
This means that if all shareholders elected the fixed price consideration and
assuming that the CVR had no value, each unaffiliated Indigo shareholder
75
would receive a minimum blended per share price of $7.23 ($7.50 per share for
82% of his or her Indigo common shares and $6.00 per share for 18% of his or
her Indigo common shares).
We considered the material negative factors described in the sections titled
"--Indigo's Purposes and Reasons for the Exchange Offer" and "--HP's Purposes
and Reasons for the Exchange Offer" and viewed them as insufficient to outweigh
the positive factors.
We considered a number of factors, including the historical trading price of
Indigo, which during the 52 week period prior to the announcement of the
proposed transaction ranged from $2.97 to $8.63, the premiums paid in public
company change of control transactions, the potential for HP to create positive
revenue and cost synergies, the potential that the integration of Indigo into
HP may not proceed well, the possibility that the commercial printing market
may be slow to adopt digital technologies, and the near-term impact of the
transaction on the operating results of HP and the Imaging and Printing Systems
segment. In addition, we considered the challenge of addressing Indigo's stated
need for an offer price, which was significantly higher than the market price,
and the possibility of reducing the risk of overpaying if a portion of the
purchase price could be contingent upon the future performance of the Indigo
business. We did not perform an analysis of the net book value or liquidation
value of Indigo. However, we believe that the consideration offered to Indigo
shareholders is in excess of Indigo's net book value and in excess of Indigo's
liquidation value.
Effects of the Exchange Offer; Plans or Proposals After the Exchange Offer
Post-Closing Restructuring
Immediately after the exchange offer is completed, Indigo will be a
majority-owned subsidiary of HP. The offer agreement provides that following
completion of the exchange offer, we may but are not required to effectuate a
corporate restructuring, which we refer to as the post-closing restructuring of
Indigo and its subsidiaries, which may include, without limitation:
(1) the commencement of a compulsory acquisition by us of Indigo common
shares from any remaining minority shareholder in accordance with Section
2:92a of the Dutch Civil Code;
(2) the sale and transfer by Indigo, or any of its subsidiaries, to us,
or any of our affiliates, of all or a portion of the assets of Indigo
(including capital stock of a subsidiary) or its subsidiaries;
(3) the transfer of employees from Indigo or an Indigo subsidiary to us
or any of our affiliates, and the transfer of employees from us or any of
our affiliates to Indigo or an Indigo subsidiary;
(4) the amendment of Indigo's articles of association to permit the
creation, among other things, of separate classes of shares;
(5) the liquidation or merger of an Indigo subsidiary into Indigo or us
or any of our affiliates;
(6) the distribution of an extraordinary dividend on the shares of Indigo
or a particular class or classes of shares of Indigo;
(7) the effectuation by Indigo and one or more Dutch subsidiaries of ours
of a legal merger within the meaning of Section 2:309 of the Dutch Civil
Code;
(8) the termination of the listing of Indigo's shares on the Nasdaq
National Market;
(9) the deregistration of Indigo under the Exchange Act and the cessation
of Indigo's reporting obligations thereunder; or
(10) any one or more combinations of any of the foregoing actions.
Upon the completion of the exchange offer, we may but are not obligated to
exercise the acquisition warrant in order to reach the 95% ownership threshold
necessary to commence a compulsory acquisition in accordance with Section 2:92a
of the Dutch Civil Code.
76
Reduced Liquidity of Indigo Common Shares; Possibly No Longer Included for
Quotation
The tender and exchange of Indigo common shares pursuant to the exchange
offer will reduce the number of holders of Indigo common shares and the number
of Indigo common shares that might otherwise trade publicly and could adversely
affect the liquidity and market value of the remaining Indigo common shares
held by the public. Indigo common shares are included for quotation and
principally traded on the Nasdaq National Market. Depending on the number of
Indigo common shares acquired pursuant to the exchange offer, Indigo common
shares, following completion of the exchange offer, may no longer meet the
requirements of the Nasdaq National Market for continued listing. The
requirements for continued inclusion in the Nasdaq National Market, among other
things, require that an issuer have either:
. at least 750,000 publicly-held shares, held by at least 400 stockholders
of round lots, with a market value of at least $5 million and net
tangible assets of at least $4 million and at least two registered and
active market makers for the shares; or
. at least 1,100,000 publicly-held shares, held by at least 400
stockholders of round lots, with a market value of at least $15 million
and at least four registered and active market markers, and either:
- a market capitalization of at least $50 million; or
- total assets and total revenue of at least $50 million each for the
most recently completed fiscal year or two of the last three most
recently completed fiscal years.
Even if the requirements for continued inclusion in the Nasdaq National
Market are not satisfied, the shares might nevertheless continue to be included
in a different tier of Nasdaq with quotations published in the Nasdaq
"additional list" or in one of the "local lists," but, if the number of holders
of the shares were to fall below 300, the number of publicly held shares were
to fall below 500,000 or there were not at least two registered and active
market makers for the shares, applicable Nasdaq rules provide that the shares
would no longer be "qualified" for Nasdaq reporting and Nasdaq would cease to
provide any quotations. Shares held directly or indirectly by directors,
officers or beneficial owners of more than 10% of the shares are not considered
as being publicly held for this purpose. If, following the completion of the
exchange offer, the Indigo common shares no longer meet the requirements for
continued inclusion in the Nasdaq National Market or in any other tier of
Nasdaq and the shares are no longer included in the Nasdaq National Market or
in any other tier of Nasdaq, the market for Indigo common shares could be
adversely affected.
If the Indigo common shares no longer meet the requirements for continued
inclusion in any tier of Nasdaq so that the Indigo common shares would no
longer be listed on a regulated stock market within the meaning of Section
2:86c of the Dutch Civil Code, any transfer of Indigo common shares will
require the execution of a notarial deed of transfer, to be executed in The
Netherlands in the presence of a civil law notary practicing in
The Netherlands, the costs of which will have to be borne by the transferor or
the transferee of those shares.
Notwithstanding the foregoing practical restriction on the transfer of
Indigo common shares, it remains possible that those shares would continue to
trade in the over-the-counter market and that price quotations would be
reported by other sources. The extent of the public market for Indigo common
shares and the availability of quotations for Indigo common shares, however,
would depend upon the number of holders of shares remaining at that time, the
interest in maintaining a market in Indigo common shares on the part of
securities firms, the possible termination of registration of the shares under
the Exchange Act, as described below, and other factors. HP cannot predict
whether the reduction in the number of Indigo common shares that might
otherwise trade publicly and the formalities surrounding the transfer of those
shares would have an adverse or beneficial effect on the market price for, or
marketability of, the Indigo common shares. In addition, after the completion
of the exchange offer, we may delist the Indigo common shares from the Nasdaq
National Market regardless of whether the requirements for continued inclusion
are satisfied.
According to Indigo, there were, as of December 31, 2001, 110,680,527 Indigo
common shares issued and outstanding.
77
Federal Reserve Board Regulations; Status as "Margin Securities"
Federal Reserve Board regulations restrict the extension or maintenance of
credit for the purpose of buying or carrying margin stock if the credit is
secured directly or indirectly by margin stock. Such secured credit may not be
extended or maintained in an amount that exceeds the maximum loan value of the
margin stock. The Indigo common shares are presently "margin securities" under
the regulations of The Federal Reserve Board, which therefore has the effect,
among other things, of allowing brokers to extend credit on the collateral of
Indigo common shares. Depending on factors similar to those described above
with respect to market quotations, following completion of the exchange offer,
the Indigo common shares may no longer constitute "margin securities" for the
purposes of the Federal Reserve Board's margin regulations, in which event the
Indigo common shares would not be eligible as collateral for margin loans made
by brokers.
Registration under the Securities Exchange Act of 1934
Indigo common shares are currently registered under the Exchange Act. Indigo
can terminate that registration upon application to the Securities and Exchange
Commission if the outstanding shares are not listed on a national securities
exchange or listed on an automated inter-dealer quotation system, or if there
are fewer than 300 holders of record of Indigo common shares. Termination of
registration of the Indigo common shares under the Exchange Act would reduce
the information that Indigo must furnish to its shareholders and to the
Securities and Exchange Commission. In addition, if Indigo common shares are no
longer registered under the Exchange Act, the requirements of Rule 13e-3 under
the Exchange Act with respect to "going private" transactions would no longer
be applicable to Indigo. Furthermore, the ability of "affiliates" of Indigo and
persons holding "restricted securities" of Indigo to dispose of these
securities pursuant to Rule 144 under the Securities Act may be impaired or
eliminated. If registration of the shares under the Exchange Act were
terminated, they would no longer be eligible for Nasdaq reporting or for
continued inclusion on the Federal Reserve Board's list of "margin securities"
and would not provide reports or information to its public shareholders, other
than as required by Dutch law.
Benefits and Detriments of the Exchange Offer
Indigo's beliefs as to the benefits and detriments of the exchange offer to
Indigo, its affiliates and unaffiliated Indigo shareholders are described above
under "--Indigo's Purposes and Reasons for the Exchange Offer," and "--Indigo's
Belief Regarding the Fairness of the Exchange Offer." HP's beliefs as to the
benefits and detriments of the exchange offer to Indigo, its affiliates and
unaffiliated Indigo shareholders are described above under "--HP's Purposes and
Reasons for the Exchange Offer," and "--HP's Belief Regarding the Fairness of
the Exchange Offer."
HP's Interest in Net Book Value and Net Earnings of Indigo
Following completion of the exchange offer, assuming that HP owns 100% of
Indigo's common shares, HP's direct interest in Indigo's net book value and net
earnings (losses) will increase to 100% and HP and its affiliates will be
entitled to any benefits resulting from that interest, including all income
generated by operations of the Indigo business and any future increase in the
value of Indigo's assets. Similarly, HP will also bear the risk of any losses
generated by operations of the Indigo business, and any future decrease in the
value of Indigo's assets. Indigo's total net book value was $108 million at
September 30, 2001 and net loss before cumulative effect of an accounting
change was $12 million for the nine months ended September 30, 2001 and $10
million for the year ended December 31, 2000.
United States Federal Income Tax Consequences of the Exchange Offer
The following discussion represents the opinion of Wilson Sonsini Goodrich &
Rosati, Professional Corporation, counsel to HP, with respect to the material
United States federal income tax consequences to holders of Indigo common
shares who tender shares in the exchange offer. This discussion is based on
current
78
United States federal income tax law, which is subject to change at any time,
possibly with retroactive effect, in a manner that could affect the information
set forth below.
This discussion is intended only as a summary and does not purport to be a
complete analysis of all of the potential tax effects of the exchange offer for
all categories of Indigo shareholders. In particular, this discussion does not
deal with all United States federal income tax considerations that may be
relevant to Indigo shareholders in light of their particular circumstances
(such as shareholders who are insurance companies, tax-exempt organizations,
dealers in securities, shareholders who hold their Indigo common shares as part
of a hedge, appreciated financial position, straddle, or conversion
transaction, who are subject to the alternative minimum tax provisions of the
Internal Revenue Code, who are foreign persons, or who acquired their shares
upon exercise of stock options or in other compensatory transactions). In
addition, the following discussion does not address the tax consequences of the
exchange offer under foreign, state, or local tax laws. It is assumed for
purposes of the following discussion that the Indigo common shares are, and
that the HP common stock and the CVRs will be, held as capital assets for
United States federal income tax purposes.
Taxable Transaction. Newco is not controlled by HP within the meaning of
Section 368(c) of the Internal Revenue Code, and the consideration in the
exchange offer does not consist solely of HP voting stock. As a result, the
exchange of Indigo common shares for shares of HP common stock, CVRs and cash
instead of fractional shares of HP common stock pursuant to the exchange offer
will be a taxable transaction to the Indigo shareholders for United States
federal income tax purposes.
Receipt of HP Common Stock. An Indigo shareholder receiving only HP common
stock (and cash instead of fractional shares) will recognize gain or loss in an
amount equal to the difference between (1) the sum of the fair market value of
HP common stock and the cash received instead of fractional shares and (2) the
shareholder's adjusted tax basis in its Indigo common shares. Gain or loss must
be calculated separately for each block of Indigo common shares (i.e., shares
acquired at the same cost in a single transaction) exchanged pursuant to the
exchange offer. Such gain or loss will be capital gain or loss and will be
long-term capital gain or loss if the shareholder's holding period is more than
one year. Capital losses are deductible only to the extent of capital gains
plus, in the case of taxpayers other than corporations, $3,000 of ordinary
income. Capital losses that are not currently deductible may be carried forward
to other years, subject to certain limitations. The initial tax basis of the HP
common stock received by Indigo shareholders in the exchange offer will equal
the value of such stock on the date of the exchange, and the holding period of
the HP common stock will begin on the day following the date of the exchange.
Receipt of HP Common Stock and CVRs. The United States federal income tax
treatment of Indigo shareholders receiving HP common stock and CVRs is not
entirely clear. Such treatment will depend in part on whether the receipt of
the HP common stock and the CVRs is a "closed transaction" or an "open
transaction" for United States federal income tax purposes, and in part on
whether the CVRs are treated as a right to payment under a contract or as a
debt instrument for United States federal income tax purposes. As discussed
below, open transaction treatment will apply only if the fair market value of
the CVRs cannot be ascertained at the time of exchange. Because the amount
payable under the CVRs is entirely contingent upon future events, the CVRs
should not be treated as debt instruments for United States federal income tax
purposes.
Treatment as Closed Transaction. If the transaction is closed for United
States federal income tax purposes, the shareholder's gain or loss on the
exchange of the Indigo common shares will be computed as described above,
taking into account the fair market value of the CVRs on the date of the
exchange, and the shareholder's initial tax basis in the CVRs will equal such
value. The holding period of the CVRs will begin on the day following the date
of the exchange. The installment method of reporting any gain will not be
available with respect to the sale of the Indigo common shares.
If a payment is made with respect to a CVR following the three-year
measuring period, the shareholder will recognize gain in the amount by which
the payment (other than the portion characterized as interest as described
below) exceeds the shareholder's tax basis in the CVR. If no payment is made or
the payment is less than the
79
shareholder's tax basis in the CVR, the shareholder will recognize a loss. Such
gain or loss will be long-term capital gain or loss.
Although not free from doubt, any payment in the future to a holder of a CVR
should be treated as a payment under a contract for the sale or exchange of
Indigo common shares to which Section 483 of the Internal Revenue Code applies.
Under Section 483, a portion of the payment pursuant to a CVR will be treated
as interest, which will be ordinary income to the holder of the CVR. The
interest amount will equal the excess of the amount received over its present
value at the closing of the exchange offer, calculated using the applicable
federal rate as the discount rate. The applicable federal rate is a rate
reflecting an average of market yields on Treasury debt obligations for
different ranges of maturities that is published monthly by the Internal
Revenue Service. The relevant applicable federal rate will be the lower of the
lowest applicable federal rate in effect during the 3-month period ending with
the month that includes the date on which the offer agreement was signed or the
lowest applicable federal rate in effect during the 3-month period ending with
the month that includes the date of the exchange. The maturity range of the
relevant applicable federal rate will correspond to the period from the date of
the exchange to the date the amount is received or deemed received. The holder
of a CVR must include in income Section 483 interest using such holder's
regular method of accounting (such amount being taken into account when paid,
in the case of a cash method holder, and when fixed, in the case of an accrual
method holder). The portion of the payment pursuant to a CVR that is not
treated as interest under Section 483 will be treated as sales proceeds from
the exchange of the CVRs, as discussed above.
In the event that the CVRs are treated as debt instruments for United States
federal income tax purposes, the tax treatment would be as described above
except that, instead of including interest income at the time of payment under
Section 483, a holder would be required to include currently an amount in
income as interest (based on the yield of "comparable" debt instruments) in
advance of the receipt of any payment, regardless of a holder's method of
accounting.
Treatment as Open Transaction. If the receipt of the HP common stock and
the CVRs is treated as an "open transaction" for United States federal income
purposes, the shareholder would not take the CVRs into account on the date of
the exchange for purposes of determining gain or loss with respect to the sale
of Indigo common shares. Instead, in such event, the shareholder would take no
tax basis in the CVR, but would be subject to tax as payments with respect to
the CVR are made or deemed made in accordance with the holder's regular method
of accounting. A portion of such payments would be treated as interest income
under Section 483 (as discussed above) and the balance, in general, as capital
gain. It is the position of the Internal Revenue Service, reflected by Treasury
Regulations, that only in "rare and extraordinary cases" is the value of
property so uncertain that open transaction treatment is available. It should
be noted that a CVR will be received in lieu of additional shares of HP common
stock, and that HP common stock is publicly traded and therefore readily
susceptible of valuation. Although there is no authority directly on point with
respect to the CVRs, we believe the better view, given the position of the
Internal Revenue Service, is that open transaction reporting should not apply
with respect to a CVR. Accordingly, holders are urged to consult their tax
advisors regarding this issue.
Treatment of Shareholders Not Participating in the Exchange Offer. Indigo
shareholders who do not sell their Indigo common shares pursuant to the
exchange offer and who receive payment for their shares in a compulsory
acquisition of common shares in accordance with Section 2.92a of the Dutch
Civil Code or in a legal merger within the meaning of Section 2:309 of the
Dutch Civil Code will recognize gain or loss (and may recognize an amount of
interest income) attributable to any payment received pursuant to those
transactions. Such gain or loss (other than interest income) will be capital
gain or loss and will be long-term capital gain or loss if the shareholder's
holding period is more than one year.
Passive Foreign Investment Companies. Indigo may be classified as a
"passive foreign investment company" ("PFIC") for United States federal income
tax purposes if certain tests are met. Indigo will be a PFIC with respect to a
shareholder if, for any taxable year in which the shareholder held the Indigo
common shares, either (i) 75% or more of its gross income for the taxable year
is "passive income" for United States federal
80
income tax purposes; or (ii) the average value during the taxable year
(calculated quarterly) of its assets that produce passive income or that are
held for the production of passive income is at least 50% of the average value
of all of its assets for such year.
If Indigo were to be classified as a PFIC, any gain realized as a result of
the exchange of Indigo common shares would be taxable as ordinary income, and
the shareholder would be subject to an interest charge on taxes deemed deferred
by such shareholder (unless the shareholder elected to be currently taxable on
his or her pro-rata share of Indigo's ordinary earnings and profits and
long-term capital gains for each year (at ordinary income and capital gains
rates, respectively), even if no dividend distributions were received). Based
on the nature of Indigo's income and assets, Indigo does not believe that it
should be classified as a PFIC for the taxable year ending on the date of the
exchange, and for purposes of its opinion, counsel has assumed that Indigo will
not be so classified.
Treatment of HP and Indigo. Neither HP nor Indigo will recognize gain or
loss for United States federal income tax purposes solely as a result of the
exchange offer.
Backup Withholding. Indigo shareholders may be subject to backup
withholding at the rate of 30% with respect to cash received instead of
fractional shares pursuant to the exchange offer or upon a payment under the
CVRs unless the shareholder provides a correct taxpayer identification number
in the manner required or certifies that it is not subject to backup
withholding or is an "exempt recipient." The rate of backup withholding is
scheduled to be reduced over time to 29% in 2005. Backup withholding is not an
additional tax, but rather may be credited against the taxpayer's tax liability
for the year.
Shareholders are urged to consult their own tax advisors regarding the
federal, state, local, foreign, and other tax consequences of the exchange
offer in light of their particular circumstances.
Relationships Between HP and Indigo
Except for the voting, tender, tender and option, and affiliate agreements
described in the section titled "Agreements Related to the Offer Agreement" and
as otherwise described in this prospectus, neither we nor, to the best of our
knowledge, any of our directors, executive officers or affiliates has any
agreement, arrangement or understanding with any other person with respect to
any Indigo securities. Except as described herein, there have been no
negotiations, transactions or material contacts during the past two years
between us, or to the best of our knowledge any of our directors, executive
officers or affiliates, on the one hand, and Indigo or any of its directors,
executive officers or affiliates, on the other hand, concerning any: (1)
merger, (2) consolidation, (3) acquisition, (4) tender offer for or other
acquisition of Indigo securities, (5) election of Indigo's directors or (6)
sale or other transfer of a material amount of Indigo's assets.
Except as otherwise set forth herein, neither we nor, to the best of our
knowledge, any of our directors, executive officers or affiliates has had
during the past two years any transaction with Indigo or any of its directors,
executive officers or affiliates that would require disclosure under the rules
and regulations of the Securities and Exchange Commission applicable to the
exchange offer.
Except as otherwise set forth herein, neither we nor, to the best of our
knowledge, any of our directors, executive officers or affiliates beneficially
owns or has any right to acquire, directly or indirectly, any Indigo common
shares.
Except as otherwise set forth herein, neither we nor, to the best of our
knowledge, any of our directors, executive officers or affiliates has effected
any transaction in Indigo common shares during the past 60 days.
Strategic Affiliation Agreement
We and Indigo have been familiar with each other's businesses for many
years. In November 1998, we entered into a strategic affiliation agreement with
Indigo pursuant to which we agreed, among other things (1) to
81
explore the co-development and sales cooperation between Indigo and us, (2) to
identify necessary factors to achieve broad market adoption of Indigo's
technology, and (3) to form a strategic alliance for exploring future products
and applications. In September 2000, we made the equity investment in Indigo
described below.
The Stock Purchase Agreement
On September 13, 2000, Hewlett-Packard Europe B.V., a wholly-owned
subsidiary of Hewlett-Packard Company, agreed to purchase 14,814,814 newly
issued common shares of Indigo pursuant to a stock purchase agreement between
Indigo and Hewlett-Packard Europe B.V. In addition, Indigo agreed to grant to
Hewlett-Packard Europe B.V. (1) a warrant, which we refer to as the acquisition
warrant, to purchase 14,814,815 Indigo common shares, at a price of $6.75 per
common share, upon the acquisition of all or substantially all of the
outstanding capital stock of Indigo by us or any of our subsidiaries, and (2) a
warrant, which we refer to as the performance warrant, to purchase up to
12,000,000 common shares, at a price of $6.75 per common share, upon the
delivery by us of specified revenue to Indigo. For every $100 million of cash
revenues generated by us or any of our subsidiaries and paid to Indigo, the
performance warrant vests with respect to the right to purchase
2,000,000 common shares of Indigo. On October 17, 2000, Indigo issued
14,814,814 common shares to Hewlett-Packard Europe B.V., as contemplated in the
stock purchase agreement and issued the warrants. A portion of the proceeds was
used by Indigo to redeem Indigo preferred shares. The Indigo common shares
purchased by Hewlett-Packard Europe B.V. pursuant to the stock purchase
agreement, and those issued or issuable upon exercise of the acquisition
warrant and the performance warrant, are subject to a registration rights
agreement, dated as of October 17, 2000, by and between Hewlett-Packard Europe
B.V. and Indigo. As of the date of this prospectus no rights to purchase Indigo
common shares have vested under the performance warrant.
The references to, and summary and description of the stock purchase
agreement, the performance warrant, the registration rights agreement and the
acquisition warrant are qualified in their entirety by reference to the copies
of the stock purchase agreement, the performance warrant, the registration
rights agreement and the acquisition warrant, which were previously filed as
exhibits 1, 2, 3 and 5, respectively, to the Schedule 13D filed by
Hewlett-Packard Company and Hewlett-Packard Europe B.V. on October 27, 2000 and
are incorporated herein by reference.
The OEM Agreement and the Co-Development Agreement
On September 13, 2000, in connection with the transactions contemplated by
the stock purchase agreement discussed in the section above, we and Indigo
entered into (1) an OEM agreement to establish a commercial relationship to
enable the sale of certain of Indigo's products by us on an OEM basis, and (2)
a co-development agreement for the joint development of future products. We
anticipate terminating or substantially revising these agreements upon the
closing of the exchange offer.
Pursuant to the OEM agreement, we agreed to select one or more
Indigo-manufactured printers that we will sell on an OEM basis as an HP
product. Indigo has granted us most favored OEM status with respect to prices
and payment terms. Indigo warrants the OEM printers and spare parts purchased
by us against defects arising from faulty materials or workmanship for a
three-month period following receipt by us. The OEM Agreement terminates on
December 31, 2003 and is automatically extended for additional three-year
periods unless we give Indigo 90 days notice of termination.
The Indigo product which we initially selected for distribution under the
OEM Agreement is similar in configuration to Indigo's Platinum press. We
commenced selling this product in June 2001 as the HP 6600 digital press. In
December 2001, Indigo and HP agreed to add several different models of Indigo
presses to the products we could purchase under the OEM Agreement and we
satisfied our prior commitment to purchase 6600 digital presses by issuing a
purchase order for $5,010,000 for such additional Indigo products in the fourth
quarter of 2001.
82
Pursuant to the co-development agreement, we and Indigo agreed to cooperate
in the development of a family of low-cost digital color printers. We agreed to
define the technical specifications of such products. We agreed to focus on the
development of the formatter and system, while Indigo agreed to focus on the
development of the ink and engine. We agreed to finance up to $25 million of
Indigo's R&D activities related to the project over a three-year period, which
funding shall be matched by Indigo. The agreement also provides for the
relocation of approximately 10 HP technical experts to Indigo's facilities in
Israel. Each party shall have the right to brand and sell such products.
Transfer prices for such products shall be based upon a margin sharing formula
that varies based upon the branding and mode of sale of the product. The
co-development agreement terminates, by its terms, in 2020 (subject to renewal
by us for 2 additional five-year terms) but can be unilaterally terminated by
us on June 30, 2002 or September 30, 2003.
Pursuant to the co-development agreement, we paid Indigo $5,000,000 in
December 2000 and in December 2001 we paid Indigo an additional $3,750,000.
After such payment, we may determine within ten days of June 30, 2002 whether
to continue with the co-development agreement or terminate the agreement. If we
decide to terminate the agreement within such ten day period, we shall have no
obligation to make any further payments under the agreement other than fair
"exit charges" payable to Indigo. If we elect to continue with the
co-development agreement, we will be required to make additional payments under
the agreement of $3,750,000 in June 2002 and $12,500,000 in January 2003.
The Shareholders Agreement
In connection with the transactions contemplated by the stock purchase
agreement, Gemini Systems Corporation N.V., Toscal N.V., OZF Ltd., Visionvest
Corporation N.V., Walthroup Corporation N.V., Deering Corporation N.V., S-C
Indigo CV, Hewlett-Packard Europe B.V., HP and Indigo entered into a
shareholders agreement, dated as of September 13, 2000. The shareholders
agreement was previously filed as Exhibit 4 to the Schedule 13D filed by HP and
Hewlett-Packard Europe B.V. on October 27, 2000, and is incorporated by
reference herein.
Pursuant to the terms of the shareholders agreement, the common shares owned
by Hewlett-Packard Europe B.V. may be transferred pursuant only to (1) a
registration statement filed with the Securities and Exchange Commission or (2)
any exemption from registration subject to receipt of an opinion of counsel
that such transfer is exempt from registration. Under the shareholders
agreement, Indigo and the major shareholders of Indigo, as such term is defined
in the shareholders agreement, have a right of first refusal or a right of
first offer, as applicable, with respect to certain sales by Hewlett-Packard
Europe B.V., occurring after October 17, 2001 but on or before October 17,
2002, of any of the common shares subject to the shareholders agreement.
The shareholders agreement also provides Hewlett-Packard Europe B.V. a right
of first refusal. Until the earlier of October 17, 2003 or HP's failure to make
certain payments to Indigo under the co-development agreement, if Indigo or the
major shareholders propose to enter into any agreement with a third party that
would prevent Hewlett-Packard Europe B.V. from purchasing all or substantially
all of the assets or all of the outstanding capital stock of Indigo, then
Hewlett-Packard Europe B.V. has the right to enter into such transaction with
Indigo or the major shareholders, as the case may be, on substantially the same
terms proposed with the third party.
The shareholders agreement also provides (i) a right to enable us to sell
our shares along with other major Indigo shareholders under certain
circumstances after October 17, 2002, (ii) an obligation to require us to sell
our shares along with other major Indigo shareholders under certain
circumstances after October 17, 2004, and (iii) certain anti-dilution rights in
favor of Hewlett-Packard Europe B.V. until October 17, 2003.
Hewlett-Packard Europe B.V. and the major shareholders have agreed in the
shareholders agreement that, for as long as each of the shareholders of Indigo
affiliated with the Landa Family Trust, in the aggregate, and S-C Indigo CV
owns 62.5% of the common shares held by them as of October 17, 2000, the
supervisory board of
83
Indigo shall include (1) a designee of Hewlett-Packard Europe B.V., (2) two
designees of S-C Indigo CV and, (3) that number of designees of the
shareholders affiliated with the Landa Family Trust as represents a majority of
the supervisory board. Pursuant to the shareholders agreement, until the
earlier of (1) October 17, 2005 and (2) such time when the shareholders
affiliated with the Landa Family Trust cease to own, in the aggregate, at least
62.5% of the common shares held by them as of October 17, 2000, each of
Hewlett-Packard Europe B.V. and S-C Indigo CV must vote its common shares as
directed by a majority of the major shareholders with respect to any matter
except a merger or consolidation of Indigo requiring a vote of Indigo's
shareholders under Dutch law, any disposition of assets of Indigo, any change
of control of Indigo or any liquidation of Indigo.
Under the terms of the shareholders agreement, if Hewlett-Packard Europe
B.V. transfers any of its common shares subject to the shareholders agreement
to a party other than an affiliate, certain rights of Hewlett-Packard Europe
B.V. lapse, including, but not limited to, the right of first refusal,
anti-dilution rights and the right to designate a nominee to the supervisory
board.
Hewlett-Packard Europe B.V., the major shareholders and their respective
affiliates are subject, pursuant to the shareholders agreement, to customary
standstill provisions until October 17, 2003. Such limitations may be waived
only by the supervisory board of Indigo or the chief executive officer of
Indigo. Such limitations have been waived with respect to HP by Benzion Landa,
Indigo's Chairman and Chief Executive Officer, in connection with the exchange
offer.
Purchases of Indigo Common Shares
Except as described above in the section titled "--The Stock Purchase
Agreement," neither we nor our subsidiaries purchased any other Indigo common
shares during the past two years. Following the completion of the exchange
offer, we and our subsidiaries may from time to time purchase Indigo common
shares, subject to applicable law.
Indigo Stock Options
Indigo has granted Dr. Joel Birnbaum, the member of Indigo's supervisory and
combined boards designated by Hewlett-Packard Europe B.V. pursuant to the
shareholders' agreement described above, options to purchase 15,000 Indigo
common shares.
Summary Indigo Financial Projections
The financial projections described below are being included in this
prospectus pursuant to Item 15 of Schedule 13E-3 and are not intended as a
representation from management of Indigo or HP of the future financial results
of Indigo.
The financial projections included in this prospectus have been prepared by
and are the responsibility of Indigo's management. Neither Kesselman &
Kesselman, a member of PricewaterhouseCoopers International Limited,
independent auditors for Indigo, nor Ernst & Young LLP, independent auditors
for HP, have examined or compiled the accompanying prospective financial
information and, accordingly, Kesselman & Kesselman, a member of
PricewaterhouseCoopers International Limited, and Ernst & Young LLP do not
express an opinion or any other form of assurance with respect thereto. The
Kesselman & Kesselman report included in this prospectus relates to Indigo's
historical financial information. It does not extend to the financial
projections and should not be read to do so.
As a matter of course, Indigo does not publicly disclose projections as to
future revenues or earnings and these projections were not originally prepared
with a view towards public disclosure. However, in February 2001, Indigo
prepared financial projections, the material portion of which are stated below,
in connection with an analyst call with respect to Indigo's fourth quarter
financial results for fiscal year 2000. Indigo subsequently
84
made these projections publicly available by posting them on Indigo's website
in February 2001. Thereafter, Indigo shared these projections with us. From
time to time during our negotiations with Indigo regarding the exchange offer,
Indigo's management orally reaffirmed to us the revenue growth rate in the
February 2001 projections described below.
These projections constitute forward-looking statements that reflect
numerous assumptions made by Indigo's management, including Indigo's ability to
achieve strategic goals, objectives and targets over applicable periods, as
well as continued successful placement of Indigo's UltraStream product,
increased benefits derived from Indigo's commercial relationship with us,
placement of additional sales people in targeted markets and a decrease in
marketing expenses due to lack of high profile commercial shows as was the case
in fiscal year 2000. These assumptions involve judgments with respect to future
business decisions, all of which are difficult or impossible to predict and
many of which are beyond Indigo's control or, after the exchange offer, our
control. In addition, factors such as industry performance, market acceptance
of new products, changes in customer preferences, general business, economic,
regulatory, market and financial conditions, all of which are difficult to
predict, may cause these projections or the underlying assumptions to these
projections to be inaccurate. In particular, the growth assumptions were driven
by analyst estimates of the general growth in the industry. Accordingly, these
projections may not be realized, and actual results in the future may be
materially greater or less than those contained in these projections. See the
section titled "Cautionary Statement Regarding Forward-Looking Information" on
page 29 of this prospectus. The projections were not prepared with a view to
compliance with published guidelines of the Securities and Exchange Commission
regarding projections, and were not prepared in accordance with the guidelines
established by the American Institute of Certified Public Accountants for
preparation and presentation of financial projections. Indigo shareholders are
cautioned not to rely on these projections.
In developing these projections, Indigo's management relied on many
assumptions including that:
. revenues would be consistent with industry analyst projections;
. revenue would increase in the long-term;
. gross margins would decrease in the short-term and increase in the
long-term;
. research and development spending would grow at a slower pace than
revenue;
. general and administrative expenses would remain relatively flat; and
. sales expense would grow slower than revenues.
You should refer to the Indigo unaudited condensed consolidated interim
financial statements for the three and nine month periods ending September 30,
2001 and 2000 included elsewhere in this prospectus, as these results differ
significantly from those set out in the projections below. Indigo's actual
results have and may also in the future differ significantly from those set out
in the projections below.
Given the passage of time and other developments since the date of the
projections that may affect the financial condition of Indigo, Indigo does not
believe that the following projections accurately reflect the current or future
financial condition of Indigo. Neither we nor Indigo intend to update or
otherwise revise the following projections to reflect circumstances existing
after the date when made or to reflect the occurrence of future events in the
event that any or all of the assumptions underlying the following projections
are shown to be in error.
85
As compared to its actual results for the year ended December 31, 2000,
Indigo projected that (1) its revenue growth, (2) its gross margin, (3) its
research and development expenses and its sales, general and administrative
expenses, in each case as a percentage of revenue, and (4) its earnings per
share would be as follows:
2000 2001/(2)/ Long Term/(3)/
------ ------------- -------------
Revenue...................... $164.8 +20% +30%
Gross Margin................. 49.2% 46-49% 48-51%
R&D.......................... 11.9% 10-10.5% 9-10%
SG&A......................... 43.7% 36-39% 30-32%
Earnings per share........... $(0.11)/(1)/ $(0.04)-$0.02 6-12%
--------
(1) Loss per share before cumulative effect of an accounting change and before
dividend requirement. After cumulative effect of an accounting change and
after dividend requirement the loss per share is $0.93.
(2) Contrary to the projection provided for the year 2001, the actual results
for the nine months ended September 30, 2001 were as follows:
Revenues (compared to the nine months ending September 30,
2000).................................................... +17%
Gross Margin............................................... 40%
R&D........................................................ 10%
SG&A....................................................... 41%
Earnings per share......................................... $(0.11)
(3) 2002 and 2003. Based on the current economic climate, Indigo believes that
these projections are no longer relevant.
Subsequent to providing to us the projections described above, Indigo
provided Gleacher with financial projections in connection with the preparation
of Gleacher's fairness opinion. These financial projections did not materially
differ from the projections described above, except that the financial
projections provided to Gleacher included revenue growth rates during the years
2002 to 2005 of 25.2%, 25.1%, 25.0% and 25.0%, respectively. Based on the
current economic climate, Indigo now believes that the revenue growth rate it
would likely achieve as a stand-alone entity for 2002 is no more than
approximately 15-20%.
86
THE EXCHANGE OFFER
The following is a description of the material aspects of the exchange
offer, including the offer agreement. While we believe that the following
description covers the material terms of the exchange offer, the description
may not contain all of the information that is important to you. We encourage
you to read carefully this entire prospectus, including the offer agreement
attached to this prospectus as Annex A and the form of CVR agreement attached
to this prospectus as Annex B-1, for a more complete understanding of the
exchange offer.
Description of the Exchange Offer
The Exchange Offer
Through Newco, our newly-purchased indirect subsidiary, we are offering to
exchange, at the election of the tendering Indigo shareholder and subject to
the allocation mechanism described below under "Allocation Rules for the Fixed
Offer Price and Contingent Offer Price," either (1) the fixed offer price,
which consists of a fraction of a share of HP common stock that has a value
equal to $7.50, subject to adjustment, in HP common stock, as determined in
accordance with the offer agreement, or (2) the contingent offer price, which
consists of (A) a fraction of a share of HP common stock that has a value equal
to $6.00, subject to adjustment, as determined in accordance with the offer
agreement, plus (B) one non-transferable contingent value right, which is
referred to in this prospectus as a "CVR," entitling its holder to a cash
payment from Newco of up to $4.50 if our consolidated net revenues from the
sale or lease of LEP Digital Press Products and Consumables (as such terms are
defined in the CVR agreement) reach specified revenue milestones over a
three-year period after completion of the exchange offer, in return for each
outstanding Indigo common share that is validly tendered and not properly
withdrawn, upon the terms and subject to the conditions set forth in this
prospectus and in the related election form/letter of transmittal. The amount
paid under each CVR increases linearly from $0 to $4.50 as such cumulative
revenues increase from $1.0 billion to $1.6 billion over the three-year period.
No payment will be made under the CVR if the cumulative revenue is less than or
equal to $1.0 billion. No payment in excess of $4.50 will be made under the CVR
if the cumulative revenue is greater than $1.6 billion. Hewlett-Packard Company
will guarantee the contingent payment obligations of our subsidiary under the
CVRs. For a description of the procedures for making such an election, see
"--Election Procedures."
Fixed Offer Price and Contingent Offer Price
The number of shares of HP common stock that each tendering Indigo
shareholder will receive in the exchange offer will be determined by dividing
$7.50 or $6.00, as the case may be, by the average closing sales price of HP
common stock on the New York Stock Exchange during the twenty (20) consecutive
trading days ending on the trading day on which the third most recent closing
of the U.S. markets prior to the expiration of the exchange offer occurs.
However, the average HP closing sales price to be used in such calculation
shall not be less than $16.69 or more than $23.68. The total number of Indigo
common shares that will be exchanged for each of the above-described elections
is limited as described below under "--Allocation Rules for the Fixed Offer
Price and Contingent Offer Price."
For those Indigo shareholders receiving the fixed offer price, the following
fixed offer price ratios shall apply:
. If this 20-day average HP closing sales price is less than $16.69 then
each Indigo common share shall be exchanged for 0.4494 of a share of HP
common stock.
. If this 20-day average HP closing sales price is greater than $23.68
then each Indigo common share shall be exchanged for 0.3167 of a share
of HP common stock.
. If this 20-day average HP closing sales price is equal to or greater
than $16.69 and equal to or less than $23.68 then each Indigo common
share shall be exchanged for a share of HP common stock multiplied by
the quotient obtained by dividing $7.50 by such 20-day average HP
closing sales price.
87
For those Indigo shareholders receiving the contingent offer price, the
following contingent offer price ratios shall apply:
. If this 20-day average HP closing sales price is less than $16.69 then
each Indigo common share shall be exchanged for (1) 0.3595 share of HP
common stock and (2) one CVR.
. If this 20-day average HP closing sales price is greater than $23.68
then each Indigo common share shall be exchanged for (1) 0.2534 share of
HP common stock and (2) one CVR.
. If this 20-day average HP closing sales price is equal to or greater
than $16.69 and equal to or less than $23.68 then each Indigo common
share shall be exchanged for (1) a share of HP common stock multiplied
by the quotient obtained by dividing $6.00 by such 20-day average HP
closing sales price and (2) one CVR.
Pursuant to the offer agreement, the fixed offer price, the contingent offer
price and any other applicable numbers or amounts shall be adjusted to reflect
appropriately the effect of any stock split, reverse stock split, stock
dividend (including any distribution or dividend of securities convertible into
or exchangeable for HP common stock or Indigo common shares), extraordinary
cash dividend, reorganization, reclassification, combination, exchange of
shares or other like change with respect to HP common stock or Indigo common
shares occurring or having a record date on or after the date of the offer
agreement and prior to the closing of the exchange offer.
Illustrative Table of Fixed Offer Prices and Contingent Offer Prices and
Value of Offer Consideration
The columns in the following table present, based upon illustrative values
of the average closing sales price of HP common stock with a range of $13.00 to
$27.00 per share:
. the amount of shares of HP common stock that would be issued for one
Indigo common share at each of the average closing sales prices of HP
common stock presented in the table; and
. illustrative values of the total consideration that would be issued in
connection with the exchange offer for one Indigo common share based on
an assumed discount rate of 15% and estimating that the CVR payout, if
any, would take place approximately 39 months after the close of the
exchange offer.
88
Value of Offer Consideration--Fixed Offer Price
----------------------------------------------------
20-day Average Closing Sales Price Fixed Offer Value of HP
of HP Common Stock Price Ratio Common Stock CVR Total
---------------------------------- ----------- ------------ -------------------- -----
$13.00.............. 0.4494 $5.84 Not Applicable $5.84
15.00.............. 0.4494 6.74 Not Applicable 6.74
16.69.............. 0.4494 7.50 Not Applicable 7.50
20.00.............. 0.3750 7.50 Not Applicable 7.50
23.68.............. 0.3167 7.50 Not Applicable 7.50
25.00.............. 0.3167 7.92 Not Applicable 7.92
27.00.............. 0.3167 8.55 Not Applicable 8.55
Value of Offer Consideration--Contingent Offer Price
$0.00 CVR Payment in 2005
----------------------------------------------------
Present Value of CVR
Contingent Payment at 15%
20-day Average Closing Sales Price Offer Value of HP Discount Rate
of HP Common Stock Price Ratio Common Stock (Not Guaranteed) Total
---------------------------------- ----------- ------------ -------------------- -----
$13.00.............. 0.3595 $4.67 $0.00 $4.67
15.00.............. 0.3595 5.39 0.00 5.39
16.69.............. 0.3595 6.00 0.00 6.00
20.00.............. 0.3000 6.00 0.00 6.00
23.68.............. 0.2534 6.00 0.00 6.00
25.00.............. 0.2534 6.33 0.00 6.33
27.00.............. 0.2534 6.84 0.00 6.84
Value of Offer Consideration--Contingent Offer Price
$2.25 CVR Payment in 2005
----------------------------------------------------
Present Value of CVR
Contingent Payment at 15%
20-day Average Closing Sales Price Offer Value of HP Discount Rate
of HP Common Stock Price Ratio Common Stock (Not Guaranteed) Total
---------------------------------- ----------- ------------ -------------------- -----
$13.00.............. 0.3595 $4.67 $1.39 $6.06
15.00.............. 0.3595 5.39 1.39 6.78
16.69.............. 0.3595 6.00 1.39 7.39
20.00.............. 0.3000 6.00 1.39 7.39
23.68.............. 0.2534 6.00 1.39 7.39
25.00.............. 0.2534 6.33 1.39 7.72
27.00.............. 0.2534 6.84 1.39 8.23
Value of Offer Consideration---Contingent Offer Price
$4.50 CVR Payment in 2005
-----------------------------------------------------
Present Value of CVR
Contingent Payment at 15%
20-day Average Closing Sales Price Offer Value of HP Discount Rate
of HP Common Stock Price Ratio Common Stock (Not Guaranteed) Total
---------------------------------- ----------- ------------ -------------------- -----
$13.00.............. 0.3595 $4.67 $2.77 $7.44
15.00.............. 0.3595 5.39 2.77 8.16
16.69.............. 0.3595 6.00 2.77 8.77
20.00.............. 0.3000 6.00 2.77 8.77
23.68.............. 0.2534 6.00 2.77 8.77
25.00.............. 0.2534 6.34 2.77 9.11
27.00.............. 0.2534 6.84 2.77 9.61
The values of HP common stock in the table above are illustrative only and
do not represent the actual amounts per Indigo common share that might be
realized by any Indigo shareholder on or after completion of the exchange
offer. The amount any Indigo shareholder will actually realize upon resale in
the market of HP common stock received by the shareholder in the exchange offer
will depend upon the market price of HP
89
common stock at the time of resale by the shareholder, which will fluctuate
depending upon any number of reasons, including those specific to HP and those
that influence the trading prices of equity securities generally.
Neither HP nor Indigo makes any recommendation as to whether you should
elect to receive the fixed offer price or the contingent offer price pursuant
to the exchange offer. You must make your own decision with respect to such
election. See "Special Factors--United States Federal Income Tax Consequences
of the Exchange Offer" for a description of certain consequences to U.S.
taxpayers related to receiving the fixed offer price or the contingent offer
price pursuant to the exchange offer.
Transfer Charges
If you are the record owner of your Indigo common shares and you tender
those shares directly to the exchange agent, you will not incur any brokerage
fees or commissions. If you own your Indigo common shares through a broker or
other nominee, and your broker tenders those shares on your behalf, your broker
may charge you a commission for doing so. You should consult with your broker
or nominee to determine whether any charges will apply.
Access to Corporate Files; Obtaining Counsel or Appraisal Services
Neither we nor Indigo has made any provisions in connection with the
exchange offer to grant unaffiliated shareholders of Indigo access to the
corporate files of either us or Indigo or to obtain counsel or appraisal
services at the expense of us or Indigo.
Conditions to the Exchange Offer
Our obligation to accept for exchange, and to deliver a combination of
shares of HP common stock and CVRs in exchange for, Indigo common shares
pursuant to the exchange offer is subject to the satisfaction or, where
permissible, the waiver of the conditions set forth in the offer agreement, as
summarized in the section titled "The Offer Agreement--Conditions to the
Exchange Offer," including the minimum tender condition that the number of
Indigo common shares validly tendered and not properly withdrawn shall
represent at least ninety-five percent of the outstanding Indigo common shares,
excluding treasury shares, plus that number of Indigo common shares issuable
upon the exercise of Indigo warrants, other than those warrants held by us or
any of our subsidiaries or specified principal shareholders of Indigo.
Allocation Rules for the Fixed Offer Price and Contingent Offer Price
The total number of Indigo common shares that will be exchanged for each of
the fixed offer price and the contingent offer price is limited as described in
the offer agreement. If either election is oversubscribed, Indigo's
shareholders who have tendered into the exchange offer will be subject to
allocation to comply with the ceiling on the number of Indigo common shares
associated with each election as described in the offer agreement. The
allocation mechanism is complex and not easily summarized. This summary may not
contain all of the information that is important to you. Accordingly, we urge
you to read carefully the offer agreement in its entirety.
Maximum Number of Indigo Common Shares Associated with Indigo Shareholder
Elections
The offer agreement provides that:
. the maximum number of Indigo common shares that are permitted to be
exchanged for the fixed offer price is limited to the number by which,
as of immediately following the expiration time of the exchange offer:
- (1) fifty percent of the sum of (A) the outstanding Indigo common
shares, excluding treasury shares and any Indigo common shares held
by us or any of our affiliates, and (B) the number of Indigo common
shares issuable upon the exercise of Indigo options and warrants,
excluding warrants held by us or any of our subsidiaries, exceeds
90
- (2) the number of Indigo common shares issuable upon the exercise of
Indigo options and warrants, excluding warrants held by HP or any of
its subsidiaries;
and
. the maximum number of Indigo common shares that are permitted to be
exchanged for the contingent offer price is limited to the number equal
to, as of immediately following the expiration time of the exchange
offer:
- fifty percent of the sum of (A) the outstanding Indigo common shares,
excluding treasury shares and any Indigo common shares held by HP or
any of its affiliates, and (B) the number of Indigo common shares
issuable upon the exercise of Indigo options and warrants, excluding
warrants held by HP or any of its subsidiaries.
Based on Indigo's capitalization as of December 31, 2001, (1) the maximum
number of Indigo common shares that would be permitted to be exchanged for the
fixed offer price would range from 39,635,525, assuming that no outstanding
Indigo options or warrants are exercised, to 56,230,187, assuming that all
outstanding Indigo options or warrants are exercised, and (2) the maximum
number of Indigo common shares that would be permitted to be exchanged for the
contingent offer price would be 56,230,188.
Pursuant to the tender and option agreements, the foundation, which we refer
to as the Landa Family Trust, of which Benzion Landa, Indigo's Chairman and
Chief Executive Officer, is a beneficiary, and entities directly or indirectly
owned by the Landa Family Trust have agreed, to the extent that either the
fixed offer price or the contingent offer price is oversubscribed, to elect
automatically to receive the undersubscribed consideration alternative for up
to all of the Indigo common shares held by each of those shareholders. Such
entities hold approximately 47.6 million of the outstanding Indigo common
shares as of December 31, 2001. The allocation mechanism described below shall
apply only to the extent that either of the fixed offer price or contingent
offer price remains oversubscribed after giving effect to the automatic
election by the Landa Family Trust controlled entities to receive the
undersubscribed consideration alternative.
S-C Indigo CV, one of Indigo's major shareholders, which holds 24.6 million
shares, has agreed to tender its Indigo common shares into the exchange offer
but has not agreed to elect to automatically receive the undersubscribed
consideration alternative. However, because S-C Indigo owns 24.6 million shares
and must elect to exchange all of its shares for either the fixed offer price
or the contingent offer price as discussed in this prospectus, the likelihood
that the offer price that S-C Indigo elects to receive will be oversubscribed
is increased. Based upon Indigo's capitalization as of December 31, 2001, the
24.6 million shares held by such shareholder would represent approximately 62%
of the Indigo common shares that may be exchanged for the fixed offer price and
approximately 44% of the Indigo common shares that may be exchanged for the
contingent offer price. In the event that the offer price that S-C Indigo
elects to receive is oversubscribed, its election will result in a decrease in
the percentage of a shareholder's Indigo common shares that will be exchanged
for the offer price that such shareholder elects if it also has elected to
receive the oversubscribed form of consideration.
Allocation Mechanism
As of December 31, 2001, Indigo's capitalization was as follows:
. 95,865,713 Indigo common shares, excluding treasury shares and the
14,814,814 Indigo common shares held by us and our affiliates, are
outstanding;
. 47,566,222 of those outstanding Indigo common shares are held by the
Indigo shareholders which are parties to the tender and option agreement
pursuant to which those shareholders have agreed, to the extent that
either the fixed offer price or the contingent offer price is
oversubscribed, to elect automatically to receive the undersubscribed
consideration alternative for up to all of the Indigo common shares held
by each of those shareholders; and
91
. 16,594,662 Indigo common shares are issuable upon exercise of
outstanding stock options and warrants.
The offer agreement provides that, if the aggregate number of Indigo common
shares that are tendered for the fixed offer price, which we refer to as the
requested fixed offer price amount, exceeds the maximum number of Indigo common
shares that are permitted to be exchanged for the fixed offer price, each
Indigo shareholder who has tendered Indigo common shares for the fixed offer
price shall receive, with respect to each such common share of Indigo:
. the number of shares of HP common stock equal to the product of (1) the
exchange ratio for the fixed offer price, and (2) the fixed price
proration factor described below;
. the additional number of shares of HP common stock equal to the product
of (1) the exchange ratio for the contingent offer price, and (2) one
minus the fixed price proration factor described below; and
. the number of CVRs equal to one minus the fixed price proration factor
described below.
The offer agreement provides that, if the aggregate number of Indigo common
shares that are tendered for the contingent offer price, which we refer to as
the requested contingent offer price amount, exceeds the maximum number of
Indigo common shares that are permitted to be exchanged for the contingent
offer price, each Indigo shareholder who has tendered Indigo common shares for
the contingent offer price shall receive, with respect to each such common
share of Indigo:
. the number of shares of HP common stock equal to the product of (1) the
exchange ratio for the contingent offer price, and (2) the contingent
price proration factor described below;
. the additional number of shares of HP common stock equal to the product
of (1) the exchange ratio for the fixed offer price, and (2) one minus
the contingent price proration factor described below; and
. the number of CVRs equal to the contingent price proration factor
described below.
See the section titled "--Description of the Exchange Offer--Fixed Offer
Price and Contingent Offer Price" above for a description of the calculations
of the respective exchange ratios for the fixed offer price and the contingent
offer price.
The offer agreement defines the fixed price proration factor as a fraction,
expressed as a decimal and rounded to the fourth decimal place (1) the
numerator of which is the maximum number of Indigo common shares that are
permitted to be exchanged for the fixed offer price, and (2) the denominator of
which is the revised fixed offer price amount (the requested fixed offer price
amount plus any adjustments resulting to such from common shares that Indigo
shareholders subject to the tender and option agreement are obligated to accept
as a result of oversubscription).
The offer agreement defines the contingent price proration factor as a
fraction, expressed as a decimal and rounded to the fourth decimal place (1)
the numerator of which is the maximum number of Indigo common shares that may
be exchanged for the contingent offer price, and (2) the denominator of which
is the revised contingent offer price amount (the requested contingent offer
price amount plus any adjustments resulting to such amount from common shares
that Indigo shareholders subject to the tender and option agreement are
obligated to accept as a result of oversubscription).
Illustrative Examples of Allocation Mechanism
Because of the limitations on the number of Indigo common shares that are
permitted to be exchanged for either the fixed offer price or the contingent
offer price as described above, Indigo shareholders who elect to receive either
the fixed offer price or the contingent offer price may experience a range of
actual outcomes based upon the elections of other Indigo shareholders.
92
We have set forth below several illustrative examples showing the potential
effects of the allocation rules provided for in the offer agreement based on
Indigo's capitalization as of December 31, 2001. For purposes of the following
examples, we have excluded the impact of fractional shares. Furthermore, we
have assumed in these examples that all Indigo shareholders have tendered their
Indigo common shares into the exchange offer.
The foregoing assumptions are for illustrative purposes only and are not
necessarily indicative of the actual factors that will be used in applying the
allocation rules.
Example One
The following table illustrates one possible outcome in which neither the
fixed offer price nor the contingent offer price is oversubscribed. In this
scenario, you would receive the form of consideration alternative that you
requested for all of the Indigo common shares that you tender. We cannot assure
you that either the fixed offer price or the contingent offer price will not be
oversubscribed so that you will in fact receive your requested form of
consideration alternative for all of the Indigo common shares that you tender.
No Allocation
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 0 47,566,222
Number of shares tendered by the other Indigo shareholders...................... 39,635,525 8,663,966
Excess (deficit) of number of Indigo common shares tendered..................... 0 0
In the above example, as neither the fixed offer price nor the contingent
offer price was oversubscribed, the range of potential per share present values
for Indigo shareholders who are not party to the tender and option agreements
would be as follows assuming (1) a payout of the CVR, if any, 39 months after
the close, and (2) an illustrative range of $13.00 to $27.00 per share for the
20-day average closing sales prices of HP common stock, which would result in
the values of HP common stock and the present values of the CVR payments set
forth under the column headings titled "Value of HP Common Stock" and "Present
Value of CVR Payment at 15%," respectively, in the section titled
"--Description of the Exchange Offer--Illustrative Table of Fixed Offer Prices
and Contingent Offer Prices and Value of Offer Consideration:"
Range of Potential
Shareholder Tendering For: Per Share Present Values Assumptions/Analysis
-------------------------- ---------------------------------------- ------------------------------------------
Fixed Offer Price $5.84-$8.55--value of HP stock Based on a range of 20-day average closing
HP sales prices of $13.00 to $27.00.
Contingent Offer Price (1) $4.67-$6.84--value of HP stock; Based on (1) a range of 20-day average
closing HP sales prices of $13.00 to
plus $27.00 and (2) a range of CVR payments
of $0.00 up to $4.50 discounted to present
(2) $0.00-$2.77--present value of CVR value using a 15% discount rate.
payment.
93
Example Two
The following table illustrates one possible outcome in which the fixed
offer price is oversubscribed. However, in the following example, the
allocation rules will be applied only to the 47,566,222 shares owned by the
Landa Family Trust controlled entities because those entities have agreed to
automatically allocate their shares from the oversubscribed election to the
undersubscribed election and the shares that they hold are sufficient in number
to ensure that the other Indigo shareholders' requests to receive the fixed
offer price will be observed.
Allocation Applied only to the Landa Family Trust Controlled Entities
Pre-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 47,566,222 0
Number of shares tendered by the other Indigo shareholders...................... 38,299,491 10,000,000
Excess (deficit) of number of Indigo common shares tendered..................... 46,230,188 (46,230,188)
Because the excess number of shares tendered for the fixed offer price is
less than the total number of shares tendered by the Landa Family Trust
controlled entities for the fixed offer price as shown in the illustrative
table above, the allocation rules will be applied only to the Landa Family
Trust controlled entities and all other Indigo shareholders will receive their
requested form of consideration alternative as described below:
First step: calculate the ceilings on the number of Indigo common shares
that are permitted to be exchanged for the applicable offer price as
described above in the section titled "--Maximum Number of Indigo Common
Shares Associated with Indigo Shareholder Elections:"
Ceiling on number of Indigo common shares that are permitted
to be exchanged for the applicable offer price.............. 39,635,525 56,230,188
Second step: determine how many Indigo shares held by shareholders other
than the Landa Family Trust controlled entities have tendered into the
exchange offer for the applicable offer price:
Number of shares tendered by the other Indigo shareholders...... 38,299,491 10,000,000
Third step: determine how many Indigo shares held by the Landa Family
Trust controlled entities have been tendered into the exchange offer for the
applicable offer:
Number of shares tendered by the Landa Family Trust controlled entities... 47,566,222 0
Fourth step: calculate the excess/deficit, if any, of the number of
Indigo common shares tendered for the applicable offer price by subtracting
(1) the sum of (A) the shares tendered by shareholders other than the Landa
Family Trust controlled entities, and (B) the shares initially tendered by
the Landa Family Trust controlled entities, from (2) the respective ceiling
for the applicable offer price:
Excess (deficit) of number of Indigo common shares tendered..... 46,230,188 (46,230,188)
94
Fifth step: as the fixed offer price is oversubscribed, give effect to
the mandatory election provided for in the tender and option agreement such
that the Landa Family Trust controlled entities will receive the contingent
offer price to the extent that the fixed offer price is oversubscribed:
Number of shares tendered by the Landa Family Trust controlled entities............. 1,336,034 46,230,188
Sixth step: after giving effect to the mandatory election provided for
by the Landa Family Trust controlled entities, as the fixed offer price is
no longer oversubscribed, the allocation rules will not be applied to the
other Indigo shareholders electing to receive the fixed offer price as shown
in the illustrative table below:
Allocation Applied only to the Landa Family Trust Controlled Entities
Post-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 1,336,034 46,230,188
Number of shares tendered by the other Indigo shareholders...................... 38,299,491 10,000,000
Excess (deficit) of number of Indigo common shares tendered..................... 0 0
In the above example, as the fixed offer price was oversubscribed but the
allocation rules were applied only to the Landa Family Trust controlled
entities, the range of potential per share present values for Indigo
shareholders which are not party to the tender and option agreements would be
as follows assuming (1) a payout of the CVR, if any, 39 months after the close,
and (2) an illustrative range of $13.00 to $27.00 per share for the 20-day
average closing sales prices of HP common stock, which would result in the
values of HP common stock and the present values of the CVR payments set forth
under the column headings titled "Value of HP Common Stock" and "Present Value
of CVR Payment at 15%," respectively, in the section titled "--Description of
the Exchange Offer--Illustrative Table of Fixed Offer Prices and Contingent
Offer Prices and Value of Offer Consideration:"
Range of Potential
Shareholder Tendering For: Per Share Present Values Assumptions/Analysis
-------------------------- ---------------------------------------- ------------------------------------------
Fixed Offer Price $5.84-$8.55--value of HP stock Based on a range of 20-day average
closing HP sales prices of $13.00 to
$27.00.
Contingent Offer Price (1) $4.67-$6.84--value of HP stock; Based on (1) a range of 20-day average
closing HP sales prices of $13.00 to
plus $27.00 and (2) a range of CVR payments
of $0.00 up to $4.50 discounted to present
(2) $0.00-$2.77--present value of CVR value using a 15% discount rate.
payment.
95
Example Three-A
The following table illustrates one possible outcome in which (1) the fixed
offer price is oversubscribed and (2) the Landa Family Trust controlled
entities do not own sufficient Indigo common shares to ensure that the other
Indigo shareholders' requests to receive the fixed offer price will be
observed. As a result, the allocation rules will be applied to all other Indigo
shareholders requesting the fixed offer price and those Indigo shareholders
will be required to accept the contingent offer price for some of the Indigo
common shares that they have tendered.
Allocation applied to all Indigo shareholders requesting the fixed offer price
(no Indigo options or warrants exercised prior to the expiration of the
exchange offer)
Pre-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 47,566,222 0
Number of shares tendered by the other Indigo shareholders...................... 48,299,491 0
Excess (deficit) of number of Indigo common shares tendered..................... 56,230,188 (56,230,188)
The excess number of shares tendered for the fixed offer price is greater
than the total number of shares tendered by the Landa Family Trust controlled
entities for the fixed offer price as shown in the illustrative table above. As
a result, after giving effect to the mandatory election provided for in the
tender and option agreement such that the Landa Family Trust controlled
entities will receive the contingent offer price for all of their Indigo common
shares, the allocation rules will be applied to all Indigo shareholders
electing to receive the fixed offer price as described below:
First step: calculate the ceilings on the number of Indigo common shares
that are permitted to be exchanged for the applicable offer price as
described above in the section titled "--Maximum Number of Indigo Common
Shares Associated with Indigo Shareholder Elections:"
Ceiling on number of Indigo common shares that are permitted to
be exchanged for the applicable offer price................... 39,635,525 56,230,188
Second step: determine how many Indigo shares held by shareholders other
than the Landa Family Trust controlled entities have tendered into the
exchange offer for the applicable offer price:
Number of shares tendered by the other Indigo shareholders........... 48,299,491 0
Third step: determine how many Indigo shares held by the Landa Family
Trust controlled entities have been tendered into the exchange offer for the
applicable offer price:
Number of shares tendered by the Landa Family Trust controlled entities... 47,566,222 0
Fourth step: calculate the excess/deficit, if any, of the number of
Indigo common shares tendered for the applicable offer price by subtracting
(1) the sum of the shares tendered by (A) shareholders other than the Landa
Family Trust controlled entities and (B) the shares initially tendered by
the Landa Family Trust controlled entities from (2) the respective ceiling
for the applicable offer price:
Excess (deficit) of number of Indigo common shares tendered..... 56,230,188 (56,230,188)
96
Fifth step: as the fixed offer price is oversubscribed, give effect to
the mandatory election provided for in the tender and option agreement such
that the Landa Family Trust controlled entities will receive the contingent
offer price to the extent that the fixed offer price is oversubscribed and
the Landa Family Trust controlled entities will receive the contingent offer
price for all of their Indigo common shares:
Number of shares tendered by the Landa Family Trust controlled entities... 0 47,566,222
Sixth step: after giving effect to the mandatory election provided for
by the Landa Family Trust controlled entities, as the fixed offer price is
still oversubscribed, the allocation rules will be applied to all other
Indigo shareholders electing to receive the fixed offer price as shown in
the illustrative table below such that the fixed offer price is no longer
oversubscribed:
Allocation applied to all Indigo shareholders requesting the fixed offer price
Post-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 0 47,566,222
Number of shares tendered by the other Indigo shareholders...................... 39,635,525 8,663,966
Excess (deficit) of number of Indigo common shares tendered..................... 0 0
As a result of the application of the allocation rules in the example
illustrated by the above table, if you had tendered 100 Indigo common shares
for the fixed offer price: (1) you would receive the fixed offer price for
82.06 of your Indigo common shares, and (2) you would receive the contingent
offer price for 17.94 of your Indigo common shares.
In the above example, we calculated the number of Indigo common shares for
which you would receive the fixed offer price by multiplying the number of
Indigo common shares that you tendered by the fixed price proration factor,
which is determined by dividing (1) 39,635,525, the maximum number of shares
that are permitted to be exchanged for the fixed offer price, by (2)
48,299,491, the aggregate number of shares tendered by all Indigo shareholders
for the fixed offer price, after giving effect to the mandatory election by the
Landa Family Trust controlled entities to tender up to all of their Indigo
common shares for the undersubscribed form of consideration alternative. We
then subtracted the resulting number from the total number of Indigo common
shares tendered by you to determine the number of Indigo common shares for
which you would receive the contingent offer price.
In the above example, as the fixed offer price was oversubscribed (and the
contingent offer price was undersubscribed) and the allocation rules were
applied to the Landa Family Trust controlled entities and the other Indigo
shareholders, the range of potential per share present values for Indigo
shareholders which are not party to the tender and option agreements would be
as follows assuming (1) a payout of the CVR, if any, 39 months after the close,
and (2) an illustrative range of $13.00 to $27.00 per share for the 20-day
average closing sales prices of HP common stock, which would result in the
values of HP common stock and the present values of the CVR payments set forth
under the column headings titled "Value of HP Common Stock" and "Present Value
of CVR
97
Payment at 15%," respectively, in the section titled "--Description of the
Exchange Offer--Illustrative Table of Fixed Offer Prices and Contingent Offer
Prices and Value of Offer Consideration:"
Range of Potential
Shareholder Tendering For: Per Share Present Values Assumptions/Analysis
-------------------------- -------------------------------------------- ------------------------------------------
Fixed Offer Price A weighted per share value consisting of: Based on (1) a range of 20-day average
closing HP sales prices of $13.00 to
(1) 82.06% of $5.84-$8.55 in value of $27.00 and (2) a range of CVR payments
HP common stock for the Indigo common of $0.00 up to $4.50 discounted to present
shares to be exchanged for the fixed offer value using a 15% discount rate.
price; and
(2) 17.94% of the sum of:
(A) $4.67-$6.84--value of HP
common stock, plus
(B) $0.00-$2.77--present value of
CVR payment,
for the Indigo common shares to be
exchanged for the contingent offer price.
Therefore, based upon our assumptions, if you had tendered 100 Indigo common
shares for the fixed offer price, the known per share value consideration you
would receive would range from $5.63 to $8.24, the sum of (1) $4.79 to $7.01
per share (82.06% of $5.84-$8.55 for the fixed offer price) and (2) $0.84 to
$1.23 per share (17.94% of $4.67-$6.84 for the contingent offer price). In
addition, you would receive 17.94 CVRs, which on a present value basis could
payout between $0.00 and $49.69 ($2.77 x 17.94 CVRs). This would result in a
range of total consideration on a present value basis for your 100 tendered
Indigo common shares of (A) assuming no CVR payout, $563.01 to $824.32, or
(B) assuming a full payout for the 17.94 CVRs, $612.70 to $874.01.
98
Example Three-B
The following table illustrates a variation on the above Example Three-A. In
the following table, we have changed our underlying assumption to assume that
all Indigo options and warrants are exercised before the expiration of the
exchange offer, which impacts the ceiling on the number of Indigo common shares
that are permitted to be exchanged for the fixed offer price as well as the
resulting proration factor in the scenario in which the fixed offer price is
oversubscribed (and the contingent offer price is undersubscribed).
Allocation applied to all Indigo shareholders requesting the fixed offer price
(all Indigo options and warrants exercised prior to the expiration of the
exchange offer)
Pre-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that
are permitted to be exchanged for the
applicable offer price......................... 56,230,187 56,230,188
Number of shares tendered by the Landa Family
Trust controlled entities...................... 47,566,222 0
Number of shares tendered by the other Indigo
shareholders................................... 64,894,153 0
Excess (deficit) of number of Indigo common
shares tendered................................ 56,230,188 (56,230,188)
The excess number of shares tendered for the fixed offer price is greater
than the total number of shares tendered by the Landa Family Trust controlled
entities for the fixed offer price as shown in the illustrative table above. As
a result, after giving effect to the mandatory election provided for in the
tender and option agreement such that the Landa Family Trust controlled
entitles will receive the contingent offer price for all of their Indigo common
shares, the allocation rules will be applied to all Indigo shareholders
electing to receive the fixed offer price as described below.
First step: calculate the ceilings on the number of Indigo common
shares that are permitted to be exchanged for the applicable offer price as
described above in the section titled "--Maximum Number of Indigo Common
Shares Associated with Indigo Shareholder Elections:"
Ceiling on number of Indigo common shares that
are permitted to be exchanged for the
applicable offer price......................... 56,230,187 56,230,188
Second step: determine how many Indigo shares held by shareholders other
than the Landa Family Trust controlled entities have tendered into the
exchange offer for the applicable offer price:
Number of shares tendered by the other Indigo
shareholders................................... 64,894,153 0
Third step: determine how many Indigo shares held by the Landa Family
Trust controlled entities have been tendered into the exchange offer for the
applicable offer:
Number of shares tendered by the Landa Family
Trust controlled entities...................... 47,566,222 0
Fourth step: calculate the excess/deficit, if any, of the number of
Indigo common shares tendered for the applicable offer price by subtracting
(1) the sum of (A) the shares tendered by shareholders other than the Landa
Family Trust controlled entities, and (B) the shares initially tendered by
the Landa Family Trust controlled entities, from (2) the respective ceiling
for the applicable offer price:
Excess (deficit) of number of Indigo common
shares tendered................................ 56,230,188 (56,230,188)
Fifth step: as the fixed offer price is oversubscribed, give effect to
the mandatory election provided for in the tender and option agreement such
that the Landa Family Trust controlled entities will receive the contingent
offer price to the extent that the fixed offer price is oversubscribed and
the Landa Family Trust controlled entities will receive the contingent offer
price for all of their Indigo common shares:
Number of shares tendered by the Landa Family
Trust controlled entities...................... 0 47,566,222
99
Sixth step: after giving effect to the mandatory election provided for
by the Landa Family Trust controlled entities, as the fixed offer price is
still oversubscribed, the allocation rules will be applied to all Indigo
shareholders electing to receive the fixed offer price as shown in the
illustrative table below such that the fixed offer price is no longer
oversubscribed:
Allocation applied only to all Indigo shareholders requesting the fixed offer
price
Post-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that
are permitted to be exchanged for the
applicable offer price......................... 56,230,187 56,230,188
Number of shares tendered by the Landa Family
Trust controlled entities...................... 0 47,566,222
Number of shares tendered by the other Indigo
shareholders................................... 56,230,187 8,663,966
Excess (deficit) of number of Indigo common
shares tendered................................ 0 0
As a result of the application of the allocation rules in the example
illustrated by the above table, if you had tendered 100 Indigo common shares
for the fixed offer price: (1) you would receive the fixed offer price for
86.65 of your Indigo common shares, and (2) you would receive the contingent
offer price for 13.35 of your Indigo common shares.
In the above example, we calculated the number of Indigo common shares for
which you would receive the fixed offer price by multiplying the number of
Indigo common shares that you tendered by the fixed price proration factor,
which is determined by dividing (1) 56,230,187, the maximum number of shares
that are permitted to be exchanged for the fixed offer price, by (2)
64,894,153, the aggregate number of shares tendered by all Indigo shareholders
for the fixed offer price, after giving effect to the mandatory election by the
Landa Family Trust controlled entities to tender up to all of their Indigo
common shares for the undersubscribed form of consideration alternative. We
then subtracted the resulting number from the total number of Indigo common
shares tendered by you to determine the number of Indigo common shares for
which you would receive the contingent offer price.
100
In the above example, as the fixed offer price was oversubscribed (and the
contingent offer price was undersubscribed) and the allocation rules were
applied to the Landa Family Trust controlled entities and the other Indigo
shareholders, the range of potential per share present values for Indigo
shareholders which are not party to the tender and option agreements would be
as follows assuming (1) a payout of the CVR, if any, 39 months after the close,
and (2) an illustrative range of $13.00 to $27.00 per share for the 20-day
average closing sales prices of HP common stock, which would result in the
values of HP common stock and the present values of the CVR payments set forth
under the column headings titled "Value of HP Common Stock" and "Present Value
of CVR Payment at 15%," respectively, in the section titled "Description of the
Exchange Offer--Illustrative Table of Fixed Offer Prices and Contingent Offer
Prices and Value of Offer Consideration:"
Range of Potential
Shareholder Tendering For: Per Share Present Values Assumptions/Analysis
-------------------------- -------------------------------------------- ------------------------------------------
Fixed Offer Price A weighted per share value consisting of: Based on (1) a range of 20-day average
closing HP sales prices of $13.00 to
(1) 86.65% of $5.84-$8.55 in value of $27.00 and (2) a range of CVR payments
HP common stock for the Indigo common of $0.00 up to $4.50 discounted to present
shares to be exchanged for the fixed offer value using a 15% discount rate.
price; and
(2) 13.35% of the sum of:
(A) $4.67-$6.84--value of HP
common stock, plus
(B) $0.00-$2.77--present value of
CVR payment,
for the Indigo common shares to be
exchanged for the contingent offer price.
Therefore, based upon our assumptions, if you had tendered 100 Indigo common
shares for the fixed offer price, the known per share value consideration you
would receive would range from $5.68 to $8.32, the sum of (1) $5.06 to $7.41
per share (86.65% of $5.84-$8.55 for the fixed offer price) and (2) $0.62 to
$0.91 per share (13.35% of $4.67-$6.84 for the contingent offer price). In
addition, you would receive 13.35 CVRs, which on a present value basis could
payout between $0.00 and $36.98 ($2.77 x 13.35 CVRs). This would result in a
range of total consideration on a present value basis for your 100 tendered
Indigo common shares of (A) assuming no CVR payout, $568.38 to $832.17, or
(B) assuming a full payout for the 13.35 CVRs, $605.36 to $869.15.
101
Example Four-A
The following table illustrates one possible outcome in which the contingent
offer price is oversubscribed. However, in the following example, the
allocation rules will be applied only to the 47,566,222 shares owned by the
Landa Family Trust controlled entities because those entities have agreed to
automatically allocate their shares from the oversubscribed election to the
undersubscribed election and the shares that they hold are sufficient in number
to ensure that the other Indigo shareholders' requests to receive the
contingent offer price will be observed.
Allocation applied only to the Landa Family Trust controlled entities
(no Indigo options or warrants exercised prior to the expiration of the
exchange offer)
Pre-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 0 47,566,222
Number of shares tendered by the other Indigo shareholders...................... 0 48,299,491
Excess (deficit) of number of Indigo common shares tendered..................... (39,635,525) 39,635,525
Because the excess number of shares tendered for the contingent offer price
is less than the total number of shares tendered by the Landa Family Trust
controlled entities for the contingent offer price as shown in the illustrative
table above, the allocation rules will be applied only to the Landa Family
Trust controlled entities and all other Indigo shareholders will receive their
requested form of consideration alternative as described below.
First step: calculate the ceilings on the number of Indigo common shares
that are permitted to be exchanged for the applicable offer price as
described above in the section titled "--Maximum Number of Indigo Common
Shares Associated with Indigo Shareholder Elections:"
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Second step: determine how many Indigo shares held by shareholders other
than the Landa Family Trust controlled entities have tendered into the
exchange offer for the applicable offer price:
Number of shares tendered by the other Indigo shareholders........... 0 48,299,491
Third step: determine how many Indigo shares held by the Landa Family
Trust controlled entities have been tendered into the exchange offer for the
applicable offer price:
Number of shares tendered by the Landa Family Trust controlled entities... 0 47,566,222
Fourth step: calculate the excess/deficit, if any, of the number of
Indigo common shares tendered for the applicable offer price by subtracting
(1) the sum of the shares tendered by (A) shareholders other than the Landa
Family Trust controlled entities and (B) the shares initially tendered by
the Landa Family Trust controlled entities from (2) the respective ceiling
for the applicable offer price:
Excess (deficit) of number of Indigo common shares tendered..... (39,635,525) 39,635,525
Fifth step: as the contingent offer price is oversubscribed, give effect
to the mandatory election provided for in the tender and option agreement
such that the Landa Family Trust controlled entities will receive the fixed
offer price to the extent that the contingent offer price is oversubscribed:
Number of shares tendered by the Landa Family Trust controlled entities... 39,635,525 7,930,697
102
Sixth step: after giving effect to the mandatory election provided for
by the Landa Family Trust controlled entities, as the contingent offer price
is no longer oversubscribed, the allocation rules will not be applied to the
other Indigo shareholders electing to receive the contingent offer price as
shown in the illustrative table below:
Allocation applied only to the Landa Family Trust controlled entities
Post-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 39,635,525 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 39,635,525 7,930,697
Number of shares tendered by the other Indigo shareholders...................... 0 48,299,491
Excess (deficit) of number of Indigo common shares tendered..................... 0 0
In the above example, as the contingent offer price was oversubscribed (and
the fixed offer price was undersubscribed) and the allocation rules were
applied only to the Landa Family Trust controlled entities and not to the other
Indigo shareholders, the range of potential per share present values for Indigo
shareholders which are not party to the tender and option agreements would be
as follows assuming (1) a payout of the CVR, if any, 39 months after the close,
and (2) an illustrative range of $13.00 to $27.00 per share for the 20-day
average closing sales prices of HP common stock, which would result in the
values of HP common stock and the present values of the CVR payments set forth
under the column headings titled "Value of HP Common Stock" and "Present Value
of CVR Payment at 15%," respectively, in the section titled "--Illustrative
Table of Fixed Offer Prices and Contingent Offer Prices and Value of Offer
Consideration:"
Range of Potential
Shareholder Tendering For: Per Share Present Values Assumptions/Analysis
-------------------------- ---------------------------------------- ------------------------------------------
Fixed Offer Price $5.84-$8.55--value of HP stock Based on a range of 20-day average
closing HP sales prices of $13.00 to
$27.00.
Contingent Offer Price (1) $4.67-$6.84--value of HP stock; Based on (1) a range of 20-day average
closing HP sales prices of $13.00 to
plus $27.00 and (2) a range of CVR payments
of $0.00 up to $4.50 discounted to present
(2) $0.00-$2.77--present value of CVR value using a 15% discount rate.
payment.
103
Example Four-B
The following table illustrates a variation on the above Example Four-A. In
the following table, we have changed our underlying assumption to assume that
all Indigo options and warrants are exercised before the expiration of exchange
offer, which impacts the ceiling on the number of Indigo common shares that are
permitted to be exchanged for the fixed offer price as well as the resulting
proration factor in the scenario in which the contingent offer price is
oversubscribed (and the fixed offer price is undersubscribed). Therefore, as
the Landa Family Trust controlled entities do not own sufficient Indigo common
shares to ensure that the other Indigo shareholders' requests to receive the
contingent offer price will be observed, the allocation rules will be applied
to all other Indigo shareholders requesting the contingent offer price and
those Indigo shareholders will be required to accept the fixed offer price for
some of the Indigo common shares that they have tendered.
Allocation applied to all Indigo shareholders requesting the contingent offer
price
(all Indigo options and warrants exercised prior to the expiration of the
exchange offer)
Pre-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 56,230,187 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 0 47,566,222
Number of shares tendered by the other Indigo shareholders...................... 0 64,894,153
Excess (deficit) of number of Indigo common shares tendered..................... (56,230,187) 56,230,187
The excess number of shares tendered for the contingent offer price is
greater than the total number of shares tendered by the Landa Family Trust
controlled entities for the contingent offer price as shown in the illustrative
table above. As a result, after giving effect to the mandatory election
provided for in the tender and option agreement such that the Landa Family
Trust controlled entitles will receive the fixed offer price for all of their
Indigo common shares, the allocation rules will be applied to all Indigo
shareholders electing to receive the contingent offer price as described below.
First step: calculate the ceilings on the number of Indigo common shares
that are permitted to be exchanged for the applicable offer price as
described above in the section titled "--Maximum Number of Indigo Common
Shares Associated with Indigo Shareholder Elections:"
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 56,230,187 56,230,188
Second step: determine how many Indigo shares held by shareholders other
than the Landa Family Trust controlled entities have tendered into the
exchange offer for the applicable offer price:
Number of shares tendered by the other Indigo shareholders........... 0 64,894,153
Third step: determine how many Indigo shares held by the Landa Family
Trust controlled entities have been tendered into the exchange offer for the
applicable offer:
Number of shares tendered by the Landa Family Trust controlled entities... 0 47,566,222
Fourth step: calculate the excess/deficit, if any, of the number of
Indigo common shares tendered for the applicable offer price by subtracting
(1) the sum of (A) the shares tendered by shareholders other than the Landa
Family Trust controlled entities, and (B) the shares initially tendered by
the Landa Family Trust controlled entities, from (2) the respective ceiling
for the applicable offer price:
Excess (deficit) of number of Indigo common shares tendered.......... (56,230,187) 56,230,187
104
Fifth step: as the contingent offer price is oversubscribed, give effect
to the mandatory election provided for in the tender and option agreement
such that the Landa Family Trust controlled entities will receive the fixed
offer price to the extent that the contingent offer price is oversubscribed
and the Landa Family Trust controlled entities will receive the fixed offer
price for all of their Indigo common shares:
Number of shares tendered by the Landa Family Trust controlled entities... 47,566,222 0
Sixth step: after giving effect to the mandatory election provided for
by the Landa Family Trust controlled entities, as the contingent offer price
is still oversubscribed, the allocation rules will be applied to all Indigo
shareholders electing to receive the contingent offer price as shown in the
illustrative table below such that the contingent offer price is no longer
oversubscribed:
Allocation applied only to all Indigo shareholders requesting the contingent
offer price
Post-Allocation Rules
Fixed Contingent
Offer Price Offer Price
----------- -----------
Ceiling on number of Indigo common shares that are permitted to be exchanged for
the applicable offer price.................................................... 56,230,187 56,230,188
Number of shares tendered by the Landa Family Trust controlled entities......... 47,566,222 0
Number of shares tendered by the other Indigo shareholders...................... 8,663,965 56,230,188
Excess (deficit) of number of Indigo common shares tendered..................... 0 0
As a result of the application of the allocation rules in the example
illustrated by the above table, if you had tendered 100 Indigo common shares
for the contingent offer price: (1) you would receive the contingent offer
price for 86.65 of your Indigo common shares, and (2) you would receive the
fixed offer price for 13.35 of your Indigo common shares.
In the above example, we calculated the number of Indigo common shares for
which you would receive the contingent offer price by multiplying the number of
Indigo common shares that you tendered by the contingent price proration
factor, which is determined by dividing (1) 56,230,188, the maximum number of
shares that are permitted to be exchanged for the contingent offer price, by
(2) 64,894,153, the aggregate number of shares tendered by all Indigo
shareholders for the contingent offer price, after giving effect to the
mandatory election by the Landa Family Trust controlled entities to tender up
to all of their Indigo common shares for the undersubscribed form of
consideration alternative. We then subtracted the resulting number from the
total number of Indigo common shares tendered by you to determine the number of
Indigo common shares for which you would receive the fixed offer price.
105
In the above example, as the contingent offer price was oversubscribed (and
the fixed offer price was undersubscribed) and the allocation rules were
applied to the Landa Family Trust controlled entities and the other Indigo
shareholders, the range of potential per share present values for Indigo
shareholders which are not party to the tender and option agreements would be
as follows assuming (1) a payout of the CVR, if any, 39 months after the close,
and (2) an illustrative range of $13.00 to $27.00 per share for the 20-day
average closing sales prices of HP common stock, which would result in the
values of HP common stock and the present values of the CVR payments set forth
under the column headings titled "Value of HP Common Stock" and "Present Value
of CVR Payment at 15%," respectively, in the section titled "Description of the
Exchange Offer--Illustrative Table of Fixed Offer Prices and Contingent Offer
Prices and Value of Offer Consideration:"
Range of Potential
Shareholder Tendering For: Per Share Present Values Assumptions/Analysis
-------------------------- -------------------------------------------- ------------------------------------------
Contingent Offer Price A weighted per share value consisting of: Based on (1) a range of 20-day average
closing HP sales prices of $13.00 to
(1) 86.65% of the sum of: $27.00 and, (2) a range of CVR payments
of $0.00 up to $4.50 discounted to present
(A) $4.67-$6.84--value of HP value using a 15% discount rate.
common stock, plus
(B) $0.00-$2.77--present value of
CVR payment,
for the Indigo common shares to be
exchanged for the contingent offer price;
and
(2) 13.35% of $5.84-$8.55 in value of
HP common stock for the Indigo common
shares to be exchanged for the fixed offer
price.
Therefore, based upon our assumptions, if you had tendered 100 Indigo common
shares for the contingent offer price, the known per share value consideration
you would receive would range from $4.83 to $7.07, the sum of (1) $4.05 to
$5.93 per share (86.65% of $4.67-$6.84 for the contingent offer price) and (2)
$0.78 to $1.14 per share (13.35% of $5.84-$8.55 for the fixed offer price). In
addition, you would receive 86.65 CVRs, which on a present value basis could
payout between $0.00 and $240.02 ($2.77 x 86.65 CVRs). This would result in a
range of total consideration on a present value basis for your 100 tendered
Indigo common shares of (A) assuming no CVR payout, $482.62 to $706.83, or (B)
assuming a full payout for the 86.65 CVRs, $722.64 to $946.85.
Post-Closing Restructuring
Through Newco, our newly-purchased indirect subsidiary, we are making the
exchange offer in order to acquire all of the outstanding Indigo common shares.
After the completion of the exchange offer, we may, but are not required to,
effectuate a corporate restructuring of Indigo. This post-closing
restructuring, if implemented by us in our sole discretion, may include among
other things:
. the commencement of a compulsory acquisition in accordance with Section
2:92a of the Dutch Civil Code by us of Indigo common shares from any
remaining minority Indigo shareholders, as described below in the
section titled "--Compulsory Acquisition;"
. the sale and transfer by Indigo, or any of its subsidiaries, to us, or
any of our affiliates, of all or a portion of the assets of Indigo
(including capital stock of a subsidiary) or its subsidiaries;
. the transfer of employees from Indigo or an Indigo subsidiary to us or
any of our affiliates, and the transfer of employees from us or any of
our affiliates to Indigo or an Indigo subsidiary;
. the amendment of Indigo's articles of association to permit the
creation, among other things, of separate classes of shares;
106
. the liquidation or merger of an Indigo subsidiary into Indigo or us or
any of our affiliates;
. the distribution of an extraordinary dividend on the Indigo common
shares or a particular class or classes of shares of Indigo, as
described below in the section titled "--Post-Closing Dividend;"
. the effectuation by Indigo and one or more of our Dutch subsidiaries of
a legal merger within the meaning of Section 2:309 of the Dutch Civil
Code, as described below in the section titled "--Post-Closing Legal
Merger;"
. the termination of the listing of the Indigo common shares on the Nasdaq
National Market;
. the deregistration of Indigo under the Exchange Act and the cessation of
Indigo's reporting obligations thereunder; or
. any one or more combinations of the foregoing actions.
Compulsory Acquisition
Section 2:92a of the Dutch Civil Code contains a procedure for the
compulsory acquisition of shares owned by minority shareholders of a "naamloze
vennootschap" or "N.V.," a limited liability company, such as Indigo. As soon
as we and our affiliates, other than Indigo, hold for our own account at least
95% of the issued share capital of Indigo, we and such affiliates may institute
proceedings against the other minority shareholders of Indigo, in accordance
with Section 2:92a of the Dutch Civil Code, in order to force those minority
Indigo shareholders to transfer their Indigo common shares to us. The
compulsory acquisition may be initiated at any time upon fulfillment of the 95%
ownership condition. The proceedings are instituted by means of a writ of
summons served upon each of the minority shareholders in accordance with the
provisions of the Dutch Code of Civil Procedure. The proceedings are held
before the Enterprise Division of the Court of Appeals in Amsterdam, The
Netherlands, which is referred to as the Enterprise Division. The Enterprise
Division may render the following judgments:
1. deny the claim for compulsory acquisition in relation to all minority
shareholders if it is established that (A) one or more minority
shareholders will incur considerable financial loss by the forced
transfer of their Indigo common shares that would not be compensated by
the fixed price for their Indigo common shares, (B) one or more minority
shareholders holds one or more shares in which, according to Indigo's
articles of association, a special control right regarding Indigo is
vested, or (C) the plaintiffs have waived their rights to institute
these proceedings vis-a-vis one or more of the minority shareholders;
2. if the claim is not denied (A) appoint one or three auditors to advise
the Enterprise Division as to the price to be paid for the minority
shareholders' Indigo common shares after which the Enterprise Division
will fix such price, or (B) fix the price to be paid for the Indigo
common shares of the minority shareholders if the Enterprise Division
does not deem it necessary to appoint auditors, for instance, if the
plaintiffs have already provided the Enterprise Division with sufficient
evidence that the price offered is reasonable; and
3. if the claim is not denied, award the claim for compulsory acquisition
by way of an order to the minority shareholders to transfer their
shares, as well as an order to the plaintiffs to pay the minority
shareholders the price fixed with interest against transfer of their
unencumbered shares.
If the Enterprise Division fixes the price to be paid for the Indigo common
shares of the minority Indigo shareholders, such price shall be increased by
the statutory interest rate applicable in The Netherlands, at present 8% per
annum, for the period from a date determined by the Enterprise Division to the
date of payment of the price. However, any dividends or other distributions,
including any post-closing dividend, made by Indigo to its shareholders during
that period will be deemed to be partial payments towards the price fixed.
The minority Indigo shareholders will be required to transfer their Indigo
common shares, against payment of the price set by the Enterprise Division,
only once a final, nonappealable judgment described in clause
107
(3) above has been obtained. The plaintiffs, by notification sent directly to
the minority Indigo shareholders whose addresses are known and by means of an
advertisement in a national daily newspaper in The Netherlands, will notify the
minority Indigo shareholders of the date and place of payment for the Indigo
common shares and the price to be paid for the Indigo common shares. The
plaintiffs also may pay the price for the minority shareholders' Indigo common
shares, inclusive of interest accrued thereon, in escrow to the Kingdom of The
Netherlands. By this payment, the plaintiffs become the holders of the Indigo
common shares by operation of law subject to the same notice obligations. Any
encumbrance on any Indigo common shares for which payment in escrow has been
made will be released from such Indigo common shares and will transfer to the
funds paid for such shares. At such time, the minority Indigo shareholders
would cease to have any rights in their Indigo common shares, including with
respect to voting thereof. Their only right will be the right to receive
payment therefor upon proper transfer of their Indigo common shares.
Because the compulsory acquisition would require a court proceeding and
possibly expert valuation, receipt of funds could be substantially delayed, and
the price paid to Indigo shareholders in the compulsory acquisition may be more
or less than the consideration issued in the exchange offer.
Post-Closing Dividend
As part of the post-closing restructuring that we may implement in our sole
discretion, we may transfer subsidiaries of Indigo to our affiliates for fair
market value. Indigo would then declare and pay a pro rata dividend of
substantially all of the proceeds of such transfer as a post-closing dividend
to its shareholders, which would consist of us or our affiliates and the
remaining Indigo shareholders. Receipt of a post-closing dividend by
non-tendering Indigo shareholders could have adverse tax consequences to such
shareholders and reduce the amount payable in any compulsory acquisition we
initiate, which is described in the section above titled "--Compulsory
Acquisition." In addition, there may be dividend withholding consequences under
Dutch tax laws in connection with such post-closing dividend.
Post-Closing Legal Merger
Section 2:309 of the Dutch Civil Code provides for the possibility to merge
one company into another company, as long as they are both limited liability
companies incorporated under Dutch law, pursuant to which the merging company
will cease to exist and be "absorbed" by the surviving entity. As a result of
such a legal merger, the assets and liabilities of the merging entity are
transferred to the surviving entity by operation of law and the shareholders of
the merging entity receive shares in the surviving entity in accordance with an
exchange ratio based on the value of the merging companies. As a part of the
contemplated post-closing restructuring, we may decide to effect a legal merger
between Indigo and a newly-incorporated or existing Dutch subsidiary of HP.
Dutch law provides that if, on the basis of the exchange ratio, a
shareholder is not even entitled to one share in the surviving entity, that
shareholder will receive cash instead of shares. However, the total amount of
cash to be distributed to shareholders as a result of the merger may not exceed
10% of the nominal value of the shares allocated as a result of the merger. By
increasing the aggregate nominal value of the shares that will be allocated by
the surviving Dutch HP subsidiary in the legal merger between Indigo and that
subsidiary and by making the denominations of individual shares sufficiently
large, the individual remaining shareholders of Indigo may not be entitled to
receive even one share in that surviving HP subsidiary. In that event, Indigo
would cease to exist and the remaining shareholders of Indigo would then be
paid an amount in cash rather than receiving shares in the surviving HP
subsidiary.
Other Post-Closing Actions
Following the completion of the exchange offer, we may also from time to
time purchase Indigo common shares, subject to Dutch law and other applicable
law, at market prices then prevailing. Such prices may be higher or lower than
the consideration issued in the exchange offer.
108
Pursuant to the offer agreement, Indigo has agreed to take all actions,
effective no earlier than the completion of the exchange offer, that are
reasonably necessary or desirable to accomplish the post-closing restructuring,
if implemented by us in our sole discretion, as described in this section.
There can be no assurance, however, that we will undertake any of the
actions contemplated by the post-closing restructuring or that Indigo
shareholders who do not tender their Indigo common shares pursuant to the
exchange offer will receive any consideration for their Indigo common shares
from HP at any subsequent time. In addition, if we, in our sole discretion,
implement a post-closing restructuring to acquire any remaining Indigo common
shares not tendered into the exchange offer, it may be expected that the
aggregate consideration payable to the remaining minority Indigo shareholders
will be equivalent to the fixed offer price. However, the form of the
consideration paid to remaining minority Indigo shareholders in any
post-closing restructuring will be cash.
In light of our post-closing restructuring options, we have not determined
whether the Indigo common shares obtained in the exchange offer will be
retained, retired, held in treasury or otherwise disposed of.
Timing of the Exchange Offer
The initial expiration time of the exchange offer is 12:00 noon, New York
City time, on March 22, 2002, but we may, and in some cases may be obligated
to, extend the exchange offer from time to time, in which case the term
"expiration time" means the latest time and date on which the exchange offer,
as so extended, expires; provided, however, that in no event shall we be
required to extend the exchange offer beyond August 30, 2002. For more
information, you should read the discussion in the section below titled
"--Extension, Termination, Waiver and Amendment of the Exchange Offer."
Extension, Termination, Waiver and Amendment of the Exchange Offer
We expressly reserve the right, subject to the provisions of the offer
agreement, to extend the period of time during which our exchange offer remains
open, and we can do so by giving oral or written notice to the exchange agent.
We are not making any assurances that we will exercise our right to extend the
exchange offer, although subject to the terms of the offer agreement, we have
agreed to extend the exchange offer for successive extension periods not in
excess of ten business days per extension if, at the scheduled expiration of
the exchange offer (1) any of the conditions to the exchange offer has not been
satisfied or, where permissible, waived, (2) such conditions are reasonably
capable of being satisfied in our sole judgment, and (3) none of the events set
forth in paragraphs (a) to (c) or (f) to (h) of Annex I to the offer agreement
that would permit us not to accept tendered shares has occurred. This topic is
more fully described in the section titled "The Offer Agreement--The Exchange
Offer--Extensions of the Exchange Offer." During an extension, all Indigo
common shares previously tendered and not properly withdrawn will remain
subject to the exchange offer, subject to your right to withdraw your Indigo
common shares. You should read the discussion in the section titled
"--Withdrawal Rights" for more details.
We reserve the right to make any changes in the terms and conditions of the
exchange offer by giving oral or written notice of the change to the exchange
agent. However, without the prior written consent of Indigo, we cannot:
. decrease the offer price;
. change the form or combination of consideration to be paid in the
exchange offer;
. reduce the number of Indigo common shares to be purchased in the
exchange offer;
. amend the conditions set forth in Annex I to the offer agreement to
broaden the scope of such conditions, add any additional conditions, or
otherwise amend any other material terms of the exchange offer in a
manner materially adverse to Indigo shareholders;
109
. extend the exchange offer, except as described below and except that we
may extend the exchange offer without Indigo's consent (1) if at the
scheduled expiration date of the exchange offer any of the conditions to
the exchange offer have not been satisfied or waived, or (2) for any
period required by any rule, regulation, interpretation or position of
the Securities and Exchange Commission or its staff; or
. amend the minimum condition, except as described below.
We expressly reserve the right to and may unilaterally amend or waive the
minimum condition to reduce the percentage of outstanding Indigo common shares
required to be validly tendered in accordance with the terms of the exchange
offer, provided, that we shall extend the exchange offer for a period of not
fewer than ten business days after any such amendment or waiver.
We are required to follow any extension, termination, amendment or delay, as
promptly as practicable, with a public announcement. In the case of an
extension, the announcement is required to be issued no later than 9:00 a.m.,
New York City time, on the next business day after the previously scheduled
expiration time. Subject to applicable law, including Rules 14d-4(d) and
14d-6(c) under the Exchange Act, which require that any material change in the
information published, sent or given to shareholders in connection with the
exchange offer be promptly sent to shareholders in a manner reasonably designed
to inform shareholders of the change, and without limiting the manner in which
we may choose to make any public announcement, we assume no obligation to
publish, advertise or otherwise communicate any public announcement other than
by making a release to the Dow Jones News Service.
If we make a material change in the terms of the exchange offer or the
information concerning the exchange offer, or if we waive a material condition
of the exchange offer, we will extend the exchange offer to the extent required
under the Exchange Act. If, prior to the expiration time and after obtaining
Indigo's prior written consent, we change the percentage of Indigo common
shares being sought or the consideration offered to you, that change will apply
to all shareholders whose Indigo common shares are accepted for exchange
pursuant to the exchange offer. If at the time notice of that change is first
published, sent or given to you, the exchange offer is scheduled to expire at
any time earlier than the tenth business day from and including the date that
the notice is first so published, sent or given, we are required to extend the
exchange offer until the expiration of that ten business day period. For
purposes of the exchange offer, a "business day" means any day, other than a
Saturday, Sunday or U.S. federal holiday and shall consist of the time period
from 12:01 a.m. through 12:00 midnight U.S. Eastern time.
Exchange of Indigo Common Shares; Delivery of Consideration
Upon the terms of, and subject to the conditions to, the exchange offer
including, if the exchange offer is extended or amended, the terms and
conditions of the extension or amendment, we are required to accept for
exchange, and to deliver a combination of shares of HP common stock and CVRs in
exchange for, Indigo common shares that are validly tendered and not properly
withdrawn, promptly after the expiration time. In addition, subject to
applicable rules of the Securities and Exchange Commission, we expressly
reserve the right to delay acceptance for exchange or the exchange of Indigo
common shares in order to comply with any applicable law. In all cases,
exchange of Indigo common shares tendered and accepted for exchange pursuant to
the exchange offer will be made only after timely receipt by the exchange agent
of:
. certificates for the Indigo common shares or a confirmation of a
book-entry transfer of the Indigo common shares in the exchange agent's
account at The Depository Trust Company, which is referred to in this
prospectus as the "DTC;" and
. a properly completed and duly executed letter of transmittal or a
manually signed facsimile of that document, and any other required
documents.
For purposes of the exchange offer, we will be deemed to have accepted for
exchange Indigo common shares validly tendered and not properly withdrawn as,
if and when we notify the exchange agent of our
110
acceptance of the tenders of those Indigo common shares. The exchange agent is
required to then deliver shares of HP common stock, CVRs, if any (or notices of
beneficial ownership to the extent the CVRs are issued in the form of global
certificates), and cash instead of fractional shares of HP common stock in
exchange for the Indigo common shares promptly after receipt of the notice
referred to in the preceding sentence. The exchange agent will act as our agent
for the purpose of receiving shares of HP common stock and any cash to be paid
instead of any fractional shares of HP common stock and transmitting a
certificate or certificates for HP common stock, CVRs, if any, and cash, if
any, to you. You will not receive any interest on any cash that HP pays to you,
even if there is a delay in making the exchange.
If we do not accept any tendered Indigo common shares for exchange pursuant
to the terms and conditions of the exchange offer for any reason, or if
certificates are submitted for more Indigo common shares than are accepted, we
are required to return certificates for the unexchanged Indigo common shares to
the tendering shareholder or, in the case of Indigo common shares tendered by
book-entry transfer of unexchanged Indigo common shares into the exchange
agent's account at the address on the back page of this prospectus, pursuant to
the procedures described in the section titled "--Procedure for Tendering," the
Indigo common shares will be credited to an account maintained within DTC, as
soon as practicable following expiration or termination of the exchange offer.
Cash Instead of Fractional Shares of HP Common Stock
No fractional shares of HP common stock will be issued in connection with
the exchange offer. Instead, each tendering holder of Indigo common shares who
would otherwise be entitled to receive a fraction of a share of HP common stock
in the exchange offer, after aggregating all fractional shares of HP common
stock that otherwise would be received by such holder, will receive cash
rounded to the nearest whole cent, without interest, equal to the product
obtained by multiplying such fraction by the closing price of one share of HP
common stock, as reported on the New York Stock Exchange, on the first date
that HP accepts Indigo common shares for exchange in the exchange offer.
Withdrawal Rights
Your tender of Indigo common shares pursuant to the exchange offer is
irrevocable, except that Indigo common shares tendered pursuant to the exchange
offer may be withdrawn at any time prior to the expiration time.
For your withdrawal to be effective, the exchange agent must receive from
you a written letter, telex or facsimile transmission notice of withdrawal at
the address set forth on the back cover of this prospectus, and your notice
must include your name, address, social security number, the certificate
number(s) and the number of Indigo common shares to be withdrawn as well as the
name of the registered holder, if it is different from that of the person who
tendered the Indigo common shares.
A financial institution must guarantee all signatures on the notice of
withdrawal unless the Indigo common shares have been tendered for the account
of any eligible institution. Most banks, savings and loan associations and
brokerage houses are able to provide these signature guarantees for you. The
financial institution must be a participant in the Securities Transfer Agents
Medallion Program, or an "eligible institution." If Indigo common shares have
been tendered pursuant to the procedures for book-entry tender discussed under
the caption below titled "--Procedure for Tendering," any notice of withdrawal
must specify the name and number of the account at DTC to be credited with the
withdrawn Indigo common shares and must otherwise comply with the DTC
procedures. If certificates have been delivered to the exchange agent, the name
of the registered holder and the serial numbers of the particular certificates
evidencing the Indigo common shares withdrawn must also be furnished to the
exchange agent, as stated above, prior to the physical release of the
certificates. We will decide all questions regarding the form and validity,
including time of receipt, of any notice of withdrawal, in our sole discretion,
and our decision shall be final and binding.
111
Neither we, the exchange agent, the information agent nor any other person
will be under any duty to give notification of any defects or irregularities in
any notice of withdrawal or will incur any liability for failure to give any
notification. Any Indigo common shares properly withdrawn will be deemed not to
have been validly tendered for purposes of the exchange offer. However, you may
tender withdrawn Indigo common shares by following one of the procedures
discussed in the sections below titled "--Procedure for Tendering" or
"--Guaranteed Delivery" at any time prior to the expiration time.
Election Procedures
Each holder of tendered Indigo common shares will have the right to make an
election, subject to the provisions relating to fractional shares of HP common
stock described in the section above titled "--Description of the Exchange
Offer" and the limitations described in the section above titled "--Allocation
Rules for the Fixed Offer Price and Contingent Offer Price," to receive for all
such holder's tendered Indigo common shares either the fixed offer price or the
contingent offer price.
Subject to the limitations referred to in the immediately preceding
paragraph, in the exchange offer (1) each tendered Indigo common share for
which a valid election to receive the fixed offer price has been received and
each non-electing Indigo common share will be exchanged for the fixed offer
price, and (2) each tendered Indigo common share for which a valid election to
receive the contingent offer price has been received will be exchanged for the
contingent offer price.
To the extent that you validly tender your Indigo common shares and do not
withdraw them but do not indicate in your transmittal letter whether to elect
the fixed offer price or the contingent offer price, you will be deemed to have
elected to receive the fixed offer price for all Indigo common shares that you
tender, subject to the limitations referred to above.
Procedure for Tendering
For you to validly tender Indigo common shares pursuant to the exchange
offer:
. the enclosed election form/letter of transmittal, properly completed and
duly executed or a manually executed facsimile of that document, along
with any required signature guarantees, or an agent's message in
connection with a book-entry transfer, and any other required documents,
must be transmitted to and received by the exchange agent at the address
set forth on the back cover of this prospectus, and certificates for
tendered Indigo common shares must be received by the exchange agent at
the address set forth on the back cover of this prospectus or the Indigo
common shares must be tendered pursuant to the procedures for book-entry
tender described below (and a confirmation of receipt of the tender
received, which confirmation we refer to below as a "book-entry
confirmation"), in each case before the expiration time; or
. you must comply with the guaranteed delivery procedures described below.
Both of these procedures described above must be completed by the expiration
time.
The term agent's message means a message, transmitted by DTC to, and
received by, the exchange agent and forming a part of a book-entry
confirmation, which states that DTC has received an express acknowledgement
from the participant in DTC tendering the Indigo common shares which are the
subject of the book-entry confirmation, that the participant has received and
agrees to be bound by the terms of the letter of transmittal and that we may
enforce that agreement against the participant.
The exchange agent is required to establish accounts with respect to the
Indigo common shares at DTC for purposes of the exchange offer within two (2)
business days after the date of this prospectus, and any financial institution
that is a participant in DTC may make book-entry delivery of the Indigo common
shares by causing
112
DTC to transfer tendered Indigo common shares into the exchange agent's account
in accordance with DTC's procedure for the transfer. However, although delivery
of Indigo common shares may be effected through book-entry at DTC, the letter
of transmittal (or a manually signed facsimile thereof), with any required
signature guarantees, or an agent's message in connection with a book-entry
transfer, and any other required documents, must, in any case, be transmitted
to and received by the exchange agent at the address on the back cover of this
prospectus prior to the expiration time, or the guaranteed delivery procedures
described below must be followed.
Signatures on all letters of transmittal must be guaranteed by an eligible
institution, except in cases in which Indigo common shares are tendered either
by a registered holder of Indigo common shares who has not completed the box
titled "Special Issuance Instructions" on the letter of transmittal or for the
account of an eligible institution.
If the certificates for Indigo common shares are registered in the name of a
person other than the person who signs the letter of transmittal, or if
certificates for unexchanged Indigo common shares are to be issued to a person
other than the registered holder(s), the certificates must be endorsed or
accompanied by appropriate stock powers, in either case signed exactly as the
name or names of the registered owner or owners appear on the certificates,
with the signature(s) on the certificates or stock powers guaranteed in the
manner HP has described above.
The method of delivery of Indigo share certificates and all other required
documents, including delivery through DTC, is at your option and risk, and the
delivery will be deemed made only when actually received by the exchange agent.
If delivery is by mail, HP recommends registered mail with return receipt
requested, properly insured. In all cases, you should allow sufficient time to
ensure timely delivery.
To prevent backup federal income tax withholding with respect to cash
received instead of fractional shares pursuant to the exchange offer or upon a
payment under the CVRs, you must provide the exchange agent with your correct
taxpayer identification number and certify whether you are subject to
withholding of federal income tax by completing the substitute Form W-9
included in the letter of transmittal. Some shareholders (including, among
others, all corporations and some foreign individuals) are not subject to these
backup withholding and reporting requirements. In order for a foreign
individual to qualify as an exempt recipient, the shareholder must submit a
Form W-8BEN or other Form W-8, signed under penalties of perjury, attesting to
that individual's exempt status.
Guaranteed Delivery
If you wish to tender Indigo common shares pursuant to the exchange offer
and your certificates are not immediately available or you cannot deliver the
certificates and all other required documents to the exchange agent prior to
the expiration time or cannot complete the procedure for book-entry transfer on
a timely basis, your Indigo common shares may nevertheless be tendered, as long
as all of the following conditions are satisfied:
. you make your tender by or through an eligible institution;
. the enclosed notice of guaranteed delivery, properly completed and duly
executed, substantially in the form enclosed with this prospectus, is
received by the exchange agent as provided below on or prior to the
expiration time; and
. the certificates for all tendered Indigo common shares or a confirmation
of a book-entry transfer of tendered securities into the exchange
agent's account at DTC as described above, in proper form for transfer,
together with a properly completed and duly executed letter of
transmittal or a manually signed facsimile thereof, with any required
signature guarantees (or, in the case of a book-entry transfer, an
agents message) and all other documents required by the letter of
transmittal are received by the exchange agent within three (3) New York
Stock Exchange trading days after the date of execution of the notice of
guaranteed delivery.
113
You may deliver the notice of guaranteed delivery by hand or transmit it by
facsimile transmission or mail to the exchange agent and you must include a
signature guarantee by an eligible institution in the form provided in that
notice.
In all cases, we are required to exchange Indigo common shares tendered and
accepted for exchange pursuant to the exchange offer only after timely receipt
by the exchange agent of certificates for Indigo common shares (or timely
confirmation of a book-entry transfer of tendered securities into the exchange
agent's account at DTC as described above), properly completed and duly
executed letter(s) of transmittal or manually signed facsimile(s) thereof, or
an agent's message in connection with a book-entry transfer, and any other
required documents.
By executing a letter of transmittal as described above, you irrevocably
appoint our designees as your attorneys-in-fact and proxies, each with full
power of substitution, to the full extent of your rights with respect to your
Indigo common shares tendered and accepted for exchange by us and with respect
to any and all other Indigo common shares and other securities (other than the
shares of HP common stock) issued or issuable in respect of the Indigo common
shares on or after the expiration of the exchange offer. That appointment is
effective when and only to the extent that, we accept the Indigo common shares
for exchange pursuant to the exchange offer. All of these proxies shall be
considered coupled with an interest in the tendered Indigo common shares and
therefore shall not be revocable. Upon the effectiveness of the appointment,
all prior proxies that you have given will be revoked and you may not give any
subsequent proxies (and, if given, they will not be deemed effective). With
respect to the Indigo common shares for which the appointment is effective, our
designees will be empowered, among other things, to exercise all of your voting
and other rights as they, in their sole discretion, deem proper at any annual,
special or adjourned meeting of Indigo shareholders or otherwise. we reserve
the right to require that, in order for Indigo common shares to be deemed
validly tendered immediately upon our exchange of the shares, we must be able
to exercise full voting rights with respect to the tendered Indigo common
shares.
We, in our sole discretion, will determine questions regarding the validity,
form, eligibility, including time of receipt, and acceptance for exchange of
any tender of Indigo common shares and its determination shall be final and
binding. We reserve the absolute right to reject any and all tenders of Indigo
common shares that we determine are not in proper form or the acceptance of or
exchange for which may, in the opinion of our counsel, be unlawful. We also
reserve the absolute right to waive any defect or irregularity in the tender of
any Indigo common shares. No tender of Indigo common shares will be deemed to
have been validly made until all defects and irregularities in tenders of
Indigo common shares have been cured or waived. Neither we, the exchange agent,
the information agent nor any other person will be under any duty to give
notification of any defects or irregularities in the tender of any Indigo
common shares or will incur any liability for failure to give notification. Our
interpretation of the terms and conditions of the exchange offer (including the
letter of transmittal and instructions thereto) will be final and binding.
The tender of Indigo common shares pursuant to any of the procedures
described above will constitute a binding agreement between us and you upon the
terms and subject to the conditions to the exchange offer.
Accounting Treatment of the Exchange Offer
In accordance with United States generally accepted accounting principles,
HP will account for the exchange offer using the purchase method of accounting.
Under this method of accounting, HP will record the market value of its common
stock issued in connection with the exchange offer, the fair value of the
options to purchase Indigo common shares assumed in connection with the
exchange offer and the amount of direct transaction costs associated with the
exchange offer as the estimated purchase price of acquiring Indigo. HP will
allocate the estimated purchase price to the net tangible and amortizable
intangible assets acquired, intangible assets with indefinite lives and
in-process research and development, based on their respective fair values at
the date of the completion of the exchange offer. Any excess of the estimated
purchase price over those fair values
114
will be accounted for as goodwill. The future cash payout, if any, under the
CVR obligation would be accounted for as an increase in goodwill when incurred.
In accordance with the Statement of Financial Accounting Standards No. 142,
"Goodwill and Other Intangible Assets," goodwill and intangible assets with
indefinite lives resulting from business combinations completed subsequent to
June 30, 2001 will not be amortized but instead will be tested for impairment
at least annually (more frequently if certain indicators are present). In the
event that the management of HP determines that the value of goodwill or
intangible assets with indefinite lives has become impaired, HP will incur an
accounting charge for the amount of impairment during the fiscal quarter in
which the determination is made. In addition, in the event that the management
of HP determines that the useful life of any intangible assets with indefinite
lives has become definite, the intangible asset will be amortized over its
remaining useful life, and HP will incur an accounting charge related to such
amortization during each fiscal quarter of the intangible asset's remaining
useful life.
Regulatory Filings and Approvals Required to Complete the Exchange Offer
We and Indigo have agreed, pursuant to the offer agreement, to use
commercially reasonable efforts to take, or cause to be taken, all reasonable
actions, and to do, or cause to be done, and to assist and cooperate with the
other parties including, all things reasonably necessary, proper or advisable,
to obtain any regulatory clearance, waiver, approval or authorization that is
necessary to enable us and Indigo to consummate and make effective the
transaction; provided, however, that nothing in the offer agreement shall be
deemed to require us or Indigo or any subsidiary or affiliate thereof to make
proposals, execute or carry out agreements or submit to orders providing for a
sale, license or other disposition or the holding separate (through the
establishment or a trust or otherwise) of any assets or categories of assets of
ours, any of our affiliates or Indigo or its subsidiaries or the holding
separate of any Indigo common shares or imposing or seeking to impose any
limitation on the ability of us or any of our subsidiaries or affiliates to
conduct their business or own such assets or to acquire, hold or exercise full
rights of ownership of the Indigo common shares. Other than clearance under the
antitrust laws applicable to the transaction which are described below, the
Israeli approvals applicable to the transaction which are described below, the
Securities and Exchange Commission declaring effective the registration
statement on Form S-4 relating to this transaction, of which this prospectus is
a part, we do not believe that any additional material governmental filings are
required with respect to the transaction.
Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
the transaction may not be completed until HP and Indigo each notify and
furnish information to the Federal Trade Commission and the Antitrust Division
of the United States Department of Justice and specified waiting period
requirements have been satisfied. We have made the notifications required under
the Hart-Scott-Rodino Act to the Federal Trade Commission and the Antitrust
Division of the United States Department of Justice, and the waiting period
under the Hart-Scott-Rodino Act was terminated on October 1, 2001.
At any time during or after the statutory waiting periods and before or
after the completion of the exchange offer, either the Antitrust Division of
the United States Department of Justice or the Federal Trade Commission could
take any action under United States antitrust laws that it deems necessary or
desirable, including seeking to enjoin the completion of the exchange offer or
seeking the divestiture of assets of us or Indigo. Private parties and state
attorneys general may also bring actions under United States antitrust laws
depending on the circumstances. Although we believe that neither the exchange
offer nor the post-closing restructuring raises concerns under United States
antitrust laws, we can give no assurance that a challenge to the exchange offer
or the post-closing restructuring on antitrust grounds will not be made or, if
a challenge is made, that we and Indigo would prevail.
We and Indigo also conduct operations internationally, where other antitrust
or competition regulatory filings or approvals are required in connection with
the completion of the exchange offer. HP and Indigo believe that
antitrust-related regulatory filings in connection with the completion of the
exchange offer are necessary in
115
Austria, Brazil, Germany, Israel, Italy and Portugal. We have made all these
required foreign antitrust filings. The applicable antitrust clearances in
Austria, Germany and Italy have been granted. However, we have not yet received
antitrust clearance in Brazil, Israel or Portugal. Antitrust clearance in
Brazil is not required before the closing of the exchange offer. The foreign
antitrust authorities or private parties could also take any action available
to them under the relevant foreign antitrust laws that they deem necessary or
desirable, including seeking to enjoin the completion of the exchange offer or
seeking the divestiture of assets of us or Indigo. In addition, in some
jurisdictions a competitor, customer or other third party could initiate a
private action under the antitrust laws challenging or seeking to enjoin the
exchange offer, before or after it is completed. Although we believe that
neither the exchange offer nor the post-closing restructuring raises concerns
under foreign antitrust laws and though we fully intend to comply with the
antitrust laws of any other jurisdiction in which the transaction is subject to
review, we can give no assurance that a challenge to the exchange offer or the
post-closing restructuring on antitrust grounds will not be made or, if a
challenge is made, that we and Indigo would prevail.
Israeli Restrictive Trade Practices Law
Under Israel's Restrictive Trade Practices Law, 1988, a merger (which for
purposes of this law includes the acquisition of one quarter or more of a
company's share capital), which meets certain conditions, is subject to the
approval of the Israeli Commissioner of Restrictive Trade Practices. It is
therefore a condition to our obligation to the closing of the exchange offer
that such approval is given. We made the required filing with the Israeli
Commissioner of Restrictive Trade Practices on January 21, 2002, but have not
yet received the required approval.
Office of The Chief Scientist
To the extent that a research and development program developed by a company
has been funded by the Office of the Chief Scientist, the Office of the Chief
Scientist's consent would be required for the transfer of the means of control
in the company to a non-Israeli entity. The Office of the Chief Scientist is
part of Israel's Ministry of Trade and Industry and provides research and
development grants to Israeli companies in order to encourage research and
development in industry, subject to an obligation to repay the grants by means
of royalties on the sale of products deriving from programs funded by the
grants. Indigo Electronic Printing Systems Ltd., referred to as IEPS, has
obtained grants from the Office of the Chief Scientist for different
development programs. The Office of the Chief Scientist's approval for the
closing of the exchange offer is required.
The conditions of grants provided by the Office of the Chief Scientist
generally place limitations on the transfer of know-how and the manufacture
outside of Israel of products funded by such grants. These conditions apply to
the grants received by IEPS from the Office of Chief Scientist. The consent of
the Office of Chief Scientist to Indigo's ownership of know-how funded by the
Office of Chief Scientist is required under the offer agreement.
Under the offer agreement, we have agreed to provide an undertaking to
comply with the laws and regulations of the Office of the Chief Scientist and
to confirm to the Office of the Chief Scientist that after the closing of the
exchange offer, Indigo will continue its operations in a manner consistent with
Indigo's previous undertakings to the Office of the Chief Scientist. However,
we cannot assure you that these actions will be sufficient for the consents of
the Office of the Chief Scientist, as required under the offer agreement, to be
granted. Indigo submitted the request for this approval to the Office of the
Chief Scientist on October 30, 2001.
In December 2001, Indigo reached an agreement with the Office of the Chief
Scientist for the early repayment of royalties, pursuant to which Indigo paid
the Office of the Chief Scientist approximately $15 million in 2002 in
settlement of potential future royalty obligations. Indigo's prepayment of
future royalties will end Indigo's obligation to make royalty payments with
respect to grants received from the Office of the Chief Scientist during the
years 1993-2001, and will enable Indigo to join a program, funded by the Office
of the Chief Scientist, for the development of generic projects with no royalty
payment obligations. However, such
116
prepayment will not remove any limitations on the transfer of know-how or on
the manufacture outside of Israel of products funded by such grants.
Notwithstanding such prepayment, in the event that the consent of the OCS is
given to manufacture products funded by grants provided by the OCS, depending
on the percentage of manufacturing taking place outside of Israel, increased
royalties would be payable to the OCS.
Israeli Investment Center
The Investment Center, which is also a part of Israel's Ministry of Industry
and Trade, provides various benefits to Israeli companies, including grants to
finance capital investments and tax benefits ranging from reduced rates of
Israeli company tax to a full tax exemption for a fixed period, depending on a
number of factors. IEPS's production facilities in Nes Ziona was granted
Approved Enterprise status by the Investment Center and, accordingly, IEPS is
entitled to receive tax benefits from the Investment Center in respect of that
facility. In general, the consent of the Investment Center is required for any
change in the ownership structure of a company that was granted Approved
Enterprise status. The approval of the Investment Center to the closing of the
exchange offer is required under the offer agreement. Indigo submitted the
request for this approval to the Investment Center on November 19, 2001 and
received this approval on December 26, 2001. We also have agreed to comply with
the laws and regulations of the Investment Center and to confirm to the
Investment Center that after the closing of the exchange offer, Indigo will
continue its operations in a manner consistent with Indigo's previous
undertakings to the Investment Center.
Israeli Income Tax Authorities
Under the offer agreement, Indigo is to prepare and file an application to
the Israeli Income Tax Commissioner for a pre-ruling confirming that the
conversion of Indigo stock options for HP stock options will not result in a
requirement for an immediate Israeli tax payment and that Israeli taxation will
be deferred until the exercise of such converted stock options, or in the case
of Indigo stock options which are part of a stock option plan which is subject
to Section 102 of the Israeli Income Tax Ordinance, until the actual sale of
the shares of HP common stock by the option holders. The offer agreement also
provides that, subject to certain conditions, Indigo shall be allowed to comply
with any conditions contained in the ruling or reasonable requests made by the
Israeli Tax Commissioner in connection with its delivery of such ruling. Indigo
filed its application for such ruling on January 2, 2002.
Israeli Securities Authority
The exchange of Indigo stock options held by Israeli employees of Indigo, or
its subsidiaries, for HP stock options will require the publication of a
prospectus under the Israeli Securities Law, 1968 unless an exemption, pursuant
to Section 15D of the Israeli Securities Law, 1968, from the requirement is
given by the Israeli Securities Authority. Therefore, the receipt of such
exemption is required under the offer agreement. We have not yet applied for
this exemption.
Indigo Appraisal Rights
Dutch law does not recognize the concept of appraisal or dissenters' rights
and, accordingly, holders of shares of a Netherlands company, such as Indigo,
have no appraisal rights. However, on the basis of a general rule of Dutch
corporate law, the management of a company (and the other shareholders) must
act towards a shareholder in accordance with the "principles of reasonableness
and fairness." Acts in violation of those principles may be challenged through
court proceedings.
U.S. State Takeover Laws
A number of states of the United States have adopted takeover laws and
regulations which purport, to varying degrees, to be applicable to attempts to
acquire securities of corporations that are incorporated in such
117
states or whose business operations have, substantial economic effects in such
states, or have substantial assets, security holders, principal executive
offices or principal places of business therein. We do not believe that any of
these statutes will apply to the exchange offer by their terms and have not
attempted to comply with any state takeover statutes in connection with the
exchange offer. We reserve the right to challenge the validity of applicability
of any state law allegedly applicable to the exchange offer and nothing in this
prospectus and no action taken in connection herewith is intended as a waiver
of that right. In the event it is asserted that one or more state takeover
statutes is applicable to the exchange offer, and an appropriate court does not
determine that it is inapplicable or invalid as applied to the exchange offer,
we may be required to file certain information with, or receive approvals from,
the relevant state authorities, and we may be unable to accept or pay for
Indigo common shares tendered in the exchange offer or may be delayed in
continuing or completing the exchange offer. In such case, we may not be
obligated to accept, or pay for, any Indigo common shares tendered in the
exchange offer under the terms of the offer agreement, as described in the
section titled "The Offer Agreement--Conditions to the Exchange Offer."
Rule 13e-3 Transactions
The Securities and Exchange Commission has adopted Rule 13e-3 under the
Exchange Act, which is applicable to certain "going private" transactions. We
believe that Rule 13e-3 will not be applicable to a compulsory acquisition or
any open-market purchases subsequent to the completion of the exchange offer,
each as described in the section titled "--Post-Closing Restructuring," if, at
the time of such action, Indigo is no longer registered under the Exchange Act.
See the section titled "Special Factors--Effects of the Exchange Offer; Plans
or Proposals After the Exchange Offer." If applicable, Rule 13e-3 would require
that, among other things, certain financial information concerning Indigo and
certain information relating to the fairness of the compulsory acquisition and
the consideration offered to minority Indigo shareholders be filed with the
Securities and Exchange Commission and distributed to minority Indigo
shareholders prior to the consummation of any such transaction.
Fees and Expenses
We have retained Georgeson Shareholder Communications, Inc. to act as
information agent in connection with the exchange offer. The information agent
may contact holders of Indigo common shares by mail, telephone, telex,
telegraph, e-mail and personal interview and may request brokers, dealers and
other nominee shareholders to forward material relating to the exchange offer
to beneficial owners of Indigo common shares. We will agree to pay the
information agent reasonable and customary compensation for these services in
addition to reimbursing the information agent for its reasonable out-of-pocket
expenses. We will agree to indemnify the information agent against certain
liabilities and expenses in connection with the exchange offer, including
certain liabilities under the U.S. federal securities laws.
In addition, we have retained Computershare Trust Company of New York as the
exchange agent. We also have retained Citibank N.A. as the exchange agent in
Luxembourg. We have agreed to pay the exchange agents reasonable and customary
compensation for their services in connection with the exchange offer, have
agreed to reimburse the exchange agents for their reasonable out-of-pocket
expenses and have agreed to indemnify the exchange agents against certain
liabilities and expenses, including certain liabilities under the U.S. federal
securities laws.
Except as described above, we have not agreed to pay any fees or commissions
to a broker, dealer or other person for soliciting tenders of Indigo common
shares pursuant to the exchange offer. We have agreed to reimburse brokers,
dealers, commercial banks and trust companies and other nominees, upon request,
for customary clerical and mailing expenses incurred by them in forwarding
offering materials to their customers.
118
The estimated aggregate fees and expenses to be incurred by us, on the one
hand, and by Indigo and its affiliates other than us, on the other hand, in
connection with the completion of the exchange offer are as follows:
Indigo HP
---------- ----------
Advisory Fees and Expenses................................. $5,500,000 $ 0
Legal and Accounting Fees and Expenses..................... 4,000,000 3,000,000
Depository and Paying Agent Fees and Expenses.............. 0 20,000
Printing and Mailing Costs................................. 30,000 350,000
Solicitation Fees and Expenses............................. 0 20,000
Securities and Exchange Commission Filing Fee.............. 0 200,000
Other Regulatory Filing Fees............................... 0 300,000
Miscellaneous Expenses..................................... 0 0
---------- ----------
Total................................................... $9,530,000 $3,890,000
========== ==========
The offer agreement provides that fees and expenses incurred in connection
with the offer agreement and the transactions contemplated thereby will be paid
by the party that incurred them.
Source and Amount of Funds
The source and amount of funds or other consideration to be used by Newco,
our newly-purchased indirect subsidiary, to purchase the Indigo common shares
in connection with the exchange offer are newly issued shares of HP common
stock, which Newco will purchase from HP for cash, and CVRs to be issued by
Newco. HP will guarantee the contingent payment obligations of Newco under the
CVRs. However, we anticipate that Newco will have access to sufficient capital
to make any payments under the CVRs.
Restrictions on Sales of Shares of HP Common Stock Received in the Exchange
Offer
The shares of HP common stock to be issued in the exchange offer will be
registered under the Securities Act and will be freely transferable under the
Securities Act, except for shares of HP common stock issued to any person who
is deemed to be an "affiliate" of Indigo prior to the exchange offer. Persons
who may be deemed to be "affiliates" of Indigo prior to the exchange offer
include individuals or entities that control, are controlled by, or are under
common control of Indigo prior to the exchange offer, and may include officers
and directors, as well as principal shareholders of Indigo prior to the
exchange offer. Persons who may be deemed to be affiliates of Indigo prior to
the exchange offer may not sell any of the shares of HP common stock received
by them in the exchange offer except pursuant to:
. an effective registration statement under the Securities Act covering
the resale of those shares;
. an exemption under paragraph (d) of Rule 145 under the Securities Act; or
. any other applicable exemption under the Securities Act.
Our registration statement on Form S-4, of which this prospectus forms a
part, does not cover the resale of shares of HP common stock to be received in
the exchange offer by persons who may be deemed to be affiliates of Indigo
prior to the exchange offer.
Listing of Shares of HP Common Stock Issued in the Exchange Offer on the New
York Stock Exchange and Pacific Exchange
We will use our commercially reasonable efforts to cause the listing on the
New York Stock Exchange and the Pacific Exchange, effective as of the closing
time, of the shares of HP common stock issuable, and those required to be
reserved for issuance, in connection with the exchange offer, subject to
official notice of issuance.
119
Delisting and Deregistration of Indigo Common Shares after the Exchange Offer
Pursuant to the offer agreement, we, after the closing of the exchange
offer, may effectuate a post-closing restructuring of Indigo and its
subsidiaries, which may include, without limitation, the termination of the
listing of Indigo common shares on the Nasdaq National Market and
deregistration under the Exchange Act. See the section titled "Special
Factors--Effects of the Exchange Offer; Plans or Proposals After the Exchange
Offer" for a description of the possible effects of such delisting and
deregistration on the liquidity and market value of the remaining Indigo common
shares held by the public and not tendered pursuant to the exchange offer.
120
THE OFFER AGREEMENT
The following summary describes the material provisions of the offer
agreement. The provisions of the offer agreement are complicated and not easily
summarized. This summary may not contain all of the information about the offer
agreement that is important to you. The offer agreement is attached to this
prospectus as Annex A and is incorporated by reference into this prospectus,
and HP and Indigo encourage you to read it carefully in its entirety for a more
complete understanding of the offer agreement.
The Exchange Offer
Terms of the Exchange Offer
Under the terms of the offer agreement, we have agreed to commence through
our newly-formed subsidiary as promptly as practicable an exchange offer for
all outstanding Indigo common shares. We are causing our newly-formed
subsidiary to offer to exchange each Indigo common share that is validly
tendered and not properly withdrawn for either the fixed offer price or the
contingent offer price.
The initial expiration date of the exchange offer is 12:00 noon, New York
City time, on March 22, 2002.
Extensions of the Exchange Offer
We have the right to extend the exchange offer (1) if at the scheduled
expiration date of the exchange offer any of the conditions to the exchange
offer shall not have been satisfied or waived; or (2) for any period required
by any rule, regulation, interpretation or position of the Securities and
Exchange Commission or the staff thereof applicable to the exchange offer.
We are not making any assurances that we will exercise our right to extend
the exchange offer, although, subject to the terms of the offer agreement, we
have agreed to extend the exchange offer for successive extension periods not
in excess of ten (10) business days per extension if, at the scheduled
expiration of the exchange offer (1) any of the conditions to the exchange
offer has not been satisfied or, where permissible, waived, (2) such conditions
are reasonably capable of being satisfied in our sole judgment, and (3) none of
the following events that would permit us not to accept tendered shares has
occurred and is continuing at the time of the expiration of the offer:
. there shall be pending any suit, action or proceeding by any
governmental entity against us, Indigo, any subsidiary of Indigo or any
of our subsidiaries (i) seeking to prohibit or impose any material
limitations on our ownership or operation (or that of any of our
subsidiaries or affiliates) of all or a material portion of their or
Indigo's businesses or assets, or to compel us or its subsidiaries and
affiliates to dispose of or hold separate any material portion of the
business or assets of Indigo or us and their respective subsidiaries, in
each case taken as a whole, (ii) challenging the acquisition by us of
any Indigo common shares under the exchange offer, seeking to restrain
or prohibit the making or completion of the exchange offer or the
performance of any of the other transactions contemplated by the offer
agreement, the tender agreements, or the voting agreements (including
the voting provisions thereunder), or seeking to obtain from Indigo or
us any damages that are material in relation to Indigo and its
subsidiaries taken as a whole, (iii) seeking to impose material
limitations on our ability, or render us unable, to accept for payment,
pay for or purchase some or all of the Indigo common shares pursuant to
the exchange offer, (iv) seeking to impose material limitations on our
ability effectively to exercise full rights of ownership of the Indigo
common shares, including, without limitation, the right, to vote the
Indigo common shares purchased on all matters properly presented to
Indigo's shareholders, (v) compelling us or our affiliates to dispose of
or hold separate any portion of the business or assets or shares of
Indigo or us and our respective subsidiaries, (vi) obligating Indigo, us
or any of our respective subsidiaries to pay material damages in
connection with the transactions contemplated by the offer agreement, or
(vii) which otherwise is reasonably likely to have a material adverse
effect on Indigo, as
121
determined in accordance with the offer agreement, or, as a result of
the transactions contemplated by the offer agreement, a material adverse
effect on us, as determined in accordance with the offer agreement;
. there shall be any law, statute, rule, regulation, ordinance, judgment,
order, decree or injunction enacted, entered, enforced, promulgated, or
deemed applicable, pursuant to an authoritative interpretation by or on
behalf of a government entity, to the exchange offer, or any other
action shall be taken by any governmental entity, other than the
application to the exchange offer of applicable waiting periods or
approvals under the Hart-Scott-Rodino Act or any foreign antitrust or
competition law and any Israeli governmental approvals required pursuant
to Israeli legal requirements for the completion of the exchange offer,
including approval of the Office of the Chief Scientist of the Israeli
Ministry of Trade & Industry, the Israeli Investment Center of the
Israeli Ministry of Trade & Industry and the Israeli Commissioner of
Restrictive Trade Practices and receipt by HP of the Israeli securities
law exemption described in Section 6.11(d) of the offer agreement, that,
is reasonably likely to result, directly or indirectly, in any of the
consequences referred to in clauses (i) through (vii) of the foregoing
paragraph;
. there shall have occurred (i) any general suspension of trading in, or
limitation on prices for, securities on the New York Stock Exchange, for
a period in excess of 24 hours (excluding suspensions or limitations
resulting solely from physical damage or interference with such
exchanges not related to market conditions), (ii) a declaration of a
banking moratorium or any suspension of payments in respect of banks in
the United States (whether or not mandatory), (iii) a commencement of a
war, armed hostilities or other international or national calamity
directly involving the United States, (iv) a commencement of a war or
escalation of armed hostilities or a general mobilization or other
international or national calamity directly involving Israel that is or
is reasonably likely to be materially adverse to Indigo's ability to
conduct business in Israel, (v) any limitation (whether or not
mandatory) by any United States governmental authority on the extension
of credit generally by banks or other financial institutions, or (vi) in
the case of any of the foregoing existing at the time of the
commencement of the offer, a material acceleration or worsening thereof;
. Indigo shall not have received the consents, waivers and approvals
required to be obtained in connection with the consummation of the
transactions contemplated by the offer agreement;
. the extraordinary general meeting of shareholders of Indigo shall not
have passed on the appointments of members of Indigo's supervisory and
management boards and the amendment of Indigo's articles of association
in accordance with Section 1.3 of the offer agreement; or
. the offer agreement shall have been terminated in accordance with its
terms.
So long as the conditions to the exchange offer are reasonably capable of
being satisfied in our sole judgment and none of the foregoing events has
occurred, we have agreed to the foregoing extensions of the exchange offer
until all conditions to the exchange offer are satisfied or, if permissible,
waived, or until the offer agreement is terminated in accordance with its terms.
In addition, if we exercise our right to amend or waive the minimum
condition to reduce the percentage of outstanding Indigo common shares required
to be validly tendered in accordance with the terms of the exchange offer, the
offer agreement provides that we are required to extend the exchange offer for
a period of not fewer than ten (10) business days after any such amendment or
waiver.
Prompt Payment for Indigo Common Shares in the Exchange Offer
Subject to the terms of the exchange offer and the offer agreement, and the
satisfaction or waiver to the extent permitted, of the conditions to the
exchange offer, we are required to accept for exchange all Indigo
122
common shares validly tendered and not properly withdrawn pursuant to the
exchange offer promptly after the applicable expiration date of the exchange
offer, as it may be extended pursuant to the offer agreement, and is required
to exchange all accepted Indigo common shares promptly after acceptance.
Fractional shares of HP common stock will not be issued in the exchange
offer. Instead, each tendering shareholder who would otherwise be entitled to a
fractional share (after aggregating all fractional shares of HP common stock
that otherwise would be received by the shareholder in the exchange offer) will
receive cash (rounded up to the nearest whole cent), without interest, equal to
the price obtained by multiplying that fraction by the closing sale price of
one share of HP common stock on the New York Stock Exchange on the first day on
which we accept shares in the exchange offer.
Indigo's Management and Supervisory Boards following the Exchange Offer
Under the terms of the offer agreement, Indigo has agreed to convene an
extraordinary general meeting of its shareholders, or EGM, no later than five
(5) business days prior to the expiration date of the exchange offer to accept
the resignation from the management board and the supervisory board of the
existing members thereof and to appoint new members to the management boards as
designated by us, as further described in the offer agreement. The new members
designated by us for appointment to the management board will be Charles N.
Charnas, J.C.A. van Diemen and R.E.J. De-Boer. Mr. Charnas is employed by HP as
its Assistant Secretary and Senior Managing Counsel, while Messrs. De-Boer and
van Diemen are employed by our Netherlands subsidiary as Legal Counsel and Tax
Manager, respectively. These resignations and appointments will be effective as
of, and conditional upon the occurrence of, the closing of the exchange offer.
We do not intend to maintain the supervisory board of Indigo after the
completion of the exchange offer.
Treatment of Indigo Stock Options and Warrants
Indigo Stock Options
Under the terms of the offer agreement, we have agreed to take all actions
necessary to convert each outstanding option to purchase Indigo common shares
that is outstanding immediately prior to the closing of the exchange offer,
also referred to as an "Indigo stock option," into a stock option to purchase
shares of HP common stock subject to HP's 2000 Stock Plan with substantially
equal value and substantially equivalent provisions as the Indigo stock option
effective immediately after the closing of the exchange offer.
Each Indigo stock option that is converted into HP stock options shall (1)
be exercisable for, and represent the right to acquire, that number of shares
of HP common stock (rounded down to the nearest whole share in the case of
Indigo stock options intended to qualify as incentive stock options under
Section 422 of the Internal Revenue Code, and rounded up in the case of other
Indigo stock options), equal to (A) the number of Indigo common shares subject
to such Indigo stock option in effect immediately prior to the closing of the
exchange offer, multiplied by (B) the exchange ratio applicable to Indigo
common shares exchanged for the fixed offer price; and (2) have an exercise
price per share of HP common stock equal to (A) the exercise price per Indigo
share subject to such Indigo stock option in effect immediately prior to the
closing time of the exchange offer, divided by (B) the exchange ratio
applicable to Indigo common shares exchanged for the fixed offer price (rounded
up to the nearest whole cent in the case of Indigo stock options intended to
qualify as incentive stock options under Section 422 of the Internal Revenue
Code, and rounded down in the case of other Indigo stock options).
Pursuant to the offer agreement, Indigo agreed to use commercially
reasonable efforts, to the extent we provide funding for such activity, to
repurchase, subject to the terms and conditions of the stock option agreement
and applicable stock option plan, prior to the closing of the exchange offer
each Indigo stock option that is outstanding and held by an optionee who is not
an employee of Indigo or any of its subsidiaries.
123
If necessary, we have agreed to file a registration statement on Form S-8,
with respect to the shares of HP common stock issuable with respect to the
Indigo stock options that are converted into HP stock options, no later than
one (1) business day after the completion of the exchange offer and to cause
such HP common stock to be listed for trading on the New York Stock Exchange
and the Pacific Exchange. We are not required to register any shares issuable
upon exercise of stock options which are not eligible to be registered on Form
S-8.
Option shares subject to an outstanding Indigo stock option that,
immediately prior to the completion of the exchange offer, are unvested or are
subject to a repurchase option, risk of forfeiture or other condition, will
continue to be unvested or subject to the same option, risk or other condition
upon conversion after the completion of the exchange offer unless the relevant
agreement provides that the option, risk or condition will be altered or will
terminate upon completion of the exchange offer.
Indigo Warrants
Unless we and Indigo agree otherwise, the offer agreement requires Indigo to
request that all holders of warrants to acquire Indigo shares, also referred to
as an Indigo warrant, exercise the Indigo warrants prior to the closing of the
exchange offer. As of the effective time of a post-closing restructuring
satisfying the applicable provisions covering mergers, consolidations and/or
other similar transactions of the Indigo warrants, if any, each remaining
outstanding Indigo warrant shall cease to represent a right to acquire Indigo
shares and shall be converted automatically into a warrant to purchase either
shares of HP common stock based on the fixed offer price or, to the extent the
holder thereof makes an effective written election prior to the closing of the
exchange offer, shares of HP common stock and CVRs based on the contingent
offer price in an amount, at an exercise price and subject to such terms and
conditions determined as provided below.
Each Indigo warrant so substituted by us shall be subject to, and
exercisable upon, the same terms and conditions as under the applicable Indigo
warrant and the applicable warrant agreement related thereto, except that:
. except as set forth below, each substituted Indigo warrant shall (1) be
exercisable for, and represent the right to acquire that number of
shares of HP common stock (rounded to the nearest whole share) equal to
(A) the number of Indigo shares subject to such Indigo warrant in effect
immediately prior to the date we initially accept for payment shares
tendered in the exchange offer multiplied by (B) the exchange ratio
applicable to Indigo common shares exchanged for the fixed offer price;
and (2) have an exercise price per share of the HP common stock subject
to such substituted Indigo warrant equal to (A) the exercise price per
Indigo share subject to such Indigo warrant in effect immediately prior
to the date we initially accept for payment shares tendered in the
exchange offer divided by (B) the exchange ratio applicable to Indigo
common shares exchanged for the fixed offer price (rounded up to the
nearest whole cent); or
. to the extent the holder thereof makes an effective written election
prior to the closing of the exchange offer, such substituted Indigo
warrant shall (1) be exercisable for, and represent the right to acquire
a number of units equal to the number of Indigo shares subject to such
Indigo warrant in effect immediately prior to the date we initially
accept for payment shares tendered in the exchange offer, each such unit
comprised of that number of shares of HP common stock and CVRs equal to
the contingent offer price, and (2) have an exercise price per such unit
subject to such substituted Indigo warrant equal to the exercise price
per Indigo share subject to such Indigo warrant in effect immediately
prior to the date we initially accept for payment shares tendered in the
exchange offer.
If and to the extent necessary or required by the terms of the Indigo
warrants or pursuant to the terms of any warrant agreement related thereto,
each of us and Indigo has agreed to request the consent of each holder of
outstanding Indigo warrants to the foregoing treatment of such Indigo warrants.
Indigo is also required to provide any notice to warrantholders required under
the terms of each Indigo warrant in connection with the exchange offer.
124
Termination of Indigo Employee Stock Purchase Plans
Indigo's employee stock purchase plans permit eligible Indigo employees to
purchase Indigo common shares at a discount pursuant to such employee's
participation in the relevant Indigo employee stock purchase plan. Prior to the
closing of the exchange offer, the Indigo employee stock purchase plans will be
terminated pursuant to the terms of such plans. It is expected that Indigo will
agree to take all actions that are necessary to effect the foregoing.
Representations and Warranties
The offer agreement contains a number of customary representations and
warranties relating to, among other things, certain aspects of the respective
businesses and assets of each of the parties and their ability to complete the
transaction. The representations and warranties of each party will expire upon
completion of the exchange offer.
Conduct of Indigo's Business Prior to Completion of the Exchange Offer
The offer agreement provides that, until the termination of the offer
agreement pursuant to its terms or the acceptance for exchange of Indigo common
shares pursuant to the exchange offer, each of Indigo and its subsidiaries will
carry on its business in the usual, regular and ordinary course in
substantially the same manner as heretofore conducted and in material
compliance with all applicable laws and regulations, pay its debts and taxes
when due subject to good faith disputes over such debts or taxes, pay or
perform other material obligations when due, and use its commercially
reasonable efforts consistent with past practices and policies to (1) preserve
intact its present business organization, (2) keep available the services of
its present officers and employees; and (3) preserve its relationships with
customers, suppliers, distributors, licensors, licensees and others with which
it has significant business dealings. The offer agreement also requires that,
until Indigo common shares are accepted for exchange pursuant to the exchange
offer, neither Indigo nor any of its subsidiaries will, without our prior
written consent:
. waive any stock repurchase rights, accelerate, amend or change the
period of exercisability or vesting of options or restricted shares, or
reprice options granted under any employee, consultant, director or
other stock plans or authorize cash payments in exchange for any options
granted under any such plans;
. grant any severance or termination pay or benefits, or payments or
benefits triggered by a change of control or acquisition (including the
exchange offer), to any employee except to persons who are employees of
Indigo as of the date of the offer agreement pursuant to written
agreements outstanding, or written policies existing, on the date of the
offer agreement; provided, however, that Indigo shall not grant, or
offer to grant, any such severance or termination payments or benefits,
or payments or benefits triggered upon a change of control or
acquisition (including the exchange offer), to any person who is hired
or offered employment with Indigo on or after the date of the offer
agreement, or adopt any new severance plan, or amend or modify or alter
in any manner any severance plan, agreement or arrangement existing on
the date hereof, or take any other action that would trigger the payment
of any severance payments or other benefits pursuant to any agreement;
. transfer or license to any person or entity or otherwise extend, amend
or modify any rights to Indigo's intellectual property, or enter into
grants to transfer or license to any person future patent rights, other
than non-exclusive licenses granted to resellers and end-users in the
ordinary course of business consistent with past practices;
. declare, set aside or pay any dividends on or make any other
distributions (whether in cash, stock, equity securities or property) in
respect of any capital stock or split, combine or reclassify any capital
stock or issue or authorize the issuance of any other securities in
respect of, in lieu of or in substitution for any capital stock, except
for dividends or other distributions paid to Indigo by any of its
wholly-owned subsidiaries;
125
. purchase, redeem or otherwise acquire, directly or indirectly, any
shares of capital stock of Indigo or its subsidiaries;
. issue, deliver, sell, authorize, pledge or otherwise encumber or propose
any of the foregoing with respect to any shares of capital stock or any
securities convertible into shares of capital stock, or subscriptions,
rights, warrants or options to acquire any shares of capital stock or
any securities convertible into shares of capital stock, or enter into
other agreements or commitments of any character obligating it to issue
any such shares or convertible securities, or grant any equity-based
compensation whether payable in cash or stock, other than the issuance
delivery and/or sale of (x) Indigo shares pursuant to the exercise of
stock options, warrants and convertible preferred stock outstanding as
of the date of the offer agreement, and (y) Indigo common shares
issuable to participants in Indigo's employee stock purchase plan
consistent with the terms thereof;
. cause, permit or propose any amendments to Indigo's articles of
association (or similar governing instruments of any of Indigo's
subsidiaries);
. acquire or agree to acquire by merging or consolidating with, or by
purchasing any equity interest in or a material portion of the assets
of, or by any other manner, any business or any corporation,
partnership, association or other business organization or division
thereof, or otherwise acquire or agree to acquire all or substantially
all of the assets of any of the foregoing, or purchase any equity
interest in any of the foregoing or enter into any joint ventures,
strategic partnerships or alliances;
. sell, lease, license, encumber or otherwise dispose of any properties or
assets except sales or leases of inventory in the ordinary course of
business consistent with past practice, and except for the sale, lease
or disposition (other than through licensing, unless permitted by
Section 5.1(c) of the offer agreement) of property or assets which are
not material, individually or in the aggregate, to the business of
Indigo and its subsidiaries, taken as a whole;
. materially modify, amend or terminate any existing lease, license or
contract affecting the use, possession or operation of any material
properties or material assets; grant or otherwise create or consent to
the creation of any easement, covenant, restriction, assessment or
charge which would materially and adversely affect Indigo's use, or the
value of, any material owned property or leased property; convey,
assign, sublease, license or otherwise transfer all or any portion of
any material real property or any interest or rights therein; commit any
waste or nuisance on any such property; or make any material changes in
the construction or condition of any such property;
. incur any indebtedness for borrowed money or guarantee any such
indebtedness of another person, issue or sell any debt securities or
options, warrants, calls or other rights to acquire any debt securities
of Indigo or any of its subsidiaries, enter into any "keep well" or
other agreement to maintain any financial statement condition or enter
into any arrangement having the economic effect of any of the foregoing
other than in connection with the financing of working capital
consistent with past practice;
. adopt or amend any employee benefit plan, policy or arrangement; any
employee stock purchase or employee stock option plan; or enter into any
employment contract or collective bargaining agreement (other than offer
letters and letter agreements entered into in the ordinary course of
business consistent with past practice with employees who are terminable
"at will"); pay any special bonus or special remuneration to any
director or employee other than consistent with past practice; or
increase the salaries or wage rates or fringe benefits (including rights
to severance or indemnification) of its directors, officers, employees
or consultants except, in each case, as may be required by law or for
normally scheduled increases in the ordinary course;
. (i) pay, discharge, settle or satisfy any material litigation (whether
or not commenced prior to the date of the offer agreement) or any
material claims, liabilities or obligations (absolute, accrued, asserted
or unasserted, contingent or otherwise), other than the payment,
discharge, settlement or satisfaction, in the ordinary course of
business consistent with past practice or in accordance with their
terms, or liabilities recognized or disclosed in the most recent
consolidated financial statements (or the notes thereto) of Indigo
included in Indigo's reports filed with the Securities and Exchange
Commission or
126
incurred since the date of such financial statements in the ordinary
course of business consistent with past practices, or (ii) waive the
benefits of, agree to modify in any manner, terminate, release any
person from or knowingly fail to enforce any confidentiality or similar
provisions of any agreement to which Indigo or any of its subsidiaries
is a party or of which Indigo or any of its subsidiaries is a
beneficiary;
. except in the ordinary course of business consistent with past practice,
modify, amend or terminate any contract or waive, delay the exercise of,
release or assign any material rights or claims thereunder;
. except as required by U.S. GAAP, revalue any of its assets or make any
change in accounting methods, principles or practices;
. make any payment or series of related payments outside the ordinary
course of business, or enter into any contract or series of related
contracts outside the ordinary course of business requiring Indigo or
any of its subsidiaries to pay, in excess of $250,000 in the aggregate;
. make any tax election or accounting method change inconsistent with past
practice that, individually or in the aggregate, would be reasonably
likely to affect adversely in any material respect the tax liability or
tax attributes of Indigo or any of its subsidiaries, taken as a whole,
settle or compromise any material tax liability;
. hire any employee; or
. agree in writing or otherwise to take any of the actions described in
above.
Commercially Reasonable Efforts to Complete the Exchange Offer
Subject to the terms of the offer agreement, we and Indigo are required to
use commercially reasonable efforts to take all reasonable actions necessary to
complete the exchange offer.
Indigo is Prohibited from Considering Other Acquisition Proposals
Indigo has agreed that it will not, directly or indirectly:
. solicit, initiate, encourage or induce the making, submission or
announcement of any Acquisition Proposal (as defined below);
. engage or participate in any discussions or negotiations regarding, or
furnish to any person any information relating to Indigo or its
subsidiaries or afford access to the business, properties, assets, books
or records of Indigo or its subsidiaries to, any person that has made,
or take any other action intended to assist or facilitate any inquiries
or the making, submission or announcement of any proposal that
constitutes or would reasonably be expected to lead to, any Acquisition
Proposal;
. approve, endorse or recommend any Acquisition Proposal; or
. enter into any letter of intent or similar document or any contract,
agreement or commitment contemplating or otherwise relating to any
Acquisition Transaction (as defined below).
Indigo must as promptly as practicable, and in any event within 24 hours,
advise HP orally and in writing of (1) any request for information which Indigo
reasonably believes would lead to an Acquisition Proposal, or of any
Acquisition Proposal, or any inquiry with respect to or which Indigo reasonably
believes would lead to any Acquisition Proposal, (2) the material terms and
conditions of such request, Acquisition Proposal or inquiry, and (3) the
identity of the person or group making any such request, Acquisition Proposal
or inquiry. Indigo is required to keep HP informed in all material respects of
the status and details, including material amendments or proposed amendments,
of any such request, Acquisition Proposal or inquiry.
An "Acquisition Proposal" means any offer or proposal, other than an offer
or proposal by HP, relating to any Acquisition Transaction.
127
An "Acquisition Transaction" means any transaction or series of related
transactions, other than the transactions contemplated by the offer agreement
involving:
. any acquisition or purchase from Indigo by any person or group, as
defined under Section 13(d) of the Exchange Act and the rules and
regulations thereunder, of more than a 10% interest in the total
outstanding voting securities of Indigo or any of its subsidiaries or
any tender offer or exchange offer that if consummated would result in
any person or group, as defined under Section 13(d) of the Exchange Act
and the rules and regulations thereunder, beneficially owning 10% or
more of the total outstanding voting securities of Indigo or any of its
subsidiaries or any acquisition, consolidation, business combination or
similar transaction involving Indigo pursuant to which the shareholders
of Indigo immediately preceding such transaction hold less than 90% of
the equity interests in the surviving or resulting entity of such
transaction;
. any sale, lease, other than in the ordinary course of business,
exchange, transfer, license, other than in the ordinary course of
business, acquisition or disposition of more than 10% of the assets of
Indigo; or
. any liquidation, dissolution, recapitalization or other significant
corporate reorganization of Indigo.
The terms of the offer agreement do not prohibit Indigo or its management
and supervisory boards from taking and disclosing to Indigo shareholders a
position with respect to a tender or exchange offer by a third party pursuant
to Rule 14d-9 and 14e-2(a) promulgated under the Exchange Act. However, Indigo
or its management and supervisory boards may not withhold, withdraw, modify or
change in a manner adverse to us, or fail to make, any of its recommendations
in favor of our exchange offer as required under the offer agreement in
connection with, or approve, endorse or recommend, any Acquisition Proposal.
Employee Benefits
The offer agreement provides that, to the extent required by applicable
local law, we will assume, perform and discharge Indigo's obligations, or cause
Indigo to perform and discharge such obligations, under all employment
agreements, except where employees agree to waive their rights under such
employment agreements or accept other rights or benefits in lieu of the rights
and benefits provided in such employment agreements.
The offer agreement also provides that we will continue the employment of
all of Indigo's employees, including employees on leaves of absence, except
where we reasonably conclude that any employee's position is redundant in
relation to our operational needs. The offer agreement also provides that
Indigo employees will initially receive a package of compensation and benefits,
including without limitation, equity compensation that is approximately
equivalent in the aggregate to the compensation and benefits they had received
from Indigo immediately prior to the closing of the exchange offer.
We have also agreed that our U.S. benefit plans that provide health,
disability, life insurance or other welfare benefits (1) shall provide Indigo
employees and their dependents and beneficiaries with immediate eligibility and
coverage after the closing of the exchange offer, (2) shall waive any
exclusions or limitations with respect to pre-existing conditions, waiting
periods, evidence of insurability or good health, and actively-at-work
requirements, and (3) shall either (A) provide that any expenses incurred
through the closing of the exchange offer by Indigo employees or their covered
dependents shall be taken into account for purposes of satisfying applicable
deductible, co-insurance and maximum out-of-pocket provisions, or (B) reimburse
Indigo employees for any duplicate payment of such expenses. We have also
agreed to use our best efforts to provide similarly advantageous transition
arrangements under its non-U.S. benefit plans.
We have also agreed to assume, honor and be responsible for any accrued but
unused vacation time to which any Indigo employee is entitled pursuant to the
vacation policy applicable to such employee immediately prior to the closing of
the exchange offer. We shall allow each Indigo employee to use such accrued but
unused vacation time under the terms and subject to the conditions of HP's
vacation or flexible time off policies and programs, including any terms and
conditions of the same that allow unused vacation time to be paid in cash upon
an
128
employee's termination of employment with HP. An Indigo employee's continuous
service with Indigo shall be recognized in determining the Indigo employee's
rate of accrual for future vacation time (1) under our U.S. vacation or
flexible time off policies and programs and (2) to the extent it is reasonable
under local conditions, under our non-U.S. vacation policies and programs.
Conditions to the Exchange Offer
Our obligation to accept for exchange, and to deliver shares of HP common
stock and CVRs in exchange for, Indigo common shares that are validly tendered
and not properly withdrawn, is subject to the satisfaction or, where
permissible, the waiver of the conditions described in the offer agreement,
including the following conditions:
The Minimum Tender Condition
Prior to the expiration date of the exchange offer, as it may be extended
pursuant to the offer agreement, there must be validly tendered, in accordance
with the terms of the exchange offer, and not withdrawn, a number of Indigo
common shares that, when added to any Indigo common shares owned by us or our
subsidiaries, is equal to at least ninety-five percent (95%) of the sum of:
. the total number of Indigo common shares outstanding immediately prior
to the expiration date of the exchange offer, as it may be extended
pursuant to the offer agreement, excluding for this purpose any Indigo
common shares that are held in the treasury of Indigo; and
. the total number of Indigo common shares issuable upon the exercise or
conversion of all warrants to acquire Indigo common shares, excluding
for this purpose any warrants held by HP or its subsidiaries or the
warrants held by Walthroup Corporation N.V., Visionvest Corporations
N.V., Gemini Systems Corporation N.V., Toscal N.V., OZF Ltd. and Deering
Corporation N.V.
Other Conditions to the Exchange Offer
The exchange offer is also subject to the conditions that, before the
expiration of the exchange offer, as it may be extended pursuant to the offer
agreement,
. the applicable waiting periods or approvals under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended, and under any foreign
antitrust laws must have expired or been terminated or been obtained, as
applicable;
. Indigo must have received approval from the Office of the Chief
Scientist of the Israeli Ministry of Industry and Trade, without
obligation to pay materially increased royalties, of the ownership by
Indigo of all intellectual property created, discovered, arising or
resulting from any research or development that has, directly or
indirectly, in whole or in part, been funded or financed by any grants,
incentives, including tax incentives, or subsidies from the government
of the State of Israel or any of its agencies from any foreign
governmental or administrative agency;
. Indigo must have obtained any Israeli governmental approvals required
pursuant to Israeli legal requirements for the completion of the
exchange offer, including approval of the Office of the Chief Scientist
of the Israeli Ministry of Industry and Trade, the Israeli Investment
Center of the Israeli Ministry of Industry and Trade and the Israeli
Commissioner of Restrictive Trade Practices;
. we must have obtained (1) an exemption from the requirements of the
Israeli Securities Authority from the requirements of the Israeli
Securities Law, 1968, concerning publication of a prospectus in respect
of the exchange of Indigo stock options for HP stock options, and (2) a
pre-ruling regarding the inapplicability of the prospectus requirement
pursuant to the Israeli Securities Law, 1968, in respect of the exchange
offer for Indigo common shares and the exchange of Indigo warrants for
HP warrants, which we also refer to as the Israel Securities Exemption;
129
. the Registration Statement on Form S-4 relating to the exchange offer
must have become effective under the Securities Act, and must not be the
subject of any stop order or proceedings seeking a stop order;
. the shares of HP common stock to be issued in the exchange offer must
have been approved for listing on the New York Stock Exchange, subject
to official notice of issuance, or must be exempt from such requirement
under then applicable laws, regulations and rules of the New York Stock
Exchange;
. seventy-five percent (75%) of specified individuals identified by us and
Indigo must continue to be employees of Indigo at the closing of the
exchange offer;
. at any time on or after September 6, 2001 and before the time of
acceptance for exchange of any Indigo common shares, none of the
following events shall have occurred and be continuing:
- there must not be pending any suit, action or proceeding by any
governmental entity against HP, Indigo, any subsidiary of Indigo or
any of our subsidiaries (1) seeking to prohibit or impose any
material limitations on our ownership or operation (or that of any of
its subsidiaries or affiliates) of all or a material portion of their
or Indigo's businesses or assets, or to compel us or our subsidiaries
and affiliates to dispose of or hold separate any material portion of
the business or assets of Indigo or HP and their respective
subsidiaries, in each case taken as a whole, (2) challenging the
acquisition by HP of any Indigo common shares under the exchange
offer, seeking to restrain or prohibit the making or completion of
the exchange offer or the performance of any of the other
transactions contemplated by the offer agreement, the tender
agreements, or the voting agreements (including the voting provisions
thereunder), or seeking to obtain from Indigo or us any damages that
are material in relation to Indigo and its subsidiaries taken as a
whole, (3) seeking to impose material limitations on our ability, or
render us unable, to accept for payment, pay for or purchase some or
all of the Indigo common shares pursuant to the exchange offer,
(4) seeking to impose material limitations on our ability effectively
to exercise full rights of ownership of Indigo common shares,
including, without limitation, the right to vote Indigo common shares
purchased on all matters properly presented to Indigo's shareholders,
(5) compelling us or our affiliates to dispose of or hold separate
any portion of the business or assets or shares of Indigo or us and
our respective subsidiaries, (6) obliging Indigo, us or any of our
respective subsidiaries to pay material damages in connection with
the transactions contemplated by the offer agreement, or (7) which
otherwise is reasonably likely to have a material adverse effect on
Indigo, as determined in accordance with the offer agreement or, as a
result of the transactions contemplated by the offer agreement, a
material adverse effect on us, as determined in accordance with the
offer agreement;
- there must not be any law, statute, rule, regulation, ordinance,
judgment, order, decree or injunction enacted, entered, enforced,
promulgated, or deemed applicable, pursuant to an authoritative
interpretation by or on behalf of a government entity, to the
exchange offer, or any other action taken by any governmental entity,
other than the application to the exchange offer of applicable
waiting periods or approvals under the Hart-Scott-Rodino Act or any
foreign antitrust or competition law and any Israeli governmental
approvals required pursuant to Israeli legal requirements for the
completion of the exchange offer, including approval of the Office of
the Chief Scientist of the Israeli Ministry of Industry and Trade,
the Israeli Investment Center of the Israeli Ministry of Industry and
Trade and the Israeli Commissioner of Restrictive Trade Practices and
receipt by us of the Israeli Securities Exemption, that, is
reasonably likely to result, directly or indirectly, in any of the
consequences referred to in clauses (1) through (7) of the above
paragraph;
- there must not have occurred (1) any general suspension of trading
in, or limitation on prices for, securities on the New York Stock
Exchange, for a period in excess of 24 hours (excluding suspensions
or limitations resulting solely from physical damage or interference
with such exchanges not related to market conditions), (2) a
declaration of a banking moratorium or any
130
suspension of payments in respect of banks in the United States
(whether or not mandatory), (3) a commencement of a war, armed
hostilities or other international or national calamity directly
involving the United States, (4) a commencement of a war or
escalation of armed hostilities or a general mobilization or other
international or national calamity directly involving Israel that is
or is reasonably likely to be materially adverse to Indigo's ability
to conduct business in Israel, (5) any limitation (whether or not
mandatory) by any United States governmental authority on the
extension of credit generally by banks or other financial
institutions, or (6) in the case of any of the foregoing existing at
the time of the commencement of the exchange offer, a material
acceleration or worsening thereof;
- the representations and warranties of Indigo contained in the offer
agreement:
(i) shall not have been true and correct in all respects (if
qualified by material adverse effect on Indigo, as determined in
accordance with the offer agreement, materiality or other
qualifications based on the word "material" or similar phrases)
or in all material respects (if not so qualified) as of the date
of the offer agreement; provided that, for purposes of
determining the accuracy of Indigo's representations and
warranties for purposes of this clause (i) any update of or
modification to Indigo's disclosure letter made or purported to
have been made after the date of the offer agreement shall be
disregarded; or
(ii) with respect to the representations and warranties regarding
Indigo's organization, qualification, articles of association,
capitalization, authority relative to the offer agreement,
Securities and Exchange Commission filings and financial
statements, brokers, opinion of financial advisor and board
approval contained in the offer agreement, which we refer to as
the "special representations," shall not be true and correct in
all respects (if qualified by material adverse effect on Indigo,
as determined in accordance with the offer agreement,
materiality or other qualifications based on the word "material"
or similar phrases) or in all material respects (if not so
qualified) on and as of the time and date of the expiration of
the exchange offer with the same force and effect as if made on
or as of such time, except for those representations listed
above which address matters only as of a particular date which
representations shall have been true and correct in all respects
(if qualified by material adverse effect on Indigo, as
determined in accordance with the offer agreement, materiality
or other qualifications based on the word "material" or similar
phrases) or in all material respects (if not so qualified) as of
such particular date; provided that, for purposes of determining
the accuracy of the representations listed above for purposes of
this clause (ii) any update of or modification to Indigo's
disclosure letter made or purported to have been made after the
date of the offer agreement shall be disregarded; or
(iii) with respect to the representations and warranties that are not
special representations listed in clause (ii) above, shall not
be true and correct in all respects on and as of the time and
date of the expiration of the exchange offer with the same force
and effect as if made on or as of such time, except (A) in the
aggregate, as does not, and could not reasonably be expected to,
constitute a material adverse effect on Indigo, as determined in
accordance with the offer agreement, and (B) for those
representations and warranties which address matters only as of
a particular date which representations shall have been true and
correct (subject to material adverse effect qualification set
forth in the preceding clause (A)) as of such particular date;
provided, that for purposes of determining the accuracy of
Indigo's representations and warranties other than the
representations listed in clause (ii) above for purposes of this
clause (iii), (x) all material adverse effect on Indigo, as
determined in accordance with the offer agreement, and
materiality qualifications and other qualifications based on the
word "material" or similar phrases contained in such
representations and warranties shall be disregarded, and (y) any
update of or modification to Indigo's disclosure letter made or
purported to have been made after the date of the offer
agreement shall be disregarded;
131
- Indigo must have performed in all material respects any obligation
and complied in all material respects with any agreement or covenant
of Indigo to be performed or complied with by it under the offer
agreement;
- Indigo must have received the consents, waivers and approvals
required to be obtained in connection with the consummation of the
transactions contemplated by the offer agreement;
- the extraordinary general meeting of shareholders of Indigo must have
passed on the appointments of members of Indigo's management board
and supervisory board and the amendment of Indigo's articles of
association in accordance with the offer agreement; and
- the offer agreement must not have been terminated in accordance with
its terms.
The foregoing conditions are for the sole benefit of HP and may be waived by
HP, in whole or in part at any time and from time to time in the sole
discretion of HP prior to the expiration of the exchange offer. The failure by
HP at any time to exercise any of the foregoing rights shall not be deemed a
waiver of any such right and each such right shall be deemed an ongoing right
which may be asserted at any time and from time to time.
As used in the offer agreement, "material adverse effect" as it relates to
Indigo means any change or effect that, individually or when taken together
with all other such changes or effects that have occurred prior to the date of
determination of the material adverse effect is, or is reasonably likely to be,
materially adverse to the business, assets, including intangible assets,
financial condition or results of operation of Indigo and its subsidiaries,
taken as a whole. However, in no event shall any of the following be deemed to
constitute a material adverse effect as it relates to Indigo:
. any change or effect that results or arises primarily and directly from
changes affecting the digital commercial printing industry generally or
the worldwide economy generally, which changes or effects do not
disproportionately affect Indigo;
. any change or effect primarily and directly resulting from the pendency
of the exchange offer or the transactions contemplated by the offer
agreement; or
. any change in Indigo's stock price or trading volume.
To successfully assert the exception in either of the first two bullet
points listed above, Indigo must show by a preponderance of the evidence that
such exception is applicable.
As used in the offer agreement, "material adverse effect" as it relates to
HP means any change or effect that, individually or when taken together with
all other such changes or effects that have occurred prior to the date of
determination of the material adverse effect, is or is reasonably likely to be
materially adverse to the business, assets, including intangible assets,
financial condition, or results of operations of HP and its subsidiaries, taken
as a whole. However, in no event shall any of the following be deemed to
constitute a material adverse effect as it relates to us:
. any change or effect that results or arises primarily and directly from
changes affecting any of the industries in which we operate generally or
the worldwide economy generally, which change or effect does not
disproportionately affect us;
. any change or effect primarily and directly resulting from the pendency
of the exchange offer or the transactions contemplated by the offer
agreement; or
. any change in our stock price or trading volume.
To successfully assert the exception in either of the first two bullet
points listed above, we must show by a preponderance of the evidence that such
exception is applicable.
132
Termination of the Offer Agreement
Termination by Mutual Agreement
We and Indigo may terminate the offer agreement at any time prior to the
completion of the exchange offer by mutual written consent.
Termination by either HP or Indigo
Either we or Indigo may terminate the offer agreement at any time prior to
the completion of the exchange offer if:
. the exchange offer expires or terminates in accordance with the terms of
the offer agreement without HP having accepted for exchange any Indigo
common shares;
. the exchange offer has not been completed on or before August 30, 2002,
except that the right to terminate the offer agreement for the reason
identified in this bullet point is not available to any party whose
action or failure to act has been a principal cause of, or resulted in
the failure of, the exchange offer to have been completed on or before
such date if the action or failure to act constitutes a material breach
of the offer agreement; or
. there is any applicable law or regulation that makes completion of the
exchange offer illegal or otherwise prohibited, or any final and
nonappealable judgment, injunction, order or decree of any court or
governmental body that enjoins HP or Indigo from completing the exchange
offer.
Termination by HP
We may terminate the offer agreement at any time prior to the acceptance for
exchange of Indigo common shares pursuant to the exchange offer, if any of the
following occurs, which we refer to as a triggering event:
. Indigo's management board or supervisory board or any committee thereof
approves or recommends to Indigo shareholders any acquisition proposal,
as defined in the offer agreement;
. Indigo's management board or supervisory board or any committee thereof
for any reason withholds, withdraws, amends or modifies its
recommendation in favor of the exchange offer;
. Indigo fails to include the recommendation in this registration
statement or the Schedule 14d-9;
. Indigo shall have breached the no solicitation provisions of the offer
agreement in any material respect;
. any of Walthroup Corporation N.V., Visionvest Corporation N.V., Gemini
Systems Corporation N.V., Toscal N.V., OZF Ltd., or Deering Corporation
N.V., or any of such entity's affiliates breaches the provisions of any
of the voting agreements or the tender agreements in any material
respect; or
. a tender or exchange offer is commenced by a person unaffiliated with
us, and Indigo does not send to Indigo shareholders pursuant to Rule
14e-2 promulgated under the Securities Act, within ten (10) business
days after such tender or exchange offer is first published, sent or
given, a statement disclosing that Indigo recommends rejection of such
tender or exchange offer.
In addition, we may terminate the offer agreement, at any time prior to the
acceptance for exchange of Indigo common shares pursuant to the exchange offer,
if:
. Indigo materially breaches any covenant or agreement in the offer
agreement; or
. any representation or warranty of Indigo was untrue when made or becomes
untrue or inaccurate such that, pursuant to the terms of the offer
agreement, we would not be required to accept for exchange any Indigo
common shares tendered pursuant to the exchange offer if the expiration
of the exchange offer had occurred on such date.
133
If, however, the breach of the covenant or agreement by Indigo, or the
untruth of the representation or warranty of Indigo, is curable by Indigo
through the exercise of commercially reasonable efforts, then HP may not
terminate the offer agreement until the earlier of thirty (30) days after
delivery of written notice from HP to Indigo of the breach or untruth or
inaccuracy, or the date on which Indigo ceases to exercise commercially
reasonable efforts to cure the breach or untruth or inaccuracy.
Termination by Indigo
Indigo may terminate the offer agreement, at any time prior to the
acceptance for exchange of Indigo common shares pursuant to the exchange offer,
if:
. we materially breach any covenant or agreement in the offer agreement; or
. any representation or warranty of us was untrue or inaccurate when made
or becomes untrue or inaccurate such that, in the aggregate the untruths
or inaccuracies would reasonably be expected to have a material adverse
effect on us.
If, however, the breach of the covenant or agreement by us, or the untruth
or inaccuracy of the representation or warranty of us, is curable by us through
the exercise of commercially reasonable efforts, then Indigo may not terminate
the offer agreement until the earlier of thirty (30) days after delivery of
written notice from Indigo to us of the breach or untruth or inaccuracy, or the
date on which we cease to exercise commercially reasonable efforts to cure the
breach or untruth or inaccuracy.
If the offer agreement is terminated pursuant to any of the provisions
described above in this section, the offer agreement will become void and of no
effect, with no liability on the part of us or Indigo, other than liability for
any intentional or willful breach of or fraud in connection with the offer
agreement or the payment by Indigo or us of the fees described below, as the
case may be.
Payment of Termination Fee; Expenses
If we terminate the offer agreement before Indigo common shares are accepted
for exchange pursuant to the exchange offer as a result of (1) Indigo's
material breach of any covenant or agreement in the offer agreement, or (2) any
representation or warranty of Indigo's being untrue or inaccurate when made or
becoming untrue or inaccurate such that, pursuant to the terms of the offer
agreement, we would not be required to accept for exchange any Indigo common
shares tendered pursuant to the exchange offer if the expiration of the
exchange offer had occurred on such date, Indigo has agreed to reimburse all of
our fees and expenses, including without limitation, costs of internal, legal,
accounting and similar professional services incurred in connection with the
offer agreement and the transactions contemplated by the offer agreement.
However, the foregoing reimbursement fee will not in any event exceed U.S. $2
million.
If we terminate the offer agreement before Indigo common shares are accepted
for exchange pursuant to the exchange offer as a result of the occurrence of a
triggering event, as defined in the offer agreement, Indigo has agreed to pay
us a termination fee equal to U.S. $27 million and to reimburse all of HP's
fees and expenses, including without limitation, costs of internal, legal,
accounting and similar professional services incurred in connection with the
offer agreement, and the transactions contemplated by the offer agreement.
However, the foregoing reimbursement fee will not in any event exceed U.S. $2
million. See the above section titled "--Termination of the Offer
Agreement--Termination by HP" for the definition of triggering event.
If Indigo terminates the offer agreement as a result of (1) our material
breach of any covenant or agreement in the offer agreement, or (2) any
representation or warranty of us being untrue or inaccurate when made or
becoming untrue or inaccurate such that, in the aggregate, the untruths or
inaccuracies would reasonably be expected to have a material adverse effect on
us, we have agreed to reimburse all of Indigo's fees and expenses, including
without limitation, costs of internal, legal, accounting and similar
professional services incurred in
134
connection with the offer agreement. However, the foregoing reimbursement fee
will not in any event exceed U.S. $2 million.
The offer agreement provides that all expenses, other than any termination
fees incurred in connection with the offer agreement and the transactions
contemplated by the offer agreement, are to be paid by the party incurring such
expenses.
Amendments to the Offer Agreement
Subject to applicable law, the offer agreement may be amended by us or
Indigo at any time prior to the completion of the exchange offer by the
execution of an instrument in writing signed on behalf of us and Indigo.
135
DESCRIPTION OF THE CVRs
The following summary describes the material provisions of the CVRs. The
provisions of the CVRs are complicated and not easily summarized. This summary
may not contain all of the information about the CVRs that is important to you.
The form of CVR agreement is attached to this prospectus as Annex B-1 and is
incorporated by reference into this prospectus, and we encourage you to read it
carefully for a more complete understanding of the CVRs.
Summary
The CVRs will be issued under a CVR agreement, between Newco, our
newly-purchased indirect subsidiary, and J.P. Morgan Trust Company, National
Association, as trustee. The CVRs will be unsecured obligations of Newco. The
contingent payment obligations of our subsidiary will be guaranteed by
Hewlett-Packard Company and will rank equally with all other unsecured
obligations of HP. The form of corporate guaranty by Hewlett-Packard Company is
attached to this prospectus as Annex B-2 and is incorporated by reference into
this prospectus.
There are many uncertainties associated with the CVRs and there is no
assurance that any payment on the CVRs will be made. See "Risk Factors--Risks
Related to the Contingent Value Rights" for a description of such uncertainties.
The definitions of selected terms used in the following summary are set
forth below under "--Selected Definitions Related to the CVR Agreement."
Contingent Payment
The holder of each Indigo common share that is validly tendered and not
properly withdrawn in the exchange offer for the contingent offer price will
receive $6.00, subject to adjustment, in HP common stock and one
non-transferable contingent value right, or "CVR," for each Indigo common share
so exchanged. Indigo common shares that are exchanged for the fixed offer price
will not receive any CVRs.
Nominal Potential Payout in 2005
Each CVR will entitle the holder to a contingent cash payment from Newco of
up to $4.50 if we achieve a total of up to $1.6 billion in Revenue, as defined
below and in the form of CVR agreement, over the three-year period commencing
on the first day of the first calendar month occurring after the closing of the
exchange offer, which three-year period is referred to in this prospectus as
the "CVR Measuring Period." The future cash payout for each CVR increases
linearly from $0 to $4.50 as Revenue increases from $1.0 billion to $1.6
billion during the CVR Measuring Period. No payment will be made under the CVR
if such Revenue is less than or equal to $1.0 billion. No payment will be made
in excess of $4.50 under the CVR if such Revenue is greater than $1.6 billion.
136
Present Value of the Potential Payout in 2005
In addition to the risk that some or all of the potential CVR payout may not
be realized, you should also consider that any amounts payable will not be
realized until more than three years after the close of the exchange offer and
as such, the present value, taking into account the time value of money, will
be lower than any amount paid in 2005. The following chart illustrates the
impact the time value of money has when present valuing future cash payments
over a three-year period and assuming a range of discount factors.
Present Value of Future CVR Payout
12% 15% 18%
Discount Discount Discount
Potential CVR Payout in 39 Months* Rate Rate Rate
---------------------------------- -------- -------- --------
$0.00............................................ $ 0 $ 0 $ 0
$1.00............................................ $0.68 $0.62 $0.56
$2.00............................................ $1.36 $1.23 $1.12
$3.00............................................ $2.04 $1.85 $1.68
$4.00............................................ $2.71 $2.46 $2.24
$4.50............................................ $3.05 $2.77 $2.52
--------
* Note: Because of the need to generate a CVR report and the potential audit
process, we have estimated that the CVR payout, if any, would take place
approximately 39 months after the close of the exchange offer. Depending on
the circumstances, this period could be longer.
The following table calculates the present value of the Contingent Offer
Price assuming a $6.00 value of the HP common stock and the present value of a
range of potential cash payments under the CVR assuming a range of discount
factors.
Present Value of Contingent Offer Price
12% 15% 18%
Discount Discount Discount
Potential CVR Payout in 39 Months* Rate Rate Rate
---------------------------------- -------- -------- --------
$0.00............................................ $6.00 $6.00 $6.00
$1.00............................................ $6.68 $6.62 $6.56
$2.00............................................ $7.36 $7.23 $7.12
$3.00............................................ $8.04 $7.85 $7.68
$4.00............................................ $8.71 $8.46 $8.24
$4.50............................................ $9.05 $8.77 $8.52
--------
* Note: Because of the need to generate a CVR report and the potential audit
process, we have estimated that the CVR payout, if any, would take place
approximately 39 months after the close of the exchange offer. Depending on
the circumstances, this period could be longer.
Payment at Maturity Date
The future cash payout, if any, of the CVRs will be determined and payable
after the end of the CVR Measuring Period.
CVR Agreement
Immediately prior to the closing of the exchange offer, Newco and the
trustee will enter into the CVR agreement substantially in the form attached to
this prospectus as Annex B-1. We will cause the CVR agreement to
137
be qualified under the Trust Indenture Act of 1939, as amended. The terms of
the CVRs include those stated in the CVR agreement and those made part of the
CVR agreement by reference to the Trust Indenture Act.
The contingent payment obligations of Newco under the CVR agreement will be
guaranteed by Hewlett-Packard Company pursuant to a guarantee to be entered
into by Newco and HP concurrently with the execution of the CVR agreement. The
guarantee will be substantially in the form attached to this prospectus as
Annex B-2.
Among other things, the CVR agreement will provide that:
. HP and its affiliates shall be entitled, in their sole discretion, to
establish and modify from time to time all aspects of HP's program for
the development, manufacturing, marketing and sale of any products,
including, without limitation, the LEP Digital Press Products and
Consumables, including product design, functionality and features,
development processes, roadmaps and timelines, evaluation, testing and
release readiness, procurement of materials and components,
manufacturing, marketing and sales and staffing and funding for any of
the foregoing, any or all of which may be performed by HP or its
affiliates using its internal resources or by third parties pursuant to
outsourcing or other contractual relationships with HP or its
affiliates; and
. HP and its affiliates will have no obligation to initiate or continue
research, development, commercialization, marketing or sales activities
with respect to any products, including, without limitation, the LEP
Digital Press Products and Consumables and, in HP's sole and subjective
discretion, HP and its affiliates may abandon efforts to research,
develop, commercialize, market or sell any or all products, including,
without limitation, the LEP Digital Press Products and Consumables.
Selected Definitions Related to the CVR Agreement
For purposes of the CVRs and the CVR agreement:
. "Revenue" means the actual net revenue from the sale or lease of LEP
Digital Press Products and Consumables, as defined below and in the form
of CVR agreement, by HP and its affiliates, and its successors and
assigns under the CVR agreement, during the CVR Measuring Period plus
the Residual Calculation, as defined below and in the form of CVR
agreement. Actual net revenue is to be based on U.S. GAAP, as applied by
HP consistent with its financial Securities and Exchange Commission
reporting practices as of the beginning of the CVR Measuring Period, or
in the case of successors or assigns under the CVR agreement which are
not affiliates of HP, as such successors or assigns account for net
revenue under their standard accounting practices.
. "Residual Calculation" means the present value, as of the end of the CVR
Measuring Period, of remaining minimum contractually committed payments
associated with LEP Digital Press Products placed during the CVR
Measuring Period under operating leases, provided the placement of such
LEP Digital Press Products has not been and will not be recognized as a
sale under U.S. GAAP, as applied by HP consistent with its financial
Securities and Exchange Commission reporting practices as of the
beginning of the CVR Measuring Period. The present value will be
determined by using a discount rate of twelve percent (12%) per year.
. "LEP Digital Press Products" means digital press products, including
accessories and options (e.g., finishing equipment and sheet feeders),
which utilize Indigo technology that enables the creation of a printed
image employing a liquid composition of charged, pigmented thermoplastic
particles that are being transferred from an image-bearing surface to a
final substrate.
. "Consumables" means (1) consumables and accessories that in each case
have a commercial use which is limited to the support and use of LEP
Digital Press Products, and (2) support services directly related to the
initial installation of and the ongoing repair and maintenance of LEP
Digital Press Products.
138
Description of the CVR Certificates
CVRs Issued in Global Form
Newco will issue the CVRs pursuant to the CVR agreement between Newco and
the trustee. Except in certain limited instances, the CVRs will be issued in
the form of one or more global certificates, registered in the name of the
trustee, as depositary, or any successor depositary. Upon the issuance of a
global certificate, the depositary will credit on its records the respective
number of CVRs held by each beneficial owner and will provide each beneficial
owner with a notice indicating the respective number of CVRs credited to such
beneficial owner. Ownership of interests in such global certificate will be
shown on, and the transfer of those ownership interests will be effected only
through, records maintained by the depositary. The laws of some jurisdictions
may require that certain purchasers of securities take physical delivery of
such securities in definitive form.
So long as the depositary is the registered holder and owner of such global
certificate, the depositary will be considered the sole owner and holder of the
related CVRs for all purposes of such CVRs and for all purposes under the CVR
agreement. Except as set forth in the CVR agreement, owners of beneficial
interests in a global certificate:
. will not be entitled to have the CVRs represented by such global
certificate registered in their names;
. will not receive or be entitled to receive physical delivery of CVRs in
definitive form; and
. will not be considered to be the owners or holders of any CVRs under the
CVR agreement or such global certificate.
Accordingly, each person owning a beneficial interest in a global
certificate must rely on the procedures of the depositary to exercise any
rights of a holder of CVRs under the CVR agreement or such global certificate.
Payment of principal of and interest, if any, on CVRs represented by a
global certificate will be made by us to the depositary as the registered owner
and holder of such global certificate. We expect that the depositary, upon
receipt of any payment of principal or interest, if any, in respect of a global
certificate, will immediately transfer funds to the accounts designated by the
beneficial owners in amounts proportionate to their respective beneficial
interests in the principal amount of such global certificate as shown on the
records of the depositary.
Subject to the further restrictions on transfer described below, unless and
until it is exchanged in whole or in part for CVRs in definitive form, a global
certificate may not be transferred except as a whole by the depositary to a
successor depositary.
Restrictions on Transfer of the CVRs
We are registering the CVRs under the registration statement of which this
prospectus forms a part. The CVRs are not currently listed on any securities
exchange and we do not plan to list the CVRs in the future. In addition, the
CVRs are non-transferable, except for the following permitted transfers:
. the transfer of any or all of the CVRs upon death by will or intestacy;
. the transfer by instrument to an inter vivos or testamentary trust in
which the CVRs are to be passed to beneficiaries upon the death of the
trustee;
. transfer to an affiliate of a CVR holder;
. if the CVR holder is a partnership or limited liability or similar
company, a distribution by the transferring entity to its limited
partners or members;
. by gift; or
. a sale or transfer to HP or one of its affiliates.
However, in the event of any such permitted transfer, the transferee, other
than HP or one of its affiliates is required to agree to be bound by these
restrictions on transfer.
139
AGREEMENTS RELATED TO THE OFFER AGREEMENT
The following description of agreements related to the offer agreement
describe the material terms of certain voting agreements, the tender agreements
and the tender and option agreement entered into as of the date of the offer
agreement. These agreements are attached as Annex C to this prospectus and are
incorporated by reference into this prospectus. We encourage you to read these
agreements carefully.
Parties to the Related Agreements
As an inducement to HP to enter into the offer agreement:
. each of Walthroup Corporation N.V., Visionvest Corporation N.V., Gemini
Systems Corporation N.V., Toscal N.V., OZF Ltd. and Deering Corporation
N.V. and certain directors, executive officers and major shareholders of
Indigo entered into a voting agreement with HP as described below;
. S-C Indigo CV entered into a voting agreement with HP as described below;
. certain directors, executive officers and major shareholders of Indigo
entered into a tender agreement with HP as described below;
. S-C Indigo CV entered into a tender agreement with HP as described
below; and
. each of Walthroup Corporation N.V., Visionvest Corporation N.V., Gemini
Systems Corporation N.V., Toscal N.V., OZF Ltd. and Deering Corporation
N.V. entered into a tender and option agreement with HP as described
below.
In addition, on November 7, 2001, the Landa Family Trust entered into a
tender and option agreement and a voting agreement with HP as described below.
These shareholder agreements cover, in the aggregate, 72,394,307 common
shares of Indigo, which represented approximately 65.4% of the outstanding
Indigo common shares as of December 31, 2001.
Voting Agreements
Pursuant to the voting agreements, each of the Indigo shareholders who is a
party thereto agreed, among other things, to vote its Indigo common shares:
. in favor of the appointment of the new members of Indigo's management
board as set forth in the offer agreement;
. in favor of the amendment of Indigo's articles of association as
contemplated by the offer agreement;
. in favor of the post-closing restructuring and any action required in
furtherance thereof as contemplated by the offer agreement;
. against certain alternative transactions; and
. in favor of waiving any notice that may have been or may be required
relating to the exchange offer or any of the other transactions
contemplated by the offer agreement, including the post-closing
restructuring.
Pursuant to the voting agreements, each of the Indigo shareholders who is a
party thereto also agreed not to transfer its Indigo common shares to any party
from the date of the voting agreements, unless such party agrees: (1) to
execute a counterpart to the voting agreement and to execute an irrevocable
proxy substantially in the form set forth as Exhibit A to the voting
agreements; and (2) to hold such Indigo common shares, or such interest
therein, subject to all of the terms and conditions of the voting agreement. In
furtherance of the foregoing, each of the Indigo shareholders who is a party to
a voting agreement granted HP an irrevocable proxy to vote such shareholder's
Indigo common shares as described above.
140
The voting agreements and the irrevocable proxies will terminate on the
earlier of the closing of the exchange offer or the termination of the offer
agreement pursuant to its terms; provided, that the voting agreement and
irrevocable proxy between HP and S-C Indigo CV will terminate on December 30,
2002, if such date is earlier.
Tender Agreements
Pursuant to the tender agreements, each of the Indigo shareholders who is a
party thereto agreed to tender its Indigo common shares, including any
subsequently acquired Indigo common shares, in the exchange offer pursuant to
and in accordance with the terms of the offer agreement. Each of these
shareholders further agreed not to withdraw any of the Indigo common shares it
tenders unless the offer is terminated or has expired. Each of these
shareholders also agreed not to transfer its Indigo common shares to any party
from the date of the tender agreement, unless such party agrees: (1) to execute
a counterpart to the tender agreement; and (2) to hold such Indigo common
shares, or such interest therein, subject to all of the terms and conditions of
the tender agreement.
The tender agreements will terminate on the earlier of the closing of the
exchange offer or the termination of the offer agreement pursuant to its terms;
provided, that the tender agreement between HP and S-C Indigo CV will terminate
on December 30, 2002, if such date is earlier.
Tender and Option Agreements
A foundation, which we refer to as the Landa Family Trust, of which Mr.
Landa, Indigo's Chairman and Chief Executive Officer, is a beneficiary, and the
following entities directly or indirectly owned by the Landa Family Trust are
parties to tender and option agreements: Walthroup Corporation N.V., Visionvest
Corporation N.V., Gemini Systems Corporation N.V., Toscal N.V., OZF Ltd. and
Deering Corporation N.V. Pursuant to the tender and option agreement, each of
these entities controlled by the Landa Family Trust has agreed to tender its
Indigo common shares, including any subsequently acquired Indigo common shares,
in the exchange offer under substantially the same terms as the tender
agreements described above.
In addition, each of these entities controlled by the Landa Family Trust
has, pursuant to the tender and option agreement, granted us an irrevocable
option, under specified circumstances, to purchase all of its Indigo common
shares. This option is only exercisable by us upon such shareholder's breach of
its obligations to tender its Indigo common shares into the exchange offer or
upon such shareholder's breach of any other material agreement or covenant on
the part of such shareholder set forth in the tender and option agreement.
Pursuant to the tender and option agreement, each of these entities
controlled by the Landa Family Trust has also agreed, to the extent that either
the fixed offer price or the contingent offer price is oversubscribed, to elect
automatically to receive the undersubscribed consideration alternative for up
to all of the Indigo common shares held by such shareholder.
Pursuant to the tender and option agreement, the Landa Family Trust agreed
to support all such agreements of these entities controlled by the trust.
The tender and option agreements will terminate on the earlier of the
closing of the exchange offer or the termination of the offer agreement
pursuant to their terms.
Affiliate Agreements
Each of the entities controlled by the Landa Family Trust that are party to
the tender and option agreement has also entered into an agreement with us
under which such entity acknowledged that its shares of HP common stock issued
in connection with the exchange offer would be subject to the restrictions set
forth in Rule 145 and, accordingly, such entity agreed not to sell, transfer or
otherwise dispose of such HP common stock unless the sale, transfer or other
disposition is made in compliance with the requirements of Rule 145(d), or is
made in reliance on a written opinion of counsel delivered to us that such
sale, transfer or disposition is otherwise exempt from registration under the
Securities Act.
141
INDIGO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read in conjunction with the interim
unaudited condensed consolidated financial statements and related notes for the
periods ended September 30, 2001 and 2000 contained elsewhere in this
prospectus as well as Form 20-F incorporated by reference into this prospectus.
The discussion in this section contains forward-looking statements based upon
current expectations that involve risks and uncertainties, such as Indigo's
plans, objectives and intentions. The actual results may differ materially from
those indicated in such forward-looking statements.
Overview
See the section in this prospectus titled "Summary--Parties to the Exchange
Offer--Indigo N.V."
Significant Events in 2001 and 2002
1. On July 25, 2001, Indigo introduced the Platinum, a new Digital Offset
Color press which achieves very high image quality and functionality at a base
configuration price below $200,000. The new press is designed to bring the
benefits of digital printing to commercial printers, trade shops, repro houses,
in-plant and quick printers. Platinum is a Series 1 product, based on a similar
print engine as the first Indigo product introduced in 1993, and on the Imaging
Electronics of the TurboStream. Platinum is enhanced with ITT (Image Tracking
Technology), a technical capability of locking the laser beam to the right
location based on continuous feedback on its actual location. ITT enables
overcoming inaccuracies and imperfections of mechanics and electro-optics, and
compensating for them. Therefore, these imperfections, which cause print
defects, are now compensated for, and the print defects are reduced, enabling a
higher quality print image. In addition, Platinum is positioned at a lower
price point than its predecessor, the TurboStream, enabling the customer a less
expensive price point to the Indigo product range. Indigo believes that
Platinum, with its high quality printing and lower price, will enable further
penetration into the market. The introduction of Platinum goes well in line
with Indigo's strategy of continuously introducing higher performance, lower
priced products to the market, for increased market penetration and expanded
customer profitability.
2. On September 6, 2001, Indigo N.V. and Hewlett Packard Company ("HP")
entered into an agreement pursuant to which HP or a subsidiary of HP to be
formed will offer to acquire all of the outstanding equity of Indigo not
already owned by HP in exchange for a combination of shares of HP stock and
non-transferable contingent value rights (CVRs) entitling the holder to a
contingent cash payment based on the achievement of certain revenue milestones.
In exchange for each share of Indigo stock, shareholders of Indigo will receive
either $7.50 in HP common stock, or $6.00 in HP common stock plus one CVR
entitling its holder to a cash payment of up to $4.50 per share if HP
consolidated net revenues from the sale or lease of LEP Digital Press Products
and Consumables (as such terms are defined in the CVR agreement) achieve a
total of $1.6 billion in revenue over a three-year post-closing period. The
value of each CVR increases linearly from $0 to $4.50 as cumulative revenues
increase from $1.0 billion to $1.6 billion.
The HP common stock to be issued in each case will be determined based on
the average closing price during the 20 trading days ending three trading days
prior to expiration of the offer, with the average trading price to be used in
such calculation not to be less than $16.69 or more than $23.68. The agreement
provides that the total number of Indigo common shares that may be exchanged
for each consolidation alternative is limited. The exchange represents a deal
valued at approximately $629 million in HP common stock (based on the closing
price of HP shares on September 5, 2001) as well as a maximum contingent cash
payment of approximately $253 million.
The acquisition is subject to a 95% minimum exchange condition, customary
closing conditions and normal regulatory reviews.
142
If HP terminates the exchange offer due to the occurrence of a triggering
event, which would include the Indigo boards' approval or recommendation of any
other acquisition proposal, the withholding, withdrawal, amendment or
modification of the Indigo boards' recommendation in favor of the exchange
offer, or failure to recommend rejection of any other third party tender or
exchange offer, Indigo will be required to pay HP a termination fee of $27
million and reimburse HP for expenses of up to $2 million.
3. On September 27, 2001, Indigo and Nilpeter A/S announced an OEM agreement
to provide digital label printing solutions. As part of this alliance, inline
finishing solutions for Indigo's WebStream 100/200/400 digital presses will be
sold through Indigo as a single package.
4. The Government of Israel encourages research and development projects
through special funding from the Office of the Chief Scientist ("OCS") of the
Israeli Ministry of Industry and Trade, Indigo, through its Israeli subsidiary,
Indigo Electronic Printing Systems Ltd., had received grants from the OCS for
the development of certain of its products. Under the terms of the OCS'
participation, a royalty equal to a percentage of the net sales of products,
including related service revenues, developed in an OCS-funded project must be
paid, beginning with the commencement of sales of products developed with grant
funds.
In October 2001, pursuant to a special OCS-initiated program aimed at large
companies, Indigo applied to make a discounted prepayment of future royalties,
which would end its obligation to make royalty payments for past grants
received.
In December 2001, Indigo reached an agreement with the OCS for the early
repayment of royalties. Pursuant to the agreement, Indigo paid the OCS
approximately $15 million in 2002 in settlement of potential future royalty
obligations.
Indigo's prepayment of future royalties will end Indigo's obligation to make
royalty payments with respect to grants received from the OCS during the years
1993-2001, and will enable Indigo to join an OCS-funded program for the
development of generic projects with no royalty payment obligations.
Notwithstanding such prepayment, in the event that consent of the OCS is given
to manufacture products funded by grants provided by the OCS, depending on the
percentage of manufacturing taking place outside of Israel, increased royalties
would be payable to the OCS.
See also the section titled "The Exchange Offer" in this prospectus.
Market trends
The printing industry is a worldwide, highly segmented industry, with a
number of sites estimated at about 400,000 (mostly small businesses), fewer
than 2% of which have already adopted digital color printing. The printing
industry sees continuous growth, but with increased competition between
customers, and therefore reduced gross margins.
Digital color printing answers several market trends:
1. Shorter print runs--a result of shorter product life cycle, faster
product changes, segmenting products into markets, desire for reduced inventory
and reduced waste;
2. High quality printing and increased use of color--customers demand high
quality color printing, on a wide substrate variety;
3. Shorter turnaround time--end users want on-demand production, just in
time, full flexibility, and the ability to do their color printing at the last
possible moment;
4. Targeting and personalization--customers want their printing targeted to
the audience, and even personalized to the single user, to get improved
response rates and better business results. Color personalization, with text
and images, has already shown increased response rates; and
143
5. Remote printing--the "print and distribute" concept gets customers more
value and reduced costs compared to the older "print and distribute."
These market trends are answered by digital color printing, and
specifically, Indigo digital color printing, which combines the quality of
offset color printing with the flexibility of digital imaging. Indigo offers
customers expanded opportunities and market applications, and increased
profitability compared to conventional color printing.
Specifically in a slowing worldwide economy, digital color printing offers
additional market opportunities which compensate for reduced revenues and
margins in the conventional printing world.
Competition in digital color printing is increasing, with larger, stronger
vendors like Xerox and Heidelberg joining. However, Indigo believes that its
superior technology enables higher print quality on a wider range of
substrates, and the strength and market presence of HP will enable it to
capture increased market share and additional customers worldwide. Indigo will
continue to develop products market trends, and with HP, will even be able to
accelerate the development of products, and to get to market forcefully and to
existing and new customers and market segments.
Future products
Indigo maintains its strategy of continuously introducing new products,
which target new/expanded markets, higher performance, lower costs. Therefore,
Indigo is continuing to invest in technology development and R&D, towards new
products. In the printing industry, the directions for product development are
as follows:
1. Reduced Total Cost of Ownership--this includes all prices that effect the
customer: the machine, the operation (labor), the environment (space costs,
electricity and other), the consumables, and any other price element,
2. Increased performance--this includes higher print quality, higher
throughput, increased print format, more enabled applications, and
3. Specialized/customized applications--specific products targeted into
specific markets.
The Indigo product roadmap addresses all of these directions, with the
strategy of mainly addressing the high performance commercial printing market
and photofinishing market, and reduced/ more opportunistic focus on other
markets.
Risks and uncertainties following HP's exchange offer
1. Indigo depends on strategic relationships and business alliances for
continued growth of its business. These relationships range from OEM and
distribution relationships with other companies to cooperative marketing
programs and joint customer seminars with software companies. In some of these
relationships, the third party is not contractually committed to make any
particular level of purchases from Indigo and can, effectively, terminate the
relationship at will. Divergence in strategy or change in focus by, or
competitive product offerings by, any of these companies could harm the Indigo
business. However, since the announcement of the exchange offer, Indigo's
strategic relationships and business alliances have not been negatively
affected in any material way as a result of the announcement of exchange offer.
In addition, Indigo has contracts with some of its suppliers, distributors,
customers, licensors and other business partners. Some of these contracts
require Indigo to obtain the consent of these other parties in connection with
HP's exchange offer. If the respective parties' consent cannot be obtained,
these contracts may be terminated and Indigo may need to locate alternate
suppliers or may suffer a loss of potential future revenue from digital press
products that utilize Indigo technology. However, since the announcement of the
exchange offer, Indigo has not experienced any difficulty with its major
suppliers, distributors, customers, licensors or other business partners.
144
2. The printing equipment industry is highly competitive, and many of the
industry participants possess greater management, financial, technical,
manufacturing, marketing, sales, distribution and other resources than Indigo
does. We believe that our ability to compete depends on factors both within and
outside of our control, including the performance and acceptance of the Indigo
products as well as the successful manufacturing, marketing, distribution and
customer support of these products. Some of Indigo's competitors have developed
color-printing products that target the short-run color printing market and
thereby compete with Indigo's presses. These competitors have substantially
greater financial, distribution, management and other resources than Indigo
does. There is no assurance that competitors will not develop additional
products, utilizing existing or new technology, that are competitive in price
and/or performance with Indigo's presses, and there can be no assurance that we
can compete effectively with any such products and their distribution channels.
However, while Indigo has experienced minor reservations from a few of its
customers in terms of future product orders since the announcement of the
signing of the offer agreement, Indigo has not experienced any material change
in its customers' purchasing decisions to date in any material way.
Operating Results
The third quarter of 2001 compared with the third quarter of 2000 and the
first nine months of 2001 compared with the first nine months of 2000.
Total revenue in the third quarter of 2001 increased by 14% to $44.1
million, from $38.7 million in the third quarter of 2000. Equipment sales in
the third quarter of 2001 increased by 14% to $23.7 million, from $20.8 million
in the third quarter of 2000. Indigo attributes the increase in equipment
revenues in the third quarter of 2001, as compared to the third quarter of
2000, primarily to a 22% increase in the number of systems sold, that was
reflected in a 19% increase in revenue. This increase was partially offset by
4% due to lower average selling prices of equipment in the third quarter of
2001. Total revenue in the first nine months of 2001 increased by 17% to $134.7
million, from $115.4 million in the first nine months of 2000. Equipment sales
in the first nine months of 2001 increased by 18% to $76.7 million, from
$64.8 million in the comparable period of 2000. Indigo attributes the increase
in equipment revenues during the first nine months of 2001, as compared to the
first nine months of 2000, to an increase of 23% in the number of systems sold,
that was reflected in a 20% increase of revenue. This increase was partially
offset by a 2% decrease in average selling price.
Post-sales revenues in the third quarter of 2001 were at a record high of
$20.3 million, a 14% increase as compared to $17.9 million in the third quarter
of 2000. Post-sales revenues in the first nine months of 2001 increased by 15%
to $58.1 million, from $50.6 million in the comparable period of 2000. The
increase in post-sales revenues in the third quarter and nine-month period
ending September 30, 2001, as compared to the third quarter and nine-month
period ending September 30, 2000, is due mainly to growth in the installed
base. Indigo uses a strategy known as a "razor/razor blade" business model, of
rapidly increasing the size of the installed base by placing with customers as
many units as possible, even at reduced margins, in order to enjoy the high
margin revenue stream from post-sales activities (i.e., providing consumables
and service) for years to come.
Gross margin on equipment sales decreased to $6.7 million in the third
quarter of 2001, compared to $9.3 million in the third quarter of 2000. Gross
margin as a percentage of equipment sales decreased to 28% in the third quarter
of 2001, compared with 45% in the third quarter of 2000. Gross margin on
equipment sales decreased to $23.6 million in the first nine months of 2001,
compared to $25.2 million in the first nine months of 2000. Gross margin as a
percentage of equipment sales decreased to 30.9% in the first nine months of
2001, compared with 39% in the comparable period of 2000. The decrease of 17%
in gross margin as a percentage of equipment sales in the third quarter of
2001, as compared to the third quarter of 2000, is primarily attributable to
price erosion in the U.S. (9%), lower-margin sales through Indigo's indirect
channels (3%), and costs associated with the launch of the Platinum press (3%).
The decrease of 8.1% in gross margin as a percentage of equipment sales in the
nine-month period ending September 30, 2001, as compared to the nine-month
period ending September 30, 2000, is primarily attributable to lower-margin
sales through Indigo's indirect channels (3.5%), lower-margin sales in Europe
(1.5%) and costs associated with the launch of Indigo's Platinum press (1%).
145
Gross margin on post-sales revenue decreased to $10.0 million in the third
quarter of 2001, compared to a gross margin of $10.2 million in the third
quarter of 2000. Gross margin as a percentage of post-sales revenue for the
third quarter of 2001 decreased to 49%, compared with a gross margin of 57% in
the third quarter of 2000. Gross margin on post-sales revenue increased to
$30.6 million in the first nine months of 2001, compared to a gross margin of
$28.4 million in the first nine months of 2000. However, gross margin as a
percentage of post-sales revenue for the first nine months of 2001 decreased to
52.7%, compared to a gross margin of 56.2% in the comparable period of 2000.
The decrease in gross margin as a percentage of post-sales revenue in the third
quarter and nine-month period ending September 30, 2001, as compared to the
third quarter and nine-month period ending September 30, 2000, is attributable
primarily to an increased share of 9.5% on September 30, 2001 compared to 3.6%
on September 30, 2000 of UltraStream presses in Indigo's installed base. The
imaging products for the UltraStream presses, included in post-sales revenue,
are less mature than the imaging products for Indigo's other presses and
deliver a lower gross margin.
Gross research and development costs, before participation grants, increased
to $7.0 million in the third quarter of 2001, from $6.2 million in the third
quarter of 2000. Net research and development costs, after participation grants
by the Office of the Chief Scientist and HP, decreased to $3.8 million in the
third quarter of 2001, compared to $5.3 million in the third quarter of 2000.
Gross research and development costs, before participation grants, increased to
$20.5 million in the first nine months of 2001, from $17.7 million in the first
nine months of 2000. Net research and development costs, after participation
grants by the Office of the Chief Scientist and HP, decreased to $13.0 million
in the first nine months of 2001, compared to $14.5 million in the comparable
period of 2000. The increase in research and development costs in the third
quarter and nine-month period ending September 30, 2001, as compared to the
third quarter and nine-month period ending September 30, 2000, reflects the
increase in resources related to Indigo's strategic agreement with HP. Indigo
continues to focus on the enhancements of the UltraStream, the Publisher and
Photo-e-Print families, as well as co-development with HP.
The decrease in net research and development costs in the third quarter and
nine-month period ending September 30, 2001, as compared to the third quarter
and nine-month period ending September 30, 2000, is related to participation
from HP and an increase in government funding in 2001 on behalf of research and
development projects performed during 2000 and 2001. Participation from HP was
$1.5 million and $3.5 million, respectively, in the third quarter and
nine-month period ending September 30, 2001, as compared to nil in the third
quarter and nine-month period ending September 30, 2000. Government funding in
2001 increased to $1.7 million and $4.0 million in the third quarter and
nine-month period ending September 30, 2001, as compared to $0.9 million and
$3.2 million in the third quarter and nine-month period ending September 30,
2000.
Starting in the third quarter of 2001, Indigo classifies its royalty
payments to the Government of Israel, relating to research and development
grants, to cost of goods sold. Previously, Indigo classified these royalty
payments to selling, general and administrative expenses. The amounts
reclassified for the three month period ended September 30, 2000 and for the
nine month period ended September 30, 2000 were $0.75 million and $2.3 million,
respectively. The amounts classified as above for the three month period ended
September 30, 2001 and for the nine-month period ended September 30, 2001 were
$1.0 million and $3.1 million, respectively.
During 1998, Indigo joined an additional program of the Office of the Chief
Scientist known as the "Magnet Program." The Magnet Program's mission is to
optimize national investment in research and development by encouraging generic
technology development for mid- and long-term projects, as well as by
initiating cooperation between companies and academia at the pre-competitive
stage. Magnet Program funding includes financing of 66% of the program budget
with no commitment to pay royalties to the Office of the Chief Scientist. The
participation received from the Magnet Program is included in the participation
received from the Office of the Chief Scientist.
Selling, general and administrative expenses increased to $20.9 million in
the third quarter of 2001, compared to $16.3 million in the third quarter of
2000. This increase is primarily related to $1.2 million
146
HP-Indigo acquisition related expenses, an increase of $0.7 million in the
allowance for doubtful accounts due to the loss of several customers who have
ceased operations due to the economic environment, $1.8 million in marketing
costs related to the Print 01 show in Chicago in September 2001 and $1 million
due to the continued increase in the direct sales force.
Interest income, net of interest expense was $1.1 million in the third
quarter of 2001, compared to $0.2 million in the third quarter of 2000. The
increase in interest income is mainly a result of $1 million interest income
generated from deposits.
Indigo operates worldwide and in a variety of currencies. When operating in
currencies other than the U.S. dollar, Indigo's cash flows and earnings are
exposed to fluctuations in foreign currency exchange rates. Indigo attempts to
reduce this exposure through operational strategies and hedge-oriented
financial instruments.
Indigo does not enter into derivative contracts for trading purposes, nor is
it a party to any leveraged financial instruments. Balance sheet hedges protect
Indigo from fluctuations in balance sheet accounts linked to non-U.S. dollar
currencies. Cash flow hedges protect Indigo from fluctuations in income and
expenses incurred in subsidiaries that operate in non-U.S. dollar-based
environments.
To date, Indigo has utilized monetary assets and liabilities, forward
contracts and purchased option contracts to mitigate the exposure from changes
in foreign currency rates. However, there can be no assurance that the steps
taken will be successful in protecting Indigo from the above-described risks.
Provision for income taxes decreased to $10,000 in the third quarter of
2001, compared to $464,000 in the third quarter of 2000. The decrease in income
taxes is a result of a one-time reduction in income taxes during the third
quarter of 2001. Income taxes include taxes on income reported by Indigo to the
respective taxing jurisdictions.
The cumulative effect of an accounting change, net as of the beginning of
year 2000, was a loss of $1.9 million. The accounting change is attributed to
the adoption of SAB 101 "Revenue Recognition in Financial Statements."
Net loss was $7.0 million in the third quarter of 2001, compared to a net
loss of $2.4 million in the third quarter of 2000. Net loss applicable for
common shares outstanding was $7.0 million in the third quarter of 2001,
compared to a net loss applicable for Indigo common shares outstanding of $64.0
million in the third quarter of 2000. Net loss was $12.5 million in the first
nine months of 2001 and 2000, and the net loss applicable for common shares
outstanding was $12.5 million in the first nine months of 2001, compared to a
net loss applicable for Indigo common shares outstanding of $81.9 million in
the first nine months of 2000. During the third quarter of 2000, Indigo reached
an agreement with the holders of most of the Series A Preferred Shares to
convert these shares to Indigo common shares. As a result, a one-time charge of
$58.7 million related to the inducement to convert the preferred shares was
included in the calculation of loss per share, in addition to the current
charge of $2.9 million regarding the preferred shares dividends. Basic and
diluted loss per Indigo common share was $0.06 for the third quarter of 2001,
compared to $0.81 for the third quarter of 2000. Basic and diluted loss per
Indigo common share was $0.11 for the first nine months of 2001, compared to
$1.04 for the first nine months of 2000.
2000 compared with 1999
On September 14, 2000, Indigo and HP announced a broad strategic alliance to
co-develop high-end, digital color-printing systems. As part of the alliance,
HP made a $100 million equity investment in Indigo and signed an agreement to
OEM select products from Indigo's line of high-production digital
color-printing presses. Under the terms of the agreement, HP and Indigo agreed
to collaborate to develop and bring to market future digital color-printing
solutions.
147
In 2000, pursuant to Securities and Exchange Commission, Staff Accounting
Bulletin No. 101, "Revenue Recognition in Financial Statements," Indigo
implemented a change in its revenue recognition policy. Previously, Indigo had
recognized revenue upon shipment of equipment, which preceded installation,
provided collectibility was reasonably assured, future obligations of Indigo
were considered insignificant and the costs of such obligations could be
reasonably estimated. Under the new policy, revenue on sales of equipment to
customers is recognized upon installation at the customer's site within the
reporting period, where applicable, provided collectibility is reasonably
assured, future obligations of Indigo are considered insignificant and the
costs of such obligations can be reasonably estimated.
Total revenue, which is comprised of revenues from equipment, post-sales
activities, license fees and royalties, increased by 13.7% to $164.8 million in
2000 from $145.0 million in 1999 (implementation of SAB 101 in 1999 would have
resulted in total revenue of $146.2 million in year 1999).
Equipment revenues increased by 21.1% to $95.3 million in 2000 compared with
$78.7 million in 1999 (implementation of SAB 101 in 1999 would have resulted in
equipment revenue of $79.9 million in year 1999). During 2000, Indigo's unit
sales increased by 24% compared to 1999 primarily due to unit sales of the new
generation of ultra-high speed Digital Offset Color presses--the UltraStream
2000, an increase of 95% in unit sales of the e-Print Pro+, that was partially
offset by a 50% decrease in unit sales of the high-margin MultiStream system.
The increase in equipment revenues was offset by $4.7 million due to the
devaluation of the Euro and British pound.
Post-sales revenues, which include revenues from consumable products and
service, increased by 12.0% to $69.4 million in 2000 from $62.0 million in
1999. The increase is primarily attributable to the increased installed base.
The increase in post-sales revenues was offset by $3.1 million due to the
devaluation of the Euro and British pound.
Revenues from license fees and royalties were $0.09 million for 2000,
compared to $4.3 million for 1999. The 1999 revenues from licensing fees and
royalties resulted primarily from patent-licensing agreements relating to
document scanning and handling technologies.
Equipment and post-sales revenues in North America increased by 46.9% to
$71.1 million in 2000 from $48.4 million in 1999.
Equipment and post-sales revenues in Europe increased by 7.1% to $75.8
million in 2000 from $70.8 million in 1999 after the negative impact of $7.8
million due to the devaluation of the Euro and British pound during 2000.
Equipment and post-sales revenues in other territories increased by 45% to $8.7
million in 2000 from $6.0 million in 1999. The increase in these revenues is
primarily attributable to the increase of sales in Latin America.
Gross margin (net of royalties and license fees) increased by 22.7% to $81.1
million in 2000 from $66.1 million in 1999 (implementation of SAB 101 in 1999
would have resulted in gross margin of $66.7 million in year 1999). Gross
margin as a percentage of revenues increased to 49.2% in 2000 compared with
47.0% in 1999. Gross margin on equipment sales increased by 23.0% to $41.7
million in 2000, compared to $33.9 million in 1999. Gross margin as a
percentage of equipment sales for 2000 increased to 43.7% compared with 43.1%
in 1999. The increase is attributable primarily to sales of the UltraStream
2000. Gross margin on post-sales revenues increased by 22.4% to $39.4 million
in 2000, compared to a gross margin of $32.2 million in 1999. Gross margin as a
percentage of post-sales revenues for 2000 increased to 56.8% compared with
52.0% in 1999. The improvement in 2000 is attributable primarily to increased
post-sales revenues as a result of the increased installed base, improvement in
the reliability of consumable products, and to the continuing improvement in
equipment reliability resulting in a reduction of cost of service per unit.
Gross research and development costs, before participation grants, increased
to $24.4 million in 2000 from $20.4 million in 1999. The high level of costs
during the last two years reflects Indigo's focus on the
148
development of new products, including the products which were first presented
in the Drupa exhibition in Dusseldorf, Germany, in May 2000, and the
Photo-e-Print products.
Net research and development costs, after participation grants, increased to
$19.5 million in 2000, from $14.2 million in 1999. Participation grants from
the Israeli Office of the Chief Scientist decreased to $4.9 million in 2000
compared to $6.2 million in 1999. The high level in the Chief Scientist's
participation in the last two years is directly associated with the development
of Indigo's new products and Indigo's participation in the Magnet Program.
Indigo was committed to pay royalties to the Chief Scientist upon successful
completion of projects that the Chief Scientist funds, and upon sales of the
resulting products, until the amount of the grant has been repaid. This expense
has been reflected in selling, general and administrative expenses (See also
section 4 to "--Significant Events in 2001 and 2002").
Selling, general and administrative expenses increased to $71.9 million
during 2000 from $57.6 million in 1999. The increase primarily reflects an
increase of $4.3 million in selling expenses due to an increase of 33% in the
number of sales personnel, which is consistent with Indigo's policy of
increasing its presence in the direct sales market. The increase is also
attributable to an increase of $6.1 million in marketing expenses due to the
Drupa exhibition in May 2000 and the Graph-Expo exhibition in September 2000.
Interest income and other, net of interest expense and other, was $1.8
million in 2000, compared to interest income, net of interest expense, of $0.7
million in 1999. The increase is primarily a result of $1.5 million interest
income generated from the increase in cash, cash equivalents, short-term
deposits and marketable securities and a decrease in short-term loans in the
fourth quarter of 2000 following HP's equity investment in Indigo of
$100 million, as described above.
Indigo operates worldwide and in a variety of currencies. When operating in
several currencies other than the U.S. dollar, Indigo's cash flows and earnings
are exposed to fluctuations in foreign currency exchange rates. Indigo attempts
to reduce this exposure through operational strategies and hedge-oriented
financial instruments.
Indigo does not enter into derivative contracts for trading or speculative
purposes, nor is it a party to any leveraged financial instruments. Cash flow
hedges protect Indigo from fluctuations in income and expenses incurred in
subsidiaries that operate in non-U.S. dollar-based environments.
Provision for income taxes includes taxes on income reported by Indigo to
the respective taxing jurisdictions. Provision for income taxes increased to
$1.1 million in 2000 from $0.7 million in 1999.
The cumulative effect of an accounting change, net as of the beginning of
year 2000, was a loss of $1.9 million. The accounting change is attributed to
the adoption of SAB 101, "Revenue Recognition in Financial Statements," as
described above.
Net loss increased to $11.6 million in 2000 compared to a net loss of $1.4
million for 1999. Basic and diluted loss per common share before the cumulative
effect of an accounting change, net, was $0.90 and $0.16 for 2000 and 1999,
respectively. Basic and diluted loss per common share after the cumulative
effect of an accounting change, net, was $0.93 and $0.16 for 2000 and 1999,
respectively. The increase in net loss is primarily attributed to the increase
in selling and marketing expenses and research and development expenses as
described above.
1999 compared with 1998
Total revenue, which is comprised of revenues from equipment, post-sales
activities, license fees and royalties, decreased by 2% to $145.0 million in
1999 from $147.4 million in 1998.
149
Equipment revenues remained flat at $78.7 million in 1999 compared with
$79.0 million in 1998. During 1999, number of units sold increased by 22%
compared to 1998. However, the average selling price of the systems was reduced
by 20% following the introduction and sale of the e-Print Pro+ during the
second half of 1999. The combination of these two factors, and the negative net
impact of $0.7 million relating to exchange rate changes of the German mark and
British pound, led to equipment revenues remaining at the same levels as in
1998.
Post-sales revenues, which include revenues from consumable products and
service, increased by 7% to $62.0 million in 1999 from $58.0 million in 1998.
The increase is attributable to the increased installed base. The increase in
post-sales revenues was offset by $0.5 million relating to net impact of
exchange rate changes of the German mark and British pound.
Revenues from license fees and royalties were $4.3 million for 1999,
compared to $10.3 million for 1998. The 1999 revenues from licensing fees and
royalties resulted primarily from patent-licensing agreements relating to
document scanning and handling technologies.
During 1999, Indigo undertook a new strategy targeted at the lower end of
its market by introducing a new system, the e-Print Pro+, with a list price of
$149,000. Under an OEM agreement with A.B. Dick, A.B. Dick is marketing its own
branded digital press that incorporates this technology. This system was
targeted at copy shops, in-plant printers, quick printers and small commercial
printers. During the second half of 1999, the e-Print Pro+ became Indigo's most
popular unit, increasing Indigo's installed base, but lowering Indigo's average
selling price of units sold.
Equipment and post-sales revenues in North America increased by 3% to $48.4
million in 1999 from $46.9 million in 1998. Equipment and post-sales revenues
in Europe increased by 3.2% to $70.8 million in 1999 from $68.6 million in
1998. The lower sales activity in North America as compared to Europe is
primarily attributable to fewer available sales channels in North America.
Sales of equipment to Toyo Ink, Indigo's distributor in Japan and much of
Southeast Asia and the Pacific Rim, increased by 20% to $7.7 million in 1999
from $6.4 million in 1998. Total revenues from Toyo Ink in 1999 and 1998
constituted 11% of Indigo's equipment and post-sales revenues. During the third
quarter of 1998, Indigo signed an agreement with Toyo Ink to repurchase from
Toyo Ink's inventory 30 systems to be upgraded to one of Indigo's newly
announced products (the e-Print Pro+). The transaction was initiated by Indigo
in order to be able to supply the demand for the newly announced e-Print Pro+
and included a repurchase of systems at a purchase price lower than Indigo's
own manufacturing cost for the product. Sixteen of these systems were upgraded
to the e-Print Pro+ and resold during the fourth quarter of 1998 and the
remaining systems were resold during the first half of 1999.
Gross margin (net of royalties and license fees) remained flat at $66.1
million in 1999 from $66.0 million in 1998. Gross margin as a percentage of
revenues decreased to 47% in 1999 compared with 48% in 1998. Gross margin on
equipment sales decreased by 17% to $33.9 million in 1999, compared to $40.8
million in 1998. Gross margin as a percentage of equipment sales for 1999
decreased to 43% compared with 52% in 1998. The decrease in gross margin as a
percentage of equipment sales is primarily attributable to the increase in
sales of the lower priced e-Print Pro+ during 1999. Gross margin on post-sales
revenues increased by 28% to $32.2 million in 1999, compared to a gross margin
of $25.2 million in 1998. Gross margin as a percentage of post-sales revenues
for 1999 increased to 52% compared with 43% in 1998. The improvement in 1999 is
attributed primarily to increased revenue from the increased installed base,
improvement in the reliability of imaging products, and to the continuing
improvement in equipment reliability resulting in a reduction of cost of
service per unit.
Gross research and development costs, before participation grants, decreased
to $20.4 million in 1999 from $21.0 million in 1998. The high level of costs
during those two years reflects Indigo's focus on the development of new
products, including those unveiled in February 2000.
150
Net research and development costs, after participation grants, decreased to
$14.2 million in 1999, from $16.7 million in 1998. Participation grants from
the Chief Scientist increased to $6.2 million in 1999 compared to $4.4 million
in 1998. The increase in the Chief Scientist's participation is directly
associated with the development of Indigo's new products and Indigo's
participation in the Magnet Program.
Selling, general and administrative expenses decreased to $57.6 million
during 1999 from $61.5 million in 1998. The reduction was primarily in the
areas of general and administrative costs, a decrease of $5.9 million, due to
Indigo's restructuring in 1998, as well as Indigo's continuing efforts to
reduce its general and administrative costs. This decrease was partially offset
by an increase of 57% in the number of sales personnel, which is consistent
with Indigo's policy to increase its presence in the direct sales market. In
December 1998, the Company announced a senior management restructuring,
resulting in severance pay costs of $ 2,764,000. The reorganization of the
management structure was along functional--rather than geographic--lines.
Previously, the Company had been managed as three independent geographic
entities--Indigo America, Indigo Europe, and Indigo Israel. The reorganized
structure centralized each operating function under its own corporate head and
streamlined the management structure. As part of the reorganization, certain
senior executives stepped down. The restructuring resulted in yearly savings,
primarily in the areas of general and administrative expenses, of approximately
$10 million. During 1999, Indigo paid all outstanding payments relating to the
1998 and prior year's restructuring.
Interest income and other, net of interest expense and other, was $0.7
million in 1999, compared to interest income, net of interest expense, of $0.8
million in 1998. Indigo operates worldwide and in a variety of currencies. When
operating in several currencies other than the U.S. dollar, Indigo's cash flows
and earnings are exposed to fluctuations in foreign currency exchange rates.
Indigo attempts to reduce this exposure through operational strategies and
hedge-oriented financial instruments.
Indigo does not enter into derivative contracts for trading or speculative
purposes, nor is it a party to any leveraged financial instruments. Cash flow
hedges protect Indigo from fluctuations in income and expenses incurred in
subsidiaries that operate in non-U.S. dollar-based environments.
Provision for income taxes includes taxes on income reported by Indigo to
the respective taxing jurisdictions. Provision for income taxes decreased to
$0.7 million in 1999 from $2.4 million in 1998. This decrease is primarily a
result of a revision of estimates made by Indigo in 1999 with respect to tax
liabilities by a net amount of approximately $1.5 million.
Net loss decreased by 73% to $1.4 million in 1999 compared to a net loss of
$5.1 million for 1998. Basic and diluted loss per common share was $0.16 and
$0.22 for 1999 and 1998, respectively.
In 1999, Indigo sold for less than $1 million the distribution, marketing,
sale, service and support business relating to the 536 Series to Ferber &
Hanusa GmbH System Digital Reprografie, based in Germany. The production of the
536 Series was ceased in 1995. The gain of $0.6 million related to this sale
was included within "Interest income and other income, net," in the Company's
Consolidated Statements of Operations.
Liquidity and Capital Resources
Indigo's cash and cash equivalents and restricted cash were $18.9 million at
September 30, 2001, compared to $47.8 million at December 31, 2000. Indigo's
short-term deposits and marketable securities were $48.4 million at September
30, 2001, compared to $47.2 million at December 31, 2000, while its long-term
marketable securities were $9.5 million at September 30, 2001, compared to nil
at December 31, 2000. The reduction in cash and cash equivalents and restricted
cash is primarily associated with capital expenditures of $11.4 million,
investment in long-term marketable securities, net, of $9.6 million as well as
a $6.3 million decrease in accounts payable and accrued expenses.
151
The long term securities represent corporate and bank fixed rate bonds, with
interest rate ranges between 5.4% and 7.6% and with maturity dates through 2003.
Indigo's accounts receivable was $40.7 million at September 30, 2001 and
December 31, 2000.
Indigo's inventory levels decreased to $47.4 million at September 30, 2001,
compared to $47.8 million at December 31, 2000. The decrease is mainly a result
of $2.6 million decrease in raw materials, work in process and finished goods
of systems and spare parts, offset by a $2.2 million increase in raw materials,
work in process and finished goods of imaging products.
Indigo's fixed assets, net, increased by $3.0 million to $26.0 million as of
September 30, 2001, compared to $23.0 million at December 31, 2000. The
increase in fixed assets, net, is primarily a result of $5.9 million additional
products capitalized in Indigo's training and demo centers, as well as $3.2
million capital expenditure relating to the expansion of the ink manufacturing
plant in Israel, $1.8 million equipment for R&D and $0.3 million investments in
additional office space in Israel, $2.2 million re-designation of Indigo's
units used for R&D to inventory (to be sold to customers as used systems at
decreased price) less depreciation expenses of $6.0 million.
During 2001, Indigo signed three new independent agreements with two major
Israeli banks and with Citibank N.A. The total bank facilities (including an
existing facility with a third Israeli bank), provide for total advances up to
$50.0 million. The facilities expire on various dates during 2002. Indigo has
the option to extend certain of the facilities upon the fulfillment of certain
requirements.
As of September 30, 2001, Indigo's working capital was $78.7 million, a
decrease of $29.9 million compared to working capital of $108.6 million at
December 31, 2000. The decrease in working capital is mainly a result of a
$27.4 million decrease in cash and cash equivalents and a $12.9 million
increase in short-term loans payable, which was offset by a $8.4 million
decrease in accounts payable and accrued expenses.
Cash flows used in operating activities increased to $14.2 million during
the nine-month period ending September 30, 2001, compared to $9.4 million in
the comparable period of 2000. This increase is attributed primarily to a
decrease in accounts payable and accrued expenses. Cash flows from financing
activities increased to $6.8 million during the nine-month period ending
September 30, 2001, compared to $1.6 million in the comparable period of 2000.
This increase is attributed primarily to receipt of $12.9 million of short-term
loans which was partially offset by $7.9 million relating to the purchase of
treasury stock and stock issuance costs.
Litigation
One of Indigo's Israeli subsidiaries is party to a dispute regarding the
amount of rent payable pursuant to a long-term lease for a tract of land
adjacent to Indigo's manufacturing facilities in Nes-Ziona, Israel. The dispute
involves issues of contract interpretation and real estate appraisal.
Arbitration proceedings commenced in March 1998, and in August 1999 the
arbitrator issued his decision, which was invalidated by the Tel Aviv District
Court in June 2001. In July 2001, the landlord petitioned Israel's Supreme
Court for permission to appeal the District Court's ruling, and in October
2001, Indigo's subsidiary filed its response to such petition. A hearing on the
petition has been scheduled for September 2002. In the event that the parties
are unable to resolve the dispute amicably, Indigo intends to continue to
defend the claim vigorously, since Indigo believes that the amount of rent
sought by the landlord is unreasonable and not supported by the terms of the
lease. The maximum exposure regarding this claim would not have a significant
effect on Indigo's financial position or its results of operations.
Contingencies
a. Assuming close of the exchange offer, Indigo has agreed to pay additional
deal-related expenses of approximately $10.0 million relating to legal and
investment banking expenses and other liabilities related to the exchange
offer. See section titled "The Exchange Offer--Fees and Expenses" in this
prospectus.
152
b. Recent developments, including the September 11, 2001 terrorist attack in
the United States and the bombing of Afghanistan by the United States and its
allies, as well as future events occurring in response to or in connection with
those developments, including, without limitation, future terrorist attacks
against United States or Israeli targets, rumors or threats of war, actual
conflicts involving the United States, Israel or their allies, or trade
disruptions impacting Indigo's suppliers or customers, may adversely affect the
revenues, results of operation or financial condition of the Indigo business
especially since Indigo's research and development and manufacturing operations
are located in Israel. Any of these events could cause Indigo's customers to
defer or cancel purchases of Indigo products. The operation of the Indigo
business could be adversely affected if major hostilities involving Israel or
the United States should occur or if trade between Israel and its current
trading partners, including, without limitation, the United States, were
interrupted or curtailed.
c. See section "--Significant Events in 2001 and 2002" above, regarding the
possibility of a triggering event that will require Indigo to pay up to $29
million to HP.
Impact of Recently Issued Accounting Pronouncements
In July 2001, the FASB issued Statements of Financial Accounting Standards
No. 141 (FAS 141), "Business Combinations," and No. 142 (FAS 142), "Goodwill
and Other Intangible Assets." FAS 141 supersedes Accounting Principles Board
Opinion No. 16 (APB 16), "Business Combinations," and FAS 142 supersedes
APB 17, "Intangible Assets."
The most significant changes made by FAS 141 are: (1) requiring that the
purchase method of accounting be used for all business combinations initiated
after June 30, 2001, (2) establishing specific criteria for the recognition of
intangible assets separately from goodwill and (3) requiring unallocated
negative goodwill to be written off immediately as an extraordinary gain
(instead of being deferred and amortized).
The most significant changes made by FAS 142 are: (1) goodwill and
indefinite lived intangible assets will no longer be amortized, (2) goodwill
will be tested for impairment at least annually at the reporting unit level,
(3) intangible assets deemed to have an indefinite life will be tested for
impairment at least annually, and (4) the amortization period of intangible
assets with finite lives will no longer be limited to forty years. In addition,
FAS 142 contains certain transitional provisions, which may effect the
classification of intangible assets as well as the balance of goodwill. The
provisions for FAS 141 are effective for acquisitions consummated after June
30, 2001. The provisions of FAS 142 are effective for fiscal years beginning
after December 15, 2001 (fiscal year 2002 for Indigo). Management is currently
assessing the impact of the adoption of these new pronouncements.
In July 2001, the FASB approved the issuance of FAS 143, "Accounting for
Asset Retirement Obligations." FAS 143 prescribes the accounting for retirement
obligations associated with tangible long-lived assets, including the timing of
liability recognition and initial measurement of the liability. FAS 143
requires that an asset retirement cost should be capitalized as part of the
cost of the related long-lived asset and subsequently allocated to expense
using a systematic and rational method. FAS 143 is effective for fiscal years
beginning after June 15, 2002 (January 1, 2003 for Indigo).
In August 2001, the FASB issued FAS 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets," which is effective for fiscal periods beginning
after December 15, 2001 (January 1, 2002 for Indigo) and interim periods within
those years. FAS 144 establishes an accounting model for impairment or disposal
of long-lived assets to be disposed of by sale.
Indigo is currently evaluating the potential effects, if any, that the
adoption of these standards may have on its consolidated financial statements.
153
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK OF INDIGO
Market risks relating to Indigo's operations result primarily from changes
in exchange rates. To address this risk, Indigo uses various financial
instruments. These instruments are composed of monetary assets and liabilities,
derivative forward exchange contracts and purchased options. These financial
instruments enable Indigo to manage and reduce the impact of fluctuation in
foreign currency exchange rates. Balance sheet hedges protect Indigo from
fluctuations in balance sheet accounts that are linked to non-U.S. dollar-based
environments. Cash flow hedges protect Indigo from fluctuations in income and
expenses incurred in subsidiaries that operate in non-U.S. dollar-based
environments. Changes in interest rates do not have a material effect on
Indigo's operations. Indigo does not enter into derivative contracts for
trading or speculative purposes, nor is it a party to any leveraged financial
instruments.
Foreign Currency Risk
Indigo operates in several countries and in a variety of currencies. When
operating in currencies other than the U.S. dollar, Indigo's cash flows and
earnings are exposed to fluctuations in foreign currency exchange rates,
including exposure due to compensation expenses which are mainly in New Israeli
Shekels (NIS) and European currency. Indigo strives to limit its exposure
through "natural" hedging by attempting to have similar levels of assets and
liabilities in any one currency. The rest of the exposure, which is not set off
naturally, is mainly hedged by derivative financial instruments. Indigo enters
into foreign exchange forward contracts and purchased option contracts to hedge
a substantial portion of its foreign currency exposure. Indigo uses such
contracts to hedge exposure to changes in foreign currency exchange rates
associated with monetary assets and liabilities in the balance sheet and
anticipated sales transactions to be incurred in a foreign currency. The
exposure to Indigo is in European currencies and NIS. Indigo seeks to minimize
the risk that the fair value of its revenues and cash flow, required for its
operational expenses denominated in a currency other than U.S. dollars, will be
affected by changes in exchange rates. We do not enter into foreign currency
exchange forward and option contracts for trading purposes. Between January 1
and September 30, 2001, Indigo utilized monetary assets and liabilities,
purchased option contracts and forward contracts to reduce the exposure from
changes in foreign currency rates. The table below details the net current
assets balance (net current liabilities balance) of the balance sheet exposure,
by currency and geography (at fair value). All data in the table has been
converted into U.S. dollar equivalents (in thousands). See the explanatory
notes below the table.
European Currencies New Israeli Shekel Total
------------------------- ------------------------- -------------------------
September 30, December 31, September 30, December 31, September 30, December 31,
2001 2000 2001 2000 2001 2000
------------- ------------ ------------- ------------ ------------- ------------
The Netherlands......... $ 23,531 $17,082 $ -- $ -- $ 23,531 $ 17,082
Israel.................. (11,278) (6,596) (17,490) (20,442) (28,768) (27,038)
-------- ------- -------- -------- -------- --------
Total................ $ 12,253 $10,486 $(17,490) $(20,442) $ (5,237) $ (9,956)
======== ======= ======== ======== ======== ========
Explanatory notes:
Total exposure is the summation of the absolute figures.
The data presented in the table reflects the exposure after the use of
natural hedging.
The data in the column under the title "European currencies" includes,
primarily, exposures in Euros, German marks, Netherlands florins and British
pound.
As of September 30, 2001, Indigo held several forward contracts to hedge
forecasted sales transactions in Euro and GBP in an aggregate notional amount
of $15.0 million and fair value of $14.7 million and to hedge balance sheet
exposure in NIS in an aggregate notional and fair value amount of $9.5 million.
Indigo's hedges reduce, but do not entirely eliminate, the impact of currency
exchange rate movements (or fluctuations). Based on the value of foreign
denominated balances at September 30, 2001 that are not hedged, either
naturally or with
154
hedging instruments, and assuming that the hedging instruments currently in
place remain effective, we estimate that a 1% adverse change in exchange rates
may result in an adverse impact on income before taxes of $0.3 million.
Indigo's outstanding debt consisted of $11.3 million in Euro, $7.1 million in
U.S. dollars and $0.03 million in NIS. The loan in Euro was taken to hedge
against fluctuation of the Euro exchange rate that would partially affect the
expected collection from accounts receivables in Europe.
Interest Rate Risk
The fair value of Indigo's cash, cash equivalents and short-term debt
portfolio at September 30, 2001 approximated its carrying value due to its
short-term nature. The cash, cash equivalents and short-term debt portfolio as
of September 30, 2001 was composed of cash, short-term deposits, marketable
securities (held-to-maturity) and short-term loans bearing mainly fixed
interest rates. A change in interest rate would have no material effect upon
the fair value of the cash, cash equivalents and short-term loans portfolio as
of September 30, 2001.
155
INDIGO MARKET PRICE DATA AND DIVIDEND INFORMATION
The following table shows, for the periods indicated, the highest and lowest
sale prices for Indigo common shares on the Nasdaq National Market for the
quarters indicated.
Low High
----- -----
1999 Calendar Year
Fourth Quarter................................... $2.56 $3.75
2000 Calendar Year
First Quarter.................................... 2.88 8.88
Second Quarter................................... 4.59 9.00
Third Quarter.................................... 5.06 8.63
Fourth Quarter................................... 2.97 6.88
2001 Calendar Year
First Quarter.................................... 3.63 6.13
Second Quarter................................... 3.30 5.49
Third Quarter.................................... 5.15 7.03
Fourth Quarter................................... 5.85 7.30
2002 Calendar Year
First Quarter (through February 15, 2002)........ 7.00 7.56
Indigo Dividend Policy
Indigo has never declared or paid any cash dividends on its common shares.
Moreover, the offer agreement prohibits Indigo from paying any dividends on its
common shares until the termination of the offer agreement in accordance with
its terms or the acceptance for exchange of Indigo common shares pursuant to
the exchange offer. If the exchange offer is completed, Indigo, in connection
with any post-closing restructuring undertaken at HP's sole discretion, may
distribute an extraordinary dividend on the shares of Indigo or a particular
class or classes of shares of Indigo.
156
COMPARISON OF RIGHTS OF HOLDERS OF HP COMMON STOCK AND INDIGO COMMON SHARES
Upon completion of the exchange offer, the shareholders of Indigo who tender
their Indigo common shares into the exchange offer will become shareowners of
HP, and the HP certificate of incorporation, the HP bylaws, and Delaware
General Corporation Law will govern the rights of former Indigo shareholders.
HP is incorporated under Delaware law and is subject to the Delaware General
Corporation Law. Indigo is incorporated in The Netherlands as a public limited
company (naamloze vennootschap) and is subject to Dutch law. The following is a
summary of material differences between the rights of holders of HP common
stock and the rights of holders of Indigo common shares. While we believe that
this description covers the material differences between the two, this summary
may not contain all of the information that is important to you.
Comparison of the Certificate of Incorporation and Bylaws of HP and Articles of
Association of Indigo
The following is a summary of the material differences between the
provisions of the certificate of incorporation and bylaws of HP and the
articles of association of Indigo. This summary is not intended to be a
complete discussion of the certificate of incorporation and bylaws of HP and
the articles of association of Indigo and it is qualified in its entirety by
reference to the applicable Delaware General Corporation Law and Dutch law, as
the case may be, as well as by reference to HP's certificate of incorporation
and bylaws and Indigo's articles of association. You should carefully read this
entire prospectus and the other documents we refer to in this prospectus for a
more complete understanding of the differences between being a shareowner of HP
and being a shareholder of Indigo. HP and Indigo have filed with the Securities
and Exchange Commission their respective certificates of incorporation and
bylaws and articles of association and will send copies of these documents to
you upon your request. See the section titled "Where You Can Find More
Information" beginning on page 166 of this prospectus.
Authorized Capital Stock
HP's certificate of incorporation authorizes the issuance of 9,900,000,000
shares of capital stock, consisting of:
. 9,600,000,000 shares of common stock, par value $0.01 per share; and
. 300,000,000 shares of preferred stock, par value $0.01 per share.
Indigo's articles of association authorize the issuance of 266,950,000
shares of capital stock, consisting of:
. 240,000,000 common shares, par value NLG 0.04 per share; and
. 26,950,000 preferred shares, par value NLG 0.04 per share.
Size of the Board of Directors
HP's certificate of incorporation provides that the number of directors
comprising the HP board of directors shall be no fewer than eight and no more
than 17. HP's certificate of incorporation further provides that the exact
number of directors comprising the HP board of directors shall be fixed, and
may be changed from time to time, within the foregoing limits, by an amendment
to HP's bylaws that has been duly adopted by the HP board of directors or HP
shareowners. HP's bylaws provide that within the range of eight to 17 directors
set forth in HP's certificate of incorporation, the exact number of directors
comprising the HP board of directors may be as fixed from time to time by the
HP board of directors. The HP board of directors currently has nine members.
Upon completion of the Compaq merger, the HP board of directors will have 13
members.
Indigo's articles of association provide for a supervisory board, a
management board, and a combined board consisting of all the members of the
supervisory board and the management board. The number of directors
157
comprising the management board is determined by the combined board. The number
of directors comprising the supervisory board is determined by the combined
board and these directors are appointed by the combined board and the general
meeting of shareholders. As of the date of this prospectus, the management
board consists of four members and the supervisory board consists of six
members.
Cumulative Voting
HP's certificate of incorporation provides that HP shareowners are entitled
to cumulate votes in connection with the election of directors.
Dutch law does not recognize the concept of cumulative voting. As a result,
Indigo shareholders are not entitled to cumulate votes in connection with the
election of directors.
Term of Directors
HP's bylaws provide that directors on the HP board of directors are elected
for a term of office to expire at the succeeding annual meeting of shareowners
after their election, with each director to hold office until such director's
successor shall have been duly elected and qualified.
Indigo's articles of association provide that directors of Indigo serve
until they resign or are dismissed.
Removal of Directors
HP's bylaws provide that any director, or the entire HP board of directors,
may be removed with or without cause by the holders of a majority of the shares
then entitled to vote at an election of directors. However, if and so long as
shareowners are entitled to cumulative voting in connection with the election
of directors, if less than the entire HP board of directors is to be removed,
no individual director may be removed from the HP board of directors without
cause if the votes cast against such director's removal would be sufficient to
elect such director if then cumulatively voted in an election of the entire HP
board of directors.
Indigo's articles of association provide that (1) any management board
member may be suspended or dismissed at the general meeting of shareholders by
a majority of the votes cast if a majority of the outstanding shares entitled
to vote are represented in person or proxy at such meeting, and (2) any
supervisory board member may be suspended or dismissed at any time by the
corporate body by which he/she was appointed. Under Dutch law, any board
member, or an entire board, may be suspended or dismissed.
Filling Vacancies on the Board of Directors
HP's bylaws provide that vacancies on the HP board of directors may be
filled by a majority of the remaining directors, even if less than a quorum, or
by the sole remaining director. However, a vacancy created by the removal of a
director by the vote of the shareowners or by court order may be filled only by
the affirmative vote of a majority of the voting power of shares represented
and voting at a duly held shareowner meeting at which a quorum is present
(which shares voting affirmatively also constitute a majority of the required
quorum).
HP's bylaws further provide that vacancies on the HP board of directors and
newly created directorships resulting from an increase in the authorized number
of directors elected by all of the HP shareowners having the right to vote as a
single class may be filled by a majority of the directors then in office,
although less than a quorum, or by a sole remaining director. However, whenever
the holders of any class or classes of stock, or any series of any class of
stock, are entitled to elect one or more directors by the provisions of HP's
certificate of incorporation, vacancies and newly created directorships of such
class or classes or series may be filled by a majority of the directors elected
by such class or classes or series then in office, or by a sole remaining
director so elected.
158
HP's bylaws also provide that if, at the time of filling any vacancy or any
newly created directorship, the directors then in office constitute less than a
majority of the whole HP board of directors (as constituted immediately prior
to any such increase), then the Delaware Court of Chancery may, upon
application of any shareowner(s) holding at least 10% of the total number of
the then outstanding shares having the right to vote for such directors,
summarily order an election to be held to fill any such vacancies or newly
created directorships, or to replace the directors chosen by the directors then
in office, and such election shall be governed by the provisions of Section 211
of the Delaware General Corporation Law as far as applicable.
Indigo's articles of association provide (1) that vacancies on the
management board may be filled by the shareholders at a general meeting of
shareholders, and (2) that vacancies on the supervisory board are filled either
by the shareholders at a general meeting of shareholders, or by the combined
board in accordance with the articles of association of Indigo.
Special Voting of Board of Directors
HP's bylaws provide that action by the board of directors may be taken by a
vote of the majority of the directors. HP's bylaws also provide that the HP
board of directors may delegate to its executive committee, or any other
committee of the HP board of directors, the authority to conduct all business
and to take all actions that may be taken by the HP board of directors unless
such delegation is not permitted under applicable law. However, no committee
shall have the power of authority to (1) approve or adopt or recommend to the
HP shareowners any action or matter that requires the approval of the HP
shareowners or (2) adopt, amend or repeal any bylaw of HP. HP's bylaws also
provide, subject to the limitation in the preceding sentence, that, unless the
full HP board of directors determines otherwise, the executive committee of the
HP board of directors shall have and may exercise all the powers and authority
of the HP board of directors in the management of the business and affairs of
the corporation.
Indigo's articles of association require that all resolutions of the
combined board shall be adopted by a majority of the votes cast, which vote
must include the vote of the chairman of the supervisory board.
Ability to Call Special Meetings of the Board of Directors
HP's bylaws provide that special meetings of the HP board of directors for
any purpose(s) may be called at any time by the chairman of the board of
directors, the vice chairman of the board of directors, the president, the
chairman of the executive committee, any vice president, the secretary or a
majority of the directors then in office.
Meetings of the management board may be called by the management board.
Indigo's articles of association provide (1) that meetings of the supervisory
board may be called by the chairman or two other supervisory board members and
(2) that the combined board shall meet whenever the chairmen or at least two
other board members deem such necessary, but at least four times a year.
Ability to Call Special Meetings of Shareowners
HP's bylaws provide that a special meeting of HP shareowners may be called
at any time by the HP board of directors, the chairman of the board of
directors, the vice chairman of the board of directors, the chairman of the
executive committee or the president, and special meetings of HP shareowners
may not be called by any other person(s).
Indigo's articles of association provide that a general meeting of the
shareholders may be convened by the combined board and that shareholders
representing in the aggregate at least one-tenth of the issued capital may
request the combined board to convene a general meeting of shareholders.
159
Limitations on Business Transacted at Meetings of Shareowners
HP's bylaws provide only such business shall be considered at a special
meeting of HP shareowners as shall have been stated in the notice for such
meeting.
Indigo's articles of association provide that business transacted at a
general meeting of Indigo shareholders is limited to the subjects specified in
the convocation or amendment at a later date in accordance with Indigo's
advance notice procedure unless the entire issued capital is represented at the
meeting and resolutions pertaining to business not specified in the convocation
are adopted unanimously.
Shareowner Nominations and Proposals at Shareowner Meetings
HP's bylaws allow shareowners to nominate candidates for election to the HP
board of directors at any annual meeting of HP shareowners. In addition, HP's
bylaws allow shareowners to propose business to be conducted at any annual
meeting of HP shareowners. However, nominations of candidates for election to
the HP board of directors and proposals for business to be conducted at an
annual meeting may only be made by a shareowner who has given timely written
notice to the corporate secretary of HP before the annual meeting.
Shareowner nominations of candidates for election to the HP board of
directors and proposals for business to be conducted at an annual meeting
cannot be brought before any annual meeting of HP shareowners unless the
nomination or proposal was brought before the annual meeting in accordance with
HP's shareowner advance notice procedures, as described in "Delivery and Notice
Requirements for Shareowner Nominations and Proposals" below.
Indigo's articles of association do not specify the procedure to nominate
candidates for election to Indigo's management board or supervisory board and
in the absence of specific provisions, such nomination takes place in
accordance with customary procedures under Dutch law. The combined board
convenes general meetings of shareholders and specifies the subjects to be
discussed at those meetings, including proposed members of the management board
or supervisory board. Furthermore, the combined board has the right to appoint
one supervisory board member (if the supervisory board consists of three, four
or five members) or two supervisory board members (if the supervisory board
consists of six or more members). Indigo's articles of association allow
shareholders representing at least one-tenth of the issued capital to propose
business to be brought before any shareholder meeting, including proposed new
members for the management board or the supervisory board. However, proposals
must be made by a shareholder in accordance with Indigo's advance notice
procedure.
Delivery and Notice Requirements for Shareowner Nominations and Proposals
HP's bylaws provide that for business to be properly brought before an
annual meeting of HP shareowners by an HP shareowner, or for a nomination of
candidates for election to the HP board of directors to be properly made by an
HP shareowner, such shareowner must have given timely notice of the proposal
for business to be conducted or of such nomination of candidates for election
to the HP board of directors in writing to the secretary of HP. To be timely,
notice of a proposal for business to be conducted at an annual meeting of HP
shareowners or of a nomination of candidates for election to the HP board of
directors must be delivered to, or mailed and received at, the principal
executive offices of HP during the earlier period to occur of (1) not later
than the close of business on the 90th day nor earlier than the close of
business on the 120th day prior to the first anniversary of the preceding
year's meeting, or (2) not less than the later of the close of business on the
45th day nor earlier than the close of business on the 75th day prior to the
first anniversary of the date on which HP first sent or gave its proxy
statement to shareowners for the preceding year's annual meeting. However, if
HP did not have an annual meeting of HP shareowners in the previous year or if
the date of the annual meeting is more than 30 days before or more than 60 days
after the anniversary date of the previous year's annual meeting, to be timely,
notice of a proposal for business to be conducted at an annual meeting of HP
shareowners or of a nomination of candidates for election to the HP board of
directors must be received not earlier than the close of business on the 120th
day prior to the meeting and not later than the close of business on the later
of (A) the 90th day prior to such meeting
160
and (B) the 10th day following the day HP publicly announces the date of the
annual meeting for the current year. In addition, for a proposal for business
to be conducted at an annual meeting, an HP shareowner must have delivered a
proxy statement and form of proxy to holders of a sufficient number of shares
of HP common stock to approve the proposal.
Indigo's articles of association provide that a general meeting of
shareholders shall be convened by the combined board and that shareholders
representing in the aggregate at least one-tenth of the issued capital may
request the combined board to convene a general meeting of shareholders. A
convocation letter, specifying the subjects to be discussed, must be mailed to
shareholders to their addresses shown in the register of shareholders. Such
convocation shall be given no later than on the fifteenth day prior to the date
of the meeting.
Shareowner Action by Written Consent in Lieu of a Shareowner Meeting
HP's certificate of incorporation provides that no action may be taken by HP
shareowners except at an annual or special meeting of the shareowners called in
accordance with HP's bylaws, and that HP shareowners may not take action by
written consent.
Indigo's articles of association provide that shareholders may take action
at annual general meetings of shareholders, or by written consent. A resolution
by written consent of Indigo shareholders must be adopted by the unanimous vote
representing the entire issued capital.
Amendment to Certificate of Incorporation and Articles of Association
Under Delaware General Corporation Law, a certificate of incorporation of a
Delaware corporation may be amended by approval of the board of directors of
the corporation and the affirmative vote of the holders of a majority of the
outstanding shares entitled to vote for the amendment, unless a higher vote is
required by the corporation's certificate of incorporation.
HP's certificate of incorporation contains does not contain provisions
requiring a vote greater than that required by Delaware General Corporation Law
to amend HP's certificate of incorporation.
Under Dutch law, articles of association may be amended by the general
meeting of shareholders in accordance with the procedures set out by law and in
the articles of association. Indigo's articles of association require that when
a proposal to amend the articles of association is to be made at a general
meeting of shareholders, such amendment must first be approved by the combined
board then be stated in the convocation regarding the meeting, a copy of the
proposed alteration quoted in full must be filed at Indigo's office until the
end of the meeting for inspection by the shareholders, and the amendment shall
require the approval of a majority of shareholders voting in person or by proxy
at the meeting.
Amendment to Bylaws
The HP board of directors is expressly authorized to make, alter, amend or
repeal HP's bylaws. HP's shareowners entitled to vote may also adopt, amend or
repeal HP's bylaws. However, HP's bylaws provide that the affirmative vote of
the holders of 66 2/3% of the outstanding shares entitled to vote thereon is
required to amend or delete the provisions of HP's bylaws relating to:
. meetings of shareowners;
. the number, election and term of directors;
. resignation and vacancies of directors;
. indemnification of officers and directors; and
. amendments to HP's bylaws.
161
Indigo's articles of association provide the basis for the management board
and the combined board to lay down further rules regarding its own decision
making process.
Payment of Expenses Incurred by Directors and Officers in Connection with
Legal Proceedings
HP's bylaws provide that HP shall advance to any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding (whether civil, criminal, administrative
or investigative), by reason of the fact that such person is or was a director
or officer of HP, prior to the final disposition of the proceeding, all
expenses incurred by such person in connection with such proceeding. However,
such payment will be made only if HP receives an undertaking by or on behalf of
such person to repay all amounts advanced if it is ultimately determined that
such person is not entitled to be indemnified by HP as authorized by HP's
bylaws or otherwise.
HP's bylaws also provide that HP shall not be required to advance expenses
to any director or officer in connection with any proceeding initiated by such
officer or director unless the proceeding was authorized in advance by the HP
board of directors.
In addition, subject to some exceptions, HP will not advance expenses to an
officer of HP (unless such officer is also a director of HP) in any action,
suit or proceeding (whether civil, criminal, administrative or investigative),
if a determination is reasonably and promptly made by the HP board of directors
by a majority vote of a quorum consisting of directors who were not parties to
the proceeding (or if such quorum is not obtainable, or even if obtainable, a
quorum of disinterested directors so directs, by independent legal counsel in a
written opinion), that the facts known to the decision-making party at the time
such determination is made demonstrate clearly and convincingly that such
person acted in bad faith or in a manner that such person did not believe to be
in or not opposed to the best interests of HP.
Indigo's articles of association provide that Indigo shall, to the full
extent permitted by Dutch law, advance expenses to each of its now acting and
former combined board members, officers, employees or agents whenever such
person is made a party or threatened to be made a party in an action, suit or
proceeding by reason of his/her service as such with Indigo.
Indemnification of Directors and Officers
HP's certificate of incorporation contains a provision eliminating the
personal liability of its directors to the company or its shareowners for
monetary damages for breach of fiduciary duty as a director to the fullest
extent permitted by applicable law. The effect of this provision is to
eliminate the personal liability of directors to the company or its
shareholders for monetary damages for actions involving a breach of their
fiduciary duty of care, including any actions involving gross negligence. The
bylaws of HP generally provide for the mandatory indemnification of, and
payment of expenses incurred by, its directors and officers to the fullest
extent permitted by applicable law unless the proceedings were initiated by the
director or officers and not authorized by the board of directors. The articles
of association of Indigo include a provision indemnifying, to the full extent
permitted by Dutch law, each of its now acting or former combined board
members, officers, employees or agents whenever such person is made a party or
threatened to be made a party in an action, suit or proceeding by reason of
his/her service as such for the company. There is no conclusive case law or any
other law or regulation that confirms that a company may indemnify its
management and supervisory board members under Dutch law. Each of HP and Indigo
also have obtained directors' and officers' liability insurance, which insures
against liabilities that its directors and officers may incur in such
capacities. HP and Indigo have also entered into indemnification agreements
with their respective directors and officers. The indemnification agreements
provide indemnification to these directors and officers under certain
circumstances for acts or omissions which may not be covered by directors' and
officers' liability insurance.
In addition, in accordance with the terms of the offer agreement and upon
completion of the exchange offer, HP has agreed to indemnify Indigo's officers
and directors, to the fullest extent provided under Indigo's articles
162
of association in effect immediately prior to the closing of the exchange offer
and any indemnification agreements as in effect on the date of the offer
agreement, as well as under applicable law until the sixth anniversary of the
closing of the exchange offer for all claims arising at or prior to the closing
of the exchange offer made against such officers or directors in their capacity
as such. HP has also agreed to maintain, at all times, assets sufficient to
satisfy its obligations with respect to such indemnification.
Section 145 of the General Corporation Law of the State of Delaware
authorizes a court to award or a corporation's board of directors to grant
indemnification to directors and officers in terms that are sufficiently broad
to permit indemnification under certain circumstances for liabilities
(including reimbursement for expenses incurred) arising under the Securities
Act of 1933. Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers or persons
controlling HP or Indigo pursuant to the foregoing provisions, HP has been
informed that, in the opinion of the Securities and Exchange Commission, such
indemnification is against public policy as expressed in the Securities Act of
1933 and is therefore unenforceable.
Shareowner Rights Plan
Under Delaware General Corporation Law, every corporation may create and
issue rights entitling the holders of such rights to purchase from the
corporation shares of its capital stock of any class or classes, subject to any
provisions in its certificate of incorporation. The price and terms of such
shares must be stated in the certificate of incorporation or in a resolution
adopted by the board of directors for the creation and issuance of such rights.
Under Dutch law, every Dutch corporation may issue rights entitling the
holders of such rights to subscribe for shares of such corporation's capital
stock of such class or classes as are defined in such corporation's articles of
association. The corporate body authorized to issue such shares will decide
upon the price of such shares and certain terms to the extent not defined in
the articles of association, including any exclusion or limitation of rights of
pre-emption. As of the date of this prospectus, Indigo has not entered into any
such shareholder rights agreement.
HP has entered into a shareowner rights agreement. The terms of the HP
rights agreement are complex and not easily summarized, particularly as they
relate to the acquisition of common stock and to exercisability. This summary
may not contain all of the information that is important to you. Accordingly,
you should carefully read the HP rights agreement, which is incorporated by
reference into this prospectus, in its entirety.
HP Shareowner Rights Plan
On August 31, 2001, the HP board of directors declared a dividend
distribution of one right for each outstanding share of HP common stock to HP
shareowners of record at the close of business on September 17, 2001. Each
right is subject to the terms of HP's rights agreement.
HP's rights agreement provides that each share of HP's outstanding common
stock will have the right to purchase one one-thousandth of a share of HP's
Series A Participating Preferred Stock at an exercise price of $180.00, subject
to adjustment. Each share of HP common stock issued in connection with the
exchange offer will have one right attached.
The rights under HP's rights agreement currently are attached to and trade
only together with outstanding certificates representing HP common stock. The
rights will separate from HP common stock and be represented by separate and
distinct certificates approximately ten days after someone acquires or
commences a tender offer for 15% or more of the outstanding HP stock.
After the rights separate from HP's common stock, certificates representing
the rights will be mailed to record holders of the common stock. Once
distributed, the rights certificates alone will represent the rights.
All shares of HP common stock issued prior to the date the rights separate
from the common stock will be issued with the rights attached. The rights are
not exercisable until the date the rights separate from the common stock. The
rights will expire on September 17, 2011 unless earlier redeemed or exchanged
by HP.
163
If an acquiror (which could be a person or group) obtains, or commences a
tender or exchange offer to obtain, 15% or more of HP common stock, then each
right will entitle the holder to purchase a number of shares of HP common stock
having a then current market value equal to two times the exercise price.
Each right will entitle the holder to purchase a number of shares of common
stock of the acquiring entity having a then current market value of twice the
purchase price if an acquiror obtains 15% or more of HP common stock and any of
the following occurs:
. HP merges into another entity;
. an acquiring entity merges into HP; or
. HP sells more than 50% of its assets or earning power.
Under HP's rights agreement, any rights that are or were owned by an
acquiror or its affiliates of more than 15% of HP's outstanding common stock
will be null and void.
HP's rights agreement provides that after an acquiror obtains 15% or more of
HP's outstanding common stock, but less than 50% of HP's outstanding common
stock, the HP board of directors may, at its option, exchange all or part of
the then outstanding and exercisable rights (other than rights owned by the
acquiror or its affiliates) for HP common stock. In such an event, the exchange
ratio is one common share per right, adjusted to reflect any stock split, stock
dividend or similar transaction.
At its option, the HP board of directors may redeem all of the outstanding
rights under the HP rights agreement at any time on or prior to the close of
business on the earlier of (1) the fifth day following the time that an
acquiror obtains 15% or more of HP's outstanding common stock or such later
date as may be determined by a majority of the board and publicly announced by
HP, or (2) September 17, 2011. The redemption price under HP's rights agreement
is $0.001 per right. The right to exercise the rights will terminate upon the
action of the HP board of directors ordering the redemption of the rights and
the only right of the holders of the rights will be to receive the redemption
price.
Holders of rights will have no rights as shareowners of HP, including
without limitation the right to vote or receive dividends, simply by virtue of
holding the rights.
The provisions of HP's rights agreement may be amended by the board of
directors prior to the date ten days after any person acquires 15% or more of
HP's common stock without approval of the holders of the rights. However, after
the date any person acquires 15% or more of HP's common stock, the rights
agreement may not be amended in any manner which would adversely affect the
interests of the holders of the rights, excluding any interests of the acquiror.
The rights issued under HP's rights agreement are designed to protect and
maximize the value of the outstanding equity interests in HP in the event of an
unsolicited attempt by an acquirer to take over HP in a manner or on terms that
are not approved by the HP board of directors. The rights are designed to deter
unfair tactics, including a gradual accumulation of shares in the open market
of a 15% or greater position, followed by a merger or a partial or two-tier
tender offer that does not treat all HP shareowners equally.
Subject to the restrictions described above, the rights may be redeemed by
HP at $0.001 per right at any time prior to the time when rights separate from
the common stock. Accordingly, the rights should not interfere with any merger
or business combination approved by the board of directors. The rights are not
intended to prevent a takeover of HP. However, the rights may have the effect
of rendering more difficult or discouraging an acquisition of HP deemed
undesirable by the HP board of directors. The rights may cause substantial
dilution to a person or group that attempts to acquire HP on terms or in a
manner not approved by the HP board of directors, except pursuant to an offer
conditioned upon redemption of the rights.
164
LEGAL MATTERS
Wilson Sonsini Goodrich & Rosati, Professional Corporation, Palo Alto,
California, will pass upon the validity of the shares of HP common stock
offered by this prospectus and certain federal income tax consequences of the
exchange offer.
EXPERTS
The consolidated financial statements and schedule of Hewlett-Packard
Company at October 31, 2001 and 2000 and for the years then ended, appearing in
Hewlett-Packard Company's Annual Report on Form 10-K for the year ended October
31, 2001, as amended on January 30, 2002, have been audited by Ernst & Young
LLP, independent auditors, as set forth in their report thereon included
therein and incorporated herein by reference. Such consolidated financial
statements and schedule are incorporated herein by reference in reliance upon
such report given on the authority of such firm as experts in accounting and
auditing.
The consolidated financial statements and schedule of Hewlett-Packard
Company for the year ended October 31, 1999 incorporated in this prospectus of
Hewlett-Packard Company by reference to the Annual Report on Form 10-K/A for
the year ended October 31, 2001, have been so incorporated in reliance on the
report of PricewaterhouseCoopers LLP, independent accountants, given on the
authority of said firm as experts in auditing and accounting.
The consolidated financial statements and schedule of Compaq Computer
Corporation at December 31, 2001 and 2000 and for the years then ended,
appearing in Compaq Computer Corporation's Annual Report on Form 10-K for the
year ended December 31, 2001, have been audited by Ernst & Young LLP,
independent auditors, as set forth in their reports thereon included therein
and incorporated herein by reference. Such consolidated financial statements
and schedule are incorporated herein by reference in reliance upon such reports
given on the authority of such firm as experts in accounting and auditing.
The consolidated financial statements and schedule of Compaq Computer
Corporation for the year ended December 31, 1999 incorporated in this
prospectus of Hewlett-Packard Company by reference to the Annual Report on Form
10-K for the year ended December 31, 2001, have been so incorporated in
reliance on the report of PricewaterhouseCoopers LLP, independent accountants,
given on the authority of said firm as experts in auditing and accounting.
The financial statements incorporated in this prospectus by reference to the
Annual Report of Indigo N.V. on Form 20-F for the year ended December 31, 2000
have been so incorporated in reliance on the report of Kesselman & Kesselman, a
member of PricewaterhouseCoopers International Limited, independent
accountants, given on the authority of said firm as experts in auditing and
accounting.
165
WHERE YOU CAN FIND MORE INFORMATION
This prospectus incorporates documents by reference which are not presented
in or delivered with this prospectus. You should rely only on the information
contained in this prospectus and in the documents that we have incorporated by
reference into this prospectus. We have not authorized anyone to provide you
with information that is different from or in addition to the information
contained in this document and incorporated by reference into this prospectus.
The following documents, which were filed by HP with the Securities and
Exchange Commission, are incorporated by reference into this prospectus:
. HP's annual report on Form 10-K for the fiscal year ended October 31,
2001, filed with the Securities and Exchange Commission on January 29,
2002 as amended on Form 10-K/A filed with the Securities and Exchange
Commission on January 30, 2002;
. HP's current report on Form 8-K, dated November 5, 2001, filed with the
Securities and Exchange Commission on November 6, 2001;
. HP's current report on Form 8-K, dated November 14, 2001, filed with the
Securities and Exchange Commission on November 14, 2001;
. HP's current report on Form 8-K, dated November 15, 2001, filed with the
Securities and Exchange Commission on November 16, 2001;
. HP's current report on Form 8-K, dated November 29, 2001, filed with the
Securities and Exchange Commission on November 30, 2001;
. HP's current report on Form 8-K, dated December 7, 2001, filed with the
Securities and Exchange Commission on December 7, 2001;
. HP's current report on Form 8-K, dated February 13, 2002, filed with the
Securities and Exchange Commission on February 14, 2002;
. HP's current report on Form 8-K, dated February 14, 2002, filed with the
Securities and Exchange Commission on February 14, 2002;
. The description of HP's common stock contained in its registration
statement on Form 8-A, filed with the Securities and Exchange Commission
on or about November 6, 1957 and any amendment or report filed with the
Securities and Exchange Commission for the purposes of updating such
description; and
. The description of HP's preferred share purchase rights contained in its
registration statement on Form 8-A, filed with the Securities and
Exchange Commission on or about September 4, 2001 and any amendment or
report filed with the Securities and Exchange Commission for the purpose
of updating such description.
The following documents, which were filed by Indigo with the Securities and
Exchange Commission, are incorporated by reference into this prospectus:
. Indigo's annual report on Form 20-F for its fiscal year ended December
31, 2000, filed with the Securities and Exchange Commission on June 28,
2001, as amended on Form 20-F/A filed with the Securities and Exchange
Commission on February 14, 2002;
. Indigo's report of foreign private issuer on Form 6-K, dated December 3,
2001, filed with the Securities and Exchange Commission on December 5,
2001; and
. Indigo's report of foreign private issuer on Form 6-K, dated February 1,
2002, filed with the Securities and Exchange Commission on February 1,
2002.
166
The following document, which was filed by Compaq with the Securities and
Exchange Commission, is incorporated by reference into this prospectus:
. Compaq's annual report on Form 10-K for the fiscal year ended December
31, 2001, filed with the Securities and Exchange Commission on January
30, 2002.
In addition, all documents filed by HP or Indigo pursuant to Section 13(a),
13(c), 14 or 15(d) of the Securities Exchange Act of 1934 after the date of
this prospectus and before the expiration of the exchange offer are deemed to
be incorporated by reference into, and to be a part of, this prospectus from
the date of filing of those documents.
Any statement contained in this prospectus or in a document incorporated or
deemed to be incorporated by reference into this prospectus will be deemed to
be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or any other subsequently filed document
that is deemed to be
incorporated by reference into this prospectus modifies or supersedes the
statement. Any statement so modified or superseded will not be deemed, except
as so modified or superseded, to constitute a part of this prospectus.
HP has supplied all information contained or incorporated by reference into
this prospectus about HP. Indigo has supplied all information contained or
incorporated by reference into this prospectus about Indigo. Compaq has
supplied all information contained or incorporated by reference into this
prospectus about Compaq.
The documents incorporated by reference into this prospectus are available
from us upon request. We will provide a copy of any and all of the information
that is incorporated by reference in this prospectus (not including exhibits to
the information unless those exhibits are specifically incorporated by
reference into this prospectus) to any person, without charge, upon written or
oral request. Any request for documents should be received by March 14, 2002 to
ensure timely delivery of the documents.
Indigo shareholders may request a copy of information incorporated by
reference into this prospectus by contacting the investor relations department
for each of HP, Indigo and Compaq at:
For information relating to HP: For information relating to Indigo: For information relating to Compaq:
Hewlett-Packard Company Indigo N.V. Compaq Computer Corporation
3000 Hanover Street c/o Indigo America, Inc. P.O. Box 692000
Palo Alto, California 94304 400 Unicorn Park Drive Houston, Texas 77269-2000
Attention: Investor Relations Woburn, Massachusetts 01801 Attention: Compaq Investor Relations,
(650) 857-1501 Attention: Investor Relations MS 110605
(781) 937-8999 (800) 433-2391
In addition, you may obtain copies of HP's information by making a request
through HP's investor relations website, http://www.hp.com/hpinfo/investor, or
sending an email to investor_relations@hp.com.
You may obtain copies of Indigo's information by sending an e-mail to
Michael King at indigoir@indigousa.com.
You may obtain copies of Compaq's information by making a request through
Compaq's investor relations website,
http://www.shareholder.com/cpq/document_request.cfm, or by sending an e-mail to
investor.relations@compaq.com.
HP and Compaq file annual, quarterly and current reports, proxy and
information statements and other information with the Securities and Exchange
Commission. Indigo files annual and current reports and other information with
the Securities and Exchange Commission. Copies of the reports, proxy and
information statements and other information filed by HP, Indigo and Compaq
with the Securities and Exchange Commission
167
may be inspected and copied at the public reference facilities maintained by
the Securities and Exchange Commission at:
450 Fifth Street, N.W.
Washington, D.C. 20549
Reports, proxy and information statements and other information concerning
HP and Compaq may be inspected at:
New York Stock Exchange
20 Broad Street
New York, New York 10005
Reports and other information concerning Indigo may be inspected at:
National Association of Securities Dealers
1735 K Street, N.W.
Washington, D.C. 20006
Copies of these materials can also be obtained by mail at prescribed rates
from the Public Reference Section of the Securities and Exchange Commission,
450 Fifth Street, N.W., Washington, D.C. 20549 or by calling the Securities and
Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission
maintains a website that contains reports, proxy statements and other
information regarding HP. The address of the Securities and Exchange Commission
website is http://www.sec.gov.
HP has filed a registration statement on Form S-4 under the Securities Act
of 1933 with the Securities and Exchange Commission with respect to HP's common
stock and the CVRs to be issued to Indigo shareholders in connection with the
exchange offer. HP, Indigo and Benzion Landa also have filed a transaction
statement on Schedule 13E-3 under the Exchange Act with the Securities and
Exchange Commission. HP also has filed a tender offer statement on Schedule TO
under the Exchange Act with the Securities and Exchange Commission with respect
to the exchange offer. This prospectus, or portions hereof, constitutes the
prospectus of HP filed as part of the registration statement and contained as
an exhibit or incorporated by reference into the transaction statement on
Schedule 13E-3 and the tender offer statement on Schedule TO. This prospectus
does not contain all of the information set forth in the registration statement
and the transaction statement on Schedule 13E-3 and the tender offer statement
on Schedule TO and respective exhibits thereto because certain parts of the
registration statement, the transaction statement on Schedule 13E-3 and the
tender offer statement on Schedule TO are omitted in accordance with the rules
and regulations of the Securities and Exchange Commission. The registration
statement, the transaction statement on Schedule 13E-3 and the tender offer
statement on Schedule TO and respective exhibits thereto are available for
inspection and copying as set forth above.
Indigo shareholders should contact Georgeson Shareholder at the address,
telephone number or Internet address listed below with any questions about the
exchange offer:
Georgeson Shareholder
111 Commerce Road
Carlstadt, New Jersey 07072
Indigo@Georgeson.com
Banks and Brokers please call (201) 896-1900
Shareholders in North America call toll-free (866) 233-9045
Shareholders outside of North America call (212) 806-6741
UNIX(R) is a registered trademark of The Open Group. Compaq is a trademark
of Compaq Information Technologies Group, L.P. in the United States and other
countries.
168
INDIGO N.V. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
INDEX
Page(s)
-------
Condensed Consolidated Interim Statements of Operations of Indigo N.V. and Subsidiaries for the
three months and nine months ended September 30, 2001 (unaudited) and 2000 (unaudited)......... F-2
Condensed Consolidated Interim Balance Sheets of Indigo N.V. and Subsidiaries as of September 30,
2001 (unaudited) and December 31, 2000......................................................... F-3
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity of Indigo N.V. and
Subsidiaries for the nine months ended September 30, 2001 (unaudited).......................... F-4
Condensed Consolidated Interim Statements of Cash Flows of Indigo N.V. and Subsidiaries for the
nine months ended September 30, 2001 (unaudited) and 2000 (unaudited).......................... F-5-6
Notes to Condensed Consolidated Interim Financial Statements of Indigo N.V. and Subsidiaries
(unaudited).................................................................................... F-7-13
F-1
INDIGO N.V. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
(In thousands and in U.S. Dollars, except loss per common share)
(unaudited)
Three months ended Nine months ended
September 30, September 30,
------------------ ------------------
2001 2000 2001 2000
-------- -------- -------- --------
Revenues:
Equipment..................................................... $ 23,701 $ 20,816 $ 76,659 $ 64,831
Post-sales.................................................... 20,349 17,878 58,077 50,617
-------- -------- -------- --------
Total revenues............................................ 44,050 38,694 134,736 115,448
-------- -------- -------- --------
Costs and expenses:
Cost of equipment............................................. 16,982 11,502 53,040 39,575
Cost of post-sales............................................ 10,337 7,663 27,522 22,179
Research and development, net................................. 3,831 5,314 13,044 14,487
Selling, general and administrative........................... 20,933 16,341 55,910 51,111
-------- -------- -------- --------
Total costs and expenses.................................. 52,083 40,820 149,516 127,352
-------- -------- -------- --------
Operating loss................................................... (8,033) (2,126) (14,780) (11,904)
Interest and other income, net................................... 1,065 219 2,450 206
-------- -------- -------- --------
Loss before provision for income taxes........................... (6,968) (1,907) (12,330) (11,698)
Provision for income taxes....................................... 10 464 135 828
-------- -------- -------- --------
Net loss before cumulative effect of an accounting change........ (6,978) (2,371) (12,465) (12,526)
Cumulative effect, at beginning of year, of an accounting change,
net............................................................ -- -- -- (1,935)
-------- -------- -------- --------
Net loss before dividend requirements............................ (6,978) (2,371) (12,465) (14,461)
Dividend on convertible preferred shares:
Current....................................................... -- (2,931) -- (8,793)
Inducement regarding conversion of Series A Preferred
Shares...................................................... -- (58,685) -- (58,685)
-------- -------- -------- --------
Net loss applicable to common shares outstanding................. $ (6,978) $(63,987) $(12,465) $(81,939)
======== ======== ======== ========
Basic and diluted weighted average number of common shares
outstanding.................................................... 110,269 79,312 110,418 78,816
======== ======== ======== ========
Basic and diluted loss per common share before cumulative effect
of an accounting change, net................................... $ (0.06) $ (0.81) $ (0.11) $ (1.01)
======== ======== ======== ========
Basic and diluted loss per common share of cumulative effect of
an accounting change, net...................................... -- -- -- $ (0.03)
======== ======== ======== ========
Basic and diluted loss per common share after cumulative effect
of an accounting change, net................................... $ (0.06) $ (0.81) $ (0.11) $ (1.04)
======== ======== ======== ========
See notes to condensed consolidated financial statements (unaudited).
F-2
INDIGO N.V. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
(In thousands and in U.S. Dollars, except share par value amounts)
(unaudited)
September 30, December 31,
2001 2000
------------- ------------
ASSETS
Current assets:
Cash and cash equivalents............................................................... $ 18,845 $ 47,458
Restricted cash......................................................................... 101 330
Short term deposits and marketable securities........................................... 48,482 47,255
Accounts receivable:
Trade, net of allowance for doubtful accounts........................................ 34,908 35,018
Other................................................................................ 3,493 3,874
Inventories............................................................................. 47,434 47,776
Other current assets.................................................................... 2,496 2,222
--------- ---------
Total current assets.............................................................. 155,759 183,933
Marketable securities, long-term............................................................ 9,498 --
Accounts receivable, long-term.............................................................. 2,311 1,848
Investments--amounts funded for employee rights upon retirement............................. 7,347 6,886
Property and equipment, net................................................................. 25,991 23,021
Other assets, net........................................................................... 819 1,092
--------- ---------
Total assets...................................................................... $ 201,725 $ 216,780
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable, trade................................................................. $ 20,454 $ 25,454
Accrued expenses........................................................................ 27,456 30,981
Loans payable, short-term............................................................... 18,374 5,428
Income taxes payable.................................................................... 1,359 906
Deferred revenue........................................................................ 6,197 6,844
Other current liabilities............................................................... 3,208 5,769
--------- ---------
Total current liabilities......................................................... 77,048 75,382
Liability for employee rights upon retirement............................................... 11,951 11,167
Other liabilities........................................................................... 5,192 5,834
--------- ---------
Total liabilities................................................................. 94,191 92,383
--------- ---------
Commitments and contingencies (note 5)
Shareholders' equity:
Common shares, NLG 0.04 par value; 240,000 shares authorized:
113,790 and 113,182 issued and outstanding on September 30, 2001 and on
December 31, 2000, respectively........................................................ 2,282 2,273
Preferred shares, NLG 0.04 par value; 26,950 authorized on September 30, 2001 and
December 31, 2000...................................................................... -- --
Additional paid-in capital.............................................................. 549,494 547,978
Accumulated deficit..................................................................... (418,251) (405,786)
Accumulated other comprehensive loss.................................................... (77) (68)
Common shares held in treasury, at cost: 3,765 and 2,751 shares on September 30, 2001
and on December 31, 2000, respectively................................................. (25,914) (20,000)
--------- ---------
Total shareholders' equity........................................................ 107,534 124,397
--------- ---------
Total liabilities and shareholders' equity........................................ $ 201,725 $ 216,780
========= =========
See notes to condensed consolidated financial statements (unaudited).
F-3
INDIGO N.V. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF
CHANGES IN SHAREHOLDERS' EQUITY
For the nine months ended September 30, 2001
(In thousands and in U.S. Dollars, except number of shares)
(unaudited)
Accumulated
Additional Other Total
Common Paid-in Comprehensive Accumulated Treasury Shareholders'
Shares Capital Loss Deficit Shares Equity
------ ---------- ------------- ----------- -------- -------------
Balance at January 1, 2001............................ $2,273 $547,978 $(68) $(405,786) $(20,000) $124,397
Comprehensive loss:
Net loss........................................... (12,465) (12,465)
Other comprehensive loss--
Realized loss on derivatives designated as
cash flow hedge.............................. 68 68
Unrealized loss on derivatives designated
as cash flow hedge........................... (77) (77)
--------
Total comprehensive loss*.......................... (12,474)
--------
Issuance of 252,475 common shares in connection
with the exercise of Employee Share Purchase
Plan................................................ 3 455 458
Issuance of 355,463 common shares in connection
with the exercise of stock options, net of
stock issuance costs................................ 6 1,061 1,067
Purchase of 1,013,500 Treasury shares................. (5,914) (5,914)
------ -------- ---- --------- -------- --------
Balance at September 30, 2001......................... $2,282 $549,494 $(77) $(418,251) $(25,914) $107,534
====== ======== ==== ========= ======== ========
--------
* Total comprehensive loss for the three month periods ended September 30,
2001 and September 30, 2000 and for the nine month periods ended September
30, 2000 are: $7,101,000, $2,450,000, $14,420,000, respectively.
See notes to condensed consolidated financial statements (unaudited).
F-4
INDIGO N.V. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(In thousands and in U.S. Dollars)
(unaudited)
Nine Months Ended
--------------------------
September 30, September 30,
2001 2000
------------- -------------
Cash flows from operating activities:
Net loss................................................................... $(12,465) $(14,461)
Adjustments to reconcile net loss to net cash flows used in
operating activities:
Depreciation, amortization and write-off of property and equipment..... 6,185 5,032
Cumulative effect of an accounting change.............................. -- 1,935
Provision for doubtful accounts........................................ 794 688
Changes in assets and liabilities:
Decrease (increase) in accounts receivable............................. (2,151) 2,599
Decrease (increase) in inventories..................................... 2,582 (12,351)
Decrease (increase) in other current assets............................ (274) 760
Increase (decrease) in accounts payable and accrued expenses........... (6,313) 6,289
Decrease in customer advances.......................................... -- (197)
Increase (decrease) in taxes payable................................... 453 (160)
Decrease in deferred revenue........................................... (647) (1,416)
Decrease in other current liabilities.................................. (2,561) --
Increase in liability for employee rights upon retirement.............. 784 1,957
Increase (decrease) in other liabilities............................... (642) 97
Loss (gain) from short term investments and marketable securities...... 68 (133)
-------- --------
Net cash flows used in operating activities......................... (14,187) (9,361)
-------- --------
Cash flows from investing activities:
Capital expenditures....................................................... (11,375) (8,789)
Decrease in restricted cash................................................ 229 83
Amount funded for employee rights upon retirement.......................... (461) (766)
Proceeds from maturity of short term deposits and marketable securities.... 32,216 17,038
Purchase of short term deposits and marketable securities.................. (41,848) (28,587)
-------- --------
Net cash flows used in investing activities......................... (21,239) (21,021)
-------- --------
Cash flows from financing activities:
Short-term loans payable................................................... 12,946 (1,702)
Purchase of treasury shares................................................ (5,914) --
Proceeds from exercise of warrants......................................... -- 1,453
Proceeds from exercise of stock options and Employee Stock Purchase Plan... 1,819 1,842
Stock issuance costs....................................................... (2,038) (33)
-------- --------
Net cash flows provided by financing activities..................... 6,813 1,560
-------- --------
Net decrease in cash and cash equivalents..................................... (28,613) (28,822)
Cash and cash equivalents, beginning of period................................ 47,458 40,690
-------- --------
Cash and cash equivalents, end of period...................................... $ 18,845 $ 11,868
======== ========
See notes to condensed consolidated financial statements (unaudited).
F-5
INDIGO N.V. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS--(Continued)
(In thousands and in U.S. Dollars)
(unaudited)
Non-cash transactions:
As of September 30, 2001 and 2000, the Company acquired additional property
and equipment for $405 and $449, respectively, which had not been paid as of
that date.
In September 2000, the Company issued a share dividend of $104,867 in
connection with the conversion of Series A Preferred Shares.
As of September 30, 2001 and 2000, the Company issued $366 and $216
respectively, share capital in connection with the exercise of stock options,
which had not been paid as of that date.
See notes to condensed consolidated financial statements (unaudited).
F-6
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(unaudited)
1. Basis of Presentation
Indigo N.V., a Netherlands company, and its wholly-owned subsidiaries (the
"Company" or "Indigo"), develop, manufacture and market proprietary Digital
Offset Color(TM) printing presses used in the production of on-demand,
short-run color digitally-printed products. The Company's presses are primarily
targeted towards the commercial and industrial markets. The Company also
manufactures a number of presses which are marketed through OEM channels. The
Company also develops, manufactures and markets consumable products for use in
its presses and provides service to its customers, activities referred to in
these financial statements as "Post-sales" activities. The Company markets
products directly and through distributors in Europe, through a wholly-owned
subsidiary in the United States and through distributors in other parts of the
world. The Company conducts its research and development and manufacturing
activities through a wholly-owned subsidiary in Israel.
The Condensed Consolidated Interim Financial Statements included herein are
unaudited and include all adjustments that management considers necessary for a
fair presentation of the results of operations of the interim periods pursuant
to the rules and regulations of the Securities and Exchange Commission. Certain
information and footnote disclosures normally included in financial statements
prepared in accordance with generally accepted accounting principles in the
United States have been condensed or omitted. These Condensed Consolidated
Interim Financial Statements should be read in conjunction with the Company's
Consolidated Financial Statements and related notes for the year ended December
31, 2000. The results of operations for the three months and nine months ended
September 30, 2001 and 2000 are not necessarily indicative of the operating
results for the full year.
Starting in the third quarter of 2001, the Company classifies its royalty
payments to the Government of Israel, resulting from research and development
grants (see note 5b) to cost of goods sold. Previously, Indigo classified these
royalty payments to selling, general and administrative expenses. The
comparative figures in these interim financial statements have been
reclassified accordingly.
Revenue recognition
(1) Equipment sales
Effective January 1, 2000 and pursuant to Securities and Exchange
Commission, Staff Accounting Bulletin No. 101, "Revenue Recognition in
Financial Statements," the Company has implemented a change in its revenue
recognition policy that has added installation as a requirement for recognition
of direct sales of equipment. Previously, the Company had recognized revenue
upon shipment of equipment, as installation being perfunctory, provided
collectibility is reasonably assured, future obligations of the Company are
considered insignificant and the costs of such obligations can be reasonably
estimated. Under the new policy, revenue on sales of equipment to customers is
recognized upon installation at the customer's site, where applicable, provided
collectibility is reasonably assured, future obligations of the Company are
considered insignificant and the costs of such obligations can be reasonably
estimated.
Revenue on sales of equipment to distributors is recognized upon delivery,
provided collectibility is reasonably assured, future obligations of the
Company are considered insignificant and the costs of such obligations can be
reasonably estimated.
Sales of equipment that do not initially meet the criteria for recognition
are recognized when all such criteria are met.
The cumulative effect of the change as of January 1, 2000, recorded in the
Statements of Operations for the year 2000, was an increase of the net loss
amounted to $1,935,000.
F-7
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENT--(Continued)
(unaudited)
Revenue from sales to leasing companies for lease to third party end-users
is recognized according to the policy of revenue recognition of equipment sales
as described above. In certain leasing transactions, the leasing company is
obligated to pay the Company an additional amount in excess of the purchase
price of the equipment if the third party performs fully under the leasing
arrangement; such additional revenue is recognized when realized.
Customer deposits and other payments received prior to sales recognition are
included in customer advances and deferred revenue in the consolidated balance
sheets.
(2) Post-sales
Post-sales revenues include revenues from imaging products, service and
click charges. Revenues from post-sale activities are generally recognized upon
shipment for products and usage for click charges. Revenues from customer
service contracts are recognized ratably over the contract period or as
services are performed.
2. HP acquisition
On September 6, 2001, Indigo N.V. and Hewlett Packard Company ("HP") entered
into an agreement pursuant to which HP or a subsidiary of HP to be formed will
offer to acquire all of the outstanding equity of Indigo not already owned by
HP in exchange for a combination of shares of HP stock and non-transferable
contingent value rights (CVRs) entitling the holder to a contingent cash
payment based on the achievement of certain revenue milestones. In exchange for
each share of Indigo stock, shareholders of Indigo will receive either $7.50 in
HP common stock, or $6.00 in HP common stock plus one CVR entitling its holder
to a cash payment of up to $4.50 per share if HP consolidated net revenues from
LEP Digital Press Products and Consumables (as such terms are defined in the
CVR agreement) achieve a total of $1.6 billion in revenue over a three-year
post-closing period. The value of each CVR increases linearly from $0 to $4.50
as cumulative revenues increase from $1.0 billion to $1.6 billion.
The HP common stock to be issued in each case will be determined based on
the average closing price during the 20 trading days ending three trading days
prior to expiration of the offer, with the average trading price to be used in
such calculation not to be less than $16.69 or more than $23.68. The agreement
provides that the total number of Indigo common shares that may be exchanged
for each consideration alternative is limited. The exchange represents a deal
valued at approximately $629 million in HP common stock (based on the closing
price of HP shares on September 5, 2001) as well as a maximum contingent cash
payment of approximately $253 million.
If HP terminates the exchange offer due to the occurrence of a triggering
event, which would include the Indigo boards' approval or recommendation of any
other acquisition proposal, the withholding, withdrawal, amendment or
modification of the Indigo boards' recommendation in favor of the exchange
offer, or failure to recommend rejection of any other third party tender or
exchange offer, Indigo will be required to pay HP a termination fee of $27
million and reimburse HP for expenses of up to $2 million.
The acquisition is subject to a 95% minimum exchange condition, customary
closing conditions and normal regulatory reviews.
F-8
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENT--(Continued)
(unaudited)
3. Inventories
Inventories consist of the following:
September 30, December 31,
2001 2000
------------- ------------
(In thousands and in
U.S. Dollars)
Raw Materials.................................... $15,238 $13,512
Work in Process.................................. 8,064 10,940
Finished Goods................................... 24,132 23,324
------- -------
$47,434 $47,776
======= =======
4. Loans payable
During 2001, Indigo signed three new independent agreements with two major
Israeli banks and with Citibank. The total bank facilities (including an
existing facility with a third Israeli bank) provide for total advances up to
$50 million. The facilities expire on various dates during 2002. Indigo has the
option to extend certain of the facilities, upon the fulfillment of certain
requirements.
5. Contingencies and royalty commitments to the Government of Israel
a. One of Indigo's Israeli subsidiaries is party to a dispute regarding the
amount of rent payable pursuant to a long-term lease for a tract of land
adjacent to Indigo's manufacturing facilities in Nes-Ziona, Israel. The dispute
involves issues of contract interpretation and real estate appraisal.
Arbitration proceedings commenced in March 1998, and in August 1999 the
arbitrator issued his decision, which was invalidated by the Tel Aviv District
Court in June 2001. In July 2001, the landlord petitioned Israel's Supreme
Court for permission to appeal the District Court's ruling, and in October
2001, Indigo's subsidiary filed its response to such petition. In the event
that the parties are unable to resolve the dispute amicably, Indigo intends to
continue to defend the claim vigorously, since the Company believes that the
amount of rent sought by the landlord is unreasonable and not supported by the
terms of the lease. The maximum exposure regarding this claim would not have a
significant effect on the Company's financial position or its results of
operations.
b. The Company is committed to pay royalties to the Government of Israel
relating to research and development grants received from the Office of the
Chief Scientist ("OCS") of the Israeli Ministry of Industry and Trade. At the
time the grants were received, successful development of the related project
was not assured. The royalty rate is 3%-3.5% of either 50% or 100% of sales of
the products, until the cumulative amount of the royalties equals 100% of the
grants received; as from January 1, 1998 for research and development grants
with the addition of an annual interest rate based on LIBOR. Repayment of such
grants is not required in the event that there are no sales of product with
respect to such grants. At September 30, 2001, the Company had received and
accrued cumulative grants, net of royalties paid and accrued, of approximately
$23 million (see however note 10 to the Condensed Consolidated Interim
Financial Statements).
c. Assuming consummation of the acquisition of Indigo by HP (see note 2),
Indigo has agreed to pay certain deal-related expenses of approximately $10.0
million relating to legal, investment banking and severance liabilities.
d. See note 2 regarding the possibility of a triggering event that will
require Indigo to pay up to $29 million to HP.
F-9
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENT--(Continued)
(unaudited)
6. Segment information
The company has two reportable segments: Equipment and Post-sales
Activities. The Equipment segment produces printing presses used in the
production of on-demand, short-run color digitally-printed products. The
Post-sales Activities segment produces imaging products and service products
that are consumed by the Equipment sold.
The accounting policies of the segments are the same as those described in
the summary of significant accounting policies (see note 2 in the 2000
Consolidated Financial Statements). The Company does not allocate assets other
than inventories to segments. The Company evaluates performance based on gross
margin.
Segment Revenues, Gross Margins for the three months ended:
September 30, 2001 September 30, 2000
---------------------------- ----------------------------
Equipment Post-sales Total Equipment Post-sales Total
--------- ---------- ------- --------- ---------- -------
(In thousands and in U.S. Dollars)
Revenues........... $23,701 $20,349 $44,050 $20,816 $17,878 $38,694
Gross Margin....... 6,719 10,012 16,731 9,314 10,215 19,529
Segment Revenues and Gross Margins for the nine months ended:
September 30, 2001 September 30, 2000
----------------------------- -----------------------------
Equipment Post-sales Total Equipment Post-sales Total
--------- ---------- -------- --------- ---------- --------
(In thousands and in U.S. Dollars)
Revenues....... $76,659 $58,077 $134,736 $64,831 $50,617 $115,448
Gross Margin... 23,619 30,555 54,174 25,256 28,438 53,694
Reconciliation of segment revenues and loss before provision for income taxes
to the Company's consolidated totals for the three months ended September 30:
2001 2000
------- -------
(In thousands and in
U.S. Dollars)
Revenues
Total revenues for reportable segments................ $44,050 $38,694
------- -------
Total consolidated revenues........................ $44,050 $38,694
======= =======
Loss before provision for income taxes
Total Gross Margin of reportable segments............. $16,731 $19,529
Research and Development, net......................... 3,831 5,314
Selling, general and administrative................... 20,933 16,341
------- -------
Operating loss........................................ (8,033) (2,126)
Interest and other income, net........................ 1,065 219
------- -------
Loss before provision for income taxes................ $(6,968) $(1,907)
======= =======
F-10
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENT--(Continued)
(unaudited)
Reconciliation of segments revenues and loss before provision for income taxes
to the Company's consolidated totals for the nine months ended September 30:
2001 2000
-------- --------
(In thousands and in
U.S. Dollars)
Revenues
Total revenues for reportable segments................ $134,736 $115,448
-------- --------
Total consolidated revenues........................ $134,736 $115,448
======== ========
Loss before provision for income taxes
Total Gross Margin of reportable segments............. $ 54,174 $ 53,694
Research and Development, net......................... 13,044 14,487
Selling, general and administrative................... 55,910 51,111
-------- --------
Operating loss........................................ (14,780) (11,904)
Interest and other income, net........................ 2,450 206
-------- --------
Loss before provision for income taxes................ $(12,330) $(11,698)
======== ========
7. Derivatives and hedging activities
Effective October 1, 2000, the Company adopted Statement of Financial
Accounting Standards ("SFAS") No. 133, "Accounting for Derivative Instruments
and Hedging Activities," as amended, which requires that all derivative
instruments be reported on the balance sheet at fair value and establishes
criteria for designation and effectiveness of transactions entered into for
hedging purposes.
The Company is exposed to market risk, such as fluctuations in foreign
currency exchange rates and changes in interest rates. To manage the volatility
relating to these exposures, the Company aggregates the exposure on a
consolidated basis to take advantage of natural offsets. For exposures that are
not offset within the Company's operations, the Company enters into various
derivative transactions pursuant to its risk management policies. Designation
is performed on a transaction basis to support hedge accounting. The changes in
fair value of these hedging instruments are offset in part or in whole by
corresponding changes in the fair value or cash flows of the underlying
exposures being hedged. The Company assesses the initial and ongoing
effectiveness of its hedging relationships in accordance with its documented
policy. Indigo does not hold or issue derivative financial instruments for
trading purposes.
Gains and losses on derivatives qualifying as cash flow hedges, as defined
in SFAS No. 133, are recorded in other comprehensive income ("OCI") to the
extent that hedges are effective until the underlying transactions are
recognized in earnings. Net losses included in OCI as of September 30, 2001
were $77 thousands.
8. Basic and diluted loss per common share
Basic net loss per share is computed by dividing the net loss available to
common shareholders for the period by the weighted average number of common
shares outstanding during the period. The calculation of diluted net loss per
share excludes potential common shares if the effect is antidilutive. Potential
common shares consist of incremental common shares issuable upon the exercise
of stock options and warrants.
As of September 30, 2001, 17,144,162 potential common shares issuable upon
exercise of outstanding stock options and warrants, and 26,814,815 potential
common shares issuable upon exercise of warrants held by HP
F-11
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENT--(Continued)
(unaudited)
and HP affiliates have been excluded from the determination of diluted net loss
per share, as their inclusion would have been antidilutive.
9. Recently issued accounting pronouncements
In July 2001, the FASB issued Statement of Financial Accounting Standard No
141 (FAS 141), Business Combinations, and No. 142 (FAS 142), Goodwill and Other
Intangible Assets. FAS 141 supersedes Accounting Principles Board Opinion No.
16 (APB 16), Business Combinations, and FAS 142 supersedes APB 17, Intangible
Assets.
The most significant changes made by FAS 141 are: (1) requiring that the
purchase method of accounting be used for all business combinations initiated
after June 30, 2001, (2) establishing specific criteria for the recognition of
intangible assets separately from goodwill and (3) requiring unallocated
negative goodwill to be written off immediately as an extraordinary gain
(instead of being deferred and amortized).
The most significant changes made by FAS 142 are: (1) goodwill and
indefinite lived intangible assets will no longer be amortized, (2) goodwill
will be tested for impairment at least annually at the reporting unit level,
(3) intangible assets deemed to have an indefinite life will be tested for
impairment at least annually, and (4) the amortization period of intangible
assets with finite lives will no longer be limited to forty years. In addition,
FAS 142 contains certain transitional provisions, which may effect the
classification of intangible assets as well as the balance of goodwill. The
provisions for FAS 141 are effective for acquisitions consummated after June
30, 2001. The provisions of FAS 142 are effective for fiscal years beginning
after December 15, 2001 (fiscal year 2002 for the Company). Management is
currently assessing the impact of the adoption of these new pronouncements.
In July 2001, the FASB approved the issuance of FAS 143, "Accounting for
Asset Retirement Obligations." FAS 143 prescribes the accounting for retirement
obligations associated with tangible long-lived assets, including the timing of
liability recognition and initial measurement of the liability. FAS 143
requires that an asset retirement cost should be capitalized as part of the
cost of the related long-lived asset and subsequently allocated to expense
using a systematic and rational method. FAS 143 is effective for fiscal years
beginning after June 15, 2002 (January 1, 2003 for the Company).
In August 2001, the FASB issued FAS 144, "Accounting for the impairment or
Disposal of Long-Lived Assets," which is effective for fiscal periods beginning
after December 15, 2001 (January 1, 2002 for the Company) and interim periods
within those years. FAS 144 establishes an accounting model for impairment or
disposal of long-lived assets to be disposed of by sale.
The Company is currently evaluating the potential effects, if any, that the
adoption of these standards may have on its consolidated financial statements.
10. Post balance sheet event--prepayment of royalties to the government of
Israel subsequent to September 30, 2001
In October 2001, pursuant to a special OCS-initiated program aimed at large
companies, Indigo applied to make a discounted prepayment of future royalties,
which would end its obligation to make royalty payments for past grants
received (see note 5b).
F-12
INDIGO N.V. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENT--(Continued)
(unaudited)
In December 2001, Indigo reached an agreement with the OCS for the early
prepayment of royalties. Pursuant to the agreement, Indigo paid the OCS
approximately $15 million in 2002 in settlement of potential future royalty
obligations.
Indigo's prepayment of future royalties will end Indigo's obligation to make
royalty payments with respect to grants received from the OCS during the years
1993-2001, and will enable Indigo to join an OCS-funded program for the
development of generic projects with no royalty payment obligations.
F-13
SCHEDULE I
INFORMATION CONCERNING DIRECTORS
AND EXECUTIVE OFFICERS OF HP
The following table sets forth the name, age and present principal
occupation or employment, and material occupations, positions, offices or
employment for the past five years, of each director and executive officer of
HP. Unless otherwise indicated, the business address and telephone number of
each such person is Hewlett-Packard Company, 3000 Hanover Street, Palo Alto,
California 94304, (650) 857-1501.
During the last five years, neither HP, nor, to the best of HP's knowledge,
any of the persons listed below:
. Has been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors); or
. Was a party to any judicial or administrative proceeding (except for
matters that were dismissed without sanction or settlement) that
resulted in a judgment, decree or final order enjoining the person from
future violations of, or prohibiting activities subject to, federal or
state securities laws, or a finding of any violation of such laws.
Other than Iain Morris, who is a citizen of the United Kingdom, each of the
persons listed below is a citizen of the United States.
Name and Business Address Age Present Principal Occupation or Employment and Five Year Employment History
------------------------- --- ---------------------------------------------------------------------------
Carleton S. Fiorina* 47 Chairman of the Board, President and Chief Executive Officer.
Ms. Fiorina became Chairman of the Board in September 2000 and was
named President, Chief Executive Officer and director of HP in July 1999.
Prior to joining HP, she served as Executive Vice President, Computer
Operations for Lucent Technologies, Inc. and oversaw the formation and
spin-off of Lucent from AT&T. She also served as Lucent's President,
Global Service Provider Business and President, Consumer Products.
Ms. Fiorina is a member of the Board of Directors of Cisco Systems, Inc.
Susan D. Bowick 53 Vice President and Director, Corporate Human Resources.
Ms. Bowick was elected a Vice President in November 1999. Between
1995 and 1997, she served as Business Personnel Manager for the
Computer Organization. She was first appointed a Vice President in 1997.
Richard A. DeMillo 55 Vice President and Chief Technology Officer.
Dr. DeMillo was appointed Chief Technology Officer in October 2000 and
was elected a Vice President in November 2000. From 1995 to 2000, he
was Vice President and General Manager at Telcordia Technologies, Inc.,
a provider of operations support systems, network software and consulting
and engineering services to the telecommunications industry. At Telcordia,
Dr. DeMillo was responsible for computer science research, internet
systems and software strategy.
Debra L. Dunn 45 Vice President, Strategy and Corporate Operations.
Ms. Dunn was elected a Vice President in November 1999. She previously
held the position of General Manager of the Executive Staff from 1998 to
1999. From 1996 to 1998 she was General Manager of the Video
Communications Division.
I-1
Name Age Present Principal Occupation or Employment and Five Year Employment History
---- --- ---------------------------------------------------------------------------
Jon E. Flaxman 44 Vice President and Controller.
Mr. Flaxman was elected a Vice President and Controller in July 2001. He
was General Manager of Computer Logistics and Distribution from 1997 to
1998. From 1998 to December 2000, he was Vice President and Chief
Financial Officer of the Enterprise Computing Business/Business Customer
Organization, and from December 2000 to June 2001 he was Vice President
of Infrastructure Reinvention. He was first appointed a Vice President in
1998.
Vyomesh Joshi 47 President, Imaging and Printing Systems.
Mr. Joshi was elected a Vice President in January 2001. He became
President of Imaging and Printing Systems in February 2001. Mr. Joshi
also is Chairman of Phogenix Imaging LLC, a joint venture between HP
and Kodak. From 1995 to 2000, he held various management positions in
Imaging and Printing Systems. Mr. Joshi was first appointed a Vice
President in 1999.
Pradeep Jotwani 47 President, Consumer Business Organization.
Mr. Jotwani was elected a Vice President in September 2000 and became
President of the Consumer Business Organization in June 2000. From 1999
to June 2000, he served as Vice President and General Manager of the
Consumer Business Organization. From 1997 to 1999, he served as Vice
President of worldwide consumer sales and marketing for the Inkjet
Products Group.
Ann M. Livermore 43 President, HP Services.
Ms. Livermore was elected a Vice President in 1995 and became General
Manager of Worldwide Customer Support Operations in 1996. She was
named General Manager of the Enterprise Computing Solutions
Organization in 1998 and was appointed President of Enterprise
Computing in April 1999. In October 1999, she became President of the
Business Customer Organization. In April 2001, she became President of
HP Services. Ms. Livermore is a member of the Board of Directors of
United Parcel Service, Inc. She is also on the board of visitors of the
Kenan-Flagler Business School at the University of North Carolina at
Chapel Hill.
Harry W. (Webb) McKinney 56 President, Business Customer Organization.
Mr. McKinney was elected a Vice President in April 2001. He is President
of the Business Customer Organization. He is also currently serving as
HP's lead for the Integration Office established in connection with the
business combination transaction with Compaq Computer Corporation.
Mr. McKinney was General Manager of the Home Products Division from
1994 to 1998, leading HP's initial entry into the consumer market for
home computing products. In 1999, he was appointed a Vice President and
became the Vice President and General Manager of the PC business within
the Computing Systems Organization. From 1996 to 2001, he held various
management positions in Computing Systems Organization.
I-2
Name Age Present Principal Occupation or Employment and Five Year Employment History
---- --- -------------------------------------------------------------------------------
Iain Morris 45 President, Embedded and Personal Systems Organization.
Mr. Morris was elected a Vice President in March 2001. He is President of
Embedded and Personal Systems. Mr. Morris joined HP after 23 years at
Motorola, Inc., where he had served as Senior Vice President and General
Manager.
Robert P. Wayman* 56 Executive Vice President, Finance and Administration and
Chief Financial Officer.
Mr. Wayman has served as Executive Vice President, Finance and
Administration since December 1992 and Chief Financial Officer of HP
since 1984. Mr. Wayman is a director of CNF Transportation, Inc., Sybase
Inc., and Portal Software, Inc. He also serves as a member of the Kellogg
Advisory Board to Northwestern University School of Business and is a
director of the Private Sector Council and Cultural Initiatives Silicon Valley.
Duane E. Zitzner 54 President, Computing Systems.
Mr. Zitzner was elected a Vice President and named General Manager of
the Personal Information Products Group in 1996. He continued as General
Manager when the Personal Information Products Group/Personal Systems
Group became a group within the Computer Products Organization in 1997
and was named President of the Computer Products Organization in April
1999. Computer Products was renamed Computing Systems in November
1999.
Philip M. Condit* 60 Chairman and Chief Executive Officer of The Boeing Company.
P.O. Box 3707 - M/S 10-10
Seattle, Washington Mr. Condit has been Chairman of The Boeing Company since February
98124-2207 1997, its Chief Executive Officer since April 1996 and a member of its
board since 1992. He served as President of The Boeing Company from
August 1992 until becoming Chairman.
Patricia C. Dunn* 48 Chairman and Chief Executive Officer of Barclays Global Investors.
45 Fremont Street,
San Francisco, California Ms. Dunn has been Global Chief Executive of Barclays Global Investors
94105 (BGI) since 1998 and its Co-Chairman from October 1995 through June
1999. Ms. Dunn oversees the activities and strategy of BGI, the world's
largest institutional investment manager, having joined the firm's
predecessor organization, Wells Fargo Investment Advisors, in 1978.
Sam Ginn* 64 Retired Chairman of Vodafone Air Touch PLC.
1 California Street,
30th Floor, Mr. Ginn served as Chairman of Vodafone AirTouch Plc from 1999,
San Francisco, California following the merger of Vodafone and AirTouch, until his retirement in
94111 May 2000. He was Chairman of the Board and Chief Executive Officer of
AirTouch from December 1993 to June 1999. Mr. Ginn is also a director
of ChevronTexaco Corporation and the Fremont Group.
Richard A. Hackborn* 64 Director.
2895 Los Altos Drive,
Meridian, Idaho 83642 Mr. Hackborn served as Chairman of the Board from January 2000 to
September 2000. He was HP's Executive Vice President, Computer Products
Organization from 1990 until his retirement in 1993 after a 33-year career
with our company. He is a director of the Boise Art Museum.
I-3
Name Age Present Principal Occupation or Employment and Five Year Employment History
---- --- ---------------------------------------------------------------------------
Walter B. Hewlett* 57 Independent Software Developer.
945 Addison Avenue,
Palo Alto, California 94301 Mr. Hewlett has been an independent software developer involved with
computer applications in the humanities for more than five years. In 1997,
Mr. Hewlett was elected to the Board of Overseers of Harvard University.
In 1994, Mr. Hewlett participated in the formation of Vermont Telephone
Company of Springfield, Vermont and currently serves as its Chairman.
Mr. Hewlett founded the Center for Computer Assisted Research in the
Humanities in 1984, for which he serves as a director. Mr. Hewlett has
been a trustee of The William and Flora Hewlett Foundation since its
founding in 1966 and currently serves as its Chairman. Mr. Hewlett also
serves as a director of the Packard Humanities Institute and the Public
Policy Institute of California. Mr. Hewlett has served as a director of
Agilent Technologies since 1999. He is the son of the late HP co-founder
William R. Hewlett.
Dr. George A. Keyworth II* 62 Chairman and Senior Fellow, The Progress and Freedom Foundation.
41 Avenida de las Casas,
Santa Fe, New Mexico 87501 Dr. Keyworth has been Chairman and Senior Fellow with The Progress &
Freedom Foundation, a public policy research institute, since 1995. He is a
director of General Atomics and Curl, Inc. Dr. Keyworth holds various
honorary degrees and is an honorary professor at Fudan University in
Shanghai, People's Republic of China.
Robert E. Knowling, Jr.* 46 Chairman and Chief Executive Officer of Internet Access Technologies, Inc.
5450 Northwest Central,
Suite 300, Mr. Knowling has been Chairman and Chief Executive Officer of Internet
Houston, Texas 77092 Access Technologies, Inc., a software development company specializing in
ASP-based productivity suites provided through the Internet, since February
2001. From July 1998 through October 2000, he was President and Chief
Executive Officer of Covad Communications Company, a national
broadband service provider of high speed Internet and network access using
DSL technology. He also served as Chairman of Covad from September
1999 to October 2000. From 1997 though July 1998, Mr. Knowling served as
the Executive Vice President of Operations and Technologies at US WEST
Communications, Inc. Mr. Knowling is a director of Ariba, Inc., Broadmedia,
Inc., Heidrick & Struggles International, Inc. and the Juvenile Diabetes
Foundation International. He also serves as a member of the advisory board
for both Northwestern University's Kellogg Graduate School of Management
and the University of Michigan Graduate School of Business.
--------
* Director of Hewlett-Packard Company.
I-4
ANNEX A
OFFER AGREEMENT
BY AND BETWEEN
HEWLETT-PACKARD COMPANY
AND
INDIGO N.V.
(as amended on February 13, 2002)
TABLE OF CONTENTS
Page
----
ARTICLE I THE OFFER............................................. A-2
1.1 The Offer.................................................. A-2
1.2 Company Actions............................................ A-4
1.3 Company Boards and Committees.............................. A-5
1.4 Stock Options; Warrants; Employee Stock Purchase Plans..... A-6
1.5 Required Withholding....................................... A-6
1.6 No Liability............................................... A-6
ARTICLE II POST CLOSING REORGANIZATION.......................... A-6
2.1 Restructuring.............................................. A-6
2.2 Co-operation of the Company................................ A-6
ARTICLE III REPRESENTATIONS AND WARRANTIES OF COMPANY........... A-7
3.1 Organization and Qualification; Subsidiaries............... A-7
3.2 Articles of Association.................................... A-8
3.3 Capitalization............................................. A-8
3.4 Authority Relative to this Agreement....................... A-9
3.5 No Conflict; Required Filings and Consents................. A-10
3.6 Compliance; Permits........................................ A-10
3.7 SEC Filings; Financial Statements.......................... A-11
3.8 No Undisclosed Liabilities................................. A-12
3.9 Absence of Certain Changes or Events....................... A-12
3.10 Absence of Litigation...................................... A-12
3.11 Employee Matters and Benefit Plans......................... A-12
3.12 Restrictions on Business Activities........................ A-16
3.13 Title to Property.......................................... A-16
3.14 Taxes...................................................... A-17
3.15 Brokers.................................................... A-20
3.16 Intellectual Property...................................... A-20
3.17 Agreements, Contracts and Commitments...................... A-23
3.18 Opinion of Financial Advisor............................... A-25
3.19 Insurance.................................................. A-25
3.20 Board Approval............................................. A-25
3.21 Environmental Matters...................................... A-25
3.22 Grants, Incentives and Subsidies........................... A-26
3.23 Disclosure................................................. A-27
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER.............. A-27
4.1 Organization............................................... A-27
4.2 Certificate of Incorporation and Bylaws.................... A-28
4.3 Capitalization............................................. A-28
4.4 Authority Relative to this Agreement....................... A-28
4.5 Issuance of Buyer Common Stock............................. A-28
4.6 No Conflict; Required Filings and Consents................. A-28
4.7 SEC Filings; Financial Statements.......................... A-29
4.8 Ownership of Company Common Stock.......................... A-29
4.9 Absences of Certain Changes or Events...................... A-29
ARTICLE V INTERIM CONDUCT....................................... A-30
5.1 Conduct of Business by Company............................. A-30
A-i
Page
----
ARTICLE VI ADDITIONAL AGREEMENTS................................ A-32
6.1 Confidentiality; Access to Information..................... A-32
6.2 No Solicitation............................................ A-32
6.3 Public Disclosure.......................................... A-33
6.4 Commercially Reasonable Efforts; Notification.............. A-33
6.5 Third Party Consents....................................... A-34
6.6 Stock Options; ESPP; Warrants.............................. A-34
6.7 Employment and Employee Benefits........................... A-36
6.8 Form S-8................................................... A-36
6.9 Indemnification............................................ A-37
6.10 Regulatory Filings......................................... A-37
6.11 Israeli Approvals.......................................... A-37
6.12 Company Shareholder Approval............................... A-38
6.13 Inspection of Real Property................................ A-39
6.14 Company Affiliate Agreements............................... A-39
6.15 NYSE Listing............................................... A-39
6.16 CVR Agreement.............................................. A-39
6.17 Consultation............................................... A-39
6.18 Registered Intellectual Property Rights.................... A-40
6.19 Company Tender and Voting Agreements....................... A-40
6.20 Employee Covenants......................................... A-40
6.21 Approved Enterprise Covenant............................... A-40
6.22 Environmental Covenant..................................... A-40
6.23 Sale of Company Shares..................................... A-40
6.24 Dutch Tax Ruling........................................... A-40
6.25 Tax Planning Cooperation................................... A-40
ARTICLE VII TERMINATION, AMENDMENT AND WAIVER................... A-41
7.1 Termination................................................ A-41
7.2 Notice of Termination; Effect of Termination............... A-42
7.3 Fees and Expenses.......................................... A-42
7.4 Amendment.................................................. A-43
7.5 Extension; Waiver.......................................... A-43
ARTICLE VIII GENERAL PROVISIONS................................. A-44
8.1 Non-Survival of Representations and Warranties............. A-44
8.2 Notices.................................................... A-44
8.3 Counterparts............................................... A-45
8.4 Entire Agreement; Third Party Beneficiaries................ A-45
8.5 Severability............................................... A-45
8.6 Other Remedies; Specific Performance....................... A-45
8.7 Governing Law.............................................. A-45
8.8 Rules of Construction...................................... A-45
8.9 Assignment................................................. A-45
8.10 Waiver of Jury Trial....................................... A-46
ARTICLE IX DEFINITIONS.......................................... A-46
9.1 Definitions................................................ A-46
9.2 Miscellaneous.............................................. A-56
A-ii
INDEX OF ANNEXES
Annex I Conditions of the Offer
INDEX OF EXHIBITS
Exhibit A Form of CVR Agreement
Exhibit B-1 Company Tender Agreement
Exhibit B-2 Company Tender and Option Agreement for the Principal Company Shareholders
Exhibit C Company Voting Agreement
Exhibit D Company Affiliate Agreement
Exhibit E Form of Amended Articles of Association of the Company
A-iii
OFFER AGREEMENT
THIS OFFER AGREEMENT (this "Agreement") is made and entered into as of
September 6, 2001, and amended as of February 13, 2002, by and between
Hewlett-Packard Company, a Delaware corporation (the "Buyer"), and Indigo N.V.,
a corporation organized under the laws of The Netherlands (the "Company").
RECITALS
A. Upon the terms and subject to the conditions set forth in the Agreement,
the Buyer and the Company intend to enter into a business combination
transaction.
B. The Company Boards have each (i) determined that the Offer is at a price
and on terms that are favorable and fair to and in the best interests of the
Company and the Company Shareholders, and (ii) approved the Offer upon the
terms and subject to the conditions set forth in this Agreement.
C. In furtherance thereof, it is proposed that the Buyer or a Subsidiary of
the Buyer shall, as promptly as practicable, commence an exchange offer (the
"Offer") to acquire all of the outstanding Company Shares, at a price for each
Company Share equal to either (i) the Fixed Offer Price or (ii) the Contingent
Price Exchange Ratio plus one CVR (together, the "Contingent Offer Price") (the
Fixed Offer Price and the Contingent Offer Price are collectively referred to
herein as the "Offer Price"), upon the terms and subject to the conditions set
forth in this Agreement.
D. Also in furtherance thereof, it is proposed that, prior to and following
the consummation of the Offer, the Buyer and the Company shall cooperate to
accomplish any one or more of the post-closing reorganizations described in
Article II hereof.
E. The CVR Certificates will be issued pursuant to a Contingent Value
Rights Agreement in substantially the form attached hereto as Exhibit A (the
"CVR Agreement") to be entered into between the Buyer and a trustee mutually
agreeable to the Company and the Buyer (the "Trustee").
F. Concurrently with the execution of this Agreement, as a condition and
inducement to the Buyer's willingness to enter into this Agreement, (i) certain
officers and directors of the Company are entering into Tender Agreements in
substantially the form attached hereto as Exhibit B-1, and the Principal
Company Shareholders are entering into Tender and Option Agreements in
substantially the form attached hereto as Exhibit B-2 (collectively, the
"Company Tender Agreements"), (ii) certain officers and directors of the
Company and certain other Company Shareholders are entering into Voting
Agreements in substantially the form attached hereto as Exhibit C
(collectively, the "Company Voting Agreements"), (iii) the Company Affiliates
are entering into the Company Affiliate Agreements in substantially the form
attached hereto as Exhibit D (collectively, the "Company Affiliate
Agreements"), and (iv) the Buyer and Benzion Landa have entered into a
Consulting Agreement (the "Consulting Agreement").
G. The Company and the Buyer intend that the Offer shall constitute a
taxable transaction under the Code.
H. Certain terms used in this Agreement are defined in Article IX hereof.
A-1
NOW, THEREFORE, in consideration of the premises and the representations,
warranties, covenants and agreements herein contained, and intending to be
legally bound hereby, the Company and the Buyer hereby agree as follows:
ARTICLE I
THE OFFER
1.1 The Offer.
(a) Provided that (i) this Agreement shall not have been terminated in
accordance with Section 7.1 and (ii) none of the events set forth in Annex I
hereto that would entitle the Buyer not to consummate the Offer shall have
occurred and be continuing, as promptly as practicable, the Buyer shall (or
shall cause a Subsidiary of the Buyer to) commence (within the meaning of Rule
14d-2 under the Exchange Act) the Offer for any and all of the Company Shares.
In the event that the Buyer shall cause a Subsidiary of the Buyer to commence
the Offer, each reference to the Buyer in this Article I and Annex I shall be
deemed, where applicable, to refer to such Subsidiary. Each Company Share
accepted by the Buyer pursuant to the Offer shall be exchanged for the right to
receive the Offer Price from the Buyer. The obligation of the Buyer to accept
for payment and to pay for any Company Shares tendered shall be subject only to
the satisfaction or waiver of: (i) the condition that there shall be validly
tendered in accordance with the terms of the Offer prior to the Expiration Time
and not withdrawn a number of Company Shares that, together with the Company
Shares then owned by the Buyer and its Subsidiaries, represents at least
ninety-five percent (95%) of the Outstanding Company Shares (the "Minimum
Condition"); and (ii) the other conditions set forth in Annex I. The Buyer
expressly reserves the right to increase the Offer Price, to waive any of the
conditions to the Offer or to make any other changes in the terms and
conditions of the Offer; provided, however, that, unless previously approved by
the Company in writing, no change may be made that: (1) decreases the Offer
Price; (2) changes the form or combination of consideration to be paid in the
Offer; (3) reduces the number of Company Shares to be purchased in the Offer;
(4) amends the conditions set forth in Annex I to broaden the scope of such
conditions, add any additional conditions, or otherwise amend any other
material term of the Offer in a manner materially adverse to the Company
Shareholders; (5) extends the Offer, except as provided in Section 1.1(b) or in
the next sentence; or (6) amends the Minimum Condition, except as provided in
the next sentence. The Buyer expressly reserves the right to amend or waive the
Minimum Condition to reduce the percentage of Outstanding Company Shares
required to be validly tendered in accordance with the terms of the Offer,
provided that the Buyer shall extend the Offer for a period of not fewer than
10 Business Days after any such amendment or waiver.
(b) (i) Subject to the terms and conditions of the Offer and this Agreement,
the Offer shall expire at midnight, New York City time, on the date that is
twenty (20) Business Days after the date the Offer is commenced; provided,
however, that, without the consent of the Company Boards, the Buyer may: (i)
from time to time extend the Offer, if at the scheduled expiration date of the
Offer any of the conditions to the Offer set forth in Annex I shall not have
been satisfied or waived, until such time as such conditions are satisfied or
waived; or (ii) extend the Offer for any period required by any rule,
regulation, interpretation or position of the SEC or the staff thereof
applicable to the Offer. The Buyer agrees that, if any one or more of the
conditions to the Offer set forth in Annex I are not satisfied and none of the
events set forth in paragraphs (a) through (c) or (f) through (h) of Annex I
that would permit the Buyer not to accept tendered Company Shares for payment
has occurred, then, provided that such conditions are reasonably capable of
being satisfied in the Buyer's sole judgment, the Buyer shall extend the Offer
from time to time for successive extension periods not in excess of 10 Business
Days per extension, unless any such condition is no longer reasonably capable
of being satisfied in the Buyer's sole judgment or any such event has occurred;
provided, however, that in no event shall the Buyer be required to extend the
Offer beyond the End Date. Subject to the terms and conditions of the Offer and
this Agreement and the satisfaction (or waiver to the extent permitted by this
Agreement) of the conditions to the Offer, the Buyer shall accept for payment
(the "Closing") all Company Shares validly tendered and not withdrawn pursuant
to the Offer that the Buyer becomes obligated to accept for payment pursuant to
the Offer as soon as practicable after the Expiration Time and shall pay for
all such Company Shares promptly after such acceptance.
A-2
(ii) No fraction of a share of Buyer Common Stock will be issued in
connection with the payment of the Offer Price upon consummation of the Offer,
but in lieu thereof each tendering Company Shareholder who would otherwise be
entitled to receive a fraction of a share of Buyer Common Stock (after
aggregating all fractional shares of Buyer Common Stock that otherwise would be
received by such holder) in the Offer shall receive from the Buyer an amount of
cash (rounded to the nearest whole cent), without interest, equal to the
product obtained by multiplying such fraction by the closing price of one (1)
share of Buyer Common Stock on the first date the Buyer accepts Company Shares
for exchange in the Offer, as reported on the NYSE.
(c) (i) In connection with the Offer, each holder of Company Shares validly
tendered and not withdrawn pursuant to the Offer that the Buyer becomes
obligated to accept for exchange pursuant to the Offer shall be entitled to
elect to receive the Offer Price in respect of such tendered Company Shares in
the form of either the Fixed Offer Price or the Contingent Offer Price;
provided, that the letter of transmittal shall require that each holder shall
elect either the Fixed Offer Price or the Contingent Offer Price for all
Company Shares tendered by such holder. To the extent that a holder has validly
tendered Company Shares and not withdrawn them but has not indicated in the
transmittal letter whether to elect the Fixed Offer Price or the Contingent
Offer Price with respect to such Company Shares tendered, such holder shall be
deemed to have elected to receive the Fixed Offer Price for all Company Shares
tendered by such holder. Notwithstanding anything in this Agreement to the
contrary: (i) the number of Company Shares that the Buyer will be obligated to
acquire in exchange for the Fixed Offer Price shall not exceed the Maximum
Fixed Price Election Number; and (ii) the number of Company Shares that the
Buyer will be obligated to acquire in exchange for the Contingent Offer Price
shall not exceed the Maximum Contingent Price Election Number.
(ii) If the aggregate number of Company Shares that the Buyer would
otherwise be obligated to acquire in exchange for the Fixed Offer Price (the
"Requested Fixed Price Amount") exceeds the Maximum Fixed Price Election
Number, each holder who has accepted the Fixed Offer Price shall receive, with
respect to each such Company Share (x) such number of shares of Buyer Common
Stock equal to the product of (A) the Fixed Offer Price and (B) the Fixed Price
Proration Factor, and (y)(1) such additional number of shares of Buyer Common
Stock equal to the product of (A), the Contingent Price Exchange Ratio and (B)
one minus the Fixed Price Proration Factor and (2) such number of CVRs equal to
one minus the Fixed Price Proration Factor.
(iii) If the aggregate number of Company Shares that the Buyer would
otherwise be obligated to acquire in exchange for the Contingent Offer Price
(the "Requested Contingent Price Amount") exceeds the Maximum Contingent Price
Election Number, each holder who has accepted the Contingent Offer Price shall
receive, with respect to each such Company Share (x)(1) such number of shares
of Buyer Common Stock equal to the product of (A) the Contingent Price Exchange
Ratio and (B) the Contingent Price Proration Factor, and (2) such number of
CVRs equal to the Contingent Price Proration Factor and (y) such additional
number of shares of Buyer Common Stock equal to the product of (A) the Fixed
Offer Price and (B) one minus the Contingent Price Proration Factor.
(iv) The Fixed Offer Price, the Contingent Price Exchange Ratio and any
other applicable numbers or amounts shall be adjusted to reflect appropriately
the effect of any stock split, reverse stock split, stock dividend (including
any distribution or dividend of securities convertible into or exchangeable for
Buyer Common Stock or Company Shares), extraordinary cash dividend,
reorganization, reclassification, combination, exchange of shares or other like
change with respect to Buyer Common Stock or Company Shares occurring or having
a record date on or after the date hereof and prior to the Closing Time.
(v) The Exchange Agent shall make all computations as to the allocation and
the proration contemplated by this Section 1.1(c), and any such computation
shall be conclusive and binding on the Company Shareholders. The Buyer and the
Company may agree to make such rules as are consistent with the Offer and this
Section 1.1(c) for the implementation of the provisions of this Section 1.1(c)
as shall be necessary or desirable to fully effect such provisions.
(d) As soon as practicable after the date of this Agreement, the Buyer shall
prepare and file with the SEC a registration statement on Form S-4 to register
the offer and sale of Buyer Common Stock and the CVRs pursuant to the Offer
(the "Registration Statement") and, to the extent the Buyer in its sole
discretion determines that it is
A-3
necessary, a Transaction Statement on Schedule 13E-3 (together with all
amendments and supplements thereto, and including all exhibits thereto, the
"Schedule 13E-3"). The Company shall execute, and join in the filing of, the
Schedule 13E-3, if applicable. The Registration Statement as declared effective
by the SEC will include a prospectus containing the information required under
Rule 14d-4(b) promulgated under the Exchange Act (the "Prospectus"). As soon as
practicable on the date the Offer is commenced, the Buyer shall file with the
SEC a Tender Offer Statement on Schedule TO (together with all amendments and
supplements thereto, and including all exhibits thereto, the "Schedule TO")
with respect to the Offer and cause the Offer Documents to be disseminated to
the Company Shareholders. The Schedule TO shall contain as an exhibit or
incorporate by reference the Prospectus (or portions thereof) and forms of the
related letter of transmittal and summary advertisement, if any. The Buyer
shall cause the Schedule TO, the Schedule 13E-3, if applicable, the Prospectus
and all amendments or supplements thereto (which together, with any supplements
or amendments thereto, collectively constitute the "Offer Documents") to comply
in all material respects with the Exchange Act and the rules and regulations
thereunder and other applicable Legal Requirements. The Buyer further agrees
that the Offer Documents, on the date first published, sent or given to the
Company Shareholders, shall not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, except that no representation or warranty
is made by the Buyer with respect to information supplied by the Company or any
of the Company Shareholders (other than the Buyer) in writing specifically for
inclusion or incorporation by reference in the Offer Documents. The Company
agrees that the information provided by the Company or any of the Company
Shareholders (other than the Buyer) in writing specifically for inclusion or
incorporation by reference in the Offer Documents shall not contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading. Each of the
Buyer and the Company shall promptly correct any information provided by it for
use in the Registration Statement or the Offer Documents if and to the extent
that such information shall have become false or misleading in any material
respect, and the Buyer shall take all steps necessary to cause the Offer
Documents as so corrected to be filed with the SEC and to be disseminated to
the Company Shareholders, in each case as and to the extent required by
applicable federal securities laws. The Company and its counsel shall be given
reasonable opportunity to review and comment on the Schedule TO, the Schedule
13E-3, if applicable, the Registration Statement and the Offer Documents prior
to the filing thereof with the SEC. The Buyer agrees to provide in writing to
the Company and its counsel any comments the Buyer or its counsel may receive
from the SEC or its staff with respect to the Offer Documents promptly after
receipt of such comments and shall provide the Company and its counsel with a
reasonable opportunity to participate in the response of the Buyer to such
comments.
1.2 Company Actions.
(a) The Company hereby approves of and consents to the Offer and represents
that each of the Company Boards, at meetings duly called and held, have (i)
unanimously determined that this Agreement and the transactions contemplated
hereby, including the Offer, are at a price and on terms that are favorable and
fair to and in the best interests of the Company and the Company Shareholders;
(ii) unanimously approved this Agreement and the transactions contemplated
hereby, including the Offer, in all respects, and (iii) unanimously resolved to
recommend that the Company Shareholders accept the Offer, tender their Company
Shares thereunder to the Buyer and vote at the EGM in favor of (x) the
appointment of new members to the Company Boards in accordance with the
designation of the Buyer and (y) the amendment of the Company's Articles of
Association in the form, as to be so amended, attached hereto as Exhibit E. The
Company consents to the inclusion of such recommendation and approval in the
Offer Documents. In addition, Gleacher & Co. LLC has delivered to the Company
Boards its opinion referred to in Section 3.18. The Company's approval of and
consent to the Offer also constitutes approval for purposes of the standstill
provisions set forth in Article 4 of that certain Shareholders' Agreement,
dated September 13, 2000, by and among the Company, the Buyer and the other
Company Shareholders named therein for the sole purpose of the Buyer making the
Offer and consummating the other transactions contemplated hereby; provided,
that in the event this Agreement is terminated pursuant to Article VII hereof,
such standstill provisions shall continue in full force and effect after such
termination.
A-4
(b) The Company shall file with the SEC, concurrently with the filing of the
Schedule TO, a Solicitation/Recommendation Statement on Schedule 14D-9
(together with all amendments and supplements thereto, and including all
exhibits thereto, the "Schedule 14D-9") containing the recommendations and
opinion described in Section 1.2(a) and shall cause the Schedule 14D-9 to be
mailed to the Company Shareholders, together with the Offer Documents, promptly
after the commencement of the Offer. The Company shall cause the Schedule 14D-9
to comply in all material respects with the Exchange Act and the rules and
regulations thereunder and other applicable Legal Requirements. The Company
further agrees that the Schedule 14D-9, on the date first published, sent or
given to the Company Shareholders, shall not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, except that no
representation or warranty is made by the Company with respect to information
supplied by the Buyer in writing specifically for inclusion or incorporation by
reference in the Schedule 14D-9. The Buyer agrees that the information provided
by it in writing specifically for inclusion or incorporation by reference in
the Schedule 14D-9 shall not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading. Each of the Company and the Buyer shall
promptly correct any information provided by it for use in the Schedule 14D-9
or the Offer Documents if and to the extent that such information shall have
become false or misleading in any material respect, and the Company further
shall take all steps necessary to cause the Schedule 14D-9 as so corrected to
be filed with the SEC and be disseminated to the Company Shareholders, in each
case as and to the extent required by applicable federal securities laws. The
Buyer and its counsel shall be given reasonable opportunity to review and
comment on the Schedule 14D-9 prior to the filing thereof with the SEC. The
Company shall provide in writing to the Buyer and its counsel any comments the
Company or its counsel may receive from the SEC or its staff with respect to
the Schedule 14D-9 promptly after receipt of such comments and shall provide
the Buyer and its counsel with a reasonable opportunity to participate in the
response of the Company to such comments.
(c) In connection with the Offer, the Company shall, or shall cause its
transfer agent, promptly following a request by the Buyer, to furnish the Buyer
with such information, including updated lists of the Company Shareholders,
mailing labels and any available listing or computer file containing the names
and addresses of all record holders of Company Shares and lists of securities
positions of Company Shares held in stock depositories, in each case as of the
most recent practicable date, and will provide to the Buyer such additional
information (including, without limitation, updated lists of the Company
Shareholders, mailing labels and lists of securities positions), and such
assistance as the Buyer or its agents may reasonably request in communicating
the Offer to the record and beneficial holders of the Company Shares.
(d) Solely in connection with the tender and purchase of the Company Shares
pursuant to the Offer and other actions contemplated in this Agreement, the
Company hereby waives any and all rights of first refusal it may have with
respect to the Company Shares owned by, or issuable to, any person, other than
rights to repurchase unvested shares, if any, that may be held by persons
pursuant to the grant of restricted stock purchase rights or following exercise
of employee stock options.
1.3 Company Boards and Committees. At any time following the execution of
this Agreement, but in any event no later than five (5) Business Days prior to
the Expiration Time, the Company shall convene an extraordinary meeting of
shareholders (the "EGM") to (i) accept the resignation from the Company Boards
of the existing members thereof and appoint the new members of the Company
Boards in accordance with the designation of the Buyer set out below and (ii)
resolve upon the amendment of the Articles of Association of the Company in the
form, as to be so amended, attached hereto as Exhibit E. The resignations and
appointments referred to in the preceding sentence will be effective as of, and
conditional upon the occurrence of, the Closing Time. As soon as practicable
after the date of execution of this Agreement and no later than 20 calendar
days prior to the date of the EGM the Buyer shall designate in writing to the
Company the new members for each of the Company Boards and furnish the Company
with all information with respect to those new members that is required to be
disclosed to the Company Shareholders under Dutch law. At the EGM, the Company
shall use its commercially reasonable efforts to secure the resignation of the
existing members of the Company Boards and
A-5
the appointment of the designees of the Buyer, all such resignations and
appointments to be effective as of, and conditional upon the occurrence of the
Closing, as aforesaid.
1.4 Stock Options; Warrants; Employee Stock Purchase Plans. At the Closing
Time: (i) all options to purchase Company Shares then outstanding and granted
under the Company Option Plans shall be treated in accordance with Section
6.6(a) hereof; (ii) all warrants to purchase Company Shares then outstanding
(collectively, the "Company Warrants") shall be treated as set forth in Section
6.6(b) hereof; and (iii) all purchase rights outstanding under Company's 1994
United States Employee Share Purchase Plan, 1994 Israel Employee Share Purchase
Plan and 1994 Netherlands Employee Share Purchase Plan (collectively, the
"ESPP") shall be treated as set forth in Section 6.6(c) hereof.
1.5 Required Withholding. Each of the Buyer and the Company and any bank
or trust company retained by the Buyer to act as the exchange agent in
connection with the Offer (an "Exchange Agent") shall be entitled to deduct and
withhold from any consideration payable or otherwise deliverable pursuant to
this Agreement to any holder or former holder of Company Shares such amounts as
may be required to be deducted or withheld therefrom under U.S. federal or
state, local or foreign law. To the extent such amounts are so deducted or
withheld, such amounts shall be treated for all purposes under this Agreement
as having been paid to the person to whom such amounts would otherwise have
been paid.
1.6 No Liability. Notwithstanding anything to the contrary in this Article
I, neither the Exchange Agent nor the Buyer nor the Company shall be liable to
a holder of shares of Buyer Common Stock or Company Shares for any amount
properly paid to a public official pursuant to any applicable abandoned
property, escheat or similar law.
ARTICLE II
POST CLOSING REORGANIZATION
2.1 Restructuring. The Buyer intends, simultaneously with or as soon as
possible after the Closing, to effectuate a corporate reorganization (the
"Post-Closing Reorganization") of the Company and its Subsidiaries, which may
include, without limitation (i) the commencement of a compulsory acquisition by
the Buyer of Company Shares from any remaining minority shareholder in
accordance with Section 2:92a of the Dutch Civil Code (the "DCC"), (ii) the
amendment of the Articles of Association of the Company to permit the creation,
among other things, of separate classes of shares, (iii) the distribution of an
extraordinary dividend on the shares of the Company or a particular class or
classes of shares of the Company, (iv) the sale and transfer by the Company, or
any of its Subsidiaries, to the Buyer, or any affiliates of the Buyer, of all
or a portion of the assets of the Company or its Subsidiaries, (v) the
effectuation by the Company and one or more Dutch Subsidiaries of the Buyer of
a legal merger within the meaning of Section 2:309 of the DCC, (vi) the
termination of the listing of the Company Shares on the Nasdaq National Market,
(vii) the deregistration of the Company under the Exchange Act and the
cessation of the Company's reporting obligations thereunder, or (viii) any one
or more combinations of any of the foregoing actions; all of which shall be
conducted in accordance with applicable laws and which, if the Buyer determines
in its sole discretion to implement any such Post-Closing Reorganization, will
in any case result in the holders of Company Shares who do not exchange such
shares in the Offer being offered or receiving in any such Post-Closing
Reorganization consideration equivalent to the Fixed Offer Price.
2.2 Co-operation of the Company. The Company shall take as of the date of
this Agreement, but effective no earlier than the consummation of the Offer,
all actions reasonably necessary or desirable to accomplish the Post-Closing
Reorganization including, without limitation (i) the convening of the necessary
meetings of the Company Shareholders and the Company Boards, (ii) the
consideration of any and all necessary or desirable resolutions by each of the
Company Boards for the purpose of the corporate reorganizations, and (iii) the
execution of any and all reasonably requested documents, agreements or deeds
that are necessary or desirable
A-6
to effectuate any of the corporate reorganizations and the filing or
registration of any or all of such documents, agreements or deeds with the
appropriate authorities or agencies. In addition, at the request of the Buyer,
the Company shall take any and all other actions that are required or desirable
to accomplish the corporate reorganization of the Company and its Subsidiaries,
so long as such actions are reasonable based on the relative detriment or
inconvenience to the Company and the relative benefit to the Buyer from such
action. With respect to all actions taken by the Company pursuant to this
Section 2.2, the Buyer shall reimburse the Company for its reasonable
out-of-pocket costs and expenses regardless of whether or not the Offer is
consummated except where the Buyer has terminated this Agreement pursuant to
Section 7.1(d), in which case the Buyer shall not be obligated so to reimburse
the Company.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF COMPANY
The Company represents and warrants to the Buyer, subject to such exceptions
as are disclosed in writing in the disclosure letter supplied by the Company to
the Buyer dated as of the date hereof (the "Company Disclosure Letter"), which
Company Disclosure Letter shall provide an exception to or otherwise qualify
the representations and warranties of the Company (i) contained in the section
of this Agreement corresponding by number to such disclosure, and (ii)
contained in any other section of this Agreement where the nature of such
exception or qualification is readily apparent from the face of such
disclosure, as follows:
3.1 Organization and Qualification; Subsidiaries.
(a) Each of the Company and its Subsidiaries is a corporation duly
organized, validly existing and in good standing (as applicable) under the laws
of the jurisdiction of its incorporation and has the requisite corporate power
and authority to own, lease and operate its assets and properties and to carry
on its business as it is now being conducted, except where the failure to do so
would not, individually or in the aggregate, have a Company Material Adverse
Effect. Neither the Company nor any of its Subsidiaries (i) has been dissolved,
and there is no action or request pending to accomplish such dissolution, (ii)
is involved in preparations for a merger as described in Section 2:309 of the
DCC or its foreign equivalent (including a merger under the Israeli Companies
Law, 1999), or (iii) has been declared bankrupt and no action or request is
pending to declare the Company or any of its Subsidiaries bankrupt or obtain an
official moratorium under Dutch or other applicable law. Each of the Company
and its Subsidiaries is in possession of all Approvals necessary to own, lease
and operate the assets and properties it purports to own, operate or lease and
to carry on its business as it is now being conducted, except where the failure
to have such Approvals would not, individually or in the aggregate, have a
Company Material Adverse Effect. The Company and each of its Subsidiaries is
and has been in compliance with the terms of the Approvals, except where the
failure to be or have been in such compliance would not, individually or in the
aggregate, result in a Company Material Adverse Effect.
(b) The Company and each of its Subsidiaries is duly qualified or licensed
to do business as a foreign corporation, and is in good standing, under the
laws of all jurisdictions where the nature of their business requires such
qualification, except where the failure to be so qualified or in good standing
would not, individually or in the aggregate, have a Company Material Adverse
Effect.
(c) Section 3.1(c) of the Company Disclosure Letter sets forth the name,
jurisdiction of incorporation and authorized and outstanding capital of each of
the Company's Subsidiaries and the jurisdictions in which each such Subsidiary
is qualified to do business. All the outstanding capital stock of each of the
Company's Subsidiaries is owned directly or indirectly by the Company free and
clear of all Encumbrances and all material claims or charges of any kind, and
is validly issued, fully paid and nonassessable. Neither the Company nor any of
its Subsidiaries has agreed nor is obligated to make nor is bound by any
Contract, as of the date hereof or as may hereafter be in effect under which it
may become obligated to make, any future investment in or capital contribution
to any other entity. Other than the Company's interests in its Subsidiaries,
neither the Company nor any of its Subsidiaries directly or indirectly owns any
equity or similar interest in or any interest convertible,
A-7
exchangeable or exercisable for, any equity or similar interest in, any
corporation, partnership, joint venture or other business, association or
entity.
(d) All branches of the Company or any of its Subsidiaries are properly
registered with all relevant Governmental Entities, including tax authorities,
and have complied with, and do comply with all applicable laws, rules and
regulations, except where the failure to do so would not, individually or in
the aggregate, have a Company Material Adverse Effect.
3.2 Articles of Association. The Company has previously furnished to the
Buyer (i) a complete and correct copy, translated into English, of its Articles
of Association, as amended to date (the "Company Charter Documents"), and (ii)
complete and correct copies, translated into English, of the certificate of
incorporation and by-laws or similar organizational documents of each of the
Company's Subsidiaries, as amended to date. Such Company Charter Documents and
equivalent organizational documents of each of the Subsidiaries of the Company
are in full force and effect, the Company is not in violation of any of the
provisions of the Company Charter Documents, and no Subsidiary of the Company
is in violation of its equivalent organizational documents.
3.3 Capitalization.
(a) The authorized capital stock of the Company consists of 240,000,000
Common Shares and 26,950,000 shares of preferred stock, par value NLG 0.04 per
share (the "Preferred Shares"). As of September 5, 2001, (i) 113,676,895 Common
Shares are issued and outstanding, including 3,749,532 Common Shares that are
held in the treasury of the Company; (ii) 7,046,392 Preferred Shares are
designated as Series A Convertible Preferred Shares, none of which are
currently issued and outstanding; (iii) 2,882,241 Preferred Shares are
designated as Series B Convertible Preferred Shares, none of which are
currently issued and outstanding; (iv) 3,853,333 Preferred Shares are
designated as Series C Convertible Preferred Shares, none of which are
currently issued and outstanding; (v) 3,515,680 Preferred Shares are designated
as Series D Convertible Preferred Shares, none of which are currently issued
and outstanding; (vi) 11,344,986 Common Shares are reserved for issuance upon
exercise of outstanding Company Stock Options under the Company Option Plans;
(vii) 4,422,806 Common Shares are not subject to outstanding options and are
reserved for issuance under the Company Option Plans; (viii) 1,268,366 Common
Shares are reserved for issuance and unissued under the ESPP; (ix) there are
outstanding warrants designated "Series A warrants" representing the right to
purchase 3,917,999 Common Shares; (x) there are outstanding warrants designated
"Series C warrants" representing the right to purchase 1,926,677 Common Shares;
(xi) there are warrants designated "Series D warrants," none of which are
outstanding; (xii) there are outstanding warrants designated "Litigation
Settlement Warrants" representing the right to purchase 2,000,000 Common
Shares; (xiii) there are outstanding warrants designated "Acquisition Warrants"
representing the right to purchase 14,814,815 Common Shares; (xiv) there are
outstanding warrants designated "Performance Warrants" representing the right
to purchase 12,000,000 Common Shares. All of the outstanding shares of the
Company's capital stock are, and all Common Shares subject to issuance as
aforesaid, upon issuance in accordance with the respective terms thereof, will
be, duly authorized, validly issued, fully paid and non-assessable. There is no
Voting Debt of the Company or any of its Subsidiaries issued and outstanding.
Section 3.3(a) of the Company Disclosure Letter contains a true copy of the
list of (i) shareholders of record of the Company, as at August 31, 2001, as
kept by the Company's transfer agent and (ii) holders of record of the Company
Warrants, as at September 2, 2001, as kept by the Company.
(b) Section 3.3(b) of the Company Disclosure Letter sets forth the following
information with respect to each Company Stock Option outstanding as of the
date of this Agreement: (i) the name and address of the optionee, with the
first name and last name in separate columns; (ii) whether the Company Stock
Option is deemed an "Incentive Stock Option" pursuant to Section 422 of the
Code; (iii) the Company Option Plan under which such Company Stock Option was
granted; (iv) the number of Common Shares subject to such Company Stock Option;
(v) the exercise price of such Company Stock Option; (vi) the date on which
such Company Stock Option was granted; (vii) the date on which such Company
Stock Option expires; (viii) the extent to which such Company Stock Option is
vested; (ix) the extent to which the exercisability of such Company Stock
Option will be accelerated in any way by the transactions contemplated by this
Agreement; (x) the status of the holder of
A-8
each Company Stock Option; and (xi) the date of termination or severance of the
holder of each Company Stock Option. The Company has made available to the
Buyer accurate and complete copies of all stock option plans pursuant to which
the Company has granted such Company Stock Options that are currently
outstanding, the form of all stock option agreements evidencing such Company
Stock Options and any stock option agreement that has been modified from the
form of stock option agreement. Section 3.3(b) of the Company Disclosure Letter
lists each such stock option plan. All Common Shares subject to issuance as
aforesaid, upon issuance on the terms and conditions specified in the
instrument pursuant to which they are issuable, would be duly authorized,
validly issued, fully paid and nonassessable. There are no commitments or
agreements of any character to which the Company is bound obligating the
Company to accelerate the vesting of any Company Stock Option as a result of
the Offer.
(c) All outstanding Common Shares, all outstanding Company Stock Options,
all outstanding Company Warrants and all outstanding shares of capital stock of
each Subsidiary of the Company have been issued and granted in compliance with
(i) all applicable securities laws and other applicable Legal Requirements and
(ii) all requirements set forth in applicable Contracts.
(d) The Company owns free and clear of all liens, pledges, hypothecations,
charges, mortgages, security interests, Encumbrances, claims, infringements,
interferences, options, right of first refusals, preemptive rights, community
property interests or restrictions of any nature (including any restriction on
the voting of any security, any restriction on the transfer of any security or
other asset, any restriction on the possession, exercise or transfer of any
other attribute of ownership of any asset but other than restrictions imposed
by federal or state securities laws) directly or indirectly through one or more
Subsidiaries, all of the outstanding shares of capital stock of each of its
Subsidiaries and, except for shares of capital stock or other similar ownership
interests of any of the Company's Subsidiaries that are owned by certain
nominee equity holders as required by the applicable law of the jurisdiction of
organization of such Subsidiaries (which shares or other interests (i) do not
materially affect the Company's control of such Subsidiary and (ii) shall in
the case of any such Israeli Subsidiary be transferred from any such nominee
equity holder to the Company prior to the Closing), there are no equity
securities, partnership interests or similar ownership interests of any class
of equity security of any Subsidiary of the Company, or any security or right
exchangeable or convertible into or exercisable for such equity securities,
partnership interests or similar ownership interests, issued, reserved for
issuance or outstanding. There are no subscriptions, options, warrants, equity
securities, partnership interests or similar ownership interests, calls, rights
(including preemptive rights), commitments or agreements of any character to
which the Company or any of its Subsidiaries is a party or by which it is bound
obligating the Company or any of its Subsidiaries to issue, deliver or sell, or
cause to be issued, delivered or sold, or repurchase, redeem or otherwise
acquire, or cause the repurchase, redemption or acquisition of, any shares of
capital stock or Voting Debt, partnership interests or similar ownership
interests of the Company or any of its Subsidiaries or obligating the Company
or any of its Subsidiaries to grant, extend, accelerate the vesting of or enter
into any such subscription, option, warrant, equity security, call, right,
commitment or agreement.
(e) There are no registration rights and there is, except for the Company
Tender and Voting Agreements, no voting trust, proxy, rights plan, antitakeover
plan or other agreement or understanding to which the Company or any of its
Subsidiaries is a party or by which they are bound with respect to any equity
security of any class of the Company or with respect to any equity security,
partnership interest or similar ownership interest of any class of any of the
Company's Subsidiaries.
3.4 Authority Relative to this Agreement. The Company has all necessary
corporate power and authority to execute and deliver this Agreement and to
perform its obligations hereunder and to consummate the transactions
contemplated hereby. The execution and delivery of this Agreement by the
Company and the consummation by the Company of the transactions contemplated
hereby have been duly and validly authorized by all necessary corporate action
on the part of the Company, including such authorization by each of the Company
Boards, and no other corporate proceedings on the part of the Company are
necessary to authorize the execution and delivery of this Agreement or to
consummate the transactions contemplated hereby. Except for the vote of the
Company Shareholders to approve the Post-Closing Reorganization, no vote of, or
consent by, the
A-9
holders of any class or series of capital stock or Voting Debt issued by the
Company is necessary to authorize the execution and delivery by the Company of
this Agreement or the consummation by it of the transactions contemplated
hereby. This Agreement has been duly and validly executed and delivered by the
Company and, assuming the due authorization, execution and delivery by the
Buyer, constitutes legal and binding obligations of the Company, enforceable
against the Company in accordance with its terms, except to the extent that
(i) enforcement thereof may be limited by bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditor rights, (ii) the enforcement thereof may be
limited by general equitable principles (regardless of whether such enforcement
is considered in a proceeding at law or in equity), and (iii) the remedy of
specific performance and injunctive and other forms of equitable relief may be
subject to equitable defenses and to the discretion of the court before which
any proceeding therefor may be brought.
3.5 No Conflict; Required Filings and Consents.
(a) The execution and delivery of this Agreement by the Company does not,
and the performance of this Agreement by the Company shall not (i) violate the
Company Charter Documents or the equivalent organizational documents of any of
the Company's Subsidiaries, (ii) subject to obtaining the consents, approvals,
authorizations and permits, and making the filings and notifications, set forth
in Section 3.5(b) below or in Section 6.5 of the Company Disclosure Letter,
conflict with or violate any law, rule, regulation, order, judgment or decree
applicable to the Company or any of its Subsidiaries or by which its or any of
their respective properties is bound or affected, or (iii) result in any breach
of or constitute a default (or an event that with notice or lapse of time or
both would become a default) under, or materially impair the Company's or any
of its Subsidiaries' rights or alter the rights or obligations of any third
party under, or give to others any rights of termination, amendment,
acceleration or cancellation of, or result in the creation of a lien or
encumbrance on any of the properties or assets of the Company or any of its
Subsidiaries pursuant to, any material note, bond, mortgage, indenture,
contract, agreement, lease, license, permit, franchise or other instrument or
obligation to which the Company or any of its Subsidiaries is a party or by
which the Company or any of its Subsidiaries or its or any of their respective
properties are bound or affected.
(b) The execution and delivery of this Agreement does not, and the
performance of this Agreement by the Company shall not, require any consent,
approval, authorization or permit of, or filing with or notification to, any
Governmental Entity or other Person (including consents from parties to loans,
contracts, leases and other agreements to which the Company or any of its
Subsidiaries is a party), except (i) applicable requirements, if any, of the
Securities Act, the Exchange Act, Blue Sky Laws, Foreign Securities Laws, the
notification requirements of the HSR Act and the Foreign Filings, the rules and
regulations of the NYSE, NASD or NASDAQ, the consent of the Investment Center,
the consent of the OCS, the approval of the Israeli Commissioner of Restrictive
Trade Practices, and the exemption from the Israel Securities Authority
concerning the publication of a prospectus, in respect of the exchange of the
Company Stock Options for the Buyer Stock Options, pursuant to Section 15D of
the Israeli Securities Law, 1968, and (ii) applicable consultation with all
trade union representatives and bodies under applicable employment laws,
including, without limitation, the Dutch SER Merger Rules and (iii) such other
consents, approvals, authorizations or permits, filings or notifications which
(A) would not prevent consummation of the Offer or the Post-Closing
Reorganization or otherwise prevent the parties hereto from performing their
respective obligations under this Agreement, and (B) would not, individually or
in the aggregate, reasonably be expected to have a Company Material Adverse
Effect, and (iv) consents required under the terms of any Lease to assignment
of such Lease in connection with the performance of this Agreement as set forth
in Section 6.5 of the Company Disclosure Letter.
3.6 Compliance; Permits.
(a) Neither the Company nor any of its Subsidiaries is in conflict with, or
in default or violation of (i) any law, rule, regulation, ordinance, order,
judgment, decree, writ or injunction of any national, state or provincial or
local government (whether or not in the United States) or agency thereof
applicable to the Company or any of its Subsidiaries or by which its or any of
their respective assets or properties is bound, or (ii) any note, bond,
A-10
mortgage, indenture, contract, agreement, lease, license, permit, franchise or
other instrument or obligation to which the Company or any of its Subsidiaries
is a party or by which the Company or any of its Subsidiaries or its or any of
their respective properties is bound, except for any conflicts, defaults or
violations that (individually or in the aggregate) would not reasonably be
expected to have a Company Material Adverse Effect. No notice, charge, claim,
action or assertion has been received by the Company or any of its Subsidiaries
or has been filed, commenced or, to the knowledge of the Company, threatened
against the Company or any of its Subsidiaries alleging any violation of any of
the foregoing.
(b) No investigation or review by any Governmental Entity is, to the
knowledge of the Company, pending or threatened against the Company or its
Subsidiaries, nor has any Governmental Entity indicated to the Company or any
of its Subsidiaries an intention to conduct the same, other than, in each such
case, those the outcome of which could not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
(c) The Company and each of its Subsidiaries hold all Company Permits. The
Company and each of its Subsidiaries have been and are in compliance in all
material respects with the terms of the Company Permits and any conditions
placed thereon. There is no action, proceeding, inquiry or investigation
pending or, to the knowledge of the Company, threatened for or contemplating
the suspension, cancellation, revocation or nonrenewal of any such permit, and
to the knowledge of the Company there is no existing fact or circumstance which
(with or without notice or lapse of time or both) is reasonably likely to
result in the suspension, limitation, cancellation, revocation or nonrenewal of
any such permit or any limitation of any such permit which would not,
individually or in the aggregate, have a Company Material Adverse Effect.
Neither the Company nor any of its Subsidiaries has received any written or, to
the knowledge of the Company, oral notice from any Governmental Entity that the
consummation of the transactions contemplated hereby will result in the
suspension, cancellation, revocation or nonrenewal of any such Company Permit.
3.7 SEC Filings; Financial Statements.
(a) The Company has made available to the Buyer a correct and complete copy
of each form, report, schedule, statement and other documents filed by the
Company with the SEC since January 1, 1998 (collectively, the "Company SEC
Reports"), which are all the forms, reports and documents required to be filed
by the Company with the SEC since such date. As of their respective dates or,
if amended, as of the date of the last such amendment, the Company SEC Reports
(i) complied in all material respects with the applicable requirements of the
Securities Act or the Exchange Act, as the case may be, and (ii) did not
contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading. None of the Company's Subsidiaries is required to file any forms,
reports or other documents with the SEC.
(b) As of their respective dates, (i) each set of consolidated financial
statements (including, in each case, any related notes thereto) contained in
the Company SEC Reports (x) was prepared from, and is in accordance with, the
books and records of the Company and its consolidated Subsidiaries, (y)
complied in all material respects with the published rules and regulations of
the SEC with respect thereto, and (z) was prepared in accordance with U.S. GAAP
applied on a consistent basis throughout the periods involved (except as may be
indicated in the notes thereto) and each fairly presents the consolidated
financial position of the Company and its consolidated Subsidiaries at the
respective dates thereof and the consolidated results of its operations and
cash flows and changes in shareholders' equity for the periods indicated; and
(ii) the Company Interim Financial Data (x) was prepared from, and in
accordance with, the books and records of the Company and its consolidated
Subsidiaries, and (y) was prepared in accordance with U.S. GAAP applied on a
consistent basis throughout the periods involved and fairly presents the
condensed consolidated statements of operations, condensed consolidated balance
sheets, and condensed consolidated statements of cash flows.
(c) The Company has previously furnished to the Buyer a complete and correct
copy of any amendments or modifications, which have not yet been filed as of
the date hereof with the SEC but which are required to be filed, to agreements,
documents or other instruments which previously had been filed by the Company
with the
A-11
SEC pursuant to the Securities Act or the Exchange Act or any material
agreements potentially required to be filed that have not been so filed.
(d) The Company does fully comply and has always fully complied in all
material respects with all applicable Netherlands statutory accounting and
reporting rules and regulations.
3.8 No Undisclosed Liabilities. Neither the Company nor any of its
Subsidiaries has any liabilities (absolute, accrued, contingent or otherwise)
of a nature required to be disclosed on a balance sheet or in the related notes
to the consolidated financial statements prepared in accordance with U.S. GAAP
which are, individually or in the aggregate, material to the business, results
of operations, assets or financial condition of the Company and its
Subsidiaries taken as a whole, except (i) liabilities provided for in the
Company's balance sheet as of June 30, 2001 or (ii) liabilities incurred since
June 30, 2001 in the ordinary course of business, none of which is material to
the business, results of operations or financial condition of the Company and
its Subsidiaries, taken as a whole. The reserves reflected in the consolidated
financial statements as of June 30, 2001 are adequate, appropriate and
reasonable and have been calculated in a consistent manner.
3.9 Absence of Certain Changes or Events. Since June 30, 2001, there has
not been: (i) any Company Material Adverse Effect, (ii) any declaration,
setting aside or payment of any dividend on, or other distribution (whether in
cash, stock or property) in respect of, any of the Company's or any of its
Subsidiaries' capital stock, or any purchase, redemption or other acquisition
by the Company of any of its Subsidiaries' capital stock or any other
securities of the Company or of its Subsidiaries or any options, warrants,
calls or rights to acquire any such shares or other securities except for
repurchases from employees following their termination pursuant to the terms of
their pre-existing stock option or purchase agreements, (iii) any split,
combination or reclassification of any of the Company's or any of Subsidiaries'
capital stock, (iv) any granting by the Company or any of its Subsidiaries of
any increase in compensation or fringe benefits, except for normal increases of
cash or non-cash benefits compensation in the ordinary course of business
consistent with past practice, or any payment by the Company or any of its
Subsidiaries of any bonus, except for bonuses made in the ordinary course of
business consistent with past practice, or any granting by the Company or any
of its Subsidiaries of any increase in severance or termination pay or any
entry by the Company or any of its Subsidiaries into any currently effective
employment, severance, termination or indemnification agreement or any
agreement the benefits of which are contingent or the terms of which are
materially altered upon the occurrence of a transaction involving the Company
of the nature contemplated hereby, (v) entry by the Company or any of its
Subsidiaries into any material licensing or other agreement with regard to the
acquisition or disposition of any Intellectual Property other than licenses in
the ordinary course of business consistent with past practice or any amendment
or consent with respect to any licensing agreement filed or required to be
filed by the Company with the SEC, (vi) any material change by the Company in
its accounting methods, principles or practices, except as required by
concurrent changes in U.S. GAAP, (vii) any material revaluation by the Company
of any of its assets, including, without limitation, writing down the value of
capitalized inventory or writing off notes or accounts receivable or any sale
of assets of the Company other than in the ordinary course of business
consistent with past practice, or (viii) any other change or event that would
have required the Buyer's consent under Section 5.1 (except for Section 5.1(r))
if such change or event had occurred after the execution of this Agreement.
3.10 Absence of Litigation. Except as specifically disclosed in the
Company SEC Reports as of the date hereof, there are no material claims,
actions, suits, inquiries, proceedings or investigations pending or, to the
knowledge of the Company, threatened (or any governmental or regulatory
investigation pending or, to the knowledge of the Company, threatened) against
the Company or any of its Subsidiaries or any properties or rights of the
Company or any of its Subsidiaries, by or before any court, arbitrator or
administrative, governmental or regulatory authority or body, domestic or
foreign.
3.11 Employee Matters and Benefit Plans.
(a) Definitions. For purposes of this Section 3.11 only, "Affiliate" shall
mean any other person or entity under common control with the Company within
the meaning of Section 414(b), (c), (m) or (o) of the Code and the regulations
issued thereunder and, for avoidance of doubt, includes each Subsidiary.
A-12
(b) Schedule. Section 3.11(b) of the Company Disclosure Letter contains an
accurate and complete list of each Company Employee Plan and each Employment
Agreement. Neither the Company nor any of its Subsidiaries has any plan or
commitment to establish any new Company Employee Plan or Employment Agreement,
to modify any Company Employee Plan or Employment Agreement (except to the
extent required by law or to conform any such Company Employee Plan or
Employment Agreement to the requirements of any applicable law, or as required
by this Agreement), or to adopt or enter into any Company Employee Plan or
Employment Agreement.
(c) Documents. The Company has provided or made available to the Buyer
correct and complete copies of: (i) all documents embodying each Company
Employee Plan and each Employment Agreement including (without limitation) all
amendments thereto and all related trust documents, administrative service
agreements, group annuity contracts, group insurance contracts, and policies
pertaining to fiduciary liability insurance covering the fiduciaries for each
Company Employee Plan; (ii) all Employment Agreements, current contracts of
employment or material particulars of the terms of employment (including,
without prejudice to the generality of the foregoing, severance, consulting,
relocation, repatriation, and expatriation arrangements) for Senior Employees;
(iii) a current template or sample of a contract of employment or the material
particulars of the terms and conditions of employment (including, without
prejudice to the generality of the foregoing, severance, consulting,
relocation, repatriation, and expatriation arrangements) for each grade or
level of Company Employee; (iv) the most recent annual actuarial valuations, if
any, prepared for each Company Employee Plan; (v) the three (3) most recent
annual reports (Form Series 5500 and all schedules and financial statements
attached thereto), if any, required under ERISA or the Code in connection with
each U.S. Employee Plan; (vi) if any Company Employee Plan is funded, the most
recent annual and periodic accounting of that Company Employee Plan assets;
(vii) the most recent summary plan description together with the summary(ies)
of material modifications thereto and in the case of International Employee
Plans the most recent participant booklets and all material announcements to
employees and participants; (viii) for U.S. Employee Plans the most recent IRS
determination letter, and for International Employee Plans evidence of plan
approval; (ix) all written communications relating to any Company Employee Plan
and any proposed Company Employee Plans in each case, relating to any
amendments, terminations, establishments, increases or decreases in benefits,
acceleration of payments or vesting schedules or other events which would
result in any material liability to the Company or any of its Affiliates; (x)
all material correspondence to or from any Governmental Entity relating to any
Company Employee Plan; (xi) for U.S. Employee Plans the three (3) most recent
plan years discrimination tests for each Company Employee Plan; and (xii) all
registration statements, annual reports (for U.S. Employee Plans, Form 11-K and
all attachments thereto) and prospectuses prepared in connection with each
Company Employee Plan.
(d) Employee Plan Compliance. (i) Each of the Company and its Subsidiaries
has performed in all material respects all obligations required to be performed
by it under, is not in default or violation of, and the Company has no
knowledge of any default or violation by any other party to each Company
Employee Plan, and each Company Employee Plan has been established and
maintained in all material respects in accordance with its terms and in
compliance with all applicable laws, statutes, orders, rules and regulations,
including but not limited to ERISA or the Code; (ii) each U.S. Employee Plan
intended to qualify under Section 401(a) of the Code and each related trust
intended to qualify under Section 501(a) of the Code has either received a
favorable determination, opinion, notification or advisory letter from the IRS
with respect to each such Company Employee Plan as to its qualified status
under the Code, including all amendments to the Code effected by the Tax Reform
Act of 1986 and subsequent legislation, or has remaining a period of time under
applicable Treasury regulations or IRS pronouncements in which to apply for
such a letter and make any amendments necessary to obtain a favorable
determination as to the qualified status of each such Company Employee Plan;
(iii) each International Employee Plan, including any amendments thereto, that
is capable of, or intended to be capable of, Plan Approval has received such
Plan Approval or there remains a period of time in which to obtain such Plan
Approval retroactive to the date of any amendment that has not previously
received such Plan Approval; (iv) no "prohibited transaction," within the
meaning of Section 4975 of the Code or Sections 406 and 407 of ERISA, and not
otherwise exempt under Section 4975 of the Code or Section 408 of ERISA (or any
administrative class exemption issued thereunder), has occurred with respect to
any Company Employee Plan that could result in material liability to the
Company or any of its Subsidiaries; (v) there are no actions, suits or, claims
pending or,
A-13
to the Company's knowledge, threatened (other than routine claims for benefits)
against any Company Employee Plan or against the assets of any Company Employee
Plan that could result in any material liability to the Company or any of its
Subsidiaries; (vi) each Company Employee Plan (other than any stock option
plan) can be amended, terminated or otherwise discontinued after the Closing
Time, without material liability to the Buyer, the Company or any of its
Affiliates (other than benefits accrued to date and ordinary administration
expenses); (vii) there are no audits, inquiries or proceedings pending or, to
the knowledge of the Company, threatened by the IRS or DOL or any other
Governmental Entity with respect to any Company Employee Plan; and (viii)
neither the Company nor any Affiliate is subject to any penalty or tax with
respect to any Company Employee Plan that could result in material liability to
the Company or any of its Subsidiaries.
(e) Pension Plan. Neither the Company nor any Affiliate has ever
maintained, established, sponsored, participated in, or contributed to, any
Pension Plan which is subject to Title IV of ERISA or Section 412 of the Code
or any equivalent non-U.S. rule or legislation.
(f) Funded Pension Plans. The latest actuarial valuation of each Funded
Pension Plan discloses that, as of the effective date of the valuation, the
aggregate value of the assets of that Funded Pension Plan is equal to or
greater than the aggregate value of its liabilities assessed on an ongoing and
terminated basis and calculated in accordance with the actuarial methods and
assumptions used in such valuation pursuant to the applicable Funded Pension
Plan and applicable Legal Requirements.
(g) Unfunded Pension Plans. In respect of each Unfunded Pension Plan, the
Company or a Subsidiary of the Company, as applicable, has made provision for
accrued liabilities in accordance with applicable Legal Requirements.
(h) Collectively Bargained, Multiemployer and Multiple Employer Plans. At
no time has the Company or any Affiliate participated in, contributed to or
been obligated to participate in or contribute to any Multiemployer Plan or
ever maintained, established, sponsored, participated in, or contributed to any
multiple employer plan, or to any plan described in Section 413 of the Code.
(i) No Post-Employment Obligations. No Company Employee Plan provides, or
reflects or represents any liability to provide retiree health insurance
coverage to any person for any reason, except as may be required by COBRA or
other applicable statute, and, to Company's knowledge after due inquiry,
neither the Company nor its Affiliates has ever represented, promised or
contracted (whether in oral or written form to any Employee (either
individually or to Employees as a group) or any other person that such
Employees(s) or other person would be provided with retiree health, except to
the extent required by statute.
(j) Health Care Compliance. Neither the Company nor any Affiliate has,
prior to the Closing Time and in any material respect, violated any of the
health care continuation requirements of COBRA, the requirements of FMLA, the
requirements of the Health Insurance Portability and Accountability Act of
1996, the requirements of the Women's Health and Cancer Rights Act of 1998, the
requirements of the Newborns' and Mothers' Health Protection Act of 1996, or
any amendment to each such act, or any similar provisions of state or foreign
law applicable to its Employees.
(k) Effect of Transaction.
(i) The execution of this Agreement and the consummation of the
transactions contemplated hereby will not (either alone or upon the
occurrence of any additional or subsequent events) constitute an event under
any Company Employee Plan, Employment Agreement, trust or loan that will or
may result in any payment (whether of severance pay or otherwise),
acceleration, forgiveness of indebtedness, vesting, distribution, increase
in benefits or obligation to fund benefits with respect to any Employee.
(ii) No payment or benefit which will or may be made by the Company or
its Affiliates with respect to any Employee will be characterized as a
"parachute payment" within the meaning of Section 280G(b)(2) of the Code.
(l) Employment Matters. The Company and each of its Subsidiaries: (i) is in
material compliance with all applicable foreign, federal, state and local laws,
rules and regulations respecting employment, employment
A-14
practices, terms and conditions of employment and wages and hours, in each
case, with respect to Employees; (ii) has withheld and reported all amounts
required by law or by Contract to be withheld and reported with respect to
wages, salaries and other payments to Employees, except where any such failure
would not result in any material liability to the Company or any of its
Subsidiaries; (iii) is not liable for any arrears of wages or any taxes or any
penalty for failure to comply with any of the foregoing, except where any such
failure would not result in any material liability to the Company or any of its
Subsidiaries; and (iv) is not liable for any payment to any trust or other
arrangement (funded or not) governed by or maintained by or on behalf of any
Governmental Entity with respect to unemployment compensation benefits, social
security or other benefits or obligations for Employees (other than routine
payments to be made in the normal course of business and consistent with past
practice), except where any such failure would not result in any material
liability to the Company or any of its Subsidiaries. There are no pending or,
to the knowledge of the Company, threatened or reasonably anticipated claims or
actions against the Company or any of its Affiliates under any worker's
compensation policy or long-term disability policy (other than routine claims
for benefits) that would result in any material liability to the Company or any
of its Subsidiaries.
(m) Labor. No work stoppage, labor strike, industrial or trade dispute, or
any dispute or negotiation with any trade union, association of trade unions,
works council, European works council or body representing Employees against
the Company or any of its Subsidiaries has occurred in the last 12 months, is
pending or, to the knowledge of the Company, threatened. The Company does not
know of any activities or proceedings of any labor union to organize any
Employees. There are no actions, suits, claims, labor disputes or grievances
pending, or, to the knowledge of the Company, threatened or reasonably
anticipated relating to any labor, safety or discrimination matters involving
any Employee, including, without limitation, charges of unfair labor practices
or discrimination complaints, which, if adversely determined, would,
individually or in the aggregate, result in any material liability to the
Company or any of its Subsidiaries. Neither the Company nor any of its
Subsidiaries has engaged in any unfair labor practices within the meaning of
the National Labor Relations Act or similar local law. Neither the Company nor
any of its Subsidiaries is presently nor has it been in the past a party to, or
bound by, or subject to any rules relating to, any recognition, procedural or
other agreement, works council or arrangement or custom between, or applying
to, one or more employers (whether or not Affiliates) and a union, group of
employees, or an employee representative body, for collective bargaining or
other negotiating or consultation purposes, labor union or union contract, or
workers' council or similar elected employee representatives with respect to
Employees and no such agreements or arrangements are is being negotiated by or
on behalf of the Company or any of its Subsidiaries.
(n) International Employee Plan. Each International Employee Plan has been
established, maintained and administered in material compliance with its terms
and conditions and with the requirements prescribed by any and all statutory or
regulatory laws that are applicable to such International Employee Plan.
Furthermore, no International Employee Plan has material unfunded liabilities,
that as of the Closing Time, will not be offset by insurance or fully accrued
or disclosed in the Company's financial statements. Except as required by law,
no condition exists that would prevent the Company or the Buyer from
terminating or amending any International Employee Plan at any time for any
reason without material liability to the Company or its Affiliates (other than
ordinary administration expenses or routine claims for benefits).
(o) Israeli Employees. Without derogating from the provisions of Section
3.11(a)-(n), with respect to Employees who reside in Israel or whose Employment
Agreements are subject to Israeli law ("Israeli Employees"):
(i) Neither the Company nor any of its Affiliates (A) is party to any
general or special collective bargaining agreement, collective bargaining
arrangements or other contract or arrangement with a labor union, trade
union or other organization or body involving any of their respective
Israeli Employees, or is otherwise required (under any legal requirement,
under any Contract or otherwise) to provide benefits or working conditions
beyond those required by law or pursuant to rules and regulations thereunder
(including extension orders (tzavei harchava) issued by the Ministry of
Labor and Welfare); (B) is a member of the Manufacturers Association of
Israel; or (C) has recognized or received a demand for recognition from any
collective bargaining representative with respect to any of their respective
Israeli Employees.
A-15
(ii) All of the Israeli Employees are "at will" employees subject to the
termination notice provisions included in Employment Agreements or
applicable law.
(iii) All Employment Agreements between the Company or any of its
Affiliates and any of their respective Israeli Employees can be terminated
by the Company or, if applicable, the relevant Affiliate upon less than
three months notice without giving rise to a claim for damages or
compensation (except for statutory severance pay).
(iv) All payments by the Company and its Affiliates into pension and
provident funds severance fund or other similar funds (including, manager's
insurance, life insurance or incapacity insurance) together with relevant
reserves reflected in the Company Interim Financial Data fully fund and
cover the liabilities of the Company and its Affiliates pursuant to all
Legal Requirements, the individual Employment Agreements or other
arrangements with respect to the Israeli Employees and any binding usage or
customs, if any, which forms part of the employment relationship of any of
the Israeli Employees, for all obligations, as at June 30, 2001, relating to
pension, severance pay, sick leave, benefits and other employee benefits,
recreation pay, incapacity insurance, life insurance, salaries and
reimbursement of expenses, vacation pay and similar liabilities and each of
the Company and its Affiliates has continued and shall continue to make all
payments and such additional "top up" payments to such pension and provident
funds, severance fund or other similar funds (including, manager's
insurance, life insurance or incapacity insurance) until the Closing Time
such that the aforementioned liabilities of the Company and its Affiliates
shall be fully covered and funded as at the Closing Time, pursuant to all
Legal Requirements.
(v) Neither the Company nor any of its Affiliates is aware of any
circumstance that could give rise to any valid claim by a current or former
Israeli Employee for compensation on termination of employment (beyond, with
respect to current Israeli Employees only, the statutory severance pay to
which employees are entitled).
(vi) All amounts that the Company and its Affiliates are legally or
contractually required either (A) to deduct, or transfer, from their
respective employees' salaries or to transfer to such employees' pension or
provident fund, manager's insurance life insurance, incapacity insurance,
continuing education fund, severance fund or other similar funds or (B) to
withhold from their employees' salaries and to pay to any Governmental
Entity as required by the Israeli Income Tax Ordinance [New Version],
Israeli social security laws and Israeli national health insurance laws or
otherwise have, in each case, been duly deducted, transferred, withheld and
paid, and neither the Company nor any of its Affiliates has any outstanding
obligation to make any such deduction, transfer, withholding or payment.
(vii) The Company and its Affiliates comply in all material respects with
all applicable Legal Requirements and Contracts relating to employment,
employment practices, wages, bonuses and other compensation matters and
terms and conditions of employment related to their respective Israeli
Employees.
3.12 Restrictions on Business Activities. There is no agreement,
commitment, judgment, injunction, order or decree binding upon the Company or
its Subsidiaries or to which the Company or any of its Subsidiaries is a party
which has or could reasonably be expected to have the effect of prohibiting or
materially impairing any business practice of the Company or any of its
Subsidiaries, any acquisition of property by the Company or any of its
Subsidiaries or the conduct of business by the Company or any of its
Subsidiaries as currently conducted.
3.13 Title to Property.
(a) Section 3.13(a) of the Company Disclosure Letter sets forth: (a) a list
of all real property currently owned, leased to, subleased to or otherwise
occupied by the Company or any of its Subsidiaries in connection with the
business of the Company or any of its Subsidiaries or Included Assets
(collectively, "Company Business Facilities"); and (ii) a list of all other
leases, subleases or other occupancy agreements currently in effect between the
Company or any of its Subsidiaries as lessor and any third parties with respect
to any Company Business Facilities, (each a "Lease" and, collectively, the
"Leases"), each amendment thereto, the commencement date, the rentable square
footage of the premises set forth in the Lease, the aggregate monthly
A-16
fixed rental, and the expiration date. The Company has provided the Buyer with
true, complete and correct copies of each Lease. Each such Lease constitutes
the entire agreement of the parties thereunder, and there are no other
agreements or arrangements whatsoever relating to the Company's or any of its
Subsidiary's use or occupancy of any of the premises described in such Leases.
Neither the Company nor any of its Subsidiaries has transferred or assigned any
interest in any Lease, other than to a Subsidiary of the Company, nor has the
Company or any of its Subsidiaries subleased or otherwise granted rights of use
or occupancy of any of the premises described therein to any other person or
entity, other than to the Company or a Subsidiary of the Company. To the extent
any Lease is required, under Israeli law, to be registered with the Israeli
Lands Registry, such Lease has been duly registered, is free of any Encumbrance
(including cautionary notices) and a copy of the extract from the Israeli Land
Registry, dated no earlier that five Business Days prior to the date hereof,
regarding title to the real property subject to any such Lease is attached as
part of Section 3.13(a) of the Company Disclosure Letter.
(b) The properties and assets owned or leased by the Company and its
Subsidiaries are sufficient to conduct the business of the Company and its
Subsidiaries as currently conducted. The Company and each of its Subsidiaries
has good title to or, in the case of the leased properties and assets, valid
leasehold interests in, all of the properties and assets, real, personal and
mixed, used in their respective businesses, including the Included Assets, free
and clear of all Encumbrances (other than mortgages made by a landlord under a
Lease of real property not situated in Israel to which mortgage the Company is
not a party but the Lease may be subject), except for liens for Taxes not yet
due and payable or which are being contested in good faith and are not material.
(c) All the Leases are in full force and effect, and there is not, under any
of such Leases, any existing default, or event of default nor has there
occurred any event which with notice or lapse of time, or both, would
constitute a default thereunder by the Company or any of its Subsidiaries, or,
to the Company's knowledge, by any other party.
3.14 Taxes.
(a) The Company and each of its Subsidiaries have timely filed all federal,
state, local and foreign returns, estimates, information statements and reports
("Returns") relating to Taxes required to be filed by the Company and each of
its Subsidiaries with any Tax authority, except such Returns which are not
material to the Company. All such Returns were correct and complete in all
material respects and were made on the proper basis. The Company and each of
its Subsidiaries have paid all Taxes shown to be due on such Returns. The
Company and each of its Subsidiaries have maintained all records required to be
maintained for tax purposes; all such information was and remains complete and
accurate in all material respects.
(b) Neither the Company nor any of its Subsidiaries is or will become liable
to pay, or make reimbursement or indemnity in respect of, any tax in
consequence of the failure by any other person (other than the Company or any
of its Subsidiaries) to discharge that tax within any specified period or
otherwise, where such tax relates to income, profits or gains, earned, accrued
or received, or to any event, transaction or circumstance occurring or arising
or deemed to occur or arise (whether wholly or partly) prior to the Closing
(including, but not limited to, taxation under Treasury Regulation Section
1.1502-6). The Company and each of its Subsidiaries have withheld with respect
to their employees, independent contractors, creditors, shareholders, and all
other third parties all federal and state income taxes, Taxes pursuant to the
Federal Insurance Contribution Act and other Taxes required to be withheld and
have timely paid over to the proper Governmental Entities all amounts required
to be withheld and paid over under all applicable laws.
(c) Neither the Company nor any of its Subsidiaries has executed any
unexpired waiver of any statute of limitations on or extending the period for
the assessment or collection of any Tax.
(d) Neither the Company nor any of its Subsidiaries is involved in any
current dispute with any tax authority or is or has in the last six years been
the subject of any investigation, audit or non-routine visit by any tax
authority. To the knowledge of the Company, neither the Company nor any of its
Subsidiaries has been notified in writing of any request for such an audit or
other examination.
A-17
(e) No material adjustment relating to any Returns filed by the Company or
any of its Subsidiaries (and no claim by a Tax authority in a jurisdiction in
which the Company or any of its Subsidiaries does not file Returns that the
Company or any of its Subsidiaries may be subject to taxation by such
jurisdiction) has been proposed in writing formally or informally by any Tax
authority to the Company or any of its Subsidiaries.
(f) Neither the Company nor any of its Subsidiaries has any liability for
any unpaid Taxes which has not been accrued for or reserved on the Company
Interim Financial Data in accordance with U.S. GAAP, whether asserted or
unasserted, contingent or otherwise, other than any liability for unpaid Taxes
that may have accrued since June 30, 2001 in connection with the operation of
the business of the Company and its Subsidiaries in the ordinary course. All
other warranties relating to specific tax matters set out in this Section 3.14
are made without prejudice to the generality of this paragraph.
(g) No tax authority has operated or agreed to operate any special
arrangement (being an arrangement which is not directly based on relevant
legislation, even if based on any published practice, including rulings) or has
agreed on any compromise in relation to any of the Company's or Subsidiaries'
tax affairs.
(h) There is no contract, agreement, plan or arrangement to which the
Company or any of its Subsidiaries is a party as of the date of this Agreement,
including but not limited to the provisions of this Agreement, covering any
Employee that, individually or collectively, would reasonably be expected to
give rise to the payment of any amount that would not be deductible pursuant to
Sections 404 or 162(m) of the Code. There is no contract, agreement, plan or
arrangement to which the Company is a party or by which it is bound to
compensate any individual for excise taxes paid pursuant to Section 4999 of the
Code.
(i) Neither the Company nor any of its Subsidiaries has filed any consent
agreement under Section 341(f) of the Code or agreed to have Section 341(f)(2)
of the Code apply to any disposition of a subsection (f) asset (as defined in
Section 341(f)(4) of the Code) owned by the Company or any of its Subsidiaries.
(j) Neither the Company nor any of its Subsidiaries (i) has any of its tax
affairs dealt with on a consolidated basis, or any other basis which allows a
combined filing, profit calculation or payment of tax for more than one person
or entity, (ii) is a party to any Tax sharing or Tax allocation agreement,
arrangement or understanding, (iii) has been involved in a business merger,
share-for-share merger, legal merger or legal demerger (split) within the
meaning of the Articles 14, 14a or 14b of the Corporate Income Tax Act and/or
3.55, 3.56 or 3.57 of the Income Tax Act (or the predecessors of these articles
under the Income Tax Act 1964) and/or Article 37 of the Legal Transfer Taxes
Act, or (iv) is a party to any joint venture, partnership or, to the knowledge
of the Company, any other arrangement that could be treated as a partnership
for income Tax purposes.
(k) The Company and each of its Subsidiaries are and have at all times been
resident for tax purposes in their place of incorporation and are not and have
not at any time been treated as resident in any other jurisdiction for any tax
purpose (including any double taxation arrangement). Neither the Company nor
any of its Subsidiaries is or has been subject to tax in any jurisdiction other
than its place of incorporation by virtue of having a permanent establishment,
a permanent representative or other place of business or taxable presence in
that jurisdiction.
(l) No relief has been claimed by and/or given to the Company or any of its
Subsidiaries, or taken into account in determining or eliminating any provision
for tax or deferred tax in the Company Interim Financial Data, which could or
might be effectively withdrawn, postponed, restricted or otherwise lost as a
result of the sale and purchase hereunder or any other event or circumstance
occurring or arising at any time after June 30, 2001.
(m) All transactions between the Company and its Subsidiaries or between
Subsidiaries have been and are on fully arm's length terms. There are no
circumstances that could cause any tax authority to make any adjustment for tax
purposes, or require any such adjustment to be made, to the terms on which any
such transaction is treated as taking place, and no such adjustment has been
made or attempted in fact.
(n) In relation to the Company and each Subsidiary: (i) each is registered
for the purposes of VAT, has been so registered at all times that it has been
required to be registered by VAT legislation, and such registration is not
A-18
subject to any conditions imposed by or agreed with the relevant tax authority;
(ii) each has complied fully with and observed in all material respects the
terms of VAT legislation; (iii) each has maintained and obtained at all times
complete, correct and up-to-date records, invoices and other documents (as the
case may be) appropriate or requisite for the purposes of VAT legislation and
has preserved such records, invoices and other documents in such form and for
such periods as are required by VAT legislation; (iv) each obtains credit for
all input tax paid or suffered by it; (v) each cannot be subjected to a
revision of the VAT position, leading to a recapture of VAT deducted on or
before Closing; (vi) each is not and has not been treated as a member of a
group for the purposes of VAT legislation, and has not applied for such
treatment; (vii) each is not and has not been subject under VAT legislation to
any penalty, fine or surcharge, or any warning or notice which could (whether
with or without other events) lead to the imposition of any penalty, fine or
surcharge, and has not been required to give any security as a condition of
making supplies for the purposes of VAT; (viii) and each has not elected rents
paid or received, and/or the acquisition of real estate, to be subject to VAT.
(o) No claim has been made by the Company or any of its Subsidiaries for the
depreciation of any asset for tax purposes, which is likely to be disallowed.
(p) Neither the Company nor any of its Subsidiaries has constituted either a
"distributing corporation" or a "controlled corporation" in a distribution of
stock qualifying for tax-free treatment under Section 355 of the Code (i) in
the two years prior to the date of this Agreement or (ii) in a distribution
which could otherwise constitute part of a "plan" or "series of related
transactions" (within the meaning of Section 355(e) of the Code) in conjunction
with the Offer and the Post-Closing Reorganization.
(q) Neither the Company nor any of its Subsidiaries (i) holds a receivable
(x) payable by another entity in which it or a Related Company has a
Participation and (y) on which it or a Related Company has claimed a loss for
corporate income tax purposes, or (ii) has outstanding debt the fair market
value of which is below its nominal value.
(r) Neither the Company nor any of its Subsidiaries has claimed any
reduction of tax by virtue of Article 13ca of the Corporate Income Tax Act.
(s) Neither the Company nor any of its Subsidiaries has a participation in
an entity that is engaged in business activities outside the Netherlands, where
previously these activities were the activities of a Related Company.
(t) In case of a liquidation of any Participation of the Company or of its
Subsidiaries that hold(s) the shares in such Participation, are entitled to a
deductible loss for corporate income tax purposes equal to the difference
between (i) the total, or the proportionate part, as the case may be, of the
liquidation proceeds derived from the liquidation of such Participation, minus
the fair market value of the shares in any other Participation that are a part
of such liquidation proceeds, and (ii) the book value of that Participation as
shown in or adopted for the purposes of the Company Interim Financial Data.
(u) Since January 1, 2001, neither the Company nor any of its Subsidiaries
has distributed or is deemed to have distributed a dividend.
(v) Neither the Company nor any of its Subsidiaries has tainted (share)
capital (besmet fusie aandelenkapitaal/agio) by reason of Article 3a of the
Dividend Withholding Tax Act.
(w) Neither the Company nor any of its Subsidiaries is a real estate
investment company within the meaning of Article 4 of the Legal Transfer Taxes
Act.
(x) All interest and other sums of an expense nature paid, payable or
accruable by the Company or any of its Subsidiaries and all sums payable or
accruable under any obligation incurred by the Company or any of its
Subsidiaries prior to the Closing and which will continue to bind the Company
or a Subsidiary after the Closing, have been and will continue to be deductible
for the purposes of corporate income tax, either in computing the profits of
the Company or a Subsidiary or in computing the corporate income tax chargeable
on it.
(y) Neither the Company nor any of its Subsidiaries has formed a reserve for
risks in relation to finance activities by virtue of Article 15b of the
Corporate Income Tax Act.
A-19
(z) Neither the Company nor any of its Subsidiaries has made an election to
report its taxable income for corporate income tax purposes in a currency other
than NLG/Euro or has requested the tax inspector to bring an action that served
to hedge a currency exchange risk on a participation, under the participation
exemption as meant in Article 13 of the Corporate Income Tax Act.
(aa) Indigo Electronic Printing Systems Limited ("IEPS") qualifies as an
"Industrial Company" within the definition of the Israeli Encouragement of
Industry (Taxes) Law, 1969. To the Company's knowledge, there is no event or
reason (including, the consummation of the Offer and the conduct and
performance of IEPS' business and operations in accordance with IEPS' or the
Company's plans and projections) that could result in IEPS ceasing to qualify
as an Industrial Company. IEPS (i) is an Approved Enterprise for the purposes
of the Israeli Encouragement of Capital Investments Law, 1959; and (ii) Section
3.14(dd) of the Company Disclosure Letter sets forth the effective Israeli
income tax rate applicable to IEPS for its last completed fiscal year and the
portions of IEPS which are Approved Enterprises and their effective Israeli
income Tax rates for the current fiscal year. For the purposes of Section
47(a1)(3) of the Israeli Encouragement of Capital Investments Law, 1959 the
proportion of foreign investment in IEPS is 90% or more.
(bb) Neither the Company nor any of its Subsidiaries is (i) a controlled
foreign corporation within the meaning of Section 957 of the Code, (ii) a
foreign personal holding company within the meaning Section 552 of the Code, or
(iii) a passive foreign investment company within the meaning of Section 1297
of the Code.
3.15 Brokers. Except for fees payable to Gleacher & Co. LLC pursuant to
an engagement letter, a true and correct copy of which has been provided to the
Buyer, the Company has not incurred, and will not incur, directly or
indirectly, any liability for brokerage or finders fees or agent's commissions
or any similar charges in connection with this Agreement or any transaction
contemplated hereby.
3.16 Intellectual Property.
(a) Section 3.16(a) of the Company Disclosure Letter contains a complete and
accurate list (by name and version number) of all material products (including
any software components) or material service offerings of the Company and any
of its Subsidiaries (collectively, the "Company Products") that have been sold,
distributed or otherwise disposed of in the five (5)-year period preceding the
date hereof or which the Company or any of its Subsidiaries intends to sell,
distribute or otherwise dispose of in the future, including without limitation
any products or service offerings under active development.
(b) Section 3.16(b) of the Company Disclosure Letter lists all Registered
Intellectual Property Rights owned by, filed in the name of, or applied for, by
the Company and any of its Subsidiaries (the "Company Registered Intellectual
Property Rights") and lists any proceedings or actions filed or pending before
any court, tribunal (including the PTO) or equivalent authority anywhere in the
world related to any of the Company Registered Intellectual Property Rights or
the Company Intellectual Property, other than proceedings to which the Company
or any of its Subsidiaries is not a party or by which any of such are not bound.
(c) Each Company Registered Intellectual Property Right is valid and
subsisting. All necessary documents and certificates in connection with such
Company Registered Intellectual Property Rights have been filed with the
relevant patent, copyright, trademark or other authorities in the United States
or foreign jurisdictions, as the case may be, for the purposes of perfecting,
prosecuting and maintaining such Registered Intellectual Property Rights.
(d) In each case in which the Company or any of its Subsidiaries has
acquired ownership of any material Intellectual Property or material
Intellectual Property Right from any person, the Company or its Subsidiaries
has obtained a valid and enforceable assignment sufficient to irrevocably
transfer all rights in and to all such Intellectual Property and the associated
Intellectual Property Rights (including the right to seek past and future
damages with respect thereto) to the Company or its Subsidiaries. The Company
or its Subsidiaries has recorded each such assignment of a material Registered
Intellectual Property Right assigned to the Company or any of its Subsidiaries
with the relevant governmental entity in accordance with applicable laws and
regulations in each jurisdiction in which such assignment is required to be
recorded.
A-20
(e) The Company has no knowledge of any facts or circumstances that would
render any material Company Intellectual Property invalid or unenforceable.
(f) All Company Intellectual Property will be fully transferable, alienable
or licensable by the Buyer without restriction and without payment of any kind
to any third party.
(g) Each item of the Company Intellectual Property is free and clear of any
Encumbrances, except for non-exclusive licenses granted to OEM's and other
resellers listed in the Company Disclosure Letter or to end-user customers in
the ordinary course of business. The Company is the exclusive owner or
exclusive licensee of all the Company Intellectual Property. Without limiting
the generality of the foregoing (i) the Company is the exclusive owner of all
material Trademarks used in connection with the operation or conduct of the
business of the Company and its Subsidiaries, including the sale, distribution
or provision of any Company Products by the Company or any of its Subsidiaries,
but excluding any non-material trademarks owned by a third party that are
licensed to the Company and used to refer to third party products that are
incorporated in or used in connection with any Company Products, (ii) the
Company owns exclusively all copyrighted works that are included or
incorporated into the Company Products or which the Company or any of its
Subsidiaries otherwise purports to own, and (iii) to the extent that any
Patents would be infringed by any Company Product, the Company is the exclusive
owner of such Patents.
(h) Neither the Company nor any of its Subsidiaries has (i) transferred
ownership of, or granted any exclusive license of or right to use, or
authorized the retention of any exclusive rights to use or joint ownership of,
any Intellectual Property or Intellectual Property Right that is or was the
Company Intellectual Property, to any other person, or (ii) permitted the
Company's rights in such Company Intellectual Property to lapse or enter the
public domain.
(i) Excluding any failure by a non-material Employee or contractor to
execute an assignment agreement that does not result in the loss of any
Intellectual Property each Employee, and any contractor who has contributed to
or participated in the creation, discovery or development of any Intellectual
Property whether on behalf of the Company or any of its Subsidiaries either:
(i) is a party to an Employment Agreement under which the Company or its
Subsidiaries is deemed or agreed to be the original owner/author, as
applicable, of such Intellectual Property; or (ii) has executed a valid and
irrevocable assignment or an agreement to assign in favor of the Company all
right, title and interest in such Intellectual Property; or (iii) in respect of
Israeli Employees, pursuant to their respective employment agreements or under
relevant Israeli law, is deemed to have assigned all right, title and interest
to such Intellectual Property to the Company and any of its Subsidiaries. All
such Intellectual Property constitutes Company Intellectual Property and no
third party owns or has any rights to any such Company Intellectual Property.
In respect of each Israeli Employee, the salary payable to each such Israeli
Employee under the terms of the relevant Employment Agreement expressly
includes a provision to the effect whereby it is agreed that such salary
includes the full remuneration payable to such Israeli Employee for any
invention made by such employee that is a service patent (as defined in the
Israeli Patents Law 1967).
(j) To the extent that any Intellectual Property or Intellectual Property
Rights have been developed or created by a third party for the Company or any
of its Subsidiaries and is incorporated into any Company Product, the Company
has a written agreement with such third party with respect thereto and the
Company thereby either (i) has obtained ownership of, and is the exclusive
owner of, or (ii) has obtained a perpetual, transferable license (sufficient
for the conduct of its business as currently conducted or proposed to be
conducted by the Company as per the Company SEC filings) to all such third
party's Intellectual Property Rights in such Intellectual Property or
Intellectual Property Rights by operation of law or by valid assignment.
(k) The Company Intellectual Property, together with any Intellectual
Property Rights licensed to the Company on a non-exclusive basis, constitute
all the Intellectual Property and Intellectual Property Rights material to the
business of the Company and its Subsidiaries as it currently is conducted or
proposed to be conducted by the Company as per the Company SEC filings or which
are used in and/or necessary to the conduct of such business, including the
design, development, manufacture, use, import and sale of the Company Products.
(l) No person who has licensed any Intellectual Property or Intellectual
Property Rights to the Company or any of its Subsidiaries has ownership rights
or license rights to improvements made by or for the Company or any of its
Subsidiaries in such Intellectual Property or Intellectual Property Rights.
A-21
(m) No open source or public library software, including any version of any
software licensed pursuant to any GNU public license, was used in the
development or modification of any software that is or was the Company
Intellectual Property or is incorporated into any Company Product.
(n) No government funding, facilities of a university, college, other
educational institution or research center or funding from third parties was
used in the development of any Company Intellectual Property. To the knowledge
of the Company, no Employee or independent contractor of the Company or any of
its Subsidiaries, who was involved in, or who contributed to, the creation or
development of any Company Intellectual Property, has performed services for
the government, university, college, or other educational institution or
research center during a period of time during which such Employee or
independent contractor was also performing services for the Company or any of
its Subsidiaries, the effect of which would confer on such government,
university, college, or other educational institution or research center any
interest in such Company Intellectual Property.
(o) All Company Intellectual Property is freely transferable, conveyable,
and/or assignable by the Company and/or the Buyer, to any entity located in any
jurisdiction in the world without any restriction, constraint, control,
supervision, or limitation whatsoever. Section 3.16(o) of the Company
Disclosure Letter describes all restrictions, constraint, control, supervision,
fees, penalties, royalties, assessments or limitations that could be imposed by
the OCS or any other Governmental Entity or quasi-governmental entity on the
ownership, place, method and scope of exploitation of any Intellectual Property
(including the operation of the business of the Company or its Subsidiaries as
it is currently conducted, including the design, development, use, import,
branding, advertising, promotion, marketing, manufacture and sale of the
Company Products. Notwithstanding anything in the Disclosure Schedule to the
contrary, none of the intellectual property developed as a result of the
Company's involvement with the Magnet Program and/or the Magnet Consortium
constitutes intellectual property which is material to the Company's
Intellectual Property estate.
(p) The operation of the business of the Company and its Subsidiaries as it
is currently conducted or proposed to be conducted by the Company as per the
Company SEC filings, including the design, development, use, import, branding,
advertising, promotion, marketing, manufacture and sale of the Company
Products, does not and will not when conducted by the Buyer and/or the Company
or its Subsidiaries in substantially the same manner following the Closing
infringe or misappropriate any Intellectual Property Right of any person,
violate any right of any person (including any right to privacy or publicity),
or constitute unfair competition or trade practices under the laws of any
jurisdiction, and neither the Company nor any of its Subsidiaries has received
notice from any person claiming that such operation or any act, product,
technology or service (including products, technology or services currently
under development) of the Company or any of its Subsidiaries infringes or
misappropriates any Intellectual Property Right of any person or constitutes
unfair competition or trade practices under the laws of any jurisdiction (nor
does the Company have knowledge of any basis therefor).
(q) No Company Intellectual Property, Company Product or service of the
Company or its Subsidiaries is subject to any proceeding or outstanding decree,
order, judgment or settlement agreement or stipulation that restricts in any
manner the use, transfer or licensing thereof by the Company or its
Subsidiaries or may be reasonably expected to materially and adversely affect
the validity, use or enforceability of such Company Intellectual Property.
(r) Other than inbound publicly available "shrink-wrap" and other
publicly-available commercial binary code end-user licenses, and outbound
"shrink-wrap" licenses in the forms set forth on Section 3.16(r) of the Company
Disclosure Letter, Section 3.16(r) of the Company Disclosure Letter lists all
material Contracts to which the Company and any of its Subsidiaries is a party
with respect to any Intellectual Property or Intellectual Property Rights. All
such Contracts are in full force and effect in accordance with their respect
terms. Neither the Company nor any of its Subsidiaries is in material breach of
and neither the Company nor any of its Subsidiaries has failed to perform in
any material respect under, any of the foregoing Contracts and, to the
Company's knowledge, as of the date hereof, no other party to any such Contract
is in breach thereof or has failed to perform in any material respect
thereunder. The consummation of the transactions contemplated by this Agreement
will neither violate nor result in the breach, modification, cancellation,
termination or suspension of such Contracts. Following the Closing Time, the
Buyer will be permitted to exercise all of the Company's rights under such
A-22
Contracts to the same extent the Company and its Subsidiaries would have been
able to had the transactions contemplated by this Agreement not occurred and
without being required to pay any additional amounts or consideration other
than fees, royalties or payments which the Company would otherwise be required
to pay had such transactions contemplated hereby not occurred.
(s) Other than in connection with the sale of its products in the ordinary
course of its business, Section 3.16(s) of the Company Disclosure Letter lists
all material Contracts between the Company or its Subsidiaries and any other
person wherein or whereby the Company or any of its Subsidiaries has agreed to,
or assumed, any obligation or duty to warrant, indemnify, reimburse, hold
harmless, guaranty or otherwise assume or incur any obligation or liability or
provide a right of rescission with respect to the infringement or
misappropriation by the Company or any of its Subsidiaries or such other person
of the Intellectual Property Rights of any person other than the Company and
its Subsidiaries.
(t) There are no Contracts between the Company (or any of its Subsidiaries)
and any other person with respect to Company Intellectual Property under which
there is any dispute regarding the scope of such agreement, or performance
under such agreement, including with respect to any payments to be made or
received by the Company or any of its Subsidiaries thereunder.
(u) To the Company's knowledge, no person is infringing or misappropriating
any Company Intellectual Property Right.
(v) The Company and each of its Subsidiaries has protected the Company's and
each of its Subsidiaries' rights in confidential information and trade secrets
of the Company and its Subsidiaries or provided by any other person to the
Company to the extent reasonable and customary in the industry in which the
Company operates. The Company has and enforces a policy requiring each Employee
of the Company or any of its Subsidiaries to execute a Proprietary Rights and
Confidentiality Agreement substantially in the form set forth in Section
3.16(v) of the Company Disclosure Letter and either (i) all current and former
Employees of the Company and its Subsidiaries who have created or modified any
of the Company Intellectual Property have executed such an agreement assigning
all of the rights of such Employees in and to such Company Intellectual
Property to the Company or (ii) if an Employee has not executed such an
agreement so assigning such rights to the Company, the Employee is deemed to
have assigned such rights to the Company by operation of law, excluding any
failure by a non-material Employee or contractor to execute an assignment
agreement that does not result in the loss of any Intellectual Property.
(w) Neither this Agreement nor the transactions contemplated by this
Agreement, including the assignment to the Buyer, by operation of law or
otherwise, of any Contracts to which the Company or any of its Subsidiaries is
a party, will result in (i) any third party being granted rights or access to,
or the placement in or release from escrow, of any Company Intellectual
Property (including source code for any software belonging to the Company or
any of its Subsidiaries), (ii) the Buyer or any of its Subsidiaries granting to
any third party any right to or with respect to any Intellectual Property or
Intellectual Property Right owned by, or licensed to, either of them pursuant
to any Contract to which the Company or any of its Subsidiaries is a party or
by which it is bound, (iii) the Buyer or any of its Subsidiaries being bound
by, or subject to, any non-compete or other restriction on the operation or
scope of their respective businesses, or (iv) the Buyer or any of its
Subsidiaries being obligated to pay any royalties or other amounts to any third
party in excess of those payable by the Company or its Subsidiaries prior to
the Closing pursuant to any Contract to which the Company or any of its
Subsidiaries is a party or by which any of them is bound.
3.17 Agreements, Contracts and Commitments.
(a) Neither the Company nor any of its Subsidiaries is a party to or is
bound by:
(i) any written employment or consulting agreement, contract or
commitment with any officer, director, Employee or member of the Company
Boards, or any service, operating or management agreement, other than those
that are terminable by the Company or any of its Subsidiaries on no more
than thirty (30) days' notice without liability or financial obligation to
the Company or any of its Subsidiaries;
A-23
(ii) any agreement of indemnification or any guaranty other than any
agreement of indemnification entered into in connection with a Lease in
respect of real property not situated in Israel for the benefit of the
landlord and its mortgage or in connection with the sale of products in the
ordinary course of business consistent with past practice pursuant to the
Company's standard form agreement previously delivered by the Company to the
Buyer;
(iii) any material Contract containing any covenant limiting in any
respect the right of the Company or any of its Subsidiaries to engage in any
line of business or to compete with any person or entity or granting any
exclusive distribution rights;
(iv) any Contract currently in force relating to the disposition or
acquisition by the Company or any of its Subsidiaries after the date of this
Agreement of a material amount of assets not in the ordinary course of
business or pursuant to which the Company or any of its Subsidiaries has any
material ownership interest in any corporation, partnership, joint venture
or other business enterprise other than the Subsidiaries of the Company;
(v) any dealer, distributor, joint marketing or development Contract
currently in force under which the Company or any of its Subsidiaries have
continuing material obligations to jointly market any product, technology or
service and which may not be canceled without penalty upon notice of ninety
(90) days or less, or any material agreement pursuant to which the Company
or any of its Subsidiaries have continuing material obligations to jointly
develop any intellectual property that will not be owned, in whole or in
part, by the Company or any of its Subsidiaries and which may not be
canceled without penalty upon notice of ninety (90) days or less;
(vi) any Contract currently in force to license any third party to
manufacture or reproduce any product, service or technology of the Company
or any of its Subsidiaries or any Contract currently in force to sell or
distribute any products, service or technology of the Company or any of its
Subsidiaries except agreements with distributors or sales representatives in
the normal course of business cancelable without penalty upon notice of
ninety (90) days or less and substantially in the form previously provided
to the Buyer;
(vii) any Contract currently in force to provide source code or design
specifications to any third party for any product or technology that is
material to the Company and its Subsidiaries taken as a whole;
(viii) any mortgages, indentures, guarantees, other Encumbrances, loans
or credit agreements, security agreements or other agreements or instruments
relating to, or securing, the borrowing of money or extension of credit
(other than mortgages made by a landlord under a Lease to which mortgage the
Company is not a party but the Lease may be subject);
(ix) any material settlement agreement under which the Company has
ongoing obligations.
(b) Other than Leases, neither the Company nor any of its Subsidiaries nor,
to the Company's knowledge, any other party to a Company Contract, is in
breach, violation or default under, and neither the Company nor any of its
Subsidiaries has received written notice that it has breached, violated or
defaulted under, any of the material terms or conditions of any of the Company
Contract in such a manner as would permit any other party to cancel or
terminate any such Company Contract, or would permit any other party to seek
material damages or other remedies (for any or all of such breaches, violations
or defaults, in the aggregate), subject to the representations and warranties
contained in Section 3.13, including without limitation, Section 3.13(c). The
Company has made available to the Buyer true and correct copies of any
Contracts (excluding purchase orders) the Company and its Subsidiaries may have
with its top ten customers measured by revenue.
(c) Neither the Company nor any of its Subsidiaries is restricted by
agreement from carrying on its business anywhere in the world.
(d) Neither the Company nor any of its Subsidiaries has any power of
attorney outstanding or any obligations or liabilities (whether absolute,
accrued, contingent or otherwise), as guarantor, surety, co-signer,
A-24
endorser, co-maker, indemnitor or otherwise in respect of the obligation of any
Person, corporation, partnership, joint venture, association, organization or
other entity.
3.18 Opinion of Financial Advisor. The Company Boards have been advised by
the Company's financial advisor, Gleacher & Co. LLC, that in its opinion, as of
the date of this Agreement, the Offer Price is fair to the holders of Company
Shares from a financial point of view, and the Company will provide a copy of
the written confirmation of such opinion to the Buyer as soon as reasonably
practicable.
3.19 Insurance. The Company and each of its Subsidiaries maintain
Insurance Policies which the Company believes are upon terms that are
reasonable and adequate for and are of the type and in amounts customarily
carried by persons conducting businesses, operations, properties and locales
similar to those of the Company and its Subsidiaries. There is no material
claim by the Company or any of its Subsidiaries pending under any of the
material Insurance Policies as to which coverage has been questioned, denied or
disputed by the underwriters of such policies or bonds. All insurance policies
referred to in this Section are valid and binding in accordance with their
terms, except to the extent such enforceability may be limited by the effect of
any applicable bankruptcy, reorganization, insolvency, moratorium or similar
law affecting creditors' rights generally and general principles of equity or
public policy (regardless of whether such enforceability is considered in a
proceeding in equity or at law), and are in full force and effect.
3.20 Board Approval. Each of the Company Boards, at a combined meeting
duly called and held on September 5, 2001, has unanimously (i) determined that
this Agreement and the transactions contemplated hereby, including the Offer,
are at a price and on terms that are favorable and fair to and in the best
interests of the Company and its shareholders; (ii) approved this Agreement and
the transactions contemplated hereby, including the Offer, in all respects; and
(iii) resolved to recommend that the Company Shareholders accept the Offer and
tender their Company Shares thereunder to the Buyer or a Subsidiary of the
Buyer and vote at the EGM in favor of (x) the appointment of new members to the
Company Boards in accordance with the designation of the Buyer, (y) the
amendment of the Company's Articles of Association attached hereto as Exhibit E
and (z) taking all actions reasonably necessary to accomplish any part of the
Post-Closing Reorganization.
3.21 Environmental Matters.
(a) Each of the Company and its Subsidiaries is in material compliance with
all Environmental Laws. Such compliance includes, but is not limited to, the
possession by the Company and each of its Subsidiaries of all permits and other
governmental Approvals required under all applicable Environmental Laws, and
compliance with the terms and conditions thereof. Each permit and other
governmental Approval currently held by the Company and each of its
Subsidiaries pursuant to the Environmental Laws is specifically identified in
the Company Disclosure Letter.
(b) Neither the Company nor any of its Subsidiaries has received any
communication (written or oral), whether from a Governmental Entity, citizens
group, employee or otherwise, that alleges that the Company or any of its
Subsidiaries is not in full compliance with any Environmental Laws. The Company
has delivered to the Buyer prior to the execution of this Agreement all
information (whether oral or written and including, but not limited to,
assessments, reports, data, results of investigations or audits) that is in the
possession of or reasonably available to the Company or any of its Subsidiaries
regarding the evaluation of material environmental matters pertaining to, or
the environmental condition of, the businesses of the Company and its
Subsidiaries or the compliance (or non-compliance) by the Company or any of its
Subsidiaries with any Environmental Laws.
(c) There is no Environmental Claim by any Person that is pending or, to the
Company's knowledge, threatened against the Company or any of its Subsidiaries,
or against any Person whose liability for any Environmental Claim the Company
or any of its Subsidiaries has retained or assumed either contractually or by
operation of law.
(d) There are no past or present actions, activities, circumstances,
conditions, events or incidents, including the release, emission, discharge,
presence or disposal of any Materials of Environmental Concern, that could
A-25
result in a risk of any material Environmental Claim being asserted against the
Company or any of its Subsidiaries or, to the knowledge of the Company, against
any Person whose liability for any Environmental Claim the Company or any of
its Subsidiaries has retained or assumed either contractually or by operation
of law.
(e) Without in any way limiting the generality of the foregoing, (i) all
on-site and off-site locations where the Company or any of its Subsidiaries has
(previously or currently) stored, disposed or arranged for the disposal of
Materials of Environmental Concern are specifically identified in the Company
Disclosure Letter, (ii) all underground storage tanks, and the capacity and
contents of such tanks, located on any property owned, leased, operated or
controlled by the Company or any of its Subsidiaries, to the Company's
knowledge, are specifically identified in the Company Disclosure Letter, (iii)
there is, to the Company's knowledge, no asbestos contained in or forming part
of any building, building component, structure or office space owned, leased,
operated or controlled by the Company or any of its Subsidiaries and (iv) no
PCBs or PCB-containing items are, to the Company's knowledge, used or stored at
any property owned, leased, operated or controlled by the Company or any of its
Subsidiaries.
(f) None of the Company or any of its Subsidiaries is, to the Company's
knowledge, subject to any order or judgement issued pursuant to any
Environmental Laws requiring (i) the performance of site assessment for
Materials of Environmental Concern, (ii) the removal or remediation of
Materials of Environmental Concern, (iii) the giving of notice to, or receiving
the approval of, any Governmental Entity or (iv) the recording or delivery to
any other Person of any disclosure document or statement pertaining to
environmental matters by virtue of the transactions contemplated hereby or as a
condition to the effectiveness of any such transactions.
(g) The Company has not sold or distributed any Materials of Environmental
Concern, or any substances, preparations, mixtures or products containing or
comprising Materials of Environmental Concern (collectively, "Company Products
of Concern"), nor to the knowledge of the Company has any other Person sold or
distributed any Company Products of Concern, in any country (including, without
limitation, the U.S., European Union, New Zealand, Australia, Japan,
Philippines, Republic of Korea, Canada and the People's Republic of China)
which has chemical registration requirements (including, without limitation,
and by way of example, the Toxic Substances Control Act, 15 U.S.C. Section 2601
et seq. and related foreign laws) except in compliance in all material respects
with all such requirements.
3.22 Grants, Incentives and Subsidies. Section 3.22 of the Company
Disclosure Letter provides a complete list of all pending and outstanding
grants, incentives (including, Tax incentives) and subsidies (collectively,
"Grants") from the Government of the State of Israel or any agency thereof, or
from any foreign governmental or administrative agency, granted to the Company
or any of its Subsidiaries, including, without limitation, (i) Approved
Enterprise Status from the Investment Center, (ii) Grants from or administered
by the OCS or by The Director General of the Israeli Ministry of Industry and
Trade, (iii) the Israel-US Binational Industrial Research and Development
Foundation (BIRD), (iv) the Magnet DPI 2000 Program ("DPI 2000"), and (v) the
Print IT Program administered by the European Union ("Print IT"). Section 3.22
of the Company Disclosure Letter includes correct copies of all documents
evidencing Grants submitted by the Company or any of its Subsidiaries, all
applications submitted in connection with any Grants and all letters of
approval, and supplements thereto, granted to the Company or any of its
Subsidiaries and, without derogating from the generality of the foregoing, in
respect of Tax incentives, the period for which Tax incentives apply and the
nature of such Tax incentives. Section 3.22 of the Company Disclosure Letter
details and attaches copies of all material undertakings of the Company or any
of its Subsidiaries given in connection with the Grants. Without limiting the
generality of the above, Section 3.22 of the Company Disclosure Letter includes
the aggregate amounts of each Grant, and the aggregate outstanding obligations
thereunder of the Company or any of its Subsidiaries with respect to royalties,
or the outstanding amounts to be paid by the OCS to the Company or any of its
Subsidiaries and the composition of such obligations or amount by the product
or product family to which it relates. The Company and its Subsidiaries are in
compliance, in all material respects, with the terms and conditions of their
respective Grants and have duly fulfilled, in all material respects, all the
undertakings relating thereto. To the Company's knowledge, the Company is not
aware of any event or other set of circumstances which might lead to the
revocation or material modification of any of the Grants. All Intellectual
Property created, discovered, arising
A-26
or resulting from any research or development that has, directly or indirectly,
in whole or in part, been funded or financed by any Grant ("Grant Funded IP")
is Company Intellectual Property, the exclusive ownership, right and title in
respect thereof vests in the Company or its Subsidiaries. Section 3.22 of the
Company Disclosure Letter details all Grant Funded IP and the relevant Grant
that funded or financed the same. To the extent any Grant Funded IP is
registered in the name of, or is owned or vests in the Company or any of its
non-Israeli Subsidiaries the Company and its Subsidiaries have received all
necessary Approvals (including, Approvals required pursuant to Section 19 of
the Israeli Encouragement of Industrial Research and Development Law 1984 and
Approvals as may be required pursuant to the terms of any letter of
undertakings given in connection therewith) in connection with the transfer to,
registration or ownership of such Grant Funded IP by, the Company or its
non-Israeli Subsidiaries as aforesaid. Copies of such Approvals are attached to
Section 3.22 of the Company Disclosure Letter. Save in respect to those limited
items of Grant Funded IP detailed in Section 3.22 of the Company Disclosure
Letter that arose or resulted from research funded, as aforesaid, by Grants
received by the Company or any of its Subsidiaries within the framework of the
DPI 2000 (such Grant Funded IP, the "Magnet IP"), none of the Grant Funded IP
is subject, under the terms of any Grant, as a result of receiving such Grant
or under the rules of the DPI 2000 or the Print IT, to licenses to third
parties. All rights of any third parties, under the terms of the DPI 2000 or
the Print IT, in and to the Grant Funded IP are detailed in Section 3.22 of the
Company Disclosure Letter. Except for the approvals of the Investment Center
and the OCS referred to in Section 6.11(a)(iii) below, no consent or approval
of any Person or any Governmental Entity is required, by reason of the
consummation of the Offer or any of the transactions contemplated hereunder, in
order to preserve the entitlement of the Company or any of its Subsidiaries to
any of the Grants. The Grant Funded IP is not Company Core Technology. The
Magnet IP does not constitute Intellectual Property that is material to the
business of the Company or any of its Subsidiaries. No government funding,
facilities of a university, college, other educational institution or research
center or funding from third parties was used in the development of any Company
Core Technology. Further, all activities related to the Company's (or any of
its Subsidiaries) overall involvement in the DPI 2000 or the Print IT, or any
other similar program, have been at all times kept fully separated from all
other development activities and no Intellectual Property or Intellectual
Property Right has been, or could be construed as being, tainted as a result of
the Company's (or any of its Subsidiaries) membership, participation (or
overall involvement with) in the DPI 2000 or the Print IT or any other similar
program.
3.23 Disclosure. The Company has not failed to disclose to the Buyer any
facts material to the business, results of operations, assets, liabilities or
financial condition of the Company or its Subsidiaries. No representation or
warranty by the Company contained in this Agreement and no statement contained
in any document (including financial statements and the Company Disclosure
Letter), certificate, or other writing furnished or to be furnished by the
Company to the Buyer or any of its representatives pursuant to the provisions
hereof or in connection with the transactions contemplated hereby, contains or
will contain any untrue statement of material fact or omits or will omit to
state any material fact necessary, in light of the circumstances under which it
was made, in order to make the statements herein or therein not misleading.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF BUYER
The Buyer represents and warrants to the Company, subject to such exceptions
as are disclosed in writing in the disclosure letter supplied by the Buyer to
the Company dated as of the date hereof (the "Buyer Disclosure Letter"), which
Buyer Disclosure Letter shall provide an exception to or otherwise qualify the
representations and warranties of the Buyer (i) contained in the section of
this Agreement corresponding by number to such disclosure, and (ii) contained
in any other section of this Agreement where the nature of such exception or
qualification is readily apparent from the face of such disclosure, as follows:
4.1 Organization. The Buyer is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has
the requisite corporate power and authority to own, lease and
A-27
operate its properties and to carry on its business as it is now being
conducted, except where the failure to do so would not, in the aggregate, have
a Buyer Material Adverse Effect. Each of the Buyer and its Subsidiaries is duly
qualified or licensed as a foreign corporation to do business, and is in good
standing, in each jurisdiction where the properties owned, leased or operated
by it or the nature of the business conducted by it makes such qualification or
licensing necessary, except where the failure to be so duly qualified or
licensed and in good standing would not, in the aggregate, have a Buyer
Material Adverse Effect.
4.2 Certificate of Incorporation and Bylaws. The Buyer is not in violation
of any provision of its certificate of incorporation or bylaws (together, the
"Buyer Charter Documents"), except where the violation of any Buyer Charter
Document would not, in the aggregate, have a Buyer Material Adverse Effect.
4.3 Capitalization. As of the date of this Agreement, the authorized
capital stock of the Buyer consists of 9,600,000,000 shares of Buyer Common
Stock and 300,000,000 shares of Buyer Preferred Stock. As of the close of
business on July 31, 2001, 1,939,159,231 shares of Buyer Common Stock were
issued and outstanding and no shares of Buyer Preferred Stock were issued or
outstanding. All of the issued and outstanding shares of Buyer Common Stock are
duly authorized, validly issued, fully paid and nonassessable.
4.4 Authority Relative to this Agreement. The Buyer has all necessary
corporate power and authority to execute and deliver this Agreement and the CVR
Agreement and to perform its obligations hereunder and thereunder and to
consummate the transactions contemplated hereby and thereby. The execution and
delivery of this Agreement and the CVR Agreement by the Buyer and the
consummation by the Buyer of the transactions contemplated hereby and thereby
have been duly and validly authorized by all necessary corporate action on the
part of the Buyer, and no other corporate proceedings on the part of the Buyer
are necessary to authorize this Agreement and the CVR Agreement or to
consummate the transactions contemplated hereby and thereby. This Agreement has
been, and the CVR Agreement shall have been on the Closing Time, duly and
validly executed and delivered by the Buyer and, assuming the due
authorization, execution and delivery by the Company, constitute legal and
binding obligations of the Buyer, enforceable against the Buyer in accordance
with their respective terms, except to the extent that (i) enforcement thereof
may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting
creditor rights, (ii) the enforcement thereof may be limited by general
equitable principles (regardless of whether such enforcement is considered in a
proceeding at law or in equity), and (iii) the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to equitable
defenses and to the discretion of the court before which any proceeding
therefor may be brought.
4.5 Issuance of Buyer Common Stock. When issued in accordance with the
terms of this Agreement, the shares of Buyer Common Stock to be issued pursuant
to the Offer will be duly authorized, validly issued, fully paid and
nonassessable and not subject to preemptive rights.
4.6 No Conflict; Required Filings and Consents.
(a) The execution and delivery of this Agreement and the CVR Agreement by
the Buyer do not, and the performance of this Agreement and the CVR Agreement
by the Buyer shall not, (i) conflict with or violate the Buyer Charter
Documents, (ii) subject to obtaining the consents, approvals, authorization and
permits, and making the filings and notifications, set forth in Section 4.6(b)
below, conflict with or violate any law, rule, regulation, order, judgment or
decree applicable to the Buyer or any of its Subsidiaries or by which it or
their respective properties are bound or affected, or (iii) result in any
breach of or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, or impair the Buyer's or any such
Subsidiary's rights or alter the rights or obligations of any third party
under, or give to others any rights of termination, amendment, acceleration or
cancellation of, or result in the creation of a lien or encumbrance on any of
the properties or assets of the Buyer or any of its Subsidiaries pursuant to,
any material note, bond, mortgage, indenture, contract, agreement, lease,
license, permit, franchise or other instrument or obligation to which the Buyer
or any of its Subsidiaries is a party or by which the Buyer or any of its
Subsidiaries or its or any of their
A-28
respective properties are bound or affected, except to the extent such
conflict, violation, breach, default, impairment or other effect could not in
the case of clauses (ii) or (iii), individually or in the aggregate, reasonably
be expected to have a Buyer Material Adverse Effect.
(b) The execution and delivery of this Agreement and the CVR Agreement by
the Buyer does not, and the performance of this Agreement and the CVR Agreement
by the Buyer shall not, require any consent, approval, authorization or permit
of, or filing with or notification to, any Governmental Entity except (i) for
applicable requirements, if any, of the Securities Act, the Exchange Act, Blue
Sky Laws, the notification requirements of the HSR Act and Foreign Filings, the
rules and regulations of the NYSE, NASD or NASDAQ, the consent of the
Investment Center, the consent of the OCS, the approval of the Israeli
Commissioner of Restrictive Trade Practices and the Israeli Securities
Exemption; (ii) applicable consultation with all trade union representatives
and bodies under applicable employment laws, including, without limitation, the
Dutch SER Merger Rules; and (iii) where the failure to obtain such consents,
approvals, authorizations or permits, or to make such filings or notifications,
(A) would not prevent consummation of the Offer or the Post-Closing
Reorganization or otherwise prevent the Buyer from performing its obligations
under this Agreement and the CVR Agreement, or (B) could not, individually or
in the aggregate, reasonably be expected to have a Buyer Material Adverse
Effect.
4.7 SEC Filings; Financial Statements
(a) A true and complete copy of each annual, quarterly and other report,
registration statement, and definitive proxy statement filed by the Buyer with
the SEC since December 31, 2000 (the "Buyer SEC Reports") is available on the
Web site maintained by the SEC at http://www.sec.gov. As of their respective
dates or, if amended, as of the date of the last such amendment, the Buyer SEC
Reports (i) complied in all material respects with the applicable requirements
of the Securities Act or the Exchange Act, as the case may be, and (ii) did not
contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading.
(b) At their respective dates, each set of consolidated financial statements
(including, in each case, any related notes thereto) contained in the Buyer SEC
Reports was prepared in accordance with U.S. GAAP applied on a consistent basis
throughout the periods involved (except as may be indicated in the notes
thereto or, in the case of unaudited statements, as permitted by Form 10-Q of
the Exchange Act) and each fairly presents the consolidated financial position
of the Buyer and its Subsidiaries at the respective dates thereof and the
consolidated results of its operations and cash flows for the periods
indicated, except that the unaudited interim financial statements were or are
subject to the absence of footnotes and normal adjustments which (in addition
to those noted therein) were not or are not expected to be material in amount.
4.8 Ownership of Company Common Stock. The Buyer and its Subsidiaries own
14,814,815 Company Shares as of the date of this Agreement.
4.9 Absences of Certain Changes or Events. Since June 30, 2001, there has
not been any Buyer Material Adverse Effect.
A-29
ARTICLE V
INTERIM CONDUCT
5.1 Conduct of Business by Company. During the period from the date of
this Agreement and continuing until the earlier of the termination of this
Agreement pursuant to its terms or the Closing Time, the Company and each of
its Subsidiaries shall carry on its business in the usual, regular and ordinary
course in substantially the same manner as heretofore conducted and in material
compliance with all applicable laws and regulations, pay its debts and taxes
when due subject to good faith disputes over such debts or taxes, pay or
perform other material obligations when due, and use its commercially
reasonable efforts consistent with past practices and policies to (i) preserve
intact its present business organization, (ii) keep available the services of
its present officers and employees and (iii) preserve its relationships with
customers, suppliers, distributors, licensors, licensees and others with which
it has significant business dealings. In addition, the Company will promptly
notify the Buyer of any material event involving its business or operations
occurring outside the ordinary course of business.
In addition, except as disclosed in Section 5.1 of the Company Disclosure
Letter, without the prior written consent of the Buyer, during the period from
the date of this Agreement and continuing until the earlier of the termination
of this Agreement pursuant to its terms or the Closing Time, the Company shall
not do any of the following and shall not permit its Subsidiaries to do any of
the following:
(a) Waive any stock repurchase rights, accelerate, amend or change the
period of exercisability or vesting of options or restricted stock, or
reprice options granted under any employee, consultant, director or other
stock plans or authorize cash payments in exchange for any options granted
under any such plans;
(b) Grant any severance or termination pay or benefits, or payments or
benefits triggered by a change of control or acquisition (including the
Offer), to any Employee except to persons who are Employees of the Company
as of the date hereof pursuant to written agreements outstanding, or written
policies existing, on the date hereof and disclosed on Section 3.11 of the
Company Disclosure Letter (provided, however, that the Company shall not
grant, or offer to grant, any such severance or termination payments or
benefits, or payments or benefits triggered upon a change of control or
acquisition (including the Offer), to any person who is hired or offered
employment with the Company on or after the date hereof), or adopt any new
severance plan, or amend or modify or alter in any manner any severance
plan, agreement or arrangement existing on the date hereof, or take any
other action that would trigger the payment of any severance payments or
other benefits pursuant to any agreement;
(c) Transfer or license to any person or entity or otherwise extend,
amend or modify any rights to the Company Intellectual Property, or enter
into grants to transfer or license to any person future patent rights, other
than non-exclusive licenses granted to resellers and end-users in the
ordinary course of business consistent with past practices;
(d) Declare, set aside or pay any dividends on or make any other
distributions (whether in cash, stock, equity securities or property) in
respect of any capital stock or split, combine or reclassify any capital
stock or issue or authorize the issuance of any other securities in respect
of, in lieu of or in substitution for any capital stock, except for
dividends or other distributions paid to the Company by any of its
wholly-owned Subsidiaries;
(e) Purchase, redeem or otherwise acquire, directly or indirectly, any
shares of capital stock of the Company or its Subsidiaries;
(f) Issue, deliver, sell, authorize, pledge or otherwise encumber or
propose any of the foregoing with respect to any shares of capital stock or
any securities convertible into shares of capital stock, or subscriptions,
rights, warrants or options to acquire any shares of capital stock or any
securities convertible into shares of capital stock, or enter into other
agreements or commitments of any character obligating it to issue any such
shares or convertible securities, or grant any equity-based compensation
whether payable in cash or stock, other than the issuance delivery and/or
sale of (x) Company Shares pursuant to the exercise of
A-30
stock options, warrants and convertible preferred stock outstanding as of
the date of this Agreement, and (y) Company Shares issuable to participants
in the ESPP consistent with the terms thereof;
(g) Cause, permit or propose any amendments to the Company's Articles of
Association (or similar governing instruments of any of its Subsidiaries);
(h) Acquire or agree to acquire by merging or consolidating with, or by
purchasing any equity interest in or a material portion of the assets of, or
by any other manner, any business or any corporation, partnership,
association or other business organization or division thereof, or otherwise
acquire or agree to acquire all or substantially all of the assets of any of
the foregoing, or purchase any equity interest in any of the foregoing or
enter into any joint ventures, strategic partnerships or alliances;
(i) Sell, lease, license, encumber or otherwise dispose of any properties
or assets except sales or leases of inventory in the ordinary course of
business consistent with past practice, and except for the sale, lease or
disposition (other than through licensing unless permitted by Section
5.1(c)) of property or assets which are not material, individually or in the
aggregate, to the business of the Company and its Subsidiaries, taken as a
whole;
(j) Materially modify, amend or terminate any existing lease, license or
contract affecting the use, possession or operation of any material
properties or material assets; grant or otherwise create or consent to the
creation of any easement, covenant, restriction, assessment or charge which
would materially and adversely affect the Company's use, or the value of,
any material owned property or leased property; convey, assign, sublease,
license or otherwise transfer all or any portion of any material real
property or any interest or rights therein; commit any waste or nuisance on
any such property; or make any material changes in the construction or
condition of any such property;
(k) Incur any indebtedness for borrowed money or guarantee any such
indebtedness of another person, issue or sell any debt securities or
options, warrants, calls or other rights to acquire any debt securities of
the Company or any of its Subsidiaries, enter into any "keep well" or other
agreement to maintain any financial statement condition or enter into any
arrangement having the economic effect of any of the foregoing other than in
connection with the financing of working capital consistent with past
practice;
(l) Adopt or amend any employee benefit plan, policy or arrangement; any
employee stock purchase or employee stock option plan; or enter into any
employment contract or collective bargaining agreement (other than offer
letters and letter agreements entered into in the ordinary course of
business consistent with past practice with employees who are terminable "at
will"); pay any special bonus or special remuneration to any director or
employee other than consistent with past practice; or increase the salaries
or wage rates or fringe benefits (including rights to severance or
indemnification) of its directors, officers, employees or consultants
except, in each case, as may be required by law or for normally scheduled
increases in the ordinary course;
(m) (i) pay, discharge, settle or satisfy any material litigation
(whether or not commenced prior to the date of this Agreement) or any
material claims, liabilities or obligations (absolute, accrued, asserted or
unasserted, contingent or otherwise), other than the payment, discharge,
settlement or satisfaction, in the ordinary course of business consistent
with past practice or in accordance with their terms, or liabilities
recognized or disclosed in the most recent consolidated financial statements
(or the notes thereto) of the Company included in the Company SEC Reports or
incurred since the date of such financial statements in the ordinary course
of business consistent with past practices, or (ii) waive the benefits of,
agree to modify in any manner, terminate, release any person from or
knowingly fail to enforce any confidentiality or similar provisions of any
agreement to which the Company or any of its Subsidiaries is a party or of
which the Company or any of its Subsidiaries is a beneficiary;
(n) Except in the ordinary course of business consistent with past
practice, modify, amend or terminate any Company Contract or waive, delay
the exercise of, release or assign any material rights or claims thereunder;
A-31
(o) Except as required by U.S. GAAP, revalue any of its assets or make
any change in accounting methods, principles or practices;
(p) Make any payment or series of related payments outside the ordinary
course of business, or enter into any Contract or series of related
Contracts outside the ordinary course of business requiring the Company or
any of its Subsidiaries to pay, in excess of $250,000 in the aggregate;
(q) Make any Tax election or accounting method change inconsistent with
past practice that, individually or in the aggregate, would be reasonably
likely to adversely affect in any material respect the Tax liability or Tax
attributes of the Company or any of its Subsidiaries, taken as a whole,
settle or compromise any material Tax liability;
(r) Hire any employee; or
(s) Agree in writing or otherwise to take any of the actions described in
Section 5.1 (a) through (r) above.
ARTICLE VI
ADDITIONAL AGREEMENTS
6.1 Confidentiality; Access to Information. The parties acknowledge that
the Company and the Buyer have previously executed a Confidentiality Agreement,
which will continue in full force and effect in accordance with its terms. The
Company will afford the Buyer and its accountants, counsel and other
representatives reasonable access during normal business hours, upon reasonable
notice, to the properties, books, records and personnel of the Company during
the period prior to the Closing Time to obtain all information concerning the
business, including the status of product development efforts, properties,
results of operations and personnel of the Company and its Subsidiaries, as the
Buyer may reasonably request. No information or knowledge obtained by the Buyer
in any investigation pursuant to this Section 6.1 will affect or be deemed to
modify any representation or warranty contained herein or the conditions to the
obligations of the parties to consummate the Offer.
6.2 No Solicitation.
(a) From and after the date of this Agreement until the Closing Time or
termination of this Agreement pursuant to Article VII, the Company and its
Subsidiaries will not, nor will they authorize or permit any of their
respective officers, directors, affiliates or employees or any investment
banker, attorney, accountant, consultant or other agent, advisor or
representative retained by any of them to, directly or indirectly, (i) solicit,
initiate, encourage or induce the making, submission or announcement of any
Acquisition Proposal, (ii) engage or participate in any discussions or
negotiations regarding, or furnish to any person any information relating to
the Company or any of its Subsidiaries or afford access to the business,
properties, assets, books or records of the Company or any of its Subsidiaries
to any person that has made, or take any other action intended to assist or
facilitate any inquiries or the making, submission, or announcement of any
proposal that constitutes or would reasonably be expected to lead to, any
Acquisition Proposal, (iii) approve, endorse or recommend any Acquisition
Proposal or (iv) enter into any letter of intent or similar document or any
contract, agreement or commitment contemplating or otherwise relating to any
Acquisition Transaction; provided, however, that nothing contained in this
Section 6.2(a) shall prohibit the Company or the Company Boards from taking and
disclosing to the Company Shareholders a position with respect to a tender or
exchange offer by a third party pursuant to Rules 14d-9 and 14e-2(a)
promulgated under the Exchange Act; provided, further, that the aforementioned
proviso shall not permit the Company or the Company Boards to withhold,
withdraw, modify or change in a manner adverse to the Buyer, or fail to make,
any of its Recommendations in connection with, or approve, endorse or
recommend, any Acquisition Proposal.
(b) In addition to the obligations of the Company set forth in paragraph (a)
of this Section 6.2, the Company as promptly as practicable, and in any event
within 24 hours, shall advise the Buyer orally and in writing of
A-32
(i) any request for information which the Company reasonably believes would
lead to an Acquisition Proposal or of any Acquisition Proposal, or any inquiry
with respect to or which the Company reasonably believes would lead to any
Acquisition Proposal, (ii) the material terms and conditions of such request,
Acquisition Proposal or inquiry, and (iii) the identity of the person or group
making any such request, Acquisition Proposal or inquiry. The Company will keep
the Buyer informed in all material respects of the status and details
(including material amendments or proposed amendments) of any such request,
Acquisition Proposal or inquiry.
6.3 Public Disclosure. The Buyer and the Company will consult with each
other, and agree, before issuing any press release, and will consult with each
other and to the extent practicable, agree, before otherwise making any public
statement with respect to the Offer, this Agreement, the other party, or an
Acquisition Proposal, and will not issue any such press release or make any
such public statement prior to such agreement or consultation, as applicable,
except as may be required by law or any listing agreement with a national
securities exchange, in which case reasonable efforts to consult with the other
party will be made prior to any such release or public statement.
6.4 Commercially Reasonable Efforts; Notification.
(a) Upon the terms and subject to the conditions set forth in this
Agreement, each of the parties agrees to use its commercially reasonable
efforts to take, or cause to be taken, all reasonable actions, and to do, or
cause to be done, and to assist and cooperate with the other parties in doing,
all things reasonably necessary, proper or advisable to consummate and make
effective, in the most expeditious manner practicable, the transactions
contemplated by this Agreement, including to accomplish the following:
(i) causing of the conditions precedent set forth on Annex I hereto be
satisfied, (ii) the obtaining of all necessary actions or nonactions, waivers,
consents, approvals, orders and authorizations from Governmental Entities and
the making of all necessary registrations, declarations and filings (including
registrations, declarations and filings with Governmental Entities, if any) and
the taking of all commercially reasonable steps as may be necessary to avoid
any suit, claim, action, investigation or proceeding by any Governmental
Entity, (iii) the defending of any suits, claims, actions, investigations or
proceedings, whether judicial or administrative, challenging this Agreement or
the consummation of the transactions contemplated hereby, including seeking to
have any stay or temporary restraining order entered by any court or other
Governmental Entity vacated or reversed and (iv) the execution or delivery of
any additional instruments reasonably necessary to consummate the transactions
contemplated by, and to fully carry out the purposes of, this Agreement. In
connection with and without limiting the foregoing, the Company and the Company
Boards shall, if any state or foreign takeover statute or similar statute or
regulation is or becomes applicable to this Agreement or any of the
transactions contemplated by this Agreement, use its best efforts to take, or
cause to be taken, all reasonable actions to ensure that the transactions
contemplated by this Agreement may be consummated as promptly as practicable on
the terms contemplated by this Agreement and otherwise to minimize the effect
of such statute or regulation on this Agreement and the transactions
contemplated hereby. Notwithstanding anything herein to the contrary, nothing
in this Agreement shall be deemed to require the Buyer or the Company or any
Subsidiary or affiliate thereof to make proposals, execute or carry out
agreements or submit to orders providing for the sale, license or other
disposition or holding separate (through the establishment of a trust or
otherwise) of any assets or categories of assets of the Buyer, any of its
affiliates or Company or its Subsidiaries or the holding separate of the
Company Shares or imposing or seeking to impose any limitation on the ability
of the Buyer or any of its subsidiaries or affiliates to conduct their business
or own such assets or to acquire, hold or exercise full rights of ownership of
the Company Shares.
(b) Each of Company and Buyer will give prompt notice to the other of (i)
any notice or other communication from any person alleging that the consent of
such person is or may be required in connection with the transactions
contemplated hereby, (ii) any notice or other communication from any
Governmental Entity in connection with the transactions contemplated hereby,
(iii) any litigation relating to, involving or otherwise affecting Company, the
Buyer or their respective Subsidiaries that relates to the consummation of the
transactions contemplated hereby. The Company shall give prompt notice to the
Buyer upon becoming aware that any representation or warranty made by it
contained in this Agreement has become materially untrue or inaccurate, or of
any failure of the Company to comply with or satisfy in any material respect
any covenant,
A-33
condition or agreement to be complied with or satisfied by it under this
Agreement; provided, however, that no such notification shall affect the
representations, warranties, covenants or agreements of the parties or the
conditions to the obligations of the parties under this Agreement.
6.5 Third Party Consents. As soon as practicable following the date
hereof, the Company will use commercially reasonable efforts to obtain all
consents, waivers and approvals set forth in Section 6.5 of the Company
Disclosure Letter or otherwise required as a result of the pendency or
consummation of the Offer.
6.6 Stock Options; ESPP; Warrants.
(a) Stock Options. Unless the Buyer and the Company agree otherwise and
subject to local laws, the Buyer shall take all actions necessary to convert
each outstanding option to purchase Company Shares (each, a "Company Stock
Option" and, collectively, the "Company Stock Options") that is outstanding
immediately prior to the Closing Time into a stock option to purchase the Buyer
Shares subject to the Buyer 2000 Stock Plan with substantially equal value and
substantially equivalent provisions as the Company Stock Option (collectively,
the "Buyer Stock Options"), effective immediately after the Closing Time.
(i) Unless the Buyer and the Company agree otherwise and subject to local
laws, the Company shall use commercially reasonable efforts, to the extent
the Buyer provides funding for such activity, to repurchase prior to the
Closing Time each outstanding Company Stock Option that is outstanding and
held by an optionee who is not an employee of the Company or any of its
Subsidiaries.
(ii) Unless the Buyer and the Company agree otherwise and subject to
local laws, each Buyer Stock Option covering a Company Stock Option intended
to qualify as an incentive stock option under Section 422 of the Code (A)
shall be exercisable for, and represent the right to acquire, that number of
shares of Buyer Common Stock (rounded down to the nearest whole share) equal
to (i) the number of Company Shares subject to such Company Stock Option in
effect immediately prior to the Closing Time multiplied by (ii) the Fixed
Offer Price; and (B) shall have an exercise price per share of Buyer Common
Stock subject to such converted Company Stock Option equal to (i) the
exercise price per Company Share subject to such Company Stock Option in
effect immediately prior to the Closing Time divided by (ii) the Fixed Offer
Price (rounded up to the nearest whole cent). With respect to all other
outstanding Company Stock Options, the Buyer shall determine whether the
Buyer Stock Options covering all other such Company Stock Options shall (A)
(x) be exercisable for, and represent the right to acquire, that number of
shares of Buyer Common Stock (rounded up to the nearest whole share) equal
to (i) the number of Company Shares subject to such Company Stock Option in
effect immediately prior to the Closing Time multiplied by (ii) the Fixed
Offer Price; and (y) have an exercise price per share of Buyer Common Stock
subject to such converted Company Stock Option equal to (i) the exercise
price per Company Share subject to such Company Stock Option in effect
immediately prior to the Closing Time divided by (ii) the Fixed Offer Price
(rounded down to the nearest whole cent) (the "Fixed Option Alternative") or
(B) (x) be exercisable for, and represent the right to acquire shares of
Buyer Common Stock pursuant to the terms of the Fixed Option Alternative or,
to the extent the holder thereof makes an effective written election prior
to the Closing Time, (y) (I) be exercisable for, and represent the right to
acquire, a number of units equal to the number of Company Shares subject to
such Company Stock Option in effect immediately prior to the Closing Time,
each such unit comprised of that number of shares of Buyer Common Stock and
CVRs equal to the Contingent Offer Price and (II) have an exercise price per
such unit equal to the exercise price per Company Share subject to such
Company Stock Option in effect immediately prior to the Closing Time.
(iii) The Company shall use commercially reasonable efforts to obtain an
executed copy of each Buyer Stock Option. Copies of each Buyer Stock Option
that are not executed and returned to the Buyer shall not be entered into
the Buyer's computer system.
(iv) Each Company Stock Option may be subject to a blackout period for as
brief a period as is reasonably practicable, and in any event not more than
two weeks, after the Closing Time due to administrative constraints. Holders
of a converted Company Stock Option will not be able to exercise any such
option during any such blackout period.
A-34
(v) The Company and the Buyer further agree that each of the Company
Option Plans and agreements shall be amended, to the extent necessary, to
reflect the transactions contemplated by this Agreement.
(b) Company Warrants. Unless the Buyer and the Company agree otherwise, the
Company shall request that all holders of the Company Warrants exercise the
Company Warrants prior to the Closing Time. As of the effective time of a
Post-Closing Reorganization satisfying the applicable provisions covering
mergers, consolidations and/or other similar transactions of the Company
Warrants, if any, each remaining outstanding Company Warrant shall cease to
represent a right to acquire Company Shares and shall be converted
automatically into a warrant to purchase either shares of Buyer Common Stock
based on the Fixed Offer Price or, to the extent the holder thereof makes an
effective written election prior to the Closing Time, shares of Buyer Common
Stock and CVRs based on the Contingent Offer Price (collectively, the "New
Buyer Warrants") in an amount, at an exercise price and subject to such terms
and conditions determined as provided below. Each Company Warrant so
substituted by the Buyer shall be subject to, and exercisable upon, the same
terms and conditions as under the applicable Company Warrant and the applicable
warrant agreement related thereto, except that (i) each substituted Company
Warrant shall be exercisable for, and represent the right to acquire, either
(I) that number of shares of the Buyer Common Stock (rounded to the nearest
whole share) equal to (A) the number of Company Shares subject to such Company
Warrant in effect immediately prior to the Closing Time multiplied by (B) the
Fixed Offer Price; and (ii) the exercise price per share of the Buyer Common
Stock subject to such substituted Company Warrant shall be an amount equal to
(A) the exercise price per Company Share subject to such Company Warrant in
effect immediately prior to the Closing Time divided by (B) the Fixed Offer
Price (rounded up to the nearest whole cent) or (II) a number of units equal to
(A) the number of Company Shares subject to such Company Warrant in effect
immediately prior to the Closing Time, each such unit comprised of that number
of shares of Buyer Common Stock and CVRs equal to the Contingent Offer Price
and (ii) the exercise price per such unit subject to such substituted Company
Warrant shall be an amount equal to the exercise price per Company Share
subject to such Company Warrant in effect immediately prior to the Closing
Time. If and to the extent necessary or required by the terms of the Company
Warrants or pursuant to the terms of any warrant agreement related thereto,
each of the Buyer and the Company shall request the consent of each holder of
outstanding Company Warrants to the foregoing treatment of such Company
Warrants. The Company will provide any notice to warrantholders required under
the terms of each Company Warrant in connection with the Offer.
(c) ESPP.
(i) Prior to the Closing Time, each of the Company's ESPPs shall be
terminated pursuant to the terms of each applicable plan. Prior to the
Closing Time, the Company shall take all actions (including, giving adequate
notice to all participants and, if appropriate, amending the terms of each
of the Company's ESPPs) that are necessary to give effect to the termination
of the Company's ESPP as contemplated by this Section 6.6(c)(i).
(ii) After the Closing Time, eligible employees of the Company may enroll
and participate in the next purchase period of the Buyer's 2000 Employee
Stock Purchase Plan (the "2000 ESPP"), subject to the terms and conditions
of the 2000 ESPP, as soon as administratively practicable as determined by
the Buyer.
(iii) After the Closing Time, in the event that the Buyer determines that
eligible employees of the Company cannot participate in the 2000 ESPP May 1,
2002 purchase period because participation is not administratively
practicable, eligible employees of the Company may participate in the
Buyer's phantom employee stock purchase plan (the "Phantom ESPP"), a copy of
which has been provided to the Company by the Buyer prior to the Closing
Time, in lieu of the 2000 ESPP, subject to the terms and conditions of the
Phantom ESPP. The Phantom ESPP will distribute cash in lieu of stock to its
participants according to the terms and conditions of the Phantom ESPP; such
distribution is subject to applicable withholding taxes. No eligible
employee can participate in the Phantom ESPP beyond November 1, 2002, unless
otherwise determined by the Buyer's Executive Committee of the Board of
Directors in its sole discretion.
A-35
6.7 Employment and Employee Benefits.
(a) Employees. To the extent required by applicable local law, the Buyer
shall assume, perform and discharge the Company's and its Affiliates'
obligations, or cause the Company and its Affiliates to perform and discharge
such obligations, under all Employment Agreements, except where employees agree
to waive their rights under such Employment Agreements or accept other rights
or benefits in lieu of the rights and benefits provided in such Employment
Agreements. The Buyer shall continue the employment of all of the Company's and
its Affiliates' employees, including employees on leaves of absence (together,
"Transferred Employees"), except where the Buyer reasonably concludes that any
employee's position is redundant in relation to the Buyer's operational needs.
Transferred Employees shall initially receive a package of compensation and
benefits (including, without limitation, equity compensation) that is
approximately equivalent in the aggregate to the compensation and benefits they
had received from Company or its Affiliates immediately prior to the Closing
Time.
(b) Employee Benefit Plans. The Buyer's U.S. Benefit Plans that provide
health, disability, life insurance or other welfare benefits shall provide
Transferred Employees and their dependents and beneficiaries with immediate
eligibility and coverage after the Closing Time, shall waive any exclusions or
limitations with respect to pre-existing conditions, waiting periods, evidence
of insurability or good health, and actively-at-work requirements, and shall
either (i) provide that any expenses incurred through the Closing Time by
Transferred Employees or their covered dependents shall be taken into account
for purposes of satisfying applicable deductible, co-insurance and maximum
out-of-pocket provisions, or (ii) reimburse Transferred Employees for any
duplicate payment of such expenses. The Buyer shall use its best efforts to
provide similarly advantageous transition arrangements under its non-U.S.
Benefit Plans.
(c) Vacation. As of the Closing Time, the Buyer shall assume, honor and be
responsible for any accrued but unused vacation time to which any Transferred
Employee is entitled pursuant to the vacation policy applicable to such
employee immediately prior to the Closing Time. The Buyer shall allow each
Transferred Employee to use such accrued but unused vacation time under the
terms and subject to the conditions of the Buyer's vacation or Flexible Time
Off ("FTO") policies and programs, including any terms and conditions of the
same that allow unused vacation time to be paid in cash upon an employee's
termination of employment with the Buyer. A Transferred Employee's continuous
service with the Company and its Affiliates shall be recognized in determining
the Transferred Employee's rate of accrual of future vacation time (i) under
the Buyer's U.S. vacation or FTO policies and programs and (ii) to the extent
it is reasonable under local conditions, under the Buyer's non-U.S. vacation
policies and programs.
(d) 401(k) Plan. The Company shall 100% vest all plan participants, and
terminate, effective as of the day immediately preceding the date the Company
becomes a member of the same Controlled Group of Corporations (as defined in
Section 414(b) of the Code) as the Buyer (the "401(k) Termination Date"), any
and all 401(k) plans unless the Buyer provides notice to the Company that such
401(k) plan(s) shall not be terminated. The Buyer shall receive from the
Company evidence that the Company's plan(s) and/or program(s) have been
terminated pursuant to resolutions of each of the Company Boards (the form and
substance of such resolutions shall be subject to review and approval of the
Buyer), effective as of the 401(k) Termination Date. To the extent permitted by
the Buyer's applicable plan and otherwise practicable, the Buyer shall take
appropriate steps to enable continuing employees to roll over distributions
from the terminated plans (including promissory notes for plan loans) to a
tax-qualified defined contribution plan or plans maintained by the Buyer or an
affiliate.
6.8 Form S-8. If necessary, the Buyer (i) agrees to file a registration
statement on Form S-8 for the shares of Buyer Common Stock issuable with
respect to the Buyer Stock Options as soon as is reasonably practicable after
the Closing Date, and in any event no later than one (1) Business Day after the
Closing Time; (ii) shall cause all such shares of Buyer Common Stock to be
listed on the NYSE and the Pacific Exchange; and (iii) shall properly authorize
issuance of and reserve an adequate number of shares equal to the number of
shares of Buyer Common Stock issuable under all such Buyer Stock Options. The
Buyer shall not be required to register any shares issuable upon exercise of
stock options which are not eligible to be registered on Form S-8, as
determined in good faith by the Buyer and its counsel.
A-36
6.9 Indemnification. Buyer hereby agrees, from and after the Closing Time,
to indemnify, defend and hold harmless the Company's officers and directors, to
the fullest extent provided under the Company Charter Documents as in effect
immediately prior to the Closing Time and any indemnification agreements as in
effect on the date of this Agreement and under applicable law until the sixth
(6th) anniversary of the Closing Time for all claims arising at or prior to the
Closing Time made against such officers or directors in their capacities as
such. Buyer will at all times maintain assets sufficient to satisfy its
obligations under this Section 6.9. All such indemnification agreements are
listed on Section 6.9 of the Company Disclosure Letter.
6.10 Regulatory Filings. Promptly after the date of this Agreement, the
Company and the Buyer each shall file with the FTC and the DOJ Notification and
Report Forms relating to the transactions contemplated herein as required by
the HSR Act, as well as make any Foreign Filings that are necessary, material
or appropriate. The Company and the Buyer each shall (a) cooperate and
coordinate with one another in the making of such filings, (b) supply the other
with any information which may be required in order to effectuate such filings,
and (c) supply any additional information which reasonably may be required by
the FTC, the DOJ or the competition or acquisition control authorities of any
other Governmental Entity; provided, however, that the Buyer shall not be
required to agree to any divestiture by the Buyer or the Company or any of the
Buyer's Subsidiaries or affiliates of shares of capital stock or of any
business, assets or property of the Buyer, or its Subsidiaries or affiliates,
or of the Company, or its Subsidiaries or affiliates, or the imposition of any
limitation on the ability of any of them to conduct their businesses or to own
or exercise control of such assets, properties and stock.
6.11 Israeli Approvals.
(a) Government Filings. Each of the Buyer and the Company shall use its
commercially reasonable efforts to deliver and file, as promptly as practicable
after the date of this Agreement, each notice, report or other document
required to be delivered by such party to or filed by such party with any
Israeli Governmental Entity with respect to the Offer. Without limiting the
generality of the foregoing:
(i) As promptly as practicable after the date of this Agreement, the
Company and the Buyer shall prepare and file the notifications required
under the Israeli Restrictive Trade Practices Law, 1968 in connection with
the Offer and the transactions contemplated hereunder;
(ii) The Company and the Buyer shall respond as promptly as practicable
to any inquiries or requests received from the Israeli Restrictive Trade
Practices Commissioner for additional information or documentation; and
(iii) The Company shall use all commercially reasonable efforts to
obtain, as promptly as practicable after the date of this Agreement, the
following consents: (x) approval of the OCS and (y) approval of the
Investment Center. In this connection, if required, the Buyer shall provide
to the OCS and the Investment Center any information reasonably requested by
such authorities and shall, without limitation of the foregoing, execute an
undertaking in customary form in which the Buyer undertakes to comply with
the OCS laws and regulations and confirm to the OCS and the Investment
Center that the Company shall continue after the Closing Time to operate in
a manner consistent with its previous undertakings to the OCS and the
Investment Center.
(b) Legal Proceedings. Each of the Buyer and the Company shall (i) give the
other party prompt notice of the commencement of any legal or administrative
proceeding by or before any Israeli Governmental Entity with respect to the
Offer or the transactions contemplated hereunder, (ii) keep the other party
informed as to the status of any such legal or administrative proceeding, and
(iii) promptly inform the other party of any communication to the Israeli
Restrictive Trade Practices Commissioner, the OCS, the Investment Center, the
Israel Securities Authority, or any other Israeli Governmental Entity regarding
the Offer, or any of the other transactions contemplated by this Agreement. The
Buyer and the Company will consult and cooperate with one another, and will
consider in good faith the views of one another, in connection with any
analysis, appearance, presentation, memorandum, brief, argument, opinion or
proposal made or submitted in connection with any Israeli legal or
A-37
administrative proceeding relating to the Offer. In addition, except as may be
prohibited by any Israeli Governmental Entity or by any Israeli legal
requirement, in connection with any such legal or administrative proceeding
under or relating to the Israeli Restrictive Trade Practices Law or any other
Israeli antitrust or fair trade law, each party hereto will permit authorized
representatives of the other party to be present at each meeting or conference
relating to any such legal or administrative proceeding and to have access to
and be consulted in connection with any document, opinion or proposal made or
submitted to any Israeli Governmental Entity in connection with any such legal
or administrative proceeding.
(c) Israeli Income Tax Ruling. As soon as reasonably practicable after the
execution of this Agreement, the Company shall cause the Company's Israeli
counsel, advisors and accountants to prepare and file with the Israeli Income
Tax Commissioner an application for a ruling confirming that the conversion of
the Company Stock Options into the Buyer Stock Options will not result in a
requirement for an immediate Israeli tax payment and that the Israeli taxation
will be deferred until the exercise of the Buyer Stock Options, or in the event
of substituted Company Stock Options which are part of a "Section 102 Plan,"
until the actual sale of the shares of Buyer Common Stock by the option holders
(the "Israeli Income Tax Ruling"). Each of the Company and the Buyer shall
cause their respective Israeli counsel to coordinate all activities, and to
cooperate with each other, with respect to the preparation and filing of such
application and in the preparation of any written or oral submissions that may
be necessary, proper or advisable to obtain the Israeli Income Tax Ruling.
Subject to the terms and conditions hereof, the Company shall use reasonable
best efforts to promptly take, or cause to be taken, all action and to do, or
cause to be done, all things necessary, proper or advisable under applicable
Law to obtain the Israeli Income Tax Rulings, or as appropriate the
confirmation referred to in Annex I, as promptly as practicable.
Notwithstanding any provisions contained in Section 5.1 hereof to the contrary,
the Company shall be permitted to comply with any conditions contained in the
ruling described in this Section 6.11 or reasonable requests made by the
Israeli Tax Commissioner in connection with its delivery of such ruling;
provided, however, (i) that the Company shall give the Buyer at least three (3)
days written notice of any such conditions or requests prior to compliance with
such conditions or requests, and (ii) that in no event shall the Company comply
with any such condition or request in the event any such condition or request
might reasonably be expected to (A) have a Company Material Adverse Effect, (B)
prohibit or impair any business practice of the Company, any acquisition of
property by the Company or any of its subsidiaries or the conduct of business
by the Company of any of its subsidiaries, or (C) adversely impact or
materially delay the consummation of the Offer or any of the other transactions
contemplated by this Agreement.
(d) Israeli Securities Law Exemption. As soon as reasonably practicable
after the execution of this Agreement, the Buyer shall prepare and file with
the Israeli securities authority ("ISA") an application (i) for an exemption
from the requirements of the Israeli Securities Law, 1968 concerning the
publication of a prospectus in respect of the exchange of the Company Options
for the Buyer Stock Options, pursuant to Section 15D of the Securities Law of
Israel and (ii) for a pre-ruling regarding the inapplicability of the
prospectus requirement pursuant to the Israeli Securities Law, 1968, in respect
of the exchange offer of the Company Shares for the Offer Price and the
exchange of Company Warrants for New Buyer Warrants (the "Israeli Securities
Exemption"). Each of the Buyer and the Company shall cause their respective
Israeli counsel to coordinate all activities, and to cooperate with each other,
with respect to the determination of such facts as are required to assess the
Buyer's obligations under the Israeli Securities Law, 1968, and with respect to
the preparation and filing of such application and in the preparation of any
written or oral submissions that may be necessary, proper or advisable to
obtain the Israeli Securities Exemption. Subject to the terms and conditions
hereof, the Buyer and the Company shall use their respective commercially
reasonable efforts to promptly take, or cause to be taken, all action and to
do, or cause to be done, all things necessary, proper or advisable under
applicable Law to obtain the Israeli Securities Exemption as promptly as
practicable.
6.12 Company Shareholder Approval. If approval of the Company Shareholders
is required in order to consummate the Post-Closing Reorganization or any of
the transactions contemplated thereby, the Company as soon as practicable
following the Closing Time, shall submit such transactions to the Company
Shareholders for approval as provided by Dutch Law.
A-38
6.13 Inspection of Real Property. Subject to and in accordance with
Leases, from and after the date of this Agreement, the Buyer and its agents,
contractors and representatives shall have the right and privilege, upon at
least seventy-two (72) hours prior notice to the Company, of entering upon any
or all of the Company Business Facilities during reasonable business hours and
of reviewing, at the Buyer's sole expense, the Company's and its Subsidiaries'
books and records regarding such properties from time to time as needed to make
any inspections, evaluations, surveys or tests which the Buyer may reasonably
deem necessary or appropriate. Without limiting the generality of the
foregoing, the Buyer and its agents, contractors and representatives shall have
the right, at the Buyer's sole expense, and privilege of conducting such
engineering studies, seismic tests, environmental studies (including, without
limitation, surface and subsurface tests, borings and samplings) and surveys of
such properties and such feasibility studies as the Buyer deems necessary or
appropriate and to investigate all matters relating to zoning, use and
compliance with other applicable laws regarding the use and occupancy of such
properties and any proposed impositions, assessments and governmental
regulations affecting such properties. The Company shall, and shall procure
that its Subsidiaries shall, cooperate reasonably with the Buyer in completing
such inspections and evaluations. the Buyer's exercise of its right to inspect
such properties, or the Buyer's election not to inspect any property, shall in
no way be interpreted as a waiver of any of the Buyer's rights or remedies
contained in this Agreement, including, without limitation, the Buyer's right
to rely on the Company's representations and warranties made herein.
6.14 Company Affiliate Agreements. Set forth in Section 6.14 of the
Company Disclosure Letter is a complete and accurate list of those persons who
may be deemed to be, in the Company's reasonable judgment, the Company
Affiliates. The Company will provide the Buyer with such information and
documents as the Buyer reasonably requests for purposes of reviewing such list.
The Company has delivered herewith written Company Affiliate Agreements
substantially in the form attached hereto as Exhibit D executed by all Company
Affiliates as of the date hereof. Each Company Affiliate Agreement will be in
full force and effect as of the Closing Time. The Buyer will be entitled to
place appropriate legends on the certificates evidencing any Buyer Common Stock
to be received by a Company Affiliate pursuant to the terms of this Agreement,
and to issue appropriate stop transfer instructions to the transfer agent for
the Buyer Common Stock, consistent with the terms of the Company Affiliate
Agreement.
6.15 NYSE and Pacific Exchange. The Buyer agrees to use its commercially
reasonable efforts to cause the listing on the NYSE and on the Pacific
Exchange, effective as of the Closing Time, of the shares of Buyer Common Stock
issuable, and those required to be reserved for issuance, in connection with
the Offer, subject to official notice of issuance.
6.16 CVR Agreement. The Buyer, at or prior to the consummation of the
Offer, shall cause the CVR Agreement to be duly authorized, executed and
delivered by the Buyer or a Subsidiary of the Buyer.
6.17 Consultation.
(a) Employee Consultation. The Company and each of its Subsidiaries shall
procure compliance with, and satisfaction of, all obligations under the
European Communities Council Directive of 14 February 1977 (77/187/EEC) (the
"Acquired Rights Directive"), equivalent national laws or regulations, or any
applicable works council or agreements to provide information about the Offer
to employees (or employee representatives of such employees) of the Company or
any of its Subsidiaries affected by the Offer and, where required, to consult
with such employees or employee representatives and, as the case may be, to
continue the consultations with Dutch employees or employee representatives
pursuant to the Dutch SER Merger Rules. The Company shall be deemed not to have
complied with its obligations under this Section 6.17 if the Company or any of
its Subsidiaries has failed prior to the date of this Agreement to satisfy any
such obligations in relation of the Offer applying prior to the date of this
Agreement.
(b) Israeli Employees Consultation. As soon as practicable, and at a time
and manner as reasonably determined by the Buyer, after the commencement of the
Offer, the Company shall procure that IEPS and P.F.E. Investments Limited
shall, in accordance with the Buyer's reasonable directions, notify the current
Israeli
A-39
Employees of the proposed acquisition of Company Shares contemplated hereunder
and, together with representatives of the Buyer, hold consultations with such
Employees, in such manner as may be mutually agreed upon by the Buyer and the
Company as aforesaid, regarding such proposed acquisition.
6.18 Registered Intellectual Property Rights. The Company shall use its
commercially reasonable efforts to deliver to the Buyer prior to the Closing
Time a written list of all actions that must be taken by the Company or any of
its Subsidiaries within one hundred and eighty (180) days of the date 90 days
after the execution of this Agreement, including the payment of any
registration, maintenance or renewal fees or the filing of any responses to PTO
(or any equivalent authority anywhere in the world) office actions, documents,
applications or certificates for the purposes of obtaining, maintaining,
perfecting or preserving or renewing any Registered Intellectual Property
Rights.
6.19 Company Tender and Voting Agreements. The Company shall use its best
efforts to obtain and deliver to the Buyer executed Company Tender Agreements
and executed Company Voting Agreements from each of the Company's directors and
executive officers as soon as practicable after the date of this Agreement.
6.20 Employee Covenants. The Company shall use its commercially reasonable
efforts to retain all Company Employees.
6.21 Approved Enterprise Covenant. The Company shall use its best efforts
to cause IEPS to obtain any and all remaining, if any, approvals required for
IEPS' status as an Approved Enterprise for the purpose of the Israeli
Encouragement of Capital Investments Law, 1959.
6.22 Environmental Covenant. The Company shall cooperate with the Buyer in
the review of the Company's regulatory matters, and shall, upon request of the
Buyer, made in good faith, take all such actions, implement such registrations,
submit such permit applications and seek all such Approvals as may be required,
in the good faith judgment of the Buyer, by Environmental Laws to insure that
the Company and the products it manufactures, sells or distributes are, and
have been at all relevant times, in compliance with all Environmental Laws in
all relevant jurisdictions.
6.23 Sale of Company Shares. None of the Buyer or any of its Subsidiaries
shall sell or otherwise transfer any of such Company Shares (other than to the
Buyer or a Subsidiary of the Buyer) until the earlier of the Closing Time or
the termination of this Agreement pursuant to Article VII.
6.24 Dutch Tax Ruling. Promptly after the date of this Agreement, the
Company and the Buyer jointly shall file with The Netherlands competent tax
authorities an advance tax ruling request, in which the tax authorities are
asked to confirm that the conversion of Company Stock Options held by optionees
who are employees of the Company or any of its Subsidiaries into Buyer Stock
Options will not qualify as an exercise or an alienation within the meaning of
Article 10a(3) of the Wage Withholding Tax Act. The Company shall use all
commercially reasonable effort to obtain this advance tax ruling prior to the
Closing.
6.25 Tax Planning Cooperation. Prior to the Closing, the Company shall use
its commercially reasonable efforts to cooperate in Buyer's development and
implementation of a comprehensive tax planning strategy for the combined
entity. The Company shall use its best efforts to obtain any tax rulings that
the Buyer requests be obtained.
A-40
ARTICLE VII
TERMINATION, AMENDMENT AND WAIVER
7.1 Termination. This Agreement may be terminated and the Offer may be
abandoned at any time prior to the Closing Time:
(a) by mutual written agreement of the Company and the Buyer; or
(b) by either the Company or the Buyer, if:
(i) the Offer shall have expired or been terminated in accordance
with the terms of this Agreement without the Buyer or a Subsidiary of
the Buyer having accepted for exchange any Company Shares pursuant to
the Offer; or
(ii) the Offer has not been consummated on or before August 30, 2002
(the "End Date"); provided, however, that the right to terminate this
Agreement under this Section 7.1(b)(ii) shall not be available to any
party whose failure to fulfill any obligation under this Agreement has
been the principal cause of or resulted in the failure of the Offer to
have been consummated on or before such date and such action or failure
to act constitutes a material breach of this Agreement; or
(iii) there shall be any applicable law or regulation that makes
consummation of the Offer illegal or otherwise prohibited or any
judgment, injunction, order or decree of any court or governmental body
having competent jurisdiction enjoining the Company or the Buyer from
consummating the Offer is entered and such judgment, injunction,
judgment or order shall have become final and nonappealable; or
(c) by the Company, prior to the Closing Time, upon a material breach of
any covenant or agreement on the part of the Buyer set forth in this
Agreement, or if any representation or warranty of the Buyer shall have been
untrue or inaccurate when made or shall have become untrue or inaccurate
such that, in the aggregate, in the case of such representations and
warranties, such untruths or inaccuracies would reasonably be expected to
have a Buyer Material Adverse Effect; provided, that if such untruth or
inaccuracy in the Buyer's representations and warranties or breach by the
Buyer is curable by the Buyer through exercise of its commercially
reasonable efforts, then the Company may not terminate this Agreement
pursuant to this Section 7.1(c) until the earlier of (i) the expiration of a
thirty (30) day period after delivery of written notice from the Company to
the Buyer of such untruth or inaccuracy or breach, or (ii) the Buyer's
ceasing to exercise commercially reasonable efforts to cure such untruth or
inaccuracy or breach, provided that the Buyer continues to exercise
commercially reasonable efforts to cure such untruth or inaccuracy or breach
(it being understood that the Company may not terminate this Agreement
pursuant to this Section 7.1(c) if such untruth or inaccuracy or breach by
the Buyer is cured during such thirty-day period);
(d) by the Buyer, prior to the Closing Time, upon a breach of any
covenant or agreement on the part of the Company set forth in this
Agreement, or if any representation or warranty of the Company shall have
been untrue or inaccurate when made or shall have become untrue or
inaccurate such that the Buyer or a Subsidiary of the Buyer would not have
been required to accept for exchange any Company Shares tendered pursuant to
the Offer by virtue of clause (e) or (d), respectively, of the condition
(vi) of Annex I hereto if the expiration of the Offer had occurred on such
date, provided that, if such untruth or inaccuracy in the Company's
representations and warranties or breach by the Company is curable by the
Company through exercise of its commercially reasonable efforts, then the
Buyer may not terminate this Agreement pursuant to this Section 7.1(d) until
the earlier of (i) the expiration of a thirty (30) day period after delivery
of written notice from the Buyer to the Company of such untruth or
inaccuracy or breach, or (ii) the Company's ceasing to exercise commercially
reasonable efforts to cure such untruth or inaccuracy or breach, provided
that the Company continues to exercise commercially reasonable efforts to
cure such untruth or inaccuracy or breach (it being understood that the
Buyer may not terminate this Agreement pursuant to this Section 7.1(d) if
such untruth or inaccuracy or breach by the Company is cured during such
thirty-day period); or
(e) by the Buyer if a Triggering Event shall have occurred.
A-41
The party desiring to terminate this Agreement pursuant to this Section 7.1
(other than pursuant to Section 7.1(a)) shall give notice of such termination
to the other party.
7.2 Notice of Termination; Effect of Termination. Any proper termination
of this Agreement under Section 7.1 above will be effective immediately (or if
the termination is pursuant to Section 7.1(c) or (d) above and the proviso is
applicable, at such time as such provision provides for) upon the delivery of
written notice of the terminating party to the other parties hereto. In the
event of the termination of this Agreement under Section 7.1, this Agreement
shall be of no further force or effect without liability of any party (or any
stockholder, director, officer, employee, agent, consultant or representative
of such party) to the other party hereto, except (i) as set forth in this
Section 7.2, Section 7.3 and Article VIII, each of which shall survive the
termination of this Agreement, and (ii) that nothing herein shall relieve any
party from liability for any intentional or willful breach of or fraud in
connection with this Agreement. No termination of this Agreement shall affect
the obligations of the parties contained in the Confidentiality Agreement, all
of which obligations shall survive termination of this Agreement in accordance
with their terms.
7.3 Fees and Expenses.
(a) General. Except as set forth in this Section 7.3, all attorneys',
accountants' and consultants' fees and expenses incurred in connection with
this Agreement and the transactions contemplated hereby shall be paid by the
party incurring such fees and expenses whether or not the Offer is consummated.
(b) Company Payments.
(i) If this Agreement is terminated by the Buyer prior to the Closing
Time pursuant to Section 7.1(d), the Company shall promptly, but in any
event no later than one day after the date requested by the Buyer, pay the
Buyer a fee equal to all of the Buyer's fees and expenses, including,
without limitation, costs of internal, legal, accounting and similar
professional services incurred in connection with this Agreement and the
transactions contemplated herein, in immediately available funds; provided,
however that the maximum amount payable by the Company to the Buyer under
this Section 7.3(b)(i) shall be $2,000,000.00 (the "Termination Fee").
(ii) If this Agreement is terminated by the Buyer prior to the Closing
Time pursuant to Section 7.1(e), the Company shall promptly, but in no event
later than one day after the date requested by the Buyer, pay the Buyer the
Termination Fee plus an additional fee equal to U.S. $27,000,000.00 in
immediately available funds.
(iii) The Company acknowledges that the agreements contained in this
Section 7.3(b) are an integral part of the transactions contemplated by this
Agreement, and that, without these agreements, the Buyer would not enter
into this Agreement. Accordingly, if the Company fails to pay in a timely
manner the amounts due pursuant to this Section 7.3(b), and, in order to
obtain such payment, the Buyer makes a claim that results in a judgment
against the Company, the Company shall pay to the Buyer its reasonable costs
and expenses (including reasonable attorneys' fees and expenses) in
connection with such suit, together with interest on the amounts set forth
in this Section 7.3(b) at the prime rate set by Bank of America N.T. and
S.A. in effect on the date such payment was required to be made. Payment of
the fees described in this Section 7.3(b) shall not be in lieu of damages
incurred in the event of any intentional or willful breach of or fraud in
connection with this Agreement.
(c) Buyer Payments.
(i) If this Agreement is terminated by the Company prior to the Closing
Time pursuant to Section 7.1(c), the Buyer shall promptly, but in any event
no later than one day after the date requested by the Company, pay the
Company a fee equal to all of the Company's fees and expenses, including,
without limitation, costs of internal, legal, accounting and similar
professional services incurred in connection with this Agreement and the
transactions contemplated herein, in immediately available funds; provided,
however, that the maximum amount payable by the Buyer to the Company under
this Section 7.3(c)(i) shall be $2,000,000.00.
A-42
(ii) The Buyer acknowledges that the agreements contained in this Section
7.3(c) are an integral part of the transactions contemplated by this
Agreement, and that, without these agreements, the Company would not enter
into this Agreement. Accordingly, if the Buyer fails to pay in a timely
manner the amounts due pursuant to this Section 7.3(c), and, in order to
obtain such payment, the Company makes a claim that results in a judgment
against the Buyer, the Buyer shall pay to the Company its reasonable costs
and expenses (including reasonable attorneys' fees and expenses) in
connection with such suit, together with interest on the amounts set forth
in this Section 7.3(c) at the prime rate set by Bank of America N.T. and
S.A. in effect on the date such payment was required to be made. Payment of
the fees described in this Section 7.3(c) shall not be in lieu of damages
incurred in the event of any intentional or willful breach of or fraud in
connection with this Agreement.
7.4 Amendment. Subject to applicable law, this Agreement may be amended by
the parties hereto at any time by execution of an instrument in writing signed
on behalf of each of the Buyer and the Company.
7.5 Extension; Waiver. At any time prior to the Closing Time any party
hereto may, to the extent legally allowed and except as otherwise set forth
herein (i) extend the time for the performance of any of the obligations or
other acts of the other parties hereto, (ii) waive any inaccuracies in the
representations and warranties made to such party contained herein or in any
document delivered pursuant hereto, and (iii) waive compliance with any of the
agreements or conditions for the benefit of such party contained herein. Any
agreement on the part of a party hereto to any such extension or waiver shall
be valid only if set forth in an instrument in writing signed on behalf of such
party. Delay in exercising any right under this Agreement shall not constitute
a waiver of such right.
A-43
ARTICLE VIII
GENERAL PROVISIONS
8.1 Non-Survival of Representations and Warranties. The representations,
warranties and covenants of the Company and the Buyer contained in this
Agreement shall terminate at the Closing Time, and only the covenants that by
their terms survive the Closing Time shall survive the Closing Time.
8.2 Notices. All notices and other communications hereunder shall be in
writing and shall be deemed given if delivered personally or by commercial
delivery service, or sent via telecopy (receipt confirmed) to the parties at
the following addresses or telecopy numbers (or at such other address or
telecopy numbers for a party as shall be specified by like notice):
(a) if to the Buyer, to:
Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: Chief Executive Officer
Telephone No.: (650) 857-1501
Telecopy No.: (650) 857-2977
with copies to: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Telephone No.: (650) 857-1501
Telecopy No.: (650) 857-4837
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Telecopy No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Telecopy No.: (415) 947-2099
(b) if to the Company, to:
Indigo N.V.
Kiryat Weizmann Science Park
Nes Ziona 70400
ISRAEL
Attention: Legal Department
Telecopy No.: (011) 972-8-938-1333
with a copy to:
Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Telecopy No.: (212) 351-4035
A-44
8.3 Counterparts. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement and
shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other party, it being understood that all
parties need not sign the same counterpart.
8.4 Entire Agreement; Third Party Beneficiaries. This Agreement and the
documents and instruments and other agreements among the parties hereto as
contemplated by or referred to herein, including the Company Disclosure Letter
and the Buyer Disclosure Letter (a) constitute the entire agreement among the
parties with respect to the subject matter hereof and supersede all prior
agreements and understandings, both written and oral, among the parties with
respect to the subject matter hereof, it being understood that the
Confidentiality Agreement shall continue in full force and effect until the
Closing and shall survive any termination of this Agreement; and (b) except
with respect to the Indemnified Parties pursuant to Section 6.9, are not
intended to confer upon any other person any rights or remedies hereunder.
8.5 Severability. In the event that any provision of this Agreement, or
the application thereof, becomes or is declared by a court of competent
jurisdiction to be illegal, void or unenforceable, the remainder of this
Agreement will continue in full force and effect and the application of such
provision to other persons or circumstances will be interpreted so as
reasonably to effect the intent of the parties hereto. The parties further
agree to replace such void or unenforceable provision of this Agreement with a
valid and enforceable provision that will achieve, to the extent possible, the
economic, business and other purposes of such void or unenforceable provision.
8.6 Other Remedies; Specific Performance. Except as otherwise provided
herein, any and all remedies herein expressly conferred upon a party will be
deemed cumulative with and not exclusive of any other remedy conferred hereby,
or by law or equity upon such party, and the exercise by a party of any one
remedy will not preclude the exercise of any other remedy. The parties hereto
agree that irreparable damage would occur in the event that any of the
provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. It is accordingly agreed that the
parties shall be entitled to seek an injunction or injunctions to prevent
breaches of this Agreement and to enforce specifically the terms and provisions
hereof in any court of the United States or any state having jurisdiction, this
being in addition to any other remedy to which they are entitled at law or in
equity.
8.7 Governing Law. This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York, regardless of the
laws that might otherwise govern under applicable principles of conflicts of
law thereof. EACH OF THE COMPANY AND THE BUYER HEREBY IRREVOCABLY CONSENTS TO
THE EXCLUSIVE JURISDICTION AND VENUE OF ANY COURT WITHIN THE STATE OF NEW YORK
IN CONNECTION WITH ANY MATTER BASED UPON OR ARISING OUT OF THIS AGREEMENT OF
THE MATTERS CONTEMPLATED HEREIN, AGREES THAT PROCESS MAY BE SERVED UPON THEM IN
ANY MANNER AUTHORIZED BY THE LAWS OF THE STATE OF NEW YORK FOR SUCH PERSONS AND
WAIVES ANY COVENANTS NOT TO ASSERT OR PLEAD ANY OBJECTION WHICH THEY MIGHT
OTHERWISE HAVE TO SUCH JURISDICTION, VENUE AND SUCH PROCESS.
8.8 Rules of Construction. The parties hereto agree that they have been
represented by counsel during the negotiation and execution of this Agreement
and, therefore, waive the application of any law, regulation, holding or rule
of construction providing that ambiguities in an agreement or other document
will be construed against the party drafting such agreement or document.
8.9 Assignment. No party may assign either this Agreement or any of its
rights, interests, or obligations hereunder without the prior written approval
of the other parties. Subject to the preceding sentence, this Agreement shall
be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and permitted assigns.
A-45
8.10 Waiver of Jury Trial. EACH OF THE BUYER AND THE COMPANY HEREBY
IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR THE ACTIONS OF BUYER OR COMPANY IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.
ARTICLE IX
DEFINITIONS
9.1 Definitions. As used in this Agreement, the following defined terms
shall have the meanings indicated below:
"401(k) Termination Date" has the meaning ascribed to it in Section 6.7.
"2000 ESPP" has the meaning ascribed to it in Section 6.6(c).
"Acquired Rights Directive" has the meaning ascribed to it in Section 6.17.
"Acquisition Proposal" means any offer or proposal (other than an offer or
proposal by the Buyer) relating to any Acquisition Transaction.
"Acquisition Transaction" means any transaction or series of related
transactions other than the transactions contemplated by this Agreement
involving: (A) any acquisition or purchase from the Company by any person or
"group" (as defined under Section 13(d) of the Exchange Act and the rules and
regulations thereunder) of more than a 10% interest in the total outstanding
voting securities of the Company or any of its Subsidiaries or any tender offer
or exchange offer that if consummated would result in any person or "group" (as
defined under Section 13(d) of the Exchange Act and the rules and regulations
thereunder) beneficially owning 10% or more of the total outstanding voting
securities of the Company or any of its Subsidiaries or any acquisition,
consolidation, business combination or similar transaction involving the
Company pursuant to which the shareholders of the Company immediately preceding
such transaction hold less than 90% of the equity interests in the surviving or
resulting entity of such transaction; (B) any sale, lease (other than in the
ordinary course of business), exchange, transfer, license (other than in the
ordinary course of business), acquisition or disposition of more than 10% of
the assets of the Company; or (C) any liquidation, dissolution,
recapitalization or other significant corporate reorganization of the Company.
"Affiliate" of any specified Person means any other Person directly or
indirectly controlling or controlled by or under direct or indirect common
control with such specified Person. For the purposes of this definition,
"control" when used with respect to any specified Person means the power to
direct the management and policies of such Person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise;
and the terms "controlling" and "controlled" have meanings correlative to the
foregoing.
"Agreement" has the meaning ascribed to it in the forepart of this Agreement.
"Approvals" means franchises, grants, authorizations, licenses, permits,
easements, consents, certificates, approvals and orders.
"Average Buyer Stock Price" means the average of the closing sales prices of
the Buyer Common Stock on the NYSE for the twenty (20) consecutive trading days
ending with the third trading day immediately preceding the Closing Time.
"Blue Sky Laws" means U.S. state security laws.
A-46
"Business Day" means any day, other than Saturday, Sunday or a U.S. federal
holiday, and shall consist of the time period from 12:01 a.m. through 12:00
midnight U.S. Eastern time.
"Buyer" has the meaning ascribed to it in the forepart of this Agreement.
"Buyer Charter Documents" has the meaning ascribed to it in Section 4.2.
"Buyer Common Stock" means shares of common stock of the Buyer, par value
$0.01 per share.
"Buyer Disclosure Letter" has the meaning ascribed to it in Article IV.
"Buyer Material Adverse Effect" means any change or effect that,
individually or when taken together with all other such changes or effects that
have occurred prior to the date of determination of the Buyer Material Adverse
Effect, is or is reasonably likely to be materially adverse to the business,
assets (including intangible assets), financial condition or results of
operations of the Buyer and its Subsidiaries, taken as a whole; provided,
however, that in no event shall any of the following be deemed to constitute a
Buyer Material Adverse Effect: (i) any change or effect that results or arises
primarily and directly from changes affecting any of the industries in which
the Buyer operates generally or the worldwide economy generally; or (ii) any
change or effect primarily and directly resulting from the pendency of the
Offer or the transactions contemplated by this Agreement; or (iii) any change
in the Buyer's stock price or trading volume (which changes or effects in the
case of clause (i) above does not disproportionately affect the Buyer);
provided, that to successfully assert the exception in clause (i) or (ii)
above, the Buyer must show by a preponderance of the evidence that such
exception is applicable.
"Buyer Preferred Stock" means shares of preferred stock of the Buyer, par
value $0.01 per share.
"Buyer SEC Reports" has the meaning ascribed to it in Section 4.7(a).
"Buyer Stock Options" has the meaning ascribed to it in Section 6.6(a).
"Closing" has the meaning ascribed to it in Section 1.1(b).
"Closing Time" means the date and time at which the Buyer (or a Subsidiary
of the Buyer) shall initially accept for payment Company Shares tendered in the
Offer.
"COBRA" means the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended.
"Code" means the U.S. Internal Revenue Code of 1986, as amended.
"Company" has the meaning ascribed to it in the forepart of this Agreement.
"Company Affiliate" means each affiliate of the Company within the meaning
of Rule 145 promulgated under the Securities Act.
"Company Affiliate Agreements" has the meaning ascribed to it in the
recitals to this Agreement.
"Company Boards" means the Company Management Board and the Company
Supervisory Board, collectively.
"Company Business Facility" has the meaning ascribed to it in Section
3.13(a).
"Company Charter Documents" has the meaning ascribed to it in Section 3.2.
A-47
"Company Contract" means any such agreements, contracts or commitments to
which the Company or any of its Subsidiaries is a party or by which it is bound
that are required to be disclosed in the Company Disclosure Letter, including
agreements relating to Taxes with Governmental Entities.
"Company Core Technology" means Company technology which enables the
creation of a printed image employing a liquid composition of charged,
pigmented thermoplastic particles which are being transferred from an
image-bearing surface to a final substrate.
"Company Disclosure Letter" has the meaning ascribed to it in Article III.
"Company Employees" means employees of the Company or any of its
Subsidiaries.
"Company Employee Plan" means any plan, program, policy, practice, contract,
agreement or other arrangement providing for compensation, severance,
termination pay, deferred compensation, performance awards, stock or
stock-related awards, fringe benefits or other employee benefits or
remuneration of any kind, whether written or unwritten or otherwise, funded or
unfunded, including, without limitation, each "employee benefit plan," within
the meaning of Section 3(3) of ERISA which is or has been maintained,
contributed to, or required to be contributed to, by the Company or any
Affiliate for the benefit of any Employee, or with respect to which the Company
or any Affiliate has or may have any liability or obligation.
"Company Intellectual Property" means any Intellectual Property and
Intellectual Property Rights including the Company Registered Intellectual
Property Rights that are owned by, or exclusively licensed to, the Company or
any of its Subsidiaries.
"Company Interim Financial Data" means the unaudited interim financial data
(i) that the Company publishes on a quarterly basis by way of earnings release
which consists of a condensed consolidated statements of operations, condensed
consolidated balance sheets, and (ii) the related condensed consolidated
statements of cash flows.
"Company Management Board" means the Management Board of the Company.
"Company Material Adverse Effect" means any change or effect that,
individually or when taken together with all other such changes or effects that
have occurred prior to the date of determination of the Company Material
Adverse Effect, is or is reasonably likely to be materially adverse to the
business, assets (including intangible assets), financial condition or results
of operations of the Company and its Subsidiaries, taken as a whole; provided,
however, that in no event shall any of the following be deemed to constitute a
Company Material Adverse Effect: (i) any change or effect that results or
arises primarily and directly from changes affecting the digital commercial
printing industry generally or the worldwide economy generally; or (ii) any
change or effect primarily and directly resulting from the pendency of the
Offer or the transactions contemplated by this Agreement; or (iii) any change
in the Company's stock price or trading volume (which changes or effects in the
case of clause (i) above does not disproportionately affect the Company);
provided, that to successfully assert the exception in clause (i) or (ii)
above, the Company must show by a preponderance of the evidence that such
exception is applicable.
"Company Option Plans" means the Company's International Consolidated Stock
Incentive Plan, as amended, and sub-plans, limited to Israel Stock Option Plan,
as amended, Netherlands Stock Option Plan, as amended, United States Incentive
Stock Option Plan, as amended, and United States Non-Qualified Stock Option
Plan, as amended.
"Company Permits" means all permits, licenses, variances, exemptions,
orders, approvals and other authorizations from governmental authorities which
are necessary for the ownership of the assets and properties of the Company or
any of its Subsidiaries and the carrying on of the business of the Company and
its Subsidiaries.
A-48
"Company Products" has the meaning ascribed to it in Section 3.16(a).
"Company Products of Concern" has the meaning ascribed to it in Section
3.21(h).
"Company Registered Intellectual Property Rights" has the meaning ascribed
to it in Section 3.16(b).
"Company SEC Reports" has the meaning ascribed to it in Section 3.7(a).
"Company Shares" means the common shares of the Company, par value NLG 0.04
per share.
"Company Shareholders" means holders of Company Shares.
"Company Stock Option" has the meaning ascribed to it in Section 6.6(a).
"Company Supervisory Board" means the Supervisory Board of the Company.
"Company Tender Agreements" has the meaning ascribed to it in the recitals
to this Agreement.
"Company Voting Agreements" has the meaning ascribed to it in the recitals
to this Agreement.
"Company Warrants" has the meaning ascribed to it in Section 1.4.
"Confidentiality Agreement" means the Confidentiality Agreement between the
Company and the Buyer, dated as of August 30, 2001.
"Contingent Offer Price" has the meaning ascribed to it in the recitals of
this Agreement.
"Contingent Price Exchange Ratio" means that number of shares of Buyer
Common Stock computed as follows (rounded to the fourth decimal place): (i) if
the Average Buyer Stock Price is less than or equal to $23.68 and greater than
or equal to $16.69, the Contingent Price Exchange Ratio shall be equal to the
quotient obtained by dividing U.S. $6.00 by the Average Buyer Stock Price, (ii)
if the Average Buyer Stock Price is less than $16.69, the Contingent Price
Exchange Ratio shall be equal to 0.3595, and (iii) if the Average Buyer Stock
Price is greater than $23.68, the Contingent Price Exchange Ratio shall be
equal to 0.2534.
"Contingent Price Proration Factor" means a fraction (expressed as a decimal
and rounded to the fourth decimal place) the numerator of which is the Maximum
Contingent Price Election Number and the denominator of which is the Requested
Contingent Price Amount.
"Contract" means any written or oral agreement, contract, subcontract,
lease, binding understanding, instrument, note, option, warranty, purchase
order, license, sublicense, insurance policy, benefit plan, commitment or
undertaking of any nature.
"Copyrights" has the meaning ascribed to it under "Intellectual Property" of
this Article IX.
"corporate income tax" means vennootschapsbelasting as imposed under the
Corporate Income Tax Act.
"Corporate Income Tax Act" means Wet op de vennootschapsbelasting 1969.
"CVR" means a contingent value right as defined in the CVR Certificate.
"CVR Agreement" has the meaning ascribed to it in the recitals to this
Agreement.
"CVR Certificate" means the certificate representing the CVR in the form of
attached as Annex A to the CVR Agreement.
A-49
"DCC" has the meaning ascribed to it in Section 2.1.
"dividend withholding tax" means dividendbelasting as imposed under the
Dividend Withholding Tax Act.
"Dividend Withholding Tax Act" means Wet op de dividendbelasting 1965.
"DOJ" means the Antitrust Division of the United States Department of
Justice.
"DOL" means the Department of Labor.
"DPI 2000" has the meaning ascribed to it in Section 3.22.
"Domain Names" has the meaning ascribed to it in Section 3.16.
"Dutch Law" has the meaning ascribed to it in Section 1.2.
"EGM" has the meaning ascribed to it in Section 1.3(a).
"Employee" means any current or former or retired employee, officer,
consultant or director of the Company or any Affiliate anywhere in the world.
"Employment Agreement" means each employment, severance, consulting,
relocation, repatriation, expatriation, visas, work permit or other agreement
or Contract relating to provisions of services between the Company or any
Affiliate and any Employee.
"Encumbrances" means any and all liens, charges, security interests,
options, claims, mortgages, attachments, pledges, proxies, voting trusts or
agreements, obligations, understandings or arrangements or other restrictions
on title or transfer, including restrictions imposed by any Governmental Entity.
"End Date" has the meaning ascribed to it in Section 7.1(b)(ii).
"Environmental Claim" means any claim, action, cause of action,
investigation or notice (written or oral) by any Person alleging actual or
potential liability for investigatory, cleanup or governmental response costs,
or natural resources or property damages, or personal injuries, attorney's fees
or penalties relating to (1) the presence, or release into the environment, of
any Materials of Environmental Concern at any location owned or operated by the
Company or any Company Subsidiary, now or in the past, or (2) circumstances
forming the basis of any violation, or alleged violation, of any Environmental
Law.
"Environmental Laws" means each applicable federal, state, local and foreign
law and regulation and each treaty, directive, ordinance, order, guidance rule
or code having the force of law (1) relating to pollution, protection or
preservation of human health or the environment including ambient air, surface
water, ground water, land surface or subsurface strata, and natural resources,
and including those relating to emissions, discharges, releases or threatened
releases of Materials of Environmental Concern, or otherwise relating to the
manufacturing, processing, distribution, sale, use, treatment, generation,
storage, containment (whether above ground or underground), disposal, transport
or handling of or exposure of any Person to Materials of Environmental Concern
or any product containing Materials of Environmental Concern, or the
preservation of the environment or mitigation of adverse effects thereon; and
(2) with regard to record keeping, notification, disclosure registration and
reporting requirements respecting Materials of Environmental Concern.
"ERISA" means the Employee Retirement Income Security Act of 1974, as
amended.
"ESPP" has the meaning ascribed to it in Section 1.4.
A-50
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
"Exchange Agent" has the meaning ascribed to it in Section 1.5.
"Expiration Time" means the time and date of the expiration of the Offer.
"Fixed Offer Price" means that number of shares of Buyer Common Stock
computed as follows (rounded to the fourth decimal place): (i) if the Average
Buyer Stock Price is less than or equal to U.S. $23.68 and greater than or
equal to U.S. $16.69, the Fixed Offer Price shall be equal to the quotient
obtained by dividing U.S. $7.50 by the Average Buyer Stock Price, (ii) if the
Average Buyer Stock Price is less than U.S. $16.69, the Fixed Offer Price shall
be equal to 0.4494, and (iii) if the Average Buyer Stock Price is greater than
U.S. $23.68, the Fixed Offer Price shall be equal to 0.3167.
"Fixed Option Alternative" has the meaning ascribed to it in Section 6.6(a).
"Fixed Price Proration Factor" means a fraction (expressed as a decimal and
rounded to the fourth decimal place) the numerator of which is the Maximum
Fixed Price Election Number and the denominator of which is the Requested Fixed
Price Amount.
"FMLA" means the Family Medical Leave Act of 1993, as amended.
"Foreign Securities Laws" means all relevant securities laws, other than
U.S. securities laws and Israeli securities laws, and including the securities
laws of The Netherlands, Belgium, France, Germany and Italy and any other
jurisdiction where Company Employees, Company Shareholders or holders of
Company Options or Company Warrants are located.
"Foreign Filings" means applicable requirements of antitrust or competition
laws and regulations of foreign Governmental Entities.
"FTC" means the United States Federal Trade Commission.
"FTO" has the meaning ascribed to it in Section 6.7(c).
"Funded Pension Plan" means a Pension Plan under which the assets to satisfy
the benefit obligations are legally segregated from the general assets of the
employer and are not subject to the creditors of the employer or its
Subsidiaries and Affiliates.
"GAAP" means United States generally accepted accounting principles.
"Governmental Entity" means any court, administrative agency, commission,
governmental or regulatory authority, domestic or foreign anywhere in the
world, including in those countries where the Company or any of its
Subsidiaries has Employees, activities or shareholders.
"Grant Funded IP" has the meaning ascribed to it in Section 3.22.
"Grants" has the meaning ascribed to it in Section 3.22.
"HSR Act" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, and the rules and regulations thereunder.
"HSR Approval" means the pre-merger notification requirements of the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules
and regulations thereunder.
A-51
"Included Assets" means all those assets necessary for the operation of the
business of the Company or any of its Subsidiaries, in either case, as
presently conducted.
"Income Tax Act" means Wet inkomstenbelasting 2001.
"Income Tax Act 1964" means Wet op de inkomstenbelasting 1964.
"Indemnified Parties" has the meaning ascribed to it in Section 6.9(a).
"IEPS" has the meaning ascribed to it in Section 3.14(dd).
"Insurance Policies" means insurance policies or fidelity bonds covering the
assets, business, equipment, properties, operations, Employees of the Company
and its Subsidiaries.
"Intellectual Property" means any or all of the following: (i) works of
authorship including, computer programs, algorithms, routines, source code and
executable code, whether embodied in software or otherwise, documentation,
designs, files, records and data; (ii) inventions (whether or not patentable),
improvements, and technology; (iii) proprietary and confidential information,
including technical data and customer and supplier lists, trade secrets, show
how, know how and techniques; (iv) databases, data compilations and collections
and technical data; (v) processes, devices, prototypes, schematics, bread
boards, net lists, mask works, test methodologies and hardware development
tools; (vi) logos, trade names, trade dress, trademarks, service marks, World
Wide Web addresses, uniform resource locators and domain names, tools, methods
and processes; and (vii) all instantiations of the foregoing in any form and
embodied in any media.
"Intellectual Property Rights" means any or all of the following and all
rights in, arising out of, or associated therewith: (i) all United States and
foreign patents and utility models and applications therefor and all reissues,
divisions, re-examinations, renewals, extensions, provisionals, continuations
and continuations-in-part thereof, and equivalent or similar rights anywhere in
the world in inventions and discoveries including invention disclosures
("Patents"); (ii) all trade secrets and similar rights in know-how and
confidential or proprietary information; (iii) all copyrights, copyright
registrations and applications therefor and all other rights corresponding
thereto throughout the world ("Copyrights"); (iv) all industrial designs and
any registrations and applications therefor throughout the world; (v) mask
works (including rights in the topography of integrated circuits), mask work
registrations and applications therefor, and all other rights corresponding
thereto throughout the world ("Mask Works"); (vi) all rights in World Wide Web
addresses, uniform resource locators and domain names and applications and
registrations therefor; (vii) all rights in all trade names, logos, common law
trademarks and service marks, trademark and service mark registrations and
applications therefor and all goodwill associated therewith throughout the
world ("Trademarks"); (viii) all moral and economic rights of authors and
inventors however denominated throughout the world; and (ix) any similar,
corresponding or equivalent rights to any of the foregoing anywhere in the
world.
"International Employee Plan" means each the Company Employee Plan that has
been adopted or maintained by the Company or any Affiliate, whether informally
or formally, or with respect to which the Company or any Affiliate will or may
have any liability, for the benefit of Employees who perform services outside
the United States.
"Investment Center" means the Israeli Investment Center of the Israeli
Ministry of Trade & Industry.
"IRS" means the U.S. Internal Revenue Service.
"ISA" has the meaning ascribed to it in Section 6.11(d).
"Israeli Employees" has the meaning ascribed to it in Section 3.11(m).
A-52
"Israeli Income Tax Ruling" has the meaning ascribed to it in Section
6.11(c).
"Israeli Securities Exemption" has the meaning ascribed to it in Section
6.11(d).
"Knowledge" means with respect to a party hereto, with respect to any matter
in question, knowledge of the officers or their direct reports or directors of
such party or its Subsidiaries if: (a) such individual is actually aware of
such fact or matter; or (b) a prudent individual could be expected to discover
or otherwise become aware of such fact or other matter in the course of
conducting a reasonable investigation concerning the existence of such fact or
matter.
"Leases" has the meaning ascribed to it in Section 3.13(a).
"Legal Requirements" means any federal, state, local, municipal, foreign or
other law, statute, constitution, principle of common law, resolution,
ordinance, code, edict, decree, rule, regulation, ruling or requirement issued,
enacted, adopted, promulgated, implemented or otherwise put into effect by or
under the authority of any Governmental Entity.
"Legal Transfer Taxes Act" means the Wet op belastingen van rechtsverkeer.
"Magnet IP" has the meaning ascribed to it in Section 3.22.
"Mask Works" has the meaning ascribed to it under "Intellectual Property" of
this Article IX.
"Materials of Environmental Concern" means chemicals; pollutants;
contaminants; wastes; toxic or hazardous substances, materials and wastes;
petroleum and petroleum products; asbestos and asbestos-containing materials;
polychlorinated biphenyls; lead and lead-based paints and materials;
ozone-depleting substances and radon.
"Maximum Contingent Price Election Number" means fifty percent (50%) of the
sum of the Non-Buyer Company Shares and the Option Share Number, in each case
as of the Closing Time.
"Maximum Fixed Price Election Number" means the amount by which (x) fifty
percent (50%) of the sum of the Non-Buyer Company Shares and the Option Share
Number exceeds (y) the Option Share Number, in each case as of the Closing Time.
"Minimum Condition" has the meaning ascribed to it in Section 1.1(a).
"Multiemployer Plan" means any "Pension Plan" (as defined below) which is a
"multiemployer plan," as defined in Section 3(37) of ERISA.
"NASD" means the National Association of Securities Dealers, Inc.
"NASDAQ" means National Association of Securities Dealers Automated
Quotations System.
"New Buyer Warrants" has the meaning ascribed to it in Section 6.6(b).
"Non-Buyer Company Shares" means the Outstanding Company Shares minus (i)
any Company Shares held by the Buyer or its affiliates, and minus (ii) the
Company Shares issuable upon exercise of all outstanding Company Warrants
(excluding for this purpose the Principal Shareholder Warrants and any Warrants
held by the Buyer or any of its Subsidiaries), in each case as of immediately
prior to the Closing Time.
"Non-Competition Agreements" has the meaning ascribed to it in the recitals
to this Agreement.
A-53
"NYSE" means the New York Stock Exchange.
"OCS" means the Office of the Chief Scientist of the Israeli Ministry of
Trade & Industry.
"Offer" has the meaning ascribed to it in the recitals of this Agreement.
"Offer Documents" has the meaning ascribed to it in Section 1.1(d).
"Offer Price" has the meaning ascribed to it in the recitals of this
Agreement.
"Option Share Number" means the number of Company Shares issuable upon
exercise of Company Stock Options and Company Warrants (excluding for this
purpose any Warrants held by the Buyer or any of its Subsidiaries) that have
not been exercised prior to the Closing.
"Outstanding Company Shares" means the outstanding Company Shares (excluding
for this purpose any Company Shares that are held in the treasury of the
Company) plus the Company Shares issuable upon exercise of all outstanding
Company Warrants (excluding for this purpose the Principal Shareholder Warrants
and any Warrants held by the Buyer or any of its Subsidiaries), in each case as
of immediately prior to the Closing Time.
"Participation" means an interest in a company or other qualifying entity
the profits derived from and capital gains realized on which are exempt from
corporate income tax under the participation exemption as meant in Article 13
of the Corporate Income Tax Act.
"Patents" has the meaning ascribed to it in the definition of "Intellectual
Property Rights."
"Pension Plan" means each Company Employee Plan which is an "employee
pension benefit plan," within the meaning of Section 3(2) of ERISA.
"Person" means a natural person, partnership, corporation, limited liability
company, business trust, joint stock company, trust, unincorporated
association, joint venture, Governmental Entity or other entity or organization.
"Phantom ESPP" has the meaning ascribed to it in Section 6.6(c).
"Plan Approval" means approval by, and/or registration for and/or
qualification for special tax status with, the appropriate taxation, social
security and/or supervisory authorities in the relevant country, state,
territory, or the like.
"Post-Closing Reorganization" has the meaning ascribed to it in Section 2.1.
"Preferred Shares" has the meaning ascribed to it in Section 3.3(a).
"Principal Company Shareholders" means Walthroup Corporation N.V.,
Visionvest Corporation N.V., Gemini Systems N.V., Toscal N.V., OZF Ltd., and
Deering Corporation N.V.
"Principal Shareholder Warrants" means the Company Warrants held by the
Principal Company Shareholders.
"Print IT" has the meaning ascribed to it in Section 3.22.
"Property" means any real, personal or mixed property, whether tangible or
intangible.
"Prospectus" has the meaning ascribed to it in Section 1.1(d).
A-54
"PTO" means the United States Patent and Trademark Office.
"Recommendation" has the meaning ascribed to it in the definition of
"Triggering Events."
"Registered Intellectual Property Rights" means all United States,
international and foreign: (i) Patents, including applications therefor; (ii)
registered Trademarks, applications to register Trademarks, including
intent-to-use applications, or other registrations or applications related to
Trademarks; (iii) Copyright registrations and applications to register
Copyrights; (iv) registered Mask Works and applications to register Mask Works;
and (v) any other Intellectual Property that is the subject of an application,
certificate, filing, registration or other document issued by, filed with, or
recorded by, any private, state, government or other public legal authority at
any time.
"Registration Statement" has the meaning ascribed to it in Section 1.1(d).
"Related Company" means any company (i) in which the Company (or a
Subsidiary of such Company) has or at any time had, directly or indirectly, an
interest of 33 1/3% or more, (ii) which has or at any time had an interest
directly or indirectly, of 33 1/3% or more in the Company (or a Subsidiary of
such Company), or (iii) in which a party has or at any time had directly or
indirectly, an interest of 33 1/3% or more whilst that same party has or had,
respectively, directly or indirectly, an interest of 33 1/3% or more in the
Company (or a Subsidiary of such Company).
"Returns" has the meaning ascribed to it in Section 3.14(a).
"Requested Contingent Price Amount" has the meaning ascribed to it in
Section 1.1(c).
"Requested Fixed Price Amount" has the meaning ascribed to it in Section
1.1(c).
"SEC" means the Securities and Exchange Commission.
"Schedule 13E-3" the meaning ascribed to it in Section 1.1(c).
"Schedule 14D-9" has the meaning ascribed to it in Section 1.2(b).
"Schedule TO" has the meaning ascribed to it in Section 1.1(d).
"Securities Act" means the Securities Act of 1933, as amended.
"Senior Employee" means a Company Employee earning remuneration in excess of
US $60,000 per year.
"Special Representations" has the meaning ascribed to it in Annex I.
"Subsidiary" means any Person in which an entity, directly or indirectly,
through Subsidiaries or otherwise, beneficially owns at least 50% of either the
equity interest in, the economic interest in, or the voting control of, such
Person, whether or not existing on the date of this Agreement.
"Tax" or, collectively, "Taxes", means (i) any and all U.S. federal, state,
local, Dutch, Israeli and other foreign taxes, including taxes based upon or
measured by gross receipts, income, profits, sales, use and occupation, and
value added, ad valorem, transfer, franchise, withholding, payroll, recapture,
employment, excise, property and stamp duty taxes, together with all interest,
penalties and additions imposed with respect to such amounts; (ii) any
liability for the payment of any amounts of the type described in clause (i) as
a result of being or ceasing to be a member of an affiliated, consolidated,
combined or unitary group for any period (including, without limitation, any
liability under Treas. Reg. Section 1.1502-6 or any comparable provision of
A-55
foreign, state or local law); (iii) any liability for the payment of any social
security contributions, and (iv) any liability for the payment of any amounts
of the type described in clause (i) or (ii) as a result of any express or
implied obligation to indemnify any other Person or as a result of any
obligations under any agreements or arrangements with any other Person with
respect to such amounts and including any liability for taxes of a predecessor
entity.
"Termination Fee" has the meaning ascribed to it in Section 7.3(b).
"Transferred Employees" has the meaning ascribed to it in Section 6.7(a).
"Trademarks" has the meaning ascribed to it under "Intellectual Property" of
this Article IX.
"Triggering Event" shall be deemed to have occurred if, prior to the Closing
Time: (i) either of the Company Boards or any committee thereof shall have
approved or recommended to Company Shareholders any Acquisition Proposal, (ii)
either of the Company Boards or any committee thereof shall for any reason have
withheld, withdrawn, amended or modified its recommendation in favor of the
Offer (the "Recommendation"); (iii) the Company shall have failed to include
the Recommendation in the Offer Documents or the Schedule 14D-9; (iv) the
Company shall have breached the provisions of Section 6.2 in any material
respect; (v) any of Walthroup Corporation N.V., Visionvest Corporation N.V.,
Gemini Systems N.V., Toscal N.V., OZF Ltd., and Deering Corporation N.V., or
any such entity's affiliates shall have breached the provisions of any of the
Company Voting Agreements or the Company Tender Agreements in any material
respect or (vi) a tender or exchange offer shall have been commenced by a
person unaffiliated with the Buyer, and the Company shall not have sent to the
Company Shareholder pursuant to Rule 14e-2 promulgated under the Securities
Act, within ten (10) Business Days after such tender or exchange offer is first
published sent or given, a statement disclosing that the Company recommends
rejection of such tender or exchange offer and reaffirming the Recommendation.
"Trustee" has the meaning ascribed to it in the recitals to this Agreement.
"Unfunded Pension Plan" means a Pension Plan which is not a Funded Pension
Plan.
"U.S." means the United States of America, its territories and possessions,
any State of the United States of America, and the District of Columbia.
"U.S. Employee Plan" means a Company Employee Plan which is not an
International Employee Plan.
"VAT" means value added tax or any similar sales or turnover tax of any
relevant jurisdiction.
"Voting Debt" means indebtedness having general voting rights and debt
convertible into securities having such rights.
"Wage Withholding Tax Act" means Wet op de loonbelasting 1964.
9.2 Miscellaneous. When a reference is made in this Agreement to Exhibits,
such reference shall be to an Exhibit to this Agreement unless otherwise
indicated. When a reference is made in this Agreement to Sections, such
reference shall be to a Section of this Agreement. Unless otherwise indicated
the words "include," "includes" and "including" when used herein shall be
deemed in each case to be followed by the words "without limitation." The table
of contents and headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this
Agreement. When reference is made herein to "the business of" an entity, such
reference shall be deemed to include the business of all direct and indirect
Subsidiaries of such entity. Reference to the Subsidiaries of an entity shall
be deemed to include all direct and indirect Subsidiaries of such entity.
[Remainder of page intentionally left blank.]
A-56
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized respective officers as of the date first
written above.
HEWLETT-PACKARD COMPANY
By: /s/ JOHN D. BRENNAN
______________________________________
Name: John D. Brennan
____________________________________
Title: Vice President, Strategy and
Corporate Development
_____________________________________
INDIGO N.V.
By: /s/ BENZION LANDA
______________________________________
Name: Benzion Landa
____________________________________
Title: Chairman and CEO
_____________________________________
SIGNATURE PAGE TO OFFER AGREEMENT
A-57
ANNEX I
Conditions of the Offer. Notwithstanding any other provisions of the Offer,
and in addition to (and not in limitation of) the Buyer's rights to extend and
amend the Offer at any time in its sole discretion (subject to the provisions
of the Agreement), the Buyer shall not be required to accept for exchange or,
subject to any applicable rules and regulations of the SEC, including Rule
14e-1(c) under the Exchange Act (relating to the Buyer's obligation to pay for
or return tendered Shares promptly after termination or withdrawal of the
Offer), exchange or deliver shares of Buyer Common Stock in respect of, and may
delay the acceptance for exchange or, subject to the restriction referred to
above, the exchange or delivery of shares of Buyer Common Stock in respect of,
any tendered Company Shares if by the expiration of the Offer (as it may be
extended in accordance with the requirements of Section 1.1) (i) any applicable
waiting period or approval under the HSR Act or any Foreign Filing shall not
have expired or terminated or been obtained, as applicable, (ii) the receipt of
approval from the OCS, without obligation to pay materially increased
royalties, of the ownership of any Grant Funded IP by the Company, and any
Israeli Governmental Approvals required pursuant to Israeli legal requirements
for the consummation of the Offer, including approval of the OCS, the
Investment Center and the Israeli Commissioner of Restrictive Trade Practices
and receipt by Buyer of the Israeli Securities Exemption, shall not have been
obtained, (iii) the Minimum Condition shall not have been satisfied, (iv) the
Registration Statement shall not have become effective under the Securities Act
or shall be the subject of any stop order or proceedings seeking a stop order,
(v) the shares of Buyer Common Stock to be issued in the Offer shall not have
been approved for listing on the NYSE, subject to official notice of issuance,
and shall not be exempt from such requirement under then applicable laws,
regulations and rules of the NYSE, or (vi) it shall fail to be the case that
seventy-five percent (75%) of the individuals identified in Section 6.20 of the
Company Disclosure Letter continue to be Company Employees at the Closing Time,
or (vii) at any time on or after the date of the Agreement and before the time
of acceptance for exchange for any such Company Shares, any of the following
events shall have occurred and be continuing:
(a) there shall be pending any suit, action or proceeding by any
Governmental Entity against the Buyer, the Company, any Subsidiary of the
Company or any Subsidiary of the Buyer (i) seeking to prohibit or impose any
material limitations on the Buyer's ownership or operation (or that of any
of its Subsidiaries or Affiliates) of all or a material portion of their or
the Company's businesses or assets, or to compel the Buyer or its
Subsidiaries and Affiliates to dispose of or hold separate any material
portion of the business or assets of the Company or the Buyer and their
respective Subsidiaries, in each case taken as a whole, (ii) challenging the
acquisition by the Buyer of any Company Shares under the Offer, seeking to
restrain or prohibit the making or consummation of the Offer or the
performance of any of the other transactions contemplated by this Agreement,
the Company Tender Agreements, or the Company Voting Agreements (including
the voting provisions thereunder), or seeking to obtain from the Company or
the Buyer any damages that are material in relation to the Company and its
Subsidiaries taken as a whole, (iii) seeking to impose material limitations
on the ability of the Buyer, or render the Buyer unable, to accept for
payment, pay for or purchase some or all of the Company Shares pursuant to
the Offer, (iv) seeking to impose material limitations on the ability of the
Buyer effectively to exercise full rights of ownership of the Company
Shares, including, without limitation, the right, to vote the Company Shares
purchased by it on all matters properly presented to the Company's
Shareholders, (v) compel the Buyer or its affiliates to dispose of or hold
separate any portion of the business or assets or Shares of the Company or
the Buyer and their respective Subsidiaries, (vi) oblige the Company, the
Buyer or any of their respective Subsidiaries to pay material damages in
connection with the transactions contemplated by the Agreement, or (vii)
which otherwise is reasonably likely to have a Company Material Adverse
Effect or, as a result of the transactions contemplated by this Agreement, a
Buyer Material Adverse Effect;
(b) there shall be any law, statute, rule, regulation, ordinance,
judgment, order, decree or injunction enacted, entered, enforced,
promulgated, or deemed applicable, pursuant to an authoritative
interpretation by or on behalf of a Government Entity, to the Offer, or any
other action shall be taken by any Governmental Entity, other than the
application to the Offer of applicable waiting periods or approvals under
the HSR Act or any Foreign Filing and any Israeli Governmental Approvals
required pursuant to Israeli legal
A-I-1
requirements for the consummation of the Offer, including approval of the
OCS, the Investment Center and the Israeli Commissioner of Restrictive Trade
Practices and receipt by Buyer of the Israeli Securities Exemption, that, is
reasonably likely to result, directly or indirectly, in any of the
consequences referred to in clauses (i) through (vii) of paragraph (a) above;
(c) there shall have occurred (i) any general suspension of trading in,
or limitation on prices for, securities on the NYSE, for a period in excess
of 24 hours (excluding suspensions or limitations resulting solely from
physical damage or interference with such exchanges not related to market
conditions), (ii) a declaration of a banking moratorium or any suspension of
payments in respect of banks in the United States (whether or not
mandatory), (iii) a commencement of a war, armed hostilities or other
international or national calamity directly involving the United States,
(iv) a commencement of a war or escalation of armed hostilities or a general
mobilization or other international or national calamity directly involving
Israel that is or is reasonably likely to be materially adverse to the
Company's ability to conduct business in Israel, (v) any limitation (whether
or not mandatory) by any United States governmental authority on the
extension of credit generally by banks or other financial institutions, or
(vi) in the case of any of the foregoing existing at the time of the
commencement of the Offer, a material acceleration or worsening thereof;
(d) the representations and warranties of the Company contained in this
Agreement:
(i) shall not have been true and correct in all respects (if
qualified by Company Material Adverse Effect, materiality or other
qualifications based on the word "material" or similar phrases) or in
all material respects (if not so qualified) as of the date of this
Agreement; provided that, for purposes of determining the accuracy of
the Company's representations and warranties for purposes of this clause
(i) any update of or modification to the Company Disclosure Letter made
or purported to have been made after the date of this Agreement shall be
disregarded; or
(ii) with respect to the representations and warranties contained in
Sections 3.1, 3.2, 3.3, 3.4, 3.7, 3.15, 3.18 and 3.20 (the "Special
Representations"), shall not be true and correct in all respects (if
qualified by Company Material Adverse Effect, materiality or other
qualifications based on the word "material" or similar phrases) or in
all material respects (if not so qualified) on and as of the Expiration
Time with the same force and effect as if made on or as of such time,
except for those Special Representations which address matters only as
of a particular date which Special Representations shall have been true
and correct in all respects (if qualified by Company Material Adverse
Effect, materiality or other qualifications based on the word "material"
or similar phrases) or in all material respects (if not so qualified) as
of such particular date; provided that, for purposes of determining the
accuracy of the Special Representations for purposes of this clause (ii)
any update of or modification to the Company Disclosure Letter made or
purported to have been made after the date of this Agreement shall be
disregarded; or
(iii) with respect to the representations and warranties that are not
Special Representations, shall not be true and correct in all respects
on and as of the Expiration Time with the same force and effect as if
made on or as of such time, except (A) in the aggregate, as does not,
and could not reasonably be expected to, constitute a Company Material
Adverse Effect and (B) for those representations and warranties which
address matters only as of a particular date which representations shall
have been true and correct (subject to the Company Material Adverse
Effect qualification set forth in the preceding clause (A)) as of such
particular date; provided, that for purposes of determining the accuracy
of the Company's representations and warranties other than the Special
Representations for purposes of this clause (iii), (x) all Company
Material Adverse Effect and materiality qualifications and other
qualifications based on the word "material" or similar phrases contained
in such representations and warranties shall be disregarded, and (y) any
update of or modification to the Company Disclosure Letter made or
purported to have been made after the date of this Agreement shall be
disregarded.
(e) the Company shall have failed to perform in any material respect any
obligation or to comply in any material respect with any agreement or
covenant of the Company to be performed or complied with by it under this
Agreement;
A-I-2
(f) the Company shall not have received the consents, waivers and
approvals required to be obtained in connection with the consummation of the
transactions contemplated by the Agreement;
(g) the EGM shall not have passed on the appointments of members of the
Company Boards and the amendment of the Company's Articles of Association in
accordance with Section 1.3(a); or
(h) the Agreement shall have been terminated in accordance with its terms.
The foregoing conditions are for the sole benefit of the Buyer and may be
waived by the Buyer, in whole or in part at any time and from time to time in
the sole discretion of the Buyer prior to the Expiration of the Offer. The
failure by the Buyer at any time to exercise any of the foregoing rights shall
not be deemed a waiver of any such right and each such right shall be deemed an
ongoing right which may be asserted at any time and from time to time.
A-I-3
ANNEX B-1
FORM OF
CONTINGENT VALUE RIGHTS AGREEMENT
by and between
Hewlett-Packard Erste Vermogensverwaltungs- und Beteiligungsgesellschaft mbH
and
J.P. Morgan Trust Company,
National Association, as Trustee
and
J.P. Morgan Trust Company, National Association,
as Depositary and Paying Agent
Dated as of , 2002
TABLE OF CONTENTS
Page
------
ARTICLE I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION....... B-1-1
1.1 Definitions................................................... B-1-1
1.2 Compliance and Opinions....................................... B-1-5
1.3 Form of Documents Delivered to Trustee........................ B-1-5
1.4 Acts of Holders............................................... B-1-6
1.5 Notices, etc. to Trustee and Buyer............................ B-1-6
1.6 Notice to Holders; Waiver..................................... B-1-7
1.7 Conflict with Trust Indenture Act............................. B-1-7
1.8 Effect of Headings and Table of Contents...................... B-1-7
1.9 Successors and Assigns........................................ B-1-7
1.10 Benefits of Agreement......................................... B-1-7
1.11 GOVERNING LAW................................................. B-1-7
1.12 Legal Holidays................................................ B-1-7
1.13 Separability Clause........................................... B-1-8
1.14 No Recourse Against Others.................................... B-1-8
1.15 Counterparts.................................................. B-1-8
1.16 Acceptance of Trust........................................... B-1-8
ARTICLE II SECURITY FORMS................................................ B-1-8
2.1 Forms Generally............................................... B-1-8
2.2 Legends....................................................... B-1-8
2.3 Global Securities............................................. B-1-9
2.4 Securities in Certificated Form............................... B-1-9
ARTICLE III THE SECURITIES................................................ B-1-10
3.1 Title and Terms............................................... B-1-10
3.2 Registrable Form.............................................. B-1-11
3.3 Execution, Authentication, Delivery and Dating................ B-1-11
3.4 Mutilated, Destroyed, Lost and Stolen Securities.............. B-1-11
3.5 Registration of Global Securities............................. B-1-12
3.6 Persons Deemed Owners......................................... B-1-12
3.7 Cancellation.................................................. B-1-12
ARTICLE IV THE TRUSTEE................................................... B-1-12
4.1 Certain Duties and Responsibilities........................... B-1-12
4.2 Certain Rights of Trustee..................................... B-1-13
4.3 Notice of Default............................................. B-1-14
4.4 Not Responsible for Recitals or Issuance of Securities........ B-1-14
4.5 May Hold Securities........................................... B-1-14
4.6 Money Held in Trust........................................... B-1-14
4.7 Compensation and Reimbursement................................ B-1-14
4.8 Disqualification; Conflicting Interests....................... B-1-15
4.9 Corporate Trustee Required; Eligibility....................... B-1-15
4.10 Resignation and Removal; Appointment of Successor............. B-1-15
4.11 Acceptance of Appointment of Successor........................ B-1-16
4.12 Merger, Conversion, Consolidation or Succession to Business... B-1-16
4.13 Preferential Collection of Claims Against Buyer............... B-1-16
ARTICLE V DEPOSITARY AND PAYING AGENT................................... B-1-16
5.1 Deposit of Securities......................................... B-1-16
5.2 Buyer to Provide List of Beneficial Owners; Notification...... B-1-17
B-1-i
Page
------
5.3 Registration, Permitted Transfers and Exchanges............... B-1-17
5.4 Calculation of CVR Payout..................................... B-1-17
5.5 Payments With Respect to the Securities....................... B-1-18
5.6 Redemption, etc............................................... B-1-18
5.7 Certificated Securities....................................... B-1-18
5.8 Notice to Beneficial Owners................................... B-1-18
5.9 Depositary as Proxy for Beneficial Owners..................... B-1-19
5.10 Resignation and Removal; Appointment of Successor............. B-1-19
5.11 No Obligation to Advance Funds................................ B-1-19
5.12 Depositary's and Paying Agent's Rights........................ B-1-19
5.13 Compensation and Reimbursement................................ B-1-20
ARTICLE VI HOLDERS' LISTS AND REPORTS BY TRUSTEE AND BUYER............... B-1-20
6.1 Buyer to Furnish Trustee Names and Addresses of Holders....... B-1-20
6.2 Preservation of Information................................... B-1-20
6.3 Communications to Holders..................................... B-1-20
6.4 Reports by Trustee............................................ B-1-20
6.5 Reports by Buyer.............................................. B-1-21
ARTICLE VII AMENDMENTS.................................................... B-1-21
7.1 Amendments Without Consent of Holders......................... B-1-21
7.2 Amendments with Consent of Holders............................ B-1-22
7.3 Execution of Amendments....................................... B-1-22
7.4 Effect of Amendments; Notice to Holders....................... B-1-22
7.5 Conformity with Trust Indenture Act........................... B-1-22
7.6 Reference in Securities to Amendments......................... B-1-22
ARTICLE VIII COVENANTS..................................................... B-1-23
8.1 Payment of Amounts, if any, to Holders........................ B-1-23
8.2 Maintenance of Office or Agency............................... B-1-23
8.3 Money for Security Payments to Be Held in Trust............... B-1-23
8.4 Certain Purchases and Sales................................... B-1-24
8.5 Reports....................................................... B-1-24
8.6 Audits; Dispute Resolution.................................... B-1-24
8.7 Foreign Exchange.............................................. B-1-26
8.8 Annual TIA Certification...................................... B-1-26
ARTICLE IX REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT....... B-1-26
9.1 Event of Default Defined; Waiver of Default................... B-1-26
9.2 Collection of Indebtedness by Trustee; Trustee May Prove Debt. B-1-27
9.3 Application of Proceeds....................................... B-1-28
9.4 Suits for Enforcement......................................... B-1-29
9.5 Restoration of Rights on Abandonment of Proceedings........... B-1-29
9.6 Limitations on Suits by Holders............................... B-1-29
9.7 Unconditional Right of Holders................................ B-1-29
9.8 Powers and Remedies Cumulative; Delay or Omission Not Waiver
of Default.................................................... B-1-29
9.9 Control by Holders............................................ B-1-30
9.10 Waiver of Past Defaults....................................... B-1-30
9.11 Trustee to Give Notice of Default, But May Withhold in Certain
Circumstances................................................. B-1-30
9.12 Right of Court to Require Filing of Undertaking to Pay Costs.. B-1-31
ARTICLE X CONSOLIDATION, MERGER, SALE OR CONVEYANCE..................... B-1-31
10.1 Consolidation, Merger, etc.................................... B-1-31
B-1-ii
Page
------
10.2 Successor Person Substituted.................................. B-1-31
10.3 Opinion of Counsel to Trustee................................. B-1-32
10.4 Successors.................................................... B-1-32
ARTICLE XI SATISFACTION AND DISCHARGE.................................... B-1-32
11.1 Satisfaction and Discharge of Agreement....................... B-1-32
11.2 Application of Trust Money.................................... B-1-32
11.3 Repayment to the Buyer........................................ B-1-32
Exhibit A Form of Global Security
Exhibit B-1 Form of Beneficial Owner List
Exhibit B-2 Form of Notice
Exhibit C Form of Transfer Instrument
--------
Note: This table of contents shall not, for any purpose, be deemed to be a part
of this CVR Agreement.
B-1-iii
Reconciliation and tie between Trust Indenture Act of 1939 and Contingent
Value Rights Agreement, dated as of , 2002.
Trust Indenture Act Section Agreement Section
--------------------------- -----------------
Section 310 (a)(1).................................... 4.9
(a)(2).................................... 4.9
(a)(3).................................... Not Applicable
(a)(4).................................... Not Applicable
(b)....................................... 4.8,4.10
Section 311 (a)....................................... 4.13
(b)....................................... 4.13
(c)....................................... Not Applicable
Section 312 (a)....................................... 6.1,6.2
(b)....................................... 6.3(a)
(c)....................................... 1.16, 6.3(b)
Section 313 (a)....................................... 6.4(a)
(b)....................................... 6.4(a) (b)
(c)....................................... 6.4(b)
(d)....................................... 6.4(b)
Section 314 (a)....................................... 6.5
(b)....................................... Not Applicable
(c)....................................... 1.2
(c)(1).................................... 1.2
(c)(2).................................... Not Applicable
(c)(3).................................... Not Applicable
(d)....................................... 1.2
Section 315 (a)....................................... 4.1(a)
(b)....................................... 9.11
(c)....................................... 4.1(a)
(d)....................................... 4.1(c)
(d)(1).................................... 4.1(c) (i)
(d)(2).................................... 4.1(c) (ii)
(d)(3).................................... 4.1(c) (iv)
(e)....................................... 9.12
Section 316 (a)(1)(A)................................. 9.9
(a)(1)(B)................................. 9.10
(a)(2).................................... Not Applicable
(b)....................................... 9.7
Section 317 (a)(1).................................... 9.2
(a)(2).................................... 9.2
(b)....................................... 8.3
Section 318 (a)....................................... 1.7
--------
Note: This reconciliation and tie shall not, for any purpose, be deemed to be a
part of the Agreement.
B-1-iv
THIS CONTINGENT VALUE RIGHTS AGREEMENT, (this "CVR Agreement") dated ,
2002, between Hewlett-Packard Erste Vermogensverwaltungs- und
Beteiligungsgesellschaft mbH, a corporation organized under the laws of Germany
(the "Buyer"), J.P. Morgan Trust Company, National Association, as Trustee (the
"Trustee") and J.P. Morgan Trust Company, National Association, as Depositary
and Paying Agent (in such context, the "Depositary").
A registration statement on Form S-4 (No. 333-73786) (the "Registration
Statement") with respect to the Contingent Value Rights (the "Securities" and
each a "Security"), among other securities, has been prepared and filed by
Hewlett-Packard Company with the SEC and has become effective in accordance
with the Securities Act. This CVR Agreement is entered into in connection with
the Offer Agreement (the "Offer Agreement") dated as of September 6, 2001, as
amended on February 13, 2002, by and between Hewlett-Packard Company, a
corporation organized under the laws of the state of Delaware ("HP"), and
Indigo N.V., a corporation organized under the laws of The Netherlands (the
"Company"), which sets forth the initial allocation of one Security to each
outstanding Company Share (as defined in the Offer Agreement) that is exchanged
for the Contingent Offer Price (as defined in the Offer Agreement).
ARTICLE I
DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
1.1 Definitions. For all purposes of this CVR Agreement, except as
otherwise expressly provided or unless the context otherwise requires:
(a) the terms defined in this Article have the meanings assigned to them
in this Article, and include the plural as well as the singular;
(b) all accounting terms used herein and not expressly defined herein
shall have the meanings assigned to such terms in accordance with generally
accepted accounting principles in the United States, and the term "generally
accepted accounting principles" or "GAAP" means such accounting principles
as are generally accepted and as applied by HP consistent with its financial
SEC reporting practices as of the beginning of the CVR Measuring Period;
(c) all other terms used herein which are defined in the Trust Indenture
Act (as defined herein), either directly or by reference therein, have the
respective meanings assigned to them therein; and
(d) the words "herein," "hereof" and "hereunder" and other words of
similar import refer to this CVR Agreement as a whole and not to any
particular Article, Section or other subdivision.
"Act" shall have the meaning specified in Section 1.4.
"Affiliate" of any specified Person (as defined herein) means any other
Person directly or indirectly controlling or controlled by or under direct or
indirect common control with such specified Person. For the purposes of this
definition, "control" when used with respect to any specified Person means the
power to direct the management and policies of such Person, directly or
indirectly, whether through the ownership of voting securities, by contract or
otherwise; and the terms "controlling" and "controlled" have meanings
correlative to the foregoing.
"Authorized Newspaper" means The Wall Street Journal (Western Edition), or
if The Wall Street Journal (Western Edition) shall cease to be published, or,
if the publication or general circulation of The Wall Street Journal (Western
Edition) shall be suspended for whatever reason, such other English language
newspaper of general circulation in The City of New York, New York, or San
Francisco, California as is selected by the Buyer.
"Beneficial Owners" has the meaning ascribed to it in Section 5.2(a).
"Beneficial Owner List" has the meaning ascribed to it in Section 5.2(a).
B-1-1
"Board of Directors" means the board of directors of the Buyer or any duly
authorized committee of that board.
"Board Resolution" means a copy of a resolution certified by the Secretary
or an Assistant Secretary of the Buyer, to have been duly adopted by the Board
of Directors and to be in full force and effect on the date of such
certification, and delivered to the Trustee.
"Business Day" means any day (other than a Saturday or a Sunday) on which
banking institutions in The City of New York, New York or San Francisco,
California are not authorized or obligated by law or executive order to close,
and shall consist of the time period from 12:01 a.m. to 12:00 midnight U.S.
Eastern time.
"Buyer" means the Person named as the "Buyer" in the first paragraph of this
CVR Agreement, until a successor Person shall have become such pursuant to the
applicable provisions of this CVR Agreement, and thereafter "Buyer" shall mean
such successor Person. To the extent necessary to comply with the requirements
of the provisions of Trust Indenture Act Sections 310 through 317, inclusive,
as they are applicable to the Buyer, the term "Buyer" shall include any other
obligor with respect to the Securities for the purposes of complying with such
provisions.
"Buyer Auditor Conclusion" has the meaning ascribed to it in Section 8.6(a).
"Buyer Request" or "Buyer Order" means a written request or order signed in
the name of the Buyer by the president or any vice president, the controller or
assistant controller and the treasurer or assistant treasurer or the secretary
or any assistant secretary, and delivered to the Trustee.
"Certificated Securities" means securities issued in certificated form
pursuant to Section 2.4.
"Closing Time" means [ ], 2002.
"Commission" or "SEC" means the Securities and Exchange Commission, as from
time to time constituted, created under the Exchange Act (as defined herein),
or if at any time after the execution of this instrument such Commission is not
existing and performing the duties now assigned to it under the Trust Indenture
Act, then the body performing such duties at such time.
"Company Core Technology" means Company technology that enables the creation
of a printed image employing a liquid composition of charged, pigmented
thermoplastic particles that are being transferred from an image-bearing
surface to a final substrate.
"Consumables" means (i) consumables and accessories that in each case have a
commercial use that is limited to the support and use of LEP Digital Press
Products (as defined herein) and (ii) support services directly related to the
initial installation of and the ongoing repair and maintenance of LEP Digital
Press Products.
"Corporate Trust Office" means the office of the Trustee at which at any
particular time its corporate trust business shall be principally administered,
which office at the date of execution of this CVR Agreement is located at 101
California Street, San Francisco, CA 94111.
"CVR Agreement" means this instrument as originally executed and as it may
from time to time be supplemented or amended pursuant to the applicable
provisions hereof.
"CVR Measuring Period" means the three-year period commencing on the first
day of the first calendar month occurring after the Closing Time and ending on
the last day prior to the third anniversary of such day.
"CVR Payout" has the meaning ascribed to it in Section 3.1(b)(i).
B-1-2
"CVR Report" means a written report of the Buyer, certified by an officer of
the Buyer, showing the Revenue (as defined herein) for the CVR Measuring Period
and the corresponding calculation of the CVR Payout.
"Default Interest Rate" means the 90-day London Interbank Offering Rate, as
published in an Authorized Newspaper, as such rate may change from time to
time, plus 400 basis points.
"Default Issuance Date" means the date upon which the Securities become due
and payable pursuant to Section 9.1.
"Depositary" means, with respect to any Global Securities (as defined
herein), any entity designated by the Buyer to act as Depositary for such
Global Securities (or any successor entity).
"Exchange Act" means the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.
"Exchange Act Documents" has the meaning ascribed to it in Section 6.5.
"Global Security" means a Security that is registered in the Security
Register (as defined herein) in the name of a Depositary or a nominee thereof.
"Guaranty" means the Guaranty executed by HP of even date herewith,
guaranteeing the payment of the CVR Payout, if any.
"Holder" means a Person in whose name a Security is registered in the
Security Register.
"Holders' Representative" has the meaning ascribed to it in Section 8.6(a).
"Holders Auditor Conclusion" has the meaning ascribed to it in Section
8.6(a).
"Issuance Date" means the sixtieth (60th) day following the last day of the
CVR Measuring Period (or such earlier date upon which the Buyer delivers the
CVR Report to the Trustee).
"LEP Digital Press Products" means digital press products, including
accessories and options (e.g. finishing equipment, sheet feeders) that utilize
Company Core Technology.
"Lower Limit" means one billion United States Dollars (U.S. $1,000,000,000).
"Maximum CVR Payout" has the meaning ascribed to it in Section 3.1(b)(i)(1).
"Officers' Certificate" when used with respect to the Buyer means a
certificate signed by the president or any vice president, the controller or
assistant controller and the treasurer or assistant treasurer or the secretary
or any assistant secretary of the Buyer delivered to the Trustee.
"Opinion of Counsel" means a written opinion of counsel, who may be counsel
for the Buyer.
"Outstanding" when used with respect to Securities means, as of the date of
determination, all Securities theretofore authenticated and delivered under
this CVR Agreement, except: (a) Securities theretofore cancelled by the Trustee
or delivered to the Trustee for cancellation; (b) from and after the earliest
of a Default Issuance Date or the Issuance Date, Securities for the payment of
which money in the necessary amount has been theretofore deposited with the
Trustee or any Paying Agent (other than the Buyer) in trust, or set aside and
segregated in trust by the Buyer (if the Buyer shall act as its own Paying
Agent) for the Holders of such
B-1-3
Securities; and (c) Securities in exchange for or in lieu of which other
Securities have been authenticated and delivered pursuant to this CVR
Agreement, other than any such Securities in respect of which there shall have
been presented to the Trustee proof satisfactory to it that such Securities are
held by a bona fide purchaser in whose hands the Securities are valid
obligations of the Buyer; provided, however, that in determining whether the
Holders of the requisite Outstanding Securities have given any request, demand,
direction, consent or waiver hereunder, Securities owned by the Buyer or any
Affiliate of the Buyer, whether held as treasury securities or otherwise, shall
be disregarded and deemed not to be Outstanding, except that, in determining
whether the Trustee shall be protected in relying upon any such request,
demand, direction, consent or waiver, only Securities which the Trustee knows
to be so owned shall be so disregarded.
"Paying Agent" means any Person authorized by the Buyer to pay the CVR
Payout determined pursuant to Section 5.1, if any, on any Securities on behalf
of the Buyer.
"Permitted Transfer" shall mean (i) the transfer of any or all of the
Securities on death by will or intestacy, (ii) the transfer by instrument to an
inter vivos or testamentary trust in which the Securities are to be passed to
beneficiaries upon the death of the trustee, (iii) transfers to an Affiliate of
a Holder, (iv) if the Holder is a partnership or limited liability or similar
company, a distribution by the transferring entity to its limited partners or
members, (v) by gift, or (vi) a sale or transfer to Buyer or its Affiliates;
provided, however, that the transferee or transferees in all such transfers
(other than to Buyer or its Affiliates) must agree to be bound by these
restrictions on transfer.
"Person" means any individual, corporation, partnership, joint venture,
association, joint-stock company, trust, limited liability company,
unincorporated organization or government or any agency or political
subdivision thereof.
"Residual Calculation" means the present value, as of the end of the CVR
Measuring Period, of remaining minimum contractually committed payments
associated with LEP Digital Press Products placed during the CVR Measuring
Period under operating leases, provided the placement of such LEP Digital Press
Products has not been and will not be recognized as a sale under U.S. GAAP (as
applied by HP consistent with its financial SEC reporting practices as of the
beginning of the CVR Measuring Period). The present value will be determined by
using a discount rate of twelve percent (12%) per year.
"Responsible Officer" when used with respect to the Trustee means any
officer assigned to the Corporate Trust Office and also means, with respect to
any particular corporate trust matter, any other officer of the Trustee to whom
such matter is referred because of his knowledge of and familiarity with the
particular subject.
"Revenue" means the actual net revenue from the sale or lease of LEP Digital
Press Products and Consumables by the Buyer and its Affiliates (and its
successors and assigns under this CVR Agreement) during the CVR Measuring
Period plus the Residual Calculation. Actual net revenue is to be based on U.S.
GAAP, as applied by HP consistent with its financial SEC reporting practices as
of the beginning of the CVR Measuring Period, or in the case of successors or
assigns under this CVR Agreement which are not Affiliates of Buyer, as such
successors or assigns account for net revenue under their standard accounting
practices.
"Securities" shall have the meaning set forth in the preamble to this CVR
Agreement.
"Securities Act" means the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder.
"Security Register" has the meaning ascribed to it in Section 3.5.
"Subsidiary" means each Person more than 50% of the outstanding Voting
Securities of which is owned, directly or indirectly, by the Buyer and/or one
or more Subsidiaries.
B-1-4
"Transfer Instrument" shall have the meaning ascribed to it in Section
5.3(b).
"Trust Indenture Act" means the Trust Indenture Act of 1939, as amended from
time to time, and the rules and regulations promulgated thereunder.
"Trustee" means the Person named as the "Trustee" in the first paragraph of
this CVR Agreement, until a successor Trustee shall have become such pursuant
to the applicable provisions of this CVR Agreement, and thereafter "Trustee"
shall mean such successor Trustee.
"Upper Limit" means one billion six hundred million United States Dollars
(U.S. $1,600,000,000).
"Vice President" when used with respect to the Buyer or the Trustee, means
any vice president, whether or not designated by a number or a word or words
added before or after the title of "Vice President."
1.2 Compliance and Opinions.
(a) Upon any application or request by the Buyer to the Trustee to take any
action under any provision of this CVR Agreement, the Buyer shall furnish to
the Trustee an Officers' Certificate stating that, in the opinion of the
signor, all conditions precedent, if any, provided for in this CVR Agreement
relating to the proposed action have been complied with and an Opinion of
Counsel stating, subject to customary exceptions, that in the opinion of such
counsel all such conditions precedent, if any, have been complied with, except
that, in the case of any such application or request as to which the furnishing
of such documents is specifically required by any provision of this CVR
Agreement relating to such particular application or request, no additional
certificate or opinion need be furnished.
(b) Every certificate or opinion with respect to compliance with a condition
or covenant provided for in this CVR Agreement shall include: (i) a statement
that each individual signing such certificate or opinion has read such covenant
or condition and the definitions herein relating thereto; (ii) a brief
statement as to the nature and scope of the examination or investigation upon
which the statements or opinions contained in such certificate or opinion are
based; (iii) a statement that, in the opinion of each such individual, he or
she has made such examination or investigation as is necessary to enable him to
express an informed opinion as to whether or not such covenant or condition has
been complied with; and (iv) a statement as to whether, in the opinion of each
such individual, such condition or covenant has been complied with.
1.3 Form of Documents Delivered to Trustee.
(a) In any case where several matters are required to be certified by, or
covered by an opinion of, any specified Person, it is not necessary that all
such matters be certified by, or covered by the opinion of, only one such
Person, or that they be so certified or covered by only one document, but one
such Person may certify or give an opinion with respect to some matters and one
or more other such Persons as to other matters, and any such Person may certify
or give an opinion as to such matters in one or several documents.
(b) Any certificate or opinion of an officer of the Buyer may be based,
insofar as it relates to legal matters, upon a certificate or opinion of, or
representations by, counsel. Any such certificate or Opinion of Counsel may be
based, insofar as it relates to factual matters, upon a certificate or opinion
of, or representations by, an officer or officers of the Buyer stating that the
information with respect to such factual matters is in the possession of the
Buyer.
(c) Any certificate, statement or opinion of an officer of the Buyer or of
counsel may be based, insofar as it relates to accounting matters, upon a
certificate or opinion of or representations by an accountant or firm of
accountants in the employ of the Buyer. Any certificate or opinion of any
independent firm of public accountants filed with the Trustee shall contain a
statement that such firm is independent.
(d) Where any Person is required to make, give or execute two or more
applications, requests, consents, certificates, statements, opinions or other
instruments under this CVR Agreement, they may, but need not, be consolidated
and form one instrument.
B-1-5
1.4 Acts of Holders.
(a) Any request, demand, authorization, direction, notice, consent, waiver
or other action provided by this CVR Agreement to be given or taken by Holders
may be embodied in and evidenced by one or more instruments of substantially
similar tenor signed by such Holders in person or by an agent duly appointed in
writing; and, except as herein otherwise expressly provided, such action shall
become effective when such instrument or instruments are delivered to the
Trustee and, where it is hereby expressly required, to the Buyer. Such
instrument or instruments (and the action embodied therein and evidenced
thereby) are herein sometimes referred to as the "Act" of the Holders signing
such instrument or instruments. Proof of execution of any such instrument or of
a writing appointing any such agent shall be sufficient for any purpose of this
CVR Agreement and (subject to Section 4.1) conclusive in favor of the Trustee
and the Buyer, if made in the manner provided in this Section. The Buyer may
set a record date for purposes of determining the identity of Holders entitled
to vote or consent to any action by vote or consent authorized or permitted
under this CVR Agreement. If not set by the Buyer prior to the first
solicitation of a Holder of Securities made by any Person in respect of any
such action, or, in the case of any such vote, prior to such vote, the record
date for such action shall be the later of ten days prior to the first
solicitation of such consent or the date of the most recent list of Holders
furnished to the Trustee pursuant to Section 5.2 of this CVR Agreement prior to
such solicitation. If a record date is fixed, those Persons who were Holders of
Securities at such record date (or their duly designated proxies), and only
those Persons, shall be entitled to take such action by vote or consent or,
except with respect to clause (d) below, to revoke any vote or consent
previously given, whether or not such Persons continue to be Holders after such
record date. No such vote or consent shall be valid or effective for more than
one hundred twenty (120) days after such record date.
(b) The fact and date of the execution by any Person of any such instrument
or writing may be proved in any reasonable manner that the Trustee deems
sufficient.
(c) The ownership of Securities shall be proved by the Security Register.
Neither the Buyer nor the Trustee nor any Agent of the Buyer or the Trustee
shall be affected by any notice to the contrary.
(d) At any time prior to (but not after) the evidencing to the Trustee, as
provided in this Section 1.4, of the taking of any action by the Holders of the
Securities specified in this CVR Agreement in connection with such action, any
Holder of a Security the serial number of which is shown by the evidence to be
included among the serial numbers of the Securities the Holders of which have
consented to such action may, by filing written notice at the Corporate Trust
Office and upon proof of holding as provided in this Section 1.4, revoke such
action so far as concerns such Security. Any request, demand, authorization,
direction, notice, consent, waiver or other action by the Holder of any
Security shall bind every future Holder of the same Security or the Holder of
every Security issued upon the registration of transfer thereof or in exchange
therefor or in lieu thereof, in respect of anything done, suffered or omitted
to be done by the Trustee, any Paying Agent or the Buyer in reliance thereon,
whether or not notation of such action is made upon such Security.
1.5 Notices, etc. to Trustee and Buyer.
Any request, demand, authorization, direction, notice, consent, waiver or
Act of Holders or other document provided or permitted by this CVR Agreement to
be made upon, given or furnished to, or filed with:
(a) the Trustee by any Holder, by the Buyer or by the Depositary shall be
sufficient for every purpose hereunder if made, given, furnished or filed,
in writing, to or with the Trustee at its Corporate Trust Office;
(b) the Buyer by the Trustee, by the Depositary or by any Holder shall be
sufficient for every purpose hereunder if in writing and mailed, first-class
postage prepaid, to the Buyer addressed to it at 3000 Hanover Street, Mail
Stop 20-BQ, Palo Alto, CA 94304, Attention: General Counsel, or at any other
address previously furnished in writing to the Trustee by the Buyer; or
(c) the Depositary by the Trustee, by any Holder or by the Buyer shall be
sufficient for every purpose hereunder if in writing and mailed first-class
postage prepaid, to the Depositary at 101 California Street, Suite 3800, San
Francisco, California 94111, or at such other address previously furnished
to the Trustee, Holders and Buyer in writing by the Depositary.
B-1-6
1.6 Notice to Holders; Waiver.
(a) Where this CVR Agreement provides for notice to Holders of any event,
such notice shall be sufficiently given (unless otherwise herein expressly
provided) if in writing and mailed, first-class postage prepaid or sent by
overnight delivery, to each Holder affected by such event, at its address as it
appears in the Security Register, not later than the latest date, and not
earlier than the earliest date, prescribed for the giving of such notice. In
any case where notice to Holders is given by mail, neither the failure to mail
such notice, nor any defect in any notice so mailed, to any particular Holder
shall affect the sufficiency of such notice with respect to other Holders.
Where this CVR Agreement provides for notice in any manner, such notice may be
waived in writing by the Person entitled to receive such notice, either before
or after the event, and such waiver shall be the equivalent of such notice.
Waivers of notice by Holders shall be filed with the Trustee, but such filing
shall not be a condition precedent to the validity of any action taken in
reliance upon such waiver.
(b) In case by reason of the suspension of regular mail or overnight
delivery service or by reason of any other cause, it shall be impracticable to
mail or deliver notice of any event as required by any provision of this CVR
Agreement, then any method of giving such notice as shall be satisfactory to
the Trustee shall be deemed to be a sufficient giving of such notice.
1.7 Conflict with Trust Indenture Act. If any provision hereof limits,
qualifies or conflicts with another provision hereof which is required to be
included in this CVR Agreement by any of the provisions of the Trust Indenture
Act, such required provision shall control.
1.8 Effect of Headings and Table of Contents. The Article and Section
headings herein and the Table of Contents are for convenience only and shall
not affect the construction hereof.
1.9 Successors and Assigns. All covenants and agreements in this CVR
Agreement by the Buyer shall bind its successors and assigns, whether so
expressed or not.
1.10 Benefits of Agreement. Nothing in this CVR Agreement or in the
Securities, express or implied, shall give to any Person (other than the
parties hereto and their successors hereunder, any Depositary, Paying Agent and
the Holders) any benefit or any legal or equitable right, remedy or claim under
this CVR Agreement or under any covenant or provision herein contained, all
such covenants and provisions being for sole benefit of the parties hereto and
their successors and of the Holders.
1.11 GOVERNING LAW. ALL QUESTIONS AND/OR DISPUTES CONCERNING THE
CONSTRUCTION, VALIDITY AND INTERPRETATION OF THIS CVR AGREEMENT SHALL BE
GOVERNED BY THE INTERNAL LAWS, AND NOT THE LAW OF CONFLICTS, OF THE STATE OF
DELAWARE. THE BUYER, THE TRUSTEE, THE DEPOSITARY AND EACH OF THE HOLDERS BY
THEIR ACCEPTANCE OF THE SECURITIES HEREBY IRREVOCABLY AND UNCONDITIONALLY
AGREES TO BE SUBJECT TO, AND HEREBY CONSENTS AND SUBMITS TO, THE JURISDICTION
OF THE COURTS OF THE STATE OF DELAWARE, AND AGREES THAT ANY ACTION INVOLVING
ANY EQUITABLE OR OTHER CLAIM SHALL BE BROUGHT EXCLUSIVELY IN THE DELAWARE COURT
OF CHANCERY. IN THE EVENT THAT THE DELAWARE COURT OF CHANCERY DOES NOT ACCEPT
JURISDICTION OVER ANY SUCH ACTION, THE BUYER, THE TRUSTEE, THE DEPOSITARY AND
EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES HEREBY IRREVOCABLY
AND UNCONDITIONALLY AGREES THAT ANY SUCH ACTION THEN SHALL BE BROUGHT
EXCLUSIVELY IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE.
1.12 Legal Holidays. In the event that the Issuance Date or a Default
Issuance Date, as the case may be, shall not be a Business Day, then
(notwithstanding any provision of this CVR Agreement or the Securities to the
contrary) payment on the Securities need not be made on such date, but may be
made, without the accrual of any interest thereon, on the next succeeding
Business Day with the same force and effect as if made on the Issuance Date or
a Default Issuance Date, as the case may be.
B-1-7
1.13 Separability Clause. In case any provision in this CVR Agreement or
in the Securities shall be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby.
1.14 No Recourse Against Others. A director, officer, employee or
stockholder, as such, of the Buyer, the Trustee or the Depository shall not
have any liability for any obligations of the Buyer or the Trustee under the
Securities or the Agreement or for any claim based on, in respect of or by
reason of such obligations or their creation. By accepting a Security each
Holder waives and releases all such liability. The waiver and release are part
of the consideration for the issue of the Securities.
1.15 Counterparts. This Agreement shall be signed in any number of
counterparts with the same effect as if the signatures to each counterpart were
upon a single instrument, and all such counterparts together shall be deemed an
original of this CVR Agreement.
1.16 Acceptance of Trust. J.P. Morgan Trust Company, National Association,
the Trustee named herein, hereby accepts the trusts in this CVR Agreement
declared and provided, upon the terms and conditions set forth herein.
ARTICLE II
SECURITY FORMS
2.1 Forms Generally. The Global Security or Global Securities and the
Trustee's certificate of authentication shall be in substantially the forms set
forth in Exhibit A, attached hereto and incorporated herein by this reference,
with such appropriate insertions, omissions, substitutions and other variations
as are required or permitted by this CVR Agreement and may have such letters,
numbers or other marks of identification and such legends or endorsements
placed thereon as may be required by law or any rule or regulation, all as may
be determined by the officers executing such Global Security or Global
Securities, as evidenced by their execution of the Global Security or Global
Securities. Any portion of the text of any Global Security or Global Securities
may be set forth on the reverse thereof, with an appropriate reference thereto
on the face of the Global Security or Global Securities.
The definitive Global Security or Global Securities shall be typewritten,
printed, lithographed or engraved on steel engraved borders or produced by any
combination of these methods, all as determined by the officers executing such
Global Security or Global Securities, as evidenced by their execution of such
Global Security or Global Securities.
2.2 Legends. The following legend shall appear on the face of each Global
Security:
THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE CVR
AGREEMENT HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE
DEPOSITARY OR A NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE
BUYER, THE TRUSTEE AND ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS
SECURITY FOR ALL PURPOSES.
UNLESS AND UNTIL THIS SECURITY IS EXCHANGED IN WHOLE OR IN PART FOR
REGISTERED SECURITIES IN DEFINITIVE REGISTERED FORM IN THE LIMITED
CIRCUMSTANCES REFERRED TO IN THE CVR AGREEMENT, THIS GLOBAL SECURITY MAY NOT
BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE
DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER
NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.
B-1-8
2.3 Global Securities. The provisions of Clauses (1), (2), (3), (4) and
(5) below shall apply only to any Securities that are issued in the form of
Global Securities:
(1) Each Global Security authenticated under this CVR Agreement shall be
registered in the name of the Depositary designated for such Global Security
or a nominee thereof and delivered to such Depositary or a nominee thereof
or custodian therefore, and each such Global Security shall constitute a
single Security for all purposes of this CVR Agreement.
(2) Notwithstanding any other provision in this CVR Agreement, no Global
Security may be exchanged in whole or in part for Securities registered, and
no transfer of a Global Security in whole or in part may be registered, in
the name of any Person other than the Depositary for such Global Security or
a nominee thereof, except in the limited circumstances set forth in Section
2.4, below.
(3) Subject to Clause (2) above, any exchange of a Global Security for
other Securities may be made in whole or in part, and all Securities issued
in exchange for a Global Security or any portion thereof shall be registered
in such names as the Depositary for such Global Security shall direct.
(4) Every Security authenticated and delivered upon registration of
transfer of, or in exchange for or in lieu of, a Global Security or any
portion thereof shall be authenticated and delivered in the form of, and
shall be, a Global Security, unless such Security is registered in the name
of a Person other than the Depositary for such Global Security or a nominee
thereof as provided in Section 2.4, below.
(5) The Depositary or its nominee, as registered owner of a Global
Security, shall be the Holder of such Global Security for all purposes under
the CVR Agreement and the Securities, and owners of beneficial interests in
the Global Security shall hold such interests pursuant to the applicable
procedures of the Depositary. Accordingly, any such owner's beneficial
interest in a Global Security will be shown only on, and the transfer of
such interest shall be effected only through, records maintained by the
Depositary or its nominee and such owners of beneficial interest in a Global
Security will not be considered the owners or holders thereof.
Section 2.4 Securities in Certificated Form.
(a) So long as the Depositary is the registered holder and owner of any
Global Security hereunder, the Depositary will be considered the sole owner and
holder of the related Securities for all purposes of such Securities and for
all purposes under this CVR Agreement. Except as set forth below, owners of
beneficial interests in a Global Security: (i) will not be entitled to have the
Securities represented by such Global Security registered in their names; (ii)
will not receive or be entitled to receive physical delivery of Securities in
certificated form; and (iii) will not be considered to be the owners or holders
of any Securities under the CVR Agreement or of such Global Security.
(b) The Securities represented by a Global Security or Global Securities
shall only be issued in certificated form (the "Certificated Securities") in
the following circumstances:
(i) at any time there are fewer than ten beneficial owners of the
Securities;
(ii) the Depositary notifies the Buyer that it is unwilling or unable to
continue as depositary for such Global Security and there is no successor
depositary; or
(iii) the Buyer, in its discretion, at any time determines not to have
all of the Securities represented by a Global Security and notifies the
Trustee thereof.
(c) In the event that the Buyer is required, pursuant to Section 2.4(b), to
issue Certificated Securities in exchange for Securities represented by a
Global Security, the Buyer may make such insertions, omissions, substitutions,
modifications and such other variations to the form of Global Security attached
hereto as Exhibit A, as may be determined by such officers of Buyer executing
such Certificated Securities in order to issue such Securities in certificated
form, as appropriate as determined by the Buyer in good faith. In addition, in
the event that the Buyer is required to issue Certificated Securities in
exchange for Securities represented by a Global
B-1-9
Security or Global Securities, the terms of this CVR Agreement which reference
or relate specifically to (i) a Global Security or Global Securities and are
otherwise silent as to Certificated Securities shall be deemed to be amended to
refer or relate to the Certificated Securities and (ii) Beneficial Owners with
respect to a Global Security or Global Securities and are otherwise silent as
to Holders of Securities or Holders of Certificated Securities shall be deemed
to be amended to refer to the Holders of the Certificated Securities, in each
case, as may be appropriate.
ARTICLE III
THE SECURITIES
3.1 Title and Terms.
(a) The aggregate number of Securities represented by the Global Security or
Global Securities that may be authenticated and delivered under this CVR
Agreement is limited to , representing a maximum CVR Payout of
$ , except for Securities authenticated and delivered upon registration
of permitted transfer of, or in exchange for, or in lieu of, other Securities.
(b) The Securities shall be known and designated as the "Contingent Value
Rights" of the Buyer. The Holders shall be entitled to the following
consideration, to be delivered by the Trustee in accordance with the procedures
set forth herein, as follows:
(i) On the Issuance Date, each Security outstanding immediately prior to
the Issuance Date shall be deemed cancelled and extinguished and
automatically converted into and become the right to receive the CVR Payout,
if any, as provided below in this Section 3.1(b). For purposes of this CVR
Agreement, "CVR Payout" means, for each Security outstanding immediately
prior to the Issuance Date, that amount of cash equal to:
(1) if the Revenue during the CVR Measuring Period is equal to or
greater than the Upper Limit, $4.50 (the "Maximum CVR Payout");
(2) if the Revenue during the CVR Measuring Period is less than the
Upper Limit but greater than the Lower Limit, the dollar amount equal to
the product of (x) $4.50 multiplied by the quotient obtained by dividing
(y) the number by which Revenue exceeds the Lower Limit by (z)
$600,000,000; and
(3) if the Revenue during the CVR Measuring Period is less than or
equal to the Lower Limit, $0.
(ii) On the Issuance Date, Buyer shall pay the CVR Payout for all
Securities to the Trustee by wire transfer and the Trustee shall as soon as
practicable thereafter pay the Holders of the Securities the CVR Payout
amount required hereunder;
(iii) Upon payment by the Buyer of the CVR Payout and transfer of such
amount by the Trustee to the Holder of any Global Securities in accordance
with Section 3.1(b)(ii) and subsequent payment by the Depositary to the
Beneficial Owners in accordance with Section 5.4(c), such Global Securities
shall be surrendered to the Trustee for cancellation;
(iv) The Trustee shall not be required under any circumstances to
calculate the CVR Payout and need not investigate or confirm any information
in the CVR Report or the adequacy of the CVR Payout amount but may rely
conclusively on the CVR Payout amount specified in writing by Buyer in an
Officer's Certificate delivered to the Trustee, as being sufficient for all
purposes under this CVR Agreement.
(c) Except to the extent a portion of the CVR Payout is required to be
treated as imputed interest pursuant to applicable law, the parties hereto
agree to treat the CVR Payout for all purposes as additional consideration for
the shares of the Company exchanged pursuant to the Offer Agreement.
B-1-10
(d) Each of the Holders of any Security, by acceptance thereof, agrees that:
(i) the Buyer and its Affiliates shall be entitled in their sole
discretion to establish and modify from time to time all aspects of Buyer's
and its Affiliates' program for the development, manufacturing, marketing
and sale of any products, including, without limitation, the LEP Digital
Press Products and Consumables, including product design, functionality and
features, development processes, roadmaps and timelines, evaluation, testing
and release readiness, procurement of materials and components,
manufacturing, marketing and sales and staffing and funding for any of the
foregoing (any or all of which may be performed by the Buyer or its
Affiliates using its internal resources or by third parties pursuant to
outsourcing or other contractual relationships with the Buyer or its
Affiliates); and
(ii) the Buyer and its Affiliates have no obligation to initiate or
continue research, development, commercialization, marketing or sales
activities with respect to any products, including, without limitation, the
LEP Digital Press Products and Consumables and, in the Buyer's sole and
subjective discretion, the Buyer and its Affiliates may abandon efforts to
research, develop, commercialize, market or sell any or all products,
including, without limitation, the LEP Digital Press Products and
Consumables. No joint venture, partnership or other fiduciary relationship
between the Buyer and the holders of the Securities is created by this CVR
Agreement or the Securities.
(e) Other than in the case of interest payable after a Default Issuance
Date, no interest shall accrue on any amounts payable with respect to the
Securities after Buyer transfers the CVR Payout to the Trustee.
(f) In the event that all of the Securities not previously cancelled shall
have become due and payable pursuant to the terms hereof, and the Buyer has
paid or caused to be paid or deposited with the Trustee all amounts payable to
the Holders under this CVR Agreement, then this CVR Agreement shall cease to be
of further effect and shall be deemed satisfied and discharged. Notwithstanding
the satisfaction and discharge of this CVR Agreement, the obligations of the
Buyer under Section 4.7(c) shall survive.
3.2 Registrable Form. Except as provided in Section 2.4, the Securities
issued hereunder shall be Global Securities and shall be issuable only in
registered form.
3.3 Execution, Authentication, Delivery and Dating.
(a) The Securities shall be executed on behalf of the Buyer by its president
or any vice president or its treasurer, but need not be attested. The signature
of any of these officers on the Securities may be manual or facsimile.
(b) The Securities bearing the manual or facsimile signatures of individuals
who were, at the time of execution, the proper officers of the Buyer shall bind
the Buyer, notwithstanding that such individuals or any of them have ceased to
hold such offices prior to the authentication and delivery of such Securities
or did not hold such offices at the date of such Securities.
(c) At any time and from time to time after the execution and delivery of
this CVR Agreement, the Buyer may deliver Securities executed by the Buyer to
the Trustee for authentication, together with a Buyer Order for the
authentication and delivery of such Securities; and the Trustee, in accordance
with such Buyer Order, shall authenticate and deliver such Securities as
provided in this CVR Agreement and not otherwise.
(d) Each Security shall be dated the date of its authentication.
(e) No Security shall be entitled to any benefit under this CVR Agreement or
be valid or obligatory for any purpose unless there appears on such Security a
certificate of authentication substantially in the form provided for herein
duly executed by the Trustee, by manual or facsimile signature of an authorized
officer, and such certificate upon any Security shall be conclusive evidence,
and the only evidence, that such Security has been duly authenticated and
delivered hereunder and that the Holder is entitled to the benefits of this CVR
Agreement.
3.4 Mutilated, Destroyed, Lost and Stolen Securities.
(a) If (i) any mutilated Security is surrendered to the Trustee, or (ii) the
Buyer and the Trustee receive evidence to their satisfaction of the
destruction, loss or theft of any Security, and there is delivered to the Buyer
B-1-11
and the Trustee such security or indemnity as may be required by them to save
each of them harmless, then, in the absence of notice to the Buyer or the
Trustee that such Security has been acquired by a bona fide purchaser, the
Buyer shall execute and, upon delivery of a Buyer Order, the Trustee shall
authenticate and deliver, in exchange for any such mutilated Security or in
lieu of any such destroyed, lost or stolen Security, a new Security of like
tenor and amount of Securities, bearing a number not contemporaneously
outstanding.
(b) In case any such mutilated, destroyed, lost or stolen Security has
become or is to become due and payable within fifteen days, the Buyer in its
discretion may, instead of issuing a new Security, pay to the Holder of such
Security on the Issuance Date or a Default Issuance Date, as the case may be,
all amounts due and payable with respect thereto.
(c) Upon the issuance of any new Securities under this Section, the Buyer
shall pay any tax or other governmental charge that may be imposed in relation
thereto and any other expenses (including the fees and expenses of the Trustee)
connected therewith.
(d) Every new Security issued pursuant to this Section in lieu of any
destroyed, lost or stolen Security shall constitute an original additional
contractual obligation of the Buyer, whether or not the destroyed, lost or
stolen Security shall be at any time enforceable by anyone, and shall be
entitled to all benefits of this CVR Agreement equally and proportionately with
any and all other Securities duly issued hereunder.
(e) The provisions of this Section are exclusive and shall preclude (to the
extent lawful) all other rights and remedies with respect to the replacement or
payment of mutilated, destroyed, lost or stolen Securities.
3.5 Registration of Global Securities. The Buyer shall cause to be kept at
the office of the Trustee a register (the register maintained in such office
and in any other office or agency designated pursuant to Section 10.2 being
herein sometimes referred to as the "Security Register") in which, subject to
such reasonable regulations as it may prescribe, the Buyer shall provide for
the registration of the Global Securities. The Trustee is hereby initially
appointed "Security Registrar" for the purpose of registering and transferring
the Global Securities to the extent provided for in Article II.
3.6 Persons Deemed Owners. Prior to the time of due presentment for
registration of transfer, the Buyer, the Trustee and any agent of the Buyer or
the Trustee may treat the Person in whose name any Security is registered as
the owner of such Security for the purpose of receiving payment on such
Security and for all other purposes whatsoever, whether or not such Security be
overdue, and neither the Buyer, the Trustee nor any agent of the Buyer or the
Trustee shall be affected by notice to the contrary.
3.7 Cancellation. All Securities surrendered for payment, registration of
transfer or exchange shall, if surrendered to any Person other than the
Trustee, be delivered to the Trustee and shall be promptly canceled by it. The
Buyer may at any time deliver to the Trustee for cancellation any Securities
previously authenticated and delivered hereunder which the Buyer may have
acquired in any manner whatsoever, and the Trustee shall promptly cancel all
Securities so delivered. No Securities shall be authenticated in lieu of or in
exchange for any Securities canceled as provided in this Section, except as
expressly permitted by this CVR Agreement. All cancelled Securities held by the
Trustee shall be destroyed and the Trustee shall issue a certificate of
destruction to the Buyer, unless otherwise directed by a Buyer Order.
ARTICLE IV
THE TRUSTEE
4.1 Certain Duties and Responsibilities.
(a) The Trustee, prior to the occurrence of an Event of Default with respect
to the Securities and after the curing or waiving of all Events of Default
which may have occurred, undertakes to perform such duties and only such duties
as are specifically set forth in this CVR Agreement and no implied covenants
shall be read into this CVR Agreement against the Trustee. In case an Event of
Default with respect to the Securities has occurred
B-1-12
(which has not been cured or waived), the Trustee shall exercise such of the
rights and powers vested in it by this CVR Agreement, and use the same degree
of care and skill in their exercise, as a prudent person would exercise or use
under the circumstances in the conduct of his own affairs.
(b) In the absence of bad faith on its part, prior to the occurrence of an
Event of Default and after the curing or waiving of all such Events of Default
which may have occurred, the Trustee may conclusively rely, as to the truth of
the statements and the correctness of the opinions expressed therein, upon
certificates or opinions furnished to the Trustee and conforming to the
requirements of this CVR Agreement; but in the case of any such certificates or
opinions which by any provision hereof are specifically required to be
furnished to the Trustee, the Trustee shall be under a duty to examine the same
to determine whether or not they conform to the requirements of this CVR
Agreement.
(c) No provision of this CVR Agreement shall be construed to relieve the
Trustee from liability for its own negligent action, its own negligent failure
to act, or its own willful misconduct, except that (i) this Subsection (c)
shall not be construed to limit the effect of Subsections (a) and (b) of this
Section; (ii) the Trustee shall not be liable for any error of judgment made in
good faith by a Responsible Officer, unless it shall be proved that the Trustee
was negligent in ascertaining the pertinent facts; (iii) no provision of this
CVR Agreement shall require the Trustee to expend or risk its own funds or
otherwise incur any financial liability in the performance of any of its duties
hereunder, or in the exercise of any of its rights or powers; and (iv) the
Trustee shall not be liable with respect to any action taken or omitted to be
taken by it in good faith in accordance with the direction of the Holders
pursuant to Section 9.9 relating to the time, method and place of conducting
any proceeding for any remedy available to the Trustee, or exercising any trust
or power conferred upon the Trustee, under this CVR Agreement.
(d) Whether or not therein expressly so provided, every provision of this
CVR Agreement relating to the conduct or affecting the liability of or
affording protection to the Trustee shall be subject to the provisions of this
Section and shall extend to the Depositary, Paying Agent, Securities Registrar
and any other agent of the Buyer.
4.2 Certain Rights of Trustee. Subject to the provisions of Section 4.1,
including, without limitation, the duty of care that the Trustee is required to
exercise upon the occurrence of an Event of Default:
(a) the Trustee may rely and shall be protected in acting or refraining
from acting upon any resolution, certificate, statement, instrument,
opinion, report, notice, request, direction, consent, order, bond,
debenture, note, other evidence of indebtedness or other paper or document
believed by it to be genuine and to have been signed or presented by the
proper party or parties and the Trustee need not investigate any fact or
matter stated in the document;
(b) any request or direction or order of the Buyer mentioned herein shall
be sufficiently evidenced by a Buyer Request or Buyer Order and any
resolution of the Board of Directors may be sufficiently evidenced by a
Board Resolution and the Trustee shall not be liable for any action it takes
or omits to take in good faith reliance thereon;
(c) whenever in the administration of this CVR Agreement the Trustee
shall deem it desirable that a matter be proved or established prior to
taking, suffering or omitting any action hereunder, the Trustee (unless
other evidence be herein specifically prescribed) may, in the absence of bad
faith on its part, request and rely upon an Officers' Certificate and the
Trustee shall not be liable for any action it takes or omits to take in good
faith reliance thereon or an Opinion of Counsel;
(d) the Trustee may consult with counsel and the written advice of such
counsel or any Opinion of Counsel shall be full and complete authorization
and protection in respect of any action taken, suffered or omitted by it
hereunder in good faith and in accordance with such advice or Opinion of
Counsel;
(e) the Trustee shall be under no obligation to exercise any of the
rights or powers vested in it by this CVR Agreement at the request or
direction of any of the Holders pursuant to this CVR Agreement, unless such
Holders shall have offered to the Trustee reasonable security or indemnity
against the costs, expenses and liabilities which might be incurred by it in
compliance with such request or direction;
B-1-13
(f) the Trustee shall not be bound to make any investigation into the
facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, consent, order, approval,
appraisal, bond, debenture, note, coupon, security, or other paper or
document, but the Trustee in its discretion may make such further inquiry or
investigation into such facts or matters as it may see fit;
(g) the Trustee may execute any of the trusts or powers hereunder or
perform any duties hereunder either directly or by or through agents or
attorneys and the Trustee shall not be responsible for any misconduct or
negligence on the part of any agent or attorney appointed with due care by
it hereunder; and
(h) the Trustee shall not be liable for any action taken, suffered or
omitted to be taken by it in good faith and believed by it to be authorized
or within the discretion or rights or powers conferred upon it by this CVR
Agreement.
(i) The permissive rights of the Trustee to do things enumerated in this
Agreement shall not be construed as a duty unless so specified herein.
4.3 Notice of Default. If a default occurs hereunder with respect to the
Securities, the Trustee shall give the Holders notice of any such default
actually known to it as and to the extent provided by the Trust Indenture Act;
provided, however, that in the case of any default of the character specified
in Section 9.1(b) with respect to the Securities, no such notice to Holders
shall be given until at least 30 days after the occurrence thereof. For the
purpose of this Section, the term "default" means any event that is, or after
notice or lapse of time or both would become, an Event of Default with respect
to the Securities.
4.4 Not Responsible for Recitals or Issuance of Securities. The Trustee
shall not be accountable for the Buyer's use of the Securities or the proceeds
from the Securities. The recitals contained herein and in the Securities,
except the Trustee's certificate of authentication, shall be taken as the
statements of the Buyer, and the Trustee assumes no responsibility for their
correctness. The Trustee makes no representations as to the validity,
sufficiency or priority of this CVR Agreement or of the Securities.
4.5 May Hold Securities. The Trustee, the Depositary, any Paying Agent,
Security Registrar or any other agent of the Buyer, in its individual or any
other capacity, may become the owner or pledgee of Securities, and, subject to
Sections 4.8 and 4.13, may otherwise deal with the Buyer with the same rights
it would have if it were not Trustee, Depositary, Paying Agent, Security
Registrar or such other agent.
4.6 Money Held in Trust. Money held by the Trustee in trust hereunder need
not be segregated from other funds except to the extent required by law. The
Trustee shall be under no liability for interest on any money received by it
hereunder.
4.7 Compensation and Reimbursement. The Buyer agrees:
(a) to pay to the Trustee from time to time reasonable compensation for all
services rendered by it hereunder (which compensation shall not be limited by
any provision of law in regard to the compensation of a trustee of an express
trust);
(b) except as otherwise expressly provided herein, to reimburse the Trustee
upon its request for all reasonable expenses, disbursements and advances
incurred or made by the Trustee in accordance with any provision of this CVR
Agreement (including the reasonable compensation and the expenses and
disbursements of its agents and counsel), except any such expense, disbursement
or advance as may be attributable to the Trustee's negligence or willful
misconduct; and
(c) to indemnify the Trustee and each of its agents, officers, directors and
employees (each an "indemnitee") for, and to hold it harmless against, any
loss, liability or expense (including attorneys fees and expenses) incurred
without negligence or willful misconduct on its part, arising out of or in
connection with the acceptance or administration of this trust and the
performance of its duties hereunder, including the costs and expenses of
defending itself against any claim or liability in connection with the exercise
or performance of any
B-1-14
of its powers or duties hereunder. The Buyer's payment obligations pursuant to
this Section shall survive the termination of this CVR Agreement. When a
Trustee incurs expenses after the occurrence of an Event of Default specified
in Section 9.1(c) or 9.1(d) with respect to the Buyer, the expenses are
intended to constitute expenses of administration under bankruptcy laws.
4.8 Disqualification; Conflicting Interests.
(a) If the Trustee has or shall acquire any conflicting interest within the
meaning of the Trust Indenture Act, it shall, within ninety days after
ascertaining that it has such conflicting interest, either eliminate such
conflicting interest or resign to the extent and in the manner provided by, and
subject to the provisions of, the Trust Indenture Act and this CVR Agreement.
The Buyer shall take prompt steps to have a successor appointed in the manner
provided in this CVR Agreement.
(b) In the event the Trustee shall fail to comply with the foregoing
subsection (a), the Trustee shall, within ten days of the expiration of such
ninety-day period, transmit a notice of such failure to the Holders.
4.9 Corporate Trustee Required; Eligibility. There shall at all times be a
Trustee hereunder which shall be a corporation that is eligible pursuant to the
Trust Indenture Act to act as such and has a combined capital and surplus of at
least $15 million. If such corporation publishes reports of condition at least
annually, pursuant to law or to the requirements of a supervising or examining
authority, then for the purposes of this Section, the combined capital and
surplus of such corporation shall be deemed to be its combined capital and
surplus as set forth in its most recent report of condition so published. If at
any time the Trustee shall cease to be eligible in accordance with the
provisions of this Section, it shall resign immediately in the manner and with
the effect hereinafter specified in this Article.
4.10 Resignation and Removal; Appointment of Successor.
(a) No resignation or removal of the Trustee and no appointment of a
successor Trustee pursuant to this Article shall become effective until the
acceptance of appointment by the successor Trustee under Section 4.11.
(b) The Trustee, or any trustee or trustees hereafter appointed, may resign
at any time by giving written notice thereof to the Buyer. If an instrument of
acceptance by a successor Trustee shall not have been delivered to the Trustee
within thirty days after the giving of such notice of resignation, the
resigning Trustee may petition any court of competent jurisdiction for the
appointment of a successor Trustee.
(c) The Trustee may be removed at any time by an act of the Holders of a
majority of the Outstanding Securities, delivered to the Trustee and to the
Buyer.
(d) If at any time:
(1) the Trustee shall fail to comply with Section 4.8 after written
request therefor by the Buyer or by any Holder who has been a bona fide
Holder of a Security for at least six months, or
(2) the Trustee shall cease to be eligible under Section 4.9 and shall
fail to resign after written request therefor by the Buyer or by any such
Holder, or
(3) the Trustee shall become incapable of acting or shall be adjudged a
bankrupt or insolvent, or a receiver of the Trustee or of its property shall
be appointed, or any public officer shall take charge or control of the
Trustee or of its property or affairs for the purpose of rehabilitation,
conservation or liquidation, then, in any case, (i) the Buyer, by a Buyer
Request, may remove the Trustee, or (ii) the Holder of any Security who has
been a bona fide Holder of a Security for at least six months may, on behalf
of himself and all others similarly situated, petition any court of
competent jurisdiction for the removal of the Trustee and the appointment of
a successor Trustee.
(e) If the Trustee shall resign, be removed or become incapable of acting,
or if a vacancy shall occur in the office of Trustee for any cause, the Buyer,
by a Buyer Order, shall promptly appoint a successor Trustee. If, within one
year after any removal by Holders of a majority of the Outstanding Securities,
a successor Trustee
B-1-15
shall be appointed by act of the Holders of a majority of the Outstanding
Securities delivered to the Buyer and the retiring Trustee the successor
Trustee so appointed shall, forthwith upon its acceptance of such appointment
in accordance with Section 4.11, become the successor Trustee and supersede the
successor Trustee appointed by the Buyer. If no successor Trustee shall have
been so appointed by the Buyer or the Holders of the Securities and accepted
appointment within sixty (60) days after the retiring Trustee tenders its
resignation or is removed, the retiring Trustee may, or, the Holder of any
Security who has been a bona fide Holder for at least six months may on behalf
of himself and all others similarly situated, petition any court of competent
jurisdiction for the appointment of a successor Trustee.
(f) The Buyer shall give notice of each resignation and each removal of the
Trustee and each appointment of a successor Trustee by mailing written notice
of such event by first-class mail, postage prepaid, to the Holders of
Securities as their names and addresses appear in the Security Register. Each
notice shall include the name of the successor Trustee and the address of its
Corporate Trust Office. If the Buyer fails to send such notice within ten (10)
days after acceptance of appointment by a successor Trustee, it shall not be a
default hereunder but the successor Trustee shall cause the notice to be mailed
at the expense of the Buyer.
4.11 Acceptance of Appointment of Successor.
(a) Every successor Trustee appointed hereunder shall execute, acknowledge
and deliver to the Buyer and to the retiring Trustee an instrument accepting
such appointment, and thereupon the resignation or removal of the retiring
Trustee shall become effective and such successor Trustee, without any further
act, deed or conveyance, shall become vested with all the rights, powers,
trusts and duties of the retiring Trustee; but, upon request of the Buyer or
the successor Trustee, such retiring Trustee shall, upon payment of its
charges, execute and deliver an instrument transferring to such successor
Trustee all the rights, powers and trusts of the retiring Trustee, and shall
duly assign, transfer and deliver to such successor Trustee all property and
money held by such retiring Trustee hereunder. Upon request of any such
successor Trustee, the Buyer shall execute any and all instruments for more
fully and certainly vesting in and confirming to such successor Trustee all
such rights, powers and trusts.
(b) No successor Trustee shall accept its appointment unless at the time of
such acceptance such successor Trustee shall be qualified and eligible under
this Article.
4.12 Merger, Conversion, Consolidation or Succession to Business. Any
corporation into which the Trustee may be merged or converted or with which it
may be consolidated, or any corporation resulting from any merger, conversion
or consolidation to which the Trustee shall be a party, or any corporation
succeeding to all or substantially all of the corporate trust business of the
Trustee, by sale or otherwise shall be the successor of the Trustee hereunder,
provided such corporation shall be otherwise qualified and eligible under this
Article, without the execution or filing of any paper or any further act on the
part of any of the parties hereto. In case any Securities shall have been
authenticated, but not delivered, by the Trustee then in office, any successor
by merger, conversion, sale or consolidation to such authenticating Trustee may
adopt such authentication and deliver the Securities so authenticated with the
same effect as if such successor Trustee had itself authenticated such
Securities; and such certificate shall have the full force which it is anywhere
in the Securities or in this CVR Agreement provided that the certificate of the
Trustee shall have; provided that the right to adopt the certificate of
authentication of any predecessor Trustee shall apply only to its successor or
successors by merger, conversion, sale or consolidation.
4.13 Preferential Collection of Claims Against Buyer. If and when the
Trustee shall be or shall become a creditor of the Buyer (or any other obligor
upon the Securities) the Trustee shall be subject to the provisions of the
Trust Indenture Act regarding the collection of claims against the Buyer (or
any such other obligor).
ARTICLE V
DEPOSITARY AND PAYING AGENT
5.1 Deposit of Securities. At the time of issuance of the Securities,
there shall be deposited with J.P. Morgan Trust Company, National Association,
as depositary and paying agent (in such context, including
B-1-16
any successors thereto appointed in accordance with Section 5.10, the
"Depositary" or alternatively the "Paying Agent") one or more Global Securities
registered in the name of the Depositary.
5.2 Buyer to Provide List of Beneficial Owners; Notification.
(a) Promptly following the issuance of the Securities, the Buyer shall
deliver to the Depositary a list in such form as the Depositary shall
reasonably require, of the names and addresses of beneficial owners and/or
persons holding Securities on behalf of the beneficial owners of such
Securities (together, the "Beneficial Owners" and such list the "Beneficial
Owner List"), such list substantially in the form of Exhibit B-1, attached
hereto.
(b) Within a reasonable time after receipt by the Depositary of the
Beneficial Owner List, the Depositary shall prepare and transmit to the
Beneficial Owners (i) a notice, in form and substance acceptable to the Buyer,
substantially in the form of Exhibit B-2, attached hereto, indicating the
beneficial interest in the Global Securities held by each such Beneficial
Owner, and (ii) with respect to Holders of at least 100,000 Securities, a
request that such Holders provide to the Depositary in writing wire transfer
instructions for an account of such Holder (which wire transfer instructions
shall contain sufficient information for the Depositary to effect a wire
transfer to such account).
5.3 Registration, Permitted Transfers and Exchanges.
(a) Any beneficial interest in the Global Security (or in the case that
Certificated Securities are issued pursuant to Section 2.4, a Certificated
Security) may not be sold (except to the Buyer and its Affiliates), assigned,
pledged, encumbered, or in any other manner transferred or disposed of, in
whole or in part, other than through a Permitted Transfer in accordance with
this Section 5.3 and in compliance with applicable United States' federal and
state securities laws and the terms and conditions hereof.
(b) In order to effectuate a Permitted Transfer of all or part of the
beneficial interest in the Global Security of a Beneficial Owner, the
requesting Beneficial Owner shall deliver to the Depositary a written
instrument or instruments of transfer in form reasonably satisfactory to the
Buyer, HP and the Depositary, substantially in the form of Exhibit C attached
hereto, duly executed by the Beneficial Owner or by a duly authorized
representative or attorney thereof (a "Transfer Instrument") on which the
Trustee may conclusively rely.
(c) On any Business Day on which the Depositary receives a Transfer
Instrument prior to 1:00 p.m. (Pacific Time) to reflect a specific Permitted
Transfer resulting in an increase or decrease on the Beneficial Owner List of
the beneficial interest in the Global Security held by the requesting
Beneficial Owner, and/or if applicable to indicate a transfer to a new
Beneficial Owner, the Depositary shall, no later than 3:30 p.m. (Pacific Time)
that day, either approve or disapprove such Transfer Instrument. A Transfer
Instrument received after 1:00 p.m. (Pacific Time) on any Business Day shall be
approved or disapproved by the Depositary by 9:00 a.m. (Pacific Time) the
immediately succeeding Business Day. Promptly following the approval of such
Transfer Instrument, the Depositary shall note such increase or decrease of
such Beneficial Owner's beneficial interest in the Global Security or the
addition of a new Beneficial Owner on the Beneficial Owner List and such new
Beneficial Owner's beneficial interest in the Global Security.
(d) No service charge shall be made for any registration of transfer or
exchange of beneficial ownership interests in a Global Security but the Buyer
may require payment of a sum sufficient to cover any tax or other governmental
charge that may be imposed in connection with any registration of transfer or
exchange of such beneficial interest.
5.4 Calculation of CVR Payout.
(a) The Buyer shall deliver to the Depositary, on or before the Issuance
Date:
(i) an Officers' Certificate certifying the Revenue for the CVR Measuring
Period and setting forth the calculation of the CVR Payout, if any, and
amount of the consideration per such Security payable on the Issuance Date.
The Depositary shall be protected in relying upon such Officers' Certificate
and shall be under no duty to investigate the facts underlying such
Officers' Certificate or the CVR Report; and
(ii) the CVR Report.
B-1-17
(b) As soon as practicable after the Issuance Date, and in any event not
later than ten (10) Business Days following the Issuance Date, the Depositary
shall mail a copy of the CVR Report to all Beneficial Owners of beneficial
interests in the Global Security that were converted into the right to receive
the CVR Payout, a copy of the CVR Report.
(c) Upon receipt by the Depositary of the CVR Payout from the Trustee in a
ccordance with the provisions hereof, the Depositary shall pay such amount due
each such Beneficial Owner (i) by wire transfer to Holders of at least 100,000
Securities who have delivered to the Depositary in writing wire transfer
instructions for deposit to an account no later than 14 days prior to the
Issuance Date (which wire transfer instructions shall contain sufficient
information for the Depositary to effect a wire transfer to such account), or
(ii) by U.S. dollar check in all other cases.
(d) Until surrendered and cancelled in accordance with the provisions of
this Section, each beneficial interest in the Global Security shall represent
for all purposes only the right to receive the CVR Payout.
(e) The Buyer and the Depositary shall be entitled to deduct and withhold
from the CVR Payout otherwise payable pursuant to this CVR Agreement to any
Beneficial Owner of a beneficial interest in the Global Security such amounts
as Buyer or the Depositary is required to deduct and withhold with respect to
the making of such payment under any provision of federal, state, local or
foreign tax law. To the extent that amounts are so withheld by the Buyer or the
Depositary, such withheld amounts shall be treated for all purposes of this CVR
Agreement as having been paid to the Beneficial Owner of the beneficial
interest in the Global Security in respect of which such deduction and
withholding was made.
5.5 Payments With Respect to the Securities. Payment of any amounts
pursuant to the Securities (including, without limitation, any Global
Securities) shall be made in such coin or currency of the United States of
America, as at the time is legal tender for the payment of public and private
debts. The Buyer may, at its option, pay such amounts by wire transfer or check
payable in such money; however, any payment to the Trustee shall be made by
wire transfer.
5.6 Redemption, etc. In the event of a redemption or any other similar
transaction (e.g., tender made and accepted in response to an invitation of the
Buyer or its Affiliates) necessitating a reduction in the aggregate principal
amount of Global Securities outstanding or an advance refunding of part of the
Global Securities outstanding, the Depositary, in its discretion: (a) may
request Buyer to issue and authenticate a new Global Security; or (b) may make
an appropriate notation on the Global Security indicating the date and amount
of such reduction in principal except in the case of final maturity, in which
case the certificate will be presented to Buyer prior to payment, if required.
5.7 Certificated Securities. Following the occurrence of any of the
circumstances specified in Section 2.4 of this CVR Agreement, and pursuant to
which Buyer determines that Beneficial Owners of a beneficial interest in the
Global Securities shall be required to obtain Certificated Securities, Buyer
shall notify Trustee and Depositary of the availability of Certificated
Securities. In such event, Buyer shall issue, transfer, and exchange
Certificated Securities for the Global Securities in appropriate amounts.
5.8 Notice to Beneficial Owners. If at any time the Depositary as sole and
only Holder of the Global Security or Global Securities under this CVR
Agreement receives any notice or other communication from the Trustee and
directed to the Depositary as the Holder, the Depositary shall promptly
thereafter transmit any such notice to the Beneficial Owners as appropriate
under the notice. Such notice from the Depositary shall be sufficiently given
(unless otherwise herein expressly provided) if in writing and mailed,
first-class postage prepaid, to the appropriate recipient or recipients
affected by such event, at its address as it appears on the Beneficial Owner
List or as otherwise applicable, not later than the latest date, and not
earlier than the earliest date, prescribed for the giving of such notice. In
any case where notice to the Beneficial Owners is given by mail, neither the
failure to mail such notice, nor any defect in any notice so mailed, to any
particular Beneficial Owner shall affect the sufficiency of such notice with
respect to other Beneficial Owners.
B-1-18
5.9 Depositary as Proxy for Beneficial Owners. In each instance under this
CVR Agreement where action is requested by the Holder, the Depositary as the
registered Holder of the Global Security shall act as a proxy for the
Beneficial Owners with respect to the applicable beneficial interests held by
such Beneficial Owners in the Global Security and act expressly in accordance
with the directions of the Beneficial Owners.
5.10 Resignation and Removal; Appointment of Successor.
(a) The Depositary or any Depositary or Depositaries hereafter appointed,
may:
(i) Resign at any time by giving written notice thereof to the Buyer; or
(ii) Be removed at any time by (A) an act of the Holders of a majority of
the Outstanding Securities, delivered to the Depositary and to the Buyer or
(B) a Buyer Request, delivered to the Holders.
No resignation or removal of the Depositary and no appointment of a
successor Depositary shall become effective until the acceptance of appointment
by the successor Depositary pursuant to this Section 5.10
(b) If the Depositary shall resign, be removed or become incapable of
acting, or if a vacancy shall occur in the office of Depositary for any cause,
the Buyer, by written notice of an officer thereof, shall promptly appoint a
successor Depositary. If an instrument of acceptance by a successor Depositary
shall not have been delivered to the resigning Depositary within thirty (30)
days after the giving of such notice of resignation, the resigning Depositary
may petition any court of competent jurisdiction for the appointment of a
successor Depositary.
(c) If no successor Depositary shall have been so appointed by the Buyer and
accepted appointment within sixty (60) days after the retiring Depositary
tenders its resignation or is removed, the retiring Depositary may, or, the
Holder of any Security who has been a bona fide Holder for at least six months
may on behalf of himself and all others similarly situated, petition any court
of competent jurisdiction for the appointment of a successor Depositary.
(d) The Buyer shall give notice of each resignation and each removal of the
Depositary and each appointment of a successor Depositary by mailing written
notice of such event by first-class mail, postage prepaid, to the Holders of
Securities as their names and addresses appear in the Security Register. Each
notice shall include the name of the successor Depositary and the address of
its principal office. If the Buyer fails to send such notice within ten (10)
days after acceptance of appointment by a successor Depositary, it shall not be
a default hereunder but the successor Depositary shall cause the notice to be
mailed at the expense of the Buyer.
(e) Every successor Depositary appointed hereunder shall execute,
acknowledge and deliver to the Buyer and to the retiring Depositary an
instrument accepting such appointment, and thereupon the resignation or removal
of the retiring Depositary shall become effective and such successor
Depositary, without any further act, deed or conveyance, shall become vested
with all the rights, powers, trusts and duties of the retiring Depositary; but,
upon request of the Buyer or the successor Depositary, such retiring Depositary
shall, upon payment of its charges, execute and deliver an instrument
transferring to such successor Depositary all the rights, powers and trusts of
the retiring Depositary, and shall duly assign, transfer and deliver to such
successor Depositary all property and money held by such retiring Depositary
hereunder. Upon request of any such successor Depositary, the Buyer shall
execute any and all instruments for more fully and certainly vesting in and
confirming to such successor Depositary all such rights, powers and trusts.
5.11 No Obligation to Advance Funds. Nothing herein shall be deemed to
require Depositary to advance funds on behalf of Buyer.
5.12 Depositary's and Paying Agent's Rights.
(a) Every provision of this CVR Agreement relating to the conduct or
affecting the liability of or affording protection to the Trustee shall extend
to the Depositary and Paying Agent.
(b) The Buyer agrees and each of the Beneficial Owners of any Security, by
acceptance thereof shall be deemed to have agreed, that the Trustee and the
Depositary designated hereunder may be the same Person with the separate duties
and obligations assigned to them under this CVR Agreement.
B-1-19
5.13 Compensation and Reimbursement. The Buyer agrees:
(a) to pay to the Depositary or Paying Agent, as applicable, from time to
time reasonable compensation for all services rendered by it hereunder (which
compensation shall not be limited by any provision of law in regard to the
compensation of a trustee of an express trust);
(b) except as otherwise expressly provided herein, to reimburse the
Depositary or Paying Agent, as applicable, upon its request for all reasonable
expenses, disbursements and advances incurred or made by the Depositary or
Paying Agent, as applicable, in accordance with any provision of this CVR
Agreement (including the reasonable compensation and the expenses and
disbursements of its respective agents and counsel), except any such expense,
disbursement or advance as may be attributable to the Depositary or Paying
Agent's negligence or willful misconduct; and
(c) to indemnify the Depositary and Paying Agent and each of its respective
agents, officers, directors and employees (each an "indemnitee") for, and to
hold it harmless against, any loss, liability or expense (including attorneys
fees and expenses) incurred without negligence or willful misconduct on its
part, arising out of or in connection with the acceptance or administration of
this trust and the performance of its duties hereunder, including the costs and
expenses of defending itself against any claim or liability in connection with
the exercise or performance of any of its powers or duties hereunder. The
Buyer's payment obligations pursuant to this Section shall survive the
termination of this CVR Agreement. When the Depositary or Paying Agent incurs
expenses after the occurrence of an Event of Default specified in Section
9.1(c) or 9.1(d) with respect to the Buyer, the expenses are intended to
constitute expenses of administration under bankruptcy laws.
ARTICLE VI
HOLDERS' LISTS AND REPORTS BY TRUSTEE AND BUYER
6.1 Buyer to Furnish Trustee Names and Addresses of Holders. The Buyer
will furnish or cause to be furnished to the Trustee (i) semiannually a list,
in such form as the Trustee may reasonably require, of the names and addresses
of the Holders as of a recent date, and (ii) at such times as the Trustee may
request in writing, within thirty (30) days after receipt by the Buyer of any
such request, a list, in such form as the Trustee may reasonably require, of
the names and addresses of the Holders as of a date not more than fifteen (15)
days prior to the time such list is furnished; provided, however, that if and
so long as the Trustee shall be the Security Registrar, no such list need be
furnished.
6.2 Preservation of Information. The Trustee shall preserve, in as current
a form as is reasonably practicable, the names and addresses of Holders
contained in the most recent list furnished to the Trustee as provided in
Section 6.1 and the names and addresses of Holders received by the Trustee in
its capacity as Security Registrar. The Trustee may destroy any list furnished
to it as provided in Section 6.1 upon receipt of a new list so furnished.
6.3 Communications to Holders.
(a) The rights of the Holders or Beneficial Owners to communicate with other
Holders or Beneficial Owners with respect to their rights under this CVR
Agreement and the corresponding rights and privileges of the Trustee shall be
as provided by the Trust Indenture Act.
(b) Every Holder and Beneficial Owner of Securities, by receiving and
holding the same, agrees with the Buyer and the Trustee that neither the Buyer
nor the Trustee shall be deemed to be in violation of law or held accountable
by reason of the disclosure of any such information as to the names and
addresses of the Holders or Beneficial Owners made pursuant to the Trust
Indenture Act.
6.4 Reports by Trustee.
(a) Within sixty days after October 31 of each year commencing with 2002,
the Trustee shall transmit to all Holders such reports concerning the Trustee
and its actions under this CVR Agreement as may be required pursuant to the
Trust Indenture Act at the time and in the manner provided pursuant thereto.
B-1-20
(b) A copy of each such report shall, at the time of such transmission to
the Holders, be filed by the Trustee with each stock exchange, if any, upon
which the Securities are listed, with the Commission and also with the Buyer.
The Buyer will promptly notify the Trustee when the Securities are listed on
any stock exchange.
6.5 Reports by Buyer. HP shall: (a) file with the Trustee, (i) within
fifteen days after HP is required to file the same with the Commission, copies
of the annual reports and of the information, documents and other reports (or
copies of such portions of any of the foregoing as the Commission may from time
to time by rules and regulations prescribe) which HP may be required to file
with the Commission pursuant to Section 13 or Section 15(d) of the Exchange Act
(such required information, documents and other reports, generally, the
"Exchange Act Documents"); or, (ii) if HP is not required to file its Exchange
Act Documents, quarterly and annual financial information that would be
required pursuant to Section 13 of the Exchange Act in respect of a security
listed and registered on a national securities exchange as may be prescribed
from time to time in such rules and regulations; and (b) transmit by mail to
all Holders, as their names and addresses appear in the Security Register,
within thirty days after the filing thereof with the Trustee, such summaries of
any information documents and reports required to be filed by HP pursuant to
subsection (a) of this Section as may be required by rules and regulations
prescribed from time to time by the Commission.
ARTICLE VII
AMENDMENTS
7.1 Amendments Without Consent of Holders. Without the consent of any
Holders, the Buyer and the Trustee, at any time and from time to time, may
enter into one or more amendments hereto or to the Securities, for any of the
following purposes:
(a) to convey, transfer, assign, mortgage or pledge to the Trustee as
security for the Securities any property or assets; or
(b) to evidence the succession of another Person to the Buyer, and the
assumption by any such successor of the covenants of the Buyer herein and in
the Securities; or
(c) to add to the covenants of the Buyer such further covenants,
restrictions, conditions or provisions as the authorized officers of Buyer
and the Trustee shall consider to be for the protection of the Holders of
Securities, and to make the occurrence, or the occurrence and continuance,
of a default in any such additional covenants, restrictions, conditions or
provisions an Event of Default permitting the enforcement of all or any of
the several remedies provided in this CVR Agreement as herein set forth;
provided, that in respect of any such additional covenant, restriction,
condition or provision such amendment may provide for a particular period of
grace after default (which period may be shorter or longer than that allowed
in the case of other defaults) or may provide for an immediate enforcement
upon such an Event of Default or may limit the remedies available to the
Trustee upon such an Event of Default or may limit the right of the Holders
of a majority of the Securities to waive such an Event of Default; or
(d) to cure any ambiguity, or to correct or supplement any provision
herein or in the Securities which may be defective or inconsistent with any
other provision herein; provided, that such provisions shall not materially
reduce the benefits of this CVR Agreement or the Securities to the Holders;
or
(e) to provide for the issuance of the Securities in certificated form
upon the occurrence of any of the events specified in Section 2.4 of this
CVR Agreement; or
(f) to make any other provisions with respect to matters or questions
arising under this CVR Agreement; provided, that such provisions shall not
adversely affect the interests of the Holders; or
(g) to make any amendments or changes necessary to comply or maintain
compliance with the Trust Indenture Act.
Promptly following any amendment of this CVR Agreement or the Securities in
accordance with this Section 7.1, the Trustee shall notify the Holders of the
Securities of such amendment; provided, that any failure so to notify the
Holders shall not affect the validity of such amendment.
B-1-21
7.2 Amendments with Consent of Holders.
(a) With the written consent of the Holders of not less than a majority of
the Outstanding Securities, by the Act of said Holders delivered to the Buyer
and the Trustee, the Buyer, when authorized by a Buyer Order, and the Trustee
may enter into an indenture or indentures supplemental hereto for the purpose
of adding any provisions to or changing in any manner or eliminating any of the
provisions of this CVR Agreement or of modifying in any manner the rights of
the Holders under this CVR Agreement; provided, however, that no such
supplemental indenture shall, without the consent or affirmative vote of the
Holder of each Outstanding Security affected thereby:
(i) change in a manner adverse to the Holders, (i) any provision
contained herein with respect to termination of this CVR Agreement or the
Securities, (ii) the time for payment and amount of CVR Payout to be issued
according to the terms of this CVR Agreement to the Holders of the
Securities; or
(ii) modify any of the provisions of this Section, except to increase any
such percentage of the Outstanding Securities necessary to effect an
amendment or to provide that certain other provisions of this CVR Agreement
cannot be modified or waived without the consent of the Holder of each
Security affected thereby.
(b) It shall not be necessary for any Act of Holders under this Section to
approve the particular form of any proposed amendment, but it shall be
sufficient if such Act shall approve the substance thereof.
7.3 Execution of Amendments. In executing any amendment permitted by this
Article, the Trustee shall be entitled to receive indemnity reasonably
satisfactory to it, and (subject to Section 4.1) shall be fully protected in
relying upon an Opinion of Counsel stating that the execution of such amendment
is authorized or permitted by this CVR Agreement. The Trustee shall execute any
amendment authorized pursuant to this Article VII if the amendment does not
adversely affect the Trustee's own rights, duties or immunities under this CVR
Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such
amendment.
7.4 Effect of Amendments; Notice to Holders.
(a) Upon the execution of any amendment under this Article, this CVR
Agreement and the Securities shall be modified in accordance therewith, and
such amendment shall form a part of this CVR Agreement and the Securities for
all purposes; and every Holder of Securities theretofore or thereafter
authenticated and delivered hereunder shall be bound thereby.
(b) Promptly after the execution by the Buyer and the Trustee of any
amendment pursuant to the provisions of this Article, the Buyer shall mail a
notice thereof by first class mail to the Holders of Securities at their
addresses as they shall appear on the Security Register, setting forth in
general terms the substance of such amendment. Any failure of the Buyer to mail
such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any such amendment.
7.5 Conformity with Trust Indenture Act. Every amendment executed pursuant
to this Article shall conform to the requirements of the Trust Indenture Act.
7.6 Reference in Securities to Amendments. If an amendment changes the
terms of a Security, the Trustee may require the Holder of the Security to
deliver it to the Trustee. Securities authenticated and delivered after the
execution of any amendment pursuant to this Article may, and shall if required
by the Trustee, bear a notation in form approved by the Trustee as to any
matter provided for in such amendment. If the Buyer shall so determine, new
Securities so modified as to conform, in the opinion of the Trustee and one or
more authorized officers of Buyer, to any such amendment may be prepared and
executed by the Buyer and authenticated and delivered by the Trustee in
exchange for Outstanding Securities. Failure to make the appropriate notation
or to issue a new Security shall not affect the validity of such amendment.
B-1-22
ARTICLE VIII
COVENANTS
8.1 Payment of Amounts, if any, to Holders. The Buyer will duly and
punctually pay the amounts, if any, on the Securities in accordance with the
terms of the Securities and this CVR Agreement. Such amounts shall be
considered paid on the date due if on such date the Trustee or the Paying Agent
holds in accordance with this CVR Agreement money sufficient to pay all such
amounts then due. Notwithstanding any other provision of this CVR Agreement,
the Trustee and the Paying Agent shall comply with all withholding requirements
with respect to payments to Holders that the Buyer, the Trustee or the Paying
Agent reasonably believes are applicable under the federal, state, local or
foreign tax law. Amounts withheld in compliance with such withholding
requirements shall, for purposes of this CVR Agreement, be treated as paid to
the Holder such withholding was made with respect to. The consent of Holder
shall not be required for any such withholding.
8.2 Maintenance of Office or Agency.
(a) As long as any of the Securities remain Outstanding, the Buyer will
maintain in the Borough of Manhattan, The City of New York, an office or agency
(i) where Securities may be presented or surrendered for payment, (ii) where
Securities may be surrendered for registration of transfer or exchange and
(iii) where notices and demands to or upon the Buyer in respect of the
Securities and this CVR Agreement may be served. The office or agency of the
Trustee at c/o JPMorgan Chase Bank, 55 Water Street, 234 North Building, New
York, N.Y. 10041 shall be such office or agency of the Buyer, unless the Buyer
shall designate and maintain some other office or agency for one or more of
such purposes. The Buyer or any of its Subsidiaries may act as Paying Agent,
registrar or transfer agent; provided that such Person shall take appropriate
actions to avoid the commingling of funds. The Buyer will give prompt written
notice to the Trustee of any change in the location of any such office or
agency. If at any time the Buyer shall fail to furnish the Trustee with the
address thereof, such presentations, surrenders, notices and demands may be
made or served at the Corporate Trust Office of the Trustee, and the Buyer
hereby appoints the Trustee as its agent to receive all such presentations,
surrenders, notices and demands.
(b) The Buyer may from time to time designate one or more other offices or
agencies (in or outside of The City of New York) where the Securities may be
presented or surrendered for any or all such purposes, and may from time to
time rescind such designation; provided, however, that no such designation or
rescission shall in any manner relieve the Buyer of its obligation to maintain
an office or agency in the Borough of Manhattan, The City of New York for such
purposes. The Buyer will give prompt written notice to the Trustee of any such
designation or rescission and any change in the location of any such office or
agency.
8.3 Money for Security Payments to Be Held in Trust.
(a) If the Buyer or any of its Affiliates shall at any time act as the
Paying Agent, it will, on or before the Issuance Date or the Default Issuance
Date, as the case may be, segregate and hold in trust for the benefit of the
Persons entitled thereto a sum sufficient to pay the amounts, if any, so
becoming due until such sums shall be paid to such Persons or otherwise
disposed of as herein provided, and will promptly notify the Trustee of its
action or failure so to act.
(b) Whenever the Buyer shall have one or more Paying Agents for the
Securities, it will, on or before the Issuance Date or the Default Issuance
Date, as the case may be, deposit with a Paying Agent, in same day funds, a sum
sufficient to pay the amount, if any, so becoming due; such sum to be held in
trust for the benefit of the Persons entitled to such amount, and (unless such
Paying Agent is the Trustee) the Buyer will promptly notify the Trustee of such
action or any failure so to act.
(c) The Buyer will cause each Paying Agent other than the Trustee to execute
and deliver to the Trustee an instrument in which such Paying Agent shall agree
with the Trustee, subject to the provisions of this Section, that (A) such
Paying Agent will hold all sums held by it for the payment of any amount
payable on Securities in trust for the benefit of the Persons entitled thereto
until such sums shall be paid to such Persons or otherwise disposed
B-1-23
of as herein provided and will notify the Trustee of the sums so held and (B)
that it will give the Trustee notice of any failure by the Buyer (or by any
other obligor on the Securities) to make any payment on the Securities when the
same shall be due and payable.
(d) Any money deposited with the Trustee or any Paying Agent, or then held
by the Buyer, in trust for the payment on any Security and remaining unclaimed
for one year after the Issuance Date or the Default Issuance Date, as the case
may be, shall be paid to the Buyer on Buyer Request, or (if then held by the
Buyer) shall be discharged from such trust; and the Holder of such Security
shall thereafter, look only to the Buyer for payment thereof, and all liability
of the Trustee or such Paying Agent with respect to such shares or trust money
shall thereupon cease.
8.4 Certain Purchases and Sales. Nothing contained herein shall prohibit
the Buyer or any of its Subsidiaries or Affiliates from acquiring in open
market transactions, private transactions or otherwise, the Securities.
8.5 Reports.
(a) Within sixty (60) days after the end of the CVR Measuring Period, the
Buyer shall furnish to the Trustee and the Holders the CVR Report.
(b) If any adjustments or inaccuracies in the amounts payable pursuant to
the CVR Report are determined by the Holders or Beneficial Owners in their
review of the calculation of the CVR Payout, which may be performed at the end
of the CVR Measuring Period, and the Buyer agrees to such adjustment, such
adjustments for the CVR Measuring Period may be reconciled and described in a
written report and the payment shall be adjusted to reflect such determination.
The Buyer shall keep complete and accurate records in sufficient detail to
enable the amounts payable hereunder to be determined by the Holders and their
consultants or professional advisors.
8.6 Audits; Dispute Resolution.
(a) Audits.
(i) Upon the written request of the Holders of at least a majority in
interest of the outstanding Securities within thirty (30) Business Days
after the Issuance Date, the Buyer and a representative of the Holders, who
shall be approved by the Holders of a majority in interest of the
outstanding Securities (the "Holders' Representative"), shall seek to
resolve any dispute, controversy or claim arising out of or related to the
CVR Payout. If such dispute cannot be resolved within thirty (30) Business
Days after the date of the requesting Holders' written request, then the
Buyer shall permit an independent certified public accounting firm of
nationally recognized standing selected by the requesting Holders and
reasonably acceptable to the Buyer, at the requesting Holders' expense, to
have access upon reasonable notice and during normal business hours to such
of the records of the Buyer as are reasonably necessary to verify the
accuracy of the CVR Report (the "Holders Auditor Conclusion"). No such
request shall be made more than thirty (30) Business Days after the Issuance
Date.
(ii) If such accounting firm concludes that additional CVR Payout is
owed, then:
(1) Holders Auditor Conclusion. If the Buyer agrees with the Holders
Auditor Conclusion, the Buyer shall issue the additional CVR Payout, if
any, set forth in the Holders' Auditor Conclusion within thirty (30)
Business Days of the date the requesting Holders deliver to the Buyer
such accounting firm's written report, and notwithstanding anything to
the contrary, in such case, the fees charged by such accounting firm
shall be paid by the Buyer. The additional CVR Payout shall bear
interest at the Default Interest Rate, as calculated by the Buyer, from
the Issuance Date until such CVR Payout is either delivered to the
Trustee or paid directly to the Holders entitled to such CVR Payout.
(2) Buyer Auditor Conclusion.
a) If the Buyer disagrees with the Holders Auditor Conclusion,
then the requesting Holders shall permit an independent certified
public accounting firm of nationally recognized standing
B-1-24
selected by the Buyer and reasonably acceptable to the requesting
Holders, at the Buyer's expense, to verify the accuracy of the CVR
Report (the "Buyer Auditor Conclusion") and the parties shall attempt
in good faith to resolve the dispute promptly by negotiations between
the Buyer and the Holders' Representative through telephonic
discussions or meetings at mutually acceptable times and places, and
thereafter as often as they reasonably deem necessary, to exchange
relevant information and to attempt to resolve the dispute. If a
negotiator intends to be accompanied at a meeting by an attorney, the
other negotiator shall be given at least three (3) Business Days'
notice of such intention and may also be accompanied by an attorney.
b) If the requesting Holders agree with the Buyer Auditor
Conclusion, the Buyer shall issue the additional CVR Payout, if any,
set forth in the Buyer Auditor Conclusion within thirty (30) Business
Days of the date the Buyer delivers to the requesting Holders such
accounting firm's written report, and notwithstanding anything to the
contrary, in such case, the fees charged by such accounting firm
shall be paid by Buyer. The additional CVR Payout shall bear interest
at the Default Interest Rate, as such amount is calculated by the
Buyer, from the Issuance Date until such CVR Payout is either
delivered to the Trustee or paid directly to the Holders entitled to
such CVR Payout.
c) If the dispute shall not be resolved pursuant to this Section
8(a)(ii)(2), the parties shall attempt to resolve such dispute in
accordance with the provisions of Section 8.6(b) below.
(iii) Unless the Holders of at least a majority in interest of the
outstanding Securities have objected within thirty (30) Business Days
after the Issuance Date pursuant to Section 8.6(a), upon the expiration
of thirty (30) Business Days following the Issuance Date, the
calculation of the CVR Payout issuable as set forth in the CVR Report
shall be binding and conclusive upon the Holders and the Buyer, and the
Buyer and its Affiliates shall be released from any liability or
accountability with respect to the CVR Payout and this CVR Agreement.
(iv) Each person seeking to receive information from the Buyer in
connection with an audit shall enter into, and shall cause its
accounting firm to enter into, a reasonable and mutually satisfactory
confidentiality agreement with the Buyer obligating such party to retain
all such financial information disclosed to such party in confidence
pursuant to such confidentiality agreement.
(v) All negotiations pursuant to this Section 8.6(a) are confidential
and shall be treated as compromise and settlement negotiations for
purposes of the Federal Rules of Evidence and state rules of evidence.
(b) Dispute Resolution.
(i) Non-Binding Mediation. Except as otherwise expressly set forth
in this CVR Agreement, in the event that the dispute concerning the CVR
Payout has not been resolved under the procedures set forth in Section
8.6(a) above within twenty (20) Business Days of delivery of the Buyer
Auditor Conclusion to the requesting Holders, then the Holders'
Representative and/or the Buyer shall initiate non-binding mediation of
the dispute with the assistance of a mutually agreed upon neutral
mediator from JAMS with expertise in finance and accounting, with costs
to be borne as provided in Section 8.6(b)(iii) below. Mediation shall
take place in the state of Delaware. Mediation may be scheduled to begin
any time, but with at least ten (10) Business Days' notice to all
parties. Once the mediation is initiated, the parties (i) shall
participate in the mediation in good faith and shall devote reasonable
time and energy to the mediation so as to promptly resolve the dispute
or conclude that they cannot resolve the dispute and (ii) shall not
pursue other remedies while such mediation is proceeding. If the dispute
has not been resolved by such mediation within sixty (60) days following
initiation of mediation, either party may pursue all available remedies
in the Delaware Court of Chancery. In the event that the Delaware Court
of Chancery does not accept jurisdiction over any action concerning this
CVR Agreement, either party may pursue all available remedies in the
United States District Court for the District of Delaware.
B-1-25
(ii) Statutes of Limitations. All applicable statutes of limitations
and defenses based upon the passage of time shall be tolled while the
negotiation and mediation procedures set forth in Section 8.6(b)(i) are
pending. The parties will take such action, if any, as may be reasonably
be required to effectuate such tolling.
(iii) Expenses of Mediation and/or Litigation. The Buyer and the
Holders shall bear their own attorneys fees and share the costs of
mediation equally, except as provided elsewhere in this CVR Agreement.
8.7 Foreign Exchange. For the purpose of computing Revenue generated in a
currency other than United States Dollars, such currency shall be converted
into United States Dollars using the then current method used by the Buyer in
preparing its accounts.
8.8 Annual TIA Certification. The Buyer will deliver to the Trustee,
within 120 days after the end of each fiscal year of the Buyer ending after the
date hereof, an Officers' Certificate (of which one such officer signing such
Certificate shall be the principal executive officer, principal financial
officer or principal accounting officer), stating whether or not to the
knowledge of the signers thereof the Buyer is in compliance with all of the
conditions and covenants of this CVR Agreement (without regard to any period of
grace or requirement of notice provided hereunder.)
ARTICLE IX
REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT
9.1 Event of Default Defined; Waiver of Default. "Event of Default" with
respect to the Securities, means each one of the following events which shall
have occurred and be continuing (whatever the reason for such Event of Default
and whether it shall be voluntary or involuntary or be effected by operation of
law or pursuant to any judgment, decree or order of any court or any order,
rule or regulation of any administrative or governmental body):
(a) default in the payment of all or any part of the amounts payable as
the CVR Payout, if any, in respect of any of the Securities as and when the
same shall become due and payable at the Issuance Date; or
(b) default in the performance, or breach, of any covenant or warranty of
the Buyer in respect of the Securities (other than a covenant or warranty in
respect of the Securities, a default in whose performance or whose breach is
elsewhere in this Section specifically dealt with), and continuance of such
default or breach for a period of forty-five (45) days after there has been
given, by registered or certified mail or overnight delivery service, to the
Buyer by the Trustee or to the Buyer and the Trustee by the Holders of at
least fifty percent (50%) of the Outstanding Securities, a written notice
specifying such default or breach and requiring it to be remedied and
stating that such notice is a "Notice of Default" hereunder; or
(c) a court having jurisdiction in the premises shall enter a decree or
order for relief in respect of the Buyer in an involuntary case under any
applicable bankruptcy, insolvency or other similar law now or hereafter in
effect, or appointing a receiver, liquidator, assignee, custodian, trustee
or sequestrator (or similar official) of the Buyer or for any substantial
part of its property or ordering the winding up or liquidation of its
affairs, and such decree or order shall remain unstayed and in effect for a
period of sixty (60) consecutive days; or
(d) the Buyer shall commence a voluntary case under any applicable
bankruptcy, insolvency or other similar law now or hereafter in effect, or
consent to the entry of an order for relief in an involuntary case under any
such law, or consent to the appointment of or taking possession by a
receiver, liquidator, assignee, custodian, trustee or sequestrator (or
similar official) of the Buyer or for any substantial part of its property,
or make any general assignment for the benefit of creditors.
If an Event of Default described above occurs and is continuing, then, and
in each and every such case, either the Trustee or the Trustee upon the written
request of Holders of not less than fifty percent (50%) of the
B-1-26
Securities then Outstanding hereunder by notice in writing to the Buyer (and to
the Trustee if given by the Holders), shall bring suit to appropriately protect
their rights to any amounts payable following the Issuance Date or Default
Issuance Date, or following the Issuance Date for any amounts then due and
payable, which due and payable amounts, if any, shall bear interest at the
Default Interest Rate until payment is made to the Trustee.
The foregoing provisions, however, are subject to the condition that if, at
any time after the Trustee shall have begun such suit, and before any judgment
or decree for the payment of the moneys due shall have been obtained or entered
as hereinafter provided, the Buyer shall pay or shall deposit with the Trustee
a sum sufficient to pay all amounts which shall have become due (with interest
upon such overdue amount at the Default Interest Rate to the date of such
payment or deposit) and such amount as shall be sufficient to cover reasonable
compensation to the Trustee, its agents, attorneys and counsel, and all other
expenses and liabilities incurred and all advances made, by the Trustee, and if
any and all Events of Default under this CVR Agreement, shall have been cured,
waived or otherwise remedied as provided herein, then and in every such case
the Holders of a majority of all the Securities then Outstanding, by written
notice to the Buyer and to the Trustee, may waive all defaults with respect to
the Securities, but no such waiver or rescission and annulment shall extend to
or shall affect any subsequent default or shall impair any right consequent
thereof.
9.2 Collection of Indebtedness by Trustee; Trustee May Prove Debt. The
Buyer covenants that in case default shall be made in the payment of all or any
part of the Securities when the same shall have become due and payable, whether
at the Issuance Date, a Default Issuance Date or otherwise, then upon demand of
the Trustee, the Buyer will pay to the Trustee for the benefit of the Holders
of the Securities the whole amount that then shall have become due and payable
on all Securities (with interest from the date due and payable to the date of
such payment upon the overdue amount at the Default Interest Rate); and in
addition thereto, such further amount as shall be sufficient to cover the costs
and expenses of collection, including reasonable compensation to the Trustee
and each predecessor Trustee, their respective agents, attorneys and counsel,
and any expenses and liabilities incurred, and all advances made, by the
Trustee and each predecessor Trustee, except as a result of its negligence or
willful misconduct.
The Trustee may in its discretion proceed to protect and enforce its rights
and the rights of the Holders by such appropriate judicial proceedings as the
Trustee shall deem most effectual to protect and enforce any such rights,
whether for the specific enforcement of any covenant or agreement in this CVR
Agreement or in aid of the exercise of any power granted herein, or to enforce
any other remedy.
In case the Buyer shall fail forthwith to pay such amounts upon such demand,
the Trustee, in its own name and as trustee of an express trust, shall be
entitled and empowered to institute any action or proceedings at law or in
equity for the collection of the sums so due and unpaid, and may prosecute any
such action or proceedings to judgment or final decree, and may enforce any
such judgment or final decree against the Buyer or other obligor upon such
Securities and collect in the manner provided by law out of the property of the
Buyer or other obligor upon such Securities, wherever situated, the moneys
adjudged or decreed to be payable.
In case there shall be pending proceedings relative to the Buyer or an other
obligor upon the Securities under Title 11 of the United States Code or any
other applicable Federal or state bankruptcy, insolvency or other similar law,
or in case a receiver, assignee or trustee in bankruptcy or reorganization,
liquidator, sequestrator or similar official shall have been appointed for or
taken possession of the Buyer or its property or such other obligor, or in case
of any other comparable judicial proceedings relative to the Buyer or other
obligor upon the Securities, or to the creditors or property of the Buyer or
such other obligor the Trustee, irrespective of whether the CVR Payout for any
Securities shall then be due and payable as herein expressed or otherwise and
irrespective of whether the Trustee shall have made any demand pursuant to the
provisions of this Section, shall be entitled and empowered, (but shall have no
obligation) by intervention in such proceedings or otherwise:
(a) to file and prove a claim or claims for the whole amount owing and
unpaid in respect of the Securities, and to file such other papers or
documents as may be necessary or advisable in order to have the
B-1-27
claims of the Trustee (including any claim for reasonable compensation to
the Trustee and each predecessor Trustee, and their respective agents,
attorneys and counsel, and for reimbursement of all expenses and liabilities
incurred, and all advances made, by the Trustee and each predecessor
Trustee, except as a result of negligence or willful misconduct) and of the
Holders allowed in any judicial proceedings relative to the Buyer or other
obligor upon the Securities, or to their respective property;
(b) unless prohibited by applicable law and regulations, to vote on
behalf of the Holders in any election of a trustee or a standby trustee in
arrangement, reorganization, liquidation or other bankruptcy or insolvency
proceedings or person performing similar functions in comparable
proceedings; and
(c) to collect and receive any moneys or other property payable or
deliverable on any such claims, and to distribute all amounts received with
respect to the claims of the Holders and of the Trustee on their behalf; and
any trustee, receiver, or liquidator, custodian or other similar official is
hereby authorized by each of the Holders to make payments to the Trustee,
and, in the event that the Trustee shall consent to the making of payments
directly to the Holders, to pay to the Trustee such amounts as shall be
sufficient to cover reasonable compensation to the Trustee, each predecessor
Trustee and their respective agents, attorneys and counsel, and all other
expenses and liabilities incurred, and all advances made, by the Trustee and
each predecessor Trustee, except as a result of its negligence or willful
misconduct, and all other amounts due to the Trustee or any predecessor
Trustee pursuant to Section 4.6. To the extent that such payment of
reasonable compensation, expenses, disbursements, advances and other amounts
out of the estate in any such proceedings shall be denied for any reason,
payment of the same shall be secured by a lien on, and shall be paid out of,
any and all distributions, dividends, moneys, securities and other property
which the Holders may be entitled to receive in such proceedings, whether in
liquidation or under any plan of reorganization or arrangement or otherwise.
Nothing herein contained shall be deemed to authorize the Trustee to
authorize or consent to or vote for or accept or adopt on behalf of any Holder
any plan of reorganization, arrangement, adjustment or composition affecting
the Securities, or the rights of any Holder thereof, or to authorize the
Trustee to vote in respect of the claim of any Holder in any such proceeding
except, as aforesaid, to vote for the election of a trustee in bankruptcy or
similar person.
All rights of action and of asserting claims under this CVR Agreement, or
under any of the Securities, may be enforced by the Trustee without the
possession of any of the Securities or the production thereof and any trial or
other proceedings instituted by the Trustee shall be brought in its own name as
trustee of an express trust, and any recovery of judgment, subject to the
payment of the expenses, disbursements and compensation of the Trustee, each
predecessor Trustee and their respective agents and attorneys, shall be for the
ratable benefit of the Holders.
In any proceedings brought by the Trustee (and also any proceedings
involving the interpretation of any provision of this CVR Agreement to which
the Trustee shall be a party) the Trustee shall be held to represent all the
Holders, and it shall not be necessary to make any Holders of such Securities
parties to any such proceedings.
9.3 Application of Proceeds. Any shares or monies collected by the Trustee
pursuant to this Article in respect of any Securities shall be applied in the
following order at the date or dates fixed by the Trustee upon presentation of
the several Securities in respect of which monies have been collected and
stamping (or otherwise noting) thereon the payment in exchange for the
presented Securities if only partially paid or upon surrender thereof if fully
paid:
FIRST: To the payment of costs and expenses in respect of which monies
have been collected, including reasonable compensation to the Trustee and
each predecessor Trustee and their respective agents and attorneys and of
all expenses and liabilities incurred, and all advances made, by the Trustee
and each predecessor Trustee, except as a result of its negligence or
willful misconduct, and all other amounts due to the Trustee or any
predecessor Trustee pursuant to Section 4.6;
SECOND: To the payment of the whole amount then owing and unpaid upon all
the Securities, with interest (to the extent applicable) at the Default
Interest Rate on all such amounts, and in case such shares or
B-1-28
monies shall be insufficient to pay in full the whole amount so due and
unpaid upon the Securities, then to the payment of such amounts without
preference or priority of any security over any other Security, ratably to
the aggregate of such amounts due and payable; and
THIRD: To the payment of the remainder, if any, to the Buyer or any other
Person lawfully entitled thereto.
9.4 Suits for Enforcement. Subject to Section 1.11, in case an Event of
Default has occurred and has not been waived and is continuing, the Trustee may
in its discretion proceed to protect and enforce the rights vested in it by
this CVR Agreement by such appropriate judicial proceedings as the Trustee
shall deem most effectual to protect and enforce any of such rights, either at
law or in equity or in bankruptcy or otherwise, whether for the specific
enforcement of any covenant or agreement contained in this CVR Agreement or in
aid of the exercise of any power granted in this CVR Agreement or to enforce
any other legal or equitable right vested in the Trustee by this CVR Agreement
or by law.
9.5 Restoration of Rights on Abandonment of Proceedings. In case the
Trustee or any Holder shall have proceeded to enforce any right under this CVR
Agreement and such proceedings shall have been discontinued or abandoned for
any reason, or shall have been determined adversely to the Trustee or to such
Holder, then and in every such case the Buyer and the Trustee and the Holders
shall be restored respectively to their former positions and rights hereunder,
and all rights, remedies and powers of the Buyer, the Trustee and the Holders
shall continue as though no such proceedings had been taken.
9.6 Limitations on Suits by Holders. No Holder of any Security shall have
any right by virtue or by availing of any provision of this CVR Agreement to
institute any action or proceeding at law or in equity or in bankruptcy or
otherwise upon or under or with respect to this CVR Agreement, or for the
appointment of a trustee, receiver, liquidator, custodian or other similar
official or for any other remedy hereunder, unless such Holder previously shall
have given to the Trustee written notice of default and of the continuance
thereof, as hereinbefore provided, and unless also the Holders of not less than
fifty percent (50%) of the Securities then Outstanding shall have made written
request upon the Trustee to institute such action or proceedings in its own
name as trustee hereunder and shall have offered to the Trustee such reasonable
indemnity as it may require against the costs, expenses and liabilities to be
incurred therein or thereby and the Trustee for sixty days after its receipt of
such notice, request and offer of indemnity shall have failed to institute any
such action or proceeding and no direction inconsistent with such written
request shall have been given to the Trustee pursuant to Section 9.9; it being
understood and intended, and being expressly covenanted by the taker and Holder
of every Security with every other taker and Holder and the Trustee, that no
one or more Holders of Securities shall have any right in any manner whatever
by virtue or by availing of any provision of this CVR Agreement to effect,
disturb or prejudice the rights of any other such Holder of Securities, or to
obtain or seek to obtain priority over or preference to any other such Holder
or to enforce any right under this CVR Agreement, except in the manner herein
provided and for the equal, ratable and common benefit of all Holders of
Securities. For the protection and enforcement of the provisions of this
Section, each and every Holder and the Trustee shall be entitled to such relief
as can be given either at law or in equity.
9.7 Unconditional Right of Holders. Subject to Section 1.11 and Section
8.6 and notwithstanding any other provision in this CVR Agreement and any
provision of any Security, the right of any Holder of any Security to receive
payment of the amounts payable in respect of such Security on or after the
respective due dates expressed in such Security, or to institute suit for the
enforcement of any such payment on or after such respective dates, shall not be
impaired or affected without the consent of such Holder.
9.8 Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default.
(a) Except as provided in Section 8.6, no right or remedy herein conferred
upon or reserved to the Trustee or to the Holders is intended to be exclusive
of any other right or remedy, and every right and remedy shall, to the extent
permitted by law, be cumulative and in addition to every other right and remedy
given hereunder or
B-1-29
now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other appropriate right or remedy.
(b) No delay or omission of the Trustee or of any Holder to exercise any
right or power accruing upon any Event of Default occurring and continuing as
aforesaid shall impair any such right or power or shall be construed to be a
waiver of any such Event of Default or an acquiescence therein; and, subject to
Section 8.6, every power and remedy given by this CVR Agreement or by law to
the Trustee or to the Holders may be exercised from time to time, and as often
as shall be deemed expedient, by the Trustee or by the Holders.
9.9 Control by Holders.
(a) The Holders of a majority of the Securities at the time Outstanding
shall have the right to direct the time, method, and place of conducting any
proceeding for any remedy available to the Trustee, or exercising any trust or
power conferred on the Trustee with respect to the Securities by this CVR
Agreement; provided that such direction shall not be otherwise than in
accordance with law and the provisions of this CVR Agreement; and provided
further that (subject to the provisions of Section 4.1) the Trustee shall have
the right to decline to follow any such direction if the Trustee, being advised
by counsel, shall determine that the action or proceeding so directed may not
lawfully be taken or if the Trustee in good faith by its board of directors,
the executive committee, or a trust committee of directors or responsible
officers of the Trustee shall determine that the action or proceedings so
directed would involve the Trustee in personal liability or if the Trustee in
good faith shall so determine that the actions or forebearances specified in or
pursuant to such direction would be unduly prejudicial to the interests of
Holders of the Securities not joining in the giving of said direction, it being
understood that (subject to Section 4.1) the Trustee shall have no duty to
ascertain whether or not such actions or forebearances are unduly prejudicial
to such Holders.
(b) Nothing in this CVR Agreement shall impair the right of the Trustee in
its discretion to take any action deemed proper by the Trustee and which is not
inconsistent with such direction or directions by Holders.
9.10 Waiver of Past Defaults.
(a) In the case of a default or an Event of Default specified in clause (b),
(c) or (d) of Section 9.1, the Holders of a majority of all the Securities then
Outstanding may waive any such default or Event of Default, and its
consequences except a default in respect of a covenant or provisions hereof
which cannot be modified or amended without the consent of the Holder of each
Security affected. In the case of any such waiver, the Buyer, the Trustee and
the Holders of the Securities shall be restored to their former positions and
rights hereunder, respectively; but no such waiver shall extend to any
subsequent or other default or impair any right consequent thereon.
(b) Upon any such waiver, such default shall cease to exist and be deemed to
have been cured and not to have occurred, and any Event of Default arising
therefrom shall be deemed to have been cured, and not to have occurred for
every purpose of this CVR Agreement; but no such waiver shall extend to any
subsequent or other default or Event of Default or impair any right consequent
thereon.
9.11 Trustee to Give Notice of Default, But May Withhold in Certain
Circumstances. The Trustee shall transmit to the Holders, as the names and
addresses of such Holders appear on the Security Register, notice by mail of
all defaults which have occurred and are actually known to the Trustee, such
notice to be transmitted within ninety days after the occurrence or knowledge
thereof, unless such defaults shall have been cured before the giving of such
notice (the term "default" or "Defaults" for the purposes of this Section being
hereby defined to mean any event or condition which is, or with notice or lapse
of time or both would become, an Event of Default); provided that, except in
the case of default in the payment of the CVR Payout on the Securities, the
Trustee shall be protected in withholding such notice if and so long as the
board of directors, the executive committee, or a trust committee of directors
or trustees and/or Responsible Officers of the Trustee in good faith determines
that the withholding of such notice is in the interests of the Holders.
B-1-30
9.12 Right of Court to Require Filing of Undertaking to Pay Costs. All
parties to this CVR Agreement agree, and each Holder of any Security by his
acceptance thereof shall be deemed to have agreed, that any court may in its
discretion require, in any suit for the enforcement of any right or remedy
under this CVR Agreement or in any suit against the Trustee for any action
taken, suffered or omitted by it as Trustee, the filing by any party litigant
in such suit of an undertaking to pay the costs of such suit, and that such
court may in its discretion assess reasonable costs, including attorneys' fees,
against any party litigant in such suit, having due regard to the merits and
good faith of the claims or defenses made by such party litigant; but the
provisions of this Section shall not apply to any suit instituted by the
Trustee, to any suit instituted by any Holder or group of Holders holding in
the aggregate more than ten percent (10%) of the Securities Outstanding or to
any suit instituted by any Holder for the enforcement of the payment of any
Security on or after the due date expressed in such Security.
ARTICLE X
CONSOLIDATION, MERGER, SALE OR CONVEYANCE
10.1 Consolidation, Merger, etc.
(a) The Buyer and its Affiliates shall be entitled in their sole discretion
to consolidate or merge with any Person or sell, lease, exchange, transfer,
license, or otherwise dispose of any or all of their assets (whether tangible
or intangible), including, without limitation, assets relating to the LEP
Digital Products. In the event of any such merger, consolidation, sale, lease,
exchange, transfer, license or other disposition pursuant to this Article, the
Securities shall remain subject to the benefits of the Guaranty unless
otherwise agreed to in writing by the Holders of a majority in interest of the
Securities then outstanding.
(b) In the event of a merger or consolidation in which the Buyer is not the
surviving entity or a sale, conveyance or transfer of all or substantially all
of the properties and assets of Buyer, and subject to the sole discretion of
the Buyer:
(i) the surviving Person or the purchaser, as applicable, shall expressly
assume, by an agreement supplemental hereto, executed and delivered to the
Trustee, in form satisfactory to the Trustee, the due and punctual payment
of the principal of and interest, if any, on all the Securities and the
performance or observance of every covenant of this CVR Agreement on the
part of the Buyer to be performed or observed, by supplemental agreement
satisfactory in form to the Trustee, executed and delivered to the Trustee,
by the Person (if other than the Buyer) formed by such consolidation or into
which the Buyer shall have been merged or by the Person which shall have
acquired the Buyer's assets; or
(ii) the Buyer shall remain subject to the duties and obligations
hereunder and shall remain the issuer of the Securities.
10.2 Successor Person Substituted.
(a) In case of any consolidation, merger, sale, transfer or conveyance
pursuant to Section 10.1(b)(i), and following the assumption by the successor
Person, such successor Person shall succeed to and be substituted for the Buyer
with the same effect as if it had been named herein. Such successor Person may
cause to be signed, and may issue either in its own name or in the name of the
Buyer prior to such succession any or all of the Securities issuable hereunder
which theretofore shall not have been signed by the Buyer and delivered to the
Trustee; and, upon the order of such successor Person instead of the Buyer and
subject to all the terms, conditions and limitations in this CVR Agreement
prescribed, the Trustee shall authenticate and shall deliver any Securities
which previously shall have been signed and delivered to the Trustee for
authentication, and any Securities which such successor Person thereafter shall
cause to be signed and delivered to the Trustee for that purpose. All of the
Securities so issued shall in all respects have the same legal rank and benefit
under this CVR Agreement as the Securities theretofore or thereafter issued in
accordance with the terms of this CVR Agreement as though all of such
Securities had been issued at the date of the execution hereof.
(b) In case of any such consolidation, merger, sale, transfer or conveyance,
such changes in phraseology and form (but not in substance) may be made in the
Securities thereafter to be issued as may be appropriate.
B-1-31
(c) In the event of any consolidation, merger, sale, transfer or conveyance
(other than a conveyance by way of lease) pursuant to the provisions of Section
10.1(b)(i), the Buyer or any Person which shall theretofore have become such in
the manner described in this Article shall be discharged from all obligations
and covenants under this CVR Agreement and the Securities and may be liquidated
and dissolved.
10.3 Opinion of Counsel to Trustee. In the event of any consolidation,
merger, sale, transfer or conveyance pursuant to Section 10.1, the Trustee,
subject to the provisions of Sections 4.1 and 4.2, shall receive an Officer's
Certificate and an Opinion of Counsel, as conclusive evidence that any such
consolidation, merger, sale, conveyance or transfer, and any related assumption
or liquidation complies with the applicable provisions of this CVR Agreement,
and, if a supplemental agreement is required in connection with such
transaction, such supplemental agreement complies with this Article and that
there has been compliance with all conditions precedent herein provided for
relating to such transaction.
10.4 Successors. All covenants and provisions of this CVR Agreement by or
for the benefit of the Buyer, the Trustee, the Depositary or the Holders shall
bind and inure to the benefit of their respective successors, assigns, heirs,
and personal representatives.
ARTICLE XI
SATISFACTION AND DISCHARGE
11.1 Satisfaction and Discharge of Agreement. This Agreement shall upon
Buyer's request cease to be of further effect with respect to any Securities,
and the Trustee, at the expense of Buyer, shall execute proper instruments
acknowledging satisfaction and discharge of this CVR Agreement, when:
(a) all Securities theretofore authenticated and delivered (other than
Securities which have been destroyed, lost or stolen and which have been
replaced or paid as provided in Section 3.3) have been delivered to the
Trustee for cancellation; and
(b) the Buyer has paid or caused to be paid all sums payable hereunder by
the Buyer; and
(c) the Buyer has delivered to the Trustee an Officers' Certificate and
an Opinion of Counsel, each stating that there has been compliance with all
conditions precedent herein provided for relating to the satisfaction and
discharge of this CVR Agreement.
Notwithstanding the satisfaction and discharge of this CVR Agreement, the
obligations of the Buyer to the Trustee under Section 4.7, the obligations of
the Buyer to any Depositary or Paying Agent under Section 5.12 and, if money
shall have been deposited with the Trustee pursuant to Section 8.3, the
obligations of the Trustee under Section 11.2 and Section 8.3(d) shall survive.
11.2 Application of Trust Money. Subject to the provisions of the last
paragraph of Section 8.3, all money deposited with the Trustee pursuant to
Section 3.1(b) shall be held in trust and applied by it, in accordance with the
provisions of the Securities and this CVR Agreement, to the payment, either
directly or through any Paying Agent (including the Company acting as its own
Paying Agent) as the Trustee may determine, to the Persons entitled thereto, of
the CVR Payout for whose payment such money has been deposited with the Trustee.
11.3 Repayment to the Buyer. Upon termination pursuant to Section 11.1 of
the trust established pursuant to this CVR Agreement, the Trustee and Paying
Agent shall promptly pay to the Buyer any excess money or U.S. Government
Obligations.
B-1-32
IN WITNESS WHEREOF, the parties hereto have caused this CVR Agreement to be
duly executed, all as of the day and year first above written.
HEWLETT-PACKARD ERSTE
VERMOGENSVERWALTUNGS- UND
BETEILIGUNGSGESELLSCHAFT mbH
as Buyer
By:
__________________________________
Name:
________________________________
Title:
_________________________________
J.P. MORGAN TRUST COMPANY, NATIONAL
ASSOCIATION
as Trustee
By:
__________________________________
Name:
________________________________
Title:
_________________________________
J.P. MORGAN TRUST COMPANY, NATIONAL
ASSOCIATION
as Depositary
By:
__________________________________
Name:
________________________________
Title:
_________________________________
[SIGNATURE PAGE TO CONTINGENT VALUE RIGHTS AGREEMENT]
B-1-33
EXHIBIT A
FORM OF GLOBAL SECURITY
-----------------
No. ____ Certificate for __________ Contingent Value Rights
THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE CVR AGREEMENT
HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A
NOMINEE OF THE DEPOSITARY, WHICH MAY BE TREATED BY THE BUYER, THE TRUSTEE AND
ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES.
UNLESS AND UNTIL THIS SECURITY IS EXCHANGED IN WHOLE OR IN PART FOR
REGISTERED SECURITIES IN DEFINITIVE REGISTERED FORM IN THE LIMITED
CIRCUMSTANCES REFERRED TO IN THE CVR AGREEMENT, THIS GLOBAL SECURITY MAY NOT BE
TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY
OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY
OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.
This certifies that __________, or registered assigns (the "Holder"), is the
registered holder of the number of Contingent Value Rights ("Securities") set
forth above. Each Security entitles the Holder, subject to the provisions
contained herein and in the CVR Agreement referred to on the reverse hereof, to
payments from Hewlett-Packard Erste Vermogensverwaltungs- und
Beteiligungsgesellschaft mbH, a corporation organized under the laws of Germany
(the "Buyer"), in an amount and in the form determined pursuant to the
provisions set forth on the reverse hereof and as more fully described in the
CVR Agreement referred to on the reverse hereof. Such payment shall be made on
the Issuance Date or the Default Issuance Date, each as defined in the CVR
Agreement referred to on the reverse hereof.
Payment of any amounts pursuant to this Security shall be made only to the
registered Holder (as defined in the CVR Agreement) of this Security. Such
payment shall be made in the Borough of Manhattan, The City of New York, or at
any other office or agency maintained by the Buyer for such purpose, in such
coin or currency of the United States of America as at the time is legal tender
for the payment of public and private debts; provided, however, the Buyer may
pay such amounts by wire transfer or check payable in such money. J.P. Morgan
Trust Company, National Association, has been initially appointed as Paying
Agent at its office or agency in the Borough of Manhattan, The City of New York.
Reference is hereby made to the further provisions of this Security set
forth on the reverse hereof, which further provisions shall for all purposes
have the same effect as if set forth at this place. Unless the certificate of
authentication hereon has been duly executed by the Trustee referred to on the
reverse hereof by manual signature, this Security shall not be entitled to any
benefit under the CVR Agreement, or be valid or obligatory for any purpose.
B-1-34
IN WITNESS WHEREOF, the Buyer has caused this instrument to be duly executed.
Dated: _________________ HEWLETT-PACKARD ERSTE
VERMOGENSVERWALTUNGS- UND
BETEILIGUNGSGESELLSCHAFT mbH
By:
__________________________________
Name:
________________________________
Title:
_________________________________
Attest:
_____________________________________
Authorized Signature
B-1-35
[FORM OF REVERSE OF SECURITY]
This Security is issued under and in accordance with the Contingent Value
Rights Agreement, dated as of , 2002 (the "CVR Agreement"), between the
Buyer and J.P. Morgan Trust Company, National Association, a national banking
association, as trustee (the "Trustee," which term includes any successor
Trustee under the CVR Agreement), and J.P. Morgan Trust Company, National
Association, as Depositary and Paying Agent (in such context, the "Depositary,"
which term includes any successor Depositary and Paying Agent under the CVR
Agreement), and is subject to the terms and provisions contained in the CVR
Agreement, to all of which terms and provisions the Holder of this Security
consents by acceptance hereof. The CVR Agreement is hereby incorporated herein
by reference and made a part hereof. Reference is hereby made to the CVR
Agreement for a full statement of the respective rights, limitations of rights,
duties, obligations and immunities thereunder of the Buyer, the Trustee, the
Depositary and the holders of the Securities. All capitalized terms used in
this Security without definition shall have the respective meanings ascribed to
them in the CVR Agreement. Copies of the CVR Agreement can be obtained by
contacting the Trustee.
On [ ], 2005, the Buyer shall pay to the Trustee for transfer to the
Holder hereof (or if such day is not a Business Day, without accruing any
interest, on the next succeeding Business Day), (as the same may be extended,
the "Issuance Date"), for each Security represented hereby, the CVR Payout, if
any.
The "CVR Payout" means, for each Security outstanding immediately prior to
the Issuance Date, that amount equal to (i) if the Revenue during the CVR
Measuring Period is equal to or greater than one billion six hundred million
United States Dollars (U.S. $1,600,000,000) (the "Upper Limit"), $4.50; (ii) if
the Revenue during the CVR Measuring Period is less than the Upper Limit but
greater than one billion United States Dollars (U.S. $1,000,000,000) (the
"Lower Limit"), the dollar amount equal to the product of (x) $4.50 multiplied
by the quotient obtained by dividing (y) the number by which Revenue exceeds
the Lower Limit by (z) $600,000,000; and (iii) if the Revenue during the CVR
Measuring Period is less than or equal to the Lower Limit, $0.
"HP" means Hewlett-Packard Company, a corporation organized under the laws
of the State of Delaware.
"Revenue" means the actual net revenue from the sale or lease of LEP Digital
Press Products and Consumables by the Buyer and its Affiliates during the CVR
Measuring Period plus the Residual Calculation. Actual net revenue is to be
based on U.S. GAAP, as applied by HP consistent with its financial SEC
reporting practices as of the beginning of the CVR Measuring Period.
"CVR Measuring Period" means the three-year period commencing on the first
day of the first calendar month after the Closing Time and ending on the last
day prior to the third anniversary of such day.
"LEP Digital Press Products" means digital press products, including
accessories and options (e.g. finishing equipment, sheet feeders) that utilize
Company Core Technology.
The CVR Agreement does not prohibit the Buyer or its Affiliates from
acquiring Securities.
The CVR Payout, if any, and interest thereon, if any, shall be payable by
the Buyer in such coin or currency of the United States of America as at the
time is legal tender for the payment of public and private debts; provided,
however, the Buyer may pay such amounts by its check or wire transfer payable
in such money. J.P. Morgan Trust Company, National Association has been
initially appointed as Paying Agent at its office or agency in the Borough of
Manhattan, The City of New York.
If an Event of Default occurs and is continuing, either the Trustee may or
if the Holders holding an aggregate of at least fifty percent of the
Outstanding Securities, by notice to the Buyer and to the Trustee shall bring
suit to recover all amounts then due and payable, with interest at the Default
Interest Rate from the Default Issuance Date through the date payment is made
or duly provided for.
The CVR Agreement permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the
Buyer and the rights of the holders of Securities under the CVR Agreement at
any time by the Buyer and the Trustee with the consent of the holders of a
majority of the Securities at the time outstanding.
B-1-36
No reference herein to the CVR Agreement and no provision of this Security
or of the CVR Agreement shall alter or impair the obligation of the Buyer,
which is absolute and unconditional, to pay any amounts determined pursuant to
the terms hereof and of the Agreement at the times, place and amount, and in
the manner, herein prescribed. Each of the Holders of a Security or Securities,
by acceptance thereof, agrees that: (i) the Buyer and its Affiliates shall be
entitled in their sole discretion to establish and modify from time to time all
aspects of Buyer's program for the development, manufacturing, marketing and
sale of any products, including, without limitation, the LEP Digital Press
Products and Consumables, including product design, functionality and features,
development processes, roadmaps and timelines, evaluation, testing and release
readiness, procurement or materials and components, manufacturing, marketing
and sales and staffing and funding for any of the foregoing (any or all of
which may be performed by the Buyer or its Affiliates using its internal
resources or by third parties pursuant to outsourcing or other contractual
relationships with the Buyer or its Affiliates); and (ii) the Buyer and its
Affiliates have no obligation to initiate or continue research, development,
commercialization, marketing or sales activities with respect to any products,
including, without limitation, the LEP Digital Press Products and Consumables
and, in the Buyer's sole and subjective discretion, the Buyer and its
Affiliates may abandon efforts to research, develop, commercialize, market or
sell any or all products, including, without limitation, the LEP Digital Press
Products and Consumables. No joint venture, partnership or other fiduciary
relationship between the Buyer and the holders of the Security or Securities is
created by this CVR Agreement or by the Security or Securities.
The CVR Agreement provides that the Depositary shall receive an Officers'
Certificate, on or before the Issuance Date, certifying the Revenue for the CVR
Measuring Period and setting forth the calculation of the CVR Payout, if any,
and amount of the consideration per such Security payable on the Issuance Date.
As provided in the CVR Agreement and subject to certain limitations therein
set forth, the Securities are non-transferable. A Permitted Transfer of the
Securities represented by this Security is registrable on the Security
Register, upon surrender of this Security for registration of transfer at the
office or agency of the Buyer maintained for such purpose in the Borough of
Manhattan, The City of New York, duly endorsed by, or accompanied by a written
instrument of transfer in form satisfactory to the Buyer and the Security
Registrar, duly executed by the Holder hereof or his attorney duly authorized
in writing, and thereupon one or more new Securities for the same amount of
Securities, will be issued to the designated transferee or transferees. The
Buyer hereby initially designates the office of the Trustee at c/o JPMorgan
Chase Bank, 55 Water Street, 234 North Building, New York, N.Y. 10041, as the
office for registration of transfer of this Security.
As provided in the CVR Agreement and subject to certain limitations therein
set forth, this Security is exchangeable for one or more Securities
representing the same number of Securities as represented by this Security as
requested by the Holder surrendering the same.
No service charge will be made for any registration of transfer or exchange
of Securities, but the Buyer may require payment of a sum sufficient to cover
all documentary, stamp or similar issue or transfer taxes or other governmental
charges payable in connection with any registration of transfer or exchange.
Prior to the time of due presentment of this Security for registration of
transfer, the Buyer, the Trustee and any agent of the Buyer or the Trustee may
treat the Person in whose name this Security is registered as the owner hereof
for all purposes, and neither the Buyer, the Trustee nor any agent shall be
affected by notice to the contrary.
Neither the Buyer nor the Trustee has any duty or obligation to the holder
of this Security, except as expressly set forth herein or in the CVR Agreement.
B-1-37
TRUSTEE'S CERTIFICATE OF AUTHENTICATION
This is one of the Securities referred to in the within-mentioned CVR
Agreement.
J.P. Morgan Trust Company, National
Association, as Trustee
Dated: _______________________________
By:
__________________________________
Authorized Signatory
B-1-38
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face of
this Security, shall be construed as though they were written out in full
according to the applicable laws or regulations:
TEN COM -- as tenants in common UNIF GIFT MIN ACT -- __________________
----------------------------------------------------------------------------------------------
TEN ENT -- as tenants by the
entireties (Cust)
----------------------------------------------------------------------------------------------
JT TEN -- as joint tenants with right Custodian ___________________ under
of survivorship and not as tenants in (Minor)
common Uniform Gifts to Minors Act
_______________
(State)
Additional abbreviations may also be used though not in the above list.
FORM OF ASSIGNMENT
For value received ______________________________________________ hereby
sell(s), assign(s) and transfer(s) unto
________________________________________ (Please insert social security or
other identifying number of assignee) the within Security, and hereby
irrevocably constitutes and appoints ______________________ as attorney to
transfer the said Security on the books of the Company, with full power of
substitution in the premises.
Dated:
_____________________________________
_____________________________________
Signature(s)
Signature(s) must be guaranteed by
and Eligible Guarantor Institution
with membership in an approved
signature guarantee program pursuant
to Rule 17Ad-15 under the Securities
Exchange Act of 1934.
B-1-39
EXHIBIT B-1
FORM OF BENEFICIAL OWNER LIST
B-1-40
EXHIBIT B-2
FORM OF NOTICE
B-1-41
EXHIBIT C
FORM OF TRANSFER INSTRUMENT
B-1-42
ANNEX B-2
FORM OF CORPORATE GUARANTY
BY
HEWLETT-PACKARD COMPANY
HEWLETT-PACKARD COMPANY
CORPORATE GUARANTY
(Limited Amount)
-----------------
This Corporate Guaranty (this "Guaranty") is made this day of
2002 by Hewlett-Packard Company, a Delaware corporation ("Guarantor"), for the
benefit of each Holder (as such term is defined in the CVR Agreement (as
defined below)) of Contingent Value Rights (as defined below) and
Hewlett-Packard Erste Vermogensverwaltungs- und Beteiligungsgesellschaft mbH, a
business entity organized under the laws of Germany ("Obligor").
WHEREAS, Obligor is an indirect, wholly-owned subsidiary of Guarantor and
Guarantor has an interest in the financial condition of Obligor and expects to
derive advantages from the financial accommodations described herein;
WHEREAS, pursuant to an exchange offer made by Obligor pursuant to the terms
of the Offer Agreement (the "Offer Agreement") dated as of September 6, 2001,
by and between Guarantor and Indigo N.V., a corporation organized under the
laws of The Netherlands, Obligor is issuing Contingent Value Rights (as defined
in the Offer Agreement) to each Holder;
WHEREAS, Obligor may be required to pay certain amounts to the Holders based
on the terms and conditions contained in the Offer Agreement and in the CVR
Agreement dated as of , 2002, entered into by and between Obligor
and J.P. Morgan Trust Company, National Association, as Trustee, and
J.P. Morgan Trust Company, National Association, as Depositary and Paying Agent
(the "CVR Agreement").
WHEREAS, it is a condition of the issuance of the Contingent Value Rights by
Obligor that the Holders receive the benefits of this Guaranty.
NOW, THEREFORE, for valuable consideration, the receipt whereof by Guarantor
is hereby acknowledged, and to induce the Holders to consummate the
transactions contemplated by the Offer Agreement and to induce Obligor to issue
the Contingent Value Rights, Guarantor hereby agrees as follows:
1. Guaranty.
(a) Subject to Section 4 below, Guarantor hereby unconditionally and
irrevocably guarantees to the Holders (i) the due and punctual payment in
immediately available funds of any and all sums of money that may become due
pursuant to the Contingent Value Rights and the CVR Agreement, and (ii) the
due and punctual performance of all covenants, agreements, obligations and
liabilities of Obligor under or pursuant to the Contingent Value Rights and
the CVR Agreement (all the monetary and other obligations referred to in the
preceding clauses (i) and (ii), together with interest and any and all legal
and other costs and expenses paid or incurred by the Holders or the Trustee
in connection with the collection thereof (excluding any and all legal and
other costs and expenses that the CVR Agreement provides shall be paid by
the Holders or the Trustee), being collectively called the "Obligations").
Guarantor shall pay in full or perform, as applicable, any such Obligation
promptly on demand (in the manner set forth in Section 12 hereof) following
the failure of Obligor so to pay or perform, as applicable, such Obligation
pursuant to the terms of the Contingent Value Rights and the CVR Agreement.
(b) To the fullest extent permitted by applicable law, the obligations of
Guarantor hereunder shall not be discharged, impaired or affected by (i) the
failure of any Holder or any other party to assert any claim or demand or to
enforce or exercise any right or remedy against the Obligor or any other
party under the provisions of the Contingent Value Rights and the CVR
Agreement, or (ii) by any other act or omission that may or might in any
manner or to any extent otherwise operate as a discharge of the Obligor as a
matter of law or equity.
B-2-1
(c) This Guaranty is absolute, unconditional and continuing and
constitutes an independent guaranty of payment when due and not of
collection, and is in no way conditioned on or contingent upon any attempt
to enforce in whole or in part any of Obligor's Obligations to the Holders,
the existence or continuance of Obligor as a legal entity, the consolidation
or merger of Obligor with or into any other entity, the sale, lease or
disposition by Obligor of all or substantially all of its assets to any
other entity, the bankruptcy or insolvency of Obligor, the admission by
Obligor of its inability to pay its debts as they mature, or the making by
Obligor of a general assignment for the benefit of, or entering into a
composition or arrangement with, creditors.
(d) Each failure by Obligor to pay or perform Obligations to the Holders
that are subject to this Guaranty as and when they are due shall give rise
to a separate cause of action, and separate suits may be brought hereunder
as each cause of action arises.
(e) Guarantor further guarantees that all payments made by Obligor to the
Holders on the Obligations will be, when made, final and, if any such
payment is recovered from, or repaid by, the Holders in whole or in part in
any bankruptcy, insolvency or similar proceeding instituted by or against
Obligor, this Guaranty shall continue to be fully applicable to such
Obligation to the same extent as though the payment so recovered or repaid
had never been originally made on such Obligation.
2. Unsecured Obligation. This Guaranty is an unsecured obligation of
Guarantor and shall rank pari passu with all other unsecured obligations of
Guarantor.
3. Consent to Alteration of Terms of CVR Agreement. Subject to Section 4
below, the Guarantor hereby covenants that from time to time, without notice to
or consent of the Guarantor, the performance or observance by Obligor of any
obligation under the Contingent Value Rights and the CVR Agreement may be: (i)
waived; and (ii) payment of any Obligation hereby guaranteed may be extended in
accordance with any agreement between Obligor and Holders, all without
affecting the liability of the Guarantor hereunder.
4. Maximum Liability of Guarantor. Notwithstanding any provision of this
Guaranty to the contrary, the liability of Guarantor hereunder shall not exceed
the CVR Payout, as such term is defined in the CVR Agreement, plus interest
incurred thereon pursuant to the Contingent Value Rights and the CVR Agreement
and the costs and expenses mentioned in Section 1. Notwithstanding any
provision of this Guaranty to the contrary, nothing herein shall be deemed to
expand the obligations and covenants of Obligor under or pursuant to the
Contingent Value Rights and the CVR Agreement.
5. Subrogation. No payment by Guarantor pursuant to any provision hereof
shall entitle Guarantor, by subrogation to the rights of the Holders or
otherwise to any payment by Obligor or out of the property of Obligor, except
after payment in full of all Obligations which may be or become payable to the
Holders at any time or from time to time under the Contingent Value Rights and
the CVR Agreement.
6. Continuing Guaranty. This Guaranty shall be a continuing guaranty. Any
co-guarantor or co-guarantors, or any other party liable upon or in respect of
any Obligation hereby guaranteed may be released without affecting the
liability of Guarantor. No failure or delay on the part of the Holders in
exercising any right, power or privilege hereunder and no course of dealing
between Guarantor and the Holders shall operate as a waiver thereof; nor shall
any single or partial exercise of any right, power or privilege hereunder
preclude any other or further exercise thereof or the exercise of any other
right, power or privilege. The rights, powers and remedies herein expressly
provided are cumulative and not exclusive of any rights, powers or remedies
that the Holders would otherwise have. No notice or demand on Guarantor in any
case shall entitle Guarantor to any other further notice or demand in similar
or other circumstances or constitute a waiver of the rights of the Holders to
any other or further action in any circumstances without notice or demand.
7. Binding Effect. This Guaranty shall be binding upon Guarantor and its
permitted successors and assigns and shall inure to the benefit of the Holders
and their successors and assigns. Except as provided for in
B-2-2
Section 8 below, Guarantor may not assign its obligations under this Guaranty
to any other person, by operation of law or otherwise, without the written
consent of a majority in interest of the Holders.
8. Consolidation, Merger, etc.
(a) Guarantor shall be entitled in its sole discretion to consolidate or
merge with any Person (as defined below) or sell, lease, exchange, transfer,
license, or otherwise dispose of any or all of its assets (whether tangible
or intangible). In the event of any such merger, consolidation, sale, lease,
exchange, transfer, license or other disposition, subject to Section 8(b)
below, this Guaranty shall remain in effect unless otherwise agreed to in
writing by a majority in interest of the Holders.
(b) In the event of a merger or consolidation in which Guarantor is not
the surviving entity or a sale, conveyance or transfer of all or
substantially all of the properties and assets of Guarantor, (i) the
surviving Person or the purchaser, as applicable, shall expressly assume, by
an agreement supplemental hereto, executed and delivered to the Trustee
under the CVR Agreement, in form reasonably satisfactory to the Trustee, all
obligations and covenants of Guarantor under this Guaranty, and (ii)
following the assumption of this Guaranty by such successor Person, such
successor Person shall succeed to and be substituted for Guarantor hereunder
with the same effect as if such successor Person had been named herein.
(c) In the event of any such merger, consolidation, sale, conveyance or
transfer pursuant to Section 8(b), Guarantor or any Person which shall
theretofore have become such in the manner described in this Section shall
be discharged from all obligations and covenants under this Guaranty and may
be liquidated and dissolved.
(d) For purposes of this Section 8, "Person" means any individual,
corporation, partnership, joint venture, association, joint-stock company,
trust, limited liability company, unincorporated organization or government
or other agency or political subdivision thereof.
9. Waivers. To the fullest extent permitted by law, Guarantor hereby
waives:
(a) Notice of acceptance of this Guaranty and of the incurring of any and
all of the Obligations of Obligor; and
(b) Presentment of any instrument, demand of payment, notice of
non-payment or protest thereof.
10. Notification. Whenever at any time or from time to time Guarantor
shall make any payment to the Holders hereunder on account of Guarantor's
liability hereunder, it will notify Obligor in writing that such payment is
made under this Guaranty for such purpose.
11. Partial Invalidity. If at any time any provision of this Guaranty is
or becomes illegal, invalid or unenforceable in any respect under the laws of
any jurisdiction, neither the legality, validity or enforceability of the
remaining provisions of this Guaranty nor the legality, validity or
enforceability of such provision under the laws of any other jurisdiction shall
in any way be affected or impaired thereby.
12. Enforcement by Trustee. Guarantor agrees and acknowledges and the
Holders and Obligor by acceptance of this Guaranty and the benefits conferred
hereby, agree that JP Morgan Trust Company, National Association, as Trustee
under the CVR Agreement, or any successor Trustee appointed pursuant to the CVR
Agreement, shall act on behalf of the Holders with respect to this Guaranty in
accordance with and subject to the applicable provisions of the CVR Agreement.
Any demand for performance hereunder shall be made in writing, delivered to the
Guarantor by the Trustee.
13. GOVERNING LAW; JURISDICTION. ALL QUESTIONS AND/OR DISPUTES CONCERNING
THE CONSTRUCTION, VALIDITY AND INTERPRETATION OF THIS GUARANTY SHALL BE
GOVERNED BY THE INTERNAL LAWS, AND NOT THE LAWS OF CONFLICTS, OF THE STATE OF
DELAWARE. GUARANTOR, OBLIGOR, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR
B-2-3
ACCEPTANCE OF THE CONTINGENT VALUE RIGHTS HEREBY IRREVOCABLY AND
UNCONDITIONALLY AGREES TO BE SUBJECT TO, AND HEREBY CONSENTS AND SUBMITS TO,
THE JURISDICTION OF THE COURTS OF THE STATE OF DELAWARE, AND AGREES THAT ANY
ACTION INVOLVING ANY EQUITABLE OR OTHER CLAIM SHALL BE BROUGHT EXCLUSIVELY IN
THE DELAWARE COURT OF CHANCERY. IN THE EVENT THAT THE DELAWARE COURT OF
CHANCERY DOES NOT ACCEPT JURISDICTION OVER ANY SUCH ACTION, GUARANTOR, OBLIGOR,
THE TRUSTEE, AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE CONTINGENT
VALUE RIGHTS HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ANY SUCH ACTION
THEN SHALL BE BROUGHT EXCLUSIVELY IN THE UNITED STATES DISTRICT COURT FOR THE
DISTRICT OF DELAWARE. UNLESS THE CONTEXT OTHERWISE REQUIRES, ALL TERMS USED
HEREIN WHICH ARE DEFINED IN THE UNIFORM COMMERCIAL CODE OF THE STATE OF
DELAWARE SHALL HAVE THE MEANINGS THEREIN STATED.
IN WITNESS WHEREOF, Guarantor has caused this instrument to be duly executed
and delivered by its proper officers as of the date first written above.
HEWLETT-PACKARD COMPANY
By:
----------------------------------
Name:
--------------------------------
Title:
---------------------------------
Address: 3000 Hanover Street
Palo Alto, CA 94304
Attest: ____________________________________________________________________
Name: ______________________________________________________________________
Title: _____________________________________________________________________
B-2-4
ANNEX C-1
TENDER AND OPTION AGREEMENT
BY AND AMONG
HEWLETT-PACKARD COMPANY
AND
CERTAIN PRINCIPAL SHAREHOLDERS OF INDIGO N.V.
TENDER AND OPTION AGREEMENT
THIS TENDER AND OPTION AGREEMENT (this "Agreement") is made and entered into
as of September 6, 2001, by and among Hewlett-Packard Company, a Delaware
corporation (the "Buyer"), and each of the individuals listed on the signature
pages hereto (each in his, her or its individual capacity, a "Shareholder,"
and, collectively, the "Shareholders").
WHEREAS, each of the Shareholders is, as of the date hereof, the record and
beneficial owner of common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
pages of this Agreement;
WHEREAS, the Buyer and the Company concurrently herewith are entering into
an Offer Agreement, dated as of the date hereof (the "Offer Agreement"), which
provides, among other things, (i) for the Buyer or a Subsidiary of the Buyer,
as promptly as practicable after the date hereof, to commence an exchange offer
(the "Offer") to acquire all of the outstanding Common Shares of the Company in
exchange for either (x) shares of Buyer Common Stock or (y) shares of Buyer
Common Stock plus CVRs, and (ii) for the subsequent post-closing reorganization
to be accomplished upon the terms and subject to the conditions set forth in
the Offer Agreement; and
WHEREAS, as a condition to the willingness of the Buyer to enter into the
Offer Agreement, and in order to induce the Buyer to enter into the Offer
Agreement, each of the Shareholders has agreed (solely in his, her or its
capacity as a shareholder of the Company) to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "Election" shall mean either of the Fixed Offer Price or the
Contingent Offer Price.
(b) "Oversubscribed Consideration" shall mean the consideration obtained
by tendering Shares into the Oversubscribed Election.
(c) "Oversubscribed Election" shall mean that Election, if either, for
which the aggregate number of Common Shares that has been tendered
immediately prior to the Expiration Time (and not properly withdrawn)
exceeds the Maximum Fixed Price Election Number or the Maximum Contingent
Price Election Number.
(d) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) owned by the Shareholder as of the date of this Agreement; and (ii)
all additional securities of the Company (including all additional Common
Shares and all additional options, warrants and other rights to acquire
Common Shares) of which the Shareholder acquires ownership during the period
from the date of this Agreement through the Termination Date.
(e) "Termination Date" shall mean the earlier to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; or (ii)
the Closing Time.
(f) Transfer. A Shareholder shall be deemed to have effected a "Transfer"
of Shares if such Shareholder directly or indirectly (i) sells, pledges,
encumbers, grants an option with respect to, transfers or otherwise disposes
of such Shares or any interest therein, or (ii) enters into an agreement or
commitment providing for the sale of, pledge of, encumbrance of, grant of an
option with respect to, transfer of or disposition of such Shares or any
interest therein.
C-1-1
(g) "Undersubscribed Consideration" shall mean the consideration obtained
by tendering Shares into the Undersubscribed Election.
(h) "Undersubscribed Election" shall mean, to the extent there is an
Oversubscribed Election, the other Election.
SECTION 2. Representations and Warranties of the Shareholder. Shareholder
hereby represents, warrants and covenants to the Buyer that Shareholder (i) is
the beneficial owner of the Common Shares and the options, warrants and other
rights to acquire Common Shares indicated on the signature pages of this
Agreement, free and clear of any pledges, options, rights of first refusal,
co-sale rights, attachments or other encumbrances other than as contemplated
hereby and the Shareholders' Agreement, dated September 13, 2000, by and among
the Company, the Buyer and the other Company Shareholders named therein; (ii)
does not beneficially own any securities of the Company other than the Common
Shares and options, warrants and other rights to acquire Common Shares of the
Company indicated on the signature pages of this Agreement; (iii) has full
power and authority to make, enter into and carry out the terms of this
Agreement; and (iv) the execution, delivery and performance of this Agreement
by such Shareholder and the consummation of the transactions contemplated
hereby, will not (x) require the consent, waiver, approval, or authorization of
any governmental authority or any other person or entity except as contemplated
by the Offer Agreement; or (y) violate, conflict with, result in a breach of or
the acceleration of any obligation under, or constitute a default (or an event
which with notice or the lapse of time or both would become a default) under,
or give to others any right of termination, amendment, acceleration or
cancellation of, or result in the creation of a lien or other encumbrance on
any property or asset of the Shareholder pursuant to any provision of any
indenture, mortgage, lien, lease, agreement, contract, instrument, order,
judgment, ordinance, regulation or decree to which the Shareholder is subject
or by which the Shareholder or any of Shareholder's property or assets (other
than the Company's assets, if any) is bound, in each case as would not
materially adversely affect the Shareholder's obligations hereunder.
SECTION 3. Agreement to Tender Shares.
(a) Each of the Shareholders hereby agrees that such Shareholder shall
tender, or if such Shareholder holds such shares through a broker, instruct
the broker to tender, his, her or its Common Shares into the Offer promptly,
and in any event no later than the tenth business day following the
commencement of the Offer, pursuant to and in accordance with the terms of
the Offer Agreement, and that such Shareholder shall not withdraw any Shares
so tendered unless the Offer is terminated or has expired.
(b) Each of the Shareholders hereby agrees that such Shareholder will
automatically elect to receive the Undersubscribed Consideration for up to
all of the Common Shares held by such Shareholder (the "Mandatory
Election"). Notwithstanding anything to the contrary, Section 1.1(c)(ii) and
Section 1.1(c)(iii) of the Offer Agreement, as applicable, shall be applied
to any Common Shares tendered by Company Shareholders (other than those
tendered by the Shareholders party to this Agreement) only to the extent
that Undersubscribed Consideration continues to exist after giving effect to
the Mandatory Election. To facilitate the calculation of shares subject to
the Mandatory Election in accordance with the above provisions, the Buyer
may round the number of shares proposed to be automatically elected by any
Shareholder to the nearest one hundred (100) shares.
(c) Notwithstanding anything to the contrary in this Agreement, each of
the Shareholders hereby agrees and pledges (i) either (A) to exercise no
later than the day immediately prior to the Closing Time all options,
warrants and other rights to acquire Common Shares then owned by such
Shareholder (collectively, the "Warrants") through the non-cash exercise
provisions set forth therein and (B) to immediately tender the Common Shares
received upon such exercise into the Offer; or (ii) to not exercise any of
the Warrants after the Closing Time until such time as the Post-Closing
Reorganization referred to in Article II of the Offer Agreement is
consummated.
SECTION 4. Transfer of the Shares. Except as required herein, each of the
Shareholders hereby agrees that, at all times during the period from the date
of this Agreement until the Termination Date, such Shareholder
C-1-2
shall not cause or permit any Transfer of any of the Shares to be effected,
unless each person to which any such Shares, or any interest therein, is or may
be Transferred shall have (i) executed a counterpart of this Agreement; and
(ii) agreed in writing to hold such Shares, or such interest therein, subject
to all of the terms and conditions set forth in this Agreement.
SECTION 5. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of additional Common Shares or other securities or rights of the Company by any
Shareholder, the number of Shares shall be adjusted appropriately, and this
Agreement and the rights and obligations hereunder shall attach to any
additional Common Shares or other securities or rights of the Company issued to
or acquired by any such Shareholder.
SECTION 6. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, no Shareholder will, nor will any
Shareholder authorize or permit any of such Shareholder's officers, directors,
affiliates or employees or any investment banker, attorney, accountant,
consultant or other agent, advisor or representative retained by such
Shareholder to, directly or indirectly, (i) solicit, initiate, encourage or
induce the making, submission or announcement of any Acquisition Proposal; (ii)
engage or participate in any discussions or negotiations regarding, or furnish
to any person any information relating to the Company or any of its
Subsidiaries or afford access to the business, properties, assets, books or
records of the Company or any of its Subsidiaries to any person that has made,
or take any other action intended to assist or facilitate any inquiries or the
making, submission, or announcement of any proposal that constitutes or would
reasonably be expected to lead to, any Acquisition Proposal; (iii) approve,
endorse or recommend any Acquisition Proposal; or (iv) enter into any letter of
intent or similar document or any contract, agreement or commitment
contemplating or otherwise relating to any Acquisition Transaction; provided,
this section shall not apply to any person in his capacity as a director of the
Company.
SECTION 7. Regulatory Filings. Each of the Shareholders hereby covenants
and agrees, to the extent that such Shareholder is required to do so under
applicable laws or regulations, (i) to file or cause to be filed with the FTC
and the DOJ the notifications and other information required to be filed by
such Shareholder under the HSR Act with respect to the Offer and the
transactions contemplated thereby; and (ii) to make any other Foreign Filings
required by such Shareholder of which it is aware with respect to the Offer and
the transactions contemplated thereby. Such Shareholder shall pay all filing
fees and all other fees and expenses pursuant to any such filings made by such
Shareholder that relate to such Shareholder's acquisition of Buyer Common Stock
as a result of the Offer.
SECTION 8. Further Assurances. Each of the Shareholders hereby covenants
and agrees to, upon the request of the Buyer, execute and deliver any
additional documents and take such further actions as may be reasonably
requested by the Buyer to carry out the provisions of this Agreement; provided,
that such action is consistent with, and does not create any obligations that
extend the general scope of the provisions of this Agreement.
SECTION 9. Option.
(a) The Shareholder hereby grants Buyer an irrevocable (to the extent
permitted by applicable law), exclusive option to purchase up to all of the
Shares at a per Share exercise price equal to the Contingent Price Exchange
Ratio (the "Purchase Option"). Such Purchase Option shall become exercisable by
Buyer upon the Shareholder's breach of its obligations under Section 3 of this
Agreement or upon the Shareholder's breach of any other material agreement or
covenant on the part of the Shareholder set forth in this Agreement.
(b) In the event that the Buyer elects to exercise the Purchase Option, the
Buyer shall so notify the Shareholder. Upon receipt of such notification, the
Shareholder shall deliver the Shares to the Buyer, to be held by the Buyer
pending the closing of the exercise of the Purchase Option. At the closing of
the exercise of the Purchase Option, the Buyer shall deliver to the Shareholder
the Contingent Price Exchange Ratio for each Share delivered by the Shareholder.
C-1-3
(c) The Buyer in its sole discretion may designate and assign one or more
employees, officers, directors, stockholders or direct or indirect subsidiaries
of the Buyer or other persons or organizations to exercise all or a part of the
Buyer's Purchase Option.
(d) In the event that the Buyer's Purchase Option is exercised, then upon
and following such exercise, the only remaining right of the Shareholder under
this Agreement shall be the right to receive payment for such Shares as set
forth in this Section 9, and the Shareholder shall have no right whatsoever to
tender the Shares upon its own election.
SECTION 10. Legends. If so requested by the Buyer, Shareholder agrees to
use its reasonable best efforts to place on the certificates representing the
Shares a legend stating that they are subject to this Agreement.
SECTION 11. Termination. Except as otherwise provided in this Agreement,
this Agreement, and all rights and obligations of the parties hereunder, shall
terminate and have no further force or effect immediately upon the Termination
Date; provided, however, that Sections 12 and 13 shall survive any termination
of this Agreement.
SECTION 12. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if either party (i.e., the "initiating party") institutes any action
against the other party (i.e., the "target party") to enforce the terms of this
Agreement, such target party shall pay reasonable costs and expenses,
including, without limitation, reasonable attorneys' fees and costs
(collectively, "Costs"), incurred by the initiating party in connection with
such action, provided that the initiating party is successful in all material
respects with respect to all claims (after all appeals) ("Material Success") in
its action against the target party.
SECTION 13. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of
Shareholder set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
C-1-4
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to: Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
If to the Shareholder:
To the address for notice set forth
on the signature page hereof.
With a copy to: Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
(f) Registered Shares. Each of the Shareholders shall receive Buyer Common
Stock in the Offer that is registered on Form S-4.
(g) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without giving effect to the
conflicts of law principles thereof. Each of the parties hereby irrevocably
consents to the exclusive jurisdiction and venue of any court within the State
of New York in connection with any matter based upon or arising out of this
Agreement of the matters contemplated herein, agrees that process may be served
upon them in any manner authorized by the laws of the State of New York for
such persons and waives any covenants not to assert or plead any objection
which they might otherwise have to such jurisdiction, venue and such process.
(h) Entire Agreement. This Agreement contains the entire understanding of
the parties in respect of the subject matter hereof, and supersedes all prior
negotiations and understandings between the parties with respect to such
subject matter.
C-1-5
(i) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(j) Counterparts. This Agreement may be executed by facsimile and in
several counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-1-6
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
WALTHROUP CORPORATION N.V.
By: /s/ URS BRUNNER
-----------------------------------
Name: Urs Brunner
Intertrust (Curacao) N.V.
Title: Managing Director
Address: Landhuis Joonchi
--------------------------------
Kaya Richard J. Beaujon z/n
--------------------------------------
Curacao, Netherlands Antilles
--------------------------------------
Telephone: (599-9) 7366277
------------------------------
Facsimile No.: (599-9) 7366161
---------------------------
Shares beneficially owned:
3,592,619 shares of Common Shares
440,000 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
C-1-7
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
VISIONVEST CORPORATION N.V.
By: /s/ URS BRUNNER
-----------------------------------
Name: Urs Brunner
Intertrust (Curacao) N.V.
Title: Managing Director
Address: Landhuis Joonchi
-------------------------------
Kaya Richard J. Beaujon z/n
--------------------------------------
Curacao, Netherlands Antilles
--------------------------------------
Telephone: (599-9) 7366277
------------------------------
Facsimile No.: (599-9) 7366161
---------------------------
Shares beneficially owned:
3,205,571 shares of Common Shares
640,000 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
C-1-8
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
GEMINI SYSTEMS CORPORATION N.V.
By: /s/ TIS PRAGER
-----------------------------------
Name: Tis Prager
Intertrust (Curacao) N.V.
Title: Managing Director
Address: Landhuis Joonchi
--------------------------------
Kaya Richard J. Beaujon z/n
--------------------------------------
Curacao, Netherlands Antilles
--------------------------------------
Telephone: (599-9) 7366277
------------------------------
Facsimile No.: (599-9) 7366161
---------------------------
Shares beneficially owned:
19,573,838 shares of Common Shares
0 shares of Common Shares issuable
upon the exercise of outstanding
options, warrants or other rights.
C-1-9
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
TOSCAL N.V.
By: /s/ TIS PRAGER
-----------------------------------
Name: Tis Prager
Intertrust (Curacao) N.V.
Title: Managing Director
Address: Landhuis Joonchi
--------------------------------
Kaya Richard J. Beaujon z/n
--------------------------------------
Curacao, Netherlands Antilles
--------------------------------------
Telephone: (599-9) 7366277
------------------------------
Facsimile No.: (599-9) 7366161
---------------------------
Shares beneficially owned:
25,680,283* shares of Common Shares
1,746,672** shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
--------
* Includes 8,734,270 shares of Common Shares owned indirectly by its
subsidiaries: Walthroup Corporation N.V., Visionvest Corporation N.V. and
Deering Corporation N.V.
** Includes 1,746,672 shares of Common Shares issuable upon exercise of
outstanding warrants owned indirectly by its subsidiaries: Walthroup
Corporation N.V., Visionvest Corporation N.V. and Deering Corporation N.V.
C-1-10
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
OZF LTD.
By: /s/ TIS PRAGER
-----------------------------------
Name: Tis Prager
TMF Management (BVI) Limited
Title: Managing Director
Address: P.O. Box 964
--------------------------------
Mill Mall, Road Town
--------------------------------------
Tortola, British Virgin Islands
--------------------------------------
Telephone: (1-284) 49 44997
------------------------------
Facsimile No.: (1-284) 49 44999
---------------------------
Shares beneficially owned:
2,312,101 shares of Common Shares
0 shares of Common Shares issuable
upon the exercise of outstanding
options, warrants or other rights.
C-1-11
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
DEERING CORPORATION N.V.
By: /s/ URS BRUNNER
-----------------------------------
Name: Urs Brunner
Intertrust (Curacao) N.V.
Title: Managing Director
Address: Landhuis Joonchi
--------------------------------
Kaya Richard J. Beaujon z/n
--------------------------------------
Curacao, Netherlands Antilles
--------------------------------------
Telephone: (599-9) 7366277
------------------------------
Facsimile No.: (599-9) 7366161
---------------------------
Shares beneficially owned:
1,936,080 shares of Common Shares
666,672 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
C-1-12
ANNEX C-2
TENDER AND OPTION AGREEMENT
BY AND BETWEEN
HEWLETT-PACKARD COMPANY
AND
OSCAR & ZLATA FOUNDATION
TENDER AND OPTION AGREEMENT
THIS TENDER AND OPTION AGREEMENT (this "Agreement") is made and entered into
as of November 7, 2001, by and between Hewlett-Packard Company, a Delaware
corporation (the "Buyer"), and the entity listed on the signature page hereto
(the "Foundation").
WHEREAS, the Foundation is, as of the date hereof, deemed to be the
beneficial owner of common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
page of this Agreement;
WHEREAS, the Buyer and the Company have entered into an Offer Agreement,
dated as of September 6, 2001 (the "Offer Agreement"), which provides, among
other things, (i) for the Buyer or a Subsidiary of the Buyer, as promptly as
practicable after the date hereof, to commence an exchange offer (the "Offer")
to acquire all of the outstanding Common Shares of the Company in exchange for
either (x) shares of Buyer Common Stock or (y) shares of Buyer Common Stock
plus CVRs, and (ii) for the subsequent post-closing reorganization to be
accomplished upon the terms and subject to the conditions set forth in the
Offer Agreement; and
WHEREAS, in consideration of the Buyer's entering into the Offer Agreement,
the Foundation has agreed to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "Election" shall mean either of the Fixed Offer Price or the
Contingent Offer Price.
(b) "LFT Shareholders" shall mean Gemini Systems Corporation N.V., Toscal
N.V., OZF Ltd., Visionvest Corporation N.V., Walthroup Corporation N.V. and
Deering Corporation N.V.
(c) "Oversubscribed Consideration" shall mean the consideration obtained
by tendering Shares into the Oversubscribed Election.
(d) "Oversubscribed Election" shall mean that Election, if either, for
which the aggregate number of Common Shares that has been tendered
immediately prior to the Expiration Time (and not properly withdrawn)
exceeds the Maximum Fixed Price Election Number or the Maximum Contingent
Price Election Number.
(e) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) beneficially owned or deemed to be owned by the Foundation as of the
date of this Agreement; and (ii) all additional securities of the Company
(including all additional Common Shares and all additional options, warrants
and other rights to acquire Common Shares) of which the Foundation acquires
beneficial ownership during the period from the date of this Agreement
through the Termination Date.
(f) "Termination Date" shall mean the earlier to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; or (ii)
the Closing Time.
(g) Transfer. The Foundation shall be deemed to have effected a
"Transfer" of Shares if the Foundation directly or indirectly (i) sells,
pledges, encumbers, grants an option with respect to, transfers or otherwise
disposes of such Shares or any interest therein, or (ii) enters into an
agreement or commitment providing for the sale of, pledge of, encumbrance
of, grant of an option with respect to, transfer of or disposition of such
Shares or any interest therein.
C-2-1
(h) "Undersubscribed Consideration" shall mean the consideration obtained
by tendering Shares into the Undersubscribed Election.
(i) "Undersubscribed Election" shall mean, to the extent there is an
Oversubscribed Election, the other Election.
SECTION 2. Representations and Warranties of the Foundation. The
Foundation hereby represents, warrants and covenants to the Buyer that the
Foundation (i) does not beneficially own any securities of the Company other
than the Common Shares and options, warrants and other rights to acquire Common
Shares of the Company owned by the LFT Shareholders as indicated on the
signature page of this Agreement; (ii) has full power and authority to make,
enter into and carry out the terms of this Agreement; and (iii) the execution,
delivery and performance of this Agreement by the Foundation and the
consummation of the transactions contemplated hereby, will not (x) require the
consent, waiver, approval, or authorization of any governmental authority or
any other person or entity except as contemplated by the Offer Agreement; or
(y) violate, conflict with, result in a breach of or the acceleration of any
obligation under, or constitute a default (or an event which with notice or the
lapse of time or both would become a default) under, or give to others any
right of termination, amendment, acceleration or cancellation of, or result in
the creation of a lien or other encumbrance on any property or asset of the
Foundation pursuant to any provision of any indenture, mortgage, lien, lease,
agreement, contract, instrument, order, judgment, ordinance, regulation or
decree to which the Foundation is subject or by which the Foundation or any of
the Foundation's property or assets (other than the Company's assets, if any)
is bound, in each case as would not materially adversely affect the
Foundation's obligations hereunder.
SECTION 3. Agreement to Tender Shares.
(a) The Foundation hereby agrees that the Foundation shall not take any
actions or inactions that would be contrary to the agreements of the LFT
Shareholders to tender Common Shares owned by them into the Offer pursuant to
the terms of the Tender and Option Agreement among the Buyer and the LFT
Shareholders, dated as of September 6, 2001 (the "LFT Tender and Option
Agreement").
(b) The Foundation hereby agrees that the Foundation will not take any
actions or inactions that would be contrary to the agreements of the LFT
Shareholders to automatically elect to receive the Undersubscribed
Consideration for up to all of the Common Shares held by the LFT Shareholders
pursuant to the terms of the LFT Tender and Option Agreement.
(c) The Foundation hereby agrees and pledges not to take any actions or
inactions that would be contrary to the agreements of the LFT Shareholders to
(i) either (A) to exercise no later than the day immediately prior to the
Closing Time all options, warrants and other rights to acquire Common Shares
then owned by the LFT Shareholders (collectively, the "Warrants") through the
non-cash exercise provisions set forth therein and (B) to immediately tender
the Common Shares received upon such exercise into the Offer; or (ii) to not
exercise any of the Warrants after the Closing Time until such time as the
Post-Closing Reorganization referred to in Article II of the Offer Agreement is
consummated.
SECTION 4. Transfer of the Shares. Except as required herein, the
Foundation hereby agrees that, at all times during the period from the date of
this Agreement until the Termination Date, the Foundation shall not cause or
permit any Transfer of any of the Shares to be effected, unless each person to
which any such Shares, or any interest therein, is or may be Transferred shall
have (i) executed a counterpart of this Agreement; and (ii) agreed in writing
to hold such Shares, or such interest therein, subject to all of the terms and
conditions set forth in this Agreement.
SECTION 5. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of beneficial ownership of additional Common Shares or other securities or
rights of the Company by the Foundation, the number of Shares shall be adjusted
appropriately, and this Agreement and the rights and obligations hereunder
shall attach to any additional Common Shares or other securities or rights of
the Company issued to or beneficially owned by the Foundation.
C-2-2
SECTION 6. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, the Foundation will not, and will not
authorize or permit any of the Foundation's officers, directors, affiliates or
employees or any investment banker, attorney, accountant, consultant or other
agent, advisor or representative retained by the Foundation to, directly or
indirectly, (i) solicit, initiate, encourage or induce the making, submission
or announcement of any Acquisition Proposal; (ii) engage or participate in any
discussions or negotiations regarding, or furnish to any person any information
relating to the Company or any of its Subsidiaries or afford access to the
business, properties, assets, books or records of the Company or any of its
Subsidiaries to any person that has made, or take any other action intended to
assist or facilitate any inquiries or the making, submission, or announcement
of any proposal that constitutes or would reasonably be expected to lead to,
any Acquisition Proposal; (iii) approve, endorse or recommend any Acquisition
Proposal; or (iv) enter into any letter of intent or similar document or any
contract, agreement or commitment contemplating or otherwise relating to any
Acquisition Transaction; provided, this section shall not apply to any person
in his capacity as a director of the Company.
SECTION 7. Regulatory Filings. The Foundation hereby covenants and agrees,
to the extent that the Foundation is required to do so under applicable laws or
regulations, (i) to file or cause to be filed with the FTC and the DOJ the
notifications and other information required to be filed by the Foundation
under the HSR Act with respect to the Offer and the transactions contemplated
thereby; and (ii) to make any other Foreign Filings required by the Foundation
of which it is aware with respect to the Offer and the transactions
contemplated thereby. The Foundation shall pay all filing fees and all other
fees and expenses pursuant to any such filings made by the Foundation that
relate to the Foundation's acquisition of Buyer Common Stock as a result of the
Offer.
SECTION 8. Further Assurances. The Foundation hereby covenants and agrees
to, upon the request of the Buyer, execute and deliver any additional documents
and take such further actions as may be reasonably requested by the Buyer to
carry out the provisions of this Agreement; provided, that such action is
consistent with, and does not create any obligations that extend the general
scope of the provisions of this Agreement.
SECTION 9. Option. The Foundation hereby agrees to not take any action or
inaction that would be contrary to the agreements of the LFT Shareholders in
the LFT Tender and Option Agreement to grant Buyer an irrevocable (to the
extent permitted by applicable law), exclusive option to purchase up to all of
the Shares held by the LFT Shareholders at a per Share exercise price equal to
the Contingent Price Exchange Ratio.
SECTION 10. Legends. If so requested by the Buyer, the Foundation agrees
to not take any action or inaction that would be contrary to the agreements of
the LFT Shareholders in the LFT Tender and Option Agreement to use their
reasonable best efforts to place on the certificates representing the Shares
held by the LFT Shareholders a legend stating that they are subject to the LFT
Tender and Option Agreement.
SECTION 11. Termination. Except as otherwise provided in this Agreement,
this Agreement, and all rights and obligations of the parties hereunder, shall
terminate and have no further force or effect immediately upon the Termination
Date; provided, however, that Sections 12 and 13 shall survive any termination
of this Agreement.
SECTION 12. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if either party (i.e., the "initiating party") institutes any action
against the other party (i.e., the "target party") to enforce the terms of this
Agreement, such target party shall pay reasonable costs and expenses,
including, without limitation, reasonable attorneys' fees and costs
(collectively, "Costs"), incurred by the initiating party in connection with
such action, provided that the initiating party is successful in all material
respects with respect to all claims (after all appeals) ("Material Success") in
its action against the target party.
C-2-3
SECTION 13. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of the
Foundation set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to: Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
C-2-4
If to the Foundation:
To the address for notice set forth on the signature page
hereof.
With a copy to: Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
(f) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without giving effect to the
conflicts of law principles thereof. Each of the parties hereby irrevocably
consents to the exclusive jurisdiction and venue of any court within the State
of New York in connection with any matter based upon or arising out of this
Agreement of the matters contemplated herein, agrees that process may be served
upon them in any manner authorized by the laws of the State of New York for
such persons and waives any covenants not to assert or plead any objection
which they might otherwise have to such jurisdiction, venue and such process.
(g) Entire Agreement. This Agreement contains the entire understanding of
the parties in respect of the subject matter hereof, and supersedes all prior
negotiations and understandings between the parties with respect to such
subject matter.
(h) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(i) Counterparts. This Agreement may be executed by facsimile and in
several counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-2-5
IN WITNESS WHEREOF, Buyer and the Foundation have caused this Agreement to
be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
OSCAR & ZLATA FOUNDATION
By: /s/ TIS PRAGER
-----------------------------------
Name: Tis Prager
Title:
Address: Muhlebachstr. 6
--------------------------------
CH-8008 Zurich, Switzerland
--------------------------------------
--------------------------------------
Telephone: 0041-1-254 55 55
------------------------------
Facsimile No.: 0041-1-254 55 99
---------------------------
Shares beneficially owned:*
47,566,222 shares of Common Shares
1,746,672 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
--------
* Through its relationship with Gemini Systems Corporation N.V., Toscal N.V.,
OZF Ltd., Visionvest Corporation N.V., Walthroup Corporation N.V. and Deering
Corporation N.V., Oscar & Zlata Foundation is deemed to be the beneficial
owner of the Shares owned by such entities.
C-2-6
ANNEX C-3
TENDER AGREEMENT
BY AND BETWEEN
HEWLETT-PACKARD COMPANY
AND
S-C INDIGO CV
TENDER AGREEMENT
THIS TENDER AGREEMENT (this "Agreement") is made and entered into as of
September 6, 2001, by and among Hewlett-Packard Company, a Delaware corporation
(the "Buyer"), and each of the individuals listed on the signature pages hereto
(each in his, her or its individual capacity, a "Shareholder," and,
collectively, the "Shareholders").
WHEREAS, each of the Shareholders is, as of the date hereof, the record and
beneficial owner of common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
pages of this Agreement;
WHEREAS, the Buyer and the Company concurrently herewith are entering into
an Offer Agreement, dated as of the date hereof (the "Offer Agreement"), which
provides, among other things, (i) for the Buyer or a Subsidiary of the Buyer,
as promptly as practicable after the date hereof, to commence an exchange offer
(the "Offer") to acquire all of the outstanding Common Shares of the Company in
exchange for either (x) shares of Buyer Common Stock or (y) shares of Buyer
Common Stock plus CVRs, and (ii) for the subsequent post-closing reorganization
to be accomplished upon the terms and subject to the conditions set forth in
the Offer Agreement; and
WHEREAS, as a condition to the willingness of the Buyer to enter into the
Offer Agreement, and in order to induce the Buyer to enter into the Offer
Agreement, each of the Shareholders has agreed (solely in his, her or its
capacity as a shareholder of the Company) to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) owned by the Shareholder as of the date of this Agreement; and (ii)
all additional securities of the Company (including all additional Common
Shares and all additional options, warrants and other rights to acquire
Common Shares) of which the Shareholder acquires ownership during the period
from the date of this Agreement through the Termination Date.
(b) "Termination Date" shall mean the earlier to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; (ii) the
Closing Time; or (iii) four months after the End Date as determined pursuant
to the Offer Agreement (ignoring for this purpose any amendment to such
agreement after the date hereof).
(c) Transfer. A Shareholder shall be deemed to have effected a
"Transfer" of Shares if such Shareholder directly or indirectly (i) sells,
pledges, encumbers, grants an option with respect to, transfers or otherwise
disposes of such Shares or any interest therein, or (ii) enters into an
agreement or commitment providing for the sale of, pledge of, encumbrance
of, grant of an option with respect to, transfer of or disposition of such
Shares or any interest therein.
SECTION 2. Representations and Warranties of the Shareholder. Shareholder
hereby represents, warrants and covenants to the Buyer that Shareholder (i) is
the beneficial owner of the Common Shares and the options, warrants and other
rights to acquire Common Shares indicated on the signature pages of this
Agreement, free and clear of any pledges, options, rights of first refusal,
co-sale rights, attachments or other encumbrances
C-3-1
other than as contemplated hereby and the Shareholders' Agreement, dated
September 13, 2000, by and among the Company, the Buyer and the other Company
Shareholders named therein; (ii) does not beneficially own any securities of
the Company other than the Common Shares and options, warrants and other rights
to acquire Common Shares of the Company indicated on the signature pages of
this Agreement; (iii) has full power and authority to make, enter into and
carry out the terms of this Agreement; and (iv) the execution, delivery and
performance of this Agreement by such Shareholder and the consummation of the
transactions contemplated hereby, will not (x) require the consent, waiver,
approval, or authorization of any governmental authority or any other person or
entity except as contemplated by the Offer Agreement; or (y) violate, conflict
with, result in a breach of or the acceleration of any obligation under, or
constitute a default (or an event which with notice or the lapse of time or
both would become a default) under, or give to others any right of termination,
amendment, acceleration or cancellation of, or result in the creation of a lien
or other encumbrance on any property or asset of the Shareholder pursuant to
any provision of any indenture, mortgage, lien, lease, agreement, contract,
instrument, order, judgment, ordinance, regulation or decree to which the
Shareholder is subject or by which the Shareholder or any of Shareholder's
property or assets (other than the Company's assets, if any) is bound, in each
case as would not materially adversely affect the Shareholder's obligations
hereunder.
SECTION 3. Agreement to Tender Shares. Each of the Shareholders hereby
agrees that such Shareholder shall tender, or if such Shareholder holds such
shares through a broker, instruct the broker to tender, his, her or its Common
Shares into the Offer promptly, and in any event no later than the tenth
business day following the commencement of the Offer, pursuant to and in
accordance with the terms of the Offer Agreement, and that such Shareholder
shall not withdraw any Shares so tendered unless the Offer is terminated or has
expired.
SECTION 4. Transfer of the Shares. Except as required herein, each of the
Shareholders hereby agrees that, at all times during the period from the date
of this Agreement until the Termination Date, such Shareholder shall not cause
or permit any Transfer of any of the Shares to be effected, unless each person
to which any such Shares, or any interest therein, is or may be Transferred
shall have (i) executed a counterpart of this Agreement; and (ii) agreed in
writing to hold such Shares, or such interest therein, subject to all of the
terms and conditions set forth in this Agreement.
SECTION 5. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of additional Common Shares or other securities or rights of the Company by any
Shareholder, the number of Shares shall be adjusted appropriately, and this
Agreement and the rights and obligations hereunder shall attach to any
additional Common Shares or other securities or rights of the Company issued to
or acquired by any such Shareholder.
SECTION 6. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, no Shareholder will, nor will any
Shareholder authorize or permit any of such Shareholder's officers, directors,
affiliates or employees or any investment banker, attorney, accountant,
consultant or other agent, advisor or representative retained by such
Shareholder to, directly or indirectly, (i) solicit, initiate, encourage or
induce the making, submission or announcement of any Acquisition Proposal; (ii)
engage or participate in any discussions or negotiations regarding, or furnish
to any person any information relating to the Company or any of its
Subsidiaries or afford access to the business, properties, assets, books or
records of the Company or any of its Subsidiaries to any person that has made,
or take any other action intended to assist or facilitate any inquiries or the
making, submission, or announcement of any proposal that constitutes or would
reasonably be expected to lead to, any Acquisition Proposal; (iii) approve,
endorse or recommend any Acquisition Proposal; or (iv) enter into any letter of
intent or similar document or any contract, agreement or commitment
contemplating or otherwise relating to any Acquisition Transaction; provided,
this section shall not apply to any person in his capacity as a director of the
Company.
SECTION 7. Regulatory Filings. Each of the Shareholders hereby covenants
and agrees, to the extent that such Shareholder is required to do so under
applicable laws or regulations, (i) to file or cause to be filed with
C-3-2
the FTC and the DOJ the notifications and other information required to be
filed by such Shareholder under the HSR Act with respect to the Offer and the
transactions contemplated thereby; and (ii) to make any other Foreign Filings
required by such Shareholder of which it is aware with respect to the Offer and
the transactions contemplated thereby. Such Shareholder shall pay all filing
fees and all other fees and expenses pursuant to any such filings made by such
Shareholder that relate to such Shareholder's acquisition of Buyer Common Stock
as a result of the Offer.
SECTION 8. Further Assurances. Each of the Shareholders hereby covenants
and agrees to, upon the request of the Buyer, execute and deliver any
additional documents and take such further actions as may be reasonably
requested by the Buyer to carry out the provisions of this Agreement; provided,
that such action is consistent with, and does not create any obligations that
extend the general scope of the provisions of this Agreement.
SECTION 9. [INTENTIONALLY OMITTED]
SECTION 10. Legends. If so requested by the Buyer, Shareholder agrees to
use its reasonable best efforts to place on the certificates representing the
Shares a legend stating that they are subject to this Agreement.
SECTION 11. Termination. Except as otherwise provided in this Agreement,
this Agreement, and all rights and obligations of the parties hereunder, shall
terminate and have no further force or effect immediately upon the Termination
Date; provided, however, that Sections 12 and 13 shall survive any termination
of this Agreement.
SECTION 12. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if either party (i.e., the "initiating party") institutes any action
against the other party (i.e., the "target party") to enforce the terms of this
Agreement, such target party shall pay reasonable costs and expenses,
including, without limitation, reasonable attorneys' fees and costs
(collectively, "Costs"), incurred by the initiating party in connection with
such action, provided that the initiating party is successful in all material
respects with respect to all claims (after all appeals) ("Material Success") in
its action against the target party.
SECTION 13. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of
Shareholder set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
C-3-3
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer:
Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to:
Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
If to the Shareholder:
To the address for notice set
forth on the signature page hereof.
With copies to:
Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
and
Akin, Gump, Strauss, Hauer & Feld, L.L.P.
590 Madison Avenue
New York, New York 10022
Attention: Patrick J. Dooley, Esq.
Facsimile No.: (212) 872-1002
(f) Registered Shares. The Company agrees that each of the Shareholders
shall receive Buyer Common Stock in the Offer that is registered on Form S-4.
(g) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without giving effect to the
conflicts of law principles thereof. Each of the parties hereby irrevocably
consents to the exclusive jurisdiction and venue of any court within the State
of New York in connection with any matter based upon or arising out of this
Agreement of the matters contemplated herein, agrees that process may be served
upon them in any manner authorized by the laws of the State of New York for
such persons and waives any covenants not to assert or plead any objection
which they might otherwise have to such jurisdiction, venue and such process.
C-3-4
(h) Entire Agreement. This Agreement contains the entire understanding of
the parties in respect of the subject matter hereof, and supersedes all prior
negotiations and understandings between the parties with respect to such
subject matter.
(i) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(j) Counterparts. This Agreement may be executed by facsimile and in
several counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-3-5
IN WITNESS WHEREOF, each of the Buyer and the Shareholders have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
S-C INDIGO CV
By: S-C INDIGO II CV,
its General Partner
By: S-C Graphics, Inc.,
its General Partner
By: /s/ PETER HURWITZ
-----------------------------------
Name: Peter Hurwitz
Title: Vice President
Address:
-------------------------------
-------------------------------
-------------------------------
Telephone:
------------------------------
Facsimile No.:
---------------------------
Shares beneficially owned:
24,627,537 shares of Common Shares
1,700,000 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
C-3-6
ANNEX C-4
FORM OF
TENDER AGREEMENT
BY AND AMONG
HEWLETT-PACKARD COMPANY
AND
CERTAIN SHAREHOLDERS OF INDIGO N.V.
TENDER AGREEMENT
THIS TENDER AGREEMENT (this "Agreement") is made and entered into as of
September 6, 2001, by and among Hewlett-Packard Company, a Delaware corporation
(the "Buyer"), and the individual or entity listed on the signature page hereto
(the "Shareholder").
WHEREAS, the Shareholder is, as of the date hereof, the record and
beneficial owner of common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
page of this Agreement;
WHEREAS, the Buyer and the Company concurrently herewith are entering into
an Offer Agreement, dated as of the date hereof (the "Offer Agreement"), which
provides, among other things, (i) for the Buyer or a Subsidiary of the Buyer,
as promptly as practicable after the date hereof, to commence an exchange offer
(the "Offer") to acquire all of the outstanding Common Shares of the Company in
exchange for either (x) shares of Buyer Common Stock or (y) shares of Buyer
Common Stock plus CVRs, and (ii) for the subsequent post-closing reorganization
to be accomplished upon the terms and subject to the conditions set forth in
the Offer Agreement; and
WHEREAS, as a condition to the willingness of the Buyer to enter into the
Offer Agreement, and in order to induce the Buyer to enter into the Offer
Agreement, the Shareholder has agreed (solely in his, her or its capacity as a
shareholder of the Company) to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) owned by the Shareholder as of the date of this Agreement; and (ii)
all additional securities of the Company (including all additional Common
Shares and all additional options, warrants and other rights to acquire
Common Shares) of which the Shareholder acquires ownership during the period
from the date of this Agreement through the Termination Date.
(b) "Termination Date" shall mean the earliest to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; or (ii)
the Closing Time.
(c) Transfer. The Shareholder shall be deemed to have effected a
"Transfer" of Shares if the Shareholder directly or indirectly (i) sells,
pledges, encumbers, grants an option with respect to, transfers or otherwise
disposes of such Shares or any interest therein, or (ii) enters into an
agreement or commitment providing for the sale of, pledge of, encumbrance
of, grant of an option with respect to, transfer of or disposition of such
Shares or any interest therein.
SECTION 2. Representations and Warranties of the Shareholder. The
Shareholder hereby represents, warrants and covenants to the Buyer that the
Shareholder (i) is the beneficial owner of the Common Shares and the options,
warrants and other rights to acquire Common Shares indicated on the signature
page of this Agreement, free and clear of any pledges, options, rights of first
refusal, co-sale rights, attachments or other encumbrances; (ii) does not
beneficially own any securities of the Company other than the Common Shares and
options, warrants and other rights to acquire Common Shares of the Company
indicated on the signature pages of this Agreement; (iii) has full power and
authority to make, enter into and carry out the terms of this Agreement;
C-4-1
and (iv) the execution, delivery and performance of this Agreement by the
Shareholder and the consummation of the transactions contemplated hereby, will
not (x) require the consent, waiver, approval, or authorization of any
governmental authority or any other person or entity; or (y) violate, conflict
with, result in a breach of or the acceleration of any obligation under, or
constitute a default (or an event which with notice or the lapse of time or
both would become a default) under, or give to others any right of termination,
amendment, acceleration or cancellation of, or result in the creation of a lien
or other encumbrance on any property or asset of the Shareholder pursuant to
any provision of any indenture, mortgage, lien, lease, agreement, contract,
instrument, order, judgment, ordinance, regulation or decree to which the
Shareholder is subject or by which the Shareholder or any of the Shareholder's
property or assets is bound.
SECTION 3. Agreement to Tender Shares. The Shareholder hereby agrees that
the Shareholder shall tender, or if the Shareholder holds such shares through a
broker, instruct the broker to tender, his, her or its Common Shares into the
Offer promptly, and in any event no later than the tenth business day following
the commencement of the Offer, pursuant to and in accordance with the terms of
the Offer Agreement, and that the Shareholder shall not withdraw any Shares so
tendered unless the Offer is terminated or has expired.
SECTION 4. Transfer of the Shares.
(a) Transferee of Shares to be Bound by this Agreement. The Shareholder
hereby agrees that, at all times during the period from the date of this
Agreement until the Termination Date, the Shareholder shall not cause or permit
any Transfer of any of the Shares to be effected, or discuss, negotiate or make
any offer regarding any Transfer of any of the Shares, unless each person to
which any such Shares, or any interest therein, is or may be Transferred shall
have (i) executed a counterpart of this Agreement; and (ii) agreed in writing
to hold such Shares, or such interest therein, subject to all of the terms and
conditions set forth in this Agreement.
SECTION 5. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of additional Common Shares or other securities or rights of the Company by any
Shareholder, the number of Shares shall be adjusted appropriately, and this
Agreement and the rights and obligations hereunder shall attach to any
additional Common Shares or other securities or rights of the Company issued to
or acquired by the Shareholder.
SECTION 6. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, the Shareholder will not, nor will the
Shareholder authorize or permit any of the Shareholder's officers, directors,
affiliates or employees or any investment banker, attorney, accountant,
consultant or other agent, advisor or representative retained by the
Shareholder to, directly or indirectly, (i) solicit, initiate, encourage or
induce the making, submission or announcement of any Acquisition Proposal; (ii)
engage or participate in any discussions or negotiations regarding, or furnish
to any person any information relating to the Company or any of its
Subsidiaries or afford access to the business, properties, assets, books or
records of the Company or any of its Subsidiaries to any person that has made,
or take any other action intended to assist or facilitate any inquiries or the
making, submission, or announcement of any proposal that constitutes or would
reasonably be expected to lead to, any Acquisition Proposal; (iii) approve,
endorse or recommend any Acquisition Proposal; or (iv) enter into any letter of
intent or similar document or any contract, agreement or commitment
contemplating or otherwise relating to any Acquisition Transaction.
SECTION 7. Further Assurances. The Shareholder hereby covenants and agrees
to, upon the request of the Buyer, execute and deliver any additional documents
and take such further actions as may be deemed by the Buyer to be necessary or
desirable to carry out the provisions of this Agreement.
SECTION 8. Legends. If so requested by the Buyer, Shareholder agrees to
use its best efforts to place on the certificates representing the Shares a
legend stating that they are subject to this Agreement.
C-4-2
SECTION 9. Termination. Except as otherwise provided in this Agreement,
this Agreement, and all rights and obligations of the parties hereunder, shall
terminate and have no further force or effect immediately upon the Termination
Date; provided, however, that Sections 10 and 11 shall survive any termination
of this Agreement.
SECTION 10. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if the Buyer institutes any action against the Shareholder to enforce the
terms of this Agreement, the Shareholder shall pay reasonable costs and
expenses, including, without limitation, reasonable attorneys' fees and costs,
incurred by the Buyer in connection with such action, provided that the Buyer
is successful in its action against the Shareholder.
SECTION 11. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of
Shareholder set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to: Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
C-4-3
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
If to the Shareholder:
To the address for notice set forth
on the signature page hereof.
With a copy to: Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
(f) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without giving effect to the
conflicts of law principles thereof. The Shareholder hereby irrevocably
consents to the exclusive jurisdiction and venue of any court within the State
of New York in connection with any matter based upon or arising out of this
Agreement of the matters contemplated herein, agrees that process may be served
upon the Shareholder in any manner authorized by the laws of the State of New
York for such persons and waives any covenants not to assert or plead any
objection which the Shareholder might otherwise have to such jurisdiction,
venue and such process.
(g) Entire Agreement. This Agreement contains the entire understanding of
the parties in respect of the subject matter hereof, and supersedes all prior
negotiations and understandings between the parties with respect to such
subject matter.
(h) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(i) Counterparts. This Agreement may be executed by facsimile and in
several counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-4-4
IN WITNESS WHEREOF, each of the Buyer and the Shareholder have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By:
-----------------------------------
Name:
Title:
SHAREHOLDER
By:
-----------------------------------
Name:
Title:
Address:
-------------------------------
-------------------------------
-------------------------------
Telephone:
------------------------------
Facsimile No.:
---------------------------
Shares beneficially owned:
__ shares of Common Shares
__ shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
[SIGNATURE PAGE TO TENDER AGREEMENT]
C-4-5
ANNEX C-5
VOTING AGREEMENT
BY AND BETWEEN
HEWLETT-PACKARD COMPANY
AND
OSCAR & ZLATA FOUNDATION
VOTING AGREEMENT
THIS VOTING AGREEMENT (this "Agreement") is made and entered into as of
November 7, 2001, by and between Hewlett-Packard Company, a Delaware
corporation (the "Buyer"), and the entity listed on the signature page hereto
(the "Foundation").
WHEREAS, the Foundation is, as of the date hereof, deemed to be the
beneficial owner of the common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
page of this Agreement;
WHEREAS, the Buyer and the Company have entered into an Offer Agreement,
dated as of September 6, 2001 (the "Offer Agreement"), which provides, among
other things, (i) for the Buyer or a Subsidiary of the Buyer, as promptly as
practicable after the date thereof, to commence an exchange offer (the "Offer")
to acquire all of the outstanding Common Shares of the Company in exchange for
either (x) shares of Buyer Common Stock or (y) shares of Buyer Common Stock
plus CVRs, and (ii) for the subsequent post-closing reorganization to be
accomplished upon the terms and subject to the conditions set forth in the
Offer Agreement; and
WHEREAS, in consideration of the Buyer's entering into the Offer Agreement,
the Foundation has agreed to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "LFT Shareholders" shall mean Gemini Systems Corporation N.V., Toscal
N.V., OZF Ltd., Visionvest Corporation N.V., Walthroup Corporation N.V. and
Deering Corporation N.V.
(b) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) beneficially owned by the Foundation as of the date of this
Agreement; and (ii) all additional securities of the Company (including all
additional Common Shares and all additional options, warrants and other
rights to acquire Common Shares) of which the Foundation acquires beneficial
ownership during the period from the date of this Agreement through the
Termination Date.
(c) "Termination Date" shall mean the earliest to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; or (ii)
the Closing Time.
(d) Transfer. The Foundation shall be deemed to have effected a
"Transfer" of Shares if the Foundation directly or indirectly (i) sells,
pledges, encumbers, grants an option with respect to, transfers or otherwise
disposes of such Shares or any interest therein, or (ii) enters into an
agreement or commitment providing for the sale of, pledge of, encumbrance
of, grant of an option with respect to, transfer of or disposition of such
Shares or any interest therein.
SECTION 2. Representations and Warranties of the Foundation. The
Foundation hereby represents, warrants and covenants to the Buyer that the
Foundation (i) does not beneficially own any securities of the Company other
than the Common Shares and options, warrants and other rights to acquire Common
Shares of the Company owned by the LFT Shareholders as indicated on the
signature page of this Agreement; (ii) has full power and authority to make,
enter into and carry out the terms of this Agreement; and (iii) the execution,
delivery and performance of this Agreement by the Foundation and the
consummation of the transactions
C-5-1
contemplated hereby, will not (x) require the consent, waiver, approval, or
authorization of any governmental authority or any other person or entity
except as contemplated by the Offer Agreement; or (y) violate, conflict with,
result in a breach of or the acceleration of any obligation under, or
constitute a default (or an event which with notice or the lapse of time or
both would become a default) under, or give to others any right of termination,
amendment, acceleration or cancellation of, or result in the creation of a lien
or other encumbrance on any property or asset of the Foundation pursuant to any
provision of any indenture, mortgage, lien, lease, agreement, contract,
instrument, order, judgment, ordinance, regulation or decree to which the
Foundation is subject or by which the Foundation or any of the Foundation's
property or assets (other than the Company's assets, if any) is bound, in each
case as would not materially adversely affect the Foundation's obligations
hereunder.
SECTION 3. Agreement to Vote Shares. At every meeting of the Company
shareholders called, including an extraordinary general meeting, and at every
adjournment thereof, and on every action or approval by written consent of the
Company shareholders, the Foundation shall not take any action or inaction that
would be contrary to the agreements of the LFT Shareholders in the Voting
Agreement (the "LFT Voting Agreement"), dated as of September 6, 2001, by and
among the Buyer and the LFT Shareholders to cause the Common Shares to be voted:
(a) in favor of appointment of the new members of the Company Boards in
accordance with the designation of the Buyer as set forth in the Offer
Agreement;
(b) in favor of resolution upon the amendment of the Articles of
Association of the Company as attached as an exhibit to the Offer Agreement;
(c) in favor of the Post-Closing Reorganization and any action required
in furtherance thereof; provided, however, that such action is in accordance
with all applicable laws;
(d) against any of the following actions (other than those actions that
relate to the Offer and the transactions contemplated by the Offer
Agreement): (A) any merger, consolidation, business combination, sale of
assets, reorganization or recapitalization of the Company or any subsidiary
of the Company with any party, (B) any sale, lease or transfer of any
significant part of the assets of the Company or any subsidiary of the
Company, (C) any reorganization, recapitalization, dissolution, liquidation
or winding up of the Company or any Subsidiary of the Company, (D) any
material change in the capitalization of the Company or any Subsidiary of
the Company, or the corporate structure of the Company or any Subsidiary of
the Company, or (E) any other action that is intended, or could reasonably
be expected to, impede, interfere with, delay, postpone, discourage or
adversely affect the Offer or any of the other transactions contemplated by
the Offer Agreement, including the Post-Closing Reorganization; and
(e) in favor of waiving any notice that may have been or may be required
relating to the Offer or any of the other transactions contemplated by the
Offer Agreement, including the Post-Closing Reorganization.
SECTION 4. Transfer of the Shares.
(a) Transferee of Shares to be Bound by this Agreement. Except as required
herein, the Foundation hereby agrees that, at all times during the period from
the date of this Agreement until the Termination Date, the Foundation shall not
cause or permit any Transfer of any of the Shares to be effected, unless each
person to which any such Shares, or any interest therein, is or may be
Transferred shall have (i) executed a counterpart of this Agreement; and (ii)
agreed in writing to hold such Shares, or such interest therein, subject to all
of the terms and conditions set forth in this Agreement.
(b) Transfer of Voting Rights. The Foundation hereby also agrees that, at
all times commencing with the execution and delivery of this Agreement until
the Termination Date, the Foundation shall not permit the deposit of, any
Shares in a voting trust, grant any proxy (other than the proxy executed by the
LFT Shareholders in connection with the LFT Voting Agreement (the "Proxy")) in
respect of the Shares, or permit the LFT Shareholders to enter into any
shareholder agreement or similar arrangement or commitment in contravention of
the obligations of the LFT Shareholders under the LFT Voting Agreement with
respect to any of the Shares.
C-5-2
SECTION 5. Grant of Irrevocable Proxy; Appointment of Proxy. The
Foundation hereby agrees not to take any action or inaction that would be
contrary to the agreements of the LFT Shareholders in the LFT Voting Agreement
to revoke any and all previous proxies granted with respect to the Shares by
the LFT Shareholders.
SECTION 6. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of beneficial ownership of additional Common Shares or other securities or
rights of the Company by the Foundation, the number of Shares shall be adjusted
appropriately, and this Agreement and the rights and obligations hereunder
shall attach to any additional Common Shares or other securities or rights of
the Company issued to or beneficially owned by the Foundation.
SECTION 7. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, the Foundation will not, and will not
authorize or permit any of the Foundation's officers, directors, affiliates or
employees or any investment banker, attorney, accountant, consultant or other
agent, advisor or representative retained by the Foundation to, directly or
indirectly, (i) solicit, initiate, encourage or induce the making, submission
or announcement of any Acquisition Proposal; (ii) engage or participate in any
discussions or negotiations regarding, or furnish to any person any information
relating to the Company or any of its Subsidiaries or afford access to the
business, properties, assets, books or records of the Company or any of its
Subsidiaries to any person that has made, or take any other action intended to
assist or facilitate any inquiries or the making, submission, or announcement
of any proposal that constitutes or would reasonably be expected to lead to,
any Acquisition Proposal; (iii) approve, endorse or recommend any Acquisition
Proposal; or (iv) enter into any letter of intent or similar document or any
contract, agreement or commitment contemplating or otherwise relating to any
Acquisition Transaction; provided, this section shall not apply to any person
in his capacity as a director of the Company.
SECTION 8. Further Assurances. The Foundation hereby covenants and agrees
to, upon the request of the Buyer, execute and deliver any additional documents
and take such further actions as may be reasonably requested by the Buyer to
carry out the provisions of this Agreement and to vest in the Buyer the power
to vote the Shares as contemplated by Section 3 hereof and the Proxy; provided,
that such action is consistent with and does not create any obligations that
extend the general scope of the Agreement.
SECTION 9. Registration Rights. The Foundation agrees not to exercise any
registration rights it may have with respect to the Shares (including piggyback
registration rights) prior to the Termination Date.
SECTION 10. Legends. If so requested by the Buyer, the Foundation agrees
to not take any action or inaction that would be contrary to the agreements of
the LFT Shareholders in the LFT Voting Agreement to use their reasonable best
efforts to place on the certificates representing the Shares held by the LFT
Shareholders a legend stating that they are subject to the LFT Voting Agreement
and to an irrevocable proxy.
SECTION 11. Termination. All rights and obligations of the parties
hereunder and under the Proxies shall terminate and have no further force or
effect immediately upon the Termination Date; provided, however, that Sections
12 and 13 shall survive any termination of this Agreement.
SECTION 12. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if either party (i.e. the "initiating party") institutes any action
against the other party (i.e., the "target party") to enforce the terms of this
Agreement or the Proxy, such target party shall pay reasonable costs and
expenses, including, without limitation, reasonable attorneys' fees and costs
(collectively, "Costs"), incurred by the initiating party in connection with
such action, provided that the initiating party is successful in all material
respects with respect to all claims (after all appeals) ("Material Success") in
its action against the target party.
C-5-3
SECTION 13. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of the
Foundation set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to: Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
C-5-4
If to the Foundation:
To the address for notice set forth
on the signature page hereof.
With a copy to: Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
(f) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of The Netherlands, without giving effect to the
conflicts of law principles thereof.
(g) Entire Agreement. This Agreement contain the entire understanding of
the parties in respect of the subject matter hereof, and supersede all prior
negotiations and understandings between the parties with respect to such
subject matter.
(h) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(i) Counterparts. This Agreement may be executed by facsimile and in
several counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-5-5
IN WITNESS WHEREOF, Buyer and the Foundation have caused this Agreement to
be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
OSCAR & ZLATA FOUNDATION
By: /s/ TIS PRAGER
-----------------------------------
Name: Tis Prager
Title:
Address: Muhlebschstr. 6
--------------------------------
CH-8008 Zurich, Switzerland
--------------------------------------
--------------------------------------
Telephone: 0041-1-254 55 55
------------------------------
Facsimile No.: 0041-1-254 55 99
---------------------------
Shares beneficially owned:*
47,566,222 shares of Common Shares
1,746,672 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
--------
* Through its relationship with Gemini Systems Corporation N.V., Toscal N.V.,
OZF Ltd., Visionvest Corporation N.V., Walthroup Corporation N.V. and Deering
Corporation N.V., Oscar & Zlata Foundation is deemed to be the beneficial
owner of the Shares owned by such entities.
[SIGNATURE PAGE TO VOTING AGREEMENT]
C-5-6
ANNEX C-6
VOTING AGREEMENT
BY AND BETWEEN
HEWLETT-PACKARD COMPANY
AND
S-C INDIGO CV
VOTING AGREEMENT
THIS VOTING AGREEMENT (this "Agreement") is made and entered into as of
September 6, 2001, by and among Hewett-Packard Company, a Delaware corporation
(the "Buyer"), and the individual or entity listed on the signature page hereto
(the "Shareholder").
WHEREAS, the Shareholder is, as of the date hereof, the record and
beneficial owner of the common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
pages of this Agreement;
WHEREAS, the Buyer and the Company concurrently herewith are entering into
an Offer Agreement, dated as of the date hereof (the "Offer Agreement"), which
provides, among other things, (i) for the Buyer or a Subsidiary of the Buyer,
as promptly as practicable after the date hereof, to commence an exchange offer
(the "Offer") to acquire all of the outstanding Common Shares of the Company in
exchange for either (x) shares of Buyer Common Stock or (y) shares of Buyer
Common Stock plus CVRs, and (ii) for the subsequent post-closing reorganization
to be accomplished upon the terms and subject to the conditions set forth in
the Offer Agreement; and
WHEREAS, as a condition to the willingness of the Buyer to enter into the
Offer Agreement, and in order to induce the Buyer to enter into the Offer
Agreement, the Shareholder has agreed (solely in his, her or its capacity as a
shareholder of the Company) to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) owned by the Shareholder as of the date of this Agreement; and (ii)
all additional securities of the Company (including all additional Common
Shares and all additional options, warrants and other rights to acquire
Common Shares) of which the Shareholder acquires ownership during the period
from the date of this Agreement through the Termination Date.
(b) "Termination Date" shall mean the earliest to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; (ii) the
Closing Time; or (iii) four months after the End Date as determined pursuant
to the Offer Agreement (ignoring for this purpose any amendment to such
Agreement after the date hereof).
(c) Transfer. The Shareholder shall be deemed to have effected a
"Transfer" of Shares if the Shareholder directly or indirectly (i) sells,
pledges, encumbers, grants an option with respect to, transfers or otherwise
disposes of such Shares or any interest therein, or (ii) enters into an
agreement or commitment providing for the sale of, pledge of, encumbrance
of, grant of an option with respect to, transfer of or disposition of such
Shares or any interest therein.
SECTION 2. Representations and Warranties of the Shareholder. Shareholder
hereby represents, warrants and covenants to the Buyer that Shareholder (i) is
the beneficial owner of the Common Shares and the options, warrants and other
rights to acquire Common Shares indicated on the signature pages of this
Agreement, free and clear of any pledges, options, rights of first refusal,
co-sale rights, attachments or other encumbrances other than as contemplated
hereby and the Shareholders Agreement, dated September 13, 2000, by and among
C-6-1
the Company, the Buyer and the other Company Shareholders named therein; (ii)
does not beneficially own any securities of the Company other than the Common
Shares and options, warrants and other rights to acquire Common Shares of the
Company indicated on the signature pages of this Agreement; (iii) has full
power and authority to make, enter into and carry out the terms of this
Agreement and the proxy contained herein; and (iv) the execution, delivery and
performance of this Agreement by the Shareholder and the consummation of the
transactions contemplated hereby, will not (x) require the consent, waiver,
approval, or authorization of any governmental authority or any other person or
entity except as contemplated by the Offer Agreement; or (y) violate, conflict
with, result in a breach of or the acceleration of any obligation under, or
constitute a default (or an event which with notice or the lapse of time or
both would become a default) under, or give to others any right of termination,
amendment, acceleration or cancellation of, or result in the creation of a lien
or other encumbrance on any property or asset of the Shareholder pursuant to
any provision of any indenture, mortgage, lien, lease, agreement, contract,
instrument, order, judgment, ordinance, regulation or decree to which the
Shareholder is subject or by which the Shareholder or any of Shareholder's
property or assets (other than the Company's assets, if any) is bound, in each
case as would not materially adversely affect the Shareholder's obligations
hereunder.
SECTION 3. Agreement to Vote Shares. At every meeting of the Company
Shareholders called, including an extraordinary general meeting, and at every
adjournment thereof, and on every action or approval by written consent of the
Company Shareholders, Shareholder shall cause the Common Shares to be voted:
(a) in favor of appointment of the new members of the Company Boards in
accordance with the designation of the Buyer as set forth in the Offer
Agreement;
(b) in favor of resolution upon the amendment of the Articles of
Association of the Company as attached as an exhibit to the Offer Agreement;
(c) in favor of the Post-Closing Reorganization and any action required
in furtherance thereof; provided, however, that such action is in accordance
with all applicable laws;
(d) against any of the following actions (other than those actions that
relate to the Offer and the transactions contemplated by the Offer
Agreement): (A) any merger, consolidation, business combination, sale of
assets, reorganization or recapitalization of the Company or any subsidiary
of the Company with any party, (B) any sale, lease or transfer of any
significant part of the assets of the Company or any subsidiary of the
Company, (C) any reorganization, recapitalization, dissolution, liquidation
or winding up of the Company or any Subsidiary of the Company, (D) any
material change in the capitalization of the Company or any Subsidiary of
the Company, or the corporate structure of the Company or any Subsidiary of
the Company, or (E) any other action that is intended, or could reasonably
be expected to, impede, interfere with, delay, postpone, discourage or
adversely affect the Offer or any of the other transactions contemplated by
the Offer Agreement, including the Post-Closing Reorganization; and
(e) in favor of waiving any notice that may have been or may be required
relating to the Offer or any of the other transactions contemplated by the
Offer Agreement, including the Post-Closing Reorganization.
SECTION 4. Transfer of the Shares.
(a) Transferee of Shares to be Bound by this Agreement. Except as required
herein, the Shareholder hereby agrees that, at all times during the period from
the date of this Agreement until the Termination Date, the Shareholder shall
not cause or permit any Transfer of any of the Shares to be effected, unless
each person to which any such Shares, or any interest therein, is or may be
Transferred shall have (i) executed a counterpart of this Agreement and a proxy
in the form attached hereto as Exhibit A (with such modifications as the Buyer
may reasonably request) (the "Proxy"); and (ii) agreed in writing to hold such
Shares, or such interest therein, subject to all of the terms and conditions
set forth in this Agreement.
(b) Transfer of Voting Rights. The Shareholder hereby also agrees that, at
all times commencing with the execution and delivery of this Agreement until
the Termination Date, the Shareholder shall not deposit, or permit
C-6-2
the deposit of, any Shares in a voting trust, grant any proxy (other than the
Proxy) in respect of the Shares, or enter into any shareholder agreement or
similar arrangement or commitment in contravention of the obligations of the
Shareholder under this Agreement with respect to any of the Shares.
SECTION 5. Grant of Irrevocable Proxy; Appointment of Proxy. Concurrently
with the execution of this Agreement, the Shareholder hereby revokes any and
all previous proxies granted with respect to the Shares and agrees to deliver
to the Buyer the Proxy in the form attached hereto as Exhibit A, which shall be
irrevocable to the fullest extent permissible by applicable law.
SECTION 6. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of additional Common Shares or other securities or rights of the Company by the
Shareholder, the number of Shares shall be adjusted appropriately, and this
Agreement and the rights and obligations hereunder shall attach to any
additional Common Shares or other securities or rights of the Company issued to
or acquired by the Shareholder.
SECTION 7. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, the Shareholder will not, nor will the
Shareholder authorize or permit any of the Shareholder's officers, directors,
affiliates or employees or any investment banker, attorney, accountant,
consultant or other agent, advisor or representative retained by the
Shareholder to, directly or indirectly, (i) solicit, initiate, encourage or
induce the making, submission or announcement of any Acquisition Proposal; (ii)
engage or participate in any discussions or negotiations regarding, or furnish
to any person any information relating to the Company or any of its
Subsidiaries or afford access to the business, properties, assets, books or
records of the Company or any of its Subsidiaries to any person that has made,
or take any other action intended to assist or facilitate any inquiries or the
making, submission, or announcement of any proposal that constitutes or would
reasonably be expected to lead to, any Acquisition Proposal; (iii) approve,
endorse or recommend any Acquisition Proposal; or (iv) enter into any letter of
intent or similar document or any contract, agreement or commitment
contemplating or otherwise relating to any Acquisition Transaction; provided,
this section shall not apply to any person in his capacity as a director of the
Company.
SECTION 8. Further Assurances. The Shareholder hereby covenants and agrees
to, upon the request of the Buyer, execute and deliver any additional documents
and take such further actions as may be reasonably requested by the Buyer to
carry out the provisions of this Agreement and to vest in the Buyer the power
to vote the Shares as contemplated by Section 3 hereof and the Proxy; provided,
that such action is consistent with and does not create any obligations that
extend the general scope of the Agreement.
SECTION 9. Registration Rights. Shareholder agrees not to exercise any
registration rights it may have with respect to Shareholder's Shares (including
piggyback registration rights) prior to the Termination Date.
SECTION 10. Legends. If so requested by the Buyer, Shareholder agrees to
use its reasonable best efforts to place on the certificates representing the
Shares a legend stating that they are subject to this Agreement and to an
irrevocable proxy.
SECTION 11. Termination. All rights and obligations of the parties
hereunder and under the Proxies shall terminate and have no further force or
effect immediately upon the Termination Date; provided, however, that Sections
12 and 13 shall survive any termination of this Agreement.
SECTION 12. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if either party (i.e., the "initiating party") institutes any action
against the other party (i.e., the "target party") to enforce the terms of this
Agreement or the Proxy to which the Shareholder is a party, such target party
shall pay reasonable costs and expenses, including, without limitation,
reasonable attorneys' fees and costs (collectively, "Costs"), incurred by the
initiating party in
C-6-3
connection with such action, provided that the initiating party is successful
in all material respects with respect to all claims (after all appeals)
("Material Success") in its action against the target party.
SECTION 13. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of
Shareholder set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to: Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
C-6-4
If to the Shareholder:
To the address for notice set forth
on the signature page hereof.
With copies to: Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
and
Akin, Gump, Strauss, Hauer & Feld, L.L.P.
590 Madison Avenue
New York, New York 10022
Attention: Patrick J. Dooley, Esq.
Facsimile No.: (212) 872-1002
(f) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of The Netherlands, without giving effect to the
conflicts of law principles thereof.
(g) Entire Agreement. This Agreement and the Proxy contain the entire
understanding of the parties in respect of the subject matter hereof, and
supersede all prior negotiations and understandings between the parties with
respect to such subject matter.
(h) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(i) Counterparts. This Agreement may be executed by facsimile and in
several counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-6-5
IN WITNESS WHEREOF, each of the Buyer and the Shareholder have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By: /s/ CHARLES N. CHARNAS
-----------------------------------
Name: Charles N. Charnas
Title: Assistant Secretary
S-C INDIGO CV
By: S-C INDIGO II CV,
its General Partner
By: S-C GRAPHICS, INC.,
its General Partner
By: /s/ PETER HURWITZ
-----------------------------------
Name: Peter Hurwitz
Title: Vice President
Address:
--------------------------------
--------------------------------
--------------------------------
Telephone:
------------------------------
Facsimile No.:
---------------------------
Shares beneficially owned:
24,627,537 shares of Common Shares
1,700,000 shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
[SIGNATURE PAGE TO VOTING AGREEMENT]
C-6-6
EXHIBIT A
IRREVOCABLE PROXY
The undersigned shareholder of Indigo N.V., a corporation organized under
the laws of The Netherlands (the "Company"), hereby irrevocably (to the fullest
extent permitted by law), solely in his, her or its individual capacity as a
shareholder, appoints ____________, and each of them, as the sole and exclusive
attorneys and proxies of the undersigned, with full power of substitution and
resubstitution, to vote and exercise all voting and related rights (to the full
extent that the undersigned is entitled to do so) with respect to all of the
shares of capital stock of the Company that now are or hereafter may be
beneficially owned by the undersigned, and any and all other shares or
securities of the Company issued or issuable in respect thereof on or after the
date hereof (collectively, the "Shares") in accordance with the terms of this
Proxy. The Shares beneficially owned by the undersigned shareholder of the
Company as of the date of this Proxy are listed on the final page of this
Proxy. Upon the execution of this Proxy by the undersigned, any and all prior
proxies given by the undersigned with respect to any Shares are hereby revoked
and the undersigned hereby agrees not to grant any subsequent proxies with
respect to the Shares until after the Termination Date (as defined below).
This Proxy is irrevocable (to the fullest extent permitted by law), is
coupled with an interest and is granted pursuant to that certain Voting
Agreement of even date herewith by and between Hewlett-Packard Company, a
Delaware corporation (the "Buyer"), and the undersigned shareholder, and is
granted in consideration of the Buyer entering into that certain Offer
Agreement (the "Offer Agreement"), by and between the Buyer and the Company,
which provides for the Buyer or Subsidiary of the Buyer to commence an exchange
offer (the "Offer") to acquire all of the outstanding common shares, par value
NLG 0.04 per share of the Company (the "Common Shares") and for the subsequent
post-closing reorganization (the "Post-Closing Reorganization") to be
accomplished upon the terms and subject to the conditions set forth in the
Offer Agreement. As used herein, the term "Termination Date" shall mean the
earlier to occur of (i) valid termination of the Offer Agreement pursuant to
Article VII thereof; (ii) the Closing Time; or (iii) four months after the End
Date as determined pursuant to the Offer Agreement (ignoring for this purpose
any amendment to such Agreement after the date hereof).
The attorneys and proxies named above, and each of them, are hereby
authorized and empowered by the undersigned, at any time prior to the
Termination Date, to act as the undersigned's attorney and proxy to vote the
Shares, and to exercise all voting, consent and similar rights of the
undersigned with respect to the Shares (including, without limitation, the
power to execute and deliver written consents) at every annual, special,
adjourned or postponed meeting of shareholders of the Company, including an
extraordinary meeting of shareholders, and in every written consent in lieu of
such meeting:
(a) in favor of appointment of the new members of the Company Boards in
accordance with the designation of the Buyer as set forth in the Offer
Agreement;
(b) in favor of resolution upon the amendment of the Articles of
Association of the Company as attached as an exhibit to the Offer Agreement;
(c) in favor of the Post-Closing Reorganization and any action required
in furtherance thereof; provided, however, that such action is in accordance
with all applicable laws;
(d) against any of the following actions (other than those actions that
relate to the Offer and the transactions contemplated by the Offer
Agreement): (A) any merger, consolidation, business combination, sale of
assets, reorganization or recapitalization of the Company or any subsidiary
of the Company with any party, (B) any sale, lease or transfer of any
significant part of the assets of the Company or any subsidiary of the
Company, (C) any reorganization, recapitalization, dissolution, liquidation
or winding up of the Company or any Subsidiary of the Company, (D) any
material change in the capitalization of the Company or any Subsidiary of
the Company, or the corporate structure of the Company or any Subsidiary of
the Company, or (E) any other action that is intended, or could reasonably
be expected to, impede, interfere
C-6-7
with, delay, postpone, discourage or adversely affect the Offer or any of
the other transactions contemplated by the Offer Agreement, including the
Post-Closing Reorganization; and
(e) in favor of waiving any notice that may have been or may be required
relating to the Offer or any of the other transactions contemplated by the
Offer Agreement, including the Post-Closing Reorganization.
The attorneys and proxies named above may not exercise this Proxy on any
other matter except as provided above. The undersigned shareholder may vote the
Shares on all other matters. The undersigned shareholder will abstain from
casting any votes of the Shares on any of the matters provided above and will
not contest, in the relevant meeting of shareholders or otherwise, the
exclusive right of the attorneys and proxies named above to vote the Shares on
the matters provided above in their sole discretion.
Any obligation of the undersigned hereunder shall be binding upon the
successors and assigns of the undersigned.
This Proxy shall be governed by, and construed in accordance with, the laws
of The Netherlands, without giving effect to the conflicts of laws principles
thereof.
C-6-8
This Proxy is irrevocable (to the fullest extent permitted by law). This
Proxy shall terminate, and be of no further force and effect, automatically
upon the Termination Date.
Dated:____________, 2001
Signature of Shareholder:
/s/ Peter Hurwitz
----------------------
Print Name of Shareholder:
S-C INDIGO CV
By: S-C INDIGO II CV,
its General Partner
By: S-C GRAPHICS, INC.,
its General Partner
Shares beneficially owned:
24,627,537 shares of Company Shares
1,700,000 shares of Company Shares
issuable upon the exercise of
outstanding options, warrants or
other rights
[SIGNATURE PAGE TO IRREVOCABLE PROXY]
C-6-9
ANNEX C-7
FORM OF
VOTING AGREEMENT
AND IRREVOCABLE PROXY
BY AND AMONG
HEWLETT-PACKARD COMPANY
AND
CERTAIN SHAREHOLDERS OF INDIGO N.V.
VOTING AGREEMENT
THIS VOTING AGREEMENT (this "Agreement") is made and entered into as of
September 6, 2001, by and among Hewlett-Packard Company, a Delaware corporation
(the "Buyer"), and the individual or entity listed on the signature page hereto
(the "Shareholder").
WHEREAS, the Shareholder is, as of the date hereof, the record and
beneficial owner of the common shares, par value NLG 0.04 per share, of Indigo
N.V., a corporation organized under the laws of The Netherlands (the "Company,"
and such shares, the "Common Shares"), and the Common Shares subject to
outstanding options, warrants or other rights, as set forth on the signature
pages of this Agreement;
WHEREAS, the Buyer and the Company concurrently herewith are entering into
an Offer Agreement, dated as of the date hereof (the "Offer Agreement"), which
provides, among other things, (i) for the Buyer or a Subsidiary of the Buyer,
as promptly as practicable after the date hereof, to commence an exchange offer
(the "Offer") to acquire all of the outstanding Common Shares of the Company in
exchange for either (x) shares of Buyer Common Stock or (y) shares of Buyer
Common Stock plus CVRs, and (ii) for the subsequent post-closing reorganization
to be accomplished upon the terms and subject to the conditions set forth in
the Offer Agreement; and
WHEREAS, as a condition to the willingness of the Buyer to enter into the
Offer Agreement, and in order to induce the Buyer to enter into the Offer
Agreement, the Shareholder has agreed (solely in his, her or its capacity as a
shareholder of the Company) to enter into this Agreement.
NOW, THEREFORE, in consideration of the execution and delivery by the Buyer
of the Offer Agreement and the representations, warranties, covenants and
agreements set forth herein and therein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
SECTION 1. Certain Definitions. Capitalized terms used but not defined
herein shall have the meanings ascribed to such terms in the Offer Agreement.
For purposes of this Agreement:
(a) "Shares" shall mean: (i) all securities of the Company (including all
Common Shares and all options, warrants and other rights to acquire Common
Shares) owned by the Shareholder as of the date of this Agreement; and (ii)
all additional securities of the Company (including all additional Common
Shares and all additional options, warrants and other rights to acquire
Common Shares) of which the Shareholder acquires ownership during the period
from the date of this Agreement through the Termination Date.
(b) "Termination Date" shall mean the earliest to occur of (i) valid
termination of the Offer Agreement pursuant to Article VII thereof; or (ii)
the Closing Time.
(c) Transfer. The Shareholder shall be deemed to have effected a
"Transfer" of Shares if the Shareholder directly or indirectly (i) sells,
pledges, encumbers, grants an option with respect to, transfers or otherwise
disposes of such Shares or any interest therein, or (ii) enters into an
agreement or commitment providing for the sale of, pledge of, encumbrance
of, grant of an option with respect to, transfer of or disposition of such
Shares or any interest therein.
SECTION 2. Representations and Warranties of the Shareholder. Shareholder
hereby represents, warrants and covenants to the Buyer that Shareholder (i) is
the beneficial owner of the Common Shares and the options, warrants and other
rights to acquire Common Shares indicated on the signature pages of this
Agreement, free and clear of any pledges, options, rights of first refusal,
co-sale rights, attachments or other encumbrances other than as contemplated
hereby and the Shareholders Agreement, dated September 13, 2000, by and among
the Company, the Buyer and the other Company Shareholders named therein; (ii)
does not beneficially own any securities of the Company other than the Common
Shares and options, warrants and other rights to acquire Common Shares of the
Company indicated on the signature pages of this Agreement; (iii) has full
power and
C-7-1
authority to make, enter into and carry out the terms of this Agreement and the
proxy contained herein; and (iv) the execution, delivery and performance of
this Agreement by the Shareholder and the consummation of the transactions
contemplated hereby, will not (x) require the consent, waiver, approval, or
authorization of any governmental authority or any other person or entity
except as contemplated by the Offer Agreement; or (y) violate, conflict with,
result in a breach of or the acceleration of any obligation under, or
constitute a default (or an event which with notice or the lapse of time or
both would become a default) under, or give to others any right of termination,
amendment, acceleration or cancellation of, or result in the creation of a lien
or other encumbrance on any property or asset of the Shareholder pursuant to
any provision of any indenture, mortgage, lien, lease, agreement, contract,
instrument, order, judgment, ordinance, regulation or decree to which the
Shareholder is subject or by which the Shareholder or any of Shareholder's
property or assets (other than the Company's assets, if any) is bound, in each
case as would not materially adversely affect the Shareholder's obligations
hereunder.
SECTION 3. Agreement to Vote Shares. At every meeting of the Company
Shareholders called, including an extraordinary general meeting, and at every
adjournment thereof, and on every action or approval by written consent of the
Company Shareholders, Shareholder shall cause the Common Shares to be voted:
(a) in favor of appointment of the new members of the Company Boards in
accordance with the designation of the Buyer as set forth in the Offer
Agreement;
(b) in favor of resolution upon the amendment of the Articles of
Association of the Company as attached as an exhibit to the Offer Agreement;
(c) in favor of the Post-Closing Reorganization and any action required
in furtherance thereof; provided, however, that such action is in accordance
with all applicable laws;
(d) against any of the following actions (other than those actions that
relate to the Offer and the transactions contemplated by the Offer
Agreement): (A) any merger, consolidation, business combination, sale of
assets, reorganization or recapitalization of the Company or any subsidiary
of the Company with any party, (B) any sale, lease or transfer of any
significant part of the assets of the Company or any subsidiary of the
Company, (C) any reorganization, recapitalization, dissolution, liquidation
or winding up of the Company or any Subsidiary of the Company, (D) any
material change in the capitalization of the Company or any Subsidiary of
the Company, or the corporate structure of the Company or any Subsidiary of
the Company, or (E) any other action that is intended, or could reasonably
be expected to, impede, interfere with, delay, postpone, discourage or
adversely affect the Offer or any of the other transactions contemplated by
the Offer Agreement, including the Post-Closing Reorganization; and
(e) in favor of waiving any notice that may have been or may be required
relating to the Offer or any of the other transactions contemplated by the
Offer Agreement, including the Post-Closing Reorganization.
SECTION 4. Transfer of the Shares.
(a) Transferee of Shares to be Bound by this Agreement. Except as required
herein, the Shareholder hereby agrees that, at all times during the period from
the date of this Agreement until the Termination Date, the Shareholder shall
not cause or permit any Transfer of any of the Shares to be effected, unless
each person to which any such Shares, or any interest therein, is or may be
Transferred shall have (i) executed a counterpart of this Agreement and a proxy
in the form attached hereto as Exhibit A (with such modifications as the Buyer
may reasonably request) (the "Proxy"); and (ii) agreed in writing to hold such
Shares, or such interest therein, subject to all of the terms and conditions
set forth in this Agreement.
(b) Transfer of Voting Rights. The Shareholder hereby also agrees that, at
all times commencing with the execution and delivery of this Agreement until
the Termination Date, the Shareholder shall not deposit, or permit the deposit
of, any Shares in a voting trust, grant any proxy (other than the Proxy) in
respect of the Shares, or enter into any shareholder agreement or similar
arrangement or commitment in contravention of the obligations of the
Shareholder under this Agreement with respect to any of the Shares.
C-7-2
SECTION 5. Grant of Irrevocable Proxy; Appointment of Proxy. Concurrently
with the execution of this Agreement, the Shareholder hereby revokes any and
all previous proxies granted with respect to the Shares and agrees to deliver
to the Buyer the Proxy in the form attached hereto as Exhibit A, which shall be
irrevocable to the fullest extent permissible by applicable law.
SECTION 6. Certain Events. In the event of any stock split, stock
dividend, merger, reorganization, recapitalization or other change in the
capital structure of the Company affecting the Common Shares or the acquisition
of additional Common Shares or other securities or rights of the Company by the
Shareholder, the number of Shares shall be adjusted appropriately, and this
Agreement and the rights and obligations hereunder shall attach to any
additional Common Shares or other securities or rights of the Company issued to
or acquired by the Shareholder.
SECTION 7. Certain Other Agreements. From and after the date of this
Agreement until the Termination Date, the Shareholder will not, nor will the
Shareholder authorize or permit any of the Shareholder's officers, directors,
affiliates or employees or any investment banker, attorney, accountant,
consultant or other agent, advisor or representative retained by the
Shareholder to, directly or indirectly, (i) solicit, initiate, encourage or
induce the making, submission or announcement of any Acquisition Proposal; (ii)
engage or participate in any discussions or negotiations regarding, or furnish
to any person any information relating to the Company or any of its
Subsidiaries or afford access to the business, properties, assets, books or
records of the Company or any of its Subsidiaries to any person that has made,
or take any other action intended to assist or facilitate any inquiries or the
making, submission, or announcement of any proposal that constitutes or would
reasonably be expected to lead to, any Acquisition Proposal; (iii) approve,
endorse or recommend any Acquisition Proposal; or (iv) enter into any letter of
intent or similar document or any contract, agreement or commitment
contemplating or otherwise relating to any Acquisition Transaction; provided,
this section shall not apply to any person in his capacity as a director of the
Company.
SECTION 8. Further Assurances. The Shareholder hereby covenants and agrees
to, upon the request of the Buyer, execute and deliver any additional documents
and take such further actions as may be reasonably requested by the Buyer to
carry out the provisions of this Agreement and to vest in the Buyer the power
to vote the Shares as contemplated by Section 3 hereof and the Proxy; provided,
that such action is consistent with and does not create any obligations that
extend the general scope of the Agreement.
SECTION 9. Registration Rights. Shareholder agrees not to exercise any
registration rights it may have with respect to Shareholder's Shares (including
piggyback registration rights) prior to the Termination Date.
SECTION 10. Legends. If so requested by the Buyer, Shareholder agrees to
use its reasonable best efforts to place on the certificates representing the
Shares a legend stating that they are subject to this Agreement and to an
irrevocable proxy.
SECTION 11. Termination. All rights and obligations of the parties
hereunder and under the Proxies shall terminate and have no further force or
effect immediately upon the Termination Date; provided, however, that Sections
12 and 13 shall survive any termination of this Agreement.
SECTION 12. Expenses. All fees and expenses incurred by any one party
hereto shall be borne by the party incurring such fees and expenses; provided,
that if either party (i.e. the "initiating party") institutes any action
against the other party (i.e., the "target party") to enforce the terms of this
Agreement or the Proxy to which the Shareholder is a party, such target party
shall pay reasonable costs and expenses, including, without limitation,
reasonable attorneys' fees and costs (collectively, "Costs"), incurred by the
initiating party in connection with such action, provided that the initiating
party is successful in all material respects with respect to all claims (after
all appeals) ("Material Success") in its action against the target party.
C-7-3
SECTION 13. Miscellaneous.
(a) Severability. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, then the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but, except as otherwise
specifically provided herein, neither this Agreement nor any of the rights,
interests or obligations of the parties hereto may be assigned by either of the
parties without prior written consent of the other.
(c) Amendments and Modification. This Agreement may not be modified,
amended, altered or supplemented except upon the execution and delivery of a
written agreement executed by the parties hereto.
(d) Specific Performance; Injunctive Relief. The parties hereto acknowledge
that the Buyer shall be irreparably harmed and that there shall be no adequate
remedy at law for a violation of any of the covenants or agreements of
Shareholder set forth herein. Therefore, it is agreed that, in addition to any
other remedies that may be available to the Buyer upon any such violation, the
Buyer shall have the right to enforce such covenants and agreements by specific
performance, injunctive relief or by any other means available to the Buyer at
law or in equity.
(e) Notices. All notices and other communications pursuant to this
Agreement shall be in writing and deemed to be sufficient if contained in a
written instrument and shall be deemed given if delivered personally,
telecopied, sent by nationally-recognized overnight courier or mailed by
registered or certified mail (return receipt requested), postage prepaid, to
the parties at the following address (or at such other address for a party as
shall be specified by like notice):
If to the Buyer: Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Attention: General Counsel
Facsimile: (650) 857-4837
With copies to: Wilson Sonsini Goodrich & Rosati
Professional Corporation
650 Page Mill Road
Palo Alto, California 94304-1050
Attention: Larry W. Sonsini, Esq.
Aaron J. Alter, Esq.
Facsimile No.: (650) 493-6811
and
Wilson Sonsini Goodrich & Rosati
Professional Corporation
One Market
Spear Tower, Suite 3300
San Francisco, California 94105
Attention: Steve L. Camahort, Esq.
Facsimile No.: (415) 947-2099
C-7-4
If to the Shareholder:
To the address for notice set
forth on the signature page hereof.
With a copy to: Gibson, Dunn & Crutcher LLP
200 Park Avenue
New York, New York 10166-0193
Attention: Dennis J. Friedman, Esq.
Barbara L. Becker, Esq.
Facsimile No.: (212) 351-4035
(f) Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of The Netherlands, without giving effect to the
conflicts of law principles thereof.
(g) Entire Agreement. This Agreement and the Proxy contain the entire
understanding of the parties in respect of the subject matter hereof, and
supersede all prior negotiations and understandings between the parties with
respect to such subject matter.
(h) Effect of Headings. The section headings are for convenience only and
shall not affect the construction or interpretation of this Agreement.
(i) Counterparts. This Agreement may be executed by facsimile and in several
counterparts, each of which shall be an original, but all of which together
shall constitute one and the same agreement.
[Remainder of Page Intentionally Left Blank]
C-7-5
IN WITNESS WHEREOF, each of the Buyer and the Shareholder have caused this
Agreement to be duly executed and delivered as of the date first written above.
HEWLETT-PACKARD COMPANY
By:
-----------------------------------
Name:
Title:
SHAREHOLDER
By:
-----------------------------------
Name:
Title:
Address:
-------------------------------
--------------------------------------
--------------------------------------
Telephone:
------------------------------
Facsimile No.:
---------------------------
Shares beneficially owned:
shares of Common Shares
shares of Common Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
[SIGNATURE PAGE TO VOTING AGREEMENT]
C-7-6
EXHIBIT A
IRREVOCABLE PROXY
The undersigned shareholder of Indigo N.V., a corporation organized under
the laws of The Netherlands (the "Company"), hereby irrevocably (to the fullest
extent permitted by law), solely in his, her or its individual capacity as a
shareholder, appoints ____________, and each of them, as the sole and exclusive
attorneys and proxies of the undersigned, with full power of substitution and
resubstitution, to vote and exercise all voting and related rights (to the full
extent that the undersigned is entitled to do so) with respect to all of the
shares of capital stock of the Company that now are or hereafter may be
beneficially owned by the undersigned, and any and all other shares or
securities of the Company issued or issuable in respect thereof on or after the
date hereof (collectively, the "Shares") in accordance with the terms of this
Proxy. The Shares beneficially owned by the undersigned shareholder of the
Company as of the date of this Proxy are listed on the final page of this
Proxy. Upon the execution of this Proxy by the undersigned, any and all prior
proxies given by the undersigned with respect to any Shares are hereby revoked
and the undersigned hereby agrees not to grant any subsequent proxies with
respect to the Shares until after the Termination Date (as defined below).
This Proxy is irrevocable (to the fullest extent permitted by law), is
coupled with an interest and is granted pursuant to that certain Voting
Agreement of even date herewith by and between Hewlett-Packard Company, a
Delaware corporation (the "Buyer"), and the undersigned shareholder, and is
granted in consideration of the Buyer entering into that certain Offer
Agreement (the "Offer Agreement"), by and between the Buyer and the Company,
which provides for the Buyer or Subsidiary of the Buyer to commence an exchange
offer (the "Offer") to acquire all of the outstanding common shares, par value
NLG 0.04 per share of the Company (the "Common Shares") and for the subsequent
post-closing reorganization (the "Post-Closing Reorganization") to be
accomplished upon the terms and subject to the conditions set forth in the
Offer Agreement. As used herein, the term "Termination Date" shall mean the
earlier to occur of (i) valid termination of the Offer Agreement pursuant to
Article VII thereof; or (ii) the Closing Time.
The attorneys and proxies named above, and each of them, are hereby
authorized and empowered by the undersigned, at any time prior to the
Termination Date, to act as the undersigned's attorney and proxy to vote the
Shares, and to exercise all voting, consent and similar rights of the
undersigned with respect to the Shares (including, without limitation, the
power to execute and deliver written consents) at every annual, special,
adjourned or postponed meeting of shareholders of the Company, including an
extraordinary meeting of shareholders, and in every written consent in lieu of
such meeting:
(a) in favor of appointment of the new members of the Company Boards in
accordance with the designation of the Buyer as set forth in the Offer
Agreement;
(b) in favor of resolution upon the amendment of the Articles of
Association of the Company as attached as an exhibit to the Offer Agreement;
(c) in favor of the Post-Closing Reorganization and any action required
in furtherance thereof; provided, however, that such action is in accordance
with all applicable laws;
(d) against any of the following actions (other than those actions that
relate to the Offer and the transactions contemplated by the Offer
Agreement): (A) any merger, consolidation, business combination, sale of
assets, reorganization or recapitalization of the Company or any subsidiary
of the Company with any party, (B) any sale, lease or transfer of any
significant part of the assets of the Company or any subsidiary of the
Company, (C) any reorganization, recapitalization, dissolution, liquidation
or winding up of the Company or any Subsidiary of the Company, (D) any
material change in the capitalization of the Company or any Subsidiary of
the Company, or the corporate structure of the Company or any Subsidiary of
the Company, or (E) any other action that is intended, or could reasonably
be expected to, impede, interfere with, delay, postpone, discourage or
adversely affect the Offer or any of the other transactions contemplated by
the Offer Agreement, including the Post-Closing Reorganization; and
C-7-7
(e) in favor of waiving any notice that may have been or may be required
relating to the Offer or any of the other transactions contemplated by the
Offer Agreement, including the Post-Closing Reorganization.
The attorneys and proxies named above may not exercise this Proxy on any
other matter except as provided above. The undersigned shareholder may vote the
Shares on all other matters. The undersigned shareholder will abstain from
casting any votes of the Shares on any of the matters provided above and will
not contest, in the relevant meeting of shareholders or otherwise, the
exclusive right of the attorneys and proxies named above to vote the Shares on
the matters provided above in their sole discretion.
Any obligation of the undersigned hereunder shall be binding upon the
successors and assigns of the undersigned.
This Proxy shall be governed by, and construed in accordance with, the laws
of The Netherlands, without giving effect to the conflicts of laws principles
thereof.
C-7-8
This Proxy is irrevocable (to the fullest extent permitted by law). This
Proxy shall terminate, and be of no further force and effect, automatically
upon the Termination Date.
Dated: , 2001
Signature of Shareholder: _________
Print Name of Shareholder:
Shares beneficially owned:
shares of Company Shares
shares of Company Shares
issuable upon the exercise of
outstanding options, warrants or
other rights.
[SIGNATURE PAGE TO IRREVOCABLE PROXY]
C-7-9
ANNEX C-8
FORM OF
AFFILIATE AGREEMENT
BY AND AMONG
HEWLETT-PACKARD COMPANY
AND
CERTAIN PRINCIPAL SHAREHOLDERS OF INDIGO N.V.
AFFILIATE AGREEMENT
Hewlett-Packard Company
3000 Hanover Street
Palo Alto, California 94304
Reference is made to the Offer Agreement (the "Offer Agreement") by and
between Indigo N.V., a corporation organized under the laws of The Netherlands
(the "Company"), and Hewlett-Packard Company, a Delaware corporation ("Buyer")
(capitalized terms used and not otherwise defined herein shall have the
respective meanings ascribed to them in the Offer Agreement).
Pursuant to the Offer Agreement, it is proposed that Buyer or a Subsidiary
of Buyer shall, as promptly as practicable, commence an exchange offer (the
"Offer") to acquire all of the outstanding Company Shares. The Offer Agreement
also provides that, prior to and following the consummation of the Offer, Buyer
and the Company shall co-operate to accomplish any one or more of the
post-closing reorganizations described in Article II of the Offer Agreement.
Affiliate understands that the execution and delivery of this letter by
Affiliate is a material inducement to Buyer to enter into the Offer Agreement.
Affiliate has been advised that Affiliate may be deemed to be an "affiliate"
of the Company, as the term "affiliate" is used for purposes of paragraphs (c)
and (d) of Rule 145 of the Rules and Regulations of the Securities and Exchange
Commission (the "SEC"), although nothing contained herein shall be construed as
an admission by Affiliate that Affiliate is in fact an affiliate of the
Company. Affiliate accordingly agrees not to sell, transfer or otherwise
dispose of any Buyer Common Stock or CVR issued to Affiliate pursuant to the
Offer unless (A) such sale, transfer or other disposition is made in conformity
with the requirements of Rule 145(d) promulgated under the Securities Act of
1933, as amended (the "Securities Act"), or (B) Affiliate delivers to Buyer a
written opinion of counsel, reasonably acceptable to Buyer in form and
substance, that such sale, transfer or other disposition is otherwise exempt
from registration under the Securities Act.
Buyer will give stop transfer instructions to its transfer agent with
respect to the Buyer Common Stock and, if applicable, CVRs received by
Affiliate pursuant to the Offer and there will be placed on the certificates
representing such Buyer Common Stock and, if applicable, such CVRs, or any
substitutions therefor, a legend stating in substance:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE WERE ISSUED IN A TRANSACTION
TO WHICH RULE 145 APPLIES AND MAY ONLY BE TRANSFERRED IN CONFORMITY WITH RULE
145(d) OR IN ACCORDANCE WITH A WRITTEN OPINION OF COUNSEL, REASONABLY
ACCEPTABLE TO THE ISSUER IN FORM AND SUBSTANCE, THAT SUCH TRANSFER IS EXEMPT
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933."
C-8-1
The legend set forth above shall be removed (by delivery of a substitute
certificate without such legend) and Buyer shall so instruct its transfer
agent, if Affiliate delivers to Buyer (i) satisfactory written evidence that
the securities have been sold in compliance with Rule 145 (in which case, the
substitute certificate will be issued in the name of the transferee), or (ii)
an opinion of counsel, in form and substance reasonably satisfactory to Buyer,
to the effect that public sale of the securities by the holder thereof is no
longer subject to Rule 145. Notwithstanding the foregoing, Affiliate
understands that (i) certain contractual provisions will restrict transfer of
the CVRs as described in the certificates representing such CVRs and (ii) any
transfer of any such CVRs will only be permitted if such transfer complies with
those provisions as well as the provisions of Rule 145.
Very truly yours,
--------------------------------------
Affiliate:
Acknowledged:
HEWLETT-PACKARD COMPANY
By:
----------------------
Name:
------------------
Title:
-------------------
C-8-2
ANNEX D
September 6, 2001
Combined Board
Indigo N.V.
5 Limburglaan
6221 SH Maastricht
The Netherlands
Gentlemen:
We understand that Indigo N.V. ("Indigo") and Hewlett-Packard Company ("HP")
propose to enter into an offer agreement, dated as of September 6, 2001 (the
"Offer Agreement"), pursuant to which, among other things, (A) HP or a
subsidiary of HP shall, as promptly as practicable, commence an exchange offer
(the "Offer") to acquire all of the outstanding common shares of Indigo, par
value NLG 0.04 per share (the "Indigo Shares"), with each Indigo Share to be
exchanged, at the election of the holder thereof, for either (i) the Fixed
Offer Price (as defined below) or (ii) the Contingent Offer Price (as defined
below) (collectively, the "Offer Consideration"), subject to the satisfaction
or waiver of the condition that there shall be validly tendered in accordance
with the terms of the Offer prior to the Expiration Time (as defined in the
Offer Agreement) and not withdrawn a number of Indigo Shares that, together
with the Indigo Shares then owned by HP and its subsidiaries, represents at
least ninety-five percent (95%) of the Outstanding Company Shares (as defined
in the Offer Agreement) and certain other conditions as more fully set forth in
the Offer Agreement, and (B) HP intends, simultaneously with or as soon as
possible after the Closing (as defined in the Offer Agreement), to effectuate a
corporate reorganization (the "Reorganization") of Indigo and its subsidiaries,
which Reorganization may include, without limitation (i) the commencement of a
compulsory acquisition by HP of Indigo Shares from any remaining minority
holder thereof in accordance with Section 2:92a of the Dutch Civil Code (the
"DCC"), (ii) the amendment of the Articles of Association of Indigo to permit
the creation, among other things, of separate classes of shares, (iii) the
distribution of an extraordinary dividend on the shares of Indigo or a
particular class or classes of shares of Indigo, (iv) the sale and transfer by
Indigo, or any of its subsidiaries, to HP, or any affiliates of HP, of all or a
portion of the assets of Indigo or its subsidiaries, (v) the effectuation by
Indigo and one or more Dutch subsidiaries of HP of a legal merger within the
meaning of Section 2:309 of the DCC, (vi) the termination of the listing of the
Indigo Shares on the Nasdaq National Market, (vii) the deregistration of the
Indigo Shares under the Securities Exchange Act of 1934, as amended, and the
cessation of Indigo's reporting obligations thereunder, or (viii) any one or
more combinations of any of the foregoing actions; all of which shall be
conducted in accordance with applicable laws and which, if HP determines in its
sole discretion to implement any such Reorganization, will in any case result
in the holders of Indigo Shares who do not exchange such shares in the Offer
being offered or receiving in any such Reorganization consideration equivalent
to the Fixed Offer Price (the Offer and Reorganization together, the
"Acquisition Transactions"). The actual consideration received by each
individual holder of Indigo Shares in the Acquisition Transactions will depend
on the election made by such holder and other holders, on the application of
proration and other provisions contained in the Offer Agreement, on the terms
and conditions of the Offer itself, and upon the manner and method in which the
Reorganization, if any, is accomplished. The terms and conditions of the Offer
and any Reorganization are more fully set forth in the Offer Agreement, and are
incorporated herein by reference.
The "Fixed Offer Price" means that number of shares of common stock of HP,
par value $0.01 per share (the "HP Common Stock"), computed as follows (rounded
to the fourth decimal place): (i) if the average of the closing sales prices of
the HP Common Stock on the New York Stock Exchange for the twenty (20)
consecutive trading days ending with the third trading day immediately
preceding the Closing Time (as defined in the Offer Agreement) (the "Average HP
Stock Price") is less than or equal to $23.68 and greater than or equal to
$16.69, the Fixed Offer Price shall be equal to the quotient obtained by
dividing $7.50 by the Average HP Stock Price, (ii) if the Average HP Stock
Price is less than $16.69, the Fixed Offer Price shall be equal to 0.4494, and
(iii) if
D-1
Combined Board
Indigo N.V.
September 6, 2001
Page 2
the Average HP Stock Price is greater than $23.68, the Fixed Offer Price shall
be equal to 0.3167. The "Contingent Offer Price" means the Contingent Price
Exchange Ratio (as defined below) plus one contingent value right entitling the
holder to a receive a cash payment equal to: (a) if the Revenue (as defined
below) during the three-year period commencing on the later of the first day of
the first month subsequent to the Closing Time or February 1, 2002 (the
"Measuring Period") is equal to or greater than $1.6 billion (the "Upper
Limit"), $4.50; (b) if the Revenue during the Measuring Period is equal to or
less than $1.0 billion (the "Lower Limit"), $0; and (c) if the Revenue during
the Measuring Period is less than the Upper Limit but greater than the Lower
Limit, the dollar amount equal to the product of $4.50 and the quotient
obtained by dividing (x) the number by which Revenue exceeds the Lower Limit by
(y) $600 million. The "Contingent Price Exchange Ratio" means that number of
shares of HP Common Stock computed as follows (rounded to the fourth decimal
place): (i) if the Average HP Stock Price is less than or equal to $23.68 and
greater than or equal to $16.69, the Contingent Price Exchange Ratio shall be
equal to the quotient obtained by dividing $6.00 by the Average HP Stock Price,
(ii) if the Average HP Stock Price is less than $16.69, the Contingent Price
Exchange Ratio shall be equal to 0.3595, and (iii) if the Average HP Stock
Price is greater than $23.68, the Contingent Price Exchange Ratio shall be
equal to 0.2534. "Revenue" means the actual net revenue (to be based on U.S.
generally accepted accounting principles, as applied by HP consistent with its
financial Securities and Exchange Commission reporting practices as of the
beginning of the Measuring Period) from the sale or lease of LEP Digital Press
Products and Consumables, each term as defined in the contingent value rights
agreement (the "CVR Agreement"), by HP and its affiliates during the Measuring
Period plus the present value, as of the end of the Measuring Period, of
remaining minimum contractually committed payments associated with LEP Digital
Press Products placed during the Measuring Period under operating leases (as
more fully described in the CVR Agreement). The terms and conditions of the
Fixed Offer Price and Contingent Offer Price are more fully set forth in the
Offer Agreement and the CVR Agreement, and are incorporated herein by reference.
You have asked for our opinion as to whether the Offer Consideration is
fair, from a financial point of view, to the holders of the Indigo Shares
(other than HP and its affiliates).
For purposes of the opinion set forth herein, we have:
(i) reviewed certain publicly available financial statements and other
information of Indigo and HP;
(ii) reviewed certain internal financial statements and other financial
and operating data concerning Indigo prepared by the management of Indigo;
(iii) analyzed certain financial forecasts prepared by the management of
Indigo, which forecasts Indigo's management has represented to us are
consistent with their best judgments as to the future financial performance
of Indigo and are the best currently available forecasts with respect to
such future financial performance of Indigo;
(iv) discussed the past and current operations and financial condition
and the prospects of Indigo with Indigo's management and other of its senior
executives;
(v) discussed the past and current operations and financial condition and
the prospects of HP with senior executives of HP;
(vi) reviewed the reported prices and historical trading activity of the
Indigo Shares and the HP Common Stock;
(vii) compared the financial performance of Indigo and HP and the
reported prices and historical trading activity of the Indigo Shares and the
HP Common Stock with that of certain other comparable publicly traded
companies and their securities;
D-2
Combined Board
Indigo N.V.
September 6, 2001
Page 3
(viii) reviewed the financial terms, to the extent publicly available, of
certain comparable acquisition transactions;
(ix) reviewed a draft of the Offer Agreement and certain related
documents; and
(x) performed such other analyses and considered such other factors as we
have deemed appropriate.
We have assumed and relied upon, without independent verification, the
accuracy and completeness of the financial and other information reviewed by us
for the purposes of this opinion. With respect to the financial projections
provided to us, with your consent, we have assumed that they have been
reasonably prepared and are consistent with the best currently available
estimates and judgments of Indigo's management as to the future financial
performance of Indigo. We have not, with your permission, discussed with HP
financial forecasts, with respect to HP, which were prepared by unaffiliated
financial analysts, but we have assumed that such forecasts represent the best
currently available estimates of the future financial performance of HP.
Further, HP has not provided to us any internally prepared financial forecasts
with respect to HP. We assume no responsibility for and express no view as to
such forecasts or the assumptions on which they are based, and, with respect to
Indigo, we have relied upon the assurances of Indigo's management that they are
unaware of any facts that would make the information provided to or reviewed by
us incomplete or misleading. We have also assumed, based upon the information
which has been provided to us and without assuming responsibility for
independent verification therefor, that no material undisclosed liability
exists with respect to Indigo or HP. We have not made any independent valuation
or appraisal of the assets or liabilities (contingent or otherwise) of Indigo
or HP or any of their subsidiaries, nor have we been furnished with any such
valuations or appraisals. We have assumed that the Acquisition Transactions
will be accounted for as a purchase transaction in accordance with U.S.
generally accepted accounting principles and shall constitute a taxable
transaction under the U.S. Internal Revenue Code of 1986, as amended. We have
also assumed that the Acquisition Transactions will be consummated in
accordance with the terms set forth in the Offer Agreement (which we assume
will be substantially in the form of the draft that has been provided to us)
and that all of the representations and warranties of the parties to the Offer
Agreement are true, that the covenants of each party to the Offer Agreement
will be fully complied with, and that all conditions to the Acquisition
Transactions set forth in the Offer Agreement will be satisfied and not waived,
in each case, in all respects material to our analysis. In addition, with your
permission, we have not considered the effects of, either on the financial
projections of HP or otherwise, nor have we analyzed, any recently announced
transactions involving HP. Our opinion is necessarily based on economic, market
and other conditions as in effect on, and the information made available to us
as of, the date hereof. It should be understood that, although subsequent
developments may affect this opinion, we do not have any obligation to update,
revise or reaffirm this opinion.
Our opinion addresses only the fairness, from a financial point of view, to
the holders of Indigo Shares (other than HP and its affiliates) of the Offer
Consideration, and we do not express any view as to any other term of the
proposed Acquisition Transactions or other matters contemplated by the Offer
Agreement. Our opinion does not address Indigo's underlying business decision
to effect the transactions contemplated by the Offer Agreement, nor does it
value the HP Common Stock.
We have acted as financial advisor to the Combined Board of Indigo in
connection with this transaction and will receive a financial advisory fee of
$5,500,000 for our services, which will be paid only upon the consummation of
the Offer. In addition, Indigo has agreed to indemnify us for certain
liabilities arising out of our engagement. Our advisory services and the
opinion expressed herein are provided for the information and assistance of the
Combined Board of Indigo in connection with its consideration of the Offer and
the transactions contemplated by the Offer Agreement and such opinion does not
constitute a recommendation as to whether
D-3
Combined Board
Indigo N.V.
September 6, 2001
Page 4
Indigo, or any holder of Indigo Shares, should elect to engage in any
transaction contemplated by the Offer Agreement or exchange Indigo Shares in
the Offer or what election any holder of Indigo Shares should make with respect
to the Offer if such holder chooses to exchange Indigo Shares in the Offer.
This letter is addressed to the Combined Board of Indigo, and may not be
reproduced, disseminated, quoted, used or referred to at any time, in any
manner or for any purpose, nor shall any public references to Gleacher & Co. be
made by or on behalf of Indigo, in each case without the prior written consent
of Gleacher & Co., except that this opinion may be included in its entirety in
any filing relating to the Acquisition Transactions made by Indigo with the
U.S. Securities and Exchange Commission.
Based upon and subject to the foregoing and such other matters as we
consider relevant, we are of the opinion that, as of the date hereof, the Offer
Consideration is fair, from a financial point of view, to the holders of Indigo
Shares (other than HP and its affiliates).
Very truly yours,
GLEACHER & CO. LLC
By: /s/ JOHN E. HUWILER
_______________________________
John E. Huwiler
Managing Director
D-4
The Exchange Agent for the Exchange Offer is:
Computershare Trust Company of New York
By Hand or Overnight Courier: By Mail:
Computershare Trust Company of New York Computershare Trust Company of New York
Wall Street Plaza Wall Street Station
88 Pine Street, 19th Floor P.O. Box 1010
New York, NY 10005 New York, NY 10268-1010
For Information:
(212) 701-7624
Facsimile Transmission:
(For Eligible Institutions Only)
(212) 701-7636
Confirm Facsimile Transmission:
(By Telephone Only)
(212) 701-7624
The Information Agent for the Exchange Offer is:
Georgeson Shareholder
111 Commerce Road
Carlstadt, New Jersey 07072
Indigo@Georgeson.com
Banks and Brokers please call (201) 896-1900
Shareholders in North America call toll-free (866) 233-9045
Shareholders outside of North America call (212) 806-6741
5981-0206 ENUC